Clustering O 0 0.0006063541513867676
of O 0 2.4863489670678973e-05
missense O 0 0.0006220514769665897
mutations O 0 0.00016001061885617673
in O 0 5.957377197773894e-06
the O 0 5.140793655300513e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9997816681861877
telangiectasia I-Disease 1 0.9999984502792358
gene O 0 4.961796730640344e-05
in O 0 2.3076852357917232e-06
a O 0 8.910831638786476e-06
sporadic B-Disease 0 0.001723818015307188
T I-Disease 1 0.9821946024894714
- I-Disease 0 0.2578870952129364
cell I-Disease 0 0.4358103573322296
leukaemia I-Disease 1 0.9941873550415039
. O 0 5.9258083638269454e-05

Ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999929666519165
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.022596925497055054
A B-Disease 1 0.9999960660934448
- I-Disease 1 0.9999977350234985
T I-Disease 1 1.0
) O 0 1.9023248114535818e-06
is O 0 3.669832437935838e-07
a O 0 2.4078881324385293e-06
recessive B-Disease 0 0.001594712259247899
multi I-Disease 0 0.1469331830739975
- I-Disease 1 0.9988536834716797
system I-Disease 1 0.5340083241462708
disorder I-Disease 1 0.9926309585571289
caused O 0 2.3618433260708116e-05
by O 0 6.957636173865467e-07
mutations O 0 5.068917744210921e-06
in O 0 3.7121847640264605e-07
the O 0 6.889798100928601e-07
ATM O 0 0.000360012985765934
gene O 0 5.875038368685637e-06
at O 0 8.29860073281452e-06
11q22 O 0 3.946847573388368e-05
- O 0 5.322302968124859e-05
q23 O 0 5.344880628399551e-05
( O 0 1.1582091019590735e-06
ref O 0 0.0002696971350815147
. O 0 9.240551435141242e-07
3 O 0 4.20861715610954e-06
) O 0 3.0956587124819634e-06
. O 0 1.1488745258247945e-05

The O 0 8.27307376312092e-05
risk O 0 0.00017407216364517808
of O 0 2.8224653760844376e-06
cancer B-Disease 0 0.1321970522403717
, O 0 2.4525195385649567e-06
especially O 0 2.1079715679661604e-06
lymphoid B-Disease 0 0.0023087700828909874
neoplasias I-Disease 0 0.10705739259719849
, O 0 4.363566404208541e-06
is O 0 9.371445344186213e-07
substantially O 0 2.683018465177156e-05
elevated O 0 9.683807729743421e-05
in O 0 9.029697139339987e-06
A B-Disease 1 0.9999376535415649
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 0.0018116021528840065
and O 0 3.082201828874531e-06
has O 0 5.31356226929347e-06
long O 0 1.4524793186865281e-05
been O 0 5.39929806109285e-06
associated O 0 3.995034148829291e-06
with O 0 3.994660437456332e-05
chromosomal O 1 0.9999998807907104
instability O 1 0.999886155128479
. O 0 0.00012285099364817142

By O 0 7.628346793353558e-05
analysing O 0 0.0017533771460875869
tumour B-Disease 1 0.9999951124191284
DNA O 0 0.000277203565929085
from O 0 1.2515986782091204e-05
patients O 0 9.671746374806389e-05
with O 0 2.9515413189074025e-06
sporadic B-Disease 0 0.0011234948178753257
T I-Disease 1 0.9714846611022949
- I-Disease 0 0.035955775529146194
cell I-Disease 0 0.05491965264081955
prolymphocytic I-Disease 1 0.7829572558403015
leukaemia I-Disease 1 0.9985920786857605
( O 0 1.7479906091466546e-05
T B-Disease 1 0.5841813087463379
- I-Disease 0 0.003627288620918989
PLL I-Disease 0 0.00940834078937769
) O 0 8.918407274904894e-07
, O 0 2.8297864673731965e-07
a O 0 1.2911293651995948e-06
rare O 0 4.000226908829063e-06
clonal B-Disease 0 0.0003738205705303699
malignancy I-Disease 0 0.3172640800476074
with O 0 1.4722479591000592e-06
similarities O 0 3.7444731333380332e-06
to O 0 8.460770573037735e-07
a O 0 1.0217797353107017e-05
mature B-Disease 0 2.452167245792225e-05
T I-Disease 0 0.014842298813164234
- I-Disease 0 0.0006201000651344657
cell I-Disease 0 0.030842220410704613
leukaemia I-Disease 1 0.9812601804733276
seen O 0 3.7286845326889306e-05
in O 0 5.289204182190588e-06
A B-Disease 1 0.9995797276496887
- I-Disease 1 0.9999146461486816
T I-Disease 1 0.9999997615814209
, O 0 2.139379148502485e-06
we O 0 6.165042236716545e-07
demonstrate O 0 3.7363503224696615e-07
a O 0 2.0381038723371603e-07
high O 0 1.0479745924385497e-06
frequency O 0 9.755193559612962e-07
of O 0 2.705866961605352e-07
ATM O 0 0.0076421089470386505
mutations O 0 2.7771717213909142e-05
in O 0 7.89325076766545e-06
T B-Disease 1 0.7884749174118042
- I-Disease 0 0.003992242272943258
PLL I-Disease 0 0.010361181572079659
. O 0 3.3572898246347904e-05

In O 0 6.467973435064778e-05
marked O 0 2.2242827981244773e-05
contrast O 0 5.876450359210139e-06
to O 0 9.438652455173724e-07
the O 0 9.707853223517304e-07
ATM O 0 0.01255240011960268
mutation O 0 1.578340379637666e-05
pattern O 0 6.648820999544114e-06
in O 0 9.224595487467013e-06
A B-Disease 1 0.9999734163284302
- I-Disease 1 0.9999960660934448
T I-Disease 1 0.9999998807907104
, O 0 5.994759249006165e-07
the O 0 1.3496519102318416e-07
most O 0 8.508853710509356e-08
frequent O 0 1.0550443221291061e-06
nucleotide O 0 4.194513167021796e-06
changes O 0 4.962404318575864e-07
in O 0 4.351322218099085e-07
this O 0 1.1764875580411172e-06
leukaemia B-Disease 1 0.869888961315155
were O 0 2.6849202185985632e-05
missense O 0 0.00012140276521677151
mutations O 0 7.797313446644694e-05
. O 0 1.4852482308924664e-05

These O 0 2.7679334380081855e-05
clustered O 0 0.0001039209746522829
in O 0 2.499121819710126e-06
the O 0 8.905726645025425e-07
region O 0 1.1448814802861307e-06
corresponding O 0 8.374274216293998e-07
to O 0 3.213535251234134e-07
the O 0 3.0692788755004585e-07
kinase O 0 9.369216968480032e-06
domain O 0 1.3578517155110603e-06
, O 0 2.0111288279167638e-07
which O 0 7.99930646167013e-08
is O 0 6.35293346817889e-08
highly O 0 1.7625424675316026e-07
conserved O 0 5.340419306776312e-07
in O 0 3.4800322623596003e-07
ATM O 0 0.0005899756215512753
- O 0 3.081694740103558e-05
related O 0 9.546779438096564e-07
proteins O 0 6.102429210841365e-07
in O 0 5.169758310330508e-07
mouse O 0 1.5505196643061936e-05
, O 0 7.26391704120033e-07
yeast O 0 5.359048373065889e-06
and O 0 2.03874856197217e-06
Drosophila O 0 2.654258241818752e-05
. O 0 1.29409454530105e-05

The O 0 3.9042122807586566e-05
resulting O 0 4.318029459682293e-05
amino O 0 1.3627368389279582e-05
- O 0 4.405925210448913e-05
acid O 0 3.2455523069074843e-06
substitutions O 0 1.1930467280762969e-06
are O 0 3.281739111571369e-07
predicted O 0 1.644997496441647e-06
to O 0 3.5410431564741884e-07
interfere O 0 1.1483872413009522e-06
with O 0 8.25949769023282e-07
ATP O 0 0.00975421629846096
binding O 0 2.034481985901948e-05
or O 0 7.0546370807278436e-06
substrate O 0 7.330060907406732e-05
recognition O 0 2.4275408577523194e-05
. O 0 2.7073301680502482e-05

Two O 0 3.700950037455186e-05
of O 0 7.588116659462685e-06
seventeen O 0 6.099564416217618e-05
mutated O 0 0.00011240760795772076
T B-Disease 0 0.004476288333535194
- I-Disease 0 6.046919588698074e-05
PLL I-Disease 0 0.00024253627634607255
samples O 0 8.888206139090471e-06
had O 0 1.456785321352072e-05
a O 0 2.683253342183889e-06
previously O 0 3.8549005694221705e-05
reported O 0 4.2743064113892615e-05
A B-Disease 1 0.9423352479934692
- I-Disease 1 0.9973582625389099
T I-Disease 1 0.9999881982803345
allele O 0 0.00040580733912065625
. O 0 2.811236663546879e-05

In O 0 6.136495358077809e-05
contrast O 0 2.293710713274777e-05
, O 0 2.9302625534910476e-06
no O 0 2.2585379610973177e-06
mutations O 0 9.939349183696322e-06
were O 0 2.9501286462618737e-06
detected O 0 5.596744358626893e-06
in O 0 2.1608447298149258e-07
the O 0 3.7668979757654597e-07
p53 O 0 3.596824171836488e-06
gene O 0 1.4170764188747853e-06
, O 0 2.8244372174413e-07
suggesting O 0 1.2127107993364916e-06
that O 0 2.249751105409814e-07
this O 0 6.666978151770309e-07
tumour B-Disease 1 0.9999746084213257
suppressor O 0 0.00012663882807828486
is O 0 4.1974232090069563e-07
not O 0 3.8935502288950374e-07
frequently O 0 1.3344717899599345e-06
altered O 0 4.953353254677495e-06
in O 0 1.0646341479514376e-06
this O 0 4.17724777435069e-06
leukaemia B-Disease 1 0.946445882320404
. O 0 1.8934319086838514e-05

Occasional O 0 0.0008098253747448325
missense O 0 0.001025034231133759
mutations O 0 0.00019107370462734252
in O 0 5.393544142862083e-06
ATM O 0 0.010786077938973904
were O 0 2.108093394781463e-05
also O 0 2.4419148303422844e-06
found O 0 3.5389402910368517e-06
in O 0 9.794181096367538e-06
tumour B-Disease 1 0.9999991655349731
DNA O 0 8.452231850242242e-05
from O 0 3.2053430913947523e-06
patients O 0 1.8560594980954193e-05
with O 0 2.2108126813691342e-06
B B-Disease 0 0.00410918565467
- I-Disease 0 0.0006314049824140966
cell I-Disease 0 0.0004292542871553451
non I-Disease 0 5.820172737003304e-05
- I-Disease 1 0.633844256401062
Hodgkins I-Disease 1 0.9999982118606567
lymphomas I-Disease 1 0.9925358295440674
( O 0 3.2755340271251043e-06
B B-Disease 0 0.00010551898594712839
- I-Disease 0 4.29682586400304e-05
NHL I-Disease 0 1.7417305571143515e-05
) O 0 5.085896646050969e-07
and O 0 3.878918448663171e-07
a O 0 1.6219579492826597e-06
B B-Disease 0 0.0002002489345613867
- I-Disease 0 7.418241875711828e-05
NHL I-Disease 0 4.616519436240196e-05
cell O 0 9.353399218525738e-05
line O 0 0.00010636120714480057
. O 0 2.243995368189644e-05

The O 0 1.05582093965495e-05
evidence O 0 3.1740903523314046e-06
of O 0 3.3315214409412874e-07
a O 0 8.59815600051661e-07
significant O 0 3.6404398429112916e-07
proportion O 0 9.861670378086274e-07
of O 0 2.6247153073200025e-07
loss O 0 0.00020073987252544612
- O 0 9.526099893264472e-05
of O 0 5.509531888492347e-07
- O 0 0.0015645078383386135
function O 0 5.195818175707245e-06
mutations O 0 4.7893495320749935e-06
and O 0 5.181307756174647e-07
a O 0 1.2297975899855373e-06
complete O 0 8.859906301950105e-06
absence O 0 1.4986489986767992e-06
of O 0 9.850675297684575e-08
the O 0 3.448646168635605e-07
normal O 0 1.0692333489714656e-06
copy O 0 9.9372346085147e-07
of O 0 8.998340206289868e-08
ATM O 0 0.00030521737062372267
in O 0 4.907799961983983e-07
the O 0 3.225789555472147e-07
majority O 0 7.131087045308959e-07
of O 0 6.364515456880326e-07
mutated O 0 0.0008194198017008603
tumours B-Disease 1 0.9999122619628906
establishes O 0 2.0653693354688585e-05
somatic O 0 2.9197517505963333e-05
inactivation O 0 0.00011094116780441254
of O 0 3.667306316401664e-07
this O 0 3.837531892258994e-07
gene O 0 1.2974368246432277e-06
in O 0 2.7430630211711104e-07
the O 0 5.462039212034142e-07
pathogenesis O 0 4.656820237869397e-06
of O 0 2.9314600169527694e-07
sporadic B-Disease 0 0.000132237168145366
T I-Disease 1 0.5699055790901184
- I-Disease 0 0.0008437004871666431
PLL I-Disease 0 0.001082379138097167
and O 0 1.4964097090341966e-06
suggests O 0 1.3106016467645532e-06
that O 0 2.002699801550989e-07
ATM O 0 0.00010933422890957445
acts O 0 1.5093273759703152e-06
as O 0 8.500968533553532e-07
a O 0 3.045038101845421e-05
tumour B-Disease 1 0.9999927282333374
suppressor O 0 0.0007896259194239974
. O 0 2.5930659830919467e-05

As O 0 4.2117924749618396e-05
constitutional O 0 2.186098208767362e-05
DNA O 0 9.891767695080489e-05
was O 0 6.632810982409865e-05
not O 0 9.374752494295535e-07
available O 0 3.460915536379616e-07
, O 0 3.9499272475040925e-07
a O 0 1.9068947949563153e-06
putative O 0 0.0004079558129888028
hereditary O 1 0.8860217928886414
predisposition O 0 0.06660424917936325
to O 0 7.765139889670536e-05
T B-Disease 1 0.978723406791687
- I-Disease 0 0.01580829732120037
PLL I-Disease 0 0.003082976909354329
will O 0 7.737909299976309e-07
require O 0 1.2306786629778799e-06
further O 0 1.156639427790651e-06
investigation O 0 4.2187998587905895e-06
. O 0 3.2971274777082726e-06
. O 0 1.3801893146592192e-05

Myotonic B-Disease 1 0.9999983310699463
dystrophy I-Disease 1 0.9999997615814209
protein O 0 0.01076530385762453
kinase O 0 0.001358067849650979
is O 0 2.7755349947256036e-06
involved O 0 1.2894165593024809e-06
in O 0 2.6287011678505223e-07
the O 0 2.707273836222157e-07
modulation O 0 1.910872470034519e-06
of O 0 3.3008731747941056e-07
the O 0 1.2075348649887019e-06
Ca2 O 0 5.800479993922636e-05
+ O 0 6.443353777285665e-05
homeostasis O 0 0.00016000572941266
in O 0 5.693565526598832e-06
skeletal O 0 0.04611542820930481
muscle O 0 0.057654257863759995
cells O 0 0.000287283502984792
. O 0 2.5550671125529334e-05

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.9093566536903381
DM B-Disease 1 0.9999998807907104
) O 0 9.566444350639358e-05
, O 0 2.970582727357396e-06
the O 0 8.502930199938419e-07
most O 0 1.060069962477428e-06
prevalent O 0 0.0001825320505304262
muscular B-Disease 1 0.9969276785850525
disorder I-Disease 1 0.996167004108429
in O 0 2.694277100090403e-05
adults O 0 0.02575315721333027
, O 0 6.062305146770086e-06
is O 0 1.676959072938189e-06
caused O 0 1.0185012797592208e-05
by O 0 4.414832517340983e-07
( O 0 6.572523716386058e-07
CTG O 0 3.983666829299182e-05
) O 0 4.0430109038425144e-07
n O 0 5.1382889978413004e-06
- O 0 8.832092134980485e-06
repeat O 0 1.5203820566966897e-06
expansion O 0 3.767508758301119e-07
in O 0 1.8151629888052412e-07
a O 0 3.543070192790765e-07
gene O 0 7.902559673311771e-07
encoding O 0 9.096214625969878e-07
a O 0 1.1642113122434239e-06
protein O 0 5.398865141614806e-06
kinase O 0 4.678232653532177e-05
( O 0 2.8575393571372842e-06
DM B-Disease 1 0.9991505146026611
protein O 0 8.991571121441666e-06
kinase O 0 3.850733628496528e-05
; O 0 2.6130842343263794e-06
DMPK O 0 0.0007312071393243968
) O 0 2.944176742403215e-07
and O 0 1.6322694307291385e-07
involves O 0 3.625652595928841e-07
changes O 0 4.3685361106327036e-07
in O 0 5.104190563542943e-07
cytoarchitecture O 0 8.63603490870446e-05
and O 0 4.895215624856064e-06
ion O 0 0.0001124435366364196
homeostasis O 0 0.0016100759385153651
. O 0 4.419665128807537e-05

To O 0 2.82815053651575e-05
obtain O 0 1.5042325685499236e-05
clues O 0 1.1822647138615139e-05
to O 0 7.152337389015884e-07
the O 0 5.304259502736386e-07
normal O 0 2.7958899408986326e-06
biological O 0 3.997656676801853e-06
role O 0 2.4977728685371403e-07
of O 0 1.478894233741812e-07
DMPK O 0 0.0001116474304581061
in O 0 6.521301543216396e-07
cellular O 0 4.598899249685928e-05
ion O 0 3.123704300378449e-05
homeostasis O 0 0.001643039402551949
, O 0 1.0421442766528344e-06
we O 0 3.9103775861804024e-07
have O 0 2.4542271148675354e-07
compared O 0 4.984706265531713e-07
the O 0 4.25313515961534e-07
resting O 0 1.8146858565160073e-05
[ O 0 1.6197552668018034e-06
Ca2 O 0 4.6490231397910975e-06
+ O 0 6.536596174555598e-06
] O 0 3.7820302623003954e-06
i O 0 2.487034635123564e-06
, O 0 1.1887555473322209e-07
the O 0 1.3404113019532815e-07
amplitude O 0 8.123252541736292e-07
and O 0 4.109648727990134e-07
shape O 0 1.7783304429030977e-06
of O 0 1.6322974261129275e-07
depolarization O 0 6.158429187053116e-06
- O 0 0.00020632801169995219
induced O 0 9.901912562781945e-05
Ca2 O 0 2.4108749130391516e-05
+ O 0 1.1192545571248047e-05
transients O 0 2.114173912559636e-05
, O 0 3.039370142232656e-07
and O 0 1.0035272879349577e-07
the O 0 8.86603501726313e-08
content O 0 1.6036504746352875e-07
of O 0 7.11995724600456e-08
ATP O 0 1.6811396562843584e-05
- O 0 8.797441296337638e-06
driven O 0 3.811202759607113e-06
ion O 0 2.4973305698949844e-06
pumps O 0 8.577078915550373e-06
in O 0 8.265226369985612e-07
cultured O 0 1.4150819879432674e-05
skeletal O 0 0.0002936272067017853
muscle O 0 9.711651364341378e-05
cells O 0 1.6391344388466678e-06
of O 0 1.3677455967808783e-07
wild O 0 1.2390423762553837e-06
- O 0 1.3683299584954511e-05
type O 0 5.3414146350405645e-06
and O 0 2.8342960831651e-06
DMPK O 0 0.0019402318866923451
[ O 0 6.898595529492013e-06
- O 0 4.688115950557403e-05
/ O 0 5.0068752898368984e-05
- O 0 0.0003572518180590123
] O 0 7.00086384313181e-05
knockout O 0 0.02774639055132866
mice O 0 0.004647449124604464
. O 0 4.603695197147317e-05

In O 0 7.898762851255015e-05
vitro O 0 0.0005542566650547087
- O 0 0.00025140983052551746
differentiated O 0 0.00018365301366429776
DMPK O 0 0.002781787421554327
[ O 0 1.260472163266968e-05
- O 0 7.631403423147276e-05
/ O 0 4.880851702182554e-05
- O 0 8.595432882430032e-05
] O 0 9.169732948066667e-06
myotubes O 0 1.3068500265944749e-05
exhibit O 0 1.483621076658892e-06
a O 0 1.180999788630288e-06
higher O 0 6.521079740196001e-06
resting O 0 7.140851812437177e-05
[ O 0 2.2765402718505356e-06
Ca2 O 0 5.885883638256928e-06
+ O 0 5.9500184761418495e-06
] O 0 2.4117264274536865e-06
i O 0 1.1642856634352938e-06
than O 0 1.3111900898366002e-07
do O 0 3.817088440882799e-07
wild O 0 7.001794983807486e-07
- O 0 1.162096577900229e-05
type O 0 1.4872679457766935e-05
myotubes O 0 0.00015242304652929306
because O 0 2.709045361370954e-07
of O 0 6.057676671389345e-08
an O 0 4.751751987441821e-07
altered O 0 4.411449936014833e-06
open O 0 1.2918536640427192e-06
probability O 0 6.588834366993979e-07
of O 0 2.3614319388798322e-07
voltage O 0 1.6127349226735532e-05
- O 0 9.178814070764929e-05
dependent O 0 1.1082867786171846e-05
l O 0 3.118310996796936e-05
- O 0 1.093636001314735e-05
type O 0 6.657849553448614e-06
Ca2 O 0 2.3458513169316575e-05
+ O 0 1.2785560102201998e-05
and O 0 4.06376420869492e-06
Na O 0 7.34995337552391e-05
+ O 0 2.292586759722326e-05
channels O 0 4.103975516045466e-05
. O 0 2.4131704776664265e-05

The O 0 5.975911335553974e-05
mutant O 0 9.623236110201105e-05
myotubes O 0 0.00012343197886366397
exhibit O 0 9.492529898125213e-06
smaller O 0 3.855322574963793e-06
and O 0 1.4517194131258293e-06
slower O 0 1.7778687833924778e-05
Ca2 O 0 1.1807254850282334e-05
+ O 0 3.84234726880095e-06
responses O 0 1.2004184100078419e-06
upon O 0 7.201273888313153e-07
triggering O 0 6.077332272980129e-06
by O 0 4.688708656885865e-07
acetylcholine O 0 1.1016501048288774e-05
or O 0 9.858453040578752e-07
high O 0 6.488351573352702e-06
external O 0 3.838363409158774e-05
K O 0 0.00032286683563143015
+ O 0 8.35523460409604e-05
. O 0 1.90495811693836e-05

In O 0 5.9966507251374424e-05
addition O 0 8.043313755479176e-06
, O 0 1.7393700773027376e-06
we O 0 6.748874170625641e-07
observed O 0 7.591994517497369e-07
that O 0 1.1545110112365364e-07
these O 0 1.7948951835933258e-07
Ca2 O 0 1.0896227649936918e-05
+ O 0 1.1637790521490388e-05
transients O 0 4.9320238758809865e-05
partially O 0 3.098751767538488e-05
result O 0 5.290326612339413e-07
from O 0 1.3575548507560597e-07
an O 0 1.4207824960976723e-07
influx O 0 3.978223332978814e-07
of O 0 1.5860302937653614e-07
extracellular O 0 3.486989953671582e-06
Ca2 O 0 1.0905033377639484e-05
+ O 0 2.8779909371223766e-06
through O 0 4.5441964857673156e-07
the O 0 8.709586154509452e-07
l O 0 3.3530981454532593e-05
- O 0 1.3536943697545212e-05
type O 0 9.886540283332579e-06
Ca2 O 0 4.9393765948479995e-05
+ O 0 3.956200089305639e-05
channel O 0 6.226822006283328e-05
. O 0 2.0070099708391353e-05

Neither O 0 0.00015287339920178056
the O 0 2.2520296170114307e-06
content O 0 1.7352676877635531e-06
nor O 0 6.676115162917995e-07
the O 0 1.6738196961796348e-07
activity O 0 4.179057953024312e-07
of O 0 3.3074402949750947e-07
Na O 0 2.738573675742373e-05
+ O 0 9.723245057102758e-06
/ O 0 7.612587069161236e-06
K O 0 2.02549545065267e-05
+ O 0 1.1005749001924414e-05
ATPase O 0 3.803267463808879e-05
and O 0 3.5608916277851677e-06
sarcoplasmic O 0 0.00034705601865425706
reticulum O 0 0.0002028377930400893
Ca2 O 0 5.89152768952772e-05
+ O 0 3.351742998347618e-05
- O 0 4.353389158495702e-05
ATPase O 0 7.55388755351305e-05
are O 0 6.575131692443392e-07
affected O 0 2.7173173293704167e-06
by O 0 1.782684080353647e-06
DMPK O 0 0.0018294983310624957
absence O 0 3.767738598980941e-05
. O 0 2.0947745724697597e-05

In O 0 3.1767634936841205e-05
conclusion O 0 8.159355274983682e-06
, O 0 1.0925120932370191e-06
our O 0 7.180481134128058e-07
data O 0 1.3771618796454277e-06
suggest O 0 7.07892013451783e-07
that O 0 2.3664480863772042e-07
DMPK O 0 0.00022732908837497234
is O 0 1.9356741631781915e-07
involved O 0 2.7523839207788114e-07
in O 0 1.9048431454393722e-07
modulating O 0 6.149837190605467e-06
the O 0 2.485248842276633e-07
initial O 0 5.739856874242832e-07
events O 0 3.466861642209551e-07
of O 0 2.0055017557751853e-07
excitation O 0 1.0742297490651254e-05
- O 0 0.0005732091958634555
contraction O 0 3.9262718928512186e-05
coupling O 0 2.5619377993280068e-05
in O 0 6.610935542994412e-06
skeletal O 0 0.19051766395568848
muscle O 0 0.015512258745729923
. O 0 7.569859008071944e-06
. O 0 1.7590171410120092e-05

Constitutional O 0 0.0009490361553616822
RB1 O 0 0.18442964553833008
- O 0 0.0007109524449333549
gene O 0 7.101683149812743e-05
mutations O 0 5.021377728553489e-05
in O 0 6.9478237492148764e-06
patients O 0 0.00011408147111069411
with O 0 8.33837748359656e-06
isolated O 0 0.00041217482066713274
unilateral B-Disease 0 0.00034729583421722054
retinoblastoma I-Disease 0 0.1599593609571457
. O 0 9.67493760981597e-05

In O 0 6.291007593972608e-05
most O 0 1.1999595699307974e-05
patients O 0 0.00013554017641581595
with O 0 2.965419980682782e-06
isolated O 0 0.00012312448234297335
unilateral B-Disease 0 0.00012661225628107786
retinoblastoma I-Disease 1 0.5560149550437927
, O 0 2.0024273908347823e-05
tumor B-Disease 0 0.0029308085795491934
development O 0 4.603026582117309e-07
is O 0 1.4838471429357014e-07
initiated O 0 4.661658294935478e-07
by O 0 1.3957811972886702e-07
somatic O 0 5.945174962107558e-06
inactivation O 0 5.771117139374837e-05
of O 0 1.6590826135143288e-07
both O 0 3.691472159061959e-07
alleles O 0 1.8101599152942072e-06
of O 0 3.6665019820247835e-07
the O 0 1.3828098417434376e-05
RB1 O 0 0.007063832134008408
gene O 0 4.526549673755653e-05
. O 0 1.8540886230766773e-05

However O 0 4.3698262743419036e-05
, O 0 1.4908642924638116e-06
some O 0 1.4988762586654047e-07
of O 0 1.5162885347308475e-07
these O 0 3.919637094895734e-07
patients O 0 1.0519686838961206e-05
can O 0 9.53766175371129e-07
transmit O 0 0.007320234552025795
retinoblastoma B-Disease 0 0.2443046271800995
predisposition O 0 0.0018166820518672466
to O 0 4.661961611418519e-06
their O 0 4.133563197683543e-05
offspring O 0 0.000192682578926906
. O 0 1.6665337170707062e-05

To O 0 1.5117796465347055e-05
determine O 0 5.245861302682897e-06
the O 0 7.841786668905115e-07
frequency O 0 2.7809714993054513e-06
and O 0 7.313268497455283e-07
nature O 0 3.95730978652864e-07
of O 0 1.6056368679073785e-07
constitutional O 0 5.671531198458979e-06
RB1 O 0 0.009098908863961697
- O 0 0.00017902096442412585
gene O 0 1.5964989870553836e-05
mutations O 0 1.4295806067821104e-05
in O 0 2.8546494377224008e-06
patients O 0 4.3595748138614e-05
with O 0 3.0085557227721438e-06
isolated O 0 6.16805991739966e-05
unilateral B-Disease 0 3.766926602111198e-05
retinoblastoma I-Disease 0 0.0056480541825294495
, O 0 2.143737674487056e-06
we O 0 6.126406333351042e-07
analyzed O 0 1.2669382840613252e-06
DNA O 0 1.8070104488288052e-06
from O 0 6.309719537966885e-07
peripheral O 0 7.185299909906462e-05
blood O 0 7.115593325579539e-05
and O 0 4.1036828406504355e-06
from O 0 1.2160254300397355e-05
tumor B-Disease 0 0.0940612182021141
tissue O 0 0.010631886310875416
. O 0 4.388494198792614e-05

The O 0 2.7581261747400276e-05
analysis O 0 1.0954438948829193e-05
of O 0 4.2197093534923624e-06
tumors B-Disease 1 0.999991774559021
from O 0 5.512829375220463e-06
54 O 0 3.828259286819957e-05
( O 0 9.459215561946621e-07
71 O 0 7.776216079946607e-06
% O 0 6.874203677398327e-07
) O 0 1.029887499726101e-07
of O 0 9.297232850258297e-08
76 O 0 8.895523933460936e-06
informative O 0 1.3198457054386381e-05
patients O 0 0.0004030060372315347
showed O 0 0.0001019821283989586
loss O 0 1.2958247680217028e-05
of O 0 6.715667950629722e-07
constitutional O 0 1.4724117136211134e-05
heterozygosity O 0 0.030186332762241364
( O 0 1.8727245333138853e-05
LOH O 1 0.99974125623703
) O 0 5.788015187135898e-06
at O 0 4.350998642621562e-05
intragenic O 0 0.0006726431311108172
loci O 0 8.422895916737616e-05
. O 0 1.666708521952387e-05

Three O 0 4.4719097786583006e-05
of O 0 8.519166840414982e-06
13 O 0 9.543656778987497e-05
uninformative O 0 0.1884952187538147
patients O 0 0.007345099467784166
had O 0 8.588484342908487e-05
constitutional O 0 2.431493703625165e-05
deletions O 0 0.00019340598373673856
. O 0 5.212267569731921e-05

For O 0 2.723686702665873e-05
39 O 0 4.476735193748027e-05
randomly O 0 2.0099269022466615e-05
selected O 0 1.716555743769277e-05
tumors B-Disease 1 0.9999836683273315
, O 0 4.768676262756344e-06
SSCP O 0 0.0009460569708608091
, O 0 2.4377684439969016e-06
hetero O 0 3.091502730967477e-05
- O 0 2.0533816496026702e-05
duplex O 0 0.001000313786789775
analysis O 0 1.196822154270194e-06
, O 0 2.772270590867265e-07
sequencing O 0 1.254539938599919e-06
, O 0 2.4337492732229293e-07
and O 0 1.327700260844722e-07
Southern O 0 6.196955837367568e-07
blot O 0 4.352375617600046e-05
analysis O 0 8.167367582245788e-07
were O 0 1.049985371537332e-06
used O 0 7.9574260780646e-07
to O 0 2.402239033472142e-06
identify O 0 5.227259680395946e-05
mutations O 0 6.33357121841982e-05
. O 0 1.1770310266001616e-05

Mutations O 0 0.0013388071674853563
were O 0 4.75020133308135e-05
detected O 0 4.260060450178571e-05
in O 0 1.7798879525798839e-06
21 O 0 9.200127351505216e-06
( O 0 4.5962758576933993e-07
91 O 0 2.1259231743897544e-06
% O 0 5.152688231646607e-07
) O 0 2.4761948225204833e-07
of O 0 5.683978088200092e-07
23 O 0 0.01815989427268505
tumors B-Disease 1 0.9999995231628418
with O 0 0.0013211248442530632
LOH O 1 0.999994158744812
. O 0 9.866971231531352e-05

In O 0 4.665948654292151e-05
6 O 0 3.597855175030418e-05
( O 0 1.4254338793762145e-06
38 O 0 2.5171427751047304e-06
% O 0 5.014458679397649e-07
) O 0 1.2699985063591157e-07
of O 0 2.4085397853923496e-07
16 O 0 0.008991910144686699
tumors B-Disease 1 1.0
without O 0 0.000586050795391202
LOH O 1 0.9997692704200745
, O 0 1.3100717524139327e-06
one O 0 3.2482972756042727e-07
mutation O 0 2.954179990410921e-06
was O 0 1.2312750186538324e-05
detected O 0 1.169514416687889e-05
, O 0 2.6617223625180486e-07
and O 0 3.2054700227490684e-07
in O 0 6.857742960164614e-07
9 O 0 2.123172816936858e-05
( O 0 2.418171618501219e-07
56 O 0 1.4051531707082177e-06
% O 0 2.0229049368936103e-07
) O 0 5.893866017459004e-08
of O 0 5.990392537569278e-08
the O 0 4.486347097554244e-05
tumors B-Disease 1 1.0
without O 0 0.002552902791649103
LOH O 1 0.9999711513519287
, O 0 1.3954499991086777e-06
both O 0 8.704354854671692e-07
mutations O 0 1.800119389372412e-05
were O 0 6.7746173044724856e-06
found O 0 1.3250077245174907e-05
. O 0 1.27041494124569e-05

Thus O 0 9.906446211971343e-05
, O 0 4.525514668785036e-06
a O 0 1.0549175613050465e-06
total O 0 3.370711851857777e-07
of O 0 1.4944087922685867e-07
45 O 0 2.6986663215211593e-06
mutations O 0 7.074404493323527e-06
were O 0 4.202424406685168e-06
identified O 0 4.877806077274727e-06
in O 0 4.916587840853026e-06
tumors B-Disease 1 0.9999923706054688
of O 0 1.7995159851125209e-06
36 O 0 0.0008264946518465877
patients O 0 0.00022664928110316396
. O 0 1.6091753423097543e-05

Thirty O 0 0.0005359248607419431
- O 0 0.00015102796896826476
nine O 0 6.516640496556647e-06
of O 0 6.899562094986322e-07
the O 0 9.613822840037756e-07
mutations O 0 5.47106037629419e-06
- O 0 5.473915734910406e-06
including O 0 4.431257707437908e-07
34 O 0 3.532769596858998e-06
small O 0 9.820975037655444e-07
mutations O 0 8.306075869768392e-06
, O 0 2.531471068323299e-07
2 O 0 4.4041931346328056e-07
large O 0 5.399351721280254e-07
structural O 0 3.9126847696024925e-05
alterations O 0 0.00010336239211028442
, O 0 1.930023927343427e-06
and O 0 1.4518897160087363e-06
hypermethylation O 0 9.382540156366304e-05
in O 0 6.970667982386658e-06
3 O 0 0.004364943131804466
tumors O 1 0.9999996423721313
- O 0 0.02445211447775364
were O 0 3.0455492378678173e-05
not O 0 5.079231755189539e-07
detected O 0 2.3372062969428953e-06
in O 0 1.437291814454511e-07
the O 0 2.77852507224452e-07
corresponding O 0 2.1721000393881695e-06
peripheral O 0 0.00017663900507614017
blood O 0 0.00048534272355027497
DNA O 0 0.00019878734019584954
. O 0 2.2018779418431222e-05

In O 0 9.390255581820384e-05
6 O 0 9.744973067427054e-05
( O 0 2.362561190238921e-06
17 O 0 3.043900278498768e-06
% O 0 4.999107545700099e-07
) O 0 9.345698970264493e-08
of O 0 7.058837780959948e-08
the O 0 8.378308393730549e-07
36 O 0 3.480105078779161e-05
patients O 0 1.5402711142087355e-05
, O 0 2.917459198670258e-07
a O 0 1.744187215990678e-06
mutation O 0 1.0212556844635401e-05
was O 0 1.8966431525768712e-05
detected O 0 6.907680472068023e-06
in O 0 2.466352952978923e-07
constitutional O 0 3.816880962403957e-07
DNA O 0 8.573987543059047e-06
, O 0 2.9835041459591594e-07
and O 0 1.8560403702849726e-07
1 O 0 1.4958231986383907e-07
of O 0 3.595187081373297e-08
these O 0 1.5724560853414005e-07
mutations O 0 1.914582753670402e-06
is O 0 1.2095594570382673e-07
known O 0 1.9123751826555235e-07
to O 0 2.9584779781544057e-07
be O 0 6.560224505847145e-07
associated O 0 8.370241744160012e-07
with O 0 1.8524183360568713e-06
reduced O 0 4.6402037696680054e-05
expressivity O 0 0.02177225798368454
. O 0 3.195821409462951e-05

The O 0 1.9997936760773882e-05
presence O 0 6.489391125796828e-06
of O 0 6.524636546600959e-07
a O 0 1.2985410648980178e-06
constitutional O 0 1.9291940134280594e-06
mutation O 0 2.107611180690583e-05
was O 0 0.00017782600480131805
not O 0 5.928422410761414e-07
associated O 0 3.663810446141724e-07
with O 0 1.5552454613043665e-07
an O 0 3.501251057969057e-07
early O 0 4.051717496622587e-06
age O 0 3.082626426476054e-05
at O 0 8.970712951850146e-05
treatment O 0 8.824349060887471e-05
. O 0 2.1963962353765965e-05

In O 0 5.142215741216205e-05
1 O 0 3.356886372785084e-05
patient O 0 6.0654001572402194e-05
, O 0 9.360271064906556e-07
somatic O 0 3.217941412003711e-05
mosaicism O 0 0.0009626146638765931
was O 0 4.067634290549904e-05
demonstrated O 0 2.8792921966669383e-06
by O 0 2.2138478072974976e-07
molecular O 0 2.493560941729811e-06
analysis O 0 4.502619788127049e-07
of O 0 2.0527750166365877e-07
DNA O 0 9.037632480612956e-06
and O 0 2.314354560439824e-06
RNA O 0 7.730239303782582e-06
from O 0 3.3020521641446976e-06
peripheral O 0 0.001119940890930593
blood O 0 0.0012646423419937491
. O 0 3.963382914662361e-05

In O 0 0.00014182903396431357
2 O 0 0.00016224756836891174
patients O 0 0.00016364248585887253
without O 0 1.9476935904094717e-06
a O 0 1.3503179161489243e-06
detectable O 0 9.001682337839156e-05
mutation O 0 5.9954268181172665e-06
in O 0 1.1961603831878165e-06
peripheral O 0 0.0016237724339589477
blood O 0 0.008808135986328125
, O 0 3.7311626783775864e-06
mosaicism O 0 0.00482016010209918
was O 0 0.0005670596729032695
suggested O 0 2.1328846742108e-06
because O 0 3.372004471202672e-07
1 O 0 1.7298732757353719e-07
of O 0 6.652776818327766e-08
the O 0 1.8014424085777136e-06
patients O 0 0.0010079332860186696
showed O 0 0.00866686087101698
multifocal O 1 0.999536395072937
tumors B-Disease 1 1.0
and O 0 9.200066415360197e-06
the O 0 5.948538159827876e-07
other O 0 1.3183445446429687e-07
later O 0 2.458983317410457e-06
developed O 0 6.022830802976387e-06
bilateral B-Disease 0 2.0940453396178782e-05
retinoblastoma I-Disease 0 0.045766934752464294
. O 0 4.707819243776612e-05

In O 0 3.774855940719135e-05
conclusion O 0 8.931131560530048e-06
, O 0 1.619382942408265e-06
our O 0 1.0328417374694254e-06
results O 0 1.250697096111253e-06
emphasize O 0 1.5668559854020714e-06
that O 0 1.1880653261187035e-07
the O 0 2.2455476766936044e-07
manifestation O 0 1.0720104910433292e-06
and O 0 5.441709731712763e-07
transmissibility O 0 4.747647835756652e-06
of O 0 2.385267521276546e-07
retinoblastoma B-Disease 0 0.0001436925958842039
depend O 0 1.0363986575612216e-06
on O 0 5.231804607319646e-07
the O 0 1.7588266132406716e-07
nature O 0 1.0652866677673956e-07
of O 0 2.43896707274871e-08
the O 0 1.6137207126121211e-07
first O 0 9.872350119621842e-07
mutation O 0 2.2956651264394168e-06
, O 0 8.005260099253064e-08
its O 0 7.07396026200513e-08
time O 0 1.6704804295386566e-07
in O 0 9.911511966720354e-08
development O 0 1.767538435615279e-07
, O 0 1.345586895240558e-07
and O 0 1.2031537721668428e-07
the O 0 7.098153531615026e-08
number O 0 6.883217906761274e-08
and O 0 1.2508861857440934e-07
types O 0 1.741770603302939e-07
of O 0 1.242159441972035e-07
cells O 0 2.2719771095580654e-06
that O 0 1.0309133813279914e-07
are O 0 1.663672577478792e-07
affected O 0 1.3321016467671143e-06
. O 0 1.0198890549872885e-06
. O 0 6.445747203542851e-06

Hereditary B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9999637603759766
of I-Disease 0 6.5709273258107714e-06
the I-Disease 0 3.6304520563135156e-06
fifth I-Disease 0 2.0131939891143702e-05
component I-Disease 0 2.5840722628345247e-06
of I-Disease 0 3.2116386705638433e-07
complement I-Disease 0 4.005005848739529e-06
in O 0 2.952847580672824e-06
man O 0 0.00010760207806015387
. O 0 1.0026727068179753e-05

I O 0 0.011685876175761223
. O 0 0.0004955304902978241

Clinical O 0 0.0969678983092308
, O 0 4.8013822379289195e-05
immunochemical O 0 0.0024487366899847984
, O 0 3.5960488276032265e-06
and O 0 3.836576979665551e-06
family O 0 2.845947165042162e-05
studies O 0 9.270745977119077e-06
. O 0 1.803915438358672e-05

The O 0 2.567098090366926e-05
first O 0 1.0590862075332552e-05
recognized O 0 7.427298896800494e-06
human O 0 3.2023365292843664e-06
kindred O 0 0.00035909897997044027
with O 0 0.00038713644607923925
hereditary B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9992903470993042
of I-Disease 0 5.649483796332788e-07
the I-Disease 0 1.6118608527904144e-06
fifth I-Disease 0 3.0241842978284694e-05
component I-Disease 0 3.4273448363819625e-06
of I-Disease 0 3.3865748605421686e-07
complement I-Disease 0 1.2735908057948109e-05
( O 0 1.8507339518691879e-06
C5 O 0 0.0005852397880516946
) O 0 9.136136895904201e-07
is O 0 1.250666059604555e-06
described O 0 1.999349296966102e-05
. O 0 1.4357864529301878e-05

The O 0 3.75673444068525e-05
proband O 0 0.0005050589679740369
, O 0 2.6785799036588287e-06
a O 0 1.3580718132288894e-06
20 O 0 3.1024501367937773e-06
- O 0 2.706829400267452e-05
year O 0 1.4229782436814276e-06
- O 0 2.803831193887163e-05
old O 0 4.85942218801938e-05
black O 0 3.070178354391828e-05
female O 0 9.470360237173736e-05
with O 0 0.08920837193727493
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.00026175574748776853
age O 0 7.342934259213507e-05
11 O 0 1.317715214099735e-05
, O 0 1.316859766120615e-06
lacked O 0 5.605861224466935e-05
serum O 0 0.003920685034245253
hemolytic O 0 0.0391976460814476
complement O 0 5.378397418098757e-06
activity O 0 2.254868604723015e-06
, O 0 7.679047371311754e-07
even O 0 1.4410184121516068e-06
during O 0 2.2553787857759744e-05
remission O 0 0.0006794276996515691
. O 0 2.45082064793678e-05

C5 O 0 0.037941113114356995
was O 0 0.0010586052667349577
undetectable O 0 0.0003451403172221035
in O 0 4.067122063133866e-06
her O 0 4.367897781776264e-05
serum O 0 0.0001096216292353347
by O 0 7.869535920690396e-07
both O 0 1.5394222145914682e-06
immunodiffusion O 0 0.0024748281575739384
and O 0 5.635716297547333e-05
hemolytic O 1 0.741195797920227
assays O 0 0.0005454713245853782
. O 0 4.0211365558207035e-05

Other O 0 8.543321200704668e-06
complement O 0 1.2301986316742841e-05
components O 0 8.134733434417285e-06
were O 0 4.101010745216627e-06
normal O 0 2.911699084506836e-06
during O 0 7.878293217800092e-06
remission O 0 0.00014380060019902885
of O 0 1.8461507806932786e-06
lupus O 1 0.6678951382637024
, O 0 2.3653362859477056e-06
but O 0 1.9713809251697967e-06
C1 O 0 0.0855918675661087
, O 0 1.1769847105824738e-06
C4 O 0 0.0006636634352616966
, O 0 2.3043555756885326e-06
C2 O 0 0.0009425563039258122
, O 0 7.679603868382401e-07
and O 0 1.4245804322854383e-06
C3 O 0 0.0022129970602691174
levels O 0 1.2180635167169385e-05
fell O 0 0.0001801208854885772
during O 0 2.0521776605164632e-05
exacerbations O 0 0.006365020759403706
. O 0 3.3087235351558775e-05

A O 0 0.00012802710989490151
younger O 0 9.290819434681907e-05
half O 0 1.2264956239960156e-05
- O 0 6.092147305025719e-05
sister O 0 0.00017902061517816037
, O 0 8.956480428423674e-07
who O 0 4.001279648946365e-06
had O 0 4.5378299546428025e-05
no O 0 1.2033838174829725e-05
underlying O 0 0.01050855964422226
disease O 0 0.17202576994895935
, O 0 2.3783493361406727e-06
was O 0 7.959251524880528e-05
also O 0 1.3852945812686812e-06
found O 0 9.868914503385895e-07
to O 0 9.455238796363119e-07
lack O 0 1.5406354577862658e-05
immunochemically O 0 0.006065563298761845
detectable O 0 0.001035246648825705
C5 O 0 0.0015337689546868205
. O 0 3.0655621230835095e-05

By O 0 0.00012588381650857627
hemolytic O 1 0.9787993431091309
assay O 0 0.003430659882724285
, O 0 1.7124988517025486e-05
she O 0 3.73913899238687e-05
exhibited O 0 1.4690624993818346e-05
1 O 0 1.1940177273572772e-06
- O 0 7.031732820905745e-06
2 O 0 6.208881018210377e-07
% O 0 8.731827705332762e-08
of O 0 4.6600753478287515e-08
the O 0 2.704375958728633e-07
normal O 0 4.640890892915195e-06
serum O 0 9.334208152722567e-05
C5 O 0 4.2746814870042726e-05
level O 0 1.0707036608437193e-06
and O 0 7.417534106934909e-07
normal O 0 1.7602792468096595e-06
concentrations O 0 1.9219130535930162e-06
of O 0 1.3376273955145734e-07
other O 0 3.1542421652375197e-07
complement O 0 5.704250725102611e-06
components O 0 2.938951729447581e-05
. O 0 2.3825741664040834e-05

C5 O 0 0.009224304929375648
levels O 0 4.399493263917975e-05
of O 0 8.859212243805814e-07
other O 0 4.752123743401171e-07
family O 0 2.4272644623124506e-06
members O 0 3.357135653914156e-07
were O 0 1.2158062645539758e-06
either O 0 4.5207252696854994e-07
normal O 0 1.0320510455130716e-06
or O 0 3.067192722028267e-07
approximately O 0 5.331366423888539e-07
half O 0 1.2285432831049548e-06
- O 0 0.00018409498443361372
normal O 0 6.040985681465827e-06
, O 0 8.550157417630544e-07
consistent O 0 5.508426056621829e-06
with O 0 4.70775648864219e-06
autosomal O 0 0.04081844165921211
codominant O 0 0.0021026665344834328
inheritance O 0 9.303756087319925e-06
of O 0 3.876603500430065e-07
the O 0 4.099899797438411e-06
gene O 0 0.00016333819075953215
determining O 0 0.11624708026647568
C5 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999974966049194
. O 0 6.372100324369967e-05

Normal O 0 0.007215746212750673
hemolytic O 1 0.9952864050865173
titers O 0 0.04688228294253349
were O 0 0.00011711963452398777
restored O 0 2.792341183521785e-05
to O 0 2.699392098293174e-06
both O 0 1.0136040145880543e-05
homozygous O 1 0.7463524341583252
C5 B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999874830245972
deficient I-Disease 1 0.9999998807907104
( O 0 4.955922850058414e-05
C5D B-Disease 1 0.9999992847442627
) O 0 5.0182611630589236e-06
sera O 0 9.709273399494123e-06
by O 0 2.4267637854791246e-07
addition O 0 3.0545501772394346e-07
of O 0 1.916280183422714e-07
highly O 0 3.793260475504212e-06
purified O 0 1.9610681192716584e-05
human O 0 4.472086857276736e-06
C5 O 0 0.0004534060717560351
. O 0 2.153417699446436e-05

In O 0 6.652053707512096e-05
specific O 0 2.6336183509556577e-05
C5 O 0 0.0008346412214450538
titrations O 0 0.0008758864714764059
, O 0 8.046536095207557e-06
however O 0 1.4194650930221542e-06
, O 0 3.7595549429170205e-07
it O 0 2.538941998864175e-07
was O 0 4.618655111698899e-06
noted O 0 3.3611621574891615e-07
that O 0 7.927478407054878e-08
when O 0 2.9777288546029013e-07
limited O 0 2.316248099987206e-07
amounts O 0 1.7718794254051318e-07
of O 0 1.2155716433426278e-07
C5 O 0 0.00011555029777809978
were O 0 3.5912646580982255e-06
assayed O 0 9.922831850417424e-06
in O 0 1.7652878625540325e-07
the O 0 1.6162927352070255e-07
presence O 0 1.877533719607527e-07
of O 0 1.0902935088097365e-07
low O 0 9.798684004636016e-06
dilutions O 0 1.3079122254566755e-05
of O 0 6.269142431847285e-07
either O 0 8.39471904328093e-05
C5D B-Disease 1 0.9999991655349731
serum O 0 0.02785762958228588
, O 0 9.902062174660387e-07
curving O 0 3.450545136729488e-06
rather O 0 4.014073908820137e-07
than O 0 1.1549977330105321e-07
linear O 0 6.834473538219754e-07
dose O 0 6.268619472393766e-06
- O 0 1.5187275494099595e-05
response O 0 1.088622298084374e-06
plots O 0 2.4872574613254983e-06
were O 0 6.661609859293094e-06
consistently O 0 9.172758836939465e-06
obtained O 0 1.354548430754221e-06
, O 0 3.2853651532605e-07
suggesting O 0 1.0052837069451925e-06
some O 0 3.2302872909895086e-07
inhibitory O 0 1.6620073438389227e-05
effect O 0 8.023272130230907e-06
. O 0 9.211382348439656e-06

Further O 0 6.918395956745371e-05
studies O 0 1.8808592358254828e-05
suggested O 0 9.093472726817708e-06
that O 0 1.1666531918308465e-06
low O 0 1.4904997442499734e-05
dilutions O 0 8.281480404548347e-05
of O 0 3.880104941345053e-06
C5D B-Disease 1 0.9999996423721313
serum O 0 0.1845879852771759
contain O 0 7.601081506436458e-06
a O 0 5.28078726347303e-06
factor O 0 2.8786664643121185e-06
( O 0 2.7296027838019654e-07
or O 0 5.038589847572439e-07
factors O 0 2.765315514352551e-07
) O 0 1.3513958663224912e-07
interfering O 0 6.391497890945175e-07
at O 0 1.8043137970380485e-06
some O 0 8.889436742265389e-08
step O 0 8.498876695739455e-07
in O 0 2.3566423124066205e-07
the O 0 2.209826106991386e-06
hemolytic O 0 0.05898262932896614
assay O 0 1.775628697942011e-05
of O 0 7.132297810130694e-07
C5 O 0 0.0018410970224067569
, O 0 6.085737709327077e-07
rather O 0 3.1704672665000544e-07
than O 0 1.2454226805402868e-07
a O 0 1.1102057442258229e-06
true O 0 4.178686140221544e-06
C5 O 0 0.00023510937171522528
inhibitor O 0 3.0128969228826463e-05
or O 0 9.651721484260634e-06
inactivator O 0 0.0008289499091915786
. O 0 2.3414821043843403e-05

Of O 0 3.477952122921124e-05
clinical O 0 0.0006345114670693874
interest O 0 5.998458618705627e-06
are O 0 6.99902443557221e-07
( O 0 2.2358483420248376e-07
a O 0 9.289360036746075e-07
) O 0 2.0866370675776125e-07
the O 0 2.380313759431374e-07
documentation O 0 2.5661204290372552e-06
of O 0 2.747765392996371e-06
membranous O 1 0.9993278980255127
glomerulonephritis B-Disease 1 1.0
, O 0 0.1664237082004547
vasculitis B-Disease 1 1.0
, O 0 0.022818438708782196
and O 1 0.657575249671936
arthritis B-Disease 1 1.0
in O 0 1.474167947890237e-05
an O 0 5.641742973239161e-06
individual O 0 2.8290598947933177e-06
lacking O 0 3.823304723482579e-05
C5 O 0 0.0006195893511176109
( O 0 2.5298299988207873e-07
and O 0 1.9109494076019473e-07
its O 0 3.859803712202847e-07
biologic O 0 2.5198251023539342e-05
functions O 0 8.66519599185267e-07
) O 0 3.084784907514404e-07
, O 0 1.6490895404785988e-07
and O 0 6.060115538275568e-07
( O 0 4.237701602960442e-07
b O 0 6.780422154406551e-06
) O 0 8.99554279953918e-08
a O 0 2.6676889319787733e-07
remarkable O 0 3.3274457109655486e-06
propensity O 0 0.00019766580953728408
to O 0 0.0002543098235037178
bacterial B-Disease 1 0.9999908208847046
infections I-Disease 1 0.9999938011169434
in O 0 4.721774985227967e-06
the O 0 2.839880608007661e-06
proband O 0 0.002107270061969757
, O 0 4.896299969914253e-07
even O 0 3.232370318073663e-07
during O 0 6.434223109863524e-07
periods O 0 4.92499793836032e-07
of O 0 1.6179753004053055e-07
low O 0 2.4315586415468715e-05
- O 0 7.064870442263782e-05
dose O 0 6.626614322158275e-06
or O 0 6.773918244107335e-07
alternate O 0 1.5204893770714989e-06
- O 0 5.3650208428734913e-05
day O 0 9.29800808080472e-06
corticosteroid O 0 0.001874251407571137
therapy O 0 0.0006668360438197851
. O 0 2.8182694222778082e-05

Other O 0 1.301099928241456e-05
observations O 0 2.3658512873225845e-05
indicate O 0 1.3013356692681555e-05
that O 0 6.345484848679916e-07
the O 0 2.541228923291783e-06
C5D B-Disease 1 0.9999877214431763
state O 0 6.990945848883712e-07
is O 0 1.4304204398740694e-07
compatible O 0 6.366318530126591e-07
with O 0 6.74095588237833e-07
normal O 0 8.745369996177033e-06
coagulation O 0 1.0246409146930091e-05
function O 0 1.0020428362622624e-06
and O 0 5.696448965863965e-07
the O 0 3.775875256906147e-07
capacity O 0 7.163313853197906e-07
to O 0 4.149250685259176e-07
mount O 0 2.4562677936046384e-05
a O 0 1.9409757442190312e-05
neutrophilic O 0 0.1741178333759308
leukocytosis O 0 0.11429895460605621
during O 0 0.00030421421979554
pyogenic B-Disease 1 0.980107307434082
infection I-Disease 0 0.35616379976272583
. O 0 1.0653335266397335e-05
. O 0 3.1213636248139665e-05

Susceptibility O 0 0.35553234815597534
to O 0 0.009382274933159351
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.28616300225257874
twins O 1 0.9845368266105652
: O 0 1.1733121709767147e-06
the O 0 3.2657163728799787e-07
role O 0 4.1931383520932286e-07
of O 0 1.4547418913934962e-07
genes O 0 2.5689266749395756e-06
, O 0 1.248175749424263e-06
HLA O 0 5.163093373994343e-05
, O 0 6.305369879555656e-07
and O 0 8.706056746632385e-07
the O 0 1.532099190626468e-06
environment O 0 1.217889348481549e-05
. O 0 7.86319014878245e-06

OBJECTIVE O 0 0.0001879305054899305
To O 0 1.0314054634363856e-05
determine O 0 8.318680556840263e-06
the O 0 1.2268011460037087e-06
relative O 0 5.370518920244649e-06
effects O 0 4.9036170821636915e-06
of O 0 4.2495349816817907e-07
genetic O 0 3.344159631524235e-05
and O 0 5.122524271428119e-06
environmental O 0 6.398092864401406e-06
factors O 0 1.561057160870405e-06
in O 0 2.723403667914681e-06
susceptibility O 0 0.003557015210390091
to O 0 0.039897236973047256
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.004346116911619902
AS B-Disease 1 0.9465140104293823
) O 0 7.388393896690104e-06
. O 0 9.068151484825648e-06

METHODS O 0 0.0010775363771244884
Twins O 0 0.39773547649383545
with O 0 1.6849338862812147e-05
AS B-Disease 0 0.367386132478714
were O 0 1.1830405128421262e-05
identified O 0 1.8875098248827271e-06
from O 0 2.2859555315335456e-07
the O 0 4.7093720922930515e-07
Royal O 0 0.00015584468201268464
National O 0 3.031689084309619e-05
Hospital O 0 0.2609259784221649
for O 0 0.0001333340333076194
Rheumatic B-Disease 1 0.9999997615814209
Diseases I-Disease 1 0.9586617946624756
database O 0 0.00012186264939373359
. O 0 3.365984230185859e-05

Clinical O 0 0.020068665966391563
and O 0 6.541627953993157e-05
radiographic O 0 0.0028997131157666445
examinations O 0 0.002406192012131214
were O 0 7.941737567307428e-05
performed O 0 5.341996075003408e-05
to O 0 2.3023696940072114e-06
establish O 0 8.944763976614922e-05
diagnoses O 1 0.7074076533317566
, O 0 3.573154390323907e-05
and O 0 0.007156005594879389
disease O 1 0.9791208505630493
severity O 0 0.3031911551952362
was O 0 0.006086913403123617
assessed O 0 5.7716006267583e-06
using O 0 8.050942028603458e-07
a O 0 1.433690272278909e-06
combination O 0 2.540729838074185e-06
of O 0 6.032070132278022e-07
validated O 0 6.531018880195916e-05
scoring O 0 3.797751560341567e-05
systems O 0 0.00011414392793085426
. O 0 2.549356759118382e-05

HLA O 0 0.006324970629066229
typing O 0 0.0011549829505383968
for O 0 1.9045546650886536e-05
HLA O 0 0.0003352602943778038
- O 0 0.00015524725313298404
B27 O 0 8.075766527326778e-05
, O 0 2.6614429771143477e-06
HLA O 0 2.8794383979402483e-05
- O 0 2.422106990707107e-05
B60 O 0 1.7312844647676684e-05
, O 0 6.36605761883402e-07
and O 0 6.144387612039282e-07
HLA O 0 3.341619230923243e-05
- O 0 9.57719748839736e-05
DR1 O 0 0.20221886038780212
was O 0 3.092172119067982e-05
performed O 0 4.570657438307535e-06
by O 0 3.3211861705240153e-07
polymerase O 0 7.138352884794585e-06
chain O 0 1.733164390316233e-05
reaction O 0 6.371997756104975e-07
with O 0 3.3638207241892815e-07
sequence O 0 1.2084080935892416e-06
- O 0 2.4256166852865135e-06
specific O 0 3.5003029097424587e-07
primers O 0 1.199411508423509e-05
, O 0 7.256577418957022e-07
and O 0 1.9886399513779907e-06
zygosity O 0 0.0006203335942700505
was O 0 2.5367338821524754e-05
assessed O 0 6.160297289170558e-06
using O 0 4.797582732862793e-06
microsatellite O 0 0.00040180800715461373
markers O 0 0.00040732102934271097
. O 0 3.272291723988019e-05

Genetic O 0 0.0023354918230324984
and O 0 3.9329155697487295e-05
environmental O 0 1.71365900314413e-05
variance O 0 4.713955604529474e-06
components O 0 2.1249350538710132e-05
were O 0 1.046972374751931e-05
assessed O 0 2.8698016194539377e-06
with O 0 3.188059167769097e-07
the O 0 5.014334192310343e-07
program O 0 2.0518407382041914e-06
Mx O 0 5.761010106652975e-05
, O 0 3.033543976016517e-07
using O 0 3.415633500480908e-07
data O 0 8.558903346056468e-07
from O 0 1.075219842050501e-07
this O 0 4.2985689674424066e-08
and O 0 2.5843729645202984e-07
previous O 0 3.338159046961664e-07
studies O 0 1.848760433631469e-07
of O 0 2.949221027392923e-07
twins O 0 0.00910020712763071
with O 0 3.3056282973120688e-06
AS B-Disease 0 0.48715895414352417
. O 0 1.979066655621864e-05

RESULTS O 0 0.0005599107826128602
Six O 0 1.7271533579332754e-05
of O 0 3.0633768801635597e-06
8 O 0 3.056434070458636e-05
monozygotic O 0 0.0002988663036376238
( O 0 9.08617403183598e-06
MZ O 1 0.9647594094276428
) O 0 4.432214609551011e-06
twin O 0 0.00329469027929008
pairs O 0 9.50356261455454e-05
were O 0 0.006586532574146986
disease O 0 0.034444864839315414
concordant O 0 3.288684820290655e-05
, O 0 1.1126390973004163e-06
compared O 0 1.1490315046103206e-06
with O 0 3.881978898334637e-07
4 O 0 8.957753721006156e-07
of O 0 1.735246542011737e-07
15 O 0 2.612578327898518e-06
B27 O 0 2.6004405299318023e-05
- O 0 3.49466827174183e-05
positive O 0 3.449531959631713e-06
dizygotic O 0 0.00015525466005783528
( O 0 2.5426472802791977e-06
DZ O 1 0.822465181350708
) O 0 1.1995119848506874e-06
twin O 0 0.00022576286573894322
pairs O 0 6.002962436468806e-06
( O 0 3.9615841274098784e-07
27 O 0 4.086810804437846e-06
% O 0 3.3082980621657043e-07
) O 0 1.0323616095320176e-07
and O 0 1.0544714257321175e-07
4 O 0 5.414005386228382e-07
of O 0 1.7038826172210975e-07
32 O 0 2.5584242393961176e-05
DZ O 1 0.9449917674064636
twin O 0 0.0060610161162912846
pairs O 0 2.5221763280569576e-05
overall O 0 2.4242604922619648e-05
( O 0 4.364546839497052e-07
12 O 0 9.06384570953378e-07
. O 0 1.4838499851066445e-07
5 O 0 9.086451768780535e-07
% O 0 1.1925951639568666e-06
) O 0 1.6467209889015066e-06
. O 0 7.219218332465971e-06

Nonsignificant O 0 0.0286615751683712
increases O 0 0.00010848296369658783
in O 0 3.769840986933559e-06
similarity O 0 4.801532668352593e-06
with O 0 5.727597454097122e-07
regard O 0 6.844662152616365e-07
to O 0 1.1254744549660245e-06
age O 0 0.0006637428305111825
at O 0 0.18374790251255035
disease O 0 0.20049357414245605
onset O 0 0.0009677052148617804
and O 0 1.9513522602210287e-06
all O 0 1.6756963816533244e-07
of O 0 2.3681570837652544e-07
the O 0 0.00020048889564350247
disease O 0 0.29938140511512756
severity O 0 0.00216122018173337
scores O 0 0.00010315030522178859
assessed O 0 2.4751685486990027e-05
were O 0 5.757505732617574e-06
noted O 0 1.4597702602259233e-06
in O 0 7.262736744451104e-06
disease O 0 0.06587827205657959
- O 0 0.022898543626070023
concordant O 0 0.012475275434553623
MZ O 1 0.9999645948410034
twins O 0 0.03248656541109085
compared O 0 1.1998474292340688e-05
with O 0 1.2062920177413616e-05
concordant O 0 0.010028472170233727
DZ O 1 0.999954104423523
twins O 0 0.1306208074092865
. O 0 7.683803414693102e-05

HLA O 0 0.013005136512219906
- O 0 0.0009436592808924615
B27 O 0 0.0002080103731714189
and O 0 4.882935172645375e-06
B60 O 0 6.761455006198958e-05
were O 0 6.306130671873689e-06
associated O 0 2.154440153390169e-06
with O 0 1.2493331951191067e-06
the O 0 1.8632885257829912e-05
disease O 0 0.011566024273633957
in O 0 1.2205275652377168e-06
probands O 0 0.009139475412666798
, O 0 8.26838800094265e-07
and O 0 2.91086706738497e-07
the O 0 1.3414675947842625e-07
rate O 0 8.326612146447587e-07
of O 0 3.012894751464046e-07
disease O 0 0.00015313673065975308
concordance O 0 5.547458931687288e-05
was O 0 0.00012759833771269768
significantly O 0 5.726915333070792e-06
increased O 0 2.0252400645404123e-06
among O 0 1.135896127379965e-06
DZ O 1 0.9776532649993896
twin O 0 0.0038510807789862156
pairs O 0 8.243591764767189e-06
in O 0 6.2665719724464e-07
which O 0 5.874914563719358e-07
the O 0 1.509593744231097e-06
co O 0 9.441326255910099e-05
- O 0 0.00010593101615086198
twin O 0 0.028750037774443626
was O 0 2.400017729087267e-05
positive O 0 3.516537105952011e-07
for O 0 2.4313757762683963e-07
both O 0 1.26291627111641e-06
B27 O 0 0.00011831261508632451
and O 0 9.946802492777351e-06
DR1 O 0 0.33787068724632263
. O 0 3.674763138405979e-05

Additive O 0 0.0008854306070134044
genetic O 0 0.0003540991456247866
effects O 0 8.311386045534164e-05
were O 0 1.0713170013332274e-05
estimated O 0 2.0251800378900953e-06
to O 0 5.285193083182094e-07
contribute O 0 9.570335350872483e-07
97 O 0 1.7717285345497658e-06
% O 0 3.954525880089932e-07
of O 0 1.367031075005798e-07
the O 0 6.492879833785992e-07
population O 0 1.3662116771229194e-06
variance O 0 9.748789125296753e-06
. O 0 1.3601932550955098e-05

CONCLUSION O 0 0.0003551569825503975
Susceptibility O 0 0.0008386871195398271
to O 0 2.1712612578994595e-05
AS B-Disease 0 0.4654017686843872
is O 0 2.3382385734294076e-06
largely O 0 2.6906075163424248e-06
genetically O 0 2.4129776647896506e-06
determined O 0 1.5902620589258731e-06
, O 0 3.309705505216698e-07
and O 0 2.819980124968424e-07
the O 0 4.4852626501779014e-07
environmental O 0 3.3591832107049413e-06
trigger O 0 1.8814727809512988e-05
for O 0 3.8334826513164444e-07
the O 0 1.545279155834578e-05
disease O 0 0.1053813248872757
is O 0 1.115909981308505e-06
probably O 0 1.0709706657507923e-05
ubiquitous O 0 6.201530050020665e-05
. O 0 2.6152481950703077e-05

HLA O 0 0.028239522129297256
- O 0 0.0013404302299022675
B27 O 0 0.00023659893486183137
accounts O 0 6.511211267934414e-06
for O 0 5.305889203555125e-07
a O 0 7.141186415537959e-07
minority O 0 6.941306196495134e-07
of O 0 1.6501813604463678e-07
the O 0 7.67750918839738e-07
overall O 0 8.190425432985649e-05
genetic O 0 0.0006398755358532071
susceptibility O 0 0.0002378070930717513
to O 0 9.827066605794244e-06
AS B-Disease 0 0.273203045129776
. O 0 2.774992935883347e-05

Cell O 0 0.004026635549962521
cycle O 0 0.0002851520257536322
- O 0 0.00011485317372716963
dependent O 0 1.4476850083156023e-05
colocalization O 0 1.787659857654944e-05
of O 0 4.2992334670088894e-07
BARD1 O 0 0.0011651481036096811
and O 0 3.417429525143234e-06
BRCA1 O 0 0.0001966876006918028
proteins O 0 1.9137848994432716e-06
in O 0 1.5943833204801194e-06
discrete O 0 1.627926030778326e-05
nuclear O 0 0.0001533110480522737
domains O 0 4.6017245040275156e-05
. O 0 2.2144244212540798e-05

Germ O 0 0.08182801306247711
- O 0 0.0018035955727100372
line O 0 9.176372259389609e-05
mutations O 0 1.797323056962341e-05
of O 0 5.63564299227437e-07
the O 0 2.0447303086257307e-06
BRCA1 O 0 0.00023922158288769424
gene O 0 8.353882549272384e-06
predispose O 0 1.1985550372628495e-05
women O 0 1.7394032738593523e-06
to O 0 4.115602507681615e-07
early O 0 4.951907612849027e-06
- O 1 0.839889407157898
onset O 1 0.9995253086090088
breast B-Disease 1 0.9999985694885254
and I-Disease 1 0.9999887943267822
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 4.662218998419121e-06
compromising O 0 0.0002235365245724097
the O 0 3.68502878700383e-06
genes O 0 1.72642721736338e-05
presumptive O 0 0.0005867074360139668
function O 0 3.1941015095071634e-06
as O 0 1.6644183915559552e-06
a O 0 2.0160008716629818e-05
tumor B-Disease 0 0.019476911053061485
suppressor O 0 0.0006241353112272918
. O 0 3.0516661354340613e-05

Although O 0 3.0379256713786162e-05
the O 0 5.69816120332689e-06
biochemical O 0 4.781779716722667e-05
properties O 0 9.153229257208295e-06
of O 0 7.568881983388565e-07
BRCA1 O 0 0.0003380483540240675
polypeptides O 0 1.7943670172826387e-05
are O 0 7.804110850884172e-07
not O 0 6.236173248908017e-07
understood O 0 1.424901142854651e-06
, O 0 9.940288947518638e-08
their O 0 2.964877978683944e-07
expression O 0 5.108241794005153e-07
pattern O 0 1.5899101981631247e-06
and O 0 4.799097155228083e-07
subcellular O 0 1.721053740766365e-05
localization O 0 5.854483333678218e-06
suggest O 0 1.217249405272014e-06
a O 0 9.870232133835088e-07
role O 0 1.419624823029153e-06
in O 0 1.1759703966163215e-06
cell O 0 0.0005798905622214079
- O 0 0.008700857870280743
cycle O 0 7.377324800472707e-05
regulation O 0 3.790226037381217e-05
. O 0 1.2839970622735564e-05

When O 0 0.0002606166817713529
resting O 0 0.0017412422457709908
cells O 0 3.441100852796808e-05
are O 0 1.8286508520759526e-06
induced O 0 3.0498767955577932e-05
to O 0 1.4836932678008452e-06
proliferate O 0 7.422854832839221e-05
, O 0 3.308897760234686e-07
the O 0 2.5655378976807697e-07
steady O 0 4.119641289435094e-06
- O 0 5.472276825457811e-06
state O 0 2.1250444603992946e-07
levels O 0 2.462510053646838e-07
of O 0 8.48533758812664e-08
BRCA1 O 0 7.33272190700518e-06
increase O 0 4.819571017833368e-07
in O 0 4.496509120599512e-07
late O 0 3.327414106024662e-06
G1 O 0 0.00012893491657450795
and O 0 6.939181957932306e-07
reach O 0 9.519977197669505e-07
a O 0 4.135376627800724e-07
maximum O 0 1.9467388483462855e-06
during O 0 1.0530266081332229e-05
S O 0 0.0003585654776543379
phase O 0 1.8238166376249865e-05
. O 0 1.7692529581836425e-05

Moreover O 0 0.00046532705891877413
, O 0 1.4466816537606064e-05
in O 0 5.8330992942501325e-06
S O 0 0.00018073436513077468
phase O 0 1.3885105545341503e-05
cells O 0 8.64530466060387e-06
, O 0 1.027528469421668e-06
BRCA1 O 0 3.166763417539187e-05
polypeptides O 0 7.801665560691617e-06
are O 0 5.270978249427571e-07
hyperphosphorylated O 0 4.607802111422643e-05
and O 0 2.8080748961656354e-06
accumulate O 0 1.758363032422494e-05
into O 0 8.455204465462884e-07
discrete O 0 8.002426511666272e-06
subnuclear O 0 0.0003186067333444953
foci O 0 0.000144157005706802
termed O 0 6.064186163712293e-05
" O 0 9.84337748377584e-06
BRCA1 O 0 0.0003848201595246792
nuclear O 0 0.00016176683129742742
dots O 0 0.000798350665718317
. O 0 3.9525835745735094e-05

" O 0 0.0005297387833707035
BRCA1 O 0 0.02779957838356495
associates O 0 0.003486020490527153
in O 0 8.178331881936174e-06
vivo O 0 0.00013380961900111288
with O 0 1.5016463521533296e-06
a O 0 1.6006608348106965e-05
structurally O 0 0.004120589699596167
related O 0 5.3878070502833e-06
protein O 0 2.4831173504935578e-05
termed O 0 0.0002052198542514816
BARD1 O 0 0.014182282611727715
. O 0 3.2632608053972945e-05

Here O 0 2.9987568268552423e-05
we O 0 4.3224094952165615e-06
show O 0 1.944508539963863e-06
that O 0 2.5322557917206723e-07
the O 0 3.5454124258649244e-07
steady O 0 3.975970230385428e-06
- O 0 8.192117093130946e-06
state O 0 3.3208789318450727e-07
levels O 0 4.260677997081075e-07
of O 0 1.1931817311960913e-07
BARD1 O 0 0.000516071857418865
, O 0 3.0103413450888183e-07
unlike O 0 2.3765123557950574e-07
those O 0 1.0527311644636939e-07
of O 0 2.0801003586257139e-07
BRCA1 O 0 0.0011310492409393191
, O 0 1.1548472684808075e-06
remain O 0 9.653161896494566e-07
relatively O 0 7.284305070243136e-07
constant O 0 2.0430384211067576e-06
during O 0 7.240047125378624e-06
cell O 0 0.0005181661690585315
cycle O 0 0.00020629752543754876
progression O 0 0.0002842275716830045
. O 0 3.393554288777523e-05

However O 0 0.00013845817011315376
, O 0 1.9658578821690753e-05
immunostaining O 0 0.00023550918558612466
revealed O 0 2.6303601771360263e-05
that O 0 2.0106390365981497e-06
BARD1 O 0 0.00029706384520977736
resides O 0 1.4117284990788903e-05
within O 0 2.1825671865371987e-06
BRCA1 O 0 0.00010987572022713721
nuclear O 0 3.685407500597648e-05
dots O 0 3.280283999629319e-05
during O 0 4.847468062507687e-06
S O 0 5.862350735696964e-05
phase O 0 1.0922994988504797e-06
of O 0 1.20747557730283e-07
the O 0 8.949317020778835e-07
cell O 0 0.00010626548464642838
cycle O 0 1.2456828699214384e-05
, O 0 5.136017193763109e-07
but O 0 2.2203663263553608e-07
not O 0 1.1052199511141225e-07
during O 0 3.979798464115447e-07
the O 0 7.122142733351211e-07
G1 O 0 0.00042402438702993095
phase O 0 2.771256367850583e-05
. O 0 1.566891478432808e-05

Nevertheless O 0 0.0006923347245901823
, O 0 4.642084604711272e-05
BARD1 O 0 0.0005094672087579966
polypeptides O 0 2.785983815556392e-05
are O 0 7.612591730321583e-07
found O 0 1.3566466350312112e-06
exclusively O 0 7.593797590743634e-07
in O 0 2.1686422257971572e-07
the O 0 2.224632993375053e-07
nuclear O 0 3.4388174299238017e-06
fractions O 0 7.038831881800434e-07
of O 0 9.622300467526657e-08
both O 0 2.41166787873226e-07
G1 O 0 7.37744485377334e-05
- O 0 2.3387439796351828e-05
and O 0 1.8939109622806427e-06
S O 0 0.00020889283041469753
- O 0 5.6558474170742556e-05
phase O 0 2.905067231040448e-05
cells O 0 3.1890624086372554e-05
. O 0 1.2068615433236118e-05

Therefore O 0 9.268748544855043e-05
, O 0 7.967123565322254e-06
progression O 0 2.953931107185781e-05
to O 0 1.9563610749173677e-06
S O 0 0.00037919115857221186
phase O 0 5.06510559716844e-06
is O 0 1.663060231749114e-07
accompanied O 0 4.836053904000437e-07
by O 0 8.886690494591676e-08
the O 0 1.3873091120331082e-07
aggregation O 0 9.561412070979713e-07
of O 0 3.6162182937005127e-07
nuclear O 0 3.7119814805919304e-05
BARD1 O 0 0.00016909684927668422
polypeptides O 0 7.842528248147573e-06
into O 0 3.931050287064863e-06
BRCA1 O 0 0.0003754174686037004
nuclear O 0 0.0003207217960152775
dots O 0 0.0009196120081469417
. O 0 3.426865805522539e-05

This O 0 3.6899367842124775e-05
cell O 0 0.00016903075447771698
cycle O 0 4.053202428622171e-05
- O 0 3.986395677202381e-05
dependent O 0 5.584422979154624e-06
colocalization O 0 1.5127287042560056e-05
of O 0 4.539068356734788e-07
BARD1 O 0 0.002172819571569562
and O 0 4.7258249651349615e-06
BRCA1 O 0 0.00508907763287425
indicates O 0 4.607049959304277e-06
a O 0 7.879884265094006e-07
role O 0 9.409577614860609e-07
for O 0 5.672065981343621e-07
BARD1 O 0 0.000832669495139271
in O 0 3.8859338928887155e-06
BRCA1 O 0 0.02852262556552887
- O 0 0.040340397506952286
mediated O 0 0.004652106668800116
tumor B-Disease 0 0.016507703810930252
suppression O 0 5.1799499487970024e-05
. O 0 2.826074523909483e-05

Ethnic O 0 0.00012693478493019938
differences O 0 4.781606185133569e-05
in O 0 5.394367235567188e-06
the O 0 7.364511020568898e-06
HFE O 0 0.0006472792010754347
codon O 0 4.661385901272297e-05
282 O 0 6.074638804420829e-05
( O 0 1.1970691048190929e-05
Cys O 0 0.005676557309925556
/ O 0 0.00020405210671015084
Tyr O 0 0.000717789982445538
) O 0 7.821927283657715e-06
polymorphism O 0 0.00019037102174479514
. O 0 3.6038334656041116e-05

Recent O 0 0.00010758011922007427
studies O 0 2.4819903046591207e-05
have O 0 1.0097583071910776e-05
shown O 0 1.888989754661452e-05
that O 0 0.00010593929619062692
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.07455531507730484
HH B-Disease 1 0.9999628067016602
) O 0 3.253280965509475e-06
is O 0 6.396406320163806e-07
likely O 0 1.2150434258728637e-06
to O 0 4.790176149072067e-07
be O 0 1.552915591673809e-06
caused O 0 2.5822566840361105e-06
by O 0 2.3075126875937713e-07
homozygosity O 0 2.8981663490412757e-05
for O 0 1.5529629138200107e-07
a O 0 2.2646136130788364e-06
Cys282Tyr O 0 0.00027584866620600224
mutation O 0 3.3679307307465933e-06
in O 0 3.1478836604037497e-07
the O 0 1.173816826849361e-06
HFE O 0 0.00031035920255817473
gene O 0 6.33482295597787e-06
located O 0 1.1269511560385581e-05
4 O 0 2.039447099377867e-05
. O 0 1.7943601051229052e-05

5 O 0 0.0005650768871419132
Mb O 0 0.0024190580006688833
telomeric O 0 0.0034664070699363947
to O 0 5.534744923352264e-05
HLA O 0 0.00715441070497036
- O 0 0.0006251797894947231
A O 0 7.80632981332019e-05
. O 0 2.8998139896430075e-05

Population O 0 8.714227442396805e-05
studies O 0 7.67614346841583e-06
of O 0 8.14092800283106e-07
this O 0 4.543442457816127e-07
polymorphism O 0 1.3849279639543965e-05
are O 0 3.22427951005011e-07
facilitated O 0 1.4924348761269357e-06
by O 0 1.6905842414871586e-07
the O 0 2.619838710415934e-07
fact O 0 1.9517639771038375e-07
that O 0 9.603781592204541e-08
the O 0 4.355440808012645e-07
Cys282Tyr O 0 0.00023221054289024323
mutation O 0 6.055555786588229e-06
creates O 0 1.7180602753796848e-06
a O 0 2.127663492501597e-06
Rsal O 0 6.470113294199109e-05
restriction O 0 6.326660241029458e-06
site O 0 1.7029489754349925e-05
. O 0 1.6045289157773368e-05

We O 0 5.804901957162656e-05
have O 0 5.482660981215304e-06
studied O 0 6.558713266713312e-06
the O 0 1.348758019048546e-06
codon O 0 1.528567554487381e-05
282 O 0 2.253697493870277e-05
( O 0 3.0086305287113646e-06
Cys O 0 0.0005186761263757944
/ O 0 5.282835627440363e-05
Tyr O 0 0.00011574505333555862
) O 0 8.110511657832831e-07
polymorphism O 0 4.576903847919311e-06
in O 0 4.5223725919640856e-07
different O 0 3.781223085752572e-07
ethnic O 0 2.683309730855399e-06
groups O 0 4.616647402144736e-06
. O 0 1.707857518340461e-05

In O 0 5.0828475650632754e-05
agreement O 0 8.201435775845312e-06
with O 0 1.6635805195619469e-06
previous O 0 1.703071802694467e-06
observations O 0 2.6659495233616326e-06
the O 0 1.2804173366021132e-06
Tyr O 0 9.338909148937091e-05
allele O 0 1.5624420484527946e-05
appeared O 0 7.798719707352575e-06
to O 0 8.147296739480225e-07
be O 0 8.976523986348184e-07
rare O 0 8.253261967183789e-07
or O 0 1.9517990494932747e-06
absent O 0 7.607796760566998e-06
in O 0 9.629909527575364e-07
Asiatic O 0 1.1314481525914744e-05
( O 0 1.3694294409560825e-07
Indian O 0 1.939354916657976e-07
, O 0 1.9647545457246451e-07
Chinese O 0 2.0233564157479123e-07
) O 0 7.046044743219682e-07
populations O 0 4.835786512558116e-06
. O 0 6.366425168380374e-06

The O 0 4.085563341504894e-05
highest O 0 2.430223139526788e-05
allele O 0 2.830271296261344e-05
frequency O 0 1.0486391147424001e-05
( O 0 7.548900384790613e-07
7 O 0 1.2605903521034634e-06
. O 0 2.0126830690969655e-07
5 O 0 9.826446785154985e-07
% O 0 4.5085235456099326e-07
) O 0 2.2111954933734523e-07
was O 0 2.5330557491543004e-06
found O 0 1.2712747547993786e-06
in O 0 2.2934223125048447e-06
Swedes O 0 0.0004391968250274658
. O 0 2.5374161850777455e-05

Saamis O 0 0.005858813412487507
( O 0 3.2408508559456095e-05
2 O 0 1.3862995729141403e-05
% O 0 2.5206188638549065e-06
) O 0 3.8667596413688443e-07
and O 0 5.573328394348209e-07
Mordvinians O 0 2.6169693228439428e-05
( O 0 1.7547856145938567e-07
1 O 0 2.490076553840481e-07
. O 0 7.840981197659858e-08
8 O 0 8.299095384245447e-07
% O 0 2.900802087424381e-07
) O 0 1.5120980378924287e-07
had O 0 1.9535270894266432e-06
significantly O 0 6.035274964233395e-07
lower O 0 6.403578254321474e-07
frequencies O 0 8.435021641162166e-07
of O 0 2.568106083344901e-07
the O 0 1.340034600616491e-06
Tyr O 0 0.0002134271344402805
allele O 0 8.523750875610858e-05
. O 0 1.4629556062573101e-05

Comparisons O 0 4.34294379374478e-05
with O 0 8.334912308782805e-06
allele O 0 2.172696804336738e-05
frequencies O 0 8.215949492296204e-06
based O 0 1.5633156635885825e-06
on O 0 1.5341665857704356e-06
prevalence O 0 4.932564843329601e-05
estimates O 0 2.573539177319617e-06
of O 0 8.537015219189925e-07
HH B-Disease 1 0.9921240210533142
showed O 0 5.487577072926797e-05
some O 0 2.1182742671044252e-07
disagreements O 0 3.1232093533617444e-06
with O 0 5.344562055142887e-07
the O 0 1.0241357131235418e-06
RFLP O 0 0.00021296324848663062
data O 0 5.784263066743733e-06
, O 0 5.389545663092576e-07
particularly O 0 8.897848147171317e-07
in O 0 1.640792334001162e-06
Finns O 0 0.00021068527712486684
. O 0 1.3914731425757054e-05

The O 0 6.229310383787379e-05
newly O 0 0.00016658111417200416
described O 0 6.185541133163497e-05
HFE O 0 0.002017308259382844
marker O 0 2.5286162781412713e-05
provides O 0 1.4893524848957895e-06
a O 0 7.505370263061195e-07
new O 0 2.592635439668811e-07
approach O 0 2.913597256792855e-07
to O 0 9.448687876556505e-08
the O 0 1.4151625293834513e-07
screening O 0 9.45770921134681e-07
of O 0 3.77890842173656e-07
HH B-Disease 0 0.4154830574989319
as O 0 5.129110718371521e-07
well O 0 3.2443904274259694e-07
as O 0 6.96479389716842e-08
studies O 0 8.084806069064143e-08
of O 0 3.78446181059644e-08
the O 0 2.610287026527658e-07
relationship O 0 5.247405283625994e-07
between O 0 2.9740476747974753e-07
the O 0 1.8904696617028094e-06
HFE O 0 0.01039800513535738
Tyr O 0 0.0001706837210804224
allele O 0 1.715748840069864e-05
and O 0 2.226675860583782e-06
different O 0 8.4259654613561e-06
disorders O 1 0.964468240737915
including O 0 0.00042809106525965035
cancer B-Disease 1 0.9909996390342712

Autosomal B-Disease 1 0.9997027516365051
dominant I-Disease 1 0.991513192653656
neurohypophyseal I-Disease 1 0.999966025352478
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9999312162399292
associated O 0 0.0003028056235052645
with O 0 3.995144652435556e-06
a O 0 6.237051366042579e-06
missense O 0 5.0365753850201145e-05
mutation O 0 1.3629798559122719e-05
encoding O 0 6.04831802775152e-06
Gly23 O 0 0.00021218699112068862
- O 0 0.00011126334720756859
- O 0 0.0001968389842659235
> O 0 6.805922748753801e-05
Val O 0 0.003553893184289336
in O 0 1.515131225460209e-05
neurophysin O 0 0.005479568149894476
II O 0 0.005752114113420248
. O 0 2.4184415451600216e-05

Autosomal B-Disease 1 0.9996626377105713
dominant I-Disease 1 0.9563167691230774
neurohypophyseal I-Disease 1 0.9999656677246094
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9999657869338989
( O 0 0.0002688448003027588
ADNDI B-Disease 1 0.9472389817237854
) O 0 9.567054803483188e-06
is O 0 4.834228093386628e-06
an O 0 0.0480654276907444
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.0012733107432723045
by O 0 3.1390206913783913e-06
progressive O 0 0.002705120947211981
degeneration O 0 0.0009283352992497385
of O 0 3.5873037518285855e-07
the O 0 3.824703526333906e-06
magnocellular O 0 0.00014955691585782915
neurons O 0 3.6070503028895473e-06
of O 0 1.8580222160835547e-07
the O 0 5.018261504119437e-07
hypothalamus O 0 1.2881363545602653e-05
leading O 0 1.760074496814923e-06
to O 0 5.129398914505146e-07
decreased O 0 7.319587894016877e-06
ability O 0 8.56889982969733e-07
to O 0 3.6165667438581295e-07
produce O 0 6.160710768199351e-07
the O 0 9.513841519037669e-07
hormone O 0 5.379674803407397e-06
arginine O 0 9.878002856567036e-06
vasopressin O 0 1.2047020391037222e-05
( O 0 2.1781609120807843e-06
AVP O 0 6.608705007238314e-05
) O 0 4.1957532630476635e-06
. O 0 1.0135991033166647e-05

Affected O 0 0.0010518748313188553
individuals O 0 2.0834902898059227e-05
are O 0 1.456894096918404e-06
not O 0 1.661955138843041e-06
symptomatic O 0 7.789621304254979e-05
at O 0 0.00012327462900429964
birth O 0 0.004183275159448385
, O 0 2.2593369521928253e-06
but O 0 1.4417248621612089e-06
usually O 0 7.065033059916459e-06
develop O 0 0.00047826144145801663
diabetes B-Disease 1 0.9865308403968811
insipidus I-Disease 0 0.4371029734611511
at O 0 5.949674596195109e-05
1 O 0 1.0403833584859967e-05
- O 0 0.00035756581928581
6 O 0 2.1138694137334824e-05
yr O 0 0.0008223173790611327
of O 0 9.510068252893689e-07
age O 0 2.3822152797947638e-05
. O 0 1.5089867702045012e-05

The O 0 3.6079152778256685e-05
genetic O 0 7.050944986985996e-05
locus O 0 5.8106565120397136e-05
of O 0 2.4142827896866947e-06
the O 0 6.0090780607424676e-05
disease O 0 0.36263781785964966
is O 0 5.232373609942442e-07
the O 0 1.6135865053001908e-06
AVP O 0 0.002039210870862007
- O 0 0.0019257116364315152
neurophysin O 0 0.006024352740496397
II O 0 0.0016394640551880002
( O 0 6.831176051491639e-07
NPII O 0 7.336907583521679e-05
) O 0 2.394779130554525e-07
gene O 0 6.890441568430106e-07
, O 0 2.2147114009385405e-07
and O 0 6.732250881213986e-07
mutations O 0 2.61307422988466e-06
that O 0 2.857698007119325e-07
cause O 0 4.440126303961733e-06
ADNDI B-Disease 0 0.012542251497507095
have O 0 3.6692129015136743e-06
been O 0 1.5565082094326499e-06
found O 0 5.725243568122096e-07
in O 0 1.1927278364964877e-07
both O 0 8.063953060855056e-08
the O 0 1.6848575512540265e-07
signal O 0 1.721809894661419e-06
peptide O 0 5.239024289949157e-07
of O 0 8.415177887854952e-08
the O 0 3.3440218771829677e-07
prepro O 0 5.2279381634434685e-05
- O 0 5.543228326132521e-05
AVP O 0 0.00025930828996933997
- O 0 7.892076973803341e-05
NPII O 0 0.00020986546587664634
precursor O 0 5.271624104352668e-06
and O 0 1.3839411394656054e-06
within O 0 3.021197926500463e-06
NPII O 0 0.001337547553703189
itself O 0 1.5551135220448487e-05
. O 0 1.1015408745151944e-05

An O 0 7.86920209066011e-05
affected O 0 0.0001268890337087214
girl O 0 0.0010423999046906829
who O 0 8.61875741975382e-06
presented O 0 1.7631102764426032e-06
at O 0 1.8656939573702402e-05
9 O 0 5.5661325859546196e-06
months O 0 8.747912261242163e-07
of O 0 1.104200109125486e-07
age O 0 5.048025286669144e-06
and O 0 8.90779915607709e-07
her O 0 2.389546534686815e-05
similarly O 0 6.3615211729484145e-06
affected O 0 1.8062213484881795e-06
younger O 0 3.0178921406331938e-06
brother O 0 1.726483242237009e-05
and O 0 9.494436312706966e-07
father O 0 1.2781670193362515e-05
were O 0 1.6292333384626545e-06
all O 0 6.031827126662392e-08
found O 0 3.8382492562050174e-07
to O 0 2.0203580675115518e-07
have O 0 3.92292804463068e-07
a O 0 6.802091547797318e-07
novel O 0 9.048265496858221e-07
missense O 0 6.993145689193625e-06
mutation O 0 3.94889048038749e-06
( O 0 7.649912276974646e-07
G1758 O 0 1.8967644791700877e-05
- O 0 0.0001232268987223506
- O 0 0.0016369411023333669
> O 0 0.00010873068094952032
T O 0 0.00015706154226791114
) O 0 3.268651767029951e-07
encoding O 0 6.905848977112328e-07
the O 0 5.033806473875302e-07
amino O 0 1.7720460618875222e-06
acid O 0 2.0536613192234654e-06
substitution O 0 2.3725112896499922e-06
Gly23 O 0 3.51594208041206e-05
- O 0 8.426720160059631e-05
- O 0 0.00011532518692547455
> O 0 4.532450475380756e-05
Val O 0 0.0005118798580951989
within O 0 1.7685984857962467e-05
NPII O 0 0.002660339465364814
. O 0 3.516690048854798e-05

The O 0 6.087820656830445e-05
mutation O 0 0.0003050213272217661
was O 0 8.550169150112197e-05
confirmed O 0 5.224941560300067e-06
by O 0 7.830428216948349e-07
restriction O 0 5.1020765567955095e-06
endonuclease O 0 0.0001443012588424608
analysis O 0 4.416472074808553e-05
. O 0 4.657879253500141e-05

A O 0 0.00022800613078288734
T1 O 0 0.002114205854013562
- O 0 5.6125252740457654e-05
weighted O 0 1.3577321624325123e-05
magnetic O 0 7.54584380047163e-06
resonance O 0 1.334563330601668e-05
imaging O 0 0.00020166818285360932
of O 0 1.0980921842929092e-06
the O 0 8.76984813658055e-06
fathers O 0 0.010701307095587254
pituitary O 0 0.003265426494181156
gland O 0 0.00021638428734149784
demonstrates O 0 7.706420547037851e-06
an O 0 3.7368461107689654e-06
attenuated O 0 0.0012776568764820695
posterior O 0 0.05997013300657272
pituitary O 0 0.03599696233868599
bright O 0 0.00030615110881626606
spot O 0 0.00029772703419439495
. O 0 4.5265882363310084e-05

This O 0 3.762334381463006e-05
mutation O 0 0.00022458912280853838
may O 0 2.201122151745949e-05
be O 0 4.6555538801840157e-07
valuable O 0 7.521033467128291e-07
for O 0 2.215374763636646e-07
developing O 0 1.2923219401272945e-06
models O 0 1.708032755232125e-06
of O 0 8.545657692593522e-07
dominantly B-Disease 0 0.44741886854171753
inherited I-Disease 1 0.9998821020126343
neurodegeneration I-Disease 1 1.0
, O 0 9.352987945021596e-06
as O 0 3.5715260082724853e-07
the O 0 1.8784706412589003e-07
early O 0 8.790395327196165e-07
age O 0 1.3161001106709591e-06
of O 0 1.3712028135159926e-07
onset O 0 0.004339074250310659
of O 0 2.9042168989690254e-06
symptoms O 0 0.34213367104530334
suggests O 0 3.965223640989279e-06
that O 0 3.182375394317205e-07
this O 0 2.551564080022217e-07
mutation O 0 1.6341011360054836e-05
may O 0 5.617990609607659e-06
be O 0 3.18947911637224e-07
particularly O 0 3.7446980627464654e-07
deleterious O 0 4.611182248481782e-06
to O 0 5.652102572639706e-07
the O 0 2.1315629510354484e-06
magnocellular O 0 0.00043488742085173726
neuron O 0 0.00012142754712840542
. O 0 5.488510396389756e-06
. O 0 1.1864956832141615e-05

Frequent O 0 0.0010308875935152173
inactivation O 0 0.0049592419527471066
of O 0 4.546302807284519e-05
PTEN O 0 0.01244969479739666
/ O 0 0.0007853396236896515
MMAC1 O 0 0.045112282037734985
in O 0 0.00011109012120869011
primary O 1 0.9992319345474243
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00034077465534210205

Sporadic B-Disease 1 0.999812662601471
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 8.411506132688373e-05
the O 0 2.0323773242125753e-06
most O 0 7.502486596422386e-07
common O 0 8.452321708318777e-06
male B-Disease 0 0.0316009558737278
cancer I-Disease 0 0.008446872234344482
in O 0 4.021434278911329e-07
the O 0 3.4201642051812087e-07
Western O 0 6.920195119164418e-07
world O 0 5.1822153182001784e-06
, O 0 3.0146452445478644e-07
yet O 0 8.439852194896957e-08
many O 0 1.4273933146569107e-08
of O 0 2.383586661380832e-08
the O 0 2.1721153586895525e-07
major O 0 6.742557161487639e-07
genetic O 0 2.4563069018768147e-06
events O 0 4.0885939256440906e-07
involved O 0 6.337998001981759e-07
in O 0 3.4100028756256506e-07
the O 0 6.519535986626579e-07
progression O 0 9.792685887077823e-06
of O 0 1.4555439520336222e-07
this O 0 1.3461519756674534e-06
often O 0 0.0003240710648242384
fatal O 1 0.9942119717597961
cancer B-Disease 1 0.8783330917358398
remain O 0 5.3996841415937524e-06
to O 0 1.059062469721539e-06
be O 0 5.527675511984853e-06
elucidated O 0 0.00027139074518345296
. O 0 1.5991094187484123e-05

Numerous O 0 0.00016261603741440922
cytogenetic O 0 0.0044340407475829124
and O 0 9.706541459308937e-05
allelotype O 0 0.002860492095351219
studies O 0 1.1574357813515235e-05
have O 0 5.8636196627048776e-06
reported O 0 1.4222729078028351e-05
frequent O 0 6.322667104541324e-06
loss O 0 4.312975215725601e-05
of O 0 9.654985433371621e-07
heterozygosity O 0 0.0007825411739759147
on O 0 3.446276605245657e-05
chromosomal O 1 0.6288416981697083
arm O 1 0.9556039571762085
10q O 0 0.007459096610546112
in O 0 6.825303717050701e-05
sporadic B-Disease 1 0.998749852180481
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0002161623997380957

Deletion O 0 0.0025491013657301664
mapping O 0 0.00042454389040358365
studies O 0 6.682673847535625e-05
have O 0 1.9114220776828006e-05
unambiguously O 0 0.0001667597534833476
identified O 0 6.814110292907571e-06
a O 0 1.0502137683943147e-06
region O 0 1.4061023421163554e-06
of O 0 4.7005417513901193e-07
chromosome O 0 0.0023181503638625145
10q23 O 0 5.3068750275997445e-05
to O 0 6.479617695731577e-07
be O 0 2.6068317993122037e-07
the O 0 1.761245300713199e-07
minimal O 0 2.2521951450471533e-06
area O 0 1.7826603198045632e-06
of O 0 1.150235220848117e-06
loss O 0 0.00013373844558373094
. O 0 1.5834935766179115e-05

A O 0 0.00011418835492804646
new O 0 3.2547544833505526e-05
tumor B-Disease 0 0.0007529545109719038
suppressor O 0 0.00012112942204112187
gene O 0 2.2915724912309088e-05
, O 0 3.042037178602186e-06
PTEN O 0 0.00020991670317016542
/ O 0 2.6244371838402003e-05
MMAC1 O 0 0.006576182320713997
, O 0 2.4022504021559143e-06
was O 0 2.843299625965301e-05
isolated O 0 1.1253166121605318e-05
recently O 0 7.064042620186228e-06
at O 0 6.4640171331120655e-06
this O 0 1.6173413541764603e-07
region O 0 4.1396302208340785e-07
of O 0 2.6257995955347724e-07
chromosome O 0 0.0004987756838090718
10q23 O 0 4.941637598676607e-05
and O 0 2.2851411358715268e-06
found O 0 4.565835297398735e-06
to O 0 7.656386173948704e-07
be O 0 9.773957572178915e-07
inactivated O 0 2.9902696041972376e-05
by O 0 4.227626106967364e-07
mutation O 0 3.5877149002772057e-06
in O 0 2.8112447125749895e-06
three O 0 0.10122951120138168
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.16142800450325012
lines O 0 0.002493940992280841
. O 0 4.9554029828868806e-05

We O 0 0.00017086674051824957
screened O 0 0.00037254285416565835
80 O 0 0.000970613444224
prostate B-Disease 1 0.9999984502792358
tumors I-Disease 1 0.9999998807907104
by O 0 4.402938884595642e-06
microsatellite O 0 0.0001179682367364876
analysis O 0 3.0678966140840203e-06
and O 0 2.98155509881326e-06
found O 0 9.477885214437265e-06
chromosome O 0 0.00013268770999275148
10q23 O 0 4.49564540758729e-05
to O 0 1.379324089612055e-06
be O 0 1.893221110549348e-06
deleted O 0 1.3326605767360888e-05
in O 0 2.3259597128344467e-06
23 O 0 3.2301257306244224e-05
cases O 0 4.330988303991035e-06
. O 0 1.0975897566822823e-05

We O 0 6.417734402930364e-05
then O 0 1.1040974641218781e-05
proceeded O 0 9.881432561087422e-06
with O 0 5.932211593062675e-07
sequence O 0 1.1205681857973104e-06
analysis O 0 4.3334901533853554e-07
of O 0 1.3607498772216786e-07
the O 0 6.903952680659131e-07
entire O 0 1.2146392691647634e-05
PTEN O 0 0.0003721610701177269
/ O 0 5.375847467803396e-05
MMAC1 O 0 0.0013680950505658984
coding O 0 3.312366607133299e-05
region O 0 6.392707746272208e-06
and O 0 1.1326281310175546e-05
tested O 0 7.501499931095168e-05
for O 0 1.18183697850327e-06
homozygous O 0 7.381575414910913e-05
deletion O 0 1.4189035937306471e-05
with O 0 9.710250878924853e-07
new O 0 2.1258949800539995e-06
intragenic O 0 0.0011557081015780568
markers O 0 1.768601759977173e-05
in O 0 5.450689855024393e-07
these O 0 2.2214996420188982e-07
23 O 0 8.079091458057519e-06
cases O 0 3.472751757271908e-07
with O 0 1.3969225847176858e-06
10q23 O 0 0.0010869643883779645
loss O 0 3.054467015317641e-05
of O 0 5.131892976351082e-06
heterozygosity O 0 0.0019656154327094555
. O 0 4.151142275077291e-05

The O 0 1.694007914920803e-05
identification O 0 1.162171975011006e-05
of O 0 7.407453495034133e-07
the O 0 8.232061077251274e-07
second O 0 3.6447233924263855e-06
mutational O 0 8.196174894692376e-05
event O 0 4.237994289724156e-06
in O 0 6.020575824550178e-07
10 O 0 1.773428948581568e-06
( O 0 2.937807153102767e-07
43 O 0 3.071681931032799e-06
% O 0 3.658276909845881e-06
) O 0 1.4213983376976103e-05
tumors B-Disease 1 0.9999405145645142
establishes O 0 5.745083763031289e-05
PTEN O 0 0.000966885476373136
/ O 0 0.00010760495206341147
MMAC1 O 0 0.001429787720553577
as O 0 7.241009711833613e-07
a O 0 1.0610663139232202e-06
main O 0 3.982744146924233e-06
inactivation O 0 0.00011901631660293788
target O 0 4.100728801859077e-06
of O 0 5.935708600190992e-07
10q O 0 0.0001379671011818573
loss O 0 3.8298952858895063e-05
in O 0 3.0207889722078107e-05
sporadic B-Disease 1 0.9987844824790955
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.6764226277009584e-05
. O 0 2.4966991986730136e-05

Risk O 0 0.004190022125840187
reversals O 0 0.0003299425297882408
in O 0 1.2188350410724524e-05
predictive O 0 0.00013485306408256292
testing O 0 0.0003012561646755785
for O 0 0.00045045276056043804
Huntington B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999972581863403
. O 0 8.499336399836466e-05

The O 0 2.9812152206432074e-05
first O 0 1.0413919881102629e-05
predictive O 0 5.365726610762067e-05
testing O 0 7.413072307826951e-05
for O 0 0.00016382297326344997
Huntington B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999983310699463
( O 0 2.8490792374213925e-06
HD B-Disease 0 0.12014656513929367
) O 0 1.0774591601148131e-06
was O 0 8.260243703261949e-06
based O 0 2.4756752736720955e-07
on O 0 3.4152358807659766e-07
analysis O 0 3.248892141982651e-07
of O 0 1.1167772129283549e-07
linked O 0 1.956066262209788e-05
polymorphic O 0 1.3439044778351672e-05
DNA O 0 2.7973246687906794e-05
markers O 0 1.4593927517125849e-05
to O 0 6.808685384385171e-07
estimate O 0 1.1867092553075054e-06
the O 0 2.1244366621431254e-07
likelihood O 0 9.498266990703996e-07
of O 0 2.250781250268119e-07
inheriting O 0 3.884399848175235e-05
the O 0 1.2255125056981342e-06
mutation O 0 8.659687409817707e-06
for O 0 1.8235048173664836e-06
HD B-Disease 0 0.0044429791159927845
. O 0 3.0837938538752496e-05

Limits O 0 8.080102998064831e-05
to O 0 4.63079277324141e-06
accuracy O 0 7.8925586421974e-06
included O 0 1.362009584227053e-06
recombination O 0 3.864790414809249e-06
between O 0 1.0082620747198234e-06
the O 0 1.0344168686060584e-06
DNA O 0 2.5636289137764834e-05
markers O 0 1.657028406043537e-05
and O 0 1.0837061381607782e-06
the O 0 1.0472452913745656e-06
mutation O 0 7.195725629571825e-06
, O 0 9.425824600839405e-07
pedigree O 0 4.0764025470707566e-05
structure O 0 5.251958555163583e-06
, O 0 3.626399518452672e-07
and O 0 2.469640776325832e-07
whether O 0 2.9438089654831856e-07
DNA O 0 2.511354523448972e-06
samples O 0 9.056837484422431e-07
were O 0 1.4950702507121605e-06
available O 0 4.336177141794906e-07
from O 0 8.416579930781154e-07
family O 0 7.1777408265916165e-06
members O 0 2.984417051266064e-06
. O 0 7.054503385006683e-06

With O 0 2.0017379938508384e-05
direct O 0 7.912484761618543e-06
tests O 0 1.317363330599619e-05
for O 0 4.2480195361349615e-07
the O 0 6.985493996580772e-07
HD B-Disease 0 0.0016649899771437049
mutation O 0 5.81951417188975e-06
, O 0 4.282366319330322e-07
we O 0 3.0975050435699814e-07
have O 0 1.6271653180410794e-07
assessed O 0 4.1629883185123617e-07
the O 0 6.657575113422354e-08
accuracy O 0 2.9342838843149366e-06
of O 0 1.6952630232935917e-07
results O 0 7.836277291062288e-06
obtained O 0 1.6402649407609715e-06
by O 0 1.7482793168710486e-07
linkage O 0 4.1124344534182455e-06
approaches O 0 1.1840007800856256e-06
when O 0 9.238683560397476e-07
requested O 0 2.978538020670385e-07
to O 0 2.5599680952836934e-07
do O 0 3.898008742453385e-07
so O 0 9.51449763419987e-08
by O 0 7.813302715931059e-08
the O 0 3.413965998788626e-07
test O 0 1.3818487786920741e-05
individuals O 0 3.0441267426795093e-06
. O 0 6.3373972807312384e-06

For O 0 2.2009458916727453e-05
six O 0 9.687556485005189e-06
such O 0 6.277135184973304e-07
individuals O 0 8.937394113672781e-07
, O 0 3.367190970493539e-07
there O 0 2.8041094424224866e-07
was O 0 7.019846179900924e-06
significant O 0 5.037455821366166e-07
disparity O 0 2.139464868378127e-06
between O 0 5.179410322853073e-07
the O 0 2.4625833248137496e-06
tests O 0 6.910680531291291e-05
. O 0 2.3372924260911532e-05

Three O 0 0.00010113148164236918
went O 0 6.362822750816122e-05
from O 0 2.118218844771036e-06
a O 0 3.6161743537377333e-06
decreased O 0 0.00020101296831853688
risk O 0 1.6783746104920283e-05
to O 0 3.578955443117593e-07
an O 0 5.919642944718362e-07
increased O 0 7.705406460445374e-06
risk O 0 0.00017425132682546973
, O 0 7.832070991753426e-07
while O 0 3.8681611158608575e-07
in O 0 2.587640892670606e-07
another O 0 6.74693069413479e-07
three O 0 5.210662266108557e-07
the O 0 2.2347023787006037e-06
risk O 0 6.20871942373924e-05
was O 0 2.872176446544472e-05
decreased O 0 7.058351911837235e-05
. O 0 8.653090844745748e-06

Knowledge O 0 6.215923349373043e-05
of O 0 4.8894116844167e-06
the O 0 5.39490201845183e-06
potential O 0 2.4410858259216184e-06
reasons O 0 7.284965590770298e-07
for O 0 1.1307132297133649e-07
these O 0 1.365569062272698e-07
changes O 0 4.860550575358502e-07
in O 0 6.516533517242351e-07
results O 0 6.117455086496193e-06
and O 0 1.0456504924150067e-06
impact O 0 1.0794317404361209e-06
of O 0 1.1491965778986923e-07
these O 0 3.744279979400744e-07
risk O 0 1.1425600860093255e-05
reversals O 0 8.13722363091074e-06
on O 0 3.0371818411367713e-06
both O 0 4.89100693812361e-06
patients O 0 4.7358000301755965e-05
and O 0 8.582737791584805e-07
the O 0 6.496237006103911e-07
counseling O 0 8.509481995133683e-05
team O 0 8.844862350088079e-06
can O 0 3.5551127552935213e-07
assist O 0 6.529466531901562e-07
in O 0 3.007061764037644e-07
the O 0 1.4602127862417547e-07
development O 0 9.184203975109995e-08
of O 0 8.095962300558313e-08
strategies O 0 1.5225804190777126e-06
for O 0 8.589044853124506e-08
the O 0 3.390546226000879e-07
prevention O 0 1.1126923709525727e-05
and O 0 1.029269355967699e-06
, O 0 3.865926316848345e-07
where O 0 7.165602369241242e-07
necessary O 0 7.122836223061313e-07
, O 0 3.804299808507494e-07
management O 0 9.925878430294688e-07
of O 0 4.974391742962325e-08
a O 0 5.921002866671188e-06
risk O 0 3.338456372148357e-05
reversal O 0 1.4293543699750444e-06
in O 0 1.669419873451261e-07
any O 0 1.9286611063762393e-07
predictive O 0 1.0691144780139439e-05
testing O 0 1.0290887985320296e-05
program O 0 3.461745109234471e-06
. O 0 1.1980074532402796e-06
. O 0 6.15698445471935e-06

A O 0 0.0002501557464711368
novel O 0 8.519248513039201e-05
common O 0 1.2479098586481996e-05
missense O 0 7.537985220551491e-05
mutation O 0 2.72145880444441e-05
G301C O 0 2.9187745894887485e-05
in O 0 8.147778203237976e-07
the O 0 1.0460075827722903e-06
N O 0 0.00018222736252937466
- O 0 6.16057004663162e-05
acetylgalactosamine O 0 0.00022636314679402858
- O 0 0.00011663960322039202
6 O 0 1.774357406247873e-05
- O 0 0.0005616133566945791
sulfate O 0 0.00015933597751427442
sulfatase O 0 0.00017996020324062556
gene O 0 1.6232939742621966e-05
in O 0 6.993318947934313e-06
mucopolysaccharidosis B-Disease 0 0.02188861556351185
IVA I-Disease 0 0.005469041410833597
. O 0 3.095650390605442e-05

Mucopolysaccharidosis B-Disease 1 0.9868086576461792
IVA I-Disease 1 0.9919477105140686
( O 0 0.003294211346656084
MPS B-Disease 1 0.9999992847442627
IVA I-Disease 1 0.9999991655349731
) O 0 2.8811278752982616e-05
is O 0 2.0021777800138807e-06
an O 0 1.5353725757449865e-05
autosomal B-Disease 1 0.9923226237297058
recessive I-Disease 1 0.999805748462677
lysosomal I-Disease 1 0.999990701675415
storage I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.999998927116394
caused O 0 0.006256784778088331
by O 0 3.619720928327297e-06
a O 0 0.0023543627467006445
genetic B-Disease 1 0.9999959468841553
defect I-Disease 1 0.9999397993087769
in O 0 1.186882673209766e-05
N O 0 0.024136168882250786
- O 0 0.00215899501927197
acetylgalactosamine O 0 0.00560477189719677
- O 0 0.0016285039018839598
6 O 0 4.527482087723911e-05
- O 0 0.015706244856119156
sulfate O 0 0.00042970667709596455
sulfatase O 0 0.0008087206515483558
( O 0 6.326660241029458e-06
GALNS O 0 0.0006073875119909644
) O 0 5.879555374121992e-06
. O 0 7.711757461947855e-06

In O 0 3.197199112037197e-05
previous O 0 1.3036373275099322e-05
studies O 0 3.617864422267303e-06
, O 0 1.6171051129276748e-06
we O 0 1.0542507880018093e-06
have O 0 2.8729348855449643e-07
found O 0 5.673255714100378e-07
two O 0 2.7744286512643157e-07
common O 0 9.042623787536286e-07
mutations O 0 5.081032213638537e-06
in O 0 4.678823302128876e-07
Caucasians O 0 4.609071766026318e-06
and O 0 1.105653836930287e-06
Japanese O 0 4.870382781518856e-06
, O 0 1.2538713463072781e-06
respectively O 0 1.290612908633193e-05
. O 0 1.1570318747544661e-05

To O 0 3.4011289244517684e-05
characterize O 0 5.0837494200095534e-05
the O 0 2.529374341975199e-06
mutational O 0 6.317531369859353e-05
spectrum O 0 9.549617061566096e-06
in O 0 6.900667699483165e-07
various O 0 2.773851974779973e-07
ethnic O 0 8.247258733717899e-07
groups O 0 5.823466722176818e-07
, O 0 1.0683710343073471e-06
mutations O 0 3.2565899346082006e-06
in O 0 3.6070701980861486e-07
the O 0 9.951726269719074e-07
GALNS O 0 0.0009095022105611861
gene O 0 5.824383151775692e-06
in O 0 2.913582420660532e-06
Colombian O 0 4.705117316916585e-05
MPS B-Disease 1 0.9999877214431763
IVA I-Disease 1 0.9999957084655762
patients O 0 0.016984354704618454
were O 0 0.00014574370288755745
investigated O 0 7.108248246368021e-05
, O 0 1.4977417777117807e-06
and O 0 1.5751081718917703e-06
genetic O 0 1.943804272741545e-05
backgrounds O 0 7.80208210926503e-06
were O 0 6.081066203478258e-06
extensively O 0 3.089588744842331e-06
analyzed O 0 3.773952585106599e-06
to O 0 5.034896162214864e-07
identify O 0 2.9562768304458586e-06
racial O 0 1.2911121984870988e-06
origin O 0 6.91135710439994e-07
, O 0 2.0139962941811973e-07
based O 0 3.366728549281106e-07
on O 0 7.078967314555484e-07
mitochondrial O 0 3.4077911550411955e-05
DNA O 0 2.9939621526864357e-05
( O 0 1.2283981050131842e-06
mtDNA O 0 1.1880966667376924e-05
) O 0 2.5804940833040746e-06
lineages O 0 1.6257323295576498e-05
. O 0 1.272213012271095e-05

Three O 0 0.00011261874897172675
novel O 0 6.691883027087897e-05
missense O 0 0.0002374839677941054
mutations O 0 0.000371402595192194
never O 0 0.00010758853750303388
identified O 0 1.3437967936624773e-05
previously O 0 6.253251285670558e-06
in O 0 3.554706040631572e-07
other O 0 1.398424558374245e-07
populations O 0 4.443915884166927e-07
and O 0 4.6713779511264875e-07
found O 0 1.3730808632317348e-06
in O 0 3.7674260511266766e-07
16 O 0 1.8023118855126086e-06
out O 0 3.458196999872598e-07
of O 0 1.015302260043427e-07
19 O 0 1.1970656487392262e-05
Colombian O 0 8.926150258048438e-06
MPS B-Disease 1 0.9981220364570618
IVA I-Disease 1 0.9872164130210876
unrelated O 0 1.1728964636859018e-05
alleles O 0 9.551885341352317e-06
account O 0 4.230564627505373e-06
for O 0 2.2794863525632536e-06
84 O 0 6.448930071201175e-05
. O 0 1.4822726370766759e-05

2 O 0 9.966879588318989e-05
% O 0 9.214537385560106e-06
of O 0 4.372595583390648e-07
the O 0 9.611045470592217e-07
alleles O 0 4.2620172280294355e-06
in O 0 6.284232654252264e-07
this O 0 2.999769321831991e-07
study O 0 2.8172698876005597e-06
. O 0 8.78986065799836e-06

The O 0 6.588945689145476e-05
G301C O 0 0.00026417209301143885
and O 0 8.771512511884794e-06
S162F O 0 0.00013781960296910256
mutations O 0 2.237959961348679e-05
account O 0 4.046492904308252e-06
for O 0 2.132038844138151e-06
68 O 0 0.00011083268327638507
. O 0 3.6362882383400574e-05

4 O 0 0.0003550373075995594
% O 0 3.060890594497323e-05
and O 0 8.560587957617827e-06
10 O 0 2.268057141918689e-05
. O 0 2.5088671463890933e-05

5 O 0 0.000167632766533643
% O 0 1.2973358025192283e-05
of O 0 1.74638262251392e-06
mutations O 0 2.7999993108096533e-05
, O 0 1.215952352140448e-06
respectively O 0 4.838018867303617e-06
, O 0 3.868500755288551e-07
whereas O 0 4.464475296117598e-07
the O 0 2.4417090571660083e-07
remaining O 0 2.25091093852825e-06
F69V O 0 0.000565789348911494
is O 0 2.4846016799529025e-07
limited O 0 3.15967952246865e-07
to O 0 3.231180585316906e-07
a O 0 1.8453234815751784e-06
single O 0 2.1828815079061314e-05
allele O 0 7.596942305099219e-05
. O 0 1.1292705494270194e-05

The O 0 6.418731936719269e-05
skewed O 0 0.00011537996761035174
prevalence O 0 0.0001193326897919178
of O 0 1.7518286767881364e-06
G301C O 0 0.00010563647811068222
in O 0 1.6007733165679383e-06
only O 0 8.726089504307311e-07
Colombian O 0 1.265768787561683e-05
patients O 0 2.72147426585434e-05
and O 0 1.7133708070105058e-06
haplotype O 0 1.5110747881408315e-05
analysis O 0 8.837027962727007e-07
by O 0 2.888608321427455e-07
restriction O 0 1.0619916110954364e-06
fragment O 0 7.3192804848076776e-06
length O 0 7.823015948815737e-06
polymorphisms O 0 1.6505244275322184e-05
in O 0 5.102127147438296e-07
the O 0 1.24816142488271e-06
GALNS O 0 0.0008727453532628715
gene O 0 3.4664858503674623e-06
suggest O 0 1.3506398772733519e-06
that O 0 3.8579455008402874e-07
G301C O 0 1.1275165888946503e-05
originated O 0 1.5064887293192442e-06
from O 0 4.54586086107156e-07
a O 0 1.5045704913063673e-06
common O 0 3.0471094305539737e-06
ancestor O 0 1.805505780794192e-05
. O 0 1.574784801050555e-05

Investigation O 0 4.9423964810557663e-05
of O 0 3.7606844216497848e-06
the O 0 2.850560576916905e-06
genetic O 0 1.2688846254604869e-05
background O 0 1.5822564591871924e-06
by O 0 1.8810088420195825e-07
means O 0 2.951103397208499e-07
of O 0 1.0517938875409527e-07
mtDNA O 0 3.26992221744149e-06
lineages O 0 2.1912956071901135e-06
indicate O 0 1.2352115845715161e-06
that O 0 1.4663906711120944e-07
all O 0 1.6317214601713204e-07
our O 0 2.567425326560624e-06
patients O 0 1.1352483852533624e-05
are O 0 1.4173667750583263e-07
probably O 0 5.369240625441307e-07
of O 0 1.7033870847171784e-07
native O 0 2.1128259959368734e-06
American O 0 8.707902452442795e-06
descent O 0 0.00032267082133330405

Low O 0 0.00019566966511774808
frequency O 0 5.025118662160821e-05
of O 0 5.8026389524457045e-06
BRCA1 O 0 0.0009617084870114923
germline O 0 0.00023339851759374142
mutations O 0 3.4638414945220575e-05
in O 0 3.755885018108529e-06
45 O 0 4.146528590354137e-05
German O 1 0.9960992336273193
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0006913773831911385
. O 0 3.1030755053507164e-05

In O 0 3.736515645869076e-05
this O 0 2.375885060246219e-06
study O 0 2.5100998755078763e-06
we O 0 1.7119334643211914e-06
investigated O 0 4.1490152398182545e-06
45 O 0 8.003112270671409e-06
German O 1 0.9874416589736938
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.995142707135528e-05
for O 0 2.014251094806241e-06
germline O 0 0.0003759082464966923
mutations O 0 2.0163335648248903e-05
in O 0 1.219878186020651e-06
the O 0 4.9132977437693626e-06
BRCA1 O 0 0.0012758770026266575
gene O 0 6.750851025572047e-05
. O 0 2.652527291502338e-05

We O 0 8.202414028346539e-05
identified O 0 2.769692218862474e-05
four O 0 5.916312147746794e-06
germline O 0 9.656990732764825e-05
mutations O 0 1.555727249069605e-05
in O 0 1.5778292663526372e-06
three O 0 0.00013020378537476063
breast B-Disease 1 0.9999576807022095
cancer I-Disease 1 0.9298267960548401
families O 0 1.2236147085786797e-05
and O 0 1.2203913684061263e-06
in O 0 2.8220185868121916e-06
one O 0 0.008691429160535336
breast B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.00020326062804087996
. O 0 2.3978802232704766e-07
among O 0 8.967277409510643e-08
these O 0 7.496157650166424e-08
were O 0 7.826165528967977e-07
one O 0 5.621326977234276e-07
frameshift O 0 7.151238241931424e-05
mutation O 0 5.940998107689666e-06
, O 0 3.9598202761226275e-07
one O 0 7.976420874911128e-07
nonsense O 0 1.4678049410576932e-05
mutation O 0 3.1861152365308953e-06
, O 0 3.734879214789544e-07
one O 0 4.186813100659492e-07
novel O 0 6.553246407747793e-07
splice O 0 8.232529216911644e-05
site O 0 1.778862497303635e-05
mutation O 0 7.524831289629219e-06
, O 0 6.810425929870689e-07
and O 0 1.1070064829254989e-06
one O 0 2.6699035515775904e-06
missense O 0 0.00010422168270451948
mutation O 0 7.88000033935532e-05
. O 0 2.9084161724313162e-05

The O 0 8.633878314867616e-05
missense O 0 0.00047309271758422256
mutation O 0 0.00011736503802239895
was O 0 5.3639923862647265e-05
also O 0 2.7672094802255742e-06
found O 0 3.1393142307933886e-06
in O 0 2.6356092348578386e-06
2 O 0 3.335146902827546e-05
. O 0 1.6115094695123844e-05

8 O 0 0.00025340268621221185
% O 0 1.1898655429831706e-05
of O 0 1.0696933259168873e-06
the O 0 7.308653380277974e-07
general O 0 7.175005407589197e-07
population O 0 4.841213012696244e-07
, O 0 3.0793589189670456e-07
suggesting O 0 7.797088414918107e-07
that O 0 1.5895145111244346e-07
it O 0 3.9800866602490714e-07
is O 0 6.843369533271471e-07
not O 0 7.903043297119439e-06
disease O 0 0.0013552505988627672
associated O 0 1.2352101293799933e-05
. O 0 1.73116222867975e-05

The O 0 5.8255809562979266e-05
average O 0 0.0001310035731876269
age O 0 3.47414352290798e-05
of O 0 7.307270607270766e-06
disease O 1 0.9255324006080627
onset O 0 0.1803973913192749
in O 0 7.250287126225885e-06
those O 0 5.339092240319587e-06
families O 0 3.0699851777171716e-05
harbouring O 0 0.029289159923791885
causative O 0 6.821400165790692e-05
mutations O 0 3.188661503372714e-05
was O 0 1.0644367648637854e-05
between O 0 2.479420800227672e-06
32 O 0 5.086585952085443e-05
. O 0 1.8071887097903527e-05

3 O 0 0.0003088800294790417
and O 0 4.370534952613525e-05
37 O 0 0.00018086987256538123
. O 0 4.325196277932264e-05

4 O 0 0.00042569078505039215
years O 0 2.7438964025350288e-05
, O 0 2.922275598393753e-06
whereas O 0 1.8573007309896639e-06
the O 0 6.290864575930755e-07
family O 0 1.3131816558598075e-05
harbouring O 0 0.00017226544150616974
the O 0 1.3308876987139229e-06
missense O 0 2.8611812012968585e-05
mutation O 0 1.4139703125692904e-05
had O 0 8.870305464370176e-06
an O 0 5.803242402180331e-07
average O 0 1.5696643458795734e-05
age O 0 1.4966537946747849e-06
of O 0 2.2602176841246546e-07
onset O 0 0.00013710392522625625
of O 0 2.23689858103171e-06
51 O 0 0.00014936679508537054
. O 0 2.5456276489421725e-05

2 O 0 0.0006021044100634754
years O 0 0.0001257016119780019
. O 0 6.60720543237403e-05

These O 0 1.562349461892154e-05
findings O 0 1.0738763194240164e-05
show O 0 5.111524842504878e-06
that O 0 1.2348770042081014e-06
BRCA1 O 0 0.00031461816979572177
is O 0 8.303314302793297e-07
implicated O 0 6.266910077101784e-06
in O 0 3.552428609054914e-07
a O 0 7.205203473859001e-07
small O 0 6.118640953900467e-07
fraction O 0 1.2791920198651496e-06
of O 0 6.348709121084539e-06
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.00025037501472979784
suggesting O 0 9.724506526254117e-06
the O 0 4.5691572836403793e-07
involvement O 0 1.2981200825379346e-06
of O 0 2.0524814203781716e-07
another O 0 4.429015916684875e-06
susceptibility O 0 0.00016441920888610184
gene O 0 2.4441571440547705e-05
( O 0 3.670333171612583e-06
s O 0 0.00023832959413994104
) O 0 2.445572317810729e-05

Paternal O 1 0.725757360458374
transmission O 1 0.6510015726089478
of O 0 0.0062741972506046295
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.029980916529893875

We O 0 0.00014842223026789725
report O 0 1.4946490409784019e-05
a O 0 3.5365987969271373e-06
rare O 0 5.6836811381799635e-06
case O 0 4.3726722651626915e-06
of O 0 9.160232366411947e-06
paternally O 1 0.9987742304801941
transmitted O 1 0.9999761581420898
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.6085737943649292
DM B-Disease 1 1.0
) O 0 9.075244452105835e-05
. O 0 6.249111902434379e-05

The O 0 8.234012784669176e-05
proband O 0 0.0006720981327816844
is O 0 1.566640889905102e-06
a O 0 1.776760541361e-06
23 O 0 6.745007794961566e-06
year O 0 1.691027364358888e-06
old O 0 0.0005228678928688169
, O 0 2.1882295186514966e-05
mentally B-Disease 1 0.9999990463256836
retarded I-Disease 1 0.9998584985733032
male O 0 0.0015620936173945665
who O 0 0.008341236039996147
suffers O 1 0.9996515512466431
severe O 1 0.9998086094856262
muscular B-Disease 1 0.999967098236084
weakness I-Disease 1 0.9955734014511108
. O 0 0.00015291961608454585

He O 0 0.0003762848791666329
presented O 0 3.414668026380241e-05
with O 0 7.064398232614622e-05
respiratory O 1 0.9980567097663879
and O 0 0.00010255419329041615
feeding O 0 0.017274238169193268
difficulties O 0 0.0025867559015750885
at O 0 0.0009622245561331511
birth O 0 0.02110404148697853
. O 0 3.6450368497753516e-05

His O 0 0.00044746746425516903
two O 0 0.00014680091408081353
sibs O 1 0.9713718295097351
suffer O 0 0.12155360728502274
from O 0 7.757767161820084e-05
childhood O 1 0.9307929873466492
onset O 1 0.9999740123748779
DM B-Disease 1 0.9999998807907104
. O 0 0.0004125662089791149

Their O 0 8.879172673914582e-05
late O 0 4.332358730607666e-05
father O 0 7.062236545607448e-05
had O 0 5.776391390099889e-06
the O 0 2.025740855060576e-07
adult O 0 1.5610437458235538e-06
type O 0 5.741209861298557e-06
of O 0 1.613112658560567e-06
DM B-Disease 1 1.0
, O 0 4.071557668794412e-06
with O 0 2.4486400889145443e-06
onset O 0 0.005153214558959007
around O 0 1.1802683729911223e-05
30 O 0 7.458515938196797e-06
years O 0 8.99344013305381e-06
. O 0 1.0450748959556222e-05

Only O 0 2.0629619029932655e-05
six O 0 5.2270947890065145e-06
other O 0 4.4638238705374533e-07
cases O 0 3.7908307604084257e-07
of O 0 3.4201772791675467e-07
paternal O 0 0.03709140419960022
transmission O 0 0.4785677194595337
of O 0 0.0012384537840262055
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0062554064206779
been O 0 6.502624455606565e-05
reported O 0 6.436679541366175e-05
recently O 0 0.00013080086500849575
. O 0 1.7743455828167498e-05

We O 0 4.1049108403967693e-05
review O 0 9.528129339742009e-06
the O 0 2.393971499259351e-06
sex O 0 3.948001904063858e-06
related O 0 2.5030026336025912e-06
effects O 0 1.1611748959694523e-05
on O 0 1.5438090485986322e-05
transmission O 0 0.2793503701686859
of O 0 0.0010977580677717924
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0006473448593169451

Decreased O 0 0.008370627649128437
fertility O 0 0.0004458104376681149
of O 0 2.34374169849616e-06
males O 0 1.1766988791350741e-05
with O 0 1.6328810943377903e-06
adult O 0 0.00048602971946820617
onset O 1 0.9973980188369751
DM B-Disease 1 1.0
and O 0 0.00015178779722191393
contraction O 0 0.00011156475375173613
of O 0 1.931915818431662e-07
the O 0 6.26872406428447e-07
repeat O 0 5.043194050813327e-06
upon O 0 8.360684091712756e-07
male O 0 3.6891708532493794e-06
transmission O 0 2.248780947411433e-05
contribute O 0 5.374917577682936e-07
to O 0 2.557971754413302e-07
the O 0 3.746541210603027e-07
almost O 0 9.993839285016293e-07
absent O 0 2.007558123295894e-06
occurrence O 0 1.4360795148604666e-06
of O 0 5.620073011414206e-07
paternal O 0 0.015655504539608955
transmission O 0 0.3055608868598938
of O 0 0.0019949423149228096
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0005273661226965487

Also O 0 4.8144589527510107e-05
the O 0 3.758231969186454e-06
fathers O 0 1.1744332368834876e-05
of O 0 5.045023385719105e-07
the O 0 2.7997054985462455e-06
reported O 0 6.646422843914479e-05
congenitally O 0 0.016716470941901207
affected O 0 1.0534523426031228e-05
children O 0 1.653646722843405e-05
showed O 0 1.3463829418469686e-05
, O 0 3.967020631989726e-07
on O 0 9.178413620247738e-07
average O 0 8.804374374449253e-06
, O 0 8.009487828530837e-07
shorter O 0 2.7153251721756533e-05
CTG O 0 0.00034849296207539737
repeat O 0 1.5207652722892817e-05
lengths O 0 7.643798744538799e-05
and O 0 3.3870926472445717e-06
hence O 0 7.011483376118122e-06
less O 0 9.458382919547148e-06
severe O 1 0.8925805687904358
clinical O 1 0.9028757810592651
symptoms O 1 0.5382791757583618
than O 0 8.666963822179241e-07
the O 0 3.5758175727096386e-06
mothers O 0 0.00017034602933563292
of O 0 7.914574098322191e-07
children O 0 0.0006080442690290511
with O 0 0.04009770601987839
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.000277514016488567

We O 0 7.273993833223358e-05
conclude O 0 2.4386319637415e-05
that O 0 1.7250577002414502e-06
paternal O 0 0.00028397401911206543
transmission O 0 0.25756439566612244
of O 0 0.001939122099429369
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 4.580363747663796e-05
rare O 0 8.719379366084468e-06
and O 0 8.434029041382018e-06
preferentially O 0 1.8626915334607475e-05
occurs O 0 4.95457300075941e-07
with O 0 4.789486069967097e-07
onset O 0 0.00012135369615862146
of O 0 1.6396456885559019e-06
DM B-Disease 1 0.9999986886978149
past O 0 7.388528047158616e-06
30 O 0 3.8525254240084905e-06
years O 0 1.068638994183857e-06
in O 0 3.404056769795716e-07
the O 0 1.214591634379758e-06
father O 0 4.369151429273188e-05
. O 0 2.176719817725825e-06
. O 0 7.292274858627934e-06

The O 0 0.00017734373977873474
RB1 O 0 0.010696693323552608
gene O 0 0.0001356149005005136
mutation O 0 3.352989733684808e-05
in O 0 3.2799944165162742e-06
a O 0 5.393420451582642e-06
child O 0 0.00026007089763879776
with O 0 3.95581555494573e-05
ectopic B-Disease 1 0.9999362230300903
intracranial I-Disease 1 0.9999943971633911
retinoblastoma I-Disease 1 0.9986063838005066
. O 0 0.00028464250499382615

The O 0 0.00019853332196362317
RB1 O 0 0.015791859477758408
gene O 0 0.00012578915630001575
mutation O 0 7.95057276263833e-05
was O 0 2.3702254111412913e-05
investigated O 0 6.012730864313198e-06
in O 0 6.017671125846391e-07
a O 0 6.051629952708026e-06
child O 0 0.00047209960757754743
with O 0 1.9828563381452113e-05
ectopic B-Disease 1 0.9997144341468811
intracranial I-Disease 1 0.9995923638343811
retinoblastoma I-Disease 0 0.39040353894233704
using O 0 2.113514710799791e-05
DNA O 0 5.4414231271948665e-05
obtained O 0 3.7087984310346656e-06
from O 0 3.804695154485671e-07
both O 0 2.487565495812305e-07
the O 0 9.040726354214712e-07
pineal B-Disease 0 0.00011870598973473534
and I-Disease 0 1.340769449598156e-05
retinal I-Disease 0 0.04209228232502937
tumours I-Disease 1 0.999995231628418
of O 0 1.7414581634511705e-06
the O 0 2.373484858253505e-05
patient O 0 0.0007062070071697235
. O 0 2.2179245206643827e-05

A O 0 0.0001854901493061334
nonsense O 0 0.00013860057515557855
mutation O 0 3.052387910429388e-05
in O 0 3.5380562621867284e-06
exon O 0 4.582534893415868e-05
17 O 0 1.1221809472772293e-05
( O 0 6.765267244190909e-07
codon O 0 4.520338734437246e-06
556 O 0 5.037157279730309e-06
) O 0 2.2920066555798257e-07
of O 0 1.535130991214828e-07
the O 0 1.6000589084796957e-06
RB1 O 0 0.0003940094029530883
gene O 0 2.930765504061128e-06
was O 0 9.63351340033114e-06
found O 0 7.248250426528102e-07
to O 0 3.740914280569996e-07
be O 0 3.0473373158201866e-07
present O 0 3.555017826784024e-07
homozygously O 0 1.4507515516015701e-05
in O 0 1.8366031895311608e-07
both O 0 2.0767031116974977e-07
the O 0 9.024084306474833e-07
retinal B-Disease 0 3.7253223126754165e-05
and I-Disease 0 6.123443654360017e-06
the I-Disease 0 3.931944593205117e-05
pineal I-Disease 0 0.3193199336528778
tumours I-Disease 1 0.999987006187439
. O 0 5.156263432581909e-05

The O 0 2.1536661733989604e-05
same O 0 6.207263140822761e-06
mutation O 0 1.5307017747545615e-05
was O 0 1.032666114042513e-05
present O 0 6.521898399114434e-07
heterozygously O 0 4.9912527174456045e-05
in O 0 3.6775679745915113e-07
the O 0 3.468733780209732e-07
DNA O 0 3.498952310110326e-06
from O 0 1.7667244378571922e-07
the O 0 2.0056471328189218e-07
constitutional O 0 5.284981625663931e-07
cells O 0 5.019367108616279e-07
of O 0 6.745425196186261e-08
the O 0 1.5366674688266357e-06
patient O 0 5.282412166707218e-05
, O 0 8.786857961240457e-07
proving O 0 1.4736395314685069e-05
it O 0 2.0586367099895142e-07
to O 0 2.437563182411395e-07
be O 0 2.0455638605199056e-07
of O 0 3.867394298140425e-07
germline O 0 6.074314296711236e-05
origin O 0 6.44233023194829e-06
. O 0 1.2437966688594315e-05

The O 0 2.376964403083548e-05
initial O 0 3.065342752961442e-05
mutation O 0 3.7908368540229276e-05
was O 0 2.7339292500982992e-05
shown O 0 1.1547130043254583e-06
to O 0 4.855546649196185e-07
have O 0 1.0126351526196231e-06
occurred O 0 2.6831203285837546e-06
in O 0 6.19664888290572e-07
the O 0 2.2544384137290763e-06
paternally O 0 0.00027495494578033686
derived O 0 1.926225559145678e-05
RB1 O 0 0.0006399481208063662
allele O 0 8.538606198271737e-05
. O 0 2.0928338926751167e-05

The O 0 4.713061571237631e-05
mutation O 0 8.471516775898635e-05
is O 0 1.4512570487568155e-06
in O 0 3.960628305321734e-07
an O 0 3.6129779346083524e-07
area O 0 7.911796728876652e-07
of O 0 7.25836386550327e-08
the O 0 2.968414491988369e-07
gene O 0 8.331298886332661e-07
that O 0 7.493999021335185e-08
encodes O 0 5.883611038370873e-07
the O 0 3.1136465850067907e-07
protein O 0 1.7113262629209203e-06
- O 0 6.710713932989165e-06
binding O 0 8.616329409960599e-07
region O 0 7.94189929820277e-07
known O 0 6.419720648409566e-07
as O 0 1.5489618476749456e-07
the O 0 2.3502389012719505e-07
pocket O 0 0.0022274379152804613
region O 0 2.402264044576441e-06
and O 0 1.937385832206928e-06
has O 0 2.1048417693236843e-06
been O 0 4.075368451594841e-06
detected O 0 3.3040994367183885e-06
in O 0 1.4036784534710023e-07
other O 0 9.709355452969248e-08
cases O 0 2.801479297431797e-07
of O 0 7.733623874628393e-07
retinoblastoma B-Disease 0 0.0021459453273564577
. O 0 5.109560333949048e-06
. O 0 1.8932025341200642e-05

Low O 0 0.0012051011435687542
levels O 0 2.9855340471840464e-05
of O 0 2.102550524796243e-06
beta O 0 9.270631380786654e-06
hexosaminidase O 0 6.74563052598387e-05
A O 0 6.489824500022223e-06
in O 0 4.541069756669458e-06
healthy O 0 3.8779598980909213e-05
individuals O 0 7.21846390661085e-07
with O 0 1.1578807061596308e-05
apparent O 1 0.8615092039108276
deficiency O 1 0.507056713104248
of O 0 3.1625523888578755e-07
this O 0 1.2539621820906177e-06
enzyme O 0 5.95037272432819e-05
. O 0 1.2781243640347384e-05

Appreciable O 0 0.002989113098010421
beta O 0 0.0003977502346970141
hexosaminidase O 0 0.0027815767098218203
A O 0 4.1556333599146456e-05
( O 0 2.3574475562782027e-06
hex O 0 1.9918777979910374e-05
A O 0 3.175755637130351e-06
) O 0 3.4751968769342056e-07
activity O 0 4.889076308245421e-07
has O 0 3.889163906478643e-07
been O 0 1.0284658173986827e-06
detected O 0 3.023760427822708e-06
in O 0 7.136475232982775e-07
cultured O 0 8.395424083573744e-05
skin O 0 0.01277453638613224
fibroblasts O 0 3.345949517097324e-05
and O 0 0.000265647133346647
melanoma B-Disease 1 0.9983131885528564
tissue O 0 0.26808956265449524
from O 0 1.3940631106379442e-05
healthy O 0 6.302560359472409e-05
individuals O 0 8.368230624000716e-07
previously O 0 1.3812742508889642e-05
reported O 0 1.656279528106097e-05
as O 0 5.612057520920644e-06
having O 0 0.3106384575366974
deficiency B-Disease 0 0.014141353778541088
of I-Disease 0 1.3920377739395917e-07
hex I-Disease 0 2.5275312509620562e-05
A I-Disease 0 2.0053576008649543e-06
activity O 0 7.772529784233484e-07
indistinguishable O 0 1.3331742820810177e-06
from O 0 1.3217864136549906e-07
that O 0 9.898552377762826e-08
of O 0 3.4317565678065876e-07
patients O 0 7.593928603455424e-05
with O 0 0.010027594864368439
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9653089046478271
( O 0 8.292841812362894e-06
TSD B-Disease 0 0.02100244164466858
) O 0 1.3876064258511178e-05
. O 0 2.0970292098354548e-05

Identification O 0 0.0001587883016327396
and O 0 1.4380405445990618e-05
quantitation O 0 0.00024723808746784925
of O 0 1.5329950429077144e-06
hex O 0 5.25076684425585e-05
A O 0 5.856929419678636e-06
, O 0 5.917486873840971e-07
amounting O 0 1.2670240039369673e-06
to O 0 6.899516051817045e-07
3 O 0 8.112019713735208e-06
. O 0 7.066205398587044e-06

5 O 0 0.0005334349698387086
% O 0 0.0001162491025752388
- O 0 0.0005091014318168163
6 O 0 8.535577944712713e-05
. O 0 3.408389238757081e-05

9 O 0 0.00016980939835775644
% O 0 8.649353731016163e-06
of O 0 7.024139563327481e-07
total O 0 2.5680226372060133e-06
beta O 0 5.742590019508498e-06
hexosaminidase O 0 3.579566691769287e-05
activity O 0 2.5019644454005174e-06
, O 0 4.781572329193295e-07
has O 0 5.226708026384586e-07
been O 0 5.65339121294528e-07
obtained O 0 1.4870901168251294e-06
by O 0 8.617464004601061e-07
cellulose O 0 7.627299055457115e-05
acetate O 0 6.288787699304521e-05
gel O 0 0.0012670259457081556
electrophoresis O 0 0.0001213958312291652
, O 0 2.582384695415385e-06
DEAE O 0 0.0001337863941444084
- O 0 1.8943457689601928e-05
cellulose O 0 1.3867782399756834e-05
ion O 0 9.422442417417187e-06
- O 0 2.3575987142976373e-05
exchange O 0 1.8581812355478178e-06
chromatography O 0 2.1240759451757185e-05
, O 0 9.779813581189956e-07
radial O 0 3.104259667452425e-05
immunodiffusion O 0 0.00012133621930843219
, O 0 1.549371290821e-06
and O 0 3.867356554110302e-06
radioimmunoassay O 0 0.0006288385484367609
. O 0 1.904787313833367e-05

Previous O 0 0.00017363831284455955
family O 0 5.568383858189918e-05
studies O 0 4.5564524953078944e-06
suggested O 0 3.829258275800385e-06
that O 0 3.3240729635508615e-07
these O 0 2.4765017769823316e-07
individuals O 0 7.9935472285797e-07
may O 0 4.961711965734139e-06
be O 0 9.992066907216213e-07
compound O 0 1.274465557798976e-05
heterozygotes O 0 6.535206011903938e-06
for O 0 1.0830371621750601e-07
the O 0 3.101004608652147e-07
common O 0 1.3145547654858092e-06
mutant O 0 6.817927351221442e-05
TSD B-Disease 0 0.000479465612443164
gene O 0 3.7414604321384104e-06
and O 0 5.69793769500393e-07
a O 0 1.552234493829019e-06
rare O 0 2.7814753593702335e-06
( O 0 8.605243806414364e-07
allelic O 0 1.6453474017907865e-05
) O 0 1.0660251064109616e-06
mutant O 0 3.9745253161527216e-05
gene O 0 2.3339667677646503e-05
. O 0 2.056509219983127e-05

Thus O 0 7.13471308699809e-05
, O 0 3.437060058786301e-06
the O 0 8.694465236658289e-07
postulated O 0 5.161849003343377e-06
rate O 0 1.923240461110254e-06
mutant O 0 6.250341812119586e-06
gene O 0 2.2593585526919924e-06
appears O 0 5.384999326452089e-07
to O 0 1.380508223292054e-07
code O 0 2.338773157362084e-07
for O 0 6.70610660336024e-08
the O 0 1.1122747878289374e-07
expression O 0 2.6995417101716157e-07
of O 0 1.663897961634575e-07
low O 0 1.0686863788578194e-05
amounts O 0 9.545559578327811e-07
of O 0 5.99765257902618e-07
hex O 0 8.889897435437888e-05
A O 0 2.5955596356652677e-05
. O 0 1.593478191352915e-05

Heterozygotes O 0 0.0050126356072723866
for O 0 7.786145033605862e-06
the O 0 2.9416328288789373e-06
rare O 0 6.863461294415174e-06
mutant O 0 0.0002552883524913341
may O 0 2.226014476036653e-05
be O 0 7.700490982642805e-07
indistinguishable O 0 3.860731339955237e-06
from O 0 5.149740331944486e-07
heterozygotes O 0 1.1032734619220719e-05
for O 0 3.015660183791624e-07
the O 0 1.4547573528034263e-06
common O 0 8.465068276564125e-06
TSD B-Disease 0 0.007720521185547113
mutant O 0 0.00033028682810254395
. O 0 3.0019240512046963e-05

However O 0 4.088104469701648e-05
, O 0 2.128578671545256e-06
direct O 0 1.690959607003606e-06
visualization O 0 1.4462098988587968e-05
and O 0 3.0220451208151644e-06
quantitation O 0 0.00017807881522458047
of O 0 9.026649081533833e-07
hex O 0 6.846555334050208e-05
A O 0 2.4992409635160584e-06
by O 0 2.2359634499480308e-07
the O 0 3.275866617968859e-07
methods O 0 3.8138932723086327e-06
described O 0 1.9059029000345618e-05
may O 0 5.689538284059381e-06
prevent O 0 4.412649559526471e-06
false O 0 9.252717973140534e-06
- O 0 0.0007126069394871593
positive O 0 6.177982868393883e-06
prenatal O 1 0.9854375123977661
diagnosis O 1 0.7611854076385498
of O 0 2.621573457872728e-06
TSD B-Disease 0 0.07864902168512344
in O 0 2.4827479137456976e-05
fetuses O 0 0.3042657971382141
having O 0 2.6001902369898744e-05
the O 0 1.3757481838183594e-06
incomplete O 0 0.00011255767458351329
hex B-Disease 0 0.0037879038136452436
A I-Disease 0 0.01899528130888939
deficiency I-Disease 0 0.13417792320251465
of O 0 1.216883305232841e-07
the O 0 6.902373002048989e-07
type O 0 1.585515565238893e-05
described O 0 3.931158971681725e-06
in O 0 4.192942526515253e-07
the O 0 8.382432383768901e-07
four O 0 1.2271040759515017e-05
healthy O 0 8.319077460328117e-05
individuals O 0 2.219199996034149e-05

The O 0 0.0001428900141036138
tumor B-Disease 0 0.0030985050834715366
suppressor O 0 0.0004291957593522966
gene O 0 6.566677620867267e-05
Smad4 O 0 0.0003742229600902647
/ O 0 9.891833906294778e-05
Dpc4 O 0 0.0002573129313532263
is O 0 5.95849712681229e-07
required O 0 5.395002062869025e-07
for O 0 4.065971097588772e-07
gastrulation O 0 1.768628862919286e-05
and O 0 1.442618781766214e-06
later O 0 2.2697768145008013e-06
for O 0 4.501735304529575e-07
anterior O 0 9.154487634077668e-05
development O 0 4.911091764370212e-07
of O 0 3.4135035775761935e-07
the O 0 1.816762733142241e-06
mouse O 0 0.00018181640189141035
embryo O 0 8.017481013666838e-05
. O 0 1.397942742187297e-05

Mutations O 0 0.0011929657775908709
in O 0 1.5862990039750002e-05
the O 0 1.629320831852965e-05
SMAD4 O 0 0.05543331056833267
/ O 0 0.0007863545906729996
DPC4 O 0 0.10386989265680313
tumor B-Disease 0 0.005009704269468784
suppressor O 0 0.00014170710346661508
gene O 0 8.313120815728325e-06
, O 0 5.901661666030122e-07
a O 0 6.62915340399195e-07
key O 0 1.4909040828570141e-06
signal O 0 5.139352651895024e-06
transducer O 0 1.317918849963462e-05
in O 0 4.437635254816996e-07
most O 0 2.736321960128407e-07
TGFbeta O 0 0.0001282555895159021
- O 0 4.839407483814284e-05
related O 0 9.857560598902637e-07
pathways O 0 7.22066442904179e-06
, O 0 2.6502101491132635e-07
are O 0 6.940803842780952e-08
involved O 0 2.956052469471615e-07
in O 0 2.162722836374087e-07
50 O 0 1.0187662837779499e-06
% O 0 9.253373605133675e-07
of O 0 2.8235558602318633e-06
pancreatic B-Disease 1 0.999824583530426
cancers I-Disease 1 0.989041268825531
. O 0 5.1629853260237724e-05

Homozygous O 0 0.017204640433192253
Smad4 O 0 0.015254171565175056
mutant O 0 0.005090837832540274
mice O 1 0.5978891253471375
die O 0 0.061686474829912186
before O 0 1.53290166053921e-05
day O 0 1.3026220585743431e-05
7 O 0 3.206505789421499e-05
. O 0 1.7792002836358733e-05

5 O 0 0.00024693910381756723
of O 0 4.282078589312732e-05
embryogenesis O 0 0.0008078226237557828
. O 0 8.560798596590757e-05

Mutant O 0 0.0009647791739553213
embryos O 0 0.00019118031195830554
have O 0 1.0524894605623558e-05
reduced O 0 5.758372935815714e-06
size O 0 4.784797965839971e-06
, O 0 1.0976251587635488e-06
fail O 0 9.406246135768015e-06
to O 0 5.064300125923182e-07
gastrulate O 0 0.0001606502482900396
or O 0 7.778602366670384e-07
express O 0 1.5767494687679573e-06
a O 0 9.981171160688973e-07
mesodermal O 0 3.394868326722644e-05
marker O 0 2.2086289391154423e-05
, O 0 4.889486717729596e-07
and O 0 5.674922363141377e-07
show O 0 5.770511052105576e-06
abnormal O 0 2.818968459905591e-05
visceral O 0 4.408896711538546e-05
endoderm O 0 0.00037702888948842883
development O 0 1.4951080629543867e-05
. O 0 2.0428675270522945e-05

Growth B-Disease 1 0.9968457818031311
retardation I-Disease 1 0.9999459981918335
of O 0 4.148793777858373e-06
the O 0 7.869184628361836e-06
Smad4 O 0 0.09885585308074951
- O 0 0.11516670137643814
deficient O 0 0.003672259161248803
embryos O 0 9.003591003420297e-06
results O 0 1.8609672451930237e-06
from O 0 3.857375077132019e-07
reduced O 0 6.459950782300439e-06
cell O 0 6.060023952159099e-05
proliferation O 0 5.4789293244539294e-06
rather O 0 5.207384106142854e-07
than O 0 3.4885889022007177e-07
increased O 0 3.312646640551975e-06
apoptosis O 0 4.72472129331436e-05
. O 0 9.544262866256759e-06

Aggregation O 0 0.000508577679283917
of O 0 3.3047694159904495e-05
mutant O 0 0.0003144092042930424
Smad4 O 0 0.0013128063874319196
ES O 0 0.00041712401434779167
cells O 0 1.0390805982751772e-05
with O 0 1.1041238394682296e-06
wild O 0 5.0856911002483685e-06
- O 0 3.7442132452270016e-05
type O 0 2.4735403712838888e-05
tetraploid O 0 0.00010032923455582932
morulae O 0 0.000338797050062567
rescues O 0 0.00010467674292158335
the O 0 8.159075150615536e-06
gastrulation B-Disease 0 0.0005917156813666224
defect I-Disease 0 0.0013081495417281985
. O 0 5.122798393131234e-05

These O 0 3.305869540781714e-05
results O 0 2.783328454825096e-05
indicate O 0 1.1552379874046892e-05
that O 0 1.2622216445379308e-06
Smad4 O 0 0.0001245383609784767
is O 0 5.183670168662502e-07
initially O 0 1.5297456457119551e-06
required O 0 2.559299332460796e-07
for O 0 4.451478119449348e-08
the O 0 1.1194322979690696e-07
differentiation O 0 3.744719379028538e-07
of O 0 6.867350776929015e-08
the O 0 3.0979452958490583e-07
visceral O 0 6.873941856611054e-06
endoderm O 0 6.0777099861297756e-05
and O 0 1.3730087857766193e-06
that O 0 2.1829845309184748e-07
the O 0 9.438868460165395e-07
gastrulation B-Disease 0 3.557389209163375e-05
defect I-Disease 0 5.515639713848941e-05
in O 0 4.3682152295332344e-07
the O 0 1.068974256668298e-06
epiblast O 0 0.00014204572653397918
is O 0 1.8662514378320338e-07
secondary O 0 2.3177426555776037e-06
and O 0 1.5287188261936535e-06
non O 0 5.179468189453473e-06
- O 0 0.00026231660740450025
cell O 0 0.0001056314431480132
autonomous O 0 3.77308861061465e-05
. O 0 2.045262954197824e-05

Rescued O 0 0.10640262812376022
embryos O 0 0.0023984003346413374
show O 0 0.0005946193123236299
severe O 0 0.44703811407089233
anterior O 1 0.9205737113952637
truncations O 0 0.22652029991149902
, O 0 4.755254849442281e-05
indicating O 0 5.0189413741463795e-05
a O 0 2.70584610007063e-06
second O 0 4.083180101588368e-06
important O 0 4.4540945509652374e-07
role O 0 1.5248137970047537e-06
for O 0 8.97494089713291e-07
Smad4 O 0 0.0001382455084240064
in O 0 2.1775274490209995e-06
anterior O 0 0.007164419628679752
patterning O 0 0.00034514954313635826
during O 0 3.8730813685106114e-05
embryogenesis O 0 0.0002452298649586737
. O 0 4.802325929631479e-05

Prevalence O 0 0.008123164065182209
of O 0 2.660921381902881e-05
p16 O 0 0.000352035160176456
and O 0 2.1181715055718087e-05
CDK4 O 0 0.002349463291466236
germline O 0 0.00025052737328223884
mutations O 0 2.2535556126968004e-05
in O 0 4.44190482085105e-06
48 O 0 0.0026922801043838263
melanoma B-Disease 1 0.9968871474266052
- O 0 0.3678504228591919
prone O 0 0.18860380351543427
families O 0 2.5003089831443503e-05
in O 0 3.6053615986020304e-06
France O 0 0.00019494449952617288
. O 0 2.2415997591451742e-05

The O 0 0.00022405247727874666
French O 0 0.0022729209158569574
Familial B-Disease 1 0.9957228899002075
Melanoma I-Disease 1 0.9999442100524902
Study O 0 0.0004515673208516091
Group O 0 0.0003585521480999887
. O 0 6.5733322117012e-05

Germline O 0 0.007744040805846453
mutations O 0 0.0005592365632764995
in O 0 8.686594810569659e-06
the O 0 2.890583573389449e-06
p16 O 0 2.8527460017357953e-05
and O 0 3.4385286653559888e-06
CDK4 O 0 0.003259955672547221
genes O 0 5.544395662582247e-06
have O 0 2.0731031327159144e-06
been O 0 4.9926552492252085e-06
reported O 0 2.1348666905396385e-06
in O 0 1.8995098116647569e-07
a O 0 3.8534923874067317e-07
subset O 0 8.908410791264032e-07
of O 0 1.2853528232881217e-06
melanoma B-Disease 1 0.8313689827919006
pedigrees O 0 0.007337361574172974
, O 0 2.8482425022957614e-06
but O 0 8.853764938976383e-07
their O 0 3.558270918802009e-06
prevalence O 0 0.0007807323709130287
is O 0 5.542929102375638e-07
not O 0 4.638730501937971e-07
well O 0 9.346106253360631e-07
known O 0 6.318447503872449e-06
. O 0 7.822523912182078e-06

We O 0 5.398894063546322e-05
searched O 0 9.248310379916802e-05
for O 0 2.8649778869294096e-06
such O 0 2.170087327613146e-06
germline O 0 0.00015461114526260644
mutations O 0 1.7882941392599605e-05
in O 0 1.40348845434346e-06
48 O 0 2.6658208298613317e-05
French O 0 0.0008944361470639706
melanoma B-Disease 1 0.997428834438324
- O 0 0.260264128446579
prone O 0 0.21014194190502167
families O 0 7.858999197196681e-06
selected O 0 5.248721208772622e-07
according O 0 1.8751896391222544e-07
to O 0 2.2751680717192357e-07
two O 0 2.452322576118604e-07
major O 0 7.7559877809108e-07
criteria O 0 4.4015828279952984e-06
families O 0 1.2667230748775182e-06
with O 0 5.636126729768876e-07
at O 0 1.4468155313807074e-05
least O 0 2.8170421728646033e-07
three O 0 6.500066547232564e-07
affected O 0 1.031087890623894e-06
members O 0 2.3194111520297156e-07
( O 0 2.121575732871861e-07
n O 0 1.451044954592362e-05
= O 0 2.58221280091675e-05
20 O 0 1.4742599887540564e-06
) O 0 1.890235807877616e-07
or O 0 3.123600720300601e-07
families O 0 5.354606855689781e-07
with O 0 2.45183628067025e-07
two O 0 6.71909504035284e-07
affected O 0 1.6965906297627953e-06
members O 0 1.959806610329906e-07
, O 0 1.1695735935290941e-07
one O 0 5.0924434447097155e-08
of O 0 4.135959841278236e-08
them O 0 2.8420106445992133e-07
affected O 0 5.702863177248219e-07
before O 0 3.233085692500026e-07
the O 0 1.0813155881805869e-07
age O 0 6.439489652620978e-07
of O 0 7.436006654870653e-08
50 O 0 7.900080163381062e-07
( O 0 2.885929006879451e-07
n O 0 1.192530726257246e-05
= O 0 2.7567220968194306e-05
28 O 0 4.02745490646339e-06
) O 0 1.301820446997226e-07
, O 0 1.3046141589256877e-07
and O 0 2.0535621558792627e-07
one O 0 4.109930955564778e-07
additional O 0 1.0490225577086676e-06
minor O 0 3.58199467882514e-05
criterion O 0 7.448338146787137e-05
. O 0 2.6542480554780923e-05

Sixteen O 0 0.00041822175262495875
different O 0 2.9071461540297605e-05
p16 O 0 0.0003096129512414336
germline O 0 0.0003142671484965831
mutations O 0 9.727056021802127e-05
were O 0 1.2522506040113512e-05
found O 0 2.6997499844583217e-06
in O 0 1.3153699001122732e-06
21 O 0 2.1158803065191023e-05
families O 0 2.6964974040311063e-06
, O 0 2.8348642899800325e-07
while O 0 5.249006562735303e-07
one O 0 3.919046775990864e-07
germline O 0 2.5168710635625757e-05
mutation O 0 4.757864644489018e-06
, O 0 3.571195748008904e-07
Arg24His O 0 3.2076557545224205e-05
, O 0 5.455843847812503e-07
was O 0 6.003729140502401e-06
detected O 0 4.669792815548135e-06
in O 0 5.150791935193411e-07
the O 0 2.246647454740014e-06
CDK4 O 0 0.0022851743269711733
gene O 0 2.9278571673785336e-05
. O 0 1.488100770075107e-05

The O 0 2.1377851226134226e-05
frequency O 0 2.7427138775237836e-05
of O 0 2.885713684008806e-06
p16 O 0 3.096757791354321e-05
gene O 0 6.013212896505138e-06
mutation O 0 3.922556516045006e-06
in O 0 5.332388468559657e-07
our O 0 8.576560048823012e-07
sample O 0 1.731161887619237e-06
( O 0 2.553219360379444e-07
44 O 0 1.0828548511199187e-06
% O 0 2.067841506914192e-07
) O 0 5.919180168234561e-08
is O 0 2.7985411321651554e-08
among O 0 2.6427514399074425e-08
the O 0 1.30535852349567e-07
highest O 0 2.973695018226863e-06
rates O 0 7.0011064963182434e-06
yet O 0 1.3796635585094918e-06
reported O 0 2.0218917597958352e-06
and O 0 2.925382602825266e-07
the O 0 1.0933688372460892e-06
CDK4 O 0 0.020178591832518578
mutation O 0 4.2783231037901714e-06
is O 0 1.3525523456792143e-07
the O 0 2.1977530195727013e-07
second O 0 4.721914592664689e-06
mutation O 0 7.530502898589475e-06
detected O 0 1.0220564945484512e-05
in O 0 5.607919320027577e-07
this O 0 6.031770567460626e-07
gene O 0 8.006013558770064e-06
worldwide O 0 1.0774595466500614e-05
. O 0 1.1603004168136977e-05

In O 0 4.873149373452179e-05
summary O 0 3.11851326841861e-05
, O 0 3.1013853458716767e-06
our O 0 2.0194731860101456e-06
results O 0 1.8542142470323597e-06
show O 0 1.2467861552067916e-06
frequent O 0 1.0451220759932767e-06
involvement O 0 1.1319988288960303e-06
of O 0 1.7466261681420292e-07
the O 0 7.509107717851293e-07
p16 O 0 1.251439971383661e-05
gene O 0 4.1958251131291036e-06
in O 0 2.318098722753348e-06
familial B-Disease 1 0.568219780921936
melanoma I-Disease 1 0.9978860020637512
and O 0 1.880156014522072e-05
confirm O 0 1.2267098099982832e-05
the O 0 2.4843080836944864e-07
role O 0 3.619240658281342e-07
of O 0 8.419368668910465e-08
the O 0 5.953101549494022e-07
CDK4 O 0 0.0005246228538453579
gene O 0 1.8386430156169808e-06
as O 0 3.489078039820015e-07
a O 0 1.0489151463843882e-05
melanoma B-Disease 1 0.8525762557983398
- O 0 0.0010466249659657478
predisposing O 0 0.00019282300490885973
gene O 0 1.5974403140717186e-05
. O 0 2.899401806644164e-06
. O 0 1.3704468074138276e-05

Progression O 0 0.0007797152502462268
of O 0 2.2197546059032902e-05
somatic O 0 0.0007473817095160484
CTG O 0 0.0032860550563782454
repeat O 0 8.249244274338707e-05
length O 0 2.027346818067599e-05
heterogeneity O 0 2.206157660111785e-05
in O 0 2.199941263825167e-06
the O 0 4.080307462572819e-06
blood O 0 0.0002468162274453789
cells O 0 3.96797368011903e-05
of O 0 4.721559162135236e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9991008043289185
. O 0 0.0002268213575007394

The O 0 6.0331654822221026e-05
genetic O 0 8.82323001860641e-05
basis O 0 8.466327017231379e-06
of O 0 2.952283466584049e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.09952225536108017
DM B-Disease 1 1.0
) O 0 6.356257472361904e-06
is O 0 2.744599214565824e-07
the O 0 1.467826251655424e-07
expansion O 0 5.02675447933143e-07
of O 0 1.7224292037099076e-07
an O 0 2.101005065924255e-06
unstable O 0 0.01709045097231865
CTG O 0 0.0005398664507083595
repeat O 0 5.778369541076245e-06
in O 0 3.831059416370408e-07
the O 0 4.461415414880321e-07
34 O 0 3.1142424177232897e-06
UTR O 0 9.467426025366876e-06
of O 0 2.277447350707007e-07
the O 0 2.533258566472796e-06
DM B-Disease 1 0.9998681545257568
protein O 0 1.0984882464981638e-05
kinase O 0 2.3594251615577377e-05
gene O 0 4.725856797449524e-06
on O 0 3.1252147891791537e-06
chromosome O 0 0.0005698315217159688
19 O 0 4.983828330296092e-05
. O 0 2.108660373778548e-05

One O 0 2.5430874302401207e-05
of O 0 2.286366225234815e-06
the O 0 1.3576237734014285e-06
principal O 0 1.94513540918706e-06
features O 0 6.043805456101836e-07
of O 0 4.102690240870288e-07
the O 0 2.6484380214242265e-05
DM B-Disease 1 1.0
mutation O 0 8.16883475636132e-05
is O 0 2.480127250237274e-07
an O 0 2.604726887511788e-07
extraordinarily O 0 2.088997462124098e-05
high O 0 2.8083534289180534e-06
level O 0 3.5899762451663264e-07
of O 0 1.181110818038178e-07
somatic O 0 2.587507879070472e-05
mosaicism O 0 0.0021908527705818415
, O 0 1.6300089100695914e-06
due O 0 2.2338649614539463e-06
to O 0 8.354579676961293e-07
an O 0 1.2261415349712479e-06
extremely O 0 1.024834273266606e-05
high O 0 6.593331363546895e-06
degree O 0 2.405414306849707e-06
of O 0 3.4249362101945735e-07
somatic O 0 4.3644711695378646e-05
instability O 0 1.1251931937295012e-05
both O 0 3.192537576524046e-07
within O 0 3.983170131505176e-07
and O 0 4.726325073534099e-07
between O 0 6.681376021333563e-07
different O 0 1.608004254194384e-06
tissues O 0 0.0001851183915277943
. O 0 1.6619011148577556e-05

This O 0 4.354123666416854e-05
instability O 0 0.00014006988203618675
appears O 0 1.0449653018440586e-05
to O 0 1.1194082389920368e-06
be O 0 3.1871590522314364e-07
biased O 0 1.5089474345586495e-06
towards O 0 3.600612217269372e-07
further O 0 1.7023754139700031e-07
expansion O 0 3.631372749168804e-07
and O 0 2.2843734370781021e-07
continuous O 0 6.807445629419817e-07
throughout O 0 2.6321527002437506e-07
the O 0 2.0162774205800815e-07
life O 0 1.4914658663656155e-07
of O 0 2.9448020910649575e-08
an O 0 2.2411468592054007e-07
individual O 0 1.9090605007932027e-07
, O 0 2.0027800928801298e-07
features O 0 7.752985311526572e-07
that O 0 9.848417903413065e-07
could O 0 8.801234798738733e-06
be O 0 5.279883339426306e-07
associated O 0 4.830191073779133e-07
with O 0 2.388078428339213e-07
the O 0 5.922466357333178e-07
progressive O 0 1.0667986316548195e-05
nature O 0 7.784339004501817e-07
of O 0 3.2973366614896804e-07
the O 0 2.3579541448270902e-05
disease O 0 0.0791550949215889
. O 0 2.1051522708148696e-05

Although O 0 7.87171593401581e-05
increasing O 0 2.393564864178188e-05
measured O 0 2.514045081625227e-05
allele O 0 1.9521174181136303e-05
size O 0 5.9914373196079396e-06
between O 0 6.598602794838371e-06
patients O 0 0.000985101331025362
clearly O 0 7.117443146853475e-06
correlates O 0 4.749559138872428e-06
with O 0 5.605149908660678e-07
an O 0 8.188831088773441e-07
increased O 0 6.130654128355673e-06
severity O 0 0.0006227443227544427
of O 0 2.188415464843274e-06
symptoms O 0 0.16705003380775452
and O 0 2.2089875528763514e-06
an O 0 1.0282636822012137e-06
earlier O 0 3.5497432691045105e-06
age O 0 7.427001492033014e-06
of O 0 2.6666054964152863e-07
onset O 0 0.014594470150768757
, O 0 9.517725629848428e-07
this O 0 1.659690269661951e-07
correlation O 0 3.242990715079941e-06
is O 0 5.091530965728452e-07
not O 0 2.701833921037178e-07
precise O 0 3.973589628003538e-06
and O 0 1.317026772085228e-06
measured O 0 2.6988596800947562e-05
allele O 0 9.206702088704333e-06
length O 0 1.1176247426192276e-05
cannot O 0 3.812605882558273e-06
be O 0 1.7496937232408527e-07
used O 0 3.07115897157928e-07
as O 0 6.07197421231831e-08
an O 0 1.3919779462412407e-07
accurate O 0 1.0784341611724813e-05
predictor O 0 0.00022913236171007156
of O 0 3.056286743685632e-07
age O 0 9.480507287662476e-06
of O 0 1.52480799897603e-06
onset O 0 0.024459222331643105
. O 0 2.040093022515066e-05

In O 0 3.867958002956584e-05
order O 0 5.681254151568282e-06
to O 0 1.207523382618092e-06
further O 0 1.142257474384678e-06
characterize O 0 4.922584139421815e-06
the O 0 7.018421683824272e-07
dynamics O 0 9.523751032247674e-06
of O 0 2.138277750418638e-06
DM B-Disease 1 0.9999996423721313
CTG O 0 0.025022367015480995
repeat O 0 4.844362410949543e-05
somatic O 0 5.08280390931759e-05
instability O 0 2.6988649551640265e-05
, O 0 1.0826772722793976e-06
we O 0 9.97766846921877e-07
have O 0 5.195324774831533e-07
studied O 0 3.661892833406455e-06
repeat O 0 1.2884607713203877e-05
length O 0 2.3093582512956345e-06
changes O 0 2.2813777889041376e-07
over O 0 2.42033365793759e-07
time O 0 9.902514648274519e-07
in O 0 3.933679181500338e-06
111 O 0 0.06734912842512131
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.778895914554596
with O 0 1.1043724043702241e-05
varying O 0 0.00011705622455338016
clinical O 0 0.11804113537073135
severity O 0 0.06836201995611191
and O 0 4.756574708153494e-05
CTG O 0 0.004768154583871365
repeat O 0 9.806780326471198e-06
size O 0 1.986710230994504e-06
over O 0 3.7535292563006806e-07
time O 0 3.818872471583745e-07
intervals O 0 1.3650420669364394e-06
of O 0 1.483479366015672e-07
1 O 0 2.477097496011993e-06
- O 0 0.0001011747881420888
7 O 0 1.0702906365622766e-05
years O 0 5.895613867323846e-06
. O 0 1.3834059245709796e-05

We O 0 7.466174429282546e-05
have O 0 3.870873115374707e-06
found O 0 1.1162144346599234e-06
a O 0 4.280116456811811e-07
direct O 0 8.717630066712445e-07
progression O 0 1.04190858110087e-05
of O 0 1.240207581076902e-07
the O 0 2.6502380023885053e-07
size O 0 3.368640591361327e-06
heterogeneity O 0 3.3265889669564785e-06
over O 0 4.900036856270162e-07
time O 0 8.167523333213467e-07
related O 0 5.095518531561538e-07
to O 0 5.259880708763376e-07
initial O 0 1.0280803508067038e-05
CTG O 0 0.00021030132484156638
repeat O 0 4.380899554234929e-06
size O 0 1.4734981732544838e-06
and O 0 5.131464035912359e-07
the O 0 2.9164968395889446e-07
time O 0 6.731133908033371e-07
interval O 0 3.666316843009554e-06
and O 0 7.762810696476663e-07
always O 0 9.306882020609919e-07
biased O 0 2.034906628978206e-06
towards O 0 9.250320545106661e-07
further O 0 1.4830425243417267e-06
expansion O 0 6.207233582244953e-06
. O 0 1.3735688298766036e-05

Attempts O 0 0.00019738799892365932
to O 0 1.3357767784327734e-05
mathematically O 0 3.3636606531217694e-05
model O 0 4.737968538393034e-06
the O 0 1.1615252333285753e-06
dynamics O 0 2.6157071260968223e-05
have O 0 3.474627874311409e-06
proved O 0 1.355987842543982e-05
only O 0 5.528585234060301e-07
partially O 0 0.00015402139979414642
successful O 0 3.120925839539268e-06
suggesting O 0 1.5724816648798878e-06
that O 0 1.0287330809433115e-07
individual O 0 1.270097840233575e-07
specific O 0 2.534650320740184e-07
genetic O 0 2.1584302885457873e-05
and O 0 8.36673552839784e-06
/ O 0 0.0003654060128610581
or O 0 4.612132215697784e-06
environmental O 0 2.0799288904527202e-06
factors O 0 5.496872859112045e-07
also O 0 3.232734115954372e-07
play O 0 4.6353693505807314e-07
a O 0 6.096984748182877e-07
role O 0 8.308685437441454e-07
in O 0 8.985783210846421e-07
somatic O 0 8.589483331888914e-05
mosaicism O 0 0.0007364913471974432
. O 0 4.196241206955165e-06
. O 0 1.2323851478868164e-05

Aspartylglucosaminuria B-Disease 1 0.9979342222213745
among O 0 7.888563413871452e-05
Palestinian O 0 0.00023767152742948383
Arabs O 0 9.16907811188139e-05
. O 0 4.4586879084818065e-05

Aspartylglucosaminuria B-Disease 1 0.999997615814209
( O 0 0.17965082824230194
AGU B-Disease 1 0.999998927116394
) O 0 1.9203198462491855e-05
is O 0 9.99024678094429e-07
a O 0 3.2893919978960184e-06
rare O 0 3.838367047137581e-05
disorder B-Disease 0 0.28068405389785767
of I-Disease 0 9.039364385898807e-07
glycoprotein I-Disease 0 0.01258912030607462
metabolism I-Disease 0 0.19565781950950623
caused O 0 6.007089905324392e-05
by O 0 7.312111165447277e-07
the O 0 2.0043415133841336e-05
deficiency B-Disease 0 0.04326058179140091
of I-Disease 0 2.280483641925457e-07
the I-Disease 0 2.2428325792134274e-06
lysosomal I-Disease 0 0.008963258005678654
enzyme I-Disease 0 0.00011730528785847127
aspartylglucosaminidase I-Disease 0 0.0009244930697605014
( O 0 3.6243914109945763e-06
AGA O 0 0.0008045074646361172
) O 0 5.470262749440735e-06
. O 0 7.217118763946928e-06

AGU B-Disease 1 0.9999971389770508
is O 0 0.0005392542225308716
inherited O 1 0.6138349175453186
as O 0 8.988501576823182e-06
an O 0 1.7172515072161332e-05
autosomal O 1 0.9433066248893738
recessive O 1 0.986370325088501
trait O 0 0.007312418427318335
and O 0 1.0246447345707566e-05
occurs O 0 1.1783863556047436e-06
with O 0 3.4867264275817433e-07
a O 0 2.047981752184569e-06
high O 0 1.910110040626023e-05
frequency O 0 1.1695567991409916e-05
in O 0 1.1892334441654384e-06
Finland O 0 0.0002579759166110307
because O 0 8.182827855307551e-07
of O 0 2.8501858650997747e-07
a O 0 7.0565956775681116e-06
founder O 0 0.00010380312596680596
effect O 0 1.1712511877703946e-05
. O 0 9.36332162382314e-06

While O 0 0.0001548510481370613
very O 0 1.7279855455853976e-05
few O 0 1.0578084584267344e-05
patients O 0 0.00012729258742183447
with O 0 5.295919982017949e-05
AGU B-Disease 1 0.9999995231628418
have O 0 8.114208321785554e-05
been O 0 1.457699909224175e-05
reported O 0 1.2307161341595929e-05
from O 0 8.557915407436667e-07
non O 0 3.0962846722104587e-06
- O 0 2.168018909287639e-05
Finnish O 0 0.0001757592981448397
origin O 0 3.6755873225047253e-06
, O 0 3.8199900700419676e-06
we O 0 3.41512422892265e-05
diagnosed O 1 0.710942268371582
the O 0 1.4115588783170097e-05
disorder O 0 0.32500186562538147
in O 0 4.8190568122663535e-06
8 O 0 0.00015932944370433688
patients O 0 7.491335509257624e-06
originating O 0 1.0489575288374908e-06
from O 0 5.288344482323737e-07
3 O 0 4.129688022658229e-06
unrelated O 0 2.791882707242621e-06
families O 0 1.5286692587324069e-06
, O 0 1.6903133825962868e-07
all O 0 1.1113544218233073e-07
Palestinian O 0 3.6132473724137526e-06
Arabs O 0 1.0739096296674688e-06
from O 0 2.022476621732494e-07
the O 0 2.5117614654845966e-07
region O 0 6.734305202371615e-07
of O 0 6.229753353181877e-07
Jerusalem O 0 5.808817149954848e-05
. O 0 1.1072218512708787e-05

The O 0 0.00025461066979914904
clinical O 1 0.5236256718635559
diagnosis O 1 0.9997362494468689
of O 0 0.00035348121309652925
AGU B-Disease 1 0.9999998807907104
is O 0 2.682969716261141e-05
often O 0 6.6797597355616745e-06
difficult O 0 1.4241962162486743e-05
, O 0 6.176506417432392e-07
in O 0 2.3079968514139182e-07
particular O 0 1.442752051161733e-07
early O 0 6.241867254175304e-07
in O 0 3.51571884493751e-07
the O 0 3.22523902696048e-07
course O 0 2.7686771773005603e-06
of O 0 1.590066318613026e-07
the O 0 1.4102241038926877e-05
disease O 0 0.016888419166207314
, O 0 5.902213047193072e-07
and O 0 2.731553365720174e-07
most O 0 3.3155430401166086e-08
of O 0 4.192382618839474e-08
the O 0 5.046504156780429e-06
patients O 0 0.0006172953872010112
are O 0 6.362407475535292e-06
diagnosed O 1 0.9187710285186768
after O 0 4.4762296056433115e-06
the O 0 3.2029061003413517e-07
age O 0 1.99390024135937e-06
of O 0 1.7791755624330108e-07
5 O 0 4.282755980966613e-06
years O 0 4.406652351462981e-06
. O 0 7.779569386912044e-06

However O 0 8.359251660294831e-05
, O 0 6.5680269472068176e-06
since O 0 2.613909373394563e-06
these O 0 6.215113899088465e-07
patients O 0 1.1855942830152344e-05
excrete O 0 8.973795047495514e-06
early O 0 7.633761924807914e-07
large O 0 3.5656688623930677e-07
amounts O 0 3.3101062513196666e-07
of O 0 1.4078825927299476e-07
aspartylglucosamine O 0 4.309595897211693e-05
in O 0 8.688033403814188e-07
urine O 0 3.868618296110071e-05
, O 0 3.768521992242313e-07
biochemical O 0 1.038335631164955e-05
screening O 0 6.456599749071756e-06
is O 0 3.255486262787599e-07
easy O 0 1.7981400333155761e-06
by O 0 8.733898653190408e-07
urine O 0 4.5110755308996886e-05
chromatography O 0 0.00025819294387474656
. O 0 3.895265763276257e-06
. O 0 1.5220870409393683e-05

Detection O 0 0.00039619297604076564
of O 0 1.9085440726485103e-05
heterozygous O 0 0.00024442197172902524
carriers O 0 2.9503526093321852e-05
of O 0 1.7387199022778077e-06
the O 0 5.39163920620922e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999886751174927
telangiectasia I-Disease 1 0.9999996423721313
( O 0 8.02044178271899e-06
ATM O 0 0.013607362285256386
) O 0 1.2726225122605683e-06
gene O 0 2.3048391994962003e-06
by O 0 7.595615443278803e-07
G2 O 0 0.00013033708091825247
phase O 0 1.0373161785537377e-05
chromosomal O 0 0.00043478465522639453
radiosensitivity O 0 0.0001761468593031168
of O 0 2.817619360939716e-06
peripheral O 0 0.04394960775971413
blood O 0 0.27092257142066956
lymphocytes O 0 0.0016710693016648293
. O 0 2.680098077689763e-05

In O 0 0.0054102553986012936
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999909400939941
telangiectasia I-Disease 1 1.0
( O 0 0.0048503391444683075
A B-Disease 1 0.9999948740005493
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
) O 0 1.0534946341067553e-05
patients O 0 1.7318821846856736e-05
, O 0 6.646435508628201e-07
mutations O 0 2.327515176148154e-06
in O 0 2.2683715883431432e-07
a O 0 7.208832357719075e-07
single O 0 8.984019586932845e-06
gene O 0 3.856083822029177e-06
, O 0 4.378078699573962e-07
ATM O 0 0.004984232131391764
, O 0 8.943037528297282e-07
result O 0 1.7465474684286164e-06
in O 0 3.798169245783356e-06
an O 0 0.48433342576026917
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 9.082657925318927e-06
embraces O 0 4.970421286998317e-06
a O 0 9.768366453499766e-07
variety O 0 2.0177047588276764e-07
of O 0 1.773960605078173e-07
clinical O 0 2.579589454398956e-05
features O 0 6.408064564311644e-06
and O 0 8.559232810512185e-06
manifests O 0 1.8662831280380487e-05
extreme O 0 2.3484391931560822e-05
radiosensitivity O 0 0.0015281273517757654
and O 0 9.046643185683934e-07
a O 0 1.0610764320517774e-06
strong O 0 2.695348257475416e-06
pre O 0 0.0004952332819812
- O 0 0.006162236910313368
disposition O 0 0.00011720454494934529
to O 0 1.8597485905047506e-05
malignancy B-Disease 0 0.0995943620800972
. O 0 3.9333357563009486e-05

Heterozygotes O 0 0.0013315717224031687
for O 0 1.4628104509029072e-05
the O 0 5.97027656112914e-06
ATM O 0 0.0006759246462024748
gene O 0 1.5790450561325997e-05
have O 0 1.737495040288195e-06
no O 0 2.2549393179360777e-06
clinical O 0 8.555291060474701e-06
expression O 0 1.4157243413137621e-06
of O 0 1.0733260751294438e-06
A B-Disease 1 0.9998968839645386
- I-Disease 1 0.9999912977218628
T I-Disease 1 1.0
but O 0 4.1344541386934e-05
may O 0 0.00016362594033125788
be O 0 7.718128472333774e-05
cancer B-Disease 0 0.023802874609827995
prone O 0 0.00036982278106734157
with O 0 8.553664088140067e-07
a O 0 3.306347025500145e-06
moderate O 0 2.5464458303758875e-05
increase O 0 2.6055890884890687e-06
in O 0 2.0623108412110014e-06
in O 0 3.640016984718386e-06
vitro O 0 0.000526312505826354
radiosensitivity O 0 0.00455896882340312
. O 0 2.985112769238185e-05

We O 0 0.00016931237769313157
performed O 0 6.595332524739206e-05
a O 0 7.603843641845742e-06
blind O 0 6.738913361914456e-05
chromosomal O 0 0.00020464483532123268
analysis O 0 3.660688435047632e-06
on O 0 7.986856871866621e-06
G2 O 0 0.0004048346891067922
- O 0 7.534996257163584e-05
phase O 0 1.9481209164950997e-05
lymphocytes O 0 2.755478817562107e-05
from O 0 1.2583898296725238e-06
7 O 0 1.3931327885075007e-05
unrelated O 0 3.320830364827998e-05
A B-Disease 1 0.9999624490737915
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 0.026070458814501762
, O 0 2.3184500150819076e-06
13 O 0 1.0617369298415724e-05
obligate O 0 2.5212744731106795e-05
A B-Disease 1 0.9996728897094727
- I-Disease 1 0.9999769926071167
T I-Disease 1 1.0
heterozygotes O 0 0.00014401358203031123
( O 0 3.7537836306000827e-07
parents O 0 8.30902592952043e-07
of O 0 8.828034481211944e-08
the O 0 3.3276426165684825e-06
patients O 0 1.6738127669668756e-05
) O 0 1.792741528561237e-07
, O 0 1.9350596858203062e-07
and O 0 3.5301087564221234e-07
14 O 0 1.4691848946313257e-06
normal O 0 6.854395451227902e-07
controls O 0 1.5070174868014874e-06
following O 0 6.829019980614248e-07
X O 0 0.00025171853485517204
- O 0 2.414219852653332e-05
irradiation O 0 3.270078195782844e-06
with O 0 4.506606501308852e-07
1 O 0 1.8825554661816568e-06
Gy O 0 0.0001382381160510704
in O 0 2.830968526268407e-07
order O 0 2.1486282264504553e-07
to O 0 1.2641390867429436e-07
evaluate O 0 1.2839610690207337e-06
this O 0 1.1445644787499987e-07
cytogenetic O 0 2.017279803112615e-05
method O 0 1.0917308372881962e-06
as O 0 1.9193693390207045e-07
a O 0 3.36301894776625e-07
tool O 0 3.1188726552500157e-06
for O 0 2.0711669890260964e-07
detection O 0 3.538231567290495e-06
of O 0 8.205732342503325e-07
ATM O 0 0.12594254314899445
carriers O 0 0.00011760320194298401
. O 0 1.8731514501268975e-05

Both O 0 0.00012769183376803994
A B-Disease 1 0.9935727119445801
- I-Disease 1 0.9985687732696533
T I-Disease 1 0.9999948740005493
homozygotes O 0 0.000655507086776197
and O 0 5.414829502115026e-06
heterozygotes O 0 4.698714110418223e-05
showed O 0 1.5312640243791975e-05
significantly O 0 4.977855041943258e-06
increased O 0 1.026110567181604e-06
levels O 0 1.096800588129554e-06
of O 0 3.3813174127317325e-07
radiation O 0 0.05285586416721344
- O 0 0.02681591548025608
induced O 0 0.0034679309464991093
chromatid O 0 0.1217755526304245
damage O 0 0.0002641162136569619
relative O 0 1.1432685823820066e-05
to O 0 5.794615276499826e-07
that O 0 1.9267253037469345e-07
of O 0 3.3152559808513615e-07
normal O 0 1.2896482985524926e-05
controls O 0 6.691876478726044e-05
. O 0 1.8199578335043043e-05

These O 0 1.8426997485221364e-05
results O 0 1.1765574527089484e-05
show O 0 3.293595227660262e-06
that O 0 3.0577473353332607e-07
the O 0 4.706817549049447e-07
G2 O 0 0.00012071568198734894
- O 0 3.276423376519233e-05
phase O 0 7.060735697450582e-06
chromosomal O 0 0.0011279569007456303
radiosensitivity O 0 0.001286885584704578
assay O 0 0.000382302503567189
can O 0 1.944938958331477e-06
be O 0 3.7610899994433566e-07
used O 0 3.1964034974407696e-07
for O 0 1.0186075627416358e-07
the O 0 2.813771686760447e-07
detection O 0 7.360564723057905e-06
of O 0 1.8512140513848863e-06
A B-Disease 1 0.9997919201850891
- I-Disease 1 0.9999693632125854
T I-Disease 1 0.9999992847442627
heterozygotes O 0 0.0017285427311435342
. O 0 3.788834874285385e-05

In O 0 7.457904575858265e-05
combination O 0 7.230465416796505e-05
with O 0 4.5192869038146455e-06
molecular O 0 0.00033987805363722146
genetic O 0 0.00018653339066077024
analyses O 0 3.5228087654104456e-05
, O 0 2.4079984086711193e-06
this O 0 3.1501147645940364e-07
test O 0 0.00010573240433586761
may O 0 1.4796526556892786e-05
be O 0 1.4815876170359843e-07
of O 0 3.0710470610983975e-08
value O 0 6.71304292154673e-08
in O 0 9.261940192573093e-08
studies O 0 1.3743512283781456e-07
of O 0 9.321522753680256e-08
familial B-Disease 0 4.891064963885583e-05
and I-Disease 0 5.643561507895356e-06
sporadic I-Disease 0 0.003596106544137001
cancers I-Disease 1 0.7860336303710938
aimed O 0 0.00018091211677528918
at O 0 0.00014681267202831805
determination O 0 1.6460332972201286e-06
of O 0 1.1307498226642565e-07
the O 0 2.898567572628963e-07
potential O 0 4.3308335762048955e-07
involvement O 0 6.27377175987931e-07
of O 0 2.5480233034613775e-07
ATM O 0 0.16286610066890717
mutations O 0 7.322620513150468e-05
in O 0 1.2169210094725713e-05
tumor B-Disease 1 0.5477424263954163
risk O 0 0.00014014483895152807
or O 0 2.2961598915571813e-06
development O 0 1.9507365323079284e-06
. O 0 2.272115807500086e-06
. O 0 7.727187949058134e-06

Ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999468326568604
telangiectasia I-Disease 1 0.9999984502792358
: O 0 2.0551153284031898e-05
identification O 0 9.979229616874363e-06
and O 0 2.256624156871112e-06
detection O 0 9.683897587819956e-06
of O 0 6.319649514807679e-07
founder O 0 3.9510574424639344e-05
- O 0 7.934470340842381e-05
effect O 0 1.545058353258355e-06
mutations O 0 2.1184550860198215e-06
in O 0 1.7315468880951812e-07
the O 0 4.381444966838899e-07
ATM O 0 0.0002193156979046762
gene O 0 3.725601573023596e-06
in O 0 1.4198415101418504e-06
ethnic O 0 4.606584298016969e-06
populations O 0 2.6531497496762313e-05
. O 0 1.6883212083484977e-05

To O 0 1.8376371372141875e-05
facilitate O 0 6.82561585563235e-06
the O 0 1.4204129001882393e-06
evaluation O 0 2.7920582397200633e-06
of O 0 4.798511099579628e-07
ATM O 0 0.026499079540371895
heterozygotes O 0 5.244676140137017e-05
for O 0 7.782350053275877e-07
susceptibility O 0 4.322767199482769e-05
to O 0 2.0457757727854187e-06
other O 0 2.5698259378259536e-06
diseases O 0 0.022997509688138962
, O 0 6.071094844628533e-07
such O 0 1.692829982857802e-07
as O 0 6.084622873459011e-05
breast B-Disease 1 0.9999498128890991
cancer I-Disease 1 0.9762469530105591
, O 0 6.528036465169862e-06
we O 0 1.367180061606632e-06
have O 0 3.807457460425212e-07
attempted O 0 6.090805072744843e-06
to O 0 4.3129415416842676e-07
define O 0 1.5097074310688186e-06
the O 0 1.789506143268227e-07
most O 0 1.1715238201759348e-07
common O 0 4.925439611724869e-07
mutations O 0 2.2434317088482203e-06
and O 0 2.497284583569126e-07
their O 0 5.238105131866178e-07
frequencies O 0 2.810504702210892e-05
in O 0 5.3894294978817925e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.999981164932251
telangiectasia I-Disease 1 1.0
( O 0 4.803855699719861e-05
A B-Disease 1 0.999902606010437
- I-Disease 1 0.9999772310256958
T I-Disease 1 0.9999998807907104
) O 0 2.1137268504389795e-06
homozygotes O 0 3.0418628739425912e-05
from O 0 1.1437028888394707e-06
10 O 0 2.069401261906023e-06
ethnic O 0 3.1368601867143298e-06
populations O 0 2.16754742723424e-05
. O 0 1.2518434232333675e-05

Both O 0 6.491168460343033e-05
genomic O 0 0.0001549922744743526
mutations O 0 9.48176602832973e-05
and O 0 4.462582637643209e-06
their O 0 3.542485728758038e-06
effects O 0 9.746455361892004e-06
on O 0 2.7144994874106487e-06
cDNA O 0 1.5598365280311555e-05
were O 0 1.8062029994325712e-05
characterized O 0 3.221380393370055e-05
. O 0 2.0298755771364085e-05

Protein O 0 0.00025366205954924226
- O 0 0.00010200926044490188
truncation O 0 5.843642065883614e-05
testing O 0 9.869038876786362e-06
of O 0 6.803220458095893e-07
the O 0 8.841024055072921e-07
entire O 0 2.8154649953648914e-06
ATM O 0 2.571866389189381e-05
cDNA O 0 5.954860625934089e-06
detected O 0 8.802912816463504e-06
92 O 0 4.344192802818725e-06
( O 0 5.173841941541468e-07
66 O 0 2.334455530217383e-06
% O 0 7.884094088694837e-07
) O 0 6.549298063873721e-07
truncating O 0 1.3746223885391373e-05
mutations O 0 5.9613894336507656e-06
in O 0 1.4189913599693682e-06
140 O 0 6.462088549596956e-06
mutant O 0 5.6917033361969516e-05
alleles O 0 4.792535401065834e-05
screened O 0 0.00015124543278943747
. O 0 3.364001167938113e-05

The O 0 4.026124588563107e-05
haplotyping O 0 0.0006079475278966129
of O 0 4.565430117509095e-06
patients O 0 0.0002565630420576781
with O 0 6.103085070208181e-06
identical O 0 0.0069989352487027645
mutations O 0 0.0007327445200644433
indicates O 0 4.074311618751381e-06
that O 0 2.843816560016421e-07
almost O 0 2.1265933014547045e-07
all O 0 4.408857279258882e-08
of O 0 3.7785042650284595e-08
these O 0 6.14094872730675e-08
represent O 0 1.6075290432127076e-07
common O 0 4.1744655732145475e-07
ancestry O 0 4.800443093699869e-06
and O 0 1.098791813092248e-06
that O 0 3.0647103699266154e-07
very O 0 7.330705216190836e-07
few O 0 1.537089588055096e-06
spontaneously O 0 2.269420110678766e-05
recurring O 0 2.615258017613087e-05
ATM O 0 0.08554171770811081
mutations O 0 0.00010417983867228031
exist O 0 1.2866286851931363e-05
. O 0 1.597511800355278e-05

Assays O 0 0.0009378158138133585
requiring O 0 0.00011021087266271934
minimal O 0 2.5336923499708064e-05
amounts O 0 2.9035188617854146e-06
of O 0 5.754337166763435e-07
genomic O 0 1.2123409760533832e-05
DNA O 0 4.5391720050247386e-05
were O 0 9.012851478473749e-06
designed O 0 1.5741616152809e-05
to O 0 4.870164502790431e-07
allow O 0 3.9407240137734334e-07
rapid O 0 2.7956020858255215e-06
screening O 0 4.949802132614423e-06
for O 0 4.7005551095935516e-07
common O 0 1.8705578668232192e-06
ethnic O 0 4.775448360305745e-06
mutations O 0 0.0001285820617340505
. O 0 1.5874400560278445e-05

These O 0 4.2147534259129316e-05
rapid O 0 7.628528692293912e-05
assays O 0 0.00011691421241266653
detected O 0 0.00015596272714901716
mutations O 0 2.1671672584488988e-05
in O 0 1.4930270708646276e-06
76 O 0 1.959004657692276e-05
% O 0 7.717399626017141e-07
of O 0 1.9448187060788769e-07
Costa O 0 3.254646344430512e-06
Rican O 0 1.3232485798653215e-05
patients O 0 1.760614941304084e-05
( O 0 1.3146696176136174e-07
3 O 0 4.855463657804648e-07
) O 0 9.277393786533139e-08
, O 0 6.806322971897316e-08
50 O 0 9.620759300332793e-08
% O 0 7.828622727856782e-08
of O 0 6.114650830113533e-08
Norwegian O 0 0.2114795595407486
patients O 0 4.1249000787502155e-05
( O 0 2.0061732186604786e-07
1 O 0 5.849304329785809e-07
) O 0 1.2431537754764577e-07
, O 0 9.761478025893666e-08
25 O 0 4.284269721210876e-07
% O 0 2.1431824848150427e-07
of O 0 1.5837645150895696e-07
Polish O 0 0.10233119875192642
patients O 0 0.00018938361608888954
( O 0 3.2743986366767786e-07
4 O 0 1.8085620467900299e-06
) O 0 1.1990357506874716e-07
, O 0 1.3134102516687562e-07
and O 0 2.81911411548208e-07
14 O 0 7.355978937084728e-07
% O 0 1.289210871391333e-07
of O 0 7.324199913227858e-08
Italian O 0 0.0013444318901747465
patients O 0 0.0005064278375357389
( O 0 1.8733182116648095e-07
1 O 0 6.964846193113772e-07
) O 0 1.1017366574606058e-07
, O 0 6.984162581602504e-08
as O 0 7.912342425697716e-08
well O 0 1.9747406554415647e-07
as O 0 1.5775255235439545e-07
in O 0 4.057840214954922e-07
patients O 0 1.8238978327644872e-06
of O 0 1.5510742912283604e-07
Amish O 0 0.00014307352830655873
/ O 0 1.4315139196696691e-05
Mennonite O 0 4.39027717220597e-05
and O 0 3.923754320567241e-06
Irish O 0 1.4393275705515407e-05
English O 0 1.5264233297784813e-05
backgrounds O 0 4.489175626076758e-05
. O 0 1.5849560440983623e-05

Additional O 0 0.0001023470758809708
mutations O 0 0.00014663724869024009
were O 0 1.2541232536023017e-05
observed O 0 3.5735126857616706e-06
in O 0 7.2265498829438e-07
Japanese O 0 1.9943909137509763e-06
, O 0 3.703055142523226e-07
Utah O 0 1.6632126289550797e-06
Mormon O 0 5.613944722426822e-07
, O 0 1.4918073532044218e-07
and O 0 2.7997830898129905e-07
African O 0 1.3742690043727634e-06
American O 0 5.284414328343701e-06
patients O 0 4.512551095103845e-05
. O 0 1.233896182384342e-05

These O 0 1.7680909877526574e-05
assays O 0 4.112880924367346e-05
should O 0 2.877513452403946e-06
facilitate O 0 2.5630215532146394e-06
screening O 0 1.008776598609984e-05
for O 0 3.0845192213746486e-06
A B-Disease 1 0.999004065990448
- I-Disease 1 0.9999681711196899
T I-Disease 1 0.9999998807907104
heterozygotes O 0 5.450215030577965e-05
in O 0 4.0033503978520457e-07
the O 0 5.056776331002766e-07
populations O 0 2.2925999019207666e-06
studied O 0 6.135157491371501e-06
. O 0 2.3900843189039733e-06
. O 0 7.8284347182489e-06

The O 0 0.0002503213472664356
von B-Disease 1 0.9018464684486389
Hippel I-Disease 1 0.9830911755561829
- I-Disease 0 0.4614827334880829
Lindau I-Disease 1 0.9939374923706055
tumor I-Disease 0 0.18648232519626617
suppressor O 0 0.00022268945758696645
gene O 0 1.4701500731462147e-05
is O 0 5.292506557452725e-07
required O 0 8.93945696134324e-07
for O 0 6.780937837902457e-07
cell O 0 0.00011119408009108156
cycle O 0 1.761834391800221e-05
exit O 0 1.7150125131593086e-05
upon O 0 8.490342224831693e-06
serum O 0 0.0005912157357670367
withdrawal O 0 6.96624701959081e-05
. O 0 1.9251698176958598e-05

The O 0 4.4904430978931487e-05
inactivation O 0 0.0006007896736264229
of O 0 6.076288627809845e-06
the O 0 8.718065146240406e-06
von B-Disease 1 0.9644597768783569
Hippel I-Disease 1 0.9934141635894775
- I-Disease 1 0.8088150024414062
Lindau I-Disease 1 0.9931198358535767
( I-Disease 0 1.9415885617490858e-05
VHL I-Disease 0 0.0172549020498991
) I-Disease 0 5.828261691931402e-06
tumor I-Disease 0 0.00024811626644805074
suppressor O 0 7.85402808105573e-05
gene O 0 1.9548149793990888e-05
predisposes O 0 9.09219597815536e-05
affected O 0 7.422094768116949e-06
individuals O 0 7.77230695803155e-07
to O 0 4.277566176824621e-07
the O 0 4.119063760299468e-06
human O 0 0.00017453684995416552
VHL B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999996423721313
and O 0 2.9279715818120167e-05
is O 0 1.7761387880455004e-06
associated O 0 2.6813913791556843e-06
with O 0 1.3114145076542627e-05
sporadic B-Disease 1 0.9771653413772583
renal I-Disease 1 1.0
cell I-Disease 1 0.9999991655349731
carcinomas I-Disease 1 1.0
( O 0 0.0004690779896918684
RCC B-Disease 1 0.9900611639022827
) O 0 5.843377948622219e-06
and O 0 1.7862435925053433e-05
brain B-Disease 0 0.44551727175712585
hemangioblastomas I-Disease 0 0.006198888644576073
. O 0 2.642249637574423e-05

VHL O 0 0.3026356101036072
- O 0 0.0012036269763484597
negative O 0 8.660413004690781e-05
786 O 0 0.00034435646375641227
- O 0 0.0005770373390987515
0 O 0 7.894651935203001e-05
RCC B-Disease 0 0.013944179750978947
cells O 0 2.7490350476000458e-05
are O 0 6.895141950735706e-07
tumorigenic O 0 5.283404971123673e-05
in O 0 2.462644488332444e-06
nude O 0 0.009595336392521858
mice O 0 0.0006812028586864471
which O 0 5.870361405868607e-07
is O 0 3.3128759469036595e-07
suppressed O 0 1.4834300827715197e-06
by O 0 1.7085460513044382e-07
the O 0 9.586750593371107e-07
reintroduction O 0 1.8435592210153118e-05
of O 0 5.640537892759312e-06
VHL B-Disease 0 0.005511738359928131
. O 0 5.649766171700321e-05

Remarkably O 0 0.045757126063108444
, O 0 9.892972229863517e-06
this O 0 1.1720181873897673e-06
occurs O 0 1.4415049918170553e-06
without O 0 8.110612270684214e-07
affecting O 0 1.2970582474736148e-06
the O 0 3.8827749904157827e-07
growth O 0 1.1254572882535285e-06
rate O 0 1.2257252137715113e-06
and O 0 9.718727369545377e-07
cell O 0 2.4633332941448316e-05
cycle O 0 4.325275313021848e-06
profile O 0 1.271056476070953e-06
of O 0 1.5095923799890443e-07
these O 0 4.308336940539448e-07
cells O 0 2.904125494751497e-06
in O 0 1.0360005262555205e-06
culture O 0 6.176922397571616e-06
. O 0 9.900334589474369e-06

The O 0 8.526954479748383e-05
786 O 0 0.0004414638679008931
- O 0 0.00019035287550650537
0 O 0 2.217772271251306e-05
cell O 0 2.3783153665135615e-05
line O 0 1.5192055798252113e-05
, O 0 5.065890036348719e-07
like O 0 5.185044642530556e-07
many O 0 7.782660986777046e-07
cancer B-Disease 0 0.01401375513523817
cells O 0 4.745638307213085e-06
, O 0 4.707405594217562e-07
fails O 0 1.848530700954143e-06
to O 0 2.2416300282657176e-07
exit O 0 3.289250798843568e-06
the O 0 7.545963285338075e-07
cell O 0 1.9577384591684677e-05
cycle O 0 5.653311745845713e-06
upon O 0 2.290325028297957e-06
serum O 0 0.00011336640454828739
withdrawal O 0 3.788379399338737e-05
. O 0 1.4335905689222272e-05

Here O 0 6.030956137692556e-05
, O 0 3.899305283994181e-06
it O 0 5.737656465498731e-07
is O 0 1.5399200492538512e-07
shown O 0 2.5862789243547013e-07
that O 0 7.788796096974693e-08
reintroduction O 0 7.586587571495329e-07
of O 0 6.939387731108582e-08
the O 0 2.618337759940914e-07
wild O 0 1.3250960364530329e-06
- O 0 2.5184559490298852e-05
type O 0 2.6110539693036117e-05
VHL B-Disease 0 0.001169856172055006
gene O 0 6.174743248266168e-06
restores O 0 5.6872218010539655e-06
the O 0 3.6063099173588853e-07
ability O 0 1.1980029057667707e-06
of O 0 5.91609875755239e-07
VHL O 0 0.004082732368260622
- O 0 0.0008700884063728154
negative O 0 5.937505920883268e-05
RCC B-Disease 1 0.9603114724159241
cancer I-Disease 0 0.06322525441646576
cells O 0 3.467487658781465e-06
to O 0 4.620258096110774e-07
exit O 0 4.689634806709364e-06
the O 0 9.337784945273597e-07
cell O 0 4.8680776671972126e-05
cycle O 0 6.026898972777417e-06
and O 0 1.0454291441419628e-06
enter O 0 6.653806394751882e-06
G0 O 0 0.00019372638780623674
/ O 0 2.4661538191139698e-05
quiescence O 0 4.343818000052124e-05
in O 0 3.781449777306989e-06
low O 0 0.0009817543905228376
serum O 0 0.011782006360590458
. O 0 2.233793566119857e-05

Both O 0 0.00011071416520280764
VHL O 0 0.015150821767747402
- O 0 0.00029772959533147514
positive O 0 1.031130159390159e-05
and O 0 4.304388312448282e-06
VHL O 0 0.0008387242560274899
- O 0 9.127586235990748e-05
negative O 0 8.186198101611808e-06
RCC B-Disease 0 0.0011572239454835653
cells O 0 2.8683241453109076e-06
exit O 0 3.5662442314787768e-06
the O 0 9.49500645219814e-07
cell O 0 2.855712955351919e-05
cycle O 0 4.634822289517615e-06
by O 0 6.818457904955721e-07
contact O 0 1.1174626706633717e-05
inhibition O 0 5.7088695029960945e-05
. O 0 2.7995080017717555e-05

The O 0 7.406211079796776e-05
cyclin O 0 0.0005158524145372212
- O 0 6.890833174111322e-05
dependent O 0 1.2941796740051359e-05
kinase O 0 2.0545274310279638e-05
inhibitor O 0 5.5811005950090475e-06
, O 0 6.792017757106805e-07
p27 O 0 1.654407060414087e-05
, O 0 8.10241772342124e-07
accumulates O 0 4.050029474456096e-06
upon O 0 1.3364840469876071e-06
serum O 0 4.957095006830059e-05
withdrawal O 0 5.420223715191241e-06
, O 0 3.230059348879877e-07
only O 0 8.871482037875467e-08
in O 0 1.14022078889775e-07
the O 0 1.822352402314209e-07
presence O 0 2.9894709996369784e-07
of O 0 1.6024793580982077e-07
VHL B-Disease 0 0.0020304748322814703
, O 0 3.967709574226319e-07
as O 0 9.540757872628092e-08
a O 0 3.66983584854097e-07
result O 0 3.4471469234631513e-07
of O 0 4.5499724876663095e-08
the O 0 1.9233748105307313e-07
stabilization O 0 9.362967716697312e-07
of O 0 1.597026795252532e-07
the O 0 1.023227810037497e-06
protein O 0 1.9003857232746668e-05
. O 0 1.3954385394754354e-05

We O 0 5.8314064517617226e-05
propose O 0 2.0736029910040088e-05
that O 0 7.853491297282744e-07
the O 0 4.93488073516346e-07
loss O 0 2.411816012681811e-06
of O 0 1.5458275015589606e-07
wild O 0 2.6335089842177695e-06
- O 0 0.0004060695646330714
type O 0 0.00013123911048751324
VHL B-Disease 0 0.1366623491048813
gene O 0 1.8613864085637033e-05
results O 0 9.328722626378294e-06
in O 0 7.967175861267606e-07
a O 0 9.676518857304472e-07
specific O 0 1.0572340443104622e-06
cellular O 0 0.008046326227486134
defect O 0 0.001136650680564344
in O 0 4.022621851618169e-06
serum O 0 0.0031245306599885225
- O 0 0.001590245170518756
dependent O 0 1.4349473531183321e-05
growth O 0 2.19247885979712e-06
control O 0 5.744003374275053e-06
, O 0 3.863133031245525e-07
which O 0 5.776958005299093e-07
may O 0 4.242847353452817e-06
initiate O 0 2.1726531485910527e-05
tumor B-Disease 0 0.0003768357855733484
formation O 0 4.206485391478054e-05
. O 0 1.4978194485593121e-05

This O 0 3.3790453016990796e-05
is O 0 6.5148883550136816e-06
corrected O 0 1.6794601833680645e-05
by O 0 3.659124274690839e-07
the O 0 2.8726060463668546e-07
reintroduction O 0 2.2451010863733245e-06
of O 0 2.643029404225672e-07
wild O 0 2.117542180712917e-06
- O 0 0.0001569494343129918
type O 0 0.0003057462745346129
VHL B-Disease 0 0.21337555348873138
, O 0 5.470392807183089e-06
implicating O 0 0.0019040665356442332
VHL B-Disease 0 0.005253216717392206
as O 0 7.394720569209312e-07
the O 0 4.139500049404887e-07
first O 0 6.122474133007927e-06
tumor B-Disease 0 0.0005904464051127434
suppressor O 0 1.0642895176715683e-05
involved O 0 7.668012358408305e-07
in O 0 2.1128693106220453e-07
the O 0 1.9153684149841865e-07
regulation O 0 7.83571636020497e-07
of O 0 1.4656035318694194e-07
cell O 0 7.278343400685117e-05
cycle O 0 1.132262059400091e-05
exit O 0 2.1774216293124482e-05
, O 0 8.600944170211733e-07
which O 0 4.715556087830919e-07
is O 0 2.473683480275213e-07
consistent O 0 5.130274871589791e-07
with O 0 1.3722925018555543e-07
its O 0 8.947507694756496e-07
gatekeeper O 0 5.358945418265648e-05
function O 0 1.4556094356521498e-06
in O 0 8.523665542270464e-07
the O 0 1.839660581026692e-05
kidney O 0 0.41086387634277344
. O 0 4.068200269102817e-06
. O 0 1.009224979497958e-05

Piebaldism B-Disease 1 0.9999864101409912
with O 0 0.048483483493328094
deafness B-Disease 1 1.0
: O 0 4.656684905057773e-05
molecular O 0 9.713532199384645e-05
evidence O 0 2.973400114569813e-06
for O 0 1.1706531495292438e-06
an O 0 2.4270919311675243e-05
expanded O 0 0.3025834560394287
syndrome O 1 0.9999978542327881
. O 0 5.968626282992773e-05

In O 0 4.0886116039473563e-05
a O 0 9.189991033053957e-06
South O 0 5.4855900089023635e-06
African O 0 2.538007947805454e-06
girl O 0 2.2142765374155715e-05
of O 0 5.438731704998645e-07
Xhosa O 0 0.07830026745796204
stock O 0 2.7527708880370483e-05
with O 0 3.354963610036066e-06
severe O 0 0.3301887512207031
piebaldism B-Disease 0 0.4936734139919281
and O 0 0.0003737329097930342
profound O 1 0.5814928412437439
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.21159404516220093
identified O 0 6.627916445722803e-05
a O 0 1.4426793768507196e-06
novel O 0 1.1605553709159722e-06
missense O 0 4.948763944412349e-06
substitution O 0 8.576159302720043e-07
at O 0 4.149521828367142e-06
a O 0 8.933968729252229e-07
highly O 0 6.139069341770664e-07
conserved O 0 1.392116246279329e-06
residue O 0 5.652158051816514e-06
in O 0 2.3430102658039687e-07
the O 0 3.182099419518636e-07
intracellular O 0 1.0320528417651076e-05
kinase O 0 1.2012717888865154e-05
domain O 0 1.2142603509346372e-06
of O 0 3.240827766148868e-07
the O 0 1.0952578577416716e-06
KIT O 0 0.0003990614786744118
proto O 0 0.0007541939849033952
- O 0 0.0008251839317381382
oncogene O 0 0.0003997736785095185
, O 0 9.365947335027158e-06
R796G O 0 0.00020828026754315943
. O 0 2.6199957574135624e-05

Though O 0 0.0003121711779385805
auditory B-Disease 0 0.002871786244213581
anomalies I-Disease 0 0.11435350775718689
have O 0 3.1269712053472176e-05
been O 0 7.757668754493352e-06
observed O 0 2.422860688966466e-06
in O 0 1.7373440641677007e-06
mice O 0 0.0009090265957638621
with O 0 4.724009158962872e-06
dominant O 0 0.0002071612689178437
white O 0 5.840633457410149e-05
spotting O 0 0.04333328828215599
( O 0 6.536359251185786e-06
W O 1 0.863440990447998
) O 0 8.115239324979484e-07
due O 0 1.5297864592866972e-06
to O 0 2.493004330972326e-06
KIT O 1 0.9153386950492859
mutations O 0 0.008939146995544434
, O 0 0.00011432322935434058
deafness B-Disease 1 1.0
is O 0 3.6043716136191506e-06
not O 0 6.2494319763573e-07
typical O 0 2.6506777430768125e-06
in O 0 2.718766609177692e-06
human O 0 6.1760388234688435e-06
piebaldism B-Disease 0 0.000519883877132088
. O 0 1.915124084916897e-05

Thus O 0 0.00016065131057985127
, O 0 5.217472789809108e-06
the O 0 1.3793110156257171e-06
occurrence O 0 5.822550519951619e-06
of O 0 1.7410395685146796e-06
sensorineural B-Disease 1 0.9995512366294861
deafness I-Disease 1 1.0
in O 0 0.00016136013437062502
this O 0 2.624380158522399e-06
patient O 0 4.866323070018552e-05
extends O 0 1.9073349903919734e-06
considerably O 0 3.095974534517154e-06
the O 0 3.2532702221033105e-07
phenotypic O 0 2.6548518690105993e-06
range O 0 1.1473451877463958e-06
of O 0 3.483033879092545e-07
piebaldism B-Disease 0 0.00019656574295368046
due O 0 3.2783464121166617e-06
to O 0 7.867284921303508e-07
KIT O 0 0.0026899047661572695
gene O 0 5.320184300217079e-06
mutation O 0 2.258669383081724e-06
in O 0 3.835278050701163e-07
humans O 0 8.808152074379905e-07
and O 0 7.98751159436506e-07
tightens O 0 0.001997340004891157
the O 0 1.1664340036077192e-06
clinical O 0 1.8709233700064942e-05
similarity O 0 1.5011179357315996e-06
between O 0 8.186504487639468e-07
piebaldism B-Disease 0 0.0035553593188524246
and O 0 5.768017672380665e-07
the O 0 1.785755756600338e-07
various O 0 1.9588331667819148e-07
forms O 0 1.3988316140967072e-06
of O 0 9.220932406606153e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
. O 0 1.1665903002722189e-05
. O 0 2.242852860945277e-05

Cycloheximide O 0 0.0023788362741470337
facilitates O 0 8.761906065046787e-05
the O 0 3.583314082789002e-06
identification O 0 4.571799763652962e-06
of O 0 1.3828512237523682e-06
aberrant O 0 4.02651603508275e-05
transcripts O 0 2.2587688363273628e-05
resulting O 0 5.853752099937992e-06
from O 0 8.42196811845497e-07
a O 0 1.5996408819773933e-06
novel O 0 1.5739188938823645e-06
splice O 0 0.00015727299614809453
- O 0 0.00011021865793736652
site O 0 1.0019864021160174e-05
mutation O 0 5.6569897424196824e-06
in O 0 1.3172716535336804e-06
COL17A1 O 0 0.00048589237849228084
in O 0 1.7414215562894242e-06
a O 0 1.7510556062916294e-05
patient O 0 0.0024247525725513697
with O 0 3.1148963898885995e-05
generalized O 0 0.08244562894105911
atrophic B-Disease 1 0.9997007846832275
benign I-Disease 1 0.9924902319908142
epidermolysis I-Disease 1 0.9993694424629211
bullosa I-Disease 1 0.9983610510826111
. O 0 0.0002510292688384652

Patients O 1 0.9965130686759949
with O 0 0.0005237319855950773
generalized O 0 0.2881697714328766
atrophic B-Disease 1 0.9999327659606934
benign I-Disease 1 0.9995232820510864
epidermolysis I-Disease 1 0.9997586607933044
bullosa I-Disease 1 0.9993237257003784
often O 0 0.0004432015703059733
show O 0 3.176166501361877e-05
decreased O 0 1.9482808056636713e-05
expression O 0 1.7236368421436055e-06
of O 0 6.066568971618835e-07
type O 0 0.00033922152942977846
XVII O 1 0.7360886931419373
collagen O 0 0.0002593219105619937
, O 0 1.8414277747069718e-06
a O 0 1.8757543784886366e-06
transmembrane O 0 3.1542433134745806e-05
hemidesmosomal O 0 7.035302405711263e-05
protein O 0 2.822198894136818e-06
encoded O 0 3.6525145787891233e-06
by O 0 4.245020591042703e-06
COL17A1 O 0 0.0011444669216871262
. O 0 1.0389567250967957e-05

This O 0 3.325932993902825e-05
report O 0 1.462662658013869e-05
documents O 0 4.686871761805378e-06
a O 0 3.311250793558429e-06
novel O 0 3.498498244880466e-06
splice O 0 0.0002906198787968606
- O 0 0.00025030464166775346
site O 0 2.2902440832694992e-05
mutation O 0 7.535273198300274e-06
in O 0 1.6770294450907386e-06
COL17A1 O 0 0.006615674588829279
in O 0 1.4419903209272888e-06
a O 0 1.807295484468341e-05
patient O 0 0.00048695370787754655
with O 0 1.2067003808624577e-05
generalized O 0 0.03331603854894638
atrophic B-Disease 1 0.9999189376831055
benign I-Disease 1 0.9782976508140564
epidermolysis I-Disease 1 0.9826266169548035
bullosa I-Disease 1 0.9519327282905579
, O 0 7.27671385902795e-06
and O 0 1.1076464261350338e-06
applies O 0 4.3576014263635443e-07
a O 0 3.4675096571845643e-07
new O 0 4.2705633518380637e-07
methodology O 0 2.303208702869597e-06
to O 0 3.7728335655629053e-07
define O 0 2.56317321145616e-06
and O 0 6.373942369464203e-07
characterize O 0 4.794102551386459e-06
the O 0 8.598713634455635e-07
resulting O 0 2.5601004836062202e-06
mRNA O 0 5.500278803083347e-06
splice O 0 0.00012754469935316592
variants O 0 6.026092523825355e-05
. O 0 3.94067210436333e-05

Mutational O 0 0.0036946514155715704
analysis O 0 8.050317410379648e-05
of O 0 1.3264654626254924e-05
COL17A1 O 0 0.011342935264110565
identified O 0 3.1273826607503e-05
a O 0 1.1881352293130476e-05
maternally O 0 0.001151768141426146
inherited O 0 0.05318310484290123
G O 0 0.0009045881452038884
- O 0 3.968098098994233e-05
to O 0 4.1211383177142125e-06
- O 0 0.011653466150164604
T O 0 0.00644115312024951
transversion O 0 3.5619646951090544e-05
at O 0 1.912033667395008e-06
the O 0 2.720231861985667e-07
- O 0 4.522063136391807e-06
1 O 0 2.8487133363341854e-07
position O 0 8.936567610362545e-07
of O 0 4.0670221324035083e-07
exon O 0 2.127717380062677e-05
32 O 0 2.17013293877244e-05
. O 0 1.863183751993347e-05

This O 0 3.5316152207087725e-05
acceptor O 0 6.773730274289846e-05
splice O 0 0.000382845348212868
- O 0 6.269668665481731e-05
site O 0 1.0427783308841754e-05
mutation O 0 4.056140369357308e-06
led O 0 9.001375929074129e-07
to O 0 1.9219831415284716e-07
the O 0 1.8809478774528543e-07
formation O 0 1.013284077089338e-06
of O 0 1.7375400318542233e-07
aberrant O 0 6.992612270551035e-06
transcripts O 0 3.890413154294947e-06
present O 0 9.628980706111179e-07
at O 0 1.9150564185110852e-05
extremely O 0 1.2010426871711388e-05
low O 0 9.220193169312552e-05
levels O 0 2.7682714062393643e-05
. O 0 8.09934954304481e-06

Based O 0 3.936750363209285e-05
on O 0 5.467461505759275e-06
our O 0 3.3940898447326617e-06
recent O 0 1.4944401982575073e-06
finding O 0 1.9798594621533994e-06
that O 0 9.361967272525362e-07
cycloheximide O 0 8.701580372871831e-05
stabilized O 0 0.00014907793956808746
mutant O 0 2.7693118681781925e-05
COL17A1 O 0 9.686531848274171e-05
transcripts O 0 7.05151614965871e-06
in O 0 1.8895739231084008e-06
keratinocytes O 0 2.8143242161604576e-05
homozygous O 0 2.9573839128715917e-05
for O 0 4.020050141662068e-07
a O 0 6.075744295230834e-06
frameshift O 0 0.007432543206959963
mutation O 0 3.1014304113341495e-05
, O 0 3.874607727993862e-07
the O 0 2.742911249242752e-07
effects O 0 1.1254282981099095e-06
of O 0 1.2668679971739039e-07
the O 0 8.951638506005111e-07
splice O 0 0.0006009784410707653
- O 0 5.041880649514496e-05
site O 0 4.7017974793561734e-06
mutation O 0 1.5377552244899562e-06
on O 0 4.6642108486594225e-07
splicing O 0 4.954562427883502e-06
of O 0 5.276711476653873e-07
COL17A1 O 0 0.00020638132991734892
transcripts O 0 5.3431926971825305e-06
were O 0 2.5909323539963225e-06
determined O 0 1.918020416269428e-06
using O 0 1.3332887647266034e-06
reverse O 0 1.458285260014236e-05
transcriptase O 0 3.232705421396531e-05
polymerase O 0 2.283814137626905e-05
chain O 0 2.595995283627417e-05
reaction O 0 1.2399560773701523e-06
of O 0 2.660029565504374e-07
total O 0 8.822906352179416e-07
RNA O 0 2.470774461471592e-06
from O 0 1.1968289754804573e-06
keratinocytes O 0 1.7623957319301553e-05
incubated O 0 1.64227640198078e-05
for O 0 1.5703175222370191e-06
2 O 0 1.5828896721359342e-05
. O 0 1.812110531318467e-05

5 O 0 0.000234789025853388
h O 0 0.0003117098822258413
in O 0 2.4158975975296926e-06
the O 0 8.425808459833206e-07
presence O 0 1.0042411986432853e-06
or O 0 7.388193239421526e-07
absence O 0 6.646955057476589e-07
of O 0 2.0251150090189185e-07
10 O 0 2.8890290195704438e-06
microg O 0 7.153434125939384e-05
cycloheximide O 0 6.998793833190575e-05
per O 0 5.841433448949829e-06
ml O 0 0.0002696081646718085
. O 0 1.1611992704274599e-05

Using O 0 4.064624954480678e-05
this O 0 1.87833393283654e-06
approach O 0 3.4587551454023924e-06
, O 0 5.834039598084928e-07
an O 0 8.878081416696659e-07
abnormally O 0 0.0014019294176250696
spliced O 0 0.0007246206514537334
transcript O 0 0.00013880357437301427
was O 0 9.162740025203675e-05
identified O 0 1.3858957572665531e-06
that O 0 8.816103758135796e-08
contains O 0 5.3197815930161596e-08
an O 0 9.640561415835691e-08
extra O 0 5.185865461498906e-07
264 O 0 1.8405885384709109e-06
bases O 0 1.6665707107677008e-06
upstream O 0 9.672311307440395e-07
from O 0 3.5473706816446793e-07
exon O 0 4.145424099988304e-06
32 O 0 2.474646407790715e-06
, O 0 4.1505410308673163e-07
resulting O 0 9.78854700406373e-07
in O 0 3.733785547410662e-07
a O 0 3.876177288475446e-06
premature O 0 0.00017161850701086223
termination O 0 1.819970020733308e-05
codon O 0 2.408025466138497e-05
27 O 0 1.4469769666902721e-05
bp O 0 3.647481571533717e-05
downstream O 0 5.012783731217496e-06
from O 0 4.201580736662436e-07
the O 0 1.1368671266609454e-06
cryptic O 0 4.609041570802219e-05
splice O 0 0.000682629703078419
site O 0 0.000108140884549357
. O 0 3.0465567760984413e-05

Three O 0 3.01636155199958e-05
other O 0 2.3270047222467838e-06
splice O 0 0.00017773547733668238
variants O 0 1.0849785212485585e-05
, O 0 8.065443353189039e-07
including O 0 2.2891317996709404e-07
one O 0 2.2196847737632197e-07
derived O 0 2.2860645287892112e-07
from O 0 7.876445806687116e-08
the O 0 6.780084760293903e-08
skipping O 0 6.306224236141134e-07
of O 0 1.2078695021955355e-07
exon O 0 6.8068684413447045e-06
32 O 0 7.619647021783749e-06
, O 0 5.866824608347088e-07
were O 0 2.484360493326676e-06
also O 0 2.3154007067205384e-06
identified O 0 1.6297217371175066e-05
. O 0 8.648652510601096e-06

These O 0 1.851332672231365e-05
results O 0 1.949823126778938e-05
indicate O 0 3.8953062357904855e-06
the O 0 4.588011961459415e-07
usefulness O 0 2.4984785795822972e-06
of O 0 4.3964800511275826e-07
cycloheximide O 0 0.0025860057212412357
treatment O 0 1.1357660696376115e-05
in O 0 6.970254844418378e-07
evaluating O 0 3.2803166050143773e-06
the O 0 5.957082294116844e-07
abnormal O 0 5.4500947044289205e-06
processing O 0 5.129429041517142e-07
of O 0 8.373501714231679e-08
mRNA O 0 7.022525778666022e-07
due O 0 5.103620992485958e-07
to O 0 4.483786995024275e-07
splice O 0 0.0011209058575332165
- O 0 0.00019019284809473902
site O 0 1.777495890564751e-05
mutations O 0 7.5734983511210885e-06
, O 0 5.992712885927176e-07
because O 0 5.76620266201644e-07
( O 0 1.9323175592944608e-07
i O 0 2.880802867366583e-06
) O 0 1.9577687737637461e-07
aberrant O 0 3.2221662422671216e-06
splicing O 0 5.639193204842741e-06
often O 0 1.553853280711337e-06
generates O 0 1.627151164029783e-06
a O 0 4.33597233495675e-06
premature O 0 0.00011574990639928728
termination O 0 1.454977518733358e-05
codon O 0 7.76129490986932e-06
, O 0 7.516114806094265e-07
( O 0 2.595814692085696e-07
ii O 0 8.868098120728973e-06
) O 0 2.7438426286607864e-07
transcripts O 0 1.5117590237423428e-06
with O 0 3.1796771509107202e-06
premature O 0 0.0017210541991516948
termination O 0 3.704667687998153e-05
codons O 0 5.661879640683765e-06
can O 0 6.424988328035397e-07
occur O 0 6.991945724621473e-07
at O 0 1.7477288565714844e-05
low O 0 8.63480890984647e-05
or O 0 8.563714800402522e-06
undetectable O 0 0.00015306155546568334
levels O 0 1.776523276930675e-06
due O 0 6.973951940381085e-07
to O 0 3.5425969713287486e-07
nonsense O 0 3.646141976787476e-06
- O 0 5.648509613820352e-06
mediated O 0 4.693303708336316e-06
mRNA O 0 1.2406231917339028e-06
decay O 0 3.20140225085197e-06
, O 0 4.724423661173205e-07
and O 0 6.429781933547929e-07
( O 0 2.3359778822396038e-07
iii O 0 5.999579570925562e-06
) O 0 1.0038240105814111e-07
the O 0 8.208787249941452e-08
levels O 0 1.818869321823513e-07
of O 0 3.071621179628892e-08
these O 0 4.6760042948790215e-08
transcripts O 0 9.745774605107727e-07
can O 0 3.3044449310182245e-07
be O 0 2.0786410459550098e-07
increased O 0 4.6134948661347153e-07
by O 0 1.0051840035885107e-06
cycloheximide O 0 0.0003081996401306242
. O 0 1.265908849745756e-05

A O 0 0.00021459472191054374
deletion O 0 0.0009466142510063946
mutation O 0 0.00011615866969805211
in O 0 5.5483892538177315e-06
COL17A1 O 0 0.001990534598007798
in O 0 1.3265021152619738e-06
five O 0 3.5849000141752185e-06
Austrian O 0 0.009979330003261566
families O 0 3.2822619687067345e-05
with O 0 1.3020209735259414e-05
generalized O 0 0.047605451196432114
atrophic B-Disease 1 0.9999428987503052
benign I-Disease 1 0.9895808100700378
epidermolysis I-Disease 1 0.9978359341621399
bullosa I-Disease 1 0.826204776763916
represents O 0 8.316807907249313e-06
propagation O 0 1.0267144716635812e-05
of O 0 7.954625971251517e-07
an O 0 3.5542248042474966e-06
ancestral O 0 0.00026486135902814567
allele O 0 0.00034440832678228617
. O 0 2.437469629512634e-05

Patients O 1 0.9670864939689636
with O 0 0.00030950439395383
generalized O 0 0.4223936200141907
atrophic B-Disease 1 0.9999843835830688
benign I-Disease 1 0.999874472618103
epidermolysis I-Disease 1 0.9999078512191772
bullosa I-Disease 1 0.9995924830436707
, O 0 2.1373978597694077e-05
a O 0 4.621854259312386e-06
usually O 0 2.946914491985808e-06
nonlethal O 0 1.0537618436501361e-05
form O 0 2.405742179689696e-06
of O 0 7.010099125182023e-06
junctional B-Disease 1 0.6859760880470276
epidermolysis I-Disease 1 0.9865552186965942
bullosa I-Disease 1 0.9755496382713318
, O 0 1.9910668925149366e-05
have O 0 4.573509158944944e-06
generalized O 0 3.422528243390843e-05
blistering B-Disease 0 0.014889995567500591
, O 0 0.00011470564641058445
nail B-Disease 1 0.9999986886978149
dystrophy I-Disease 1 0.9999728202819824
, O 0 0.000912094721570611
patchy B-Disease 1 0.9996119141578674
alopecia I-Disease 1 0.9999997615814209
, O 0 7.91701240814291e-05
and O 0 0.0010198900708928704
dental B-Disease 1 0.9999607801437378
abnormalities I-Disease 1 0.9999977350234985
. O 0 0.00023574191436637193

Skin B-Disease 1 0.9999569654464722
fragility I-Disease 1 0.9341297149658203
in O 0 3.500946331769228e-05
most O 0 3.248788516430068e-06
cases O 0 1.9706292277987814e-06
is O 0 6.668561809419771e-07
due O 0 2.357045104872668e-06
to O 0 1.057647409652418e-06
mutations O 0 4.677057404478546e-06
in O 0 1.822512274429755e-07
the O 0 3.21809864090028e-07
gene O 0 1.6935708799792337e-06
encoding O 0 4.644326509151142e-06
type O 0 0.0001141009561251849
XVII O 0 0.26627326011657715
collagen O 0 0.0002222948824055493
( O 0 1.0230922271148302e-05
COL17A1 O 0 0.0030612957198172808
) O 0 8.673465345054865e-06
. O 0 1.584889650985133e-05

Recently O 0 0.0012775820214301348
, O 0 1.3111568478052504e-05
we O 0 4.641280156647554e-06
reported O 0 5.6026774473139085e-06
five O 0 2.142206767530297e-06
Austrian O 0 0.0004724800237454474
families O 0 2.5294893930549733e-05
with O 0 1.4248929801397026e-05
generalized O 0 0.03708229959011078
atrophic B-Disease 1 0.9998886585235596
benign I-Disease 1 0.9766850471496582
epidermolysis I-Disease 1 0.9952782392501831
bullosa I-Disease 1 0.9949542880058289
who O 0 0.0001527109561720863
share O 0 7.4047661655640695e-06
the O 0 2.795777845676639e-06
same O 0 1.79505004780367e-05
COL17A1 O 0 0.04522722214460373
mutation O 0 0.00013725330063607544
. O 0 3.65514206350781e-05

Affected O 0 0.0005989313358440995
individuals O 0 1.4633016689913347e-05
in O 0 1.7608670077606803e-06
three O 0 1.385134623888007e-06
families O 0 6.822479008405935e-06
are O 0 5.116232841828605e-07
homozygous O 0 2.159989162464626e-05
for O 0 3.664953283077921e-07
4003delTC O 0 5.58895044378005e-05
, O 0 4.5022460426480393e-07
whereas O 0 4.622638130058476e-07
those O 0 9.478218032654695e-08
in O 0 1.9104756177057425e-07
two O 0 6.043539997335756e-07
others O 0 2.377013743171119e-06
are O 0 1.2041493846481899e-06
compound O 0 9.245003457181156e-05
heterozygotes O 0 0.0002522110298741609
. O 0 1.8291921151103452e-05

To O 0 5.943113501416519e-05
determine O 0 3.058576839976013e-05
if O 0 2.0183429114695173e-06
the O 0 4.819079322260222e-07
occurrence O 0 1.3334387176655582e-06
of O 0 2.825830165420484e-07
4003delTC O 0 5.111034261062741e-05
in O 0 6.633403017985984e-07
these O 0 2.566098373790737e-07
unrelated O 0 2.1631653908116277e-06
families O 0 8.850590234033007e-07
signifies O 0 6.39073618913244e-07
propagation O 0 5.816556836180098e-07
of O 0 7.727637552079614e-08
an O 0 4.5000138015893754e-07
ancestral O 0 2.5868936063488945e-05
allele O 0 1.6777792552602477e-05
or O 0 9.545495913698687e-07
a O 0 1.5665243608964374e-06
mutational O 0 0.00024052566732279956
hot O 0 0.00025082300999201834
spot O 0 0.000708057195879519
, O 0 1.489467422288726e-06
haplotypes O 0 6.872297035442898e-06
were O 0 6.1602618188771885e-06
determined O 0 2.350492650293745e-06
for O 0 2.7239025257586036e-07
polymorphisms O 0 1.343889016425237e-05
both O 0 2.9361882525336114e-07
within O 0 6.810880677221576e-07
and O 0 3.835771622107131e-06
flanking O 0 0.00045985638280399144
COL17A1 O 0 0.25413331389427185
. O 0 2.185410266974941e-05

Five O 0 0.00018171619740314782
intragenic O 0 0.0020769373513758183
polymorphisms O 0 0.0006205379031598568
were O 0 1.944794348673895e-05
chosen O 0 4.468374299904099e-06
based O 0 1.8284817997482605e-06
on O 0 2.2969725250732154e-06
their O 0 1.3257458704174496e-05
informativeness O 0 0.001037508132867515
. O 0 2.0048022634000517e-05

One O 0 1.6714728189981543e-05
of O 0 1.5592611362080788e-06
these O 0 7.926516332190658e-07
, O 0 9.331411661150923e-07
not O 0 6.118442570368643e-07
previously O 0 4.922912921756506e-06
reported O 0 6.7835653680958785e-06
, O 0 6.755416279702331e-07
was O 0 1.1643328434729483e-05
2988 O 0 1.3636468793265522e-05
A O 0 7.417289907607483e-06
or O 0 3.788979938690318e-06
C O 0 2.688886524992995e-05
that O 0 1.5634005023912323e-07
introduces O 0 6.598990580641839e-07
a O 0 2.9585626748485083e-07
new O 0 3.6587860563486174e-07
restriction O 0 9.169340842163365e-07
site O 0 1.8694379377848236e-06
for O 0 1.0087815098813735e-06
Eco0109 O 0 0.00017914116324391216
I O 0 9.447999764233828e-05
. O 0 1.596390939084813e-05

All O 0 1.5275911209755577e-05
the O 0 6.489539828180568e-06
4003delTC O 0 4.891307617072016e-05
alleles O 0 1.0857836969080381e-05
showed O 0 8.398088539252058e-06
the O 0 5.668734388564189e-07
same O 0 7.632990559613972e-07
haplotype O 0 1.0824040145962499e-05
for O 0 2.9276770874275826e-07
these O 0 2.6377389872322965e-07
five O 0 2.0049330942129018e-06
polymorphic O 0 6.149025284685194e-05
markers O 0 0.0003936817520298064
. O 0 3.5277811548439786e-05

Fourteen O 0 0.0005625066696666181
microsatellite O 0 0.0013721523573622108
polymorphisms O 0 0.0008176873670890927
were O 0 1.3925643543188926e-05
selected O 0 1.8521958509154501e-06
based O 0 5.729181680180773e-07
on O 0 5.99541067458631e-07
their O 0 1.2927039279020391e-06
high O 0 1.3993912943988107e-05
heterozygosity O 0 3.1686577131040394e-05
and O 0 8.15060673176049e-07
their O 0 6.168859840727237e-07
location O 0 3.765263500099536e-06
within O 0 2.0136440070928074e-06
10q23 O 0 3.6011027987115085e-05
- O 0 7.321335579035804e-05
q25 O 0 0.00010646611917763948
near O 0 0.00022209233429748565
COL17A1 O 0 0.002340899547562003
. O 0 2.880289866880048e-05

Three O 0 8.220346353482455e-05
families O 0 6.893731915624812e-05
shared O 0 2.914596552727744e-05
microsatellite O 0 0.00034294684883207083
polymorphisms O 0 0.0002931097405962646
covering O 0 0.00010820854367921129
at O 0 5.0941394874826074e-05
most O 0 5.976891657155647e-07
19 O 0 1.502019222243689e-05
cM O 0 9.194276935886592e-05
, O 0 9.324045322500751e-07
whereas O 0 7.421128884743666e-07
the O 0 3.9407541407854296e-07
others O 0 9.47472642565117e-07
shared O 0 8.331783192261355e-07
smaller O 0 7.106253292477049e-07
regions O 0 6.782554464734858e-07
consistent O 0 1.38732798404817e-06
with O 0 5.670702307725151e-07
cross O 0 9.520998901280109e-06
- O 0 7.462315988959745e-05
over O 0 4.332485730174085e-07
events O 0 3.003553672442649e-07
during O 0 4.1209284518117784e-07
passage O 0 1.617051310631723e-07
of O 0 7.40824503964177e-08
this O 0 1.4692841432406567e-07
mutation O 0 1.5171882523645763e-06
through O 0 7.135985242712195e-07
several O 0 1.1050761941078235e-06
generations O 0 1.507029628555756e-05
. O 0 8.255297871073708e-06

These O 0 2.9782993806293234e-05
results O 0 2.650095302669797e-05
indicate O 0 7.114735126378946e-06
that O 0 7.179056638051406e-07
4003delTC O 0 2.6737339794635773e-05
occurs O 0 5.033263619225181e-07
on O 0 4.5653331426365185e-07
a O 0 1.1679768476824393e-06
single O 0 1.4549194020219147e-05
ancestral O 0 3.774974902626127e-05
allele O 0 2.7854524887516163e-05
. O 0 2.830973471645848e-06
. O 0 8.682552106620278e-06

The O 0 9.106408833758906e-05
haptoglobin O 0 0.001359352725557983
- O 0 0.000287311733700335
gene O 0 5.909600804443471e-05
deletion O 0 0.00012220628559589386
responsible O 0 3.193591328454204e-05
for O 0 7.099017693690257e-06
anhaptoglobinemia B-Disease 0 0.0028434921987354755
. O 0 4.6880530135240406e-05

We O 0 7.60249313316308e-05
have O 0 3.706507186507224e-06
found O 0 2.3230336410051677e-06
an O 0 5.571170618168253e-07
allelic O 0 9.149031029664911e-06
deletion O 0 1.0751931768027134e-05
of O 0 4.132120636768377e-07
the O 0 2.2186359274201095e-06
haptoglobin O 0 0.00012076175335096195
( O 0 5.239004394752556e-07
Hp O 0 2.2058045487938216e-06
) O 0 1.5416965482017986e-07
gene O 0 5.055118208474596e-07
from O 0 1.7332304480532912e-07
an O 0 3.676284450193634e-07
individual O 0 6.917251766935806e-07
with O 0 6.750239208486164e-06
anhaptoglobinemia B-Disease 0 0.010788800194859505
. O 0 1.1800410902651493e-05

The O 0 3.663894676719792e-05
Hp O 0 9.79167889454402e-05
gene O 0 1.2788779713446274e-05
cluster O 0 7.2400953285978176e-06
consists O 0 8.616970603725349e-07
of O 0 2.0888930407636508e-07
coding O 0 7.872892638260964e-06
regions O 0 5.821074182676966e-07
of O 0 1.5458968505299708e-07
the O 0 4.569911311591568e-07
alpha O 0 2.1997882413415937e-06
chain O 0 1.1321670172037557e-05
and O 0 4.7377244527524454e-07
beta O 0 7.272512334566272e-07
chain O 0 1.956950654857792e-06
of O 0 1.0322867893819421e-07
the O 0 5.88195007367176e-07
haptoglobin O 0 2.070235859719105e-05
gene O 0 1.7725498082654667e-06
( O 0 2.3055065412336262e-07
Hp O 0 1.6794879229564685e-06
) O 0 8.064029799470518e-08
and O 0 5.700873373370996e-08
of O 0 5.3859398718714147e-08
the O 0 1.8964561832035542e-07
alpha O 0 1.3498864745997707e-06
chain O 0 6.616662176384125e-06
and O 0 4.405449089972535e-07
beta O 0 7.392972065645154e-07
chain O 0 2.0260183646314545e-06
of O 0 9.279552415364378e-08
the O 0 4.928991756969481e-07
haptoglobin O 0 4.895927122561261e-05
- O 0 2.0547664462355897e-05
related O 0 1.6574758774368092e-06
gene O 0 3.7896918456681306e-06
( O 0 5.975409749225946e-07
Hpr O 0 2.6005247491411865e-05
) O 0 2.8744804581037897e-07
, O 0 9.490446473137126e-08
in O 0 1.4560798433649325e-07
tandem O 0 9.756889994605444e-06
from O 0 4.71637434884542e-07
the O 0 6.125787308519648e-07
5 O 0 3.978891072620172e-06
side O 0 1.5752728359075263e-05
. O 0 1.3402695913100615e-05

Southern O 0 0.00025058590108528733
blot O 0 0.0011599714634940028
and O 0 2.1878289771848358e-05
PCR O 0 0.0002248627133667469
analyses O 0 2.6890586013905704e-05
have O 0 3.879512860294199e-06
indicated O 0 4.302812158130109e-06
that O 0 1.2543803507014673e-07
the O 0 2.3743940857912094e-07
individual O 0 2.5392859015482827e-07
with O 0 1.330093368778762e-06
anhaptoglobinemia B-Disease 0 0.006950042210519314
was O 0 3.322116390336305e-05
homozygous O 0 7.555449883511756e-06
for O 0 9.766041131342718e-08
the O 0 2.2393416543309286e-07
gene O 0 1.0567340495981625e-06
deletion O 0 5.209129994909745e-06
and O 0 8.330933383149386e-07
that O 0 1.335705093197248e-07
the O 0 2.392469014012022e-07
gene O 0 1.1525983154569985e-06
deletion O 0 7.700969035795424e-06
was O 0 8.234894266934134e-06
included O 0 3.8747148778384144e-07
at O 0 5.1552469813032076e-06
least O 0 1.375202174358492e-07
from O 0 1.0436266251190318e-07
the O 0 1.8497267717521026e-07
promoter O 0 3.2008831567509333e-06
region O 0 2.071943470127735e-07
of O 0 1.1840204905411156e-07
Hp O 0 2.7521816718945047e-06
to O 0 5.467156256599992e-07
Hpr O 0 2.4731985831749626e-05
alpha O 0 1.7345430478599155e-06
but O 0 2.9486446351256745e-07
not O 0 2.1168929720261076e-07
to O 0 3.8129516610752034e-07
Hpr O 0 4.032302967971191e-05
beta O 0 3.6167675716569647e-06
( O 0 1.4586054248866276e-06
Hpdel O 0 9.445360774407163e-05
) O 0 3.3552259992575273e-06
. O 0 7.1063741415855475e-06

In O 0 3.5801604099106044e-05
addition O 0 8.817179150355514e-06
, O 0 2.106036390614463e-06
we O 0 7.466718443538412e-07
found O 0 3.681659563881112e-07
seven O 0 4.812608267457108e-07
individuals O 0 1.589456957162838e-07
with O 0 3.706136055825482e-07
hypohaptoglobinemia B-Disease 0 0.00043210017611272633
in O 0 6.946312396394205e-07
three O 0 1.7741293731887708e-06
families O 0 3.0296635031845653e-06
, O 0 2.03149639332878e-07
and O 0 2.2703281388203322e-07
the O 0 2.0185804316952272e-07
genotypes O 0 2.765658109638025e-06
of O 0 7.355222209071144e-08
six O 0 5.370633857637586e-07
of O 0 9.065922768058954e-08
the O 0 5.322522156347986e-07
seven O 0 1.6426898810095736e-06
individuals O 0 2.973256414406933e-07
were O 0 1.074537635759043e-06
found O 0 7.328754918489722e-07
to O 0 6.219584065547679e-07
be O 0 3.33642879013496e-06
Hp2 O 0 0.0004898193292319775
/ O 0 9.986782242776826e-05
Hpdel O 0 0.0007325092446990311
. O 0 3.385834861546755e-05

The O 0 0.00011716286098817363
phenotypes O 0 0.00035835482412949204
and O 0 1.2598460671142675e-05
genotypes O 0 5.6422501074848697e-05
in O 0 1.0657963684934657e-06
one O 0 2.8588047484845447e-07
of O 0 7.303999183250198e-08
these O 0 7.165815674170517e-08
three O 0 3.621063626724208e-07
families O 0 1.4535120271830237e-06
showed O 0 2.6142358819924993e-06
the O 0 2.9029880010966735e-07
father O 0 1.1480214197945315e-05
to O 0 7.803709536347014e-07
be O 0 2.3695447453064844e-06
hypohaptoglobinemic B-Disease 0 5.663138654199429e-05
( O 0 3.6246152035346313e-07
Hp2 O 0 1.7845035472419113e-05
) O 0 1.9402929751777265e-07
and O 0 7.673469326618942e-07
Hp2 O 0 3.406484756851569e-05
/ O 0 4.4421080929168966e-06
Hpdel O 0 3.1303599826060236e-05
, O 0 4.2319865656281763e-07
the O 0 2.9467864237631147e-07
mother O 0 1.1282695595582481e-05
to O 0 4.0310297322321276e-07
be O 0 7.365933356595633e-07
Hp2 O 0 2.0621631847461686e-05
- O 0 1.786327084118966e-05
1 O 0 1.1473615586510277e-06
and O 0 1.0364323088651872e-06
Hp1 O 0 4.522235394688323e-05
/ O 0 1.03171041700989e-05
Hp2 O 0 4.1261235310230404e-05
, O 0 1.9305345233533444e-07
one O 0 4.676690679161766e-08
of O 0 2.600529214191738e-08
the O 0 1.0553366536214526e-07
two O 0 2.111970616169856e-07
children O 0 1.6945920151556493e-06
to O 0 3.441602132170374e-07
be O 0 1.1607944543357007e-06
hypohaptoglobinemic B-Disease 0 3.691692836582661e-05
( O 0 4.001292950306379e-07
Hp2 O 0 1.7979420590563677e-05
) O 0 3.2807750471874897e-07
and O 0 7.103461712176795e-07
Hp2 O 0 6.301749090198427e-05
/ O 0 1.3298738849698566e-05
Hpdel O 0 0.00010157683573197573
, O 0 5.599433166025847e-07
and O 0 2.563200212080119e-07
the O 0 1.5963962596288184e-07
other O 0 1.202006814082779e-07
child O 0 4.067498139193049e-06
to O 0 7.093713634276355e-07
be O 0 1.4945798056942294e-06
Hp1 O 0 2.953863440779969e-05
and O 0 2.717177494560019e-06
Hp1 O 0 0.00024001295969355851
/ O 0 3.0680363124702126e-05
Hpdel O 0 0.00014846795238554478
, O 0 9.059740477823652e-07
showing O 0 3.380596353963483e-06
an O 0 6.250850219657877e-07
anomalous O 0 9.123562449531164e-06
inheritance O 0 5.282499387249118e-06
of O 0 6.472823770309333e-07
Hp O 0 5.272316775517538e-05
phenotypes O 0 3.5557677620090544e-05
in O 0 7.876014933572151e-07
the O 0 1.6730134575482225e-06
child O 0 6.986064545344561e-05
with O 0 1.1395351066312287e-05
Hp1 O 0 0.0031449596863240004
. O 0 2.314051380380988e-05

The O 0 0.00010489777923794463
Hp2 O 0 0.0017832467565312982
/ O 0 0.00031067387317307293
Hpdel O 0 0.0010755218099802732
individuals O 0 3.2134939829120412e-06
had O 0 8.837129826133605e-06
an O 0 5.92776643770776e-07
extremely O 0 3.836236373899737e-06
low O 0 1.1749675650207791e-05
level O 0 6.063190767235938e-07
of O 0 1.528589166355232e-07
Hp O 0 5.710368895961437e-06
( O 0 2.5538622594467597e-07
mean O 0 1.0045381486634142e-06
+ O 0 2.3612005861650687e-06
/ O 0 3.4856034289987292e-06
- O 0 1.3072140063741244e-05
SD O 0 0.0064934478141367435
= O 0 5.1200979214627296e-05
0 O 0 3.2105870104714995e-06
. O 0 5.107550009597617e-07
049 O 0 1.620231705601327e-05
+ O 0 3.825520707323449e-06
/ O 0 3.4145723475376144e-06
- O 0 6.85808299749624e-06
0 O 0 3.3968456136790337e-06
. O 0 4.618654543264711e-07
043 O 0 1.4251730135583784e-05
mg O 0 1.1786958566517569e-05
/ O 0 6.668455625913339e-06
ml O 0 3.294781345175579e-05
; O 0 1.3993493439556914e-06
n O 0 1.6147232599905692e-05
= O 0 1.4082243069424294e-05
6 O 0 1.8147022728953743e-06
) O 0 1.8369149756836123e-07
, O 0 1.0406629513681764e-07
compared O 0 2.258183826597815e-07
with O 0 6.928436846465047e-08
the O 0 1.7872790181172604e-07
level O 0 9.219918979397335e-07
( O 0 9.119286659142745e-08
1 O 0 1.4731931230471673e-07
. O 0 9.762129593582358e-08
64 O 0 1.0565446473265183e-06
+ O 0 2.1047453628852963e-06
/ O 0 1.8227016198579804e-06
- O 0 4.45428304374218e-06
1 O 0 7.198191269708332e-07
. O 0 3.333806830596586e-07
07 O 0 1.9761962903430685e-05
mg O 0 1.9067902030656114e-05
/ O 0 8.34887305245502e-06
ml O 0 2.007997863984201e-05
) O 0 3.835150153008726e-07
obtained O 0 7.25051791050646e-07
from O 0 4.952277663505811e-07
52 O 0 1.160851570602972e-05
healthy O 0 3.5008979466510937e-06
volunteers O 0 2.180642695748247e-06
having O 0 6.696202490275027e-06
phenotype O 0 3.326986188767478e-05
Hp2 O 0 4.442991848918609e-05
, O 0 3.642489048161224e-07
whereas O 0 4.29119637601616e-07
the O 0 5.299496592670039e-07
serum O 0 4.4712145609082654e-05
Hp O 0 1.8373282273387304e-06
level O 0 2.6405274411445134e-07
of O 0 6.354496662197562e-08
an O 0 1.6014573134270904e-07
individual O 0 1.5270855158178165e-07
with O 0 8.618137599114561e-07
Hp1 O 0 0.0012400681152939796
/ O 0 4.3772091885330155e-05
Hpdel O 0 0.00024104105250444263
was O 0 3.64985826308839e-05
0 O 0 2.8916563678649254e-05
. O 0 1.4346202988235746e-05

50 O 0 0.00023763412900734693
mg O 0 0.00039244003710336983
/ O 0 8.214438275899738e-05
ml O 0 0.0001257843541679904
, O 0 9.120154231823108e-07
which O 0 2.492383543994947e-07
was O 0 1.170289237961697e-06
approximately O 0 1.500943227483731e-07
half O 0 1.4813177529049426e-07
the O 0 6.750109804443127e-08
level O 0 2.479886234141304e-07
of O 0 9.182504356886056e-08
Hp O 0 2.8085032681701705e-06
in O 0 4.5163213258092583e-07
control O 0 1.6190298993024044e-05
sera O 0 1.1552875548659358e-05
from O 0 2.812309674027347e-07
the O 0 7.988479069354071e-07
Hp1 O 0 0.00013325524923857301
phenotype O 0 2.4277538614114746e-05
( O 0 2.671248182650743e-07
1 O 0 3.1811467238185287e-07
. O 0 1.1333906257959825e-07
26 O 0 1.1267750323895598e-06
+ O 0 1.0802247061292292e-06
/ O 0 1.1089464351243805e-06
- O 0 4.337634891271591e-06
0 O 0 1.6234188251473824e-06
. O 0 2.933450957698369e-07
33 O 0 2.805601525324164e-06
mg O 0 1.126289316744078e-05
/ O 0 4.253404767950997e-06
ml O 0 2.0766108718817122e-05
; O 0 6.621564807574032e-07
n O 0 2.3711954781902023e-05
= O 0 2.463796226948034e-05
9 O 0 3.1947838579071686e-06
) O 0 1.7891068182507297e-07
, O 0 1.0238530734341111e-07
showing O 0 1.018455463963619e-06
a O 0 1.631056989026547e-06
gene O 0 1.0349475815019105e-05
- O 0 0.000150417021359317
dosage O 0 7.903992081992328e-05
effect O 0 1.0522947377467062e-05
. O 0 1.173162763734581e-05

The O 0 1.440426058252342e-05
other O 0 2.3926133962959284e-06
allele O 0 2.3132435671868734e-05
( O 0 1.1947910252274596e-06
Hp2 O 0 3.2543230190640315e-05
) O 0 2.2541365751749254e-07
of O 0 1.2131430082717998e-07
individuals O 0 3.683587692648871e-07
with O 0 8.129460411510081e-07
Hp2 O 0 0.0005142549052834511
/ O 0 2.5170391381834634e-05
Hpdel O 0 0.0004334694822318852
was O 0 0.0001647179597057402
found O 0 1.8084241446558735e-06
to O 0 4.948514629177225e-07
have O 0 1.2448471125026117e-06
, O 0 1.976353445343193e-07
in O 0 8.82210926533844e-08
all O 0 9.746445783775926e-08
exons O 0 2.8645572456298396e-06
, O 0 3.635818757175002e-07
no O 0 5.396010465119616e-07
mutation O 0 1.161996237897256e-06
, O 0 1.3098077999984525e-07
by O 0 2.868658555144066e-07
DNA O 0 8.635977792437188e-06
sequencing O 0 2.6474885089555755e-05
. O 0 1.4447568901232444e-05

On O 0 2.1755124180344865e-05
the O 0 1.8222739299744717e-06
basis O 0 3.81506850999358e-07
of O 0 1.1436642921580642e-07
the O 0 3.140141870972002e-07
present O 0 2.512937840037921e-07
study O 0 2.0476757356391317e-07
, O 0 1.0794919802492586e-07
the O 0 8.136846929573949e-08
mechanism O 0 3.912884380952164e-07
of O 0 1.1556180368188507e-07
anhaptoglobinemia B-Disease 0 0.0002093414805131033
and O 0 5.354806376089982e-07
the O 0 1.6045929385199997e-07
mechanism O 0 4.606135917128995e-07
of O 0 9.531989775268812e-08
anomalous O 0 8.719245670363307e-06
inheritance O 0 3.893018401868176e-06
of O 0 4.952258336743398e-07
Hp O 0 3.522519546095282e-05
phenotypes O 0 4.4998574594501406e-05
were O 0 4.400987108965637e-06
well O 0 3.0857841011311393e-06
explained O 0 2.5533230655128136e-05
. O 0 1.1611870831984561e-05

However O 0 5.975928434054367e-05
, O 0 6.975960332056275e-06
the O 0 2.178181830458925e-06
mechanism O 0 5.74447403778322e-06
of O 0 2.957861624963698e-06
hypohaptoglobinemia B-Disease 0 0.007032488938421011
remains O 0 6.544909410877153e-05
unknown O 0 0.00022782704036217183

ATM O 0 0.17922848463058472
mutations O 0 0.0008166805491782725
and O 0 2.3594520826009102e-05
phenotypes O 0 0.0014538053655996919
in O 0 0.0004322484601289034
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999932050704956
telangiectasia I-Disease 1 1.0
families O 0 0.0010594730265438557
in O 0 2.1905539142608177e-06
the O 0 1.4950076092645759e-06
British O 0 1.261830038856715e-05
Isles O 0 2.3843471353757195e-05
: O 0 2.8567825438585714e-07
expression O 0 2.629054449698742e-07
of O 0 1.1504443619969607e-07
mutant O 0 4.35993888459052e-06
ATM O 0 8.26138275442645e-05
and O 0 6.307089961410384e-07
the O 0 6.536587875416444e-07
risk O 0 9.829129339777865e-06
of O 0 2.7436017262516543e-06
leukemia B-Disease 1 0.999997615814209
, O 0 0.34600403904914856
lymphoma B-Disease 1 1.0
, O 0 0.00010778725118143484
and O 0 0.03972199186682701
breast B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9965565204620361
. O 0 5.35870021849405e-05

We O 0 6.105559441493824e-05
report O 0 3.8332559597620275e-06
the O 0 6.267695766837278e-07
spectrum O 0 2.1736332200816832e-06
of O 0 6.09601954693062e-07
59 O 0 3.0523937311954796e-05
ATM O 0 0.01652146689593792
mutations O 0 3.5908902646042407e-05
observed O 0 9.690781553217676e-06
in O 0 2.737432805588469e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999901056289673
telangiectasia I-Disease 1 1.0
( O 0 9.451406367588788e-05
A B-Disease 1 0.9999587535858154
- I-Disease 1 0.9999972581863403
T I-Disease 1 1.0
) O 0 1.1497897503431886e-05
patients O 0 1.075720319931861e-05
in O 0 9.184525424643653e-07
the O 0 2.4053590550465742e-06
British O 0 6.931754614925012e-05
Isles O 0 0.00030990823870524764
. O 0 1.807381704566069e-05

Of O 0 5.27255360793788e-05
51 O 0 0.00020633293024729937
ATM O 0 0.004781192634254694
mutations O 0 9.340368706034496e-05
identified O 0 8.560007699998096e-06
in O 0 1.3211403029345092e-06
families O 0 1.458014367017313e-06
native O 0 3.1208733730636595e-07
to O 0 2.003406507355976e-07
the O 0 2.886267509438767e-07
British O 0 6.7994265009474475e-06
Isles O 0 2.4430455596302636e-05
, O 0 9.088809633794881e-07
11 O 0 1.96366204363585e-06
were O 0 2.0574759673763765e-06
founder O 0 4.4116518438386265e-06
mutations O 0 2.8019569526804844e-06
, O 0 1.7916013916874363e-07
and O 0 2.0970105651940685e-07
2 O 0 2.944185268916044e-07
of O 0 3.7325392554521386e-08
these O 0 9.510814891200425e-08
11 O 0 2.598229457362322e-06
conferred O 0 1.8840100892703049e-06
a O 0 2.704979124246165e-06
milder O 0 0.00010399652092019096
clinical O 0 0.000855455466080457
phenotype O 0 0.0005638555740006268
with O 0 1.03807531104394e-06
respect O 0 6.990011911511829e-07
to O 0 5.849616968589544e-07
both O 0 4.352352789283032e-06
cerebellar B-Disease 0 0.04981515184044838
degeneration I-Disease 0 0.2339765876531601
and O 0 1.1357531548128463e-05
cellular O 0 0.0024893637746572495
features O 0 0.00012563378550112247
. O 0 4.128434375161305e-05

We O 0 8.373660239158198e-05
report O 0 9.885352483252063e-06
, O 0 6.731300459250633e-07
in O 0 3.4618466315805563e-07
two O 0 1.7521160771138966e-06
A B-Disease 1 0.99982750415802
- I-Disease 1 0.9999895095825195
T I-Disease 1 1.0
families O 0 7.329968411795562e-06
, O 0 2.7588538387135486e-07
an O 0 3.0670258865939104e-07
ATM O 0 0.00046147892135195434
mutation O 0 5.797494850412477e-06
( O 0 5.635347406496294e-07
7271T O 0 8.35501396068139e-06
- O 0 4.1860213968902826e-05
- O 0 0.0005619361763820052
> O 0 5.637672802549787e-05
G O 0 0.0035455345641821623
) O 0 5.091321781947045e-07
that O 0 2.649757959716226e-07
may O 0 4.011810688098194e-06
be O 0 3.7179171386014787e-07
associated O 0 3.106285078047222e-07
with O 0 1.779798424195178e-07
an O 0 6.535184979838959e-07
increased O 0 6.9225980041665025e-06
risk O 0 3.163304427289404e-05
of O 0 2.9565107979578897e-06
breast B-Disease 1 0.9998513460159302
cancer I-Disease 0 0.47118183970451355
in O 0 2.981680381708429e-06
both O 0 4.10011489293538e-06
homozygotes O 0 0.006685924716293812
and O 0 1.3388733350438997e-05
heterozygotes O 0 0.00011037979129469022
( O 0 8.639088378004089e-07
relative O 0 1.7703903722576797e-05
risk O 0 3.6731547879753634e-05
12 O 0 3.530391495587537e-06
. O 0 2.5280212412326364e-07
7 O 0 7.492271834053099e-06
; O 0 2.1017326616856735e-06
P O 0 0.014376415871083736
= O 0 3.29142676491756e-05
. O 0 4.007433744845912e-07
0025 O 0 4.388410525280051e-05
) O 0 2.1249290682590072e-07
, O 0 1.365506534511951e-07
although O 0 1.0638978409360789e-07
there O 0 1.62746019327642e-07
is O 0 1.3148388688932755e-07
a O 0 1.432931526323955e-06
less O 0 1.0205078979197424e-05
severe O 1 0.934207022190094
A B-Disease 1 0.999994158744812
- I-Disease 1 0.9999957084655762
T I-Disease 1 1.0
phenotype O 0 0.0019366263877600431
in O 0 4.394341885927133e-07
terms O 0 3.8491432974296913e-07
of O 0 7.416954161953981e-08
the O 0 4.545800038613379e-07
degree O 0 1.1625732440734282e-05
of O 0 8.421779057243839e-06
cerebellar B-Disease 1 0.7011331915855408
degeneration I-Disease 1 0.9078503251075745
. O 0 0.00012939557200297713

This O 0 4.726014594780281e-05
mutation O 0 0.00010496821778360754
( O 0 6.2826725297782104e-06
7271T O 0 8.218716538976878e-05
- O 0 0.00024051350192166865
- O 0 0.0006553533603437245
> O 0 9.07020948943682e-05
G O 0 0.0010280943242833018
) O 0 2.939253249678586e-07
also O 0 1.4376921342318383e-07
allows O 0 9.432626058014648e-08
expression O 0 1.0942162731453209e-07
of O 0 5.582957740557504e-08
full O 0 1.009452262223931e-06
- O 0 1.1329803783155512e-05
length O 0 7.494851161027327e-06
ATM O 0 0.004349306225776672
protein O 0 3.858423042402137e-06
at O 0 3.488496531645069e-06
a O 0 3.847147240776394e-07
level O 0 6.952476496735471e-07
comparable O 0 1.7375826928400784e-06
with O 0 4.6605961756540637e-07
that O 0 5.121061121826642e-07
in O 0 1.8673994190976373e-06
unaffected O 0 0.00022565052495338023
individuals O 0 3.418120513742906e-06
. O 0 5.900518772250507e-06

In O 0 2.4910674255806953e-05
addition O 0 7.40401765142451e-06
, O 0 1.7617941239223e-06
we O 0 7.152063972171163e-07
have O 0 4.794586629941477e-07
studied O 0 5.5111158872023225e-06
18 O 0 2.502830648154486e-05
A B-Disease 1 0.9987562894821167
- I-Disease 1 0.9999961853027344
T I-Disease 1 1.0
patients O 0 0.005255176220089197
, O 0 5.833645104758034e-07
in O 0 4.393696713123063e-07
15 O 0 2.626971763675101e-06
families O 0 1.5178061403275933e-06
, O 0 5.678419938703883e-07
who O 0 1.0696376193664037e-05
developed O 0 0.037104833871126175
leukemia B-Disease 1 0.9999927282333374
, O 0 0.015941180288791656
lymphoma B-Disease 1 1.0
, O 0 4.146133142057806e-05
preleukemic O 0 0.25221261382102966
T O 1 0.8128376603126526
- O 0 0.003219514386728406
cell O 0 0.005246744956821203
proliferation O 0 0.00029785765218548477
, O 0 1.0530437066336162e-05
or O 0 0.05793850123882294
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.400157245574519e-05
mostly O 0 1.9858086943713715e-06
in O 0 6.48756576993037e-06
childhood O 0 0.0018711942248046398
. O 0 3.470921001280658e-05

A O 0 5.231174509390257e-05
wide O 0 1.3207813935878221e-05
variety O 0 2.3542011149402242e-06
of O 0 5.668221092491876e-07
ATM O 0 0.05852962285280228
mutation O 0 2.500120535842143e-05
types O 0 1.5925810430417187e-06
, O 0 4.0756532371233334e-07
including O 0 4.1222449453925947e-07
missense O 0 2.7127111025038175e-05
mutations O 0 1.0252565516566392e-05
and O 0 1.174987232843705e-06
in O 0 1.5900694734227727e-06
- O 0 0.0002159675204893574
frame O 0 0.002247702796012163
deletions O 0 3.384172305231914e-05
, O 0 2.85290752799483e-06
were O 0 3.686835498228902e-06
seen O 0 1.735635237309907e-06
in O 0 8.153980957104068e-07
these O 0 1.6717822290956974e-06
patients O 0 7.505026587750763e-05
. O 0 1.7980602933675982e-05

We O 0 6.267719436436892e-05
also O 0 4.25775124313077e-06
show O 0 2.6799084480444435e-06
that O 0 2.4722919533815e-07
25 O 0 6.601136419703835e-07
% O 0 2.3656536995986244e-07
of O 0 1.0974580533229528e-07
all O 0 1.1722664794433513e-06
A B-Disease 1 0.999893307685852
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
patients O 0 0.0016706016613170505
carried O 0 2.278145620948635e-05
in O 0 1.8173936950915959e-06
- O 0 0.0004509186837822199
frame O 0 0.0012417122488841414
deletions O 0 3.249088331358507e-05
or O 0 7.299831395357614e-06
missense O 0 4.854031794820912e-05
mutations O 0 3.120550900348462e-05
, O 0 4.046964932058472e-07
many O 0 5.3009827638561546e-08
of O 0 9.133978551290056e-08
which O 0 1.4034376363269985e-06
were O 0 1.01111891126493e-05
also O 0 1.2594391591846943e-06
associated O 0 4.412420651078719e-07
with O 0 1.3875485649350594e-07
expression O 0 4.864130005444167e-07
of O 0 1.977684576104366e-07
mutant O 0 2.907268026319798e-05
ATM O 0 0.0003590549749787897
protein O 0 3.997034946223721e-05
. O 0 2.22025209950516e-05

The O 0 8.965034794528037e-05
DMPK O 0 0.0014912658371031284
gene O 0 4.526256088865921e-05
of O 0 7.15541227691574e-06
severely O 1 0.9502522945404053
affected O 0 0.2857082784175873
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9980196952819824
is O 0 9.582824532117229e-06
hypermethylated O 0 0.004140461329370737
proximal O 0 0.0003536109870765358
to O 0 2.9079833439027425e-06
the O 0 2.093993998641963e-06
largely O 0 6.392640898411628e-06
expanded O 0 3.155931335641071e-05
CTG O 0 0.0006903894827701151
repeat O 0 7.341743912547827e-05
. O 0 1.939308458531741e-05

Using O 0 0.00011338607146171853
methylation O 0 0.00018136932339984924
- O 0 0.00011157645349157974
sensitive O 0 2.3557737222290598e-05
restriction O 0 6.887630206620088e-06
enzymes O 0 6.758961262676166e-06
, O 0 6.451845138144563e-07
we O 0 6.305063493527996e-07
characterized O 0 7.16428417035786e-07
the O 0 1.7409220731678943e-07
methylation O 0 1.725370225358347e-06
pattern O 0 2.048216174443951e-06
on O 0 5.690443458661321e-07
the O 0 5.193155061533616e-07
5 O 0 1.7076433778129285e-06
side O 0 9.908087577059632e-07
of O 0 9.172841686222455e-08
the O 0 9.117205763686798e-07
CTG O 0 0.00030399300158023834
repeat O 0 4.277135758457007e-06
in O 0 2.6223662530355796e-07
the O 0 4.746588899706694e-07
DMPK O 0 0.00012164843792561442
gene O 0 9.964347782442928e-07
of O 0 1.2670140847603761e-07
normal O 0 1.9727465314645087e-06
individuals O 0 2.2026253532203555e-07
and O 0 2.8353241532386164e-07
of O 0 4.430273463640333e-07
patients O 0 6.322178523987532e-05
affected O 0 1.2399405932228547e-05
with O 0 0.0014279275201261044
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.8034597815130837e-05
showing O 0 2.0413854144862853e-05
expansions O 0 4.173588422418106e-06
of O 0 3.048625103474478e-07
the O 0 3.5918812955060275e-06
repetitive O 0 0.0002768401463981718
sequence O 0 2.493425017746631e-05
. O 0 2.164535726478789e-05

The O 0 3.70108027709648e-05
gene O 0 4.161407923675142e-05
segment O 0 2.364218198636081e-05
analyzed O 0 9.764989044924732e-06
corresponds O 0 2.6243476440868108e-06
to O 0 3.9740712054481264e-07
the O 0 4.780468998433207e-07
genomic O 0 1.2344187780399807e-05
SacI O 0 0.00010144132102141157
- O 0 4.0299277316080406e-05
HindIII O 0 4.4676256948150694e-05
fragment O 0 7.381653631455265e-06
carrying O 0 6.285933068284066e-06
exons O 0 2.288279210915789e-05
11 O 0 1.836922274378594e-05
- O 0 6.573970313183963e-05
15 O 0 1.547539977764245e-05
. O 0 1.2214370144647546e-05

There O 0 6.22343213763088e-05
is O 0 6.579976798093412e-06
constitutive O 0 1.6966660041362047e-05
methylation O 0 1.5229175005515572e-05
in O 0 1.477579075981339e-06
intron O 0 0.0001246593164978549
12 O 0 4.628082479030127e-06
at O 0 2.682966623979155e-06
restriction O 0 3.015096581293619e-07
sites O 0 2.9471405582626176e-07
of O 0 1.6603536323600565e-07
SacII O 0 4.227477256790735e-05
and O 0 1.959213932423154e-06
HhaI O 0 4.979239383828826e-05
, O 0 3.649401207894698e-07
localized O 0 2.490941596988705e-06
1 O 0 8.187284947780427e-07
, O 0 3.217129176391609e-07
159 O 0 1.3768966482530232e-06
- O 0 1.079363028111402e-05
1 O 0 6.915504400240025e-07
, O 0 2.8400924634297553e-07
232 O 0 1.5967129911587108e-06
bp O 0 7.919738891359884e-06
upstream O 0 7.554776857432444e-07
of O 0 1.4584175289655832e-07
the O 0 9.461543299948971e-07
CTG O 0 9.496840357314795e-05
repeat O 0 6.188036422827281e-06
, O 0 4.4706229118673946e-07
whereas O 0 3.896875000464206e-07
most O 0 8.52225312542032e-08
, O 0 2.439097954720637e-07
if O 0 8.410316354456882e-08
not O 0 5.158322124998449e-08
all O 0 1.6310798045537922e-08
, O 0 2.305554325232606e-08
of O 0 1.105352342989363e-08
the O 0 2.9568296255888527e-08
other O 0 1.8751245889347956e-08
sites O 0 1.6662782797993714e-07
of O 0 1.383290282319649e-07
SacII O 0 5.663894262397662e-05
, O 0 9.80429831543006e-07
HhaI O 0 4.229658952681348e-05
, O 0 4.083235864982271e-07
and O 0 8.970183102974261e-07
HpaII O 0 2.9700855520786718e-05
in O 0 2.9220953479125455e-07
this O 0 1.2028989715417993e-07
region O 0 6.313842391136859e-07
are O 0 3.0225444902498566e-07
unmethylated O 0 1.936710214067716e-05
, O 0 2.596837020973908e-07
in O 0 3.4861378139794397e-07
normal O 0 3.0601356684201164e-06
individuals O 0 1.3112838814777206e-07
and O 0 8.293882558518817e-08
most O 0 5.669708258437822e-08
of O 0 2.063456321366175e-07
the O 0 7.699544767092448e-06
patients O 0 8.431913738604635e-05
. O 0 8.344216439581942e-06

In O 0 2.088300243485719e-05
a O 0 4.0958002500701696e-06
number O 0 6.689154474770476e-07
of O 0 5.866107812835253e-07
young O 0 6.046311682439409e-06
and O 0 8.714274372323416e-06
severely O 1 0.7709824442863464
affected O 0 0.0001676076790317893
patients O 0 0.00019535963656380773
, O 0 8.284868613372964e-07
however O 0 2.5933078973139345e-07
, O 0 1.3826401357164286e-07
complete O 0 3.002276400820847e-07
methylation O 0 4.906410140392836e-07
of O 0 4.4582588287767067e-08
these O 0 6.550909859015519e-08
restriction O 0 2.355064907533233e-07
sites O 0 6.620081194341765e-07
was O 0 5.530364433070645e-06
found O 0 7.05895843111648e-07
in O 0 2.294270160518863e-07
the O 0 7.742826255707769e-07
mutated O 0 2.3569647964905016e-05
allele O 0 8.482680277666077e-05
. O 0 2.0363027942948975e-05

In O 0 2.3436130504705943e-05
most O 0 1.6294120541715529e-06
of O 0 6.154645006972714e-07
these O 0 8.995162943392643e-07
patients O 0 2.2200109015102498e-05
, O 0 6.025020979905094e-07
the O 0 7.601477705065918e-07
onset O 0 0.00043189837015233934
of O 0 1.3997978385305032e-06
the O 0 0.008166391402482986
disease O 1 0.9986244440078735
was O 1 0.7129267454147339
congenital O 1 0.999998927116394
. O 0 0.00015372894995380193

Preliminary O 0 0.0002601326268631965
in O 0 4.633623393601738e-05
vivo O 0 0.0009102459298446774
footprinting O 0 0.0014510225737467408
data O 0 7.473639016097877e-06
gave O 0 3.759199898922816e-06
evidence O 0 5.602002488558355e-07
for O 0 2.6297240651729226e-07
protein O 0 3.0955052352510393e-06
- O 0 4.957066630595364e-05
DNA O 0 8.797474947641604e-06
contact O 0 4.389510195323965e-06
in O 0 1.290673935727682e-06
normal O 0 5.648256774293259e-06
genes O 0 2.1310711417754646e-06
at O 0 7.415578238578746e-06
an O 0 1.0389776434749365e-06
Sp1 O 0 1.0607288459141273e-05
consensus O 0 9.433666150471254e-07
binding O 0 1.222767878061859e-06
site O 0 1.7570841919223312e-06
upstream O 0 9.97304596239701e-07
of O 0 1.2682230021709984e-07
the O 0 7.702973334744456e-07
CTG O 0 7.557433127658442e-05
repeat O 0 5.258263172436273e-06
and O 0 4.421287371769722e-07
for O 0 1.2818648542634037e-07
a O 0 6.763731903447479e-07
significant O 0 3.4691140626819106e-07
reduction O 0 3.054416026770923e-07
of O 0 2.655438890997175e-08
this O 0 3.5204958948042986e-08
interaction O 0 1.885374842913734e-07
in O 0 3.8207048191907234e-07
cells O 0 1.1722775070666103e-06
with O 0 2.757467711944628e-07
a O 0 6.325465619738679e-06
hypermethylated O 0 0.009547797963023186
DMPK O 0 0.0017145851161330938
gene O 0 1.3036970813118387e-05
. O 0 3.869013198709581e-06
. O 0 1.2449810128600802e-05

The O 0 0.00020309400861151516
hemochromatosis B-Disease 1 0.9999916553497314
gene O 0 0.0001646262826398015
product O 0 1.1398263268347364e-05
complexes O 0 8.852085557009559e-06
with O 0 6.302839210547972e-07
the O 0 8.426555382357037e-07
transferrin O 0 6.128244422143325e-05
receptor O 0 6.618467068619793e-06
and O 0 7.631825837961514e-07
lowers O 0 8.7089820226538e-06
its O 0 2.070282363320075e-07
affinity O 0 1.347264174000884e-06
for O 0 4.413611520703853e-07
ligand O 0 9.41522102948511e-06
binding O 0 2.0508921807049774e-05
. O 0 1.337948015134316e-05

We O 0 0.00010053802543552592
recently O 0 4.068095586262643e-05
reported O 0 7.553793238912476e-06
the O 0 7.089655582603882e-07
positional O 0 1.1652259672700893e-05
cloning O 0 3.21123616231489e-06
of O 0 3.48973344443948e-07
a O 0 1.6412210470662103e-06
candidate O 0 1.0217358976660762e-05
gene O 0 3.0862120183883235e-05
for O 0 7.046623068163171e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.6301389932632446
HFE O 1 0.9926290512084961
. O 0 0.00014016007480677217

The O 0 2.7926498660235666e-05
gene O 0 3.966664371546358e-05
product O 0 5.7498127716826275e-06
, O 0 6.007865636092902e-07
a O 0 2.4291716727020685e-07
member O 0 2.2740920258002006e-07
of O 0 1.0898588698182721e-07
the O 0 4.986546287000237e-07
major O 0 1.4518052466883091e-06
histocompatibility O 0 3.9893726352602243e-05
complex O 0 3.0760470508539584e-06
class O 0 4.399878889671527e-06
I O 0 0.00015519857697654516
- O 0 1.9114913811790757e-05
like O 0 2.121337956850766e-06
family O 0 6.278432010731194e-06
, O 0 5.799540758744115e-07
was O 0 8.305441951961257e-06
found O 0 6.560550218637218e-07
to O 0 3.089760696184385e-07
have O 0 4.699815292497078e-07
a O 0 9.022234621625103e-07
mutation O 0 4.3902637116843835e-06
, O 0 7.844449214644555e-07
Cys O 0 6.883202149765566e-05
- O 0 2.6234112738166004e-05
282 O 0 2.4032764486037195e-05
- O 0 8.971003262558952e-05
- O 0 8.31186116556637e-05
> O 0 1.5397365132230334e-05
Tyr O 0 3.582373392418958e-05
( O 0 7.549389806627005e-07
C282Y O 0 7.6007622737961356e-06
) O 0 2.380906494181545e-07
, O 0 1.4321199159894604e-07
in O 0 1.329949554929044e-07
85 O 0 9.157822660199599e-07
% O 0 3.63651196266801e-07
of O 0 6.426986374208354e-07
patient O 0 0.00010981664672726765
chromosomes O 0 0.0001039191847667098
. O 0 2.249480166938156e-05

This O 0 5.070251427241601e-05
mutation O 0 9.77089730440639e-05
eliminates O 0 3.244394974899478e-05
the O 0 1.7576574009581236e-06
ability O 0 2.9643481411767425e-06
of O 0 9.178299933410017e-07
HFE O 0 0.0009616442839615047
to O 0 2.5116441975114867e-06
associate O 0 7.547621862613596e-06
with O 0 1.756844540068414e-06
beta2 O 0 0.012109634466469288
- O 0 0.0051103802397847176
microglobulin O 0 0.002825257834047079
( O 0 8.051824806898367e-07
beta2m O 0 2.7334808692103252e-05
) O 0 3.321892734220455e-07
and O 0 5.604775878964574e-07
prevents O 0 2.5913648187270155e-06
cell O 0 2.113510709023103e-05
- O 0 8.430562593275681e-05
surface O 0 5.092959327157587e-05
expression O 0 2.3524335119873285e-05
. O 0 1.7832175217336044e-05

A O 0 0.00018118869047611952
second O 0 3.981437112088315e-05
mutation O 0 1.7585945897735655e-05
that O 0 6.387841153809859e-07
has O 0 1.0239443781756563e-06
no O 0 7.373608355010219e-07
effect O 0 3.571396689494577e-07
on O 0 1.5381043567685992e-06
beta2m O 0 0.0011792110744863749
association O 0 2.64535424321366e-06
, O 0 7.245610049722018e-07
H63D O 0 0.000674712413456291
, O 0 6.414433073587134e-07
was O 0 9.424976269656327e-06
found O 0 4.271182660886552e-07
in O 0 1.1620954154523133e-07
eight O 0 2.567253716279083e-07
out O 0 2.110963777113284e-07
of O 0 8.363477377315576e-08
nine O 0 5.171610155230155e-06
patients O 0 8.323283509525936e-06
heterozygous O 0 6.289278644544538e-06
for O 0 1.9037571519220364e-07
the O 0 1.4858511576676392e-06
C282Y O 0 0.00014232230023480952
mutant O 0 9.575791045790538e-05
. O 0 1.3144170225132257e-05

In O 0 5.020989920012653e-05
this O 0 4.120340690860758e-06
report O 0 2.500869413779583e-06
, O 0 4.94387336402724e-07
we O 0 4.03833666950959e-07
demonstrate O 0 9.415978183824336e-07
in O 0 5.849237822985742e-07
cultured O 0 7.837279554223642e-06
293 O 0 1.0688850125006866e-05
cells O 0 3.3163132684421726e-06
overexpressing O 0 3.272828325862065e-05
wild O 0 1.8044635226033279e-06
- O 0 7.2458151407772675e-06
type O 0 3.452224063948961e-06
or O 0 1.4389885336640873e-06
mutant O 0 2.118937118211761e-05
HFE O 0 0.00010914828453678638
proteins O 0 9.912530458677793e-07
that O 0 1.2699112517111644e-07
both O 0 8.119653926996762e-08
the O 0 1.9179567800620134e-07
wild O 0 9.824450444284594e-07
- O 0 1.8929877114715055e-05
type O 0 1.2158827303210273e-05
and O 0 8.409676411247347e-06
H63D O 0 0.013134639710187912
HFE O 0 0.0007191686308942735
proteins O 0 1.9195611002942314e-06
form O 0 2.1313251181709347e-06
stable O 0 2.6751724362839013e-05
complexes O 0 8.335667189385276e-06
with O 0 9.833834155870136e-07
the O 0 2.6420768790558213e-06
transferrin O 0 0.00021571767865680158
receptor O 0 4.163503763265908e-05
( O 0 4.403161256050225e-06
TfR O 0 0.00017036308418028057
) O 0 5.359068836696679e-06
. O 0 2.006684553634841e-05

The O 0 7.745953917037696e-05
C282Y O 0 0.0004530047008302063
mutation O 0 9.306850552093238e-05
nearly O 0 1.3764353752776515e-05
completely O 0 2.1227637262200005e-05
prevents O 0 1.5023854302853579e-06
the O 0 2.0027722769100365e-07
association O 0 3.794111194110883e-07
of O 0 6.827190901503855e-08
the O 0 5.292981200000213e-07
mutant O 0 3.1939660402713344e-05
HFE O 0 0.00039269845001399517
protein O 0 5.573425369220786e-06
with O 0 1.840013055698364e-06
the O 0 9.509156370768324e-06
TfR O 0 0.0011200224980711937
. O 0 2.9600758352898993e-05

Studies O 0 0.00011901959805982187
on O 0 2.752319232968148e-05
cell O 0 7.716928666923195e-05
- O 0 5.2119841711828485e-05
associated O 0 4.792904746864224e-06
transferrin O 0 2.2089490812504664e-05
at O 0 1.3022419807384722e-05
37 O 0 5.178263108973624e-06
degrees O 0 2.4722012312849984e-05
C O 0 0.00032441545045003295
suggest O 0 1.1298740218990133e-06
that O 0 1.6001840208446083e-07
the O 0 2.811312356243434e-07
overexpressed O 0 1.1694362910930067e-05
wild O 0 1.259455984836677e-06
- O 0 1.581775904924143e-05
type O 0 1.0544766155362595e-05
HFE O 0 0.0006587595562450588
protein O 0 4.0126942622009665e-06
decreases O 0 1.4375593764270889e-06
the O 0 2.0217053986471e-07
affinity O 0 8.746001753934252e-07
of O 0 1.686172339532277e-07
the O 0 1.6047289363996242e-06
TfR O 0 0.00012840954877901822
for O 0 3.882511009578593e-06
transferrin O 0 0.0004201542178634554
. O 0 3.131237826892175e-05

The O 0 8.24185335659422e-05
overexpressed O 0 0.0008224619086831808
H63D O 0 0.0021899992134422064
protein O 0 1.8547942090663128e-05
does O 0 1.90248806575255e-06
not O 0 5.500559154825169e-07
have O 0 3.442494858063583e-07
this O 0 1.0229727109845044e-07
effect O 0 2.756536900960782e-07
, O 0 1.2935447557538282e-07
providing O 0 1.6723134876883705e-07
the O 0 5.7752728821469645e-08
first O 0 1.3671824206085148e-07
direct O 0 1.6603536323600565e-07
evidence O 0 3.3784485253818275e-07
for O 0 1.1199320937294033e-07
a O 0 1.1008098681486445e-06
functional O 0 1.7237522115465254e-05
consequence O 0 1.914593667606823e-06
of O 0 1.710182857550535e-07
the O 0 2.805927806548425e-06
H63D O 0 0.06338754296302795
mutation O 0 8.35635801195167e-05
. O 0 1.3910591405874584e-05

Addition O 0 3.353568536113016e-05
of O 0 5.07718641529209e-06
soluble O 0 3.7159192288527265e-05
wild O 0 1.1164954230480362e-05
- O 0 9.334634523838758e-05
type O 0 8.731827256269753e-05
HFE O 0 0.00994864571839571
/ O 0 5.542752114706673e-05
beta2m O 0 0.0001591448235558346
heterodimers O 0 5.2194496674928814e-05
to O 0 1.8671466932573821e-06
cultured O 0 5.645904457196593e-05
cells O 0 1.4208561879058834e-05
also O 0 1.0179660421272274e-06
decreased O 0 3.3232438454433577e-06
the O 0 2.2169005831074173e-07
apparent O 0 1.8052689938485855e-06
affinity O 0 8.238682198680181e-07
of O 0 1.5723016133506462e-07
the O 0 1.228700398314686e-06
TfR O 0 5.2224866522010416e-05
for O 0 1.8980738047957857e-07
its O 0 4.317822401844751e-07
ligand O 0 2.274608959851321e-06
under O 0 3.290919948994997e-06
steady O 0 2.5359187930007465e-05
- O 0 2.9698985599679872e-05
state O 0 8.07316155260196e-07
conditions O 0 5.550066362047801e-06
, O 0 1.8991656247635547e-07
both O 0 1.296293703489937e-07
in O 0 2.885747676373285e-07
293 O 0 5.874724138266174e-06
cells O 0 1.584454935255053e-06
and O 0 6.39737663732376e-07
in O 0 3.6591352454706794e-06
HeLa O 0 0.0009535626159049571
cells O 0 2.7867226890521124e-05
. O 0 9.686317753221374e-06

Furthermore O 0 0.0001436194434063509
, O 0 9.417779438081197e-06
at O 0 5.764537490904331e-06
4 O 0 2.2139774955576286e-06
degrees O 0 3.558084790711291e-05
C O 0 0.0009276650962419808
, O 0 6.315070777418441e-07
the O 0 5.726821541429672e-07
added O 0 5.12509450345533e-06
soluble O 0 4.306588834879221e-06
complex O 0 1.117659849114716e-06
of O 0 5.363500008570554e-07
HFE O 0 0.02275615930557251
/ O 0 9.0203364379704e-05
beta2m O 0 0.00015319472004193813
inhibited O 0 9.297742508351803e-06
binding O 0 1.1145730240968987e-06
of O 0 2.4433350631625217e-07
transferrin O 0 1.4081705558055546e-05
to O 0 1.505817863289849e-06
HeLa O 0 0.00022136466577649117
cell O 0 5.401654198067263e-05
TfR O 0 5.693298589903861e-05
in O 0 8.26895586669707e-07
a O 0 4.738691586680943e-06
concentration O 0 0.0015015508979558945
- O 0 0.0016605096170678735
dependent O 0 1.439563675376121e-05
manner O 0 1.782761864888016e-05
. O 0 2.2309537598630413e-05

Scatchard O 0 0.0017780936323106289
plots O 0 7.637415546923876e-05
of O 0 3.1367765132017666e-06
these O 0 9.610687357053393e-07
data O 0 2.5618833205953706e-06
indicate O 0 1.8638019128047745e-06
that O 0 2.645162737735518e-07
the O 0 6.20838989107142e-07
added O 0 3.987878699263092e-06
heterodimer O 0 5.029040403314866e-05
substantially O 0 1.26051427287166e-05
reduced O 0 9.67873347690329e-07
the O 0 2.0793567045984673e-07
affinity O 0 2.1784642285638256e-06
of O 0 7.552968099844293e-07
TfR O 0 0.00015116787108127028
for O 0 4.438009000296006e-06
transferrin O 0 0.0006664989632554352
. O 0 5.482675624080002e-05

These O 0 7.629365427419543e-05
results O 0 6.326520087895915e-05
establish O 0 1.6938722183112986e-05
a O 0 4.237299435772002e-06
molecular O 0 2.750834210019093e-05
link O 0 1.6414060155511834e-05
between O 0 3.26102190228994e-06
HFE O 0 0.16543687880039215
and O 0 3.292489736850257e-06
a O 0 2.1422702047857456e-06
key O 0 4.256192369211931e-06
protein O 0 1.8169569102610694e-06
involved O 0 8.645500315651589e-07
in O 0 4.922791276840144e-07
iron O 0 0.0012320228852331638
transport O 0 1.0206830665993039e-05
, O 0 2.5790205882003647e-07
the O 0 3.731560980213544e-07
TfR O 0 3.2621686841594055e-05
, O 0 2.879199598737614e-07
and O 0 2.505995269075356e-07
raise O 0 7.019780809969234e-07
the O 0 1.235483040318286e-07
possibility O 0 2.637887348555523e-07
that O 0 9.905502906804031e-08
alterations O 0 3.632128255048883e-06
in O 0 4.4112508135185635e-07
this O 0 2.5678559723019134e-07
regulatory O 0 7.427249329339247e-06
mechanism O 0 2.176342241000384e-05
may O 0 9.864249477686826e-06
play O 0 9.231144986188156e-07
a O 0 5.775988256573328e-07
role O 0 9.264446134693571e-07
in O 0 3.8295985405056854e-07
the O 0 1.4077419336899766e-06
pathogenesis O 0 0.0001105588671634905
of O 0 2.8773856683983468e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00016217857773881406
. O 0 4.420946788741276e-05

Genomic O 0 0.0008167886990122497
organization O 0 5.467951268656179e-05
of O 0 3.398860826564487e-06
the O 0 6.785234745620983e-06
UBE3A O 0 0.0006993222050368786
/ O 0 7.074901805026457e-05
E6 O 0 0.00015984133642632514
- O 0 0.000208981306059286
AP O 0 0.00018978220759890974
gene O 0 1.837390118453186e-05
and O 0 2.9925224680482643e-06
related O 0 1.2812986824428663e-05
pseudogenes O 0 0.0001281114964513108
. O 0 3.2104162528412417e-05

The O 0 0.00010723568993853405
UBE3A O 0 0.0010183403501287103
gene O 0 5.657890869770199e-05
encodes O 0 3.282625038991682e-05
the O 0 4.341119620221434e-06
E6 O 0 5.208332004258409e-05
- O 0 3.7459882150869817e-05
AP O 0 3.714396007126197e-05
ubiquitin O 0 7.81384551373776e-06
- O 0 7.0341338869184256e-06
protein O 0 2.1516600554605247e-06
ligase O 0 1.6440628769487375e-06
and O 0 5.947574095443997e-07
has O 0 6.522408853015804e-07
recently O 0 4.128813543502474e-06
been O 0 7.036429110485187e-07
shown O 0 3.7814066899954923e-07
to O 0 3.5156921285306453e-07
be O 0 2.9372852168307872e-06
mutated O 0 0.0006067042122595012
in O 0 0.272197425365448
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9351926445960999
who O 0 5.166314804228023e-05
lack O 0 1.7901147657539696e-05
15q11 O 0 0.0003949924430344254
- O 0 0.0007102086092345417
q13 O 0 0.00011374148743925616
deletions O 0 2.9069851734675467e-05
or O 0 1.7279358871746808e-05
chromosome O 0 0.003823310136795044
15 O 0 6.820919224992394e-05
paternal O 0 0.01464781817048788
uniparental B-Disease 1 0.6614643931388855
disomy I-Disease 0 0.035703111439943314
. O 0 8.631277160020545e-05

Previous O 0 0.0002088740875478834
UBE3A O 0 0.0007671870989724994
cDNA O 0 6.863223825348541e-05
analysis O 0 8.583772796555422e-06
has O 0 1.7043098523572553e-06
shown O 0 1.398727590640192e-06
a O 0 7.83576126650587e-07
coding O 0 1.1234874364163261e-05
region O 0 1.2557452464534435e-06
of O 0 5.402710030466551e-07
approximately O 0 6.015449798724148e-06
2 O 0 1.6186902939807624e-05
. O 0 1.0011878657678608e-05

6 O 0 0.0005207658978179097
kb O 0 0.002608314622193575
and O 0 1.0031566489487886e-05
a O 0 5.686662916559726e-06
3 O 0 7.965345503180288e-06
- O 0 7.186581933638081e-05
untranslated O 0 0.0001627582823857665
region O 0 6.291546014836058e-06
( O 0 9.982513802242465e-07
UTR O 0 2.1519272195291705e-05
) O 0 2.8214003577886615e-07
of O 0 2.0611355466826353e-07
< O 0 7.803198059264105e-06
50 O 0 2.70356576947961e-06
bp O 0 4.397437805891968e-05
, O 0 2.4652214847264986e-07
whereas O 0 3.2165399943551165e-07
Northern O 0 2.1000926153647015e-07
analysis O 0 3.6572231465470395e-07
has O 0 3.407805309052492e-07
indicated O 0 7.858720891817939e-07
mRNA O 0 4.7445431050618936e-07
sizes O 0 9.712038036013837e-07
of O 0 2.0990154325772892e-07
5 O 0 2.0155653146503028e-06
- O 0 2.7886151656275615e-05
8 O 0 1.6937106920522638e-05
kb O 0 0.0010693921940401196
. O 0 1.995292586798314e-05

We O 0 4.421086123329587e-05
have O 0 3.0088972380326595e-06
analyzed O 0 3.460919742792612e-06
additional O 0 7.448696237588592e-07
cDNA O 0 5.6415328799630515e-06
clones O 0 5.861807949258946e-06
and O 0 3.2847168540683924e-07
provide O 0 3.0554417662642663e-07
evidence O 0 2.669709715519275e-07
for O 0 1.2292635176436306e-07
an O 0 4.3392466864133894e-07
additional O 0 1.453362415304582e-06
0 O 0 3.310039028292522e-05
. O 0 1.171655640064273e-05

5 O 0 0.00012931022502016276
kb O 0 0.00021598317835014313
of O 0 3.266375415478251e-06
5 O 0 7.829704372852575e-06
- O 0 1.2297987268539146e-05
UTR O 0 3.8976839277893305e-05
and O 0 1.2641779676414444e-06
> O 0 5.063830485596554e-06
2 O 0 1.4959716736484552e-06
kb O 0 5.9657821111613885e-05
of O 0 8.165186500264099e-07
3 O 0 1.8065027688862756e-05
- O 0 0.00025886733783409
UTR O 0 0.0005949265323579311
. O 0 2.5591587473172694e-05

We O 0 9.093184780795127e-05
have O 0 4.401847490953514e-06
established O 0 1.7944124692803598e-06
the O 0 3.712762008944992e-07
genomic O 0 3.106648364337161e-06
organization O 0 6.093723641242832e-07
of O 0 1.750414782009102e-07
UBE3A O 0 2.695788316486869e-05
and O 0 2.931219285073894e-07
the O 0 2.0683721402292576e-07
sequence O 0 8.192955078811792e-07
of O 0 6.43531507193984e-07
intron O 0 0.00027597942971624434
- O 0 0.000514088780619204
exon O 0 0.00015593745047226548
borders O 0 4.2968338675564155e-05
. O 0 2.005806345550809e-05

We O 0 0.00015929315122775733
have O 0 7.667773388675414e-06
also O 0 1.3477550737661659e-06
mapped O 0 7.804746019246522e-06
two O 0 5.139770564710489e-07
highly O 0 1.8086172985931626e-06
homologous O 0 4.333202468842501e-06
processed O 0 7.845909749448765e-06
pseudogenes O 0 1.270344637305243e-05
, O 0 1.821752675823518e-06
UBE3AP1 O 0 0.0004475062305573374
and O 0 2.8918077532580355e-06
UBE3AP2 O 0 0.0033671308774501085
, O 0 3.2383687198489497e-07
to O 0 2.3374443003376655e-07
chromosomes O 0 3.888959327014163e-06
2 O 0 7.017966368039197e-07
and O 0 5.293041454024205e-07
21 O 0 3.0022015380382072e-06
, O 0 2.5026275807249476e-07
respectively O 0 1.1612816024353378e-06
, O 0 1.885633764686645e-07
and O 0 1.982660506882894e-07
determined O 0 1.209764150189585e-06
their O 0 9.83758582151495e-07
genomic O 0 2.118712836818304e-05
organization O 0 1.0256125278829131e-05
. O 0 8.745728337089531e-06

These O 0 2.4619477699161507e-05
results O 0 2.8957212634850293e-05
will O 0 7.075599341987981e-07
form O 0 3.025304238235549e-07
the O 0 1.811816332519811e-07
basis O 0 1.5252516050168197e-07
for O 0 6.627649185020346e-08
studies O 0 2.34989812497588e-07
of O 0 1.5049837998049043e-07
mutation O 0 2.9779660053463886e-06
and O 0 8.066412533480616e-07
imprinting O 0 6.13583397353068e-05
of O 0 4.163625817454886e-06
UBE3A O 0 0.001938563073053956
. O 0 3.086247306782752e-05

Mutation O 0 0.000659125973470509
spectrum O 0 9.652875451138243e-05
and O 0 2.2133475795271806e-05
genotype O 0 0.0016797443386167288
- O 0 0.0014408824499696493
phenotype O 0 0.0004809633537661284
analyses O 0 3.738233135663904e-05
in O 0 2.048866736004129e-05
Cowden B-Disease 1 0.9918391108512878
disease I-Disease 1 0.6764177680015564
and O 0 5.297798998071812e-05
Bannayan B-Disease 1 0.9939391613006592
- I-Disease 1 0.9999656677246094
Zonana I-Disease 1 0.9999986886978149
syndrome I-Disease 1 0.9999996423721313
, O 0 8.17019372334471e-06
two O 0 3.8169080653460696e-05
hamartoma B-Disease 1 0.9931144118309021
syndromes I-Disease 1 0.9168652892112732
with O 0 9.918431896949187e-05
germline O 0 0.2879112958908081
PTEN O 0 0.02926761284470558
mutation O 0 0.0004305685870349407
. O 0 4.3179141357541084e-05

The O 0 0.0003757679951377213
tumour B-Disease 1 0.9999723434448242
suppressor O 0 0.0022056291345506907
gene O 0 0.00019464362412691116
PTEN O 0 0.0004878756881225854
, O 0 2.2284880287770648e-06
which O 0 8.814101306597877e-07
maps O 0 5.00293617733405e-06
to O 0 7.379141152341617e-06
10q23 O 0 0.00040349483606405556
. O 0 2.3785672965459526e-05

3 O 0 8.535756933270022e-05
and O 0 7.210495368781267e-06
encodes O 0 1.1988751793978736e-05
a O 0 3.233966253901599e-06
403 O 0 1.3193624909035861e-05
amino O 0 9.008692359202541e-06
acid O 0 2.4703033432160737e-06
dual O 0 5.058646365796449e-06
specificity O 0 2.3776490706950426e-05
phosphatase O 0 0.08403569459915161
( O 0 1.2136677014495945e-06
protein O 0 4.9527861847309396e-06
tyrosine O 0 3.0920160497771576e-05
phosphatase O 0 0.0008135929820127785
; O 0 1.0533893828323926e-06
PTPase O 0 3.509269663481973e-05
) O 0 3.508353643155715e-07
, O 0 2.484568426552869e-07
was O 0 7.763122994219884e-06
shown O 0 7.868695206525445e-07
recently O 0 1.1734005056496244e-06
to O 0 1.9272803797321103e-07
play O 0 6.924366857674613e-07
a O 0 5.631532644656545e-07
broad O 0 5.063820935902186e-06
role O 0 2.3923373646539403e-06
in O 0 2.353931677134824e-06
human O 0 9.702812349132728e-06
malignancy B-Disease 0 0.041665103286504745
. O 0 1.5377687304862775e-05

Somatic O 0 0.006568578537553549
PTEN O 0 0.006625729147344828
deletions O 0 0.00078931002644822
and O 0 6.980397301958874e-05
mutations O 0 9.857153054326773e-05
were O 0 9.46820273384219e-06
observed O 0 3.7434949717862764e-06
in O 0 1.6104012274809065e-06
sporadic B-Disease 0 0.00932132638990879
breast I-Disease 1 0.9994416832923889
, I-Disease 0 0.00016112996672745794
brain I-Disease 1 0.9737516045570374
, I-Disease 0 0.0002891060139518231
prostate I-Disease 1 0.9998778104782104
and I-Disease 1 0.7335523366928101
kidney I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9988435506820679
cell O 0 0.05038017779588699
lines O 0 0.0005192363751120865
and O 0 2.8106737772759516e-06
in O 0 9.549311243972625e-07
several O 0 5.645244982588338e-07
primary O 0 0.0112438490614295
tumours B-Disease 1 0.9999899864196777
such O 0 1.717591771921434e-06
as O 0 0.001641416340135038
endometrial B-Disease 1 0.9999991655349731
carcinomas I-Disease 1 1.0
, O 1 0.9986382126808167
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9963235855102539
thyroid B-Disease 1 0.9999998807907104
tumours I-Disease 1 1.0
. O 0 0.000493281171657145

In O 0 3.119616667390801e-05
addition O 0 1.0453181857883465e-05
, O 0 3.4300262541364646e-06
PTEN O 0 0.00023375618911813945
was O 0 1.1158451343362685e-05
identified O 0 2.009232048294507e-06
as O 0 1.6593658358488028e-07
the O 0 2.8284102882025763e-07
susceptibility O 0 1.2385837180772796e-05
gene O 0 3.425701379455859e-06
for O 0 6.370478899953014e-07
two O 0 9.934779518516734e-05
hamartoma B-Disease 1 0.999972939491272
syndromes I-Disease 1 0.9999756813049316
Cowden B-Disease 1 0.9999327659606934
disease I-Disease 1 0.9774887561798096
( O 0 2.0900117760902504e-06
CD B-Disease 0 0.00014850788284093142
; O 0 8.388738933717832e-06
MIM O 0 0.03272363543510437
158350 O 0 0.00014506779552903026
) O 0 8.830558044792269e-07
and O 0 1.6669363276378135e-06
Bannayan B-Disease 0 0.00035153041244484484
- I-Disease 0 0.000896967074368149
Zonana I-Disease 0 0.0008572228834964335
( I-Disease 0 1.4519824844683171e-06
BZS I-Disease 0 4.3074429413536564e-05
) I-Disease 0 8.647693334751239e-07
or I-Disease 0 1.326900587628188e-06
Ruvalcaba I-Disease 0 9.823757864069194e-05
- I-Disease 0 0.00027132139075547457
Riley I-Disease 0 0.00032679387368261814
- I-Disease 1 0.642128050327301
Smith I-Disease 1 0.9190067052841187
syndrome I-Disease 1 0.9998986721038818
( O 0 1.2501611308834981e-05
MIM O 0 0.08407220244407654
153480 O 0 0.00036945752799510956
) O 0 6.775315341656096e-06
. O 0 1.4134285265754443e-05

Constitutive O 0 0.0006946185021661222
DNA O 0 0.00020272331312298775
from O 0 1.3630565263156313e-05
37 O 0 3.912162355845794e-05
CD B-Disease 0 3.920498056686483e-05
families O 0 4.7443259063584264e-06
and O 0 9.616501301934477e-07
seven O 0 3.877116341755027e-06
BZS B-Disease 0 0.0002280643820995465
families O 0 4.074362095707329e-06
was O 0 7.4418194344616495e-06
screened O 0 1.809525565477088e-05
for O 0 6.567319360328838e-06
germline O 0 0.0011808021226897836
PTEN O 0 0.0013041147030889988
mutations O 0 0.00012111104297218844
. O 0 2.544290509831626e-05

PTEN O 0 0.07425755262374878
mutations O 0 0.0012542353942990303
were O 0 4.5162792957853526e-05
identified O 0 8.780510142969433e-06
in O 0 8.332117431564257e-07
30 O 0 6.473144367191708e-07
of O 0 1.125657504985611e-07
37 O 0 3.0612272894359194e-06
( O 0 2.0964186830951803e-07
81 O 0 1.9296116988698486e-06
% O 0 3.35123701233897e-07
) O 0 1.4490510125142464e-07
CD B-Disease 0 4.989584795112023e-06
families O 0 1.3323887060323614e-06
, O 0 1.7470075874825852e-07
including O 0 1.6043955497480056e-07
missense O 0 4.921987965644803e-06
and O 0 9.881798632704886e-07
nonsense O 0 1.3729912097915076e-05
point O 0 2.3887444058345864e-06
mutations O 0 6.382644187397091e-06
, O 0 2.8365872140057036e-07
deletions O 0 2.2033195818949025e-06
, O 0 5.424176379165146e-07
insertions O 0 1.1254862329224125e-05
, O 0 5.972105441287567e-07
a O 0 1.5120907619348145e-06
deletion O 0 6.458289863076061e-05
/ O 0 1.76460907823639e-05
insertion O 0 1.652785977057647e-05
and O 0 5.212315500102704e-06
splice O 0 0.001804310828447342
site O 0 0.0002803306852001697
mutations O 0 0.00017378621851094067
. O 0 1.9412866095080972e-05

These O 0 3.331529660499655e-05
mutations O 0 7.711389480391517e-05
were O 0 8.675468052388169e-06
scattered O 0 3.621129735620343e-06
over O 0 7.405263886539615e-07
the O 0 6.509086460937397e-07
entire O 0 1.546926341688959e-06
length O 0 1.909861339299823e-06
of O 0 2.266665433126036e-07
PTEN O 0 9.67475280049257e-05
, O 0 3.0202249945432413e-07
with O 0 1.0945731787614932e-07
the O 0 1.5479548665098264e-07
exception O 0 1.6394645285799925e-07
of O 0 3.332489839635855e-08
the O 0 1.6598438890014222e-07
first O 0 1.7226541331183398e-06
, O 0 5.897571213608899e-07
fourth O 0 8.077805432549212e-06
and O 0 9.996937251344207e-07
last O 0 5.859337761648931e-06
exons O 0 6.088917507440783e-05
. O 0 1.249825072591193e-05

A O 0 0.00015639713092241436
hot O 0 0.00013256148668006063
spot O 0 6.657181802438572e-05
for O 0 3.0129949664114974e-06
PTEN O 0 0.0001712877710815519
mutation O 0 5.172251348994905e-06
in O 0 8.998011367111758e-07
CD B-Disease 0 3.336053487146273e-05
was O 0 4.6680714149260893e-05
identified O 0 1.4825870948698139e-06
in O 0 2.4629210315652017e-07
exon O 0 4.335724497650517e-06
5 O 0 6.174904569888895e-07
that O 0 8.416798635835221e-08
contains O 0 8.608660806430635e-08
the O 0 2.475047438110778e-07
PTPase O 0 2.0348197722341865e-05
core O 0 3.1894321637082612e-06
motif O 0 1.2669092939177062e-06
, O 0 1.2832310858357232e-07
with O 0 1.468163475237816e-07
13 O 0 7.55647704409057e-07
of O 0 7.821980574362897e-08
30 O 0 7.433744144691445e-07
( O 0 1.5931294683468877e-07
43 O 0 8.935817277233582e-07
% O 0 3.861983657316159e-07
) O 0 1.957650965778157e-07
CD B-Disease 0 4.802961939276429e-06
mutations O 0 3.5420735002844594e-06
identified O 0 1.8656406837180839e-06
in O 0 5.181208848625829e-07
this O 0 1.124919663197943e-06
exon O 0 7.789517985656857e-05
. O 0 1.7567410395713523e-05

Seven O 0 6.146568921394646e-05
of O 0 3.4041581784549635e-06
30 O 0 5.753355708293384e-06
( O 0 9.04888679542637e-07
23 O 0 3.894540895998944e-06
% O 0 8.859880153977429e-07
) O 0 2.181174068027758e-07
were O 0 5.538913114833122e-07
within O 0 1.4966238381930452e-07
the O 0 2.7966422067038366e-07
core O 0 4.7518879000563174e-06
motif O 0 2.8996450964768883e-06
, O 0 3.1293970437218377e-07
the O 0 1.4822093419297744e-07
majority O 0 3.854131875868916e-07
( O 0 6.189537060663497e-08
five O 0 6.068616897891843e-08
of O 0 3.352700517211815e-08
seven O 0 4.3334651422810566e-07
) O 0 4.8316838530126915e-08
of O 0 3.0671074568999757e-08
which O 0 4.825844825973036e-07
were O 0 3.6997405459260335e-06
missense O 0 1.5742607502033934e-05
mutations O 0 1.0561986528045963e-05
, O 0 5.472597308653349e-07
possibly O 0 1.6559305322516593e-06
pointing O 0 3.1175050025922246e-06
to O 0 1.912170830564719e-07
the O 0 1.0623121937669566e-07
functional O 0 1.1983548802163568e-06
significance O 0 4.25988986307857e-07
of O 0 1.3809415122523205e-07
this O 0 5.33782269940275e-07
region O 0 6.411426511476748e-06
. O 0 9.8422797236708e-06

Germline O 0 0.07177609205245972
PTEN O 0 0.05064213275909424
mutations O 0 0.0015701012453064322
were O 0 5.537289325729944e-05
identified O 0 8.30461794976145e-06
in O 0 6.954266495995398e-07
four O 0 3.3813529398685205e-07
of O 0 1.5990718793545966e-07
seven O 0 2.1137811927474104e-06
( O 0 4.3103466396132717e-07
57 O 0 6.22255492999102e-06
% O 0 2.016376583924284e-06
) O 0 1.4575514342141105e-06
BZS B-Disease 0 7.592538895551115e-05
families O 0 8.14419581729453e-06
studied O 0 3.52794595528394e-05
. O 0 1.7485275748185813e-05

Interestingly O 0 0.0011314976727589965
, O 0 2.110442983394023e-05
none O 0 4.908024038741132e-06
of O 0 3.799658543357509e-07
these O 0 4.0853976202015474e-07
mutations O 0 6.174083409860032e-06
was O 0 4.8282013267453294e-06
observed O 0 9.140895258497039e-07
in O 0 3.064476459258003e-07
the O 0 1.088724047804135e-06
PTPase O 0 0.00014493947674054652
core O 0 3.777870369958691e-05
motif O 0 3.6223744245944545e-05
. O 0 1.1538561011548154e-05

It O 0 3.658273635664955e-05
is O 0 2.939725845862995e-06
also O 0 8.646028391012806e-07
worthy O 0 8.086607863333484e-07
of O 0 1.4889177180066326e-07
note O 0 1.4350731589729548e-06
that O 0 1.7122978590577986e-07
a O 0 8.122207191263442e-07
single O 0 9.184059308608994e-06
nonsense O 0 6.923284672666341e-06
point O 0 1.5245403801600332e-06
mutation O 0 3.22026471621939e-06
, O 0 4.700039539784484e-07
R233X O 0 1.4667498362541664e-05
, O 0 4.555764974156773e-07
was O 0 3.306419557702611e-06
observed O 0 6.029907240190369e-07
in O 0 1.2898676970962697e-07
the O 0 4.602746059845231e-07
germline O 0 2.1608399038086645e-05
DNA O 0 4.622241704055341e-06
from O 0 4.6835199896122504e-07
two O 0 7.520459917031985e-07
unrelated O 0 7.238866601255722e-06
CD B-Disease 0 5.625825360766612e-05
families O 0 8.997961231216323e-06
and O 0 2.31054355026572e-06
one O 0 1.1143213669129182e-05
BZS B-Disease 0 0.001661390531808138
family O 0 4.93313891638536e-05
. O 0 1.7690133972791955e-05

Genotype O 0 0.027009252458810806
- O 0 0.016173353418707848
phenotype O 0 0.0018724807305261493
studies O 0 1.4697996448376216e-05
were O 0 1.7946238585864194e-05
not O 0 1.3132690810380154e-06
performed O 0 5.7886445574695244e-06
on O 0 7.417477831950237e-07
this O 0 1.6036000261010486e-07
small O 0 1.1443685252743308e-06
group O 0 2.4110224785545142e-06
of O 0 8.038152827793965e-07
BZS B-Disease 0 0.0002780179784167558
families O 0 1.2297728972043842e-05
. O 0 1.5057898053782992e-05

However O 0 6.924401532160118e-05
, O 0 1.2324216186243575e-05
genotype O 0 0.0002067957684630528
- O 0 0.00013270364433992654
phenotype O 0 0.00011627514322753996
analysis O 0 2.6773589070216985e-06
inthe O 0 6.37690318399109e-05
group O 0 2.812700813592528e-06
of O 0 2.1522991744404862e-07
CD B-Disease 0 3.735967038664967e-05
families O 0 5.317150680639315e-06
revealed O 0 8.632371645944659e-06
two O 0 3.2888198120417655e-07
possible O 0 4.6618805527032237e-07
associations O 0 7.709867304583895e-07
worthy O 0 4.23979543029418e-07
of O 0 9.024121538914187e-08
follow O 0 6.788119435441331e-07
- O 0 3.616931280703284e-05
up O 0 4.079560312675312e-06
in O 0 1.174703811557265e-06
independent O 0 3.251196631026687e-06
analyses O 0 2.9530438041547313e-05
. O 0 1.3739147107116878e-05

The O 0 1.8973305486724712e-05
first O 0 1.1425077900639735e-05
was O 0 3.173232835251838e-05
an O 0 6.738815159224032e-07
association O 0 2.076466671496746e-06
noted O 0 4.792483991877816e-07
in O 0 2.212862000305904e-07
the O 0 3.452433645634301e-07
group O 0 1.1004487987520406e-06
of O 0 1.3635441575843288e-07
CD B-Disease 0 8.077968959696591e-05
families O 0 1.2193931979709305e-05
with O 0 0.0006006914773024619
breast B-Disease 1 0.999997615814209
disease I-Disease 1 0.9547282457351685
. O 0 6.452966044889763e-05

A O 0 0.00022548447304870933
correlation O 0 0.00011515069490997121
was O 0 5.132950536790304e-05
observed O 0 2.6740060548036126e-06
between O 0 5.262800755190256e-07
the O 0 4.855125439462427e-07
presence O 0 1.9771048300754046e-06
/ O 0 1.437407081539277e-05
absence O 0 1.631859845474537e-06
of O 0 1.2941555382894876e-07
a O 0 4.211074156046379e-06
PTEN O 0 0.003880651667714119
mutation O 0 2.8694512366200797e-06
and O 0 1.7332141055703687e-07
the O 0 2.053710943528131e-07
type O 0 3.499779722915264e-06
of O 0 1.0424444099044194e-06
breast O 1 0.6571004986763
involvement O 0 4.431355046108365e-05
( O 0 6.070768904464785e-06
unaffected O 0 0.00024316305643878877
versus O 0 0.0005543615552596748
benign O 0 0.17349795997142792
versus O 0 0.06663864850997925
malignant O 1 0.9888675808906555
) O 0 2.106871579599101e-05
. O 0 1.7783062503440306e-05

Specifically O 0 6.296198989730328e-05
and O 0 4.260964487912133e-06
more O 0 6.114691473158018e-07
directly O 0 1.234629735336057e-06
, O 0 3.3224279150090297e-07
an O 0 3.1447808623852325e-07
association O 0 2.3650475213798927e-06
was O 0 1.0552159437793307e-05
also O 0 3.678865994061198e-07
observed O 0 2.8288150133448653e-07
between O 0 8.764047265685804e-08
the O 0 1.2753716305269336e-07
presence O 0 2.0868101557880436e-07
of O 0 9.61360555606916e-08
a O 0 3.532432629071991e-06
PTEN O 0 0.0013590181479230523
mutation O 0 5.5592154240002856e-05
and O 0 0.0029154280200600624
malignant B-Disease 1 0.9999991655349731
breast I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9990723133087158
. O 0 0.00011037347576348111

Secondly O 0 0.0035547041334211826
, O 0 1.882081232906785e-05
there O 0 2.0424304238986224e-06
appeared O 0 5.96856853007921e-06
to O 0 3.9456804756810016e-07
be O 0 4.150145116454951e-07
an O 0 6.99840370543825e-07
interdependent O 0 0.00013205682625994086
association O 0 1.483401774748927e-06
between O 0 8.917709806155472e-07
mutations O 0 9.060855518328026e-06
upstream O 0 2.250747911602957e-06
and O 0 3.4001050153165124e-07
within O 0 1.4964882666390622e-07
the O 0 2.981618365538452e-07
PTPase O 0 1.5671785149606876e-05
core O 0 3.390466645214474e-06
motif O 0 1.4240017662814353e-06
, O 0 2.6089779225912935e-07
the O 0 1.8600964324377856e-07
core O 0 4.0445524973620195e-06
motif O 0 1.1763686416088603e-06
containing O 0 3.7152554455133213e-07
the O 0 1.3460399372888787e-07
majority O 0 1.7662611639934767e-07
of O 0 1.423522206778216e-07
missense O 0 2.628364563861396e-05
mutations O 0 1.2124820386816282e-05
, O 0 5.866421588507365e-07
and O 0 3.3272635846515186e-07
the O 0 1.9642450865831051e-07
involvement O 0 5.474800559568394e-07
of O 0 5.8347968234784275e-08
all O 0 1.5320800628160214e-07
major O 0 2.516005224606488e-06
organ O 0 0.002228060970082879
systems O 0 5.823980973218568e-05
( O 0 4.0158812453228165e-07
central O 0 1.498529059063003e-06
nervous O 0 0.000988572370260954
system O 0 1.6256455637631007e-05
, O 0 2.1705056497012265e-05
thyroid O 1 0.9000465273857117
, O 0 9.047361527336761e-05
breast O 1 0.955048680305481
, O 0 0.00014255712449084967
skin O 1 0.974177896976471
and O 0 0.014980337582528591
gastrointestinal O 1 0.999220609664917
tract O 1 0.9609430432319641
) O 0 2.4282702725031413e-05
. O 0 2.5462079065619037e-05

However O 0 7.045104575809091e-05
, O 0 3.7939046251267428e-06
these O 0 4.087665956831188e-07
observations O 0 1.6012709238566458e-06
would O 0 8.334112067132082e-07
need O 0 4.560911861517525e-07
to O 0 4.768066901306156e-07
be O 0 9.758879286891897e-07
confirmed O 0 5.380466632232128e-07
by O 0 3.830423267459082e-08
studying O 0 1.2166096041710261e-07
a O 0 1.4151328286970966e-07
larger O 0 2.5290822236456734e-07
number O 0 1.4159050465423206e-07
of O 0 2.6719666834651434e-07
CD B-Disease 0 7.106791599653661e-05
families O 0 1.8021719370153733e-05
. O 0 8.757378964219242e-06

Molecular O 0 0.3864558935165405
defects O 1 0.9996414184570312
leading O 0 8.052941848291084e-05
to O 0 3.7472239000635454e-06
human O 0 2.7419330308475764e-06
complement B-Disease 0 0.00011260231985943392
component I-Disease 1 0.8617160320281982
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999990463256836
in O 0 3.0795340535405558e-06
an O 0 1.9815427094727056e-06
African O 0 5.308274012350012e-06
- O 0 9.534169657854363e-05
American O 0 5.768271876149811e-06
family O 0 3.431911682127975e-05
. O 0 1.019741284835618e-05

Complement B-Disease 0 0.009573115967214108
component I-Disease 1 0.9808096289634705
C6 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999997615814209
( O 0 4.257643377059139e-05
C6D B-Disease 0 0.2962460219860077
) O 0 8.78029277373571e-06
was O 0 0.00886790081858635
diagnosed O 1 0.6768043637275696
in O 0 1.2115051504224539e-06
a O 0 4.6101354200800415e-06
16 O 0 1.2019639143545646e-05
- O 0 2.8493202989920974e-05
year O 0 9.713446615933208e-07
- O 0 1.772735413396731e-05
old O 0 1.532207170384936e-05
African O 0 8.004737992450828e-07
- O 0 1.0033365470007993e-05
American O 0 1.522695015410136e-06
male O 0 1.8669310520635918e-05
with O 0 0.00013707386096939445
meningococcal B-Disease 1 0.9999997615814209
meningitis I-Disease 1 0.9999980926513672
. O 0 0.00014954364451114088

The O 0 0.00019818080181721598
patients O 0 0.055652912706136703
father O 0 0.000290428230073303
and O 0 3.950012796849478e-06
two O 0 4.528943009063369e-06
brothers O 0 0.009876227006316185
also O 0 2.6373691071057692e-06
had O 0 5.449076707009226e-05
C6D B-Disease 0 0.001968794735148549
, O 0 4.3219378653702734e-07
but O 0 2.1460580512666638e-07
gave O 0 5.370377493818523e-07
no O 0 2.162223751156489e-07
history O 0 3.005760333962826e-07
of O 0 1.272424583476095e-06
meningitis B-Disease 1 0.9999798536300659
or O 0 1.0873329301830381e-05
other O 0 2.9931591143395053e-06
neisserial B-Disease 1 0.8506836295127869
infection I-Disease 0 0.10856973379850388
. O 0 3.518189623719081e-05

By O 0 1.952622005774174e-05
using O 0 1.2516559763753321e-05
exon O 0 6.10200222581625e-05
- O 0 1.7706539438222535e-05
specific O 0 1.4029892554390244e-06
polymerase O 0 1.8297749193152413e-05
chain O 0 3.7035166315035895e-05
reaction O 0 2.61520585809194e-06
( O 0 5.146509920450626e-07
PCR O 0 9.578457138559315e-06
) O 0 4.58164123529059e-07
/ O 0 1.8611642644827953e-06
single O 0 1.7305610526818782e-06
- O 0 1.3009038411837537e-05
strand O 0 1.2062333553330973e-05
conformation O 0 1.0042766007245518e-05
polymorphism O 0 4.0144204831449315e-06
as O 0 2.9135193813090154e-07
a O 0 5.147402930560929e-07
screening O 0 2.5375213681400055e-06
step O 0 1.1774574204537203e-06
and O 0 4.779001301358221e-07
nucleotide O 0 2.3259576664713677e-06
sequencing O 0 7.441319098688837e-07
of O 0 1.1376573638699483e-07
target O 0 2.3849679564591497e-06
exons O 0 6.855794254079228e-06
, O 0 7.533732286901795e-07
we O 0 4.6155190602803486e-07
determined O 0 4.696123596659163e-07
that O 0 8.407012330735597e-08
the O 0 5.15277690738003e-07
proband O 0 0.0001340700255241245
was O 0 6.727669187966967e-06
a O 0 1.6029669041017769e-06
compound O 0 1.3271564057504293e-05
heterozygote O 0 9.707144272397272e-06
for O 0 5.037003916186222e-07
two O 0 2.6541633815213572e-06
C6 O 0 0.015929441899061203
gene O 0 5.331725697033107e-05
mutations O 0 8.40154243633151e-05
. O 0 1.3316417607711628e-05

The O 0 1.560303644509986e-05
first O 0 6.277114607655676e-06
, O 0 1.3098593854010687e-06
1195delC O 0 9.545318789605517e-06
located O 0 2.1379025838541565e-06
in O 0 4.862711193709401e-07
exon O 0 9.83105110208271e-06
7 O 0 6.052669505152153e-06
, O 0 4.1977236264756357e-07
is O 0 1.2322530551500677e-07
a O 0 3.7036872413409583e-07
novel O 0 7.725971613581351e-07
mutation O 0 1.770461608430196e-06
, O 0 2.4715069457670324e-07
while O 0 2.262426050947397e-07
the O 0 1.6619409848317446e-07
second O 0 4.0108197936206125e-06
, O 0 3.795848328991269e-07
1936delG O 0 3.0694006909470772e-06
in O 0 2.1881162126646814e-07
exon O 0 4.153369900450343e-06
12 O 0 3.077648898397456e-06
, O 0 3.9509444604846067e-07
has O 0 3.046137351248035e-07
been O 0 7.787160143379879e-07
described O 0 1.2064690508850617e-06
before O 0 7.546093456767267e-07
to O 0 5.627238124361611e-07
cause O 0 8.30979934107745e-06
C6D B-Disease 0 0.0006119859754107893
in O 0 3.804125583428686e-07
an O 0 7.396483852062374e-07
unrelated O 0 3.736682174348971e-06
African O 0 1.6125173942782567e-06
- O 0 3.8723057514289394e-05
American O 0 2.633677013363922e-06
individual O 0 3.928239493689034e-06
. O 0 9.700739610707387e-06

Both O 0 8.972817886387929e-05
mutations O 0 0.00043763400753960013
result O 0 1.8846172679332085e-05
in O 0 1.6009615137591027e-05
premature O 0 0.011844037100672722
termination O 0 0.00019465736113488674
codons O 0 4.986795102013275e-05
and O 0 1.1053586604248267e-05
C6 O 0 0.0022371718659996986
null O 0 0.00022082836949266493
alleles O 0 0.0001730777876218781
. O 0 3.090471000177786e-05

Allele O 0 0.0008398800273425877
- O 0 0.00019458646420389414
specific O 0 6.488079179689521e-06
PCR O 0 8.066283771768212e-05
indicated O 0 7.5256066338624805e-06
that O 0 4.6633303441012686e-07
the O 0 4.277052028101025e-07
probands O 0 8.850296580931172e-05
two O 0 2.3105258151190355e-06
brothers O 0 0.026994505897164345
also O 0 3.2321286198566668e-06
inherited O 0 0.00014825999096501619
the O 0 7.043438472464914e-07
1195delC O 0 3.112707781838253e-05
mutation O 0 2.0323445824033115e-06
from O 0 2.7393090817895427e-07
their O 0 1.5185706843112712e-06
heterozygous O 0 3.273103357059881e-05
mother O 0 1.850220542110037e-05
and O 0 3.5835731182487507e-07
the O 0 7.544251161561988e-07
1936delG O 0 3.0837025406071916e-05
mutation O 0 2.670766662049573e-06
from O 0 5.011551706957107e-07
their O 0 2.4776170448603807e-06
homozygous O 0 0.00013910343113821
father O 0 4.4560183596331626e-05
. O 0 3.5432221920927987e-06
. O 0 1.1590174835873768e-05

PAX6 O 0 0.32547909021377563
mutations O 0 0.007217105478048325
reviewed O 0 0.0010915239108726382
. O 0 0.00033812347101047635

Mutations O 0 0.0029648211784660816
in O 0 4.767537029692903e-05
PAX6 O 0 0.002597944578155875
are O 0 2.341643948966521e-06
responsible O 0 5.144006081536645e-06
for O 0 4.39342443314672e-07
human O 0 1.8212089116786956e-06
aniridia B-Disease 1 0.9999246597290039
and O 0 1.2640124623430893e-05
have O 0 2.5568990622559795e-06
also O 0 1.5699687310188892e-06
been O 0 2.8691940769931534e-06
found O 0 2.870650178010692e-06
in O 0 4.4209600673639216e-06
patients O 0 9.393587242811918e-05
with O 0 6.80653247400187e-05
Peters B-Disease 1 0.9999994039535522
anomaly I-Disease 1 0.9999970197677612
, O 0 0.0005014445050619543
with O 1 0.9342673420906067
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999995231628418
, O 0 0.0001597873924765736
with O 0 0.00018818082753568888
autosomal B-Disease 1 0.9795927405357361
dominant I-Disease 0 0.1527419239282608
keratitis I-Disease 0 0.4590253233909607
, O 0 9.4650786195416e-06
and O 0 9.657889677328058e-06
with O 0 0.00015208477270789444
isolated B-Disease 1 0.8661021590232849
foveal I-Disease 1 0.9999990463256836
hypoplasia I-Disease 1 0.999997615814209
. O 0 0.0003928918158635497

No O 0 7.962394738569856e-05
locus O 0 9.847598266787827e-05
other O 0 1.6871741763679893e-06
than O 0 1.4319984984467737e-06
chromosome O 0 0.0005059094401076436
11p13 O 0 0.00010087760165333748
has O 0 2.032834800047567e-06
been O 0 2.888902372433222e-06
implicated O 0 1.7351720089209266e-05
in O 0 4.751008873427054e-06
aniridia B-Disease 1 0.9999791383743286
, O 0 3.180511157552246e-06
and O 0 2.866535623979871e-06
PAX6 O 0 0.002592313103377819
is O 0 6.1440124454748e-07
clearly O 0 6.201897804203327e-07
the O 0 1.6664324675730313e-07
major O 0 4.66698281798017e-07
, O 0 4.4904285800839716e-07
if O 0 1.6958743742634397e-07
not O 0 1.3182891223095794e-07
only O 0 2.219623240762303e-07
, O 0 7.715780725447985e-07
gene O 0 1.0147685316042043e-05
responsible O 0 1.1987242032773793e-05
. O 0 8.973118383437395e-06

Twenty O 0 0.00027168949600309134
- O 0 0.0001343588955933228
eight O 0 6.856212621642044e-06
percent O 0 4.447173523658421e-06
of O 0 6.250206183722185e-07
identified O 0 1.4847016245767009e-05
PAX6 O 0 0.0002721354248933494
mutations O 0 1.9677205273183063e-05
are O 0 1.4345163208417944e-06
C O 0 0.004309284966439009
- O 0 0.009167824871838093
T O 0 0.008680399507284164
changes O 0 6.196092954269261e-07
at O 0 4.240945600031409e-06
CpG O 0 2.719609074119944e-05
dinucleotides O 0 5.773395605501719e-05
, O 0 3.889208528562449e-07
20 O 0 5.940714800090063e-07
% O 0 3.6582906659532455e-07
are O 0 1.0510859738133149e-07
splicing O 0 4.8995034376275726e-06
errors O 0 8.827132660371717e-06
, O 0 3.43600078167583e-07
and O 0 1.861484122400725e-07
more O 0 3.6326223806781854e-08
than O 0 7.595334494681083e-08
30 O 0 4.686737042902678e-07
% O 0 2.5550997406753595e-07
are O 0 1.8627271458626637e-07
deletion O 0 5.094773769087624e-06
or O 0 1.8848746776711778e-06
insertion O 0 2.8177053536637686e-05
events O 0 2.0657396817114204e-05
. O 0 3.398587432457134e-05

There O 0 8.683485793881118e-05
is O 0 6.607834620808717e-06
a O 0 4.9902082537300885e-06
noticeably O 0 5.37346386408899e-05
elevated O 0 3.829647175734863e-05
level O 0 1.2080854503437877e-06
of O 0 2.8281354502723843e-07
mutation O 0 5.28645068698097e-06
in O 0 3.7572860378531914e-07
the O 0 6.880723617541662e-07
paired O 0 1.4194070899975486e-05
domain O 0 1.5528548829024658e-06
compared O 0 1.0966834906867007e-06
with O 0 2.2890316131451982e-07
the O 0 3.0712203624716494e-07
rest O 0 4.506975983531447e-07
of O 0 1.4940056303203164e-07
the O 0 1.7272898276132764e-06
gene O 0 1.596735091879964e-05
. O 0 1.4056938198336866e-05

Increased O 0 0.0001831121917348355
mutation O 0 0.00010948081035166979
in O 0 6.704087354592048e-06
the O 0 2.0981478883186355e-06
homeodomain O 0 3.314319474156946e-05
is O 0 5.894854666621541e-07
accounted O 0 1.3999259635966155e-06
for O 0 1.1740190331011036e-07
by O 0 1.784993060027773e-07
the O 0 1.063716808857862e-06
hypermutable O 0 0.000191144019481726
CpG O 0 3.423814632697031e-05
dinucleotide O 0 4.672467548516579e-05
in O 0 3.327940930830664e-06
codon O 0 3.572881905711256e-05
240 O 0 2.147677332686726e-05
. O 0 1.6879090253496543e-05

Very O 0 6.926720379851758e-05
nearly O 0 1.533093018224463e-05
all O 0 1.6809843828013982e-06
mutations O 0 1.0906520401476882e-05
appear O 0 2.1127937088749604e-06
to O 0 1.95481311493495e-06
cause O 0 4.6802626457065344e-05
loss O 0 1.3430715625872836e-05
of O 0 9.662320366032873e-08
function O 0 3.5385957630751363e-07
of O 0 6.953007414267631e-08
the O 0 4.360028924565995e-07
mutant O 0 1.1716042536136229e-05
allele O 0 2.7185719773115125e-06
, O 0 1.4606946763251472e-07
and O 0 7.664401380225172e-08
more O 0 3.4996478603943615e-08
than O 0 4.668687481057532e-08
80 O 0 1.1645217057321133e-07
% O 0 9.404421774661387e-08
of O 0 9.310062409895181e-08
exonic O 0 2.5426072170375846e-05
substitutions O 0 3.680455847643316e-06
result O 0 3.0387666356546106e-06
in O 0 2.5142351205431623e-06
nonsense O 0 6.356867379508913e-05
codons O 0 5.764098386862315e-05
. O 0 1.136429091275204e-05

In O 0 2.5177738280035555e-05
a O 0 6.367518835759256e-06
gene O 0 5.646285444527166e-06
with O 0 5.147987849341007e-07
such O 0 3.7939193475722277e-07
extraordinarily O 0 2.6787820388562977e-05
high O 0 5.686023087037029e-06
sequence O 0 5.360917612051708e-07
conservation O 0 2.6294884492017445e-07
throughout O 0 1.1484252127047512e-07
evolution O 0 2.3068746202170587e-07
, O 0 1.804384481829402e-07
there O 0 2.6400365982226504e-07
are O 0 4.856028681388125e-07
presumed O 0 4.7464163799304515e-05
undiscovered O 0 4.7357276343973354e-05
missense O 0 2.0361398128443398e-05
mutations O 0 1.4605606338591315e-05
, O 0 5.479726610246871e-07
these O 0 9.514388921161299e-08
are O 0 1.24923872135696e-07
hypothesized O 0 1.64125549417804e-06
to O 0 3.575861171611905e-07
exist O 0 4.686097838657588e-07
in O 0 2.1963680296721577e-07
as O 0 6.541620223288191e-07
- O 0 0.0011727443197742105
yet O 0 4.6196682887966745e-06
unidentified O 0 6.740603566868231e-05
phenotypes O 0 2.8253494747332297e-05
. O 0 1.8285375062987441e-06
. O 0 1.2744873856718186e-05

Genetic O 0 0.0016331302467733622
heterogeneity O 0 0.00035376843879930675
and O 0 2.5162615202134475e-05
penetrance O 0 0.0002655524294823408
analysis O 0 1.8723497987593873e-06
of O 0 3.668743886464654e-07
the O 0 2.349436954318662e-06
BRCA1 O 0 0.0047538504004478455
and O 0 1.2879042515123729e-05
BRCA2 O 0 0.0010934153106063604
genes O 0 2.5072169592021964e-05
in O 0 0.0001785986387403682
breast B-Disease 1 0.9999850988388062
cancer I-Disease 1 0.987583339214325
families O 0 0.00013867157394997776
. O 0 2.7436608434072696e-05

The O 0 0.08920788764953613
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999997615814209
Linkage O 0 0.1555745005607605
Consortium O 0 0.001349259982816875
. O 0 0.0001237152609974146

The O 0 2.4915283574955538e-05
contribution O 0 1.677068939898163e-05
of O 0 5.298109499562997e-06
BRCA1 O 0 0.0024777655489742756
and O 0 6.743978156009689e-05
BRCA2 O 0 0.4940161406993866
to O 0 0.06977847218513489
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.2971493601799011
assessed O 0 2.5983534214901738e-05
by O 0 3.800252841301699e-07
linkage O 0 3.764951179618947e-05
and O 0 3.1923259484756272e-06
mutation O 0 4.884146164840786e-06
analysis O 0 5.313109454618825e-07
in O 0 5.295242999636685e-07
237 O 0 5.421257355919806e-06
families O 0 1.714864993118681e-06
, O 0 1.5392488705856522e-07
each O 0 7.737519780448565e-08
with O 0 2.1780229531032091e-07
at O 0 1.1753171747841407e-05
least O 0 2.3730358122975304e-07
four O 0 3.834963706594863e-07
cases O 0 1.7179834799208038e-07
of O 0 2.783481477308669e-06
breast B-Disease 1 0.9999836683273315
cancer I-Disease 1 0.8557112812995911
, O 0 9.756217878020834e-07
collected O 0 8.615967885816644e-07
by O 0 6.039028903614962e-07
the O 0 0.0013597197830677032
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999983310699463
Linkage O 0 0.0037983183283358812
Consortium O 0 0.0006569948745891452
. O 0 2.8377789931255393e-05

Families O 0 0.0004646517336368561
were O 0 1.650143531151116e-05
included O 0 2.574943209765479e-06
without O 0 9.872453574644169e-07
regard O 0 5.313327164913062e-07
to O 0 2.1120592919032788e-07
the O 0 4.2363112129351066e-07
occurrence O 0 3.6064070627617184e-06
of O 0 6.004662736813771e-06
ovarian B-Disease 1 0.9999499320983887
or I-Disease 0 2.7214355213800445e-05
other I-Disease 0 1.2958915249328129e-05
cancers I-Disease 1 0.7150156497955322
. O 0 4.4382068153936416e-05

Overall O 0 0.044435661286115646
, O 0 0.0009593346039764583
disease O 1 0.8158844113349915
was O 0 0.00020795165619347245
linked O 0 4.889124829787761e-05
to O 0 2.1633716187352547e-06
BRCA1 O 0 0.00022874427668284625
in O 0 7.10365156919579e-07
an O 0 6.243951133910741e-07
estimated O 0 7.646031576769019e-07
52 O 0 2.3661057184654055e-06
% O 0 1.5225542426833272e-07
of O 0 5.858013096826653e-08
families O 0 8.030528988456354e-07
, O 0 1.4632098555011908e-07
to O 0 4.933581863042491e-07
BRCA2 O 0 4.5503362343879417e-05
in O 0 3.791116398588201e-07
32 O 0 1.9459371287666727e-06
% O 0 2.571031814113667e-07
of O 0 8.14969212115102e-08
families O 0 1.2246151754879975e-06
, O 0 1.6655252466080128e-07
and O 0 1.0708481568144634e-07
to O 0 2.744609730598313e-07
neither O 0 1.1792475334004848e-06
gene O 0 5.744642521676724e-07
in O 0 1.839039498463535e-07
16 O 0 1.593942442923435e-06
% O 0 3.3319122394459555e-07
( O 0 1.372229689877713e-07
95 O 0 5.592943352894508e-07
% O 0 4.945835030412127e-07
confidence O 0 5.112645794724813e-06
interval O 0 2.5978577468777075e-05
[ O 0 8.802140655461699e-06
CI O 0 0.00020462764950934798
] O 0 3.593319888750557e-06
6 O 0 1.4106178696238203e-06
% O 0 7.599665536872635e-07
- O 0 2.314978337381035e-05
28 O 0 9.399843293067534e-06
% O 0 9.836140861807507e-07
) O 0 2.823467752932629e-07
, O 0 2.090018824674189e-07
suggesting O 0 1.5842404081922723e-06
other O 0 6.214224868017482e-07
predisposition O 0 0.0002258491877000779
genes O 0 2.0074079657206312e-05
. O 0 1.829997927416116e-05

The O 0 3.289202504674904e-05
majority O 0 1.5352950867963955e-05
( O 0 3.0047795007703826e-06
81 O 0 4.660711965698283e-06
% O 0 5.033234629081562e-07
) O 0 1.1766104535126942e-07
of O 0 1.0561119268004404e-07
the O 0 3.595940870582126e-05
breast B-Disease 1 0.9999994039535522
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0003564200596883893
were O 0 2.3022312234388664e-05
due O 0 7.310184173547896e-06
to O 0 5.791803232568782e-06
BRCA1 O 0 0.022749407216906548
, O 0 7.365076157839212e-07
with O 0 2.595836861019052e-07
most O 0 3.216632080693671e-07
others O 0 1.0558012490946567e-06
( O 0 1.6926685475482373e-07
14 O 0 1.5743978565296857e-06
% O 0 4.493062988331076e-07
) O 0 2.3067713073032792e-07
due O 0 1.3013899433644838e-06
to O 0 4.527319106273353e-06
BRCA2 O 0 0.0007243775762617588
. O 0 1.5905070540611632e-05

Conversely O 0 0.0012262623058632016
, O 0 8.875254934537224e-06
the O 0 1.225655068992637e-06
majority O 0 1.1319599479975295e-06
of O 0 2.3083690336989093e-07
families O 0 1.5123762295843335e-06
with O 0 4.7452851958951214e-07
male B-Disease 0 1.1101781637989916e-05
and I-Disease 0 3.0313974548334954e-06
female I-Disease 0 0.02980183996260166
breast I-Disease 1 0.9998043179512024
cancer I-Disease 1 0.8909448981285095
were O 0 1.783824700396508e-05
due O 0 5.369402515498223e-06
to O 0 5.979894922347739e-06
BRCA2 O 0 0.0052919709123671055
( O 0 1.7652386077315896e-06
76 O 0 1.626473749638535e-05
% O 0 1.98073962565104e-06
) O 0 2.496090019121766e-06
. O 0 7.515236120525515e-06

The O 0 3.431937875575386e-05
largest O 0 1.9791874365182593e-05
proportion O 0 1.2558037269627675e-05
( O 0 1.1589273753997986e-06
67 O 0 7.745382390567102e-06
% O 0 9.511927601124626e-07
) O 0 1.4279629567681695e-07
of O 0 9.000468281783469e-08
families O 0 1.28677550037537e-06
due O 0 9.097368547372753e-07
to O 0 2.596879369320959e-07
other O 0 1.1973251901054027e-07
genes O 0 1.7977594097828842e-06
was O 0 1.953240280272439e-05
found O 0 1.2226105354784522e-06
in O 0 3.0569486852982664e-07
families O 0 8.238069426624861e-07
with O 0 2.47900175054383e-07
four O 0 9.360127819491026e-07
or O 0 7.564394195469504e-07
five O 0 2.3132899684696895e-07
cases O 0 1.0029723540583291e-07
of O 0 3.09907989048952e-07
female O 1 0.5138920545578003
breast B-Disease 1 0.9999957084655762
cancer I-Disease 1 0.8443768620491028
only O 0 5.337666607374558e-06
. O 0 1.825831895985175e-05

These O 0 4.891685239272192e-05
estimates O 0 4.808562880498357e-05
were O 0 1.5029248061182443e-05
not O 0 2.9389716473815497e-06
substantially O 0 1.1805543181253597e-05
affected O 0 2.0563304587994935e-06
either O 0 3.912250292614772e-07
by O 0 1.664939333068105e-07
changing O 0 1.199959342557122e-06
the O 0 4.2827173274417873e-07
assumed O 0 1.2787852938345168e-05
penetrance O 0 6.892775218148017e-06
model O 0 9.932023203873541e-07
for O 0 4.134627431540139e-07
BRCA1 O 0 0.00043301971163600683
or O 0 8.130576816256507e-07
by O 0 1.660242787693278e-07
including O 0 2.653313231348875e-07
or O 0 2.685962044779444e-06
excluding O 0 6.852186743344646e-06
BRCA1 O 0 0.000681235920637846
mutation O 0 2.4075479814200662e-05
data O 0 1.1431334314693231e-05
. O 0 1.531190901005175e-05

Among O 0 6.258176290430129e-05
those O 0 1.5998019080143422e-05
families O 0 2.2846987121738493e-05
with O 0 4.318646824685857e-05
disease O 0 0.3763801157474518
due O 0 1.681113826634828e-05
to O 0 7.004038707236759e-06
BRCA1 O 0 0.04850279539823532
that O 0 2.040896333710407e-06
were O 0 2.4625838705105707e-05
tested O 0 8.952253665484022e-06
by O 0 6.808659946955231e-08
one O 0 5.6556242356009534e-08
of O 0 2.9617176267038303e-08
the O 0 1.2290080064758513e-07
standard O 0 1.5771644257256412e-06
screening O 0 2.1576520339294802e-06
methods O 0 2.349670239709667e-06
, O 0 1.0652313449099893e-06
mutations O 0 3.1597805900673848e-06
were O 0 2.02989417630306e-06
detected O 0 4.358758360467618e-06
in O 0 2.6010059173131594e-07
the O 0 2.8371769644763845e-07
coding O 0 3.7558313579211244e-06
sequence O 0 1.0727407016020152e-06
or O 0 4.60275458635806e-07
splice O 0 3.048850157938432e-05
sites O 0 2.008691808441654e-06
in O 0 5.604791795121855e-07
an O 0 8.348669666702335e-07
estimated O 0 1.7647065533310524e-06
63 O 0 3.5102621041005477e-06
% O 0 4.818431875719398e-07
( O 0 1.2516582614807703e-07
95 O 0 8.159005915331363e-07
% O 0 1.2561908988573123e-06
CI O 0 0.00011573710071388632
51 O 0 3.1295960525312694e-06
% O 0 1.0317951364413602e-06
- O 0 2.9812665161443874e-05
77 O 0 9.156477062788326e-06
% O 0 2.7177163701708196e-06
) O 0 2.180326646339381e-06
. O 0 4.319223990023602e-06

The O 0 2.680867510207463e-05
estimated O 0 1.6922189388424158e-05
sensitivity O 0 1.9883360437233932e-05
was O 0 2.6927202270599082e-05
identical O 0 2.9518059818656184e-06
for O 0 1.2547478434044024e-07
direct O 0 4.4906639118380554e-07
sequencing O 0 3.892053427989595e-06
and O 0 8.147404741976061e-07
other O 0 4.4274136712374457e-07
techniques O 0 1.4798840311414097e-05
. O 0 1.5969879314070567e-05

The O 0 7.361822645179927e-05
penetrance O 0 0.0004025765520054847
of O 0 1.56042879098095e-05
BRCA2 O 0 0.017821457237005234
was O 0 8.266063377959654e-05
estimated O 0 3.2717441627028165e-06
by O 0 5.65722586998163e-07
maximizing O 0 3.95198367186822e-06
the O 0 1.2446334949345328e-06
LOD O 0 0.00058388413162902
score O 0 8.856839485815726e-06
in O 0 2.9079139949317323e-06
BRCA2 O 0 0.00039518772973679006
- O 0 0.00012266698468010873
mutation O 0 8.081927262537647e-06
families O 0 1.2740530337396194e-06
, O 0 1.342097135648146e-07
over O 0 1.7590564027614164e-07
all O 0 1.8684490044051927e-07
possible O 0 3.2957505027297884e-06
penetrance O 0 0.0001470427232561633
functions O 0 1.729819086904172e-05
. O 0 2.9919470762251876e-05

The O 0 3.117118831141852e-05
estimated O 0 2.688465974642895e-05
cumulative O 0 3.4724838769761845e-05
risk O 0 3.350560291437432e-05
of O 0 4.284190254111309e-06
breast B-Disease 1 0.999962329864502
cancer I-Disease 1 0.978791356086731
reached O 0 3.353520514792763e-05
28 O 0 7.717422704445198e-06
% O 0 6.252400339690212e-07
( O 0 1.9103372039808164e-07
95 O 0 1.1185587709405809e-06
% O 0 1.7209217730851378e-06
CI O 0 6.702471728203818e-05
9 O 0 3.4947902349813376e-06
% O 0 7.339036187659076e-07
- O 0 1.1602915037656203e-05
44 O 0 3.090755853918381e-06
% O 0 3.3133815691144264e-07
) O 0 7.780644750710053e-08
by O 0 7.577868643693364e-08
age O 0 8.4865496319253e-07
50 O 0 2.92502562615482e-07
years O 0 3.717750303167122e-07
and O 0 2.632966129567649e-07
84 O 0 1.4277318314270815e-06
% O 0 3.5979726931145706e-07
( O 0 1.229854547091236e-07
95 O 0 4.5983233576407656e-07
% O 0 5.771847781943507e-07
CI O 0 5.681188122252934e-05
43 O 0 2.076595364997047e-06
% O 0 5.813756160932826e-07
- O 0 6.112544724601321e-06
95 O 0 1.713262918201508e-06
% O 0 9.224685300068813e-07
) O 0 1.9700232201103063e-07
by O 0 1.9247509897013515e-07
age O 0 2.4551966362196254e-06
70 O 0 2.0777818008355098e-06
years O 0 4.2614724407030735e-06
. O 0 7.79063248046441e-06

The O 0 0.0005933127249591053
corresponding O 1 0.987825334072113
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 1 0.7315298318862915
were O 0 0.00012243747187312692
0 O 0 0.00012153480929555371
. O 0 2.1028008632129058e-05

4 O 0 0.0002186069468734786
% O 0 1.2879055248049553e-05
( O 0 1.6144053915922996e-06
95 O 0 2.7894154754903866e-06
% O 0 2.8358369945635786e-06
CI O 0 0.0003291316388640553
0 O 0 4.183830242254771e-06
% O 0 7.237930503833923e-07
- O 0 8.828774298308417e-06
1 O 0 9.414738997293171e-07
% O 0 2.7134075253343326e-07
) O 0 8.342224333546255e-08
by O 0 9.110455323479982e-08
age O 0 1.3321296137291938e-06
50 O 0 2.426124865451129e-07
years O 0 2.794575948428246e-07
and O 0 3.4865732345679135e-07
27 O 0 2.3897150640550535e-06
% O 0 2.75670515748061e-07
( O 0 1.5938772435220017e-07
95 O 0 6.742813525306701e-07
% O 0 9.498049848843948e-07
CI O 0 8.844643889460713e-05
0 O 0 3.4864078770624474e-06
% O 0 5.983335995551897e-07
- O 0 1.1849804650410078e-05
47 O 0 6.5028089011320844e-06
% O 0 6.417266149583156e-07
) O 0 1.2765362100708444e-07
by O 0 1.4172911733112414e-07
age O 0 3.3928602078958647e-06
70 O 0 2.394711373199243e-06
years O 0 3.1070692330104066e-06
. O 0 7.78818048274843e-06

The O 0 0.0001297964627156034
lifetime O 0 0.0011222476605325937
risk O 0 0.000217314314795658
of O 0 1.4381393157236744e-05
breast B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.999818742275238
appears O 0 2.08148831006838e-05
similar O 0 9.622848438084475e-07
to O 0 9.21204332371417e-07
the O 0 1.507681645307457e-06
risk O 0 5.452133700600825e-05
in O 0 1.6703575056453701e-06
BRCA1 O 0 0.0011737942695617676
carriers O 0 1.6660855180816725e-05
, O 0 8.169875513885927e-07
but O 0 3.186897856721771e-07
there O 0 2.2947054389987898e-07
was O 0 1.827721575864416e-06
some O 0 3.840357720719112e-08
suggestion O 0 2.9003649615333416e-07
of O 0 7.506817212288297e-08
a O 0 3.3488195185782388e-06
lower O 0 0.0005207765498198569
risk O 0 3.383091097930446e-05
in O 0 1.615297151147388e-06
BRCA2 O 0 0.00025960191851481795
carriers O 0 9.140659130935092e-06
< O 0 5.99967097514309e-06
50 O 0 5.525971005226893e-07
years O 0 4.166427913787629e-07
of O 0 6.264594389904232e-07
age O 0 4.399824683787301e-05
. O 0 8.822461495583411e-06

Eye B-Disease 1 0.8843379616737366
movement I-Disease 0 0.004250954370945692
abnormalities I-Disease 1 0.9923721551895142
correlate O 0 0.000521913287229836
with O 0 2.4414803192485124e-05
genotype O 0 0.20850946009159088
in O 0 7.268598710652441e-05
autosomal O 1 0.9671463966369629
dominant O 0 0.14941616356372833
cerebellar B-Disease 1 0.6576195955276489
ataxia I-Disease 1 0.9999818801879883
type I-Disease 1 0.8788439631462097
I I-Disease 1 0.592930018901825
. O 0 6.045697955414653e-05

We O 0 7.915170135674998e-05
compared O 0 2.1164287318242714e-05
horizontal O 0 0.00011993548105238006
eye O 0 0.002989627653732896
movements O 0 1.671636891842354e-05
( O 0 1.97844383365009e-06
visually O 0 7.380739134532632e-06
guided O 0 1.5885456377873197e-05
saccades O 0 0.0007399222231470048
, O 0 4.947136403643526e-06
antisaccades O 0 0.0001553121255710721
, O 0 7.336489034059923e-07
and O 0 1.0178496268054005e-06
smooth O 0 1.3082141776976641e-05
pursuit O 0 3.65532650903333e-05
) O 0 4.0635831055624294e-07
in O 0 3.1945842238201294e-07
control O 0 5.686652457370656e-06
subjects O 0 4.421259291120805e-06
( O 0 7.054946991047473e-07
n O 0 7.492591976188123e-05
= O 0 8.953722863225266e-05
14 O 0 4.392516984808026e-06
) O 0 4.758862814924214e-07
and O 0 3.6522114896797575e-06
patients O 0 5.6875742302509025e-06
with O 0 2.7936405899708916e-07
three O 0 4.3892868006878416e-07
forms O 0 5.79832999392238e-07
of O 0 9.152217899099924e-07
autosomal O 0 0.3548282980918884
dominant O 0 0.0018727962160483003
cerebellar B-Disease 0 0.005486564710736275
ataxias I-Disease 0 0.29033055901527405
type I-Disease 0 0.005979496985673904
I I-Disease 0 0.10808432847261429
spinocerebellar B-Disease 0 0.1966441422700882
ataxias I-Disease 0 0.04602859914302826
1 I-Disease 0 5.394665549829369e-06
and I-Disease 0 1.9660794805531623e-06
2 I-Disease 0 2.7908922675123904e-06
( O 0 6.110349204391241e-07
SCA1 B-Disease 0 0.00018331989122088999
, O 0 1.0418441434012493e-06
n O 0 4.0430997614748776e-05
= O 0 4.790816819877364e-05
11 O 0 3.5091441077383934e-06
; O 0 8.931464208217221e-07
SCA2 B-Disease 0 0.0010966167319566011
, O 0 1.2358595995465294e-06
n O 0 2.8645121346926317e-05
= O 0 2.6509851522860117e-05
10 O 0 7.147714313759934e-07
) O 0 2.8805396823372575e-07
and O 0 2.1425071281555574e-06
SCA3 B-Disease 1 0.9999417066574097
/ O 0 6.100274185882881e-05
Machado B-Disease 0 8.32362420624122e-05
- I-Disease 0 0.0034179221838712692
Joseph I-Disease 0 0.0020818610209971666
disease I-Disease 0 0.019511232152581215
( O 0 2.9189250199124217e-06
MJD B-Disease 1 0.9999723434448242
) O 0 1.5344708117481787e-06
( O 0 6.526390734507004e-07
n O 0 4.683477527578361e-05
= O 0 7.789984374539927e-05
16 O 0 5.893382422073046e-06
) O 0 3.287018216724391e-06
. O 0 6.91135710439994e-06

In O 0 0.0001089775250875391
SCA1 B-Disease 0 0.0011073300847783685
, O 0 6.105576630943688e-06
saccade O 0 5.14697894686833e-05
amplitude O 0 8.14738086774014e-06
was O 0 1.880466334114317e-05
significantly O 0 4.176590664428659e-06
increased O 0 2.3260749912878964e-06
, O 0 6.487606469818274e-07
resulting O 0 3.373765366632142e-06
in O 0 2.7871099064213922e-06
hypermetria B-Disease 0 0.0005482654669322073
. O 0 1.6725682144169696e-05

The O 0 9.479080472374335e-05
smooth O 0 0.0001805318024707958
pursuit O 0 0.0002573499805293977
gain O 0 0.0003282063698861748
was O 0 0.000201902148546651
decreased O 0 0.00033809654996730387
. O 0 2.3256041458807886e-05

In O 0 0.00013188205775804818
SCA2 B-Disease 0 0.0019249602919444442
, O 0 1.0611861398501787e-05
saccade O 0 0.00012218438496347517
velocity O 0 5.2344730647746474e-05
was O 0 6.992509588599205e-05
markedly O 0 0.00016336870612576604
decreased O 0 0.0001299736904911697
. O 0 2.1978043150738813e-05

The O 0 2.915920049417764e-05
percentage O 0 3.0349607186508365e-05
of O 0 2.3354441509582102e-06
errors O 0 3.836369069176726e-05
in O 0 4.064864697284065e-06
antisaccades O 0 0.004847737029194832
was O 0 8.181838347809389e-05
greatly O 0 1.8388270746072521e-06
increased O 0 6.79979564210953e-07
and O 0 1.2765084420607309e-06
was O 0 1.5625462765456177e-05
significantly O 0 1.5606343595209182e-06
correlated O 0 3.286547780589899e-06
with O 0 7.941354169815895e-07
age O 0 0.0002369108988204971
at O 0 0.16340678930282593
disease O 0 0.41588258743286133
onset O 0 0.033142101019620895
. O 0 4.012057979707606e-05

In O 0 3.70374254998751e-05
addition O 0 6.734229827998206e-06
, O 0 1.4671799135612673e-06
a O 0 1.1758470463973936e-06
correlation O 0 3.2663381261954783e-06
between O 0 6.634251121795387e-07
smooth O 0 1.8171431293012574e-05
pursuit O 0 3.651118458947167e-05
gain O 0 1.66889549291227e-05
and O 0 4.641456428089441e-07
the O 0 1.5695435706675198e-07
number O 0 1.278158663353679e-07
of O 0 2.9125996547918476e-07
trinucleotide O 0 0.00020531988411676139
repeats O 0 1.2664280802709982e-05
was O 0 3.652037776191719e-05
found O 0 1.3367643987294286e-05
. O 0 1.2422888175933622e-05

In O 0 0.0003659383219201118
SCA3 B-Disease 1 0.9998045563697815
, O 0 1.8380751498625614e-05
gaze B-Disease 0 0.0003997277526650578
- I-Disease 0 0.00011886229913216084
evoked I-Disease 0 8.031882316572592e-05
nystagmus I-Disease 0 0.007161133922636509
was O 0 5.758505722042173e-05
often O 0 1.3837760661772336e-06
present O 0 5.73370755319047e-07
as O 0 6.88282341343438e-07
was O 0 1.1388679922674783e-05
saccade O 0 5.8302106481278315e-05
hypometria O 0 8.67108246893622e-05
and O 0 1.2853161024395376e-06
smooth O 0 1.0473777365405113e-05
pursuit O 0 2.9346163501031697e-05
gain O 0 6.434537499444559e-05
was O 0 0.00020520381804089993
markedly O 0 0.00020555336959660053
decreased O 0 0.0002159510477213189
. O 0 2.158895404136274e-05

Three O 0 8.825308759696782e-05
major O 0 2.712397872528527e-05
criteria O 0 1.699399399512913e-05
, O 0 2.410838760624756e-06
saccade O 0 2.453002343827393e-05
amplitude O 0 5.460952706926037e-06
, O 0 6.314516554084548e-07
saccade O 0 1.4741919585503638e-05
velocity O 0 2.989983613588265e-06
, O 0 2.0665659405949555e-07
and O 0 2.092511834916877e-07
presence O 0 1.829418607712796e-07
of O 0 1.8012416092005878e-07
gaze B-Disease 0 0.00010722331353463233
- I-Disease 0 6.076863792259246e-05
evoked I-Disease 0 1.1464043382147793e-05
nystagmus I-Disease 0 7.939572242321447e-05
, O 0 3.816272737822146e-07
permitted O 0 3.318738777124963e-07
the O 0 2.0073578355095378e-07
correct O 0 3.892439508490497e-06
assignment O 0 1.7387563957527163e-06
of O 0 1.0352641766075976e-07
90 O 0 5.153671054358711e-07
% O 0 2.101942015997338e-07
of O 0 7.460156581373667e-08
the O 0 1.0625760751281632e-06
SCA1 B-Disease 0 0.0009219658095389605
, O 0 4.06492432603045e-07
90 O 0 2.757972765721206e-07
% O 0 1.0454635912537924e-07
of O 0 5.691898863346978e-08
the O 0 6.533041982947907e-07
SCA2 B-Disease 0 0.006511514540761709
, O 0 4.689947559199936e-07
and O 0 4.875304284723825e-07
93 O 0 1.7575652009327314e-06
% O 0 1.632369048820692e-07
of O 0 7.898500342662373e-08
the O 0 1.6221590612985892e-06
patients O 0 1.3698013390239794e-05
with O 0 3.409161536183092e-06
SCA3 B-Disease 1 0.9999985694885254
to O 0 3.5916141314373817e-06
their O 0 8.570790669182315e-06
genetically O 0 9.979067726817448e-06
confirmed O 0 1.092160073312698e-05
patient O 0 3.073289553867653e-05
group O 0 2.561111386967241e-06
and O 0 9.049214213519008e-07
, O 0 9.058695127350802e-07
therefore O 0 5.871571033821965e-07
, O 0 3.64017296305974e-07
may O 0 2.0085922187718097e-06
help O 0 9.377524179399188e-07
orient O 0 2.2594882466364652e-05
diagnoses O 0 4.5906181185273454e-05
of O 0 4.806049673788948e-07
SCA1 B-Disease 0 0.022132065147161484
, O 0 1.5079922377481125e-06
SCA2 B-Disease 0 0.0018968739314004779
, O 0 7.710234513069736e-07
and O 0 4.3170502976863645e-06
SCA3 B-Disease 1 0.9999426603317261
at O 0 2.560941175033804e-05
early O 0 3.125834609818412e-06
clinical O 0 2.7176618459634483e-05
stages O 0 7.301892765099183e-06
of O 0 4.3075934286207485e-07
the O 0 2.3058961232891306e-05
diseases O 0 0.08805764466524124
. O 0 3.4498277727834648e-06
. O 0 1.1827338312286884e-05

Genetic O 0 0.0005861580721102655
basis O 0 2.0200481230858713e-05
and O 0 1.1087814527854789e-05
molecular O 0 0.0004516539047472179
mechanism O 0 0.00048691959818825126
for O 0 0.0011424953117966652
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999991655349731
fibrillation I-Disease 1 1.0
. O 0 0.0018042224692180753

Ventricular B-Disease 1 0.9995321035385132
fibrillation I-Disease 1 0.9987095594406128
causes O 0 0.0002529674384277314
more O 0 1.7040823649949743e-06
than O 0 6.208217655512271e-07
300 O 0 5.862249281562981e-07
, O 0 2.428782579499966e-07
000 O 0 1.2941126215082477e-06
sudden O 0 9.047636012837756e-06
deaths O 0 2.9204397833382245e-06
each O 0 2.664851308509242e-07
year O 0 7.274232416421e-07
in O 0 4.0614060026200605e-07
the O 0 1.6755139995439094e-06
USA O 0 0.0001155064528575167
alone O 0 2.4124112314893864e-05
. O 0 6.678409135929542e-06

In O 0 2.2864598577143624e-05
approximately O 0 6.718007171002682e-06
5 O 0 5.822500952490373e-06
- O 0 1.2051224985043518e-05
12 O 0 1.9161773252562853e-06
% O 0 2.1775866798634524e-07
of O 0 6.607920965961966e-08
these O 0 1.5480448212201736e-07
cases O 0 2.6366751626483165e-07
, O 0 5.471464987749641e-07
there O 0 5.001239173907379e-07
are O 0 3.3048104342014994e-07
no O 0 7.911458851594944e-06
demonstrable O 1 0.5559293627738953
cardiac O 1 0.9962447285652161
or O 0 0.0001410703407600522
non O 0 0.003014721442013979
- O 1 0.990247905254364
cardiac O 1 0.9972992539405823
causes O 0 1.6120813597808592e-05
to O 0 1.5727740674265078e-06
account O 0 1.4572761983799865e-06
for O 0 1.6047826534304477e-07
the O 0 4.1914154280675575e-07
episode O 0 6.089666840125574e-06
, O 0 3.565108102066006e-07
which O 0 4.201724834729248e-07
is O 0 4.481525763821992e-07
therefore O 0 1.0775002010632306e-06
classified O 0 1.937190245371312e-05
as O 0 0.0001581174583407119
idiopathic B-Disease 1 0.9999998807907104
ventricular I-Disease 1 0.9999994039535522
fibrillation I-Disease 1 1.0
( O 0 0.006955150980502367
IVF B-Disease 1 0.9999996423721313
) O 0 5.090696504339576e-05
. O 0 3.646458935691044e-05

A O 0 0.00014896372158546
distinct O 0 2.1925914552411996e-05
group O 0 1.094439357984811e-05
of O 0 3.576397375582019e-06
IVF B-Disease 1 1.0
patients O 0 0.37989678978919983
has O 0 6.46149055683054e-06
been O 0 4.969554083800176e-06
found O 0 1.754825120769965e-06
to O 0 3.7861087776036584e-07
present O 0 2.975173742925108e-07
with O 0 4.621535936166765e-07
a O 0 4.530575552053051e-06
characteristic O 0 4.443754369276576e-05
electrocardiographic O 0 0.008214766159653664
pattern O 0 9.831103670876473e-05
. O 0 2.0343832147773355e-05

Because O 0 1.9303006411064416e-05
of O 0 8.401487434639421e-07
the O 0 6.587439997929323e-07
small O 0 5.061152705820859e-07
size O 0 7.860834898565372e-07
of O 0 1.0762908431161122e-07
most O 0 1.7368626004099497e-07
pedigrees O 0 1.1989804079348687e-05
and O 0 5.078669573777006e-07
the O 0 5.632005581901467e-07
high O 0 3.4886681532952935e-05
incidence O 0 0.00010535810724832118
of O 0 4.933016839459015e-07
sudden B-Disease 0 0.0026582323480397463
death I-Disease 0 7.804260530974716e-05
, O 0 5.506900038199092e-07
however O 0 1.9791959005033277e-07
, O 0 1.9131157102947327e-07
molecular O 0 6.586317795154173e-06
genetic O 0 4.82132736578933e-06
studies O 0 4.317459740832419e-07
of O 0 4.307634355882328e-07
IVF B-Disease 1 0.9999988079071045
have O 0 1.5347563021350652e-05
not O 0 2.2567101041204296e-06
yet O 0 1.790202418305853e-06
been O 0 5.568627784668934e-06
done O 0 1.1006609383912291e-05
. O 0 1.1276563782303128e-05

Because O 0 0.00829368457198143
IVF B-Disease 1 0.999998927116394
causes O 0 0.22674931585788727
cardiac O 1 0.9998214840888977
rhythm O 1 0.679572582244873
disturbance O 0 0.0002458103990647942
, O 0 3.7291990793164587e-06
we O 0 1.4769168501516106e-06
investigated O 0 4.474676188692683e-06
whether O 0 6.234692477846693e-07
malfunction O 0 0.00011165063915541396
of O 0 3.1019126822684484e-07
ion O 0 9.873303497442976e-06
channels O 0 2.229550045740325e-05
could O 0 3.778216341743246e-05
cause O 0 1.3927209693065379e-05
the O 0 4.667833763960516e-06
disorder O 0 0.029455462470650673
by O 0 2.481419016930886e-07
studying O 0 1.7558229501446476e-06
mutations O 0 3.2373050089518074e-06
in O 0 3.8344623476405104e-07
the O 0 1.241780864802422e-06
cardiac O 0 0.01194710936397314
sodium O 0 1.678275475569535e-05
channel O 0 7.397352601401508e-05
gene O 0 3.840340650640428e-05
SCN5A O 0 0.0008082110434770584
. O 0 2.7240810595685616e-05

We O 0 0.00011865912529174238
have O 0 5.545019575947663e-06
now O 0 1.632762746339722e-06
identified O 0 1.6668313946865965e-06
a O 0 1.106366880776477e-06
missense O 0 1.6829842934384942e-05
mutation O 0 8.695985343365464e-06
, O 0 3.8547713643311e-07
a O 0 9.062462709152896e-07
splice O 0 0.016173383221030235
- O 0 0.011731191538274288
donor O 0 8.90423689270392e-05
mutation O 0 2.771118852251675e-05
, O 0 9.40332483878592e-07
and O 0 7.20539560461475e-07
a O 0 4.212584371998673e-06
frameshift O 0 0.00013679522089660168
mutation O 0 6.505339570139768e-06
in O 0 7.264083023983403e-07
the O 0 1.0895830655499594e-06
coding O 0 1.150531170424074e-05
region O 0 1.2033250413878704e-06
of O 0 4.403445643674786e-07
SCN5A O 0 0.0022583133541047573
in O 0 2.120935732818907e-06
three O 0 1.691997931629885e-05
IVF B-Disease 1 0.999993085861206
families O 0 7.912679575383663e-05
. O 0 1.2903421520604752e-05

We O 0 5.1945029554190114e-05
show O 0 8.377473932341672e-06
that O 0 7.478163297491847e-07
sodium O 0 2.0626039258786477e-06
channels O 0 1.616161625861423e-06
with O 0 3.2114030545926653e-07
the O 0 5.756592713623832e-07
missense O 0 2.0977333406335674e-05
mutation O 0 1.7404056052328087e-05
recover O 0 3.674703839351423e-05
from O 0 7.002262236710521e-07
inactivation O 0 7.962121162563562e-05
more O 0 2.2825398104941996e-07
rapidly O 0 1.4548517128787353e-06
than O 0 1.1052663495547677e-07
normal O 0 8.271076694654766e-07
and O 0 2.526507500988373e-07
that O 0 9.073344386933968e-08
the O 0 5.58420310881047e-07
frameshift O 0 7.836701843189076e-05
mutation O 0 5.667373443429824e-06
causes O 0 7.561466190963984e-07
the O 0 3.006711892794556e-07
sodium O 0 1.9750657429540297e-06
channel O 0 4.461897333385423e-06
to O 0 7.512710453738691e-07
be O 0 9.248309424947365e-07
non O 0 2.295568720001029e-06
- O 0 6.84801852912642e-05
functional O 0 6.651761941611767e-05
. O 0 2.2381263988791034e-05

Our O 0 0.0001705241302261129
results O 0 4.6746608859393746e-05
indicate O 0 1.0037212632596493e-05
that O 0 1.2581763257912826e-06
mutations O 0 7.536221801274223e-06
in O 0 1.5244968381011859e-06
cardiac O 0 0.003091554855927825
ion O 0 2.0556681192829274e-05
- O 0 5.390025398810394e-05
channel O 0 2.4189304895116948e-05
genes O 0 2.6718698791228235e-06
contribute O 0 3.827896932762087e-07
to O 0 1.8051761685455858e-07
the O 0 3.560161303539644e-07
risk O 0 2.466607384121744e-06
of O 0 2.138562109621489e-07
developing O 0 4.9748206947697327e-05
IVF B-Disease 1 0.9999898672103882
. O 0 8.580531357438304e-06
. O 0 1.5934552720864303e-05

Molecular O 0 0.0007222930435091257
heterogeneity O 0 0.0005707055679522455
in O 0 4.579136293614283e-05
mucopolysaccharidosis B-Disease 0 0.06405942887067795
IVA I-Disease 0 0.004361152183264494
in O 0 5.3161165851634e-06
Australia O 0 3.336537020004471e-06
and O 0 7.397006243081705e-07
Northern O 0 1.135025513576693e-06
Ireland O 0 5.063907792646205e-06
: O 0 4.0623586983201676e-07
nine O 0 9.987932116928278e-07
novel O 0 7.66384459893743e-07
mutations O 0 2.45057435677154e-06
including O 0 5.756702421422233e-07
T312S O 0 8.349691779585555e-05
, O 0 5.985915549899801e-07
a O 0 7.916348181424837e-07
common O 0 8.073670301200764e-07
allele O 0 1.055930715665454e-05
that O 0 4.988301611774659e-07
confers O 0 8.26891391625395e-06
a O 0 1.3997836504131556e-05
mild O 0 0.01540267001837492
phenotype O 0 0.021830838173627853
. O 0 2.393761315033771e-05

Mucopolysaccharidosis B-Disease 1 0.9914889335632324
IVA I-Disease 1 0.9985617995262146
( O 0 0.0020886382553726435
MPS B-Disease 1 0.9999994039535522
IVA I-Disease 1 0.9999994039535522
) O 0 1.7955928342416883e-05
is O 0 1.8481553070159862e-06
an O 0 2.4308559659402817e-05
autosomal B-Disease 1 0.996301531791687
recessive I-Disease 1 0.9996978044509888
lysosomal I-Disease 1 0.9999960660934448
storage I-Disease 1 0.9999995231628418
disorder I-Disease 1 0.999998927116394
caused O 0 0.009262516163289547
by O 0 3.0811791020823875e-06
a O 0 0.001184565364383161
genetic B-Disease 1 0.9999947547912598
defect I-Disease 1 0.9999645948410034
in O 0 1.4782874131924473e-05
N O 0 0.02749243751168251
- O 0 0.0012386826565489173
acetylgalactosamine O 0 0.003353065811097622
- O 0 0.0009810798801481724
6 O 0 7.804454071447253e-05
- O 0 0.01655576191842556
sulfate O 0 0.00035722815664485097
sulfatase O 0 0.0006753142806701362
( O 0 4.951331447955454e-06
GALNS O 0 0.0006806917954236269
) O 0 4.949491085426416e-06
. O 0 6.136468527984107e-06

Previous O 0 7.960465882206336e-05
studies O 0 1.3578512152889743e-05
of O 0 2.289115400344599e-06
patients O 0 0.00023307472292799503
from O 0 1.308905325458909e-06
a O 0 4.950991751684342e-06
British O 0 0.00013819675950799137
- O 0 0.0012683444656431675
Irish O 0 1.4628914868808351e-05
population O 0 9.76330056801089e-07
showed O 0 7.1412332545151e-06
that O 0 1.252762871217783e-07
the O 0 5.63152241284115e-07
I113F O 0 0.0001347964716842398
mutation O 0 3.213166110072052e-06
is O 0 1.2931167248098063e-07
the O 0 1.2228210266584938e-07
most O 0 8.84785862353965e-08
common O 0 3.927382294932613e-07
single O 0 1.1459386769274715e-05
mutation O 0 1.6930518540902995e-05
among O 0 3.5412024317338364e-06
MPS B-Disease 1 0.999996542930603
IVA I-Disease 1 0.9999996423721313
patients O 0 0.026068150997161865
and O 0 1.1991187420790084e-05
produces O 0 2.133455200237222e-05
a O 0 9.169777331408113e-05
severe O 1 0.9935479760169983
clinical O 0 0.4383726716041565
phenotype O 1 0.7451125979423523
. O 0 6.746602593921125e-05

We O 0 0.00010144151747226715
studied O 0 5.7022698456421494e-05
mutations O 0 2.376542761339806e-05
in O 0 1.0842571782632149e-06
the O 0 1.1525235095177777e-06
GALNS O 0 0.00047010398702695966
gene O 0 2.3868224161560647e-06
from O 0 5.574242436523491e-07
23 O 0 7.4338890954095405e-06
additional O 0 5.923928711126791e-06
MPS B-Disease 1 0.9999864101409912
IVA I-Disease 1 0.9999880790710449
patients O 0 0.010952332988381386
( O 0 4.197735847810691e-07
15 O 0 6.825679861321987e-07
from O 0 2.0690742985607358e-07
Australia O 0 6.215469170456345e-07
, O 0 1.6678029624017654e-07
8 O 0 4.342500403708982e-07
from O 0 1.4175155627071945e-07
Northern O 0 5.078185267848312e-07
Ireland O 0 3.0087653613009024e-06
) O 0 2.3653109337828937e-07
, O 0 8.399382522839005e-08
with O 0 8.005946483535809e-08
various O 0 2.913672290105751e-07
clinical O 0 0.005582243669778109
phenotypes O 0 0.011065928265452385
( O 0 4.394436018628767e-06
severe O 0 0.08461597561836243
, O 0 4.5088127080816776e-06
16 O 0 6.907271654199576e-06
cases O 0 2.754313754849136e-07
; O 0 4.035199197005568e-07
intermediate O 0 9.931977729138453e-06
, O 0 6.82711231547728e-07
4 O 0 3.5058060348092113e-06
cases O 0 2.6194965130343917e-07
; O 0 1.0020121408160776e-06
mild O 0 4.530428122961894e-05
, O 0 1.7044236528818146e-06
3 O 0 1.0241485142614692e-05
cases O 0 8.535981237400847e-07
) O 0 2.119787041010568e-06
. O 0 7.552381248387974e-06

We O 0 9.903385944198817e-05
found O 0 6.042714176146546e-06
two O 0 9.077357958631183e-07
common O 0 2.0324143861216726e-06
mutations O 0 7.9765350164962e-06
that O 0 4.096907559869578e-07
together O 0 1.9361298200237798e-06
accounted O 0 3.7188431178947212e-06
for O 0 1.0734903099773874e-07
32 O 0 1.5849777810217347e-06
% O 0 1.7151498354905925e-07
of O 0 5.741565445305241e-08
the O 0 3.381736917162925e-07
44 O 0 4.535257630777778e-06
unrelated O 0 2.5862789243547013e-06
alleles O 0 4.196353074803483e-06
in O 0 7.219385906864773e-07
these O 0 1.3016556295042392e-06
patients O 0 7.234727672766894e-05
. O 0 1.5860206985962577e-05

One O 0 2.4119557565427385e-05
is O 0 2.748624865489546e-06
the O 0 1.6051178590714699e-06
T312S O 0 5.894977584830485e-05
mutation O 0 7.061220458126627e-06
, O 0 3.795681777774007e-07
a O 0 5.761091301792476e-07
novel O 0 1.403061673954653e-06
mutation O 0 4.348544734966708e-06
found O 0 1.2628789818336372e-06
exclusively O 0 1.958093207576894e-06
in O 0 4.016182174382266e-06
milder O 0 0.0008142560836859047
patients O 0 0.00042942084837704897
. O 0 3.036471753148362e-05

The O 0 2.48446249315748e-05
other O 0 2.088045221171342e-06
is O 0 1.1235772490181262e-06
the O 0 7.887131800998759e-07
previously O 0 7.530689799750689e-06
described O 0 7.217869097075891e-06
I113F O 0 3.305771679151803e-05
that O 0 6.897845423736726e-07
produces O 0 2.7055775717599317e-06
a O 0 1.6532983863726258e-05
severe O 1 0.5468584895133972
phenotype O 0 0.07709980010986328
. O 0 4.225704469718039e-05

The O 0 5.366565892472863e-05
I113F O 0 0.00023427694395650178
and O 0 9.415957720193546e-06
T312S O 0 0.0001376506988890469
mutations O 0 2.463042073941324e-05
accounted O 0 8.52439279697137e-06
for O 0 4.904318871012947e-07
8 O 0 4.659107617044356e-06
( O 0 2.0951316059836245e-07
18 O 0 1.6022332829379593e-06
% O 0 2.9607980422952096e-07
) O 0 1.206330466629879e-07
and O 0 4.013216425846622e-07
6 O 0 1.7484305772086373e-06
( O 0 9.68427613656786e-08
14 O 0 5.343832754078903e-07
% O 0 2.003717867182786e-07
) O 0 9.364094921693322e-08
of O 0 9.055674610181086e-08
44 O 0 4.610830274032196e-06
unrelated O 0 5.1611750677693635e-06
alleles O 0 4.952035396854626e-06
, O 0 1.5621591273884405e-06
respectively O 0 2.538163971621543e-05
. O 0 1.2139791579102166e-05

The O 0 6.878740532556549e-05
relatively O 0 6.718173972330987e-05
high O 0 4.578948937705718e-05
residual O 0 9.999360190704465e-05
GALNS O 0 0.0010600711684674025
activity O 0 5.252714800008107e-06
seen O 0 3.1379731808556244e-06
when O 0 6.669700383099553e-07
the O 0 5.187982310417283e-07
T312S O 0 1.0177953299717046e-05
mutant O 0 5.798330221296055e-06
cDNA O 0 3.3929636629181914e-06
is O 0 4.3372153868403984e-07
overexpressed O 0 6.605226190004032e-06
in O 0 6.095263529459771e-07
mutant O 0 1.7372516595060006e-05
cells O 0 1.7246135257664719e-06
provides O 0 2.749490306541702e-07
an O 0 2.2628661611179268e-07
explanation O 0 3.758400737297052e-07
for O 0 1.284503241549828e-07
the O 0 1.9004752402906888e-06
mild O 0 0.0011549240443855524
phenotype O 0 0.009477624669671059
in O 0 1.0888697033806238e-05
patients O 0 0.0001439133775420487
with O 0 1.6447778534711688e-06
this O 0 2.314813627890544e-06
mutation O 0 7.737258420092985e-05
. O 0 2.0185114408377558e-05

The O 0 1.960249210242182e-05
distribution O 0 7.783428372931667e-06
and O 0 8.00773875653249e-07
relative O 0 1.7941043779501342e-06
frequencies O 0 1.6646804397169035e-06
of O 0 1.540390002219283e-07
the O 0 7.294684678527119e-07
I113F O 0 2.623401269374881e-05
and O 0 1.025615574690164e-06
T312S O 0 2.3289974706131034e-05
mutations O 0 2.2025633370503783e-06
in O 0 3.016033929270634e-07
Australia O 0 7.1782835675549e-07
corresponded O 0 5.859544103259395e-07
to O 0 2.1397860905381094e-07
those O 0 1.1458084259174939e-07
observed O 0 3.175248366460437e-07
in O 0 1.2310187003095052e-07
Northern O 0 5.30921965946618e-07
Ireland O 0 3.3414185054425616e-06
and O 0 1.214343797073525e-06
are O 0 6.642595451467059e-08
unique O 0 6.507621463924806e-08
to O 0 6.994267209847749e-08
these O 0 3.831943118370873e-08
two O 0 1.3737628989929362e-07
populations O 0 3.4711098351181136e-07
, O 0 8.990362942995489e-08
suggesting O 0 2.6301250954929856e-07
that O 0 7.93083643202408e-08
both O 0 2.1482635759184632e-07
mutations O 0 3.87159298043116e-06
were O 0 3.621765245043207e-06
probably O 0 1.0841019957297249e-06
introduced O 0 4.525944916622393e-07
to O 0 2.783604031719733e-07
Australia O 0 4.387826209040213e-07
by O 0 2.388693474131287e-07
Irish O 0 1.608525735719013e-06
migrants O 0 7.463685847142187e-07
during O 0 7.254072897922015e-07
the O 0 8.699267937117838e-07
19th O 0 8.284921932499856e-06
century O 0 1.0515494068386033e-05
. O 0 1.966412855836097e-05

Haplotype O 0 0.001646378543227911
analysis O 0 4.8406443966086954e-05
using O 0 2.5476969312876463e-05
6 O 0 4.591362448991276e-05
RFLPs O 0 0.00011225764319533482
provides O 0 1.4415228406505776e-06
additional O 0 4.678279026393284e-07
data O 0 1.1968586477451026e-06
that O 0 1.5907762929145974e-07
the O 0 3.201226661531109e-07
I113F O 0 1.8016580725088716e-05
mutation O 0 1.8978959133164608e-06
originated O 0 1.0295079846400768e-06
from O 0 3.961799563967361e-07
a O 0 1.6446524568891618e-06
common O 0 3.4113600122509524e-06
ancestor O 0 3.5051085433224216e-05
. O 0 2.0594376110238954e-05

The O 0 1.7124433725257404e-05
other O 0 1.9744254586839816e-06
9 O 0 9.254076758224983e-06
novel O 0 1.7684146769170184e-06
mutations O 0 2.9499342417693697e-06
identified O 0 1.4656638995802496e-06
in O 0 4.1084967961069196e-07
these O 0 3.357446018981136e-07
23 O 0 0.00030347524443641305
patients O 0 1.5231309589580633e-05
were O 0 2.0775123630301096e-06
each O 0 2.195997268472638e-07
limited O 0 6.530686960104504e-07
to O 0 5.44508395705634e-07
a O 0 4.218043613946065e-06
single O 0 4.382722181617282e-05
family O 0 4.288020500098355e-05
. O 0 7.6118249126011506e-06

These O 0 1.2125582543376368e-05
data O 0 8.072915079537779e-06
provide O 0 1.5156451809161808e-06
further O 0 5.530715725399205e-07
evidence O 0 3.620621384925471e-07
for O 0 1.8926385791928624e-07
extensive O 0 3.4058207347698044e-06
allelic O 0 5.027218139730394e-05
heterogeneity O 0 5.405034971772693e-05
in O 0 3.393741644686088e-05
MPS B-Disease 1 0.9999967813491821
IVA I-Disease 1 0.9998093247413635
in O 0 1.532914575363975e-05
British O 0 0.00125337322242558
- O 0 0.03497873246669769
Irish O 0 0.0007001400808803737
patients O 0 3.34232063323725e-05
and O 0 9.103886782213522e-07
provide O 0 6.50188951567543e-07
evidence O 0 3.1080423923413036e-07
for O 0 2.1284093065787602e-07
their O 0 1.9899966900993604e-06
transmission O 0 9.643436351325363e-05
to O 0 8.490758887091943e-07
Australia O 0 7.647606707905652e-07
by O 0 2.131659471160674e-07
British O 0 8.166313818946946e-06
- O 0 8.334966696565971e-05
Irish O 0 5.800315193482675e-06
migrants O 0 2.611450099720969e-06
. O 0 1.419264663127251e-06
. O 0 8.777145012572873e-06

Identification O 0 0.00016309882630594075
of O 0 1.0767630556074437e-05
constitutional O 0 5.5967586376937106e-05
WT1 O 0 0.02813105098903179
mutations O 0 0.0002060808619717136
, O 0 2.3051886728353566e-06
in O 0 3.8542198126378935e-06
patients O 0 8.393566531594843e-05
with O 0 1.5288838767446578e-05
isolated O 0 0.01552241574972868
diffuse B-Disease 1 0.9870595932006836
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.087750908685848e-05
and O 0 1.6387029972975142e-06
analysis O 0 5.929146027483512e-07
of O 0 4.0249486232823983e-07
genotype O 0 0.027841970324516296
/ O 0 8.14433369669132e-05
phenotype O 0 6.429354107240215e-05
correlations O 0 5.557953500101576e-06
by O 0 2.2598015902985935e-07
use O 0 3.258057859056862e-07
of O 0 2.8586410394382256e-07
a O 0 3.962932623835513e-06
computerized O 0 0.0473974272608757
mutation O 0 0.00015638460172340274
database O 0 4.626524241757579e-05
. O 0 2.4068498532869853e-05

Constitutional O 0 0.00018059846479445696
mutations O 0 6.887062772875652e-05
of O 0 1.4885828250044142e-06
the O 0 2.846051302185515e-06
WT1 O 0 0.00019781266746576875
gene O 0 4.926529072690755e-06
, O 0 3.5248169183432765e-07
encoding O 0 1.46698118896893e-06
a O 0 5.255315045360476e-06
zinc O 0 0.01775258034467697
- O 0 0.0004524769610725343
finger O 0 0.0015460557769984007
transcription O 0 1.3968339771963656e-05
factor O 0 1.944686573551735e-06
involved O 0 1.2573846106533892e-06
in O 0 5.164966296433704e-06
renal O 1 0.971627950668335
and O 0 2.4910485080908984e-05
gonadal O 0 0.35884302854537964
development O 0 3.1183553801383823e-06
, O 0 1.062875071511371e-06
are O 0 1.3136632048826868e-07
found O 0 5.063445769337704e-07
in O 0 2.8819135877711233e-07
most O 0 3.494952522942185e-07
patients O 0 9.84000780590577e-06
with O 0 1.0289994861523155e-05
Denys B-Disease 1 0.9997565150260925
- I-Disease 1 0.9999979734420776
Drash I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999998807907104
( O 0 3.351314444444142e-05
DDS B-Disease 1 0.9999998807907104
) O 0 9.684194083092734e-06
, O 0 3.947327968489844e-06
or O 0 5.099587724544108e-05
diffuse B-Disease 1 0.981438159942627
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.00013593625044450164
DMS B-Disease 1 0.9945986270904541
) O 0 2.6235570658172946e-06
associated O 0 2.4239145659521455e-06
with O 0 7.750110853521619e-06
pseudohermaphroditism B-Disease 1 0.9999982118606567
and O 0 0.00010981842933688313
/ O 0 0.017803708091378212
or O 0 0.00032041766098700464
Wilms B-Disease 1 0.9999464750289917
tumor I-Disease 1 0.9699240326881409
( O 0 3.436605038587004e-05
WT B-Disease 1 0.9999961853027344
) O 0 1.1077160706918221e-05
. O 0 1.4356180145114195e-05

Most O 0 8.893086487660185e-05
mutations O 0 0.0010489209089428186
in O 0 0.00012134767894167453
DDS B-Disease 1 1.0
patients O 1 0.9902348518371582
lie O 0 0.0033239154145121574
in O 0 1.785847416613251e-06
exon O 0 1.8311380699742585e-05
8 O 0 3.3479129797342466e-06
or O 0 5.571011456595443e-07
exon O 0 8.649617484479677e-06
9 O 0 3.878669303958304e-06
, O 0 3.416324148020067e-07
encoding O 0 4.6604941417172085e-06
zinc O 0 0.0018114520935341716
finger O 0 0.005534852854907513
2 O 0 1.3684342775377445e-05
or O 0 6.381524144671857e-06
zinc O 0 0.001790346810594201
finger O 0 0.01613936573266983
3 O 0 1.3346014384296723e-05
, O 0 1.3877818219043547e-06
respectively O 0 6.203606062626932e-06
, O 0 1.9936672401854594e-07
with O 0 1.5098933658919123e-07
a O 0 1.2511659406300168e-06
hot O 0 2.8954562367289327e-05
spot O 0 7.848114182706922e-05
( O 0 4.4743342186848167e-07
R394W O 0 5.6799917729222216e-06
) O 0 2.233086462410938e-07
in O 0 4.2111199149985623e-07
exon O 0 3.411006400710903e-05
9 O 0 4.49256767751649e-05
. O 0 1.3318283890839666e-05

We O 0 7.061792712192982e-05
analyzed O 0 1.847469866333995e-05
a O 0 1.975996383407619e-06
series O 0 1.1068988214901765e-06
of O 0 3.6204627917868493e-07
24 O 0 0.0004320923762861639
patients O 0 0.00028200613451190293
, O 0 6.790114071009157e-07
10 O 0 8.408445069107984e-07
with O 0 2.6296440864825854e-06
isolated B-Disease 0 0.0030369916930794716
DMS I-Disease 1 0.8000443577766418
( O 0 2.969829210996977e-06
IDMS B-Disease 0 0.07391499727964401
) O 0 1.226908807439031e-06
, O 0 4.716455350717297e-07
10 O 0 1.133189016400138e-06
with O 0 5.888477517146384e-06
DDS B-Disease 1 0.9999998807907104
, O 0 6.096674042055383e-06
and O 0 1.9795554635493318e-06
4 O 0 4.907753009320004e-06
with O 0 5.3107046369405e-06
urogenital B-Disease 1 0.865514874458313
abnormalities I-Disease 1 0.9998884201049805
and O 0 0.0013870567781850696
/ O 0 0.0927237942814827
or O 0 0.0038722960744053125
WT B-Disease 1 0.9999991655349731
. O 0 0.00010852414561668411

We O 0 0.00023844870156608522
report O 0 5.966623211861588e-05
WT1 O 0 0.0008527064346708357
heterozygous O 0 0.0001503698294982314
mutations O 0 3.673007813631557e-05
in O 0 2.670983121788595e-06
16 O 0 6.074186603655107e-05
patients O 0 0.0002507197204977274
, O 0 6.032702799529943e-07
4 O 0 7.203554446277849e-07
of O 0 2.6645210482456605e-07
whom O 0 4.129254648432834e-06
presented O 0 3.478204916973482e-06
with O 0 2.1684281819034368e-05
IDMS B-Disease 1 0.9135127067565918
. O 0 3.78821678168606e-05

One O 0 0.00011372553854016587
male O 0 7.905138045316562e-05
and O 0 3.927179477614118e-06
two O 0 4.654533313441789e-06
female O 0 0.008414242416620255
IDMS B-Disease 1 0.999735414981842
patients O 0 0.007088905666023493
with O 0 2.264633440063335e-05
WT1 O 1 0.8366729021072388
mutations O 0 0.0007601434481330216
underwent O 0 0.043513767421245575
normal O 0 0.000520062749274075
puberty O 0 0.031009353697299957
. O 0 5.437190338852815e-05

Two O 0 9.454498649574816e-05
mutations O 0 0.0006524808704853058
associated O 0 3.400363493710756e-05
with O 0 1.367129971185932e-05
IDMS B-Disease 1 0.9256160259246826
are O 0 1.0969616823786055e-06
different O 0 2.554168929691514e-07
from O 0 6.140703021628724e-07
those O 0 7.349289603553188e-07
described O 0 1.1646571692836005e-05
in O 0 4.522873496171087e-05
DDS B-Disease 1 1.0
patients O 1 0.5006883144378662
. O 0 2.3797854737495072e-05

No O 0 0.00021250384452287108
WT1 O 0 0.0038363756611943245
mutations O 0 0.00016695226076990366
were O 0 1.450127729185624e-05
detected O 0 1.876183523563668e-05
in O 0 3.401807759928488e-07
the O 0 3.8605398344770947e-07
six O 0 2.7466962819744367e-06
other O 0 4.298357907828176e-06
IDMS B-Disease 1 0.9979391694068909
patients O 0 0.0005825506523251534
, O 0 1.207191758112458e-06
suggesting O 0 6.938169917702908e-06
genetic O 0 1.5958201402099803e-05
heterogeneity O 0 9.531564501230605e-06
of O 0 1.5788664313731715e-06
this O 0 2.148687417502515e-05
disease O 0 0.21350139379501343
. O 0 2.9390694180619903e-05

We O 0 9.487246279604733e-05
analyzed O 0 0.00011947935854550451
genotype O 0 0.0010504488600417972
/ O 0 0.00015566320507787168
phenotype O 0 0.0002532046346459538
correlations O 0 7.525114779127762e-05
, O 0 1.4132569958746899e-06
on O 0 7.116901201698056e-07
the O 0 1.6964986571110785e-07
basis O 0 1.226875525617288e-07
of O 0 8.775589321885491e-08
the O 0 3.3458846360190364e-07
constitution O 0 2.0601962091859605e-07
of O 0 9.407686718532204e-08
a O 0 1.8751410379991285e-06
WT1 O 0 0.00013828519149683416
mutation O 0 1.8779327319862205e-06
database O 0 8.045292361202883e-07
of O 0 3.337273994930001e-07
84 O 0 1.464926936023403e-05
germ O 0 0.00028654630295932293
- O 0 8.041209366638213e-05
line O 0 0.00011367122351657599
mutations O 0 8.043098205234855e-06
, O 0 4.1897129676726763e-07
to O 0 3.5631435935101763e-07
compare O 0 1.7736590507411165e-06
the O 0 2.41909219766967e-07
distribution O 0 4.666079291837377e-07
and O 0 6.156546987767797e-07
type O 0 2.6117140805581585e-06
of O 0 2.301468953191943e-07
mutations O 0 9.54098595684627e-06
, O 0 3.6524340885080164e-07
according O 0 1.9131339001887682e-07
to O 0 2.172618707163565e-07
the O 0 8.142542355926707e-07
different O 0 3.2552238735661376e-06
symptoms O 0 0.002047882415354252
. O 0 1.1248724149481859e-05

This O 0 3.056221248698421e-05
demonstrated O 0 5.958282054052688e-05
( O 0 2.165795194741804e-06
1 O 0 1.4342317626869772e-06
) O 0 1.6976154881831462e-07
the O 0 1.7743836622230447e-07
association O 0 3.4998055298274267e-07
between O 0 1.665396496264293e-07
mutations O 0 2.2231261027627625e-06
in O 0 1.9920858562727517e-07
exons O 0 5.7650327107694466e-06
8 O 0 2.4020625914999982e-06
and O 0 6.12488804563327e-07
9 O 0 8.380742656299844e-06
and O 0 1.8808326558428234e-06
DMS B-Disease 0 0.2886008620262146
; O 0 5.095348569739144e-07
( O 0 1.6625179455331818e-07
2 O 0 7.016755034783273e-07
) O 0 2.5172047912747075e-07
among O 0 2.7423882897892327e-07
patients O 0 7.787259164615534e-06
with O 0 2.3846928343118634e-06
DMS B-Disease 1 0.8491419553756714
, O 0 9.452659810449404e-07
a O 0 3.4374428992123285e-07
higher O 0 6.096914262343489e-07
frequency O 0 1.1957964716202696e-06
of O 0 1.5463170655038994e-07
exon O 0 6.670350558124483e-06
8 O 0 3.2854195524123497e-06
mutations O 0 2.7503240289661335e-06
among O 0 4.205212462693453e-07
46 O 0 5.0661928980844095e-06
, O 0 3.774733841055422e-06
XY O 0 0.44520819187164307
patients O 0 1.855036498454865e-05
with O 0 1.125490598496981e-06
female O 0 2.131895234924741e-05
phenotype O 0 2.7928817871725187e-05
than O 0 4.625028111604479e-07
among O 0 6.958054541428282e-07
46 O 0 9.96267408481799e-06
, O 0 5.108951427246211e-06
XY O 0 0.42743179202079773
patients O 0 2.230119935120456e-05
with O 0 5.306667958393518e-07
sexual O 0 1.3455231737680151e-06
ambiguity O 0 4.289014214009512e-06
or O 0 8.83349002833711e-06
male O 0 0.00023874126782175153
phenotype O 0 0.0013898761244490743
; O 0 1.136988544203632e-06
and O 0 1.9476674424367957e-06
( O 0 5.120162427374453e-07
3 O 0 1.952217871803441e-06
) O 0 2.218307031398581e-07
statistically O 0 1.0458899168952485e-06
significant O 0 2.0658291077779722e-07
evidence O 0 3.475879566394724e-07
that O 0 2.8518226713458716e-07
mutations O 0 2.2940150756767252e-06
in O 0 2.537085492804181e-07
exons O 0 4.641612122213701e-06
8 O 0 2.321702595509123e-06
and O 0 4.2891835505542986e-07
9 O 0 2.628886704769684e-06
preferentially O 0 1.9733449789782753e-06
affect O 0 7.591096959913557e-07
amino O 0 7.40875350402348e-07
acids O 0 3.142484388263256e-07
with O 0 9.60387396276019e-08
different O 0 2.2609916072724445e-07
functions O 0 1.368042148897075e-06
. O 0 1.9254409835411934e-06
. O 0 6.830617166997399e-06

The O 0 0.00013114578905515373
185delAG O 0 0.0010013636201620102
BRCA1 O 0 0.0011827490525320172
mutation O 0 5.2024948672624305e-05
originated O 0 1.0843061318155378e-05
before O 0 1.854245965660084e-06
the O 0 2.957891069854668e-07
dispersion O 0 3.013147079400369e-06
of O 0 1.6856964180078648e-07
Jews O 0 7.596680120514065e-07
in O 0 2.388771065398032e-07
the O 0 4.863620119976986e-07
diaspora O 0 1.062753426595009e-06
and O 0 5.880839921701408e-07
is O 0 1.7216179060142167e-07
not O 0 3.4001956805695954e-07
limited O 0 1.0136282071471214e-06
to O 0 2.290862539666705e-06
Ashkenazim O 0 0.00015341983817052096
. O 0 8.756369425100274e-06

The O 0 0.0001310824154643342
185delAG O 0 0.0010272166691720486
mutation O 0 0.00012393866200000048
in O 0 1.1071469089074526e-05
BRCA1 O 0 0.002289992058649659
is O 0 2.4698979359527584e-06
detected O 0 1.5217342479445506e-05
in O 0 1.0140013273485238e-06
Ashkenazi O 0 2.963139741041232e-05
Jews O 0 9.248177548215608e-07
both O 0 3.120361498076818e-07
in O 0 3.7195736695139203e-06
familial B-Disease 1 0.9605039954185486
breast I-Disease 1 0.9999988079071045
and I-Disease 1 0.9999436140060425
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.3765485568437725e-05
in O 0 3.1447739274881314e-06
the O 0 2.4125865820678882e-06
general O 0 1.9326726032886654e-06
population O 0 3.2003888463805197e-06
. O 0 9.561372280586511e-06

All O 0 4.555616033030674e-05
tested O 0 0.00032274468685500324
Ashkenazi O 0 0.0005508008762262762
mutation O 0 5.81160893489141e-05
carriers O 0 1.5701569282100536e-05
share O 0 2.2866236122354167e-06
the O 0 7.687796710342809e-07
same O 0 1.004571686280542e-06
allelic O 0 1.9868541130563244e-05
pattern O 0 1.8161901607527398e-05
at O 0 2.253667298646178e-05
the O 0 8.883163900463842e-06
BRCA1 O 0 0.001485798740759492
locus O 0 0.0005407017306424677
. O 0 4.290073775337078e-05

Our O 0 5.8609592088032514e-05
previous O 0 1.108347987610614e-05
study O 0 4.773221462528454e-06
showed O 0 9.812159078137483e-06
that O 0 2.6966802124661626e-07
this O 0 1.9534027728695946e-07
Ashkenazi O 0 3.064395787077956e-05
mutation O 0 6.583328286069445e-06
also O 0 9.016634407998936e-07
occurs O 0 4.623863674169115e-07
in O 0 4.861361730945646e-07
Iraqi O 0 4.2657784433686174e-06
Jews O 0 6.309773539214802e-07
with O 0 2.2513179942507122e-07
a O 0 1.4060271951166214e-06
similar O 0 4.542222086456604e-06
allelic O 0 0.00013291665527503937
pattern O 0 8.315753075294197e-05
. O 0 2.4939721697592176e-05

We O 0 4.116656054975465e-05
extended O 0 8.768877705733757e-06
our O 0 1.3353322856346495e-06
analysis O 0 6.405325052583066e-07
to O 0 2.8504877036539256e-07
other O 0 1.536941596214092e-07
non O 0 7.821785175110563e-07
- O 0 5.935056833550334e-06
Ashkenazi O 0 9.856735232460778e-06
subsets O 0 2.2657843601336936e-06
354 O 0 3.285466846136842e-06
of O 0 2.7340215069671103e-07
Moroccan O 0 4.9399091039958876e-06
origin O 0 9.295989116253622e-07
, O 0 3.0113838533907256e-07
200 O 0 8.4200405581214e-07
Yemenites O 0 1.3185335774323903e-05
and O 0 6.310808657872258e-07
150 O 0 1.1145284588565119e-06
Iranian O 0 6.6719730966724455e-06
Jews O 0 5.923646313021891e-06
. O 0 8.16917327028932e-06

Heteroduplex O 0 0.003910140600055456
analysis O 0 4.489646744332276e-05
complemented O 0 3.783898864639923e-05
by O 0 1.3633507478516549e-06
direct O 0 1.0324754384782864e-06
DNA O 0 3.467629767328617e-06
sequencing O 0 3.2096133963932516e-06
of O 0 5.409835353020753e-07
abnormally O 0 0.0001920501672429964
migrating O 0 5.11110556544736e-06
bands O 0 9.044176294992212e-06
were O 0 1.000344127533026e-05
employed O 0 5.019544551032595e-05
. O 0 1.4984838344389573e-05

Four O 0 3.441494482103735e-05
of O 0 3.3472135783085832e-06
Moroccan O 0 2.619641054479871e-05
origin O 0 3.7770382732560392e-06
( O 0 6.981451292631391e-07
1 O 0 7.887094852776499e-07
. O 0 1.8919888589152833e-07
1 O 0 4.940639541928249e-07
% O 0 3.3173148494825e-07
) O 0 1.2243017977198178e-07
and O 0 3.2856814868864603e-07
none O 0 4.3311513309163274e-07
of O 0 7.18771673291485e-08
the O 0 5.197941277401696e-07
Yemenites O 0 5.946004966972396e-05
or O 0 1.0095167226609192e-06
Iranians O 0 2.4247885903605493e-06
was O 0 5.057532234786777e-06
a O 0 6.374551162480202e-07
carrier O 0 7.5614184424921405e-06
of O 0 1.9930682526592136e-07
the O 0 2.0993106772948522e-06
185delAG O 0 0.00024006812600418925
mutation O 0 5.252253686194308e-05
. O 0 1.5560892279609106e-05

BRCA1 O 0 0.023394208401441574
allelic O 0 0.000878127699252218
patterns O 0 0.00027029585908167064
were O 0 5.282523125060834e-05
determined O 0 4.679212452174397e-06
for O 0 2.0077865769962955e-07
four O 0 2.362118891596765e-07
of O 0 7.30388833858342e-08
these O 0 1.4116713487055677e-07
individuals O 0 1.6103078337437182e-07
and O 0 2.6552723397799127e-07
for O 0 1.873069948032935e-07
12 O 0 1.0889275472436566e-06
additional O 0 3.256448906086007e-07
non O 0 1.089461534320435e-06
- O 0 2.9038541470072232e-05
Ashkenazi O 0 4.324016481405124e-05
185delAG O 0 3.2529020245419815e-05
mutation O 0 1.097938456950942e-05
carriers O 0 1.6043301002355292e-05
who O 0 3.52721253875643e-05
had O 0 0.41677358746528625
breast B-Disease 1 0.9999996423721313
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00015303441614378244

Six O 0 0.00020657388085965067
non O 0 0.00011801785876741633
- O 0 0.0004778299480676651
Ashkenazi O 0 0.00038218405097723007
individuals O 0 1.671913082645915e-06
shared O 0 1.2533835160866147e-06
the O 0 6.901115625623788e-07
common O 0 2.3861077806941466e-06
Ashkenazi O 0 0.00010983947140630335
haplotype O 0 8.142423030221835e-05
, O 0 4.089173671673052e-06
four O 0 4.462842298380565e-06
had O 0 4.783877739100717e-05
a O 0 2.3219772629090585e-06
closely O 0 2.014669689742732e-06
related O 0 6.624293860113539e-07
pattern O 0 7.6195597102923784e-06
, O 0 5.25165035014652e-07
and O 0 4.928540988657915e-07
the O 0 7.134066208891454e-07
rest O 0 1.8837623656509095e-06
( O 0 3.4355912248429377e-07
n O 0 3.949155507143587e-05
= O 0 7.584796549053863e-05
6 O 0 3.523456371112843e-06
) O 0 3.3438814739383815e-07
displayed O 0 8.519032803633309e-07
a O 0 1.2249049632373499e-06
distinct O 0 6.402823146345327e-06
BRCA1 O 0 0.0004329421208240092
allelic O 0 0.00023379763297270983
pattern O 0 0.0002679542812984437
. O 0 5.463859997689724e-05

We O 0 6.964307249290869e-05
conclude O 0 1.583209632372018e-05
that O 0 8.637259725219337e-07
the O 0 1.5479548665098264e-06
185delAG O 0 0.00019004674686584622
BRCA1 O 0 0.0007173875346779823
mutation O 0 1.746201451169327e-05
occurs O 0 1.0238290997222066e-06
in O 0 3.48182510379047e-07
some O 0 2.9483436492228066e-07
non O 0 2.041180550804711e-06
- O 0 3.257102071074769e-05
Ashkenazi O 0 2.8467753509175964e-05
populations O 0 1.0414249800305697e-06
at O 0 5.001781573810149e-06
rates O 0 2.6131540380447404e-06
comparable O 0 1.3306731716511422e-06
with O 0 1.911000424570375e-07
that O 0 3.472891023648117e-07
of O 0 1.3610383575723972e-06
Ashkenazim O 0 0.000248083146288991
. O 0 1.9205377611797303e-05

The O 0 2.696230512810871e-05
majority O 0 7.353190994763281e-06
of O 0 1.6468216017528903e-06
Jewish O 0 1.4992542674008291e-05
185delAG O 0 0.00011284373613307253
mutation O 0 1.5734533008071594e-05
carriers O 0 8.787262231635395e-06
have O 0 8.326564397975744e-07
a O 0 6.028550387782161e-07
common O 0 9.899473525365465e-07
allelic O 0 4.371468457975425e-05
pattern O 0 3.388270488358103e-05
, O 0 1.3037055168751976e-06
supporting O 0 1.2942904277224443e-06
the O 0 4.773567638949316e-07
founder O 0 6.904380825289991e-06
effect O 0 5.875424449186539e-07
notion O 0 5.767357720287691e-07
, O 0 2.397240166374104e-07
but O 0 2.204638462899311e-07
dating O 0 9.297619953940739e-07
the O 0 2.7523867629497545e-07
mutations O 0 1.0441797257954022e-06
origin O 0 2.104844725181465e-07
to O 0 1.3787990837954567e-07
an O 0 2.607189912851027e-07
earlier O 0 1.016677742882166e-06
date O 0 8.427792863585637e-07
than O 0 2.9887073083045834e-07
currently O 0 1.2687676189671038e-06
estimated O 0 3.3069336495827883e-06
. O 0 3.9116116568038706e-06

However O 0 6.849964847788215e-05
, O 0 4.2761162148963194e-06
the O 0 1.1251964906477951e-06
different O 0 7.172596951932064e-07
allelic O 0 1.248313310497906e-05
pattern O 0 1.3912475878896657e-05
at O 0 1.6630645404802635e-05
the O 0 1.5587631878588581e-06
BRCA1 O 0 0.00025518907932564616
locus O 0 4.139456359553151e-05
even O 0 1.991139470192138e-06
in O 0 2.8553225206451316e-07
some O 0 1.6972074945442728e-07
Jewish O 0 3.4577985843498027e-06
mutation O 0 5.183762368687894e-06
carriers O 0 4.824004463443998e-06
, O 0 6.749775138814584e-07
might O 0 1.303137310060265e-06
suggest O 0 4.735389040888549e-07
that O 0 1.1829719426259544e-07
the O 0 4.738447785257449e-07
mutation O 0 6.489693987532519e-06
arose O 0 3.807707798841875e-06
independently O 0 6.765371836081613e-06
. O 0 2.003694362429087e-06
. O 0 1.1897453077835962e-05

Crystal O 0 0.0011052797781303525
structure O 0 3.334062421345152e-05
of O 0 1.8908086758528952e-06
the O 0 2.1939738871878944e-05
hemochromatosis B-Disease 1 0.9999997615814209
protein O 0 0.00021827640011906624
HFE O 0 0.03619270771741867
and O 0 1.941008576977765e-06
characterization O 0 3.275452854722971e-06
of O 0 2.2130392096642026e-07
its O 0 3.402167862986971e-07
interaction O 0 1.1526619800861226e-06
with O 0 2.481855062796967e-06
transferrin O 0 0.00043856698903255165
receptor O 0 0.00010182743426412344
. O 0 2.2236083168536425e-05

HFE O 0 0.49591076374053955
is O 0 3.440759610384703e-05
an O 0 9.32355487748282e-06
MHC O 0 0.00018160499166697264
- O 0 0.00010148331784876063
related O 0 2.390832150922506e-06
protein O 0 1.922631554407417e-06
that O 0 1.3153781708297174e-07
is O 0 2.0061406758031808e-07
mutated O 0 2.5378117243235465e-06
in O 0 3.274217590387707e-07
the O 0 5.5940977290447336e-06
iron B-Disease 1 0.9996598958969116
- I-Disease 1 0.9999990463256836
overload I-Disease 1 0.9999994039535522
disease I-Disease 1 0.9999970197677612
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00397496297955513

HFE O 0 0.017494453117251396
binds O 0 0.00013679286348633468
to O 0 1.047159094014205e-05
transferrin O 0 8.710704423720017e-05
receptor O 0 2.2306005121208727e-05
( O 0 2.492538442311343e-06
TfR O 0 4.557797365123406e-05
) O 0 8.843502996569441e-07
and O 0 4.973358045390341e-07
reduces O 0 1.6611564888080466e-06
its O 0 3.5804609410661214e-07
affinity O 0 2.150293994418462e-06
for O 0 7.185523145381012e-07
iron O 0 0.0015503206523135304
- O 0 0.000585380126722157
loaded O 0 0.00015575434372294694
transferrin O 0 7.865525549277663e-05
, O 0 2.5970005026465515e-06
implicating O 0 0.00011362116492819041
HFE O 0 0.0032235169783234596
in O 0 1.4442210158449598e-05
iron O 1 0.6020529866218567
metabolism O 0 0.0015759395901113749
. O 0 2.3212563974084333e-05

The O 0 0.00016794312978163362
2 O 0 0.0002853306941688061
. O 0 0.00015250359138008207

6 O 0 0.0009350579348392785
A O 0 7.017111056484282e-05
crystal O 0 0.00013197351654525846
structure O 0 8.775177775532939e-06
of O 0 1.2884823945569224e-06
HFE O 0 0.0389094315469265
reveals O 0 1.4617841770814266e-05
the O 0 5.276123147268663e-07
locations O 0 3.548744643921964e-06
of O 0 6.802364623581525e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0017889649607241154
and O 0 3.424777105465182e-06
a O 0 7.858115168346558e-06
patch O 1 0.6410558819770813
of O 0 1.2890944844912156e-06
histidines O 0 0.01477156300097704
that O 0 1.2327590184213477e-06
could O 0 2.7142871203977847e-06
be O 0 3.365184397807752e-07
involved O 0 4.480098425574397e-07
in O 0 1.0697025345507427e-06
pH O 0 0.010252965614199638
- O 0 0.0012262581149116158
dependent O 0 1.678902845014818e-05
interactions O 0 1.0229789950244594e-05
. O 0 1.2302819413889665e-05

We O 0 9.392046194989234e-05
also O 0 7.819347047188785e-06
demonstrate O 0 1.276934017369058e-05
that O 0 3.6967924188502366e-06
soluble O 0 3.966051372117363e-05
TfR O 0 0.0001572550245327875
and O 0 6.397317974915495e-06
HFE O 0 0.011431645601987839
bind O 0 4.046085450681858e-05
tightly O 0 7.113951141946018e-05
at O 0 1.3580610357166734e-05
the O 0 3.884689760980109e-07
basic O 0 1.0520139994696365e-06
pH O 0 1.1765227100113407e-05
of O 0 1.2922315306695964e-07
the O 0 6.83646817378758e-07
cell O 0 9.192031575366855e-05
surface O 0 2.4043218218139373e-05
, O 0 8.59118927110103e-07
but O 0 2.912766490226204e-07
not O 0 2.0832808900195232e-07
at O 0 2.741410071394057e-06
the O 0 8.881146982275823e-07
acidic O 0 2.961730569950305e-05
pH O 0 3.28788191836793e-05
of O 0 8.815471232992422e-07
intracellular O 0 0.00019892025738954544
vesicles O 0 0.0009940004674717784
. O 0 4.992200410924852e-05

TfR O 0 0.42597609758377075
HFE O 0 0.22628219425678253
stoichiometry O 0 0.0008680240134708583
( O 0 1.8843351426767185e-05
2 O 0 7.133350663934834e-06
1 O 0 2.0887007394776447e-06
) O 0 3.988157288858929e-07
differs O 0 6.134439445304452e-07
from O 0 8.271400702142273e-07
TfR O 0 4.8717414756538346e-05
transferrin O 0 2.1493595340871252e-05
stoichiometry O 0 1.041020641423529e-05
( O 0 5.427343126029882e-07
2 O 0 1.2473569768189918e-06
2 O 0 1.8408325104246615e-06
) O 0 2.650268413617596e-07
, O 0 1.2400596460793167e-07
implying O 0 5.036154107074253e-07
a O 0 1.4237367906844156e-07
different O 0 8.92964351351111e-08
mode O 0 4.58111230727809e-07
of O 0 1.0660469484946589e-07
binding O 0 8.62835179304966e-07
for O 0 4.2293439150853374e-07
HFE O 0 0.002129717729985714
and O 0 2.488854306648136e-06
transferrin O 0 5.3800114983459935e-05
to O 0 1.6816964034660487e-06
TfR O 0 0.0002421640238026157
, O 0 1.1134554824820952e-06
consistent O 0 1.0124535947397817e-06
with O 0 2.432853420941683e-07
our O 0 9.761122328200145e-07
demonstration O 0 1.6189707139346865e-06
that O 0 4.471134786854236e-07
HFE O 0 0.00015218749467749149
, O 0 8.676275911057019e-07
transferrin O 0 1.4643794202129357e-05
, O 0 1.0696699064283166e-06
and O 0 2.6892375899478793e-06
TfR O 0 0.00010610571916913614
form O 0 1.7110618273363798e-06
a O 0 5.378946298151277e-06
ternary O 0 5.9884558140765876e-05
complex O 0 6.973544805077836e-05
. O 0 2.0720453903777525e-05

Identification O 0 6.379482510965317e-05
of O 0 2.996594957949128e-06
three O 0 2.653191586432513e-06
novel O 0 3.0715707453055074e-06
mutations O 0 6.427319476642879e-06
and O 0 5.48461969174241e-07
a O 0 7.337230272241868e-07
high O 0 6.5445801737951115e-06
frequency O 0 3.432179482842912e-06
of O 0 2.473018128057447e-07
the O 0 1.1760107554437127e-06
Arg778Leu O 0 0.00016337835404556245
mutation O 0 8.921384505811147e-06
in O 0 2.4262019451271044e-06
Korean O 0 0.0006489057559520006
patients O 0 8.68610295583494e-05
with O 0 2.633859548950568e-05
Wilson B-Disease 0 0.46930429339408875
disease I-Disease 0 0.05275017023086548
. O 0 2.0883559045614675e-05

Four O 0 0.00012035685358569026
mutations O 0 0.00021175446454435587
- O 0 0.00014452284085564315
- O 0 7.652214844711125e-05
R778L O 0 5.606705599348061e-05
, O 0 1.1196783589184633e-06
A874V O 0 1.1784957678173669e-05
, O 0 4.550740584363666e-07
L1083F O 0 7.185377853602404e-06
, O 0 4.529736372660409e-07
and O 0 4.147221375205845e-07
2304delC O 0 7.6197634371055756e-06
- O 0 1.2967655493412167e-05
- O 0 1.1106462807219941e-05
in O 0 3.4280930094610085e-07
the O 0 6.984401466070267e-07
copper O 0 1.88361264008563e-05
- O 0 1.0716737051552627e-05
transporting O 0 7.16668773748097e-06
enzyme O 0 2.215692575191497e-06
, O 0 4.2579284809107776e-07
P O 0 1.7684922568150796e-05
- O 0 3.5847358503815485e-06
type O 0 4.734265075967414e-06
ATPase O 0 5.2133113058516756e-05
( O 0 8.590681090936414e-07
ATP7B O 0 0.00012121989129809663
) O 0 3.0296524755613063e-07
, O 0 2.125168236943864e-07
were O 0 1.4153988558973651e-06
identified O 0 1.0386517033111886e-06
in O 0 7.820845553396794e-07
Korean O 0 4.410402470966801e-05
Patients O 0 1.4874424778099637e-05
with O 0 1.4451813513005618e-05
Wilson B-Disease 0 0.10062067210674286
disease I-Disease 0 0.007030152250081301
. O 0 1.5850771887926385e-05

Arg778Leu O 0 0.027681920677423477
, O 0 1.7336933524347842e-05
the O 0 1.7115319224103587e-06
most O 0 8.112174327834509e-07
frequently O 0 4.12540521210758e-06
reported O 0 6.596752882614965e-06
mutation O 0 1.8744705130302464e-06
of O 0 1.0967153230012627e-07
this O 0 2.0328589300788735e-07
enzyme O 0 5.0770795496646315e-06
, O 0 8.230530283981352e-07
was O 0 1.0111747542396188e-05
found O 0 5.59852537662664e-07
in O 0 1.443652166699394e-07
six O 0 2.6266710051459086e-07
of O 0 1.0531227445653712e-07
eight O 0 4.523866209638072e-06
unrelated O 0 2.3311860786634497e-05
patients O 0 8.397655619774014e-06
studied O 0 2.3567124571854947e-06
, O 0 2.2343861871831905e-07
an O 0 1.7600901003334002e-07
allele O 0 2.666612999746576e-06
frequency O 0 3.8982420846878085e-06
of O 0 1.3599795920526958e-06
37 O 0 2.770104219962377e-05
. O 0 1.1032313523173798e-05

5 O 0 0.00023558418615721166
% O 0 2.8285821827012114e-05
, O 0 1.7387133084412199e-06
which O 0 4.120661003526038e-07
is O 0 2.402004781743017e-07
considerably O 0 1.0176865998801077e-06
higher O 0 4.283289172235527e-07
than O 0 1.0371932290809127e-07
those O 0 7.974141169597715e-08
in O 0 1.5080455284532945e-07
other O 0 3.1301942726713605e-07
Asian O 0 7.369626018771669e-06
populations O 0 9.277299795940053e-06
. O 0 6.918242434039712e-06

The O 0 4.130556408199482e-05
novel O 0 3.0568335205316544e-05
single O 0 1.6892199710127898e-05
nucleotide O 0 2.407910506008193e-05
deletion O 0 2.4777380531304516e-05
, O 0 2.214243522757897e-06
2304delC O 0 2.4874683731468394e-05
, O 0 9.624436643207446e-07
was O 0 8.104666449071374e-06
found O 0 1.2484804301493568e-06
in O 0 6.882534648866567e-07
one O 0 5.644762040901696e-06
patient O 0 0.0001532449823571369
. O 0 1.4494987226498779e-05

Since O 0 0.0001492574519943446
a O 0 2.440993739583064e-05
mutation O 0 2.5786843252717517e-05
at O 0 6.634474630118348e-06
cDNA O 0 1.847424209699966e-05
nucleotide O 0 4.896674363408238e-05
2302 O 0 0.0003575888113118708
( O 0 1.1569969728952856e-06
2302insC O 0 1.6838142983033322e-05
) O 0 6.86980001773918e-07
had O 0 1.310949392063776e-05
been O 0 2.860663926185225e-06
previously O 0 4.297447958379053e-06
described O 0 1.6843125649756985e-06
, O 0 9.960901081740303e-08
this O 0 2.9608928642232968e-08
region O 0 1.8549556557445612e-07
of O 0 9.230425490613925e-08
the O 0 1.9347178294992773e-06
ATP7B O 0 0.1974824219942093
gene O 0 1.0155700692848768e-05
may O 0 4.2262176975782495e-06
be O 0 6.267390517677995e-07
susceptible O 0 6.3563061303284485e-06
to O 0 8.683022656441608e-07
gene O 0 1.4619736248278059e-05
rearrangements O 0 0.00028594807372428477
causing O 0 0.017656393349170685
Wilson B-Disease 0 0.14133578538894653
disease I-Disease 0 0.08138842135667801
. O 0 2.2550735593540594e-05

Disruption O 0 0.0006167881656438112
of O 0 1.5284538676496595e-05
splicing O 0 9.31036556721665e-05
regulated O 0 1.562567013024818e-05
by O 0 1.2111736396036576e-06
a O 0 2.9294801606738474e-06
CUG O 0 0.00035183184081688523
- O 0 2.9533028282457963e-05
binding O 0 9.964128366846126e-06
protein O 0 1.438002163922647e-05
in O 0 3.9695256418781355e-05
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999994039535522
. O 0 0.00015614992298651487

Myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 1.0
( O 1 0.994365930557251
DM B-Disease 1 1.0
) O 0 0.00016447281814180315
is O 0 4.460191576072248e-06
caused O 0 9.101984687731601e-06
by O 0 4.2234350416947564e-07
a O 0 2.017904080275912e-06
CTG O 0 5.7725366787053645e-05
expansion O 0 6.875167741782207e-07
in O 0 2.3214094824197673e-07
the O 0 4.567467044580553e-07
3 O 0 1.83038343948283e-06
untranslated O 0 2.195575143559836e-05
region O 0 1.0576001159279258e-06
of O 0 5.331788770490675e-07
the O 0 1.738481478241738e-05
DM B-Disease 1 0.9999988079071045
gene O 0 0.0001241641293745488
. O 0 3.4829841752070934e-05

One O 0 2.380503065069206e-05
model O 0 1.7691856555757113e-05
of O 0 1.1033534065063577e-05
DM B-Disease 1 0.9999997615814209
pathogenesis O 0 0.005273901391774416
suggests O 0 1.0757530617411248e-05
that O 0 7.638598162884591e-07
RNAs O 0 5.150249307916965e-06
from O 0 3.2042322573033744e-07
the O 0 2.771292599845765e-07
expanded O 0 7.918273468021653e-07
allele O 0 1.8531428622736712e-06
create O 0 6.083329253669945e-07
a O 0 7.393804253297276e-07
gain O 0 1.1737682143575512e-05
- O 0 1.2028193850710522e-05
of O 0 1.8974638749114092e-07
- O 0 0.00012028779019601643
function O 0 9.661303010943811e-07
mutation O 0 6.668186642855289e-07
by O 0 8.267900142300277e-08
the O 0 1.5770125116887357e-07
inappropriate O 0 1.250895138582564e-06
binding O 0 4.336627910106472e-07
of O 0 1.0662503058256334e-07
proteins O 0 5.532656928153301e-07
to O 0 4.482923543491779e-07
the O 0 2.921308578152093e-06
CUG O 0 0.0071668862365186214
repeats O 0 9.98245959635824e-05
. O 0 2.3035752747091465e-05

Data O 0 5.248228626442142e-05
presented O 0 1.1022386388503946e-05
here O 0 1.7333788946416462e-06
indicate O 0 1.6727486809031689e-06
that O 0 2.4867921410987037e-07
the O 0 6.377944146152004e-07
conserved O 0 3.290643917353009e-06
heterogeneous O 0 2.3112414055503905e-05
nuclear O 0 8.743510261410847e-05
ribonucleoprotein O 0 8.660990715725347e-05
, O 0 1.8181355017077294e-06
CUG O 0 0.00013450451660901308
- O 0 1.2429631169652566e-05
binding O 0 3.1132860840443755e-06
protein O 0 3.2527441362617537e-06
( O 0 8.945920626501902e-07
CUG O 0 0.00032739320886321366
- O 0 0.000342138169799
BP O 0 0.0013087177649140358
) O 0 3.32719366724632e-07
, O 0 1.9855878008456784e-07
may O 0 8.074355264398037e-07
mediate O 0 3.3671535675239284e-06
the O 0 6.845928623988584e-07
trans O 0 7.1936538006411865e-06
- O 0 6.618235056521371e-05
dominant O 0 3.054182116102311e-06
effect O 0 5.475291118273162e-07
of O 0 2.098971378927672e-07
the O 0 1.4939842003514059e-06
RNA O 0 1.7625083273742348e-05
. O 0 1.4539331459673122e-05

CUG O 1 0.6821780204772949
- O 0 0.07689464837312698
BP O 0 0.008104322478175163
was O 0 2.4089074941002764e-05
found O 0 1.4966680055295e-06
to O 0 6.253222863961128e-07
bind O 0 2.5453086891502608e-06
to O 0 3.2977331443362345e-07
the O 0 8.010007377379225e-07
human O 0 4.343976797827054e-06
cardiac O 1 0.7555372714996338
troponin O 1 0.973553478717804
T O 1 0.6905626058578491
( O 0 1.0833816759259207e-06
cTNT O 0 1.1728875506378245e-05
) O 0 4.690716650657123e-07
pre O 0 1.2303922630962916e-05
- O 0 5.054792927694507e-05
messenger O 0 5.187376245885389e-06
RNA O 0 1.3436202834782307e-06
and O 0 4.290459969524818e-07
regulate O 0 2.513055505914963e-06
its O 0 1.0594261539154104e-06
alternative O 0 7.203525910881581e-06
splicing O 0 5.905742000322789e-05
. O 0 2.0213969037286006e-05

Splicing O 0 0.0006572817801497877
of O 0 3.075113272643648e-05
cTNT O 0 0.00048270661500282586
was O 0 0.00010975467012031004
disrupted O 0 0.00027966091874986887
in O 0 2.411173772998154e-05
DM B-Disease 1 0.9999995231628418
striated O 0 0.31241992115974426
muscle O 0 0.017619535326957703
and O 0 6.964434760448057e-06
in O 0 2.5764711608644575e-06
normal O 0 3.0699440685566515e-05
cells O 0 5.871660505363252e-06
expressing O 0 1.5781257616254152e-06
transcripts O 0 2.4534597287129145e-06
that O 0 7.991877737367759e-07
contain O 0 1.2372119272185955e-05
CUG O 0 0.009941233322024345
repeats O 0 0.0001083028910215944
. O 0 2.420107375655789e-05

Altered O 0 0.0003256549243815243
expression O 0 1.646643977437634e-05
of O 0 1.6895991166165913e-06
genes O 0 1.9212282495573163e-05
regulated O 0 1.5079382137628272e-05
posttranscriptionally O 0 8.232662366935983e-05
by O 0 3.0865053304296453e-06
CUG O 0 0.012019631452858448
- O 0 0.011745375581085682
BP O 0 0.0011223481269553304
therefore O 0 2.705187853280222e-06
may O 0 4.012246790807694e-06
contribute O 0 2.79159485216951e-06
to O 0 1.167751270259032e-05
DM B-Disease 1 0.9999992847442627
pathogenesis O 0 0.0013931586872786283
. O 0 6.6059574237442575e-06
. O 0 1.8167394955526106e-05

Identification O 0 0.00012037200212944299
of O 0 6.6584275373315904e-06
a O 0 7.714854291407391e-06
novel O 0 7.583978458569618e-06
nonsense O 0 2.78880415862659e-05
mutation O 0 7.0915143624006305e-06
and O 0 8.854600537233637e-07
a O 0 1.0402040970802773e-06
missense O 0 4.784862085216446e-06
substitution O 0 8.9510751877242e-07
in O 0 3.985461489719455e-07
the O 0 7.558322749900981e-07
vasopressin O 0 7.21147171134362e-06
- O 0 3.611863940022886e-05
neurophysin O 0 8.023461850825697e-05
II O 0 5.343703378457576e-05
gene O 0 1.9190631519450108e-06
in O 0 3.987130128280114e-07
two O 0 6.545514565914345e-07
Spanish O 0 5.3107096391613595e-06
kindreds O 0 5.022915138397366e-05
with O 0 2.233090708614327e-05
familial B-Disease 1 0.996432900428772
neurohypophyseal I-Disease 1 0.9999821186065674
diabetes I-Disease 1 0.9999978542327881
insipidus I-Disease 1 0.9991883635520935
. O 0 0.00023985283041838557

Familial B-Disease 1 0.99985671043396
neurohypophyseal I-Disease 1 0.9999895095825195
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.999996542930603
( O 0 0.16793237626552582
FNDI B-Disease 1 0.9999998807907104
) O 0 3.3085845643654466e-05
is O 0 1.8324443544770475e-06
an O 0 1.3092838344164193e-05
autosomal B-Disease 1 0.9993497729301453
dominant I-Disease 1 0.9996656179428101
disease I-Disease 1 0.9992640614509583
caused O 0 0.0022814415860921144
by O 0 4.667621760745533e-05
deficiency O 1 0.7255678772926331
in O 0 1.5143016298679868e-06
the O 0 4.608856215781998e-06
antidiuretic O 0 0.00017515302170068026
hormone O 0 1.685329152678605e-05
arginine O 0 1.556264396640472e-05
vasopressin O 0 5.593632977252128e-06
( O 0 8.280176757580193e-07
AVP O 0 6.600371307285968e-06
) O 0 2.472258984198561e-07
encoded O 0 5.61422325517924e-07
by O 0 2.0463910743728775e-07
the O 0 6.432026680158742e-07
AVP O 0 6.294289778452367e-05
- O 0 4.185278885415755e-05
neurophysin O 0 0.00025815158733166754
II O 0 0.000376652751583606
( O 0 1.8949082232211367e-06
AVP O 0 0.00011129061022074893
- O 0 0.00012876292748842388
NPII O 0 0.0005194519180804491
) O 0 1.482004677200166e-06
gene O 0 5.184291694604326e-06
on O 0 4.288147010811372e-06
chromosome O 0 0.0005067571764811873
20p13 O 0 0.00028759127599187195
. O 0 2.863157533283811e-05

In O 0 3.840487261186354e-05
this O 0 2.5704778181534493e-06
study O 0 2.1156527054699836e-06
, O 0 9.073566502593167e-07
we O 0 4.5873338194724056e-07
analyzed O 0 8.56886686051439e-07
two O 0 4.461772391550767e-07
families O 0 2.7975970624538604e-06
with O 0 1.9715203052328434e-06
FNDI B-Disease 1 0.9986159801483154
using O 0 7.206302825579769e-07
direct O 0 4.514495230978355e-07
automated O 0 3.0507639166899025e-05
fluorescent O 0 1.1504028407216538e-05
, O 0 4.0115327237799647e-07
solid O 0 1.9264198272139765e-06
phase O 0 1.192066520161461e-06
, O 0 2.9470842832779454e-07
single O 0 1.2217946050441242e-06
- O 0 9.250247785530519e-06
stranded O 0 2.3458169380319305e-06
DNA O 0 1.0684341305022826e-06
sequencing O 0 1.4828416396994726e-06
of O 0 4.3518824099919584e-07
PCR O 0 3.491124516585842e-05
- O 0 4.8454476200276986e-05
amplified O 0 7.450192788382992e-05
AVP O 0 0.00042286101961508393
- O 0 0.00041893342859111726
NPII O 0 0.0010792685206979513
DNA O 0 0.00010277231194777414
. O 0 2.3498279915656894e-05

In O 0 2.8506572562037036e-05
one O 0 2.661620555954869e-06
of O 0 5.80653022552724e-07
the O 0 1.6306090628859238e-06
families O 0 1.0695621313061565e-05
, O 0 1.4121818594503566e-06
affected O 0 1.6819514030430582e-06
individuals O 0 2.6322581447857374e-07
presented O 0 4.2573884684316e-07
a O 0 8.047203436944983e-07
novel O 0 1.1666809314192506e-06
nonsense O 0 3.4980712371179834e-06
mutation O 0 1.7530888953842805e-06
in O 0 2.444579649818479e-07
exon O 0 3.8688913264195435e-06
3 O 0 3.8505532984345336e-07
of O 0 9.167140291310716e-08
the O 0 3.2001398153624905e-07
gene O 0 1.351263449578255e-06
, O 0 1.9358957104032015e-07
consisting O 0 3.623958946263883e-07
in O 0 3.5983811130790855e-07
a O 0 4.259680736140581e-06
G O 0 0.017411384731531143
to O 0 3.0430644528678386e-06
T O 0 0.011681893840432167
transition O 0 1.6962572999545955e-06
at O 0 8.784295459918212e-06
nucleotide O 0 1.3105393009027466e-05
2101 O 0 2.5846175049082376e-05
, O 0 4.059245384269161e-07
which O 0 1.8073879459734599e-07
produces O 0 2.957772551326343e-07
a O 0 2.77318548569383e-07
stop O 0 1.46451122873259e-06
signal O 0 2.4337982722499873e-06
in O 0 5.17386183673807e-07
codon O 0 7.843852472433355e-06
82 O 0 7.3112860263790935e-06
( O 0 1.3576341189036611e-06
Glu O 0 0.00022790789080318063
) O 0 8.03222917511448e-07
of O 0 1.6260219126706943e-06
NPII O 0 0.004730808548629284
. O 0 2.2047524907975458e-05

The O 0 0.00014427238784264773
premature O 0 0.00237881182692945
termination O 0 0.00010268590995110571
eliminates O 0 2.8552280127769336e-05
part O 0 1.8496663187761442e-06
of O 0 4.5139958615436626e-07
the O 0 2.0193479031149764e-06
C O 0 0.0004758463182952255
- O 0 5.3163217671681195e-05
terminal O 0 9.913637768477201e-06
domain O 0 9.579301831763587e-07
of O 0 2.6082292947648966e-07
NPII O 0 0.0019710445776581764
, O 0 2.470528954745532e-07
including O 0 1.317331594918869e-07
a O 0 6.473903795267688e-07
cysteine O 0 1.0873782230191864e-06
residue O 0 3.4401230095681967e-06
in O 0 2.436931083593663e-07
position O 0 3.705439667101018e-06
85 O 0 1.4927536540199071e-06
, O 0 2.3004157867489994e-07
which O 0 1.859207827692444e-07
could O 0 1.2590788855959545e-06
be O 0 1.7090921744511434e-07
involved O 0 2.2522972642491368e-07
in O 0 1.6322132978530135e-07
the O 0 6.507274292744114e-07
correct O 0 2.296634738740977e-05
folding O 0 0.00010466596722835675
of O 0 8.052853672779747e-07
the O 0 6.41892756902962e-06
prohormone O 0 0.0013999862130731344
. O 0 2.3688220608164556e-05

In O 0 3.239027864765376e-05
the O 0 4.109325800527586e-06
second O 0 1.6607904399279505e-05
family O 0 1.493603122071363e-05
, O 0 4.963421815773472e-07
a O 0 6.961452641007781e-07
G279A O 0 8.820442417345475e-06
substitution O 0 4.323780729009741e-07
at O 0 2.590322083051433e-06
position O 0 2.591661541373469e-06
- O 0 5.214811153564369e-06
1 O 0 1.4593037178656232e-07
of O 0 3.0734671696563964e-08
the O 0 1.6378751865886443e-07
signal O 0 4.049975359521341e-06
peptide O 0 1.22405469937803e-06
was O 0 3.135669658149709e-06
observed O 0 2.6878021230913873e-07
in O 0 1.2709435281976766e-07
all O 0 2.2476152139461192e-07
affected O 0 4.017530500277644e-06
individuals O 0 2.228156290584593e-06
. O 0 8.642312423035037e-06

This O 0 2.9407516194623895e-05
missense O 0 0.00023271809914149344
mutation O 0 4.9712969484971836e-05
, O 0 2.8925690003234195e-06
which O 0 2.7424639483797364e-06
replaces O 0 6.728433800162748e-05
Ala O 0 0.0016792030073702335
with O 0 7.842274499125779e-06
Thr O 0 0.027434902265667915
, O 0 1.2750800806315965e-06
is O 0 2.793789803945401e-07
frequent O 0 1.5452144452865468e-06
among O 0 4.997471023671096e-06
FNDI B-Disease 1 0.9999997615814209
patients O 0 0.0032822650391608477
and O 0 4.872199042438297e-06
is O 0 6.621293664466066e-07
thought O 0 9.184166174236452e-07
to O 0 1.739255992561084e-07
reduce O 0 8.974957950158569e-07
the O 0 1.7855242617770273e-07
efficiency O 0 8.052116413637123e-07
of O 0 1.0149034324058448e-07
cleavage O 0 2.483756725268904e-05
by O 0 9.617435807740549e-07
signal O 0 2.989317181345541e-05
peptidases O 0 9.404718730365857e-05
. O 0 4.591838205669774e-06
. O 0 1.3041211786912754e-05

Genetic O 0 0.0011281503830105066
heterogeneity O 0 0.0003300394455436617
of O 0 3.0215263905120082e-05
Saethre B-Disease 1 0.9823893308639526
- I-Disease 1 0.9997082352638245
Chotzen I-Disease 1 0.9999755620956421
syndrome I-Disease 1 0.9999996423721313
, O 0 6.393804596882546e-06
due O 0 4.232028913975228e-06
to O 0 1.8218794366475777e-06
TWIST O 0 8.943995635490865e-05
and O 0 1.0479272532393225e-05
FGFR O 1 0.509608268737793
mutations O 0 0.00011766883108066395
. O 0 2.2181740860105492e-05

Thirty O 0 0.00058552878908813
- O 0 0.0007131110178306699
two O 0 8.746361345401965e-06
unrelated O 0 8.837494533509016e-05
patients O 0 7.01450917404145e-05
with O 0 7.135549822123721e-07
features O 0 4.1876864997902885e-06
of O 0 4.035390247736359e-06
Saethre B-Disease 1 0.9881216287612915
- I-Disease 1 0.9998596906661987
Chotzen I-Disease 1 0.999992847442627
syndrome I-Disease 1 0.9999990463256836
, O 0 5.469166808325099e-06
a O 0 1.341550796496449e-05
common O 0 0.000167269361554645
autosomal B-Disease 1 0.8601278066635132
dominant I-Disease 0 0.07213820517063141
condition I-Disease 0 0.015277618542313576
of O 0 4.809406163985841e-06
craniosynostosis B-Disease 1 0.9987128973007202
and O 0 0.0041942899115383625
limb B-Disease 1 0.9992311000823975
anomalies I-Disease 1 0.8710992336273193
, O 0 9.780384971236344e-06
were O 0 7.834977623133454e-06
screened O 0 1.7664915503701195e-05
for O 0 1.44625005304988e-06
mutations O 0 1.4554578228853643e-05
in O 0 1.6386499055442982e-06
TWIST O 0 0.00014574035594705492
, O 0 5.31964633410098e-06
FGFR2 O 0 0.008660128340125084
, O 0 2.5466345050517702e-06
and O 0 9.634358320909087e-06
FGFR3 O 0 0.005529395304620266
. O 0 3.1408024369738996e-05

Nine O 0 0.00013293340452946723
novel O 0 2.1154382920940407e-05
and O 0 5.08531729792594e-06
three O 0 3.1248869163391646e-06
recurrent O 0 0.00032598606776446104
TWIST O 0 0.0012887781485915184
mutations O 0 0.00010114121687365696
were O 0 1.3009112990403082e-05
found O 0 4.0657605495653115e-06
in O 0 1.5895553815425956e-06
12 O 0 2.1843559807166457e-05
families O 0 1.846437771746423e-05
. O 0 1.4430177543545142e-05

Seven O 0 0.0002796169137582183
families O 0 7.482909131795168e-05
were O 0 1.401781992171891e-05
found O 0 4.113230261282297e-06
to O 0 9.958409918908728e-07
have O 0 9.464268941883347e-07
the O 0 8.088721301646729e-07
FGFR3 O 0 0.003862735815346241
P250R O 0 3.145951995975338e-05
mutation O 0 2.45576325141883e-06
, O 0 2.3582855135373393e-07
and O 0 2.364383959729821e-07
one O 0 3.5866810321749654e-07
individual O 0 1.8293523851298232e-07
was O 0 9.0435032689129e-06
found O 0 6.262557121772261e-07
to O 0 2.424441163384472e-07
have O 0 4.1437144204792276e-07
an O 0 7.822389420653053e-07
FGFR2 O 0 0.0002659590682014823
VV269 O 0 5.746130409534089e-05
- O 0 6.859286077087745e-05
270 O 0 3.586947059375234e-05
deletion O 0 0.00014243701298255473
. O 0 1.9339602658874355e-05

To O 0 3.4524407965363935e-05
date O 0 1.205380067403894e-05
, O 0 9.514259318166296e-07
our O 0 1.0136686796613503e-06
detection O 0 3.5820637549477397e-06
rate O 0 1.988820258702617e-06
for O 0 3.3136154797830386e-07
TWIST O 0 3.4737888199742883e-05
or O 0 8.158234777511097e-06
FGFR O 0 0.033382706344127655
mutations O 0 1.544074075354729e-05
is O 0 4.4956345846003387e-07
68 O 0 2.6635200356395217e-06
% O 0 3.875852883084008e-07
in O 0 4.2496444052630977e-07
our O 0 6.791236046410631e-06
Saethre B-Disease 0 0.2292320281267166
- I-Disease 1 0.9935480952262878
Chotzen I-Disease 1 0.9999219179153442
syndrome I-Disease 1 0.9999994039535522
patients O 0 0.0005478744860738516
, O 0 6.424363618862117e-07
including O 0 4.0687677937967237e-07
our O 0 1.9634862837847322e-06
five O 0 6.142404799902579e-06
patients O 0 3.224908869015053e-05
elsewhere O 0 5.735693321184954e-06
reported O 0 5.729056738346117e-06
with O 0 1.6546833876418532e-06
TWIST O 0 0.0007270824280567467
mutations O 0 0.00015667326806578785
. O 0 1.5043530765979085e-05

More O 0 1.6237459931289777e-05
than O 0 5.399833298724843e-06
35 O 0 2.9066495699225925e-06
different O 0 5.487167413775751e-07
TWIST O 0 2.5282643036916852e-05
mutations O 0 1.1604242899920791e-05
are O 0 4.551231143068435e-07
now O 0 5.899545385545935e-07
known O 0 4.424704229677445e-07
in O 0 2.4927473418756563e-07
the O 0 1.4540014490194153e-06
literature O 0 4.280090251995716e-06
. O 0 7.69983853388112e-06

The O 0 2.5054338038899004e-05
most O 0 2.1763046333944658e-06
common O 0 9.239088285539765e-07
phenotypic O 0 4.62667867395794e-06
features O 0 4.3970180740871e-06
, O 0 1.0102206715600914e-06
present O 0 2.862239512069209e-07
in O 0 1.324734313357112e-07
more O 0 3.691341277090032e-08
than O 0 5.5935736043011275e-08
a O 0 3.0732300615454733e-07
third O 0 1.3789584727419424e-06
of O 0 9.702617376206035e-08
our O 0 5.673587111232337e-06
patients O 0 5.641182724502869e-06
with O 0 7.487797120120376e-07
TWIST O 0 0.0009968322701752186
mutations O 0 3.593089786591008e-05
, O 0 4.5260787828738103e-07
are O 0 2.958094285077095e-07
coronal B-Disease 0 6.867061165394261e-05
synostosis I-Disease 0 0.0016706380993127823
, O 0 1.6922955410336726e-06
brachycephaly B-Disease 0 0.000323434651363641
, O 0 2.1945079424767755e-06
low B-Disease 0 0.0007196420338004827
frontal I-Disease 1 0.9945517182350159
hairline I-Disease 1 0.9999996423721313
, O 0 0.0004262080183252692
facial B-Disease 1 0.9976277947425842
asymmetry I-Disease 1 0.576032280921936
, O 0 0.00011911237379536033
ptosis B-Disease 1 0.8376450538635254
, O 0 1.115014310926199e-05
hypertelorism B-Disease 0 0.0022247093729674816
, O 0 1.7290514051637729e-06
broad B-Disease 0 7.77265722717857e-06
great I-Disease 0 1.2891096957901027e-05
toes I-Disease 0 0.20513394474983215
, O 0 1.9245946987211937e-06
and O 0 5.016131581214722e-06
clinodactyly B-Disease 0 0.0019176906207576394
. O 0 2.577336817921605e-05

Significant O 0 9.687621786724776e-05
intra O 0 0.00021436976385302842
- O 0 0.0003865106264129281
and O 0 6.052080152585404e-06
interfamilial O 0 9.395262895850465e-05
phenotypic O 0 1.85184817382833e-05
variability O 0 2.1389068933785893e-05
is O 0 6.784819106542272e-07
present O 0 7.575713993901445e-07
for O 0 4.789025069840136e-07
either O 0 4.700299996329704e-06
TWIST O 0 0.00029722476028837264
mutations O 0 0.00024963062605820596
or O 0 4.426346640684642e-05
FGFR O 0 0.3469385802745819
mutations O 0 0.00027673275326378644
. O 0 3.4364442399237305e-05

The O 0 5.782575317425653e-05
overlap O 0 3.746392030734569e-05
in O 0 5.650013463309733e-06
clinical O 0 6.143464270280674e-05
features O 0 5.160200544196414e-06
and O 0 4.065229404659476e-06
the O 0 8.050274118431844e-07
presence O 0 7.117037057469133e-07
, O 0 1.8650237620931875e-07
in O 0 7.399702184329726e-08
the O 0 8.486826175158058e-08
same O 0 2.1378953363182518e-07
genes O 0 2.8838655907748034e-07
, O 0 4.5756809896602135e-08
of O 0 3.713742202648973e-08
mutations O 0 5.15171507231571e-07
for O 0 4.1594635291630766e-08
more O 0 4.050891178053462e-08
than O 0 1.0482710166570541e-07
one O 0 8.888841307452822e-07
craniosynostotic B-Disease 0 0.0007151557947508991
condition I-Disease 0 2.2617045033257455e-05
- O 0 1.1373442248441279e-05
such O 0 1.8439250482060743e-07
as O 0 7.729096296316129e-07
Saethre B-Disease 0 6.80855882819742e-05
- I-Disease 0 6.176063470775262e-05
Chotzen I-Disease 0 0.0001270527282031253
, I-Disease 0 1.0967378329951316e-06
Crouzon I-Disease 0 5.793857417302206e-05
, I-Disease 0 1.199073949464946e-06
and I-Disease 0 7.24974097465747e-06
Pfeiffer I-Disease 0 0.020397350192070007
syndromes I-Disease 0 0.04973093420267105
- O 0 2.9505550628528e-05
support O 0 1.2597382692547399e-06
the O 0 5.93213201227627e-07
hypothesis O 0 9.937850791175151e-07
that O 0 1.923055634733828e-07
TWIST O 0 7.833976269466802e-06
and O 0 1.207732907460013e-06
FGFRs O 0 4.5157663407735527e-05
are O 0 1.465215149210053e-07
components O 0 3.683296085910115e-07
of O 0 6.098833438272777e-08
the O 0 1.889489738005068e-07
same O 0 5.93468428178312e-07
molecular O 0 1.5782139598741196e-05
pathway O 0 2.5016447580128442e-06
involved O 0 3.180776673161745e-07
in O 0 1.092568737703914e-07
the O 0 1.4583577012672322e-07
modulation O 0 3.953186023863964e-06
of O 0 5.535184754990041e-07
craniofacial O 0 0.3973913788795471
and O 0 3.6037683457834646e-05
limb O 0 0.37953758239746094
development O 0 3.47017044077802e-06
in O 0 2.364407009736169e-06
humans O 0 5.395952030085027e-06
. O 0 1.917296003739466e-06
. O 0 9.678193237050436e-06

Mutation O 0 0.0006697582430206239
analysis O 0 6.421878060791641e-05
of O 0 2.4459874111926183e-05
UBE3A O 1 0.9749805927276611
in O 1 0.9728293418884277
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.999870777130127
. O 0 0.00033746377448551357

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.5010620355606079
AS B-Disease 1 0.9993178844451904
) O 0 1.2350923498161137e-05
is O 0 9.963083584807464e-07
caused O 0 5.955360848020064e-06
by O 0 8.134920221891662e-07
chromosome O 0 0.0004962318926118314
15q11 O 0 9.693823085399345e-05
- O 0 4.6208533603930846e-05
q13 O 0 2.124234197253827e-05
deletions O 0 4.2369961192889605e-06
of O 0 5.738871209359786e-07
maternal O 0 0.000546513416338712
origin O 0 3.1320744255936006e-06
, O 0 6.996828574301617e-07
by O 0 1.1902523056050995e-06
paternal O 0 0.00146977580152452
uniparental B-Disease 1 0.6171387434005737
disomy I-Disease 0 0.27994710206985474
( O 0 1.6507132386323065e-05
UPD B-Disease 1 0.999958872795105
) O 0 1.6520722283530631e-06
15 O 0 1.125398284784751e-06
, O 0 1.8139498081382044e-07
by O 0 3.8002309565854375e-07
imprinting O 0 0.11463569104671478
defects O 1 0.9705655574798584
, O 0 1.8161531443183776e-06
and O 0 9.174046340376663e-07
by O 0 5.154142854735255e-07
mutations O 0 5.103448984300485e-06
in O 0 4.7373993083965615e-07
the O 0 3.8356110962922685e-06
UBE3A O 0 0.000957546173594892
gene O 0 5.092138599138707e-05
. O 0 1.8891212675953284e-05

UBE3A O 0 0.006498876493424177
encodes O 0 0.00028152685263194144
a O 0 1.989978954952676e-05
ubiquitin O 0 8.625928603578359e-05
- O 0 4.742027522297576e-05
protein O 0 7.010239642113447e-06
ligase O 0 4.672323029808467e-06
and O 0 1.196002926917572e-06
shows O 0 1.0764108992589172e-05
brain O 0 0.0013778111897408962
- O 0 9.403310832567513e-05
specific O 0 7.795165402058046e-06
imprinting O 0 0.0005967890610918403
. O 0 2.9983533750055358e-05

Here O 0 6.385507003869861e-05
we O 0 1.2182401405880228e-05
describe O 0 1.6102238078019582e-05
UBE3A O 0 0.00014249258674681187
coding O 0 4.5054392103338614e-05
- O 0 0.00014737625315319747
region O 0 1.0203950296272524e-05
mutations O 0 1.8822014681063592e-05
detected O 0 1.160669944511028e-05
by O 0 6.868254445180355e-07
SSCP O 0 0.00014511220797430724
analysis O 0 7.312432330763841e-07
in O 0 1.0796273954838398e-06
13 O 0 2.078840225294698e-05
AS B-Disease 0 0.22962084412574768
individuals O 0 1.2342412674115621e-06
or O 0 3.493094027362531e-06
families O 0 1.2051305930071976e-05
. O 0 1.5833305951673537e-05

Two O 0 6.967388617340475e-05
identical O 0 0.00013599664089269936
de O 0 7.290145003935322e-05
novo O 0 4.713623275165446e-05
5 O 0 8.080563020484988e-06
- O 0 2.5001920221257024e-05
bp O 0 1.8409416952636093e-05
duplications O 0 1.0860290785785764e-05
in O 0 1.3745443538937252e-06
exon O 0 1.37480328703532e-05
16 O 0 5.619608600682113e-06
were O 0 8.619390428066254e-06
found O 0 1.3805341041006614e-05
. O 0 1.826221887313295e-05

Among O 0 1.5981731849024072e-05
the O 0 1.9469803191896062e-06
other O 0 5.736808361689327e-07
11 O 0 2.334402097403654e-06
unique O 0 1.0302003374818014e-06
mutations O 0 1.0265715900459327e-05
, O 0 5.392630555434152e-07
8 O 0 1.703351131254749e-06
were O 0 8.872173680174456e-07
small O 0 4.1921987303794594e-07
deletions O 0 4.031208845844958e-06
or O 0 1.8534786931923009e-06
insertions O 0 3.116444349871017e-05
predicted O 0 3.253324030083604e-05
to O 0 2.616500523799914e-06
cause O 0 1.6936912288656458e-05
frameshifts O 0 0.004932521842420101
, O 0 1.7424183624825673e-06
1 O 0 1.352137360299821e-06
was O 0 5.262908416625578e-06
a O 0 5.486283498612465e-07
mutation O 0 1.4810410675636376e-06
to O 0 2.1026177421390457e-07
a O 0 4.062413268002274e-07
stop O 0 1.4901792155797011e-06
codon O 0 2.788362053252058e-06
, O 0 4.0138519352694857e-07
1 O 0 5.469143502523366e-07
was O 0 4.694700692198239e-06
a O 0 1.0362515467932099e-06
missense O 0 1.000897646008525e-05
mutation O 0 3.92097854273743e-06
, O 0 4.430666251664661e-07
and O 0 4.761877505643497e-07
1 O 0 1.894514412015269e-06
was O 0 1.0425536856928375e-05
predicted O 0 2.1422335976239992e-06
to O 0 3.03059437101183e-07
cause O 0 5.35423964720394e-07
insertion O 0 1.1711445040418766e-06
of O 0 1.9637917603176902e-07
an O 0 3.0160965707182186e-06
isoleucine O 0 0.03313298895955086
in O 0 6.480458409896528e-07
the O 0 6.714213895975263e-07
hect O 0 1.5183336472546216e-05
domain O 0 4.40574723370446e-07
of O 0 1.520706831570351e-07
the O 0 5.820851924909221e-07
UBE3A O 0 5.9884332586079836e-05
protein O 0 1.2883472209068714e-06
, O 0 1.546943906305387e-07
which O 0 1.20127225500255e-07
functions O 0 3.3073644090109156e-07
in O 0 4.1535028572070587e-07
E2 O 0 2.5310264391009696e-05
binding O 0 3.161112999805482e-06
and O 0 2.106836063830997e-06
ubiquitin O 0 1.2043206879752688e-05
transfer O 0 6.697952358081238e-06
. O 0 1.2361339940980542e-05

Eight O 0 5.196103302296251e-05
of O 0 2.748189672274748e-06
the O 0 2.0321408555901144e-06
cases O 0 1.237359697370266e-06
were O 0 1.470001461711945e-05
familial O 0 0.003538097720593214
, O 0 4.302836714487057e-06
and O 0 1.5098888752618222e-06
five O 0 1.6600290564383613e-06
were O 0 9.406622666574549e-06
sporadic O 0 6.077837315388024e-05
. O 0 1.5044161045807414e-05

In O 0 4.2216684960294515e-05
two O 0 8.65150650497526e-06
familial O 0 0.012014701962471008
cases O 0 7.545858352386858e-06
and O 0 5.394202162278816e-06
one O 0 3.2078937692858744e-06
sporadic O 0 7.382927287835628e-05
case O 0 5.023082394473022e-06
, O 0 1.1370124184395536e-06
mosaicism O 0 9.493871039012447e-05
for O 0 1.3105216112307971e-06
UBE3A O 0 0.0020377144683152437
mutations O 0 2.624156877573114e-05
was O 0 3.0263248845585622e-05
detected O 0 9.176862477033865e-06
in O 0 4.1588299382055993e-07
the O 0 7.939006536616944e-07
mother O 0 2.4926002879510634e-05
of O 0 8.054008304725357e-08
three O 0 2.3055447400111007e-06
AS B-Disease 1 0.786461591720581
sons O 0 0.06498444080352783
, O 0 2.584387743809202e-07
in O 0 1.2378950486890972e-07
the O 0 4.94326513944543e-07
maternal O 0 0.00014123859000392258
grandfather O 0 9.086780482903123e-05
of O 0 1.0177647169484771e-07
two O 0 9.650456149756792e-07
AS B-Disease 0 0.09000273793935776
first O 0 2.5899762476910837e-06
cousins O 0 0.0001561555836815387
, O 0 2.760988593308866e-07
and O 0 1.7889431092044106e-07
in O 0 1.6732769836380612e-07
the O 0 4.475878938592359e-07
mother O 0 1.6830645108711906e-05
of O 0 1.3888183048038627e-07
an O 0 3.6402075238584075e-06
AS B-Disease 1 0.5929386615753174
daughter O 0 0.03590874746441841
. O 0 2.2791538867750205e-05

The O 0 1.4391243894351646e-05
frequencies O 0 1.0873712199099828e-05
with O 0 1.2885831210951437e-06
which O 0 7.349850079663156e-07
we O 0 1.0051878689409932e-06
detected O 0 5.062024683866184e-06
mutations O 0 3.6913670555804856e-06
were O 0 2.1039927560195792e-06
5 O 0 7.553047680630698e-07
( O 0 1.5408102171932114e-07
14 O 0 6.551284741362906e-07
% O 0 1.7151089082290127e-07
) O 0 5.001744440846778e-08
of O 0 3.278297455722168e-08
35 O 0 7.441446996381273e-07
in O 0 2.064409017066282e-07
sporadic O 0 4.854667167819571e-06
cases O 0 4.2146155010414077e-07
and O 0 9.573054740030784e-07
8 O 0 2.996463535964722e-06
( O 0 1.2964346751687117e-07
80 O 0 3.4656983416425646e-07
% O 0 2.2830077739399712e-07
) O 0 5.261355440211446e-08
of O 0 4.2485055473662214e-08
10 O 0 7.808369559825223e-07
in O 0 1.657716097724915e-06
familial O 0 0.013244341127574444
cases O 0 6.132935141067719e-06
. O 0 3.43532315127959e-06
. O 0 1.3466345990309492e-05

The O 0 0.00031534460140392184
hemochromatosis B-Disease 1 0.9999871253967285
845 O 0 0.009123297408223152
G O 0 0.08328703790903091
- O 0 0.00023267706274054945
- O 0 0.00012520659947767854
> O 0 1.3901626516599208e-05
A O 0 2.8173881219117902e-06
and O 0 1.1222343800909584e-06
187 O 0 4.450762844498968e-06
C O 0 5.264544233796187e-05
- O 0 3.68556211469695e-05
- O 0 0.00017909027519635856
> O 0 7.583494152640924e-05
G O 0 0.006650178227573633
mutations O 0 1.7221995221916586e-05
: O 0 9.029154739437217e-07
prevalence O 0 1.5576126315863803e-05
in O 0 1.1399569075365434e-06
non O 0 1.0814825145644136e-05
- O 0 0.0016816835850477219
Caucasian O 0 0.0006201080977916718
populations O 0 4.188896491541527e-05
. O 0 2.3911097741802223e-05

Hemochromatosis B-Disease 1 0.9995631575584412
, O 0 0.00019801725284196436
the O 0 0.0009775952203199267
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
of I-Disease 0 8.72563396114856e-06
iron I-Disease 1 0.9694594144821167
metabolism I-Disease 0 0.04752180352807045
, O 0 3.1214676710078493e-06
leads O 0 5.109677204018226e-06
, O 0 1.3192542382967076e-06
if O 0 1.1125066521344706e-06
untreated O 0 0.0005643885233439505
, O 0 1.9928307892769226e-07
to O 0 6.332373345685482e-07
progressive O 0 0.00013952628069091588
iron B-Disease 1 0.9883084297180176
overload I-Disease 1 0.7849492430686951
and O 0 4.83910262119025e-05
premature B-Disease 0 0.12108293175697327
death I-Disease 0 0.00012030820653308183
. O 0 1.2934566257172264e-05

The O 0 0.00034370378125458956
hemochromatosis B-Disease 1 0.999995231628418
gene O 0 0.0002698905300348997
, O 0 6.706786280119559e-06
HFE O 0 0.002064913045614958
, O 0 2.8403680971678114e-06
recently O 0 1.3335047697182745e-05
has O 0 1.0507927754588309e-06
been O 0 2.7903440695808968e-06
identified O 0 1.979833086807048e-06
, O 0 1.320211708843999e-07
and O 0 1.3789805564101698e-07
characterization O 0 8.298073908008519e-07
of O 0 6.947068698082148e-08
this O 0 1.5004896170012216e-07
gene O 0 1.2490569361034431e-06
has O 0 6.941822903172579e-07
shown O 0 4.740246311030205e-07
that O 0 8.07326330232172e-08
it O 0 5.654351298289839e-08
contains O 0 6.463719159910397e-08
two O 0 2.1222840018708666e-07
mutations O 0 1.990958935493836e-06
that O 0 1.9581142396418727e-07
result O 0 5.954941002528358e-07
in O 0 4.0713297266847803e-07
amino O 0 1.434549176337896e-06
acid O 0 1.1547283520485507e-06
substitutions O 0 1.4666035212940187e-06
- O 0 3.3920546229637694e-06
cDNA O 0 5.093243544251891e-06
nucleotides O 0 4.615968919097213e-06
845 O 0 1.0855642358365003e-05
G O 0 5.466751827043481e-05
- O 0 4.860107947024517e-05
- O 0 4.4682947191176936e-05
> O 0 8.974239790404681e-06
A O 0 4.237675057083834e-06
( O 0 4.24921466901651e-07
C282Y O 0 6.179544470796827e-06
) O 0 2.403950247753528e-07
and O 0 2.1864558163997572e-07
187 O 0 2.502961933714687e-06
C O 0 4.415115836309269e-05
- O 0 0.00013564398977905512
- O 0 0.0012864058371633291
> O 0 0.00013064128870610148
G O 0 0.008694004267454147
( O 0 3.8823332033643965e-06
H63D O 0 0.00042010555625893176
) O 0 3.734227675522561e-06
. O 0 8.878777407517191e-06

Although O 0 0.01124266255646944
hemochromatosis B-Disease 1 0.9999996423721313
is O 0 1.917933150252793e-05
common O 0 5.633829005091684e-06
in O 0 3.2773589282442117e-06
Caucasians O 0 5.189146031625569e-05
, O 0 1.5419582268805243e-06
affecting O 0 5.732904355681967e-06
> O 0 3.050862687814515e-05
= O 0 6.732065958203748e-05
1 O 0 1.2612709952009027e-06
/ O 0 2.587211383797694e-06
300 O 0 5.181732944947726e-07
individuals O 0 1.2037276064802427e-07
of O 0 5.254254986652995e-08
northern O 0 4.863870799454162e-07
European O 0 1.2624166174646234e-06
origin O 0 8.323039537572186e-07
, O 0 2.3290154160804377e-07
it O 0 2.532594010062894e-07
has O 0 4.4036218582732545e-07
not O 0 3.7755654602733557e-07
been O 0 5.035871026848326e-07
recognized O 0 1.9762781278132024e-07
in O 0 2.3609432275861764e-07
other O 0 4.3637768953885825e-07
populations O 0 4.6091859076113906e-06
. O 0 6.796891739213606e-06

The O 0 2.5824640033533797e-05
present O 0 5.633613909594715e-06
study O 0 2.151463149857591e-06
used O 0 1.8423904748487985e-06
PCR O 0 2.753282751655206e-05
and O 0 6.229664109014266e-07
restriction O 0 1.1662226597763947e-06
- O 0 7.69157395552611e-06
enzyme O 0 2.0641386981878895e-06
digestion O 0 1.1815484413091326e-06
to O 0 1.5371497852356697e-07
analyze O 0 4.6137148501657066e-07
the O 0 8.176784405122817e-08
frequency O 0 4.981798156222794e-07
of O 0 8.202965062764633e-08
the O 0 5.282602728584607e-07
845 O 0 1.2348344171186909e-05
G O 0 0.00017796507745515555
- O 0 3.946305514546111e-05
- O 0 3.62526043318212e-05
> O 0 3.9577730603923555e-06
A O 0 9.025564509101969e-07
and O 0 5.409778509601892e-07
187 O 0 2.387701215411653e-06
C O 0 2.1176078007556498e-05
- O 0 2.850271630450152e-05
- O 0 3.846358595183119e-05
> O 0 1.2972541298950091e-05
G O 0 0.0001156165380962193
mutations O 0 4.730253294837894e-06
in O 0 8.777251991887169e-07
HLA O 0 4.2240688344463706e-05
- O 0 1.4455741620622575e-05
typed O 0 8.984772648545913e-06
samples O 0 2.4328401195816696e-06
from O 0 5.369896030060772e-07
non O 0 2.0166189642623067e-06
- O 0 3.145406299154274e-05
Caucasian O 0 2.322970613022335e-05
populations O 0 1.2663088000408607e-06
, O 0 1.9683741925291542e-07
comprising O 0 4.435037510575057e-07
Australian O 0 1.091478907255805e-06
Aboriginal O 0 1.5672206927774823e-06
, O 0 2.2933973298222554e-07
Chinese O 0 1.0411990558623074e-07
, O 0 1.9810258322650043e-07
and O 0 9.774591944733402e-07
Pacific O 0 1.1619602446444333e-05
Islanders O 0 3.171865682816133e-05
. O 0 1.0280745300406124e-05

Results O 0 0.0005035479553043842
showed O 0 6.425751053029671e-05
that O 0 1.212452957588539e-06
the O 0 1.418971010025416e-06
845 O 0 4.664925654651597e-05
G O 0 0.002373411087319255
- O 0 0.00026817916659638286
- O 0 0.00032959732925519347
> O 0 1.0118712452822365e-05
A O 0 3.386201115063159e-06
mutation O 0 7.410318630718393e-06
was O 0 7.057557922962587e-06
present O 0 2.3318335706790094e-07
in O 0 1.9594440914261213e-07
these O 0 1.2587916842221603e-07
populations O 0 3.386080607015174e-07
( O 0 9.698806024971418e-08
allele O 0 1.1167212505824864e-06
frequency O 0 2.209392050644965e-06
0 O 0 1.9715050711965887e-06
. O 0 1.9777336035531334e-07
32 O 0 1.774102315721393e-06
% O 0 4.243039484208566e-07
) O 0 1.2030756124659092e-07
, O 0 1.4823083915871393e-07
and O 0 4.008052485460212e-07
, O 0 4.5026669681647036e-07
furthermore O 0 9.219619414579938e-07
, O 0 2.623952184421796e-07
it O 0 2.1567640828834556e-07
was O 0 7.349945008172654e-06
always O 0 5.222293566475855e-07
seen O 0 6.485274184342416e-07
in O 0 1.6164777605354175e-07
conjunction O 0 1.2575981145346304e-06
with O 0 1.5579872751914081e-06
HLA O 0 0.0003701137029565871
haplotypes O 0 1.2330752724665217e-05
common O 0 8.475905133309425e-07
in O 0 1.2462155609682668e-06
Caucasians O 0 1.2502446224971209e-05
, O 0 5.90905017361365e-07
suggesting O 0 1.4258499732022756e-06
that O 0 4.014594594536902e-07
845 O 0 1.485970824433025e-05
G O 0 0.00959003996104002
- O 0 0.0018081063171848655
- O 0 0.0013946772087365389
> O 0 2.2174719561007805e-05
A O 0 1.7676848074188456e-05
may O 0 2.7667088943417184e-05
have O 0 7.790770837345917e-07
been O 0 3.5655162378134264e-07
introduced O 0 3.298494277714781e-07
into O 0 2.663291525095701e-07
these O 0 1.894391914447624e-07
populations O 0 8.219846563406463e-07
by O 0 6.353393473546021e-07
Caucasian O 0 5.026671715313569e-05
admixture O 0 0.00016000756295397878
. O 0 2.8866008506156504e-05

187 O 0 0.0004097494238521904
C O 0 0.0005986759206280112
- O 0 0.00014970630581956357
- O 0 0.0001177716621896252
> O 0 6.661919178441167e-05
G O 0 0.0010464285733178258
was O 0 1.1043471204175148e-05
present O 0 4.5579940888273995e-07
at O 0 2.143919573427411e-06
an O 0 2.881968441670324e-07
allele O 0 1.8943480881716823e-06
frequency O 0 2.008094270422589e-06
of O 0 1.0765490969788516e-06
2 O 0 1.438970684830565e-05
. O 0 9.489605872659013e-06

68 O 0 0.0023583746515214443
% O 0 2.9229278879938647e-05
in O 0 1.4055874544283142e-06
the O 0 6.75392186622048e-07
two O 0 8.678700851305621e-07
populations O 0 2.146405222447356e-06
analyzed O 0 3.16263549393625e-06
( O 0 2.9520688826778496e-07
Australian O 0 1.074790816346649e-06
Aboriginal O 0 1.8736446918410365e-06
and O 0 7.136488875403302e-07
Chinese O 0 1.2328578122833278e-06
) O 0 1.8138267705580802e-06
. O 0 6.554648734891089e-06

In O 0 2.5869454475468956e-05
the O 0 3.0784592581767356e-06
Australian O 0 5.432984835351817e-06
Aboriginal O 0 1.9008739400305785e-06
samples O 0 9.97706024463696e-07
, O 0 2.5828921934589744e-07
187 O 0 1.4723743788636057e-06
C O 0 9.00637314771302e-06
- O 0 1.7510539692011662e-05
- O 0 6.265125557547435e-05
> O 0 3.102382834185846e-05
G O 0 0.012878808192908764
was O 0 6.475317786680534e-05
found O 0 1.1848907206513104e-06
to O 0 3.354057014348655e-07
be O 0 5.987400300000445e-07
associated O 0 9.45800707086164e-07
with O 0 2.225951902801171e-06
HLA O 0 0.002373575931414962
haplotypes O 0 2.0830491848755628e-05
common O 0 1.7320536471743253e-06
in O 0 1.8426979977448354e-06
Caucasians O 0 1.4699104212922975e-05
, O 0 7.133930921554565e-07
suggesting O 0 1.9133415207761573e-06
that O 0 1.5523440310971637e-07
it O 0 1.9180920673989021e-07
was O 0 2.202021505581797e-06
introduced O 0 4.574380625399499e-07
by O 0 2.1534202687689685e-07
recent O 0 1.2049810038661235e-06
admixture O 0 5.5050251830834895e-05
. O 0 1.935244472406339e-05

In O 0 2.8266405934118666e-05
the O 0 2.6459042601345573e-06
Chinese O 0 1.3658520856552059e-06
samples O 0 2.9589280075015267e-06
analyzed O 0 2.393382601439953e-06
, O 0 4.6977095280453796e-07
187 O 0 2.5865354018606013e-06
C O 0 2.5708119210321456e-05
- O 0 2.7298910936224274e-05
- O 0 6.713525363011286e-05
> O 0 3.248221401008777e-05
G O 0 0.002173861488699913
was O 0 1.7404023310518824e-05
present O 0 5.893348316021729e-07
in O 0 8.231268111558165e-07
association O 0 1.3915149565946194e-06
with O 0 2.151970903696565e-07
a O 0 3.1540616873826366e-07
wide O 0 8.36294873352017e-07
variety O 0 3.1383990517497296e-07
of O 0 3.5772117712440377e-07
HLA O 0 0.0007580441888421774
haplotypes O 0 1.9583734683692455e-05
, O 0 1.2100433650630293e-06
showing O 0 5.7836896303342655e-06
this O 0 3.043375897959777e-07
mutation O 0 1.8867648350351374e-06
to O 0 3.644907735633751e-07
be O 0 5.335084551916225e-07
widespread O 0 6.366045113281871e-07
and O 0 2.0425279672053875e-06
likely O 0 1.1736792657757178e-06
to O 0 3.961440881994349e-07
predate O 0 8.357372280443087e-06
the O 0 2.302325157188534e-07
more O 0 1.7865188794985443e-07
genetically O 0 1.8177819356424152e-06
restricted O 0 9.081998655346979e-07
845 O 0 1.1218085091968533e-05
G O 0 0.00037835031980648637
- O 0 0.0002828451688401401
- O 0 0.0009712008759379387
> O 0 3.9590155211044475e-05
A O 0 1.906819306896068e-05
mutation O 0 0.00011565656313905492
. O 0 1.7442938769818284e-05

Genotype O 0 0.027753768488764763
- O 0 0.0037925420328974724
phenotype O 0 0.00412847101688385
correlations O 0 0.0010420359903946519
in O 0 0.000625545799266547
attenuated B-Disease 1 0.9998480081558228
adenomatous I-Disease 1 0.9999992847442627
polyposis I-Disease 1 0.9999954700469971
coli I-Disease 1 0.9999606609344482
. O 0 0.0004045297100674361

Germ O 0 0.06427308917045593
- O 0 0.0010219013784080744
line O 0 0.00011479668319225311
mutations O 0 1.5521425666520372e-05
of O 0 6.682076900688116e-07
the O 0 3.0616829462815076e-06
tumor B-Disease 0 0.0040328181348741055
suppressor O 0 0.00019130339205730706
APC O 0 3.342428681207821e-05
are O 0 1.04461594219174e-06
implicated O 0 4.738013740279712e-05
in O 0 4.197445741738193e-05
attenuated B-Disease 1 0.9993454813957214
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999991655349731
coli I-Disease 1 0.9999988079071045
( O 0 0.0002822691749315709
AAPC B-Disease 1 0.9999995231628418
) O 0 9.260848855774384e-06
, O 0 1.1158206234540557e-06
a O 0 2.2001427169016097e-06
variant O 0 0.0003264755941927433
of O 0 0.0001210901391459629
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999991655349731
polyposis I-Disease 1 1.0
( O 0 0.0002793901658151299
FAP B-Disease 0 0.0018290942534804344
) O 0 2.6982987037627026e-05
. O 0 3.74717747035902e-05

AAPC B-Disease 1 0.9999880790710449
is O 0 6.499767187051475e-05
recognized O 0 8.435411473328713e-06
by O 0 1.2273441143406671e-06
the O 0 6.628837354583084e-07
occurrence O 0 2.576805400167359e-06
of O 0 4.951257324137259e-07
< O 0 3.400590503588319e-05
100 O 0 3.8557454900001176e-06
colonic B-Disease 0 0.00030397967202588916
adenomas I-Disease 0 0.0002776918699964881
and O 0 1.274421151720162e-06
a O 0 4.132193225814262e-06
later O 0 7.203955465229228e-05
onset O 0 0.4017927646636963
of O 0 0.041865453124046326
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.889638224383816e-05
age O 0 3.152228600811213e-05
> O 0 2.2064939912525006e-05
40 O 0 6.000174835207872e-06
years O 0 3.0261635401984677e-06
) O 0 2.764919827313861e-06
. O 0 5.805495220556622e-06

The O 0 3.206261317245662e-05
aim O 0 2.842839057848323e-05
of O 0 6.130006795501686e-07
this O 0 3.6812454595747113e-07
study O 0 7.178173859756498e-07
was O 0 3.7664344745280687e-06
to O 0 6.697529215671238e-07
assess O 0 2.1241548893158324e-05
genotype O 0 0.0008528879843652248
- O 0 0.00033472536597400904
phenotype O 0 0.00026437974884174764
correlations O 0 8.418785000685602e-05
in O 0 7.731917867204174e-05
AAPC B-Disease 1 0.9999940395355225
families O 0 0.0004380906466394663
. O 0 5.370169674279168e-05

By O 0 3.1217863579513505e-05
protein O 0 2.617917925817892e-05
- O 0 3.1998100894270465e-05
truncation O 0 5.137259722687304e-05
test O 0 2.611803574836813e-05
( O 0 9.64223204391601e-07
PTT O 0 1.1442067261668853e-05
) O 0 1.9820120655822393e-07
assay O 0 2.779799615382217e-06
, O 0 1.743311202062614e-07
the O 0 1.1956227297105215e-07
entire O 0 5.820368755848904e-07
coding O 0 2.4787941583781503e-06
region O 0 2.718579992233572e-07
of O 0 8.009963892163796e-08
the O 0 6.740730782439641e-07
APC B-Disease 0 1.0911627214227337e-05
gene O 0 2.166782678614254e-06
was O 0 4.7959219955373555e-06
screened O 0 6.276887233980233e-06
in O 0 9.608772870706161e-07
affected O 0 3.496783392620273e-06
individuals O 0 2.706992177081702e-07
from O 0 9.931142130881199e-07
11 O 0 5.5510146921733394e-05
AAPC B-Disease 1 0.9999487400054932
kindreds O 0 0.00010963792738039047
, O 0 7.957251568768697e-07
and O 0 2.633347833125299e-07
their O 0 5.962942850601394e-07
phenotypic O 0 8.634355253889225e-06
differences O 0 6.44868623567163e-06
were O 0 2.651245449669659e-05
examined O 0 0.00016190463793464005
. O 0 1.766833520377986e-05

Five O 0 8.636793063487858e-05
novel O 0 5.8478446590015665e-05
germ O 0 0.0005020964308641851
- O 0 0.0002411801106063649
line O 0 0.0001752409152686596
APC B-Disease 0 7.541141530964524e-05
mutations O 0 1.577559669385664e-05
were O 0 3.2242103316093562e-06
identified O 0 4.2089786802534945e-06
in O 0 1.5414993868034799e-06
seven O 0 8.131856702675577e-06
kindreds O 0 0.00019363993487786502
. O 0 2.744084849837236e-05

Mutations O 0 0.0044957841746509075
were O 0 4.755957706947811e-05
located O 0 1.2800261174561456e-05
in O 0 9.388226658302301e-07
three O 0 3.1094415930965624e-07
different O 0 1.2920850167574827e-07
regions O 0 1.690148963007232e-07
of O 0 5.1485322671851463e-08
the O 0 4.180150483534817e-07
APC B-Disease 0 1.1119157534267288e-05
gene O 0 1.151097762885911e-06
( O 0 1.4489957322894043e-07
1 O 0 2.79211178622063e-07
) O 0 1.3067746351680398e-07
at O 0 7.474426979570126e-07
the O 0 2.813173693994031e-07
5 O 0 1.1346943438184098e-06
end O 0 7.231720928757568e-07
spanning O 0 2.1582322915492114e-06
exons O 0 6.508541446237359e-06
4 O 0 2.2802864805271383e-06
and O 0 9.2905912651986e-07
5 O 0 1.4797140011069132e-06
, O 0 2.4484248228873184e-07
( O 0 1.0216194823442493e-07
2 O 0 2.0672321454640041e-07
) O 0 6.396852114676221e-08
within O 0 1.3999617465287884e-07
exon O 0 2.949596819235012e-06
9 O 0 4.438254563865485e-06
, O 0 3.3718180247888085e-07
and O 0 4.2335571492913004e-07
( O 0 1.4678724369332485e-07
3 O 0 6.249592274798488e-07
) O 0 9.846505122368399e-08
at O 0 8.659610557515407e-07
the O 0 1.6815090475574834e-07
3 O 0 1.1419546126489877e-06
distal O 0 6.158934411359951e-06
end O 0 1.1183944934600731e-06
of O 0 3.3002814348037646e-07
the O 0 1.3986556268719141e-06
gene O 0 2.02947103389306e-05
. O 0 1.0539789400354493e-05

Variability O 0 0.000544746988452971
in O 0 1.515564690635074e-05
the O 0 2.6924608391709626e-06
number O 0 1.4125859024716192e-06
of O 0 3.2145093427971005e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.7730012536048889
most O 0 1.6797056332507054e-06
apparent O 0 3.145196387777105e-05
in O 0 1.9210299342375947e-06
individuals O 0 6.381959565260331e-07
with O 0 9.667054428064148e-07
mutations O 0 1.2663616871577688e-05
in O 0 5.696372795682692e-07
region O 0 2.2324784367810935e-06
1 O 0 2.5621986878832104e-06
, O 0 4.566844324926933e-07
and O 0 1.2488508218666539e-06
upper O 0 0.007767545059323311
- O 1 0.8744179606437683
gastrointestinal O 0 0.033687371760606766
manifestations O 0 2.927505374827888e-05
were O 0 1.076264106814051e-05
more O 0 6.652573460996791e-07
severe O 0 0.0021392705384641886
in O 0 3.2714569897507317e-06
them O 0 6.6182778937218245e-06
. O 0 1.7876922356663272e-05

In O 0 7.25601494195871e-05
individuals O 0 6.233613930817228e-06
with O 0 2.878935447370168e-06
mutations O 0 2.611629133753013e-05
in O 0 8.943276270656497e-07
either O 0 1.6476949440402677e-06
region O 0 2.29137822316261e-06
2 O 0 2.494693035259843e-06
or O 0 5.844955239808769e-07
region O 0 9.048869742400711e-07
3 O 0 1.6657443211443024e-06
, O 0 1.8707277149587753e-07
the O 0 1.2071036792349332e-07
average O 0 8.308463179673709e-07
number O 0 9.283765933787436e-08
of O 0 1.7598081569758506e-07
adenomas B-Disease 0 4.584379348671064e-05
tended O 0 1.0332039892091416e-05
to O 0 5.547249202209059e-07
be O 0 7.359831784015114e-07
lower O 0 3.1300407954404363e-06
than O 0 2.00189589349975e-07
those O 0 2.006557764389072e-07
in O 0 2.695597913771053e-07
individuals O 0 2.188301948535809e-07
with O 0 5.090957984066335e-07
mutations O 0 8.589095159550197e-06
in O 0 4.912857889394218e-07
region O 0 2.7686771773005603e-06
1 O 0 2.560552275099326e-06
, O 0 3.8897351828381943e-07
although O 0 5.779393745797279e-07
age O 0 1.1018624718417414e-05
at O 0 0.0009557277080602944
diagnosis O 1 0.5214826464653015
was O 0 6.637163460254669e-05
similar O 0 7.646945960004814e-06
. O 0 1.0769366781460121e-05

In O 0 0.00010132995521416888
all O 0 2.7457548640086316e-05
AAPC B-Disease 1 0.9996918439865112
kindreds O 0 0.0003268530417699367
, O 0 2.3222164600156248e-06
a O 0 9.266107099392684e-07
predominance O 0 1.899896415125113e-05
of O 0 1.2439168131095357e-06
right O 0 0.18518736958503723
- O 1 0.9998512268066406
sided O 1 0.9999988079071045
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.29774099588394165
rectal B-Disease 1 0.9999873638153076
polyp I-Disease 1 0.9987183809280396
sparing O 0 0.00038368385867215693
was O 0 0.00018447682668920606
observed O 0 3.622567965066992e-05
. O 0 2.9695758712477982e-05

No O 0 0.0015263493405655026
desmoid B-Disease 1 0.9918249845504761
tumors I-Disease 1 0.9999998807907104
were O 0 0.0001729929936118424
found O 0 6.393840976670617e-06
in O 0 1.3084735428492422e-06
these O 0 1.8623202322487487e-06
kindreds O 0 0.0002574790851213038
. O 0 2.7162988772033714e-05

Our O 0 5.865124330739491e-05
data O 0 1.509091816842556e-05
suggest O 0 7.0165669967536815e-06
that O 0 6.462307169385895e-07
, O 0 1.0696106755858636e-06
in O 0 4.577995241561439e-06
AAPC B-Disease 1 0.9999936819076538
families O 0 1.3056889656581916e-05
, O 0 2.522838258300908e-07
the O 0 1.1660319643169714e-07
location O 0 7.419359349114529e-07
of O 0 1.5289842281163146e-07
the O 0 2.217466089859954e-06
APC B-Disease 0 0.0008099395199678838
mutation O 0 7.408273813780397e-05
may O 0 2.7368087103241123e-05
partially O 0 6.818148540332913e-05
predict O 0 6.714682967867702e-06
specific O 0 2.0124575712543447e-06
phenotypic O 0 3.351966734044254e-05
expression O 0 2.7809670427814126e-05
. O 0 2.413755100860726e-05

This O 0 1.5490888472413644e-05
should O 0 4.657983936340315e-06
help O 0 1.7958076341528795e-06
in O 0 4.2505726582930947e-07
the O 0 2.934323788394977e-07
design O 0 4.420816821948392e-06
of O 0 4.830688453694165e-07
tailored O 0 0.007541992701590061
clinical O 0 0.0047336146235466
- O 0 0.11474304646253586
management O 0 2.2676418666378595e-05
protocols O 0 7.437477052008035e-06
in O 0 5.258140163277858e-07
this O 0 2.0071797734999564e-07
subset O 0 1.0686849236662965e-06
of O 0 7.967586270751781e-07
FAP B-Disease 0 0.0003707737778313458
patients O 0 0.00010687032772693783
. O 0 3.6559260934154736e-06
. O 0 1.4635109437222127e-05

Wilms B-Disease 1 0.9708192944526672
' I-Disease 0 0.01573205180466175
tumor I-Disease 0 0.01316297147423029
1 O 0 1.3933480659034103e-05
and O 0 4.7433486543013714e-06
Dax O 0 0.03503510355949402
- O 0 4.455295857042074e-05
1 O 0 1.8857934946936439e-06
modulate O 0 7.474195172108011e-06
the O 0 1.1206793715246022e-06
orphan O 0 3.1010487873572856e-05
nuclear O 0 1.1499476386234164e-05
receptor O 0 6.243085408641491e-06
SF O 0 0.00016999895160552114
- O 0 1.6349958968930878e-05
1 O 0 1.0031959618572728e-06
in O 0 6.020977707521524e-07
sex O 0 2.97469910037762e-06
- O 0 1.204964064527303e-05
specific O 0 2.00840258912649e-06
gene O 0 8.644842637295369e-06
expression O 0 1.1356621143931989e-05
. O 0 1.4429035218199715e-05

Products O 0 0.00010531341104069725
of O 0 8.772575711191166e-06
steroidogenic O 0 0.00034661422250792384
factor O 0 1.1144126801809762e-05
1 O 0 3.565213773981668e-06
( O 0 1.0152253935302724e-06
SF O 0 0.001853151130490005
- O 0 6.790221232222393e-05
1 O 0 1.763258183018479e-06
) O 0 6.439176445383055e-07
and O 0 4.469145551411202e-06
Wilms B-Disease 1 0.9462273120880127
tumor I-Disease 0 0.02991628833115101
1 O 0 3.7036520552646834e-06
( O 0 9.150698474513774e-07
WT1 O 0 9.136155858868733e-05
) O 0 4.4242145236239594e-07
genes O 0 8.267622888524784e-07
are O 0 1.5943818709729385e-07
essential O 0 3.716907031048322e-07
for O 0 2.8606208957171475e-07
mammalian O 0 7.3838223215716425e-06
gonadogenesis O 0 7.163592090364546e-05
prior O 0 2.785345714073628e-06
to O 0 1.2511276281657047e-06
sexual O 0 4.741331395052839e-06
differentiation O 0 2.6659428840503097e-05
. O 0 1.7098685930250213e-05

In O 0 7.701512367930263e-05
males O 0 4.679718040279113e-05
, O 0 2.352535830141278e-06
SF O 0 0.0006204012897796929
- O 0 3.6712284781970084e-05
1 O 0 1.5428672668349463e-06
participates O 0 9.523300832370296e-07
in O 0 1.9278702723113383e-07
sexual O 0 4.32766682934016e-07
development O 0 1.8915829969046172e-07
by O 0 1.3512799057480152e-07
regulating O 0 1.1698764410539297e-06
expression O 0 2.4887802396733605e-07
of O 0 1.2821753614389308e-07
the O 0 1.0906684337896877e-06
polypeptide O 0 0.00011801796790678054
hormone O 0 2.4272283553727902e-05
Mullerian O 0 0.00022751859796699136
inhibiting O 0 4.4305863411864266e-05
substance O 0 2.8915959774167277e-05
( O 0 5.620584488497116e-06
MIS O 0 0.02033277042210102
) O 0 8.115634045680054e-06
. O 0 1.2554383829410654e-05

Here O 0 8.622113091405481e-05
, O 0 9.863561899692286e-06
we O 0 3.334141865707352e-06
show O 0 2.6127504497708287e-06
that O 0 7.836493978174985e-07
WT1 O 0 9.393927757628262e-05
- O 0 7.796725549269468e-05
KTS O 0 0.00041945712291635573
isoforms O 0 4.855245606449898e-06
associate O 0 5.514196800504578e-06
and O 0 2.4971234324766556e-06
synergize O 0 5.929527833359316e-05
with O 0 7.103887128323549e-06
SF O 0 0.47239890694618225
- O 0 0.00022237456869333982
1 O 0 3.5801169815385947e-06
to O 0 1.0813924973263056e-06
promote O 0 7.085180186550133e-06
MIS O 0 0.04063471779227257
expression O 0 1.9812570826616138e-05
. O 0 1.3882286111766007e-05

In O 0 0.00011227798677282408
contrast O 0 7.905567326815799e-05
, O 0 1.7369568013236858e-05
WT1 O 0 0.0008307643001899123
missense O 0 0.0001817311131162569
mutations O 0 9.274850162910298e-05
, O 0 1.8944276689580875e-06
associated O 0 2.9167574666644214e-06
with O 0 3.4130196127080126e-06
male B-Disease 0 0.0009394738590344787
pseudohermaphroditism I-Disease 1 0.9999586343765259
in O 0 3.294818816357292e-05
Denys B-Disease 1 0.9930747747421265
- I-Disease 1 0.9997604489326477
Drash I-Disease 1 0.9999765157699585
syndrome I-Disease 1 0.999997615814209
, O 0 1.0611355719447602e-05
fail O 0 3.774031574721448e-05
to O 0 1.278155423278804e-06
synergize O 0 0.00018532571266405284
with O 0 1.2948883522767574e-05
SF O 1 0.8300230503082275
- O 0 0.0031238875817507505
1 O 0 2.813817081914749e-05
. O 0 1.0982023013639264e-05

Additionally O 0 0.000215199775993824
, O 0 7.66098946769489e-06
the O 0 1.7583464568815543e-06
X O 0 0.0020346911624073982
- O 0 0.0008058854145929217
linked O 0 4.166299549979158e-05
, O 0 4.5751662014481553e-07
candidate O 0 1.4540638630933245e-06
dosage O 0 5.845986379426904e-06
- O 0 9.900749319058377e-06
sensitive O 0 3.4324937132623745e-06
sex O 0 2.210283582826378e-06
- O 0 1.2149404938099906e-05
reversal O 0 3.872257821058156e-06
gene O 0 1.9684409835463157e-06
, O 0 4.840991891796875e-07
Dax O 0 0.009555535390973091
- O 0 5.2421408327063546e-05
1 O 0 1.1304398412903538e-06
, O 0 2.815129960254126e-07
antagonizes O 0 5.782596872450085e-06
synergy O 0 3.428221361900796e-06
between O 0 1.2728712590615032e-06
SF O 0 0.025990759953856468
- O 0 9.8552176496014e-05
1 O 0 1.9717872419278137e-06
and O 0 2.1742218905274058e-06
WT1 O 0 0.00014511910558212548
, O 0 3.909497650056437e-07
most O 0 1.2040443664318445e-07
likely O 0 2.652174657669093e-07
through O 0 1.4844246720713272e-07
a O 0 2.184975755881169e-07
direct O 0 3.286715752892633e-07
interaction O 0 8.690155368640262e-07
with O 0 2.6176760457019554e-06
SF O 1 0.5792627334594727
- O 0 0.002525328192859888
1 O 0 2.4222179490607232e-05
. O 0 1.1147994882776402e-05

We O 0 8.527361205779016e-05
propose O 0 4.668583278544247e-05
that O 0 4.551579422695795e-06
WT1 O 0 0.0001502249506302178
and O 0 4.024425379611785e-06
Dax O 1 0.563377857208252
- O 0 0.00122826115693897
1 O 0 4.671725946536753e-06
functionally O 0 1.171260100818472e-05
oppose O 0 8.40316204175906e-07
each O 0 1.5461901625712926e-07
other O 0 1.2380485259200213e-07
in O 0 4.3944513095084403e-07
testis O 0 3.972509512095712e-05
development O 0 7.51235972984432e-07
by O 0 4.857158728555078e-07
modulating O 0 2.5743005608092062e-05
SF O 0 0.003507870715111494
- O 0 4.132881440455094e-05
1 O 0 4.119052391615696e-06
- O 0 4.486496982281096e-05
mediated O 0 6.170070264488459e-05
transactivation O 0 0.00041956189670599997
. O 0 6.436999683501199e-06
. O 0 2.3657790734432638e-05

A O 0 0.00018588619423098862
mouse O 0 0.0003442471206653863
model O 0 6.843017763458192e-05
for O 0 5.473126293509267e-05
Prader B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.8264700174331665
- O 0 0.28246963024139404
centre O 0 0.011243924498558044
mutations O 0 0.0004980913363397121
. O 0 3.115380968665704e-05

Imprinting O 0 0.0026912125758826733
in O 0 2.1021071006543934e-05
the O 0 6.36683853372233e-06
15q11 O 0 0.00014454433403443545
- O 0 0.00012212824367452413
q13 O 0 4.7978861402953044e-05
region O 0 2.202466703238315e-06
involves O 0 1.4614013252867153e-06
an O 0 7.265870749506576e-07
imprinting O 0 9.063768084160984e-05
centre O 0 8.023231930565089e-05
( O 0 7.751935413580213e-07
IC O 0 4.221563722239807e-05
) O 0 3.681340388084209e-07
, O 0 1.1285079892786598e-07
mapping O 0 1.129668362409575e-06
in O 0 2.1392047244717105e-07
part O 0 2.166312640383694e-07
to O 0 1.5574153167108307e-07
the O 0 2.5479772602921e-07
promoter O 0 4.656238161260262e-06
and O 0 2.100869807009076e-07
first O 0 7.937704253890843e-07
exon O 0 1.5344359781011008e-05
of O 0 2.183393689847435e-06
SNRPN O 0 0.0021827539894729853
. O 0 1.7620126527617685e-05

Deletion O 0 0.0007015701266936958
of O 0 1.1272220035607461e-05
this O 0 5.2364348448463716e-06
IC O 0 0.00015710396110080183
abolishes O 0 9.960048191715032e-05
local O 0 7.068550985422917e-06
paternally O 0 5.1296035962877795e-05
derived O 0 2.8721344733639853e-06
gene O 0 2.5006547730299644e-06
expression O 0 1.2490926337704877e-06
and O 0 1.7404785239705234e-06
results O 0 5.033056368120015e-05
in O 0 0.0008266584482043982
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0013991937739774585
PWS B-Disease 1 0.999998927116394
) O 0 6.036537524778396e-05
. O 0 3.905310950358398e-05

We O 0 0.00011086851736763492
have O 0 4.062454536324367e-06
created O 0 3.308428858872503e-06
two O 0 1.0898822893068427e-06
deletion O 0 9.215658792527393e-05
mutations O 0 4.074260868947022e-05
in O 0 4.060076207679231e-06
mice O 0 0.0008058738894760609
to O 0 3.1855108773015672e-06
understand O 0 4.467599865165539e-05
PWS B-Disease 1 0.999996542930603
and O 0 2.216685743405833e-06
the O 0 5.322019092091068e-07
mechanism O 0 1.943077450050623e-06
of O 0 3.3400058896404516e-07
this O 0 1.431870146006986e-06
IC O 0 0.0006451135268434882
. O 0 2.1662910512532108e-05

Mice O 1 0.8748489618301392
harbouring O 0 0.1886245161294937
an O 0 3.0063047233852558e-05
intragenic O 0 0.0019370238296687603
deletion O 0 0.00031539477640762925
in O 0 1.1011817150574643e-05
Snrpn O 0 0.0024199592880904675
are O 0 1.6289382074319292e-06
phenotypically O 0 8.96129131433554e-05
normal O 0 5.47197350897477e-06
, O 0 4.4746329308509303e-07
suggesting O 0 1.7314887372776866e-06
that O 0 1.8378928245965653e-07
mutations O 0 1.9826748030027375e-06
of O 0 2.6805474817592767e-07
SNRPN O 0 0.005893403198570013
are O 0 5.075145281807636e-07
not O 0 5.863579985998513e-07
sufficient O 0 2.6623415578796994e-06
to O 0 5.230764600128168e-06
induce O 0 0.0037111418787389994
PWS B-Disease 1 0.9999958276748657
. O 0 4.654079384636134e-05

Mice O 0 0.12643229961395264
with O 0 9.236638106813189e-06
a O 0 3.557972377166152e-06
larger O 0 3.2705959256418282e-06
deletion O 0 3.5792658309219405e-05
involving O 0 2.082670107483864e-06
both O 0 1.420678472641157e-06
Snrpn O 0 0.0004369672969914973
and O 0 1.6093603107947274e-06
the O 0 3.3891994917212287e-06
putative O 0 0.021449454128742218
PWS O 1 0.9999997615814209
- O 0 0.01996946893632412
IC O 0 0.002171177649870515
lack O 0 4.365830591268605e-06
expression O 0 5.337792003956565e-07
of O 0 1.1676210220912253e-07
the O 0 9.594140237823012e-07
imprinted O 0 0.00028054698486812413
genes O 0 3.54068879460101e-06
Zfp127 O 0 1.2207894542370923e-05
( O 0 4.6862274416525906e-07
mouse O 0 4.741621069115354e-06
homologue O 0 5.875122496945551e-06
of O 0 6.302869337559969e-07
ZNF127 O 0 0.0043727932497859
) O 0 6.990172209953016e-07
, O 0 5.476471187648713e-07
Ndn O 0 5.649157537845895e-05
and O 0 1.0680552122721565e-06
Ipw O 0 0.00016889316611923277
, O 0 7.109670150384773e-07
and O 0 1.2239847819728311e-06
manifest O 0 7.335421742027393e-06
several O 0 1.019415549308178e-06
phenotypes O 0 5.140023858984932e-05
common O 0 6.644389941357076e-06
to O 0 0.00013652625784743577
PWS B-Disease 1 1.0
infants O 1 0.985236406326294
. O 0 7.81883136369288e-05

These O 0 1.019159026327543e-05
data O 0 8.202437129511964e-06
demonstrate O 0 4.728895419248147e-06
that O 0 3.0126878414193925e-07
both O 0 1.3133463028225378e-07
the O 0 3.6894979871249234e-07
position O 0 1.397515461576404e-06
of O 0 5.7469339509452766e-08
the O 0 2.3021932804567768e-07
IC O 0 3.144908259855583e-05
and O 0 4.801500494977518e-07
its O 0 2.905963185639848e-07
role O 0 3.7986512779752957e-07
in O 0 8.59532178765221e-08
the O 0 5.3039865832715805e-08
coordinate O 0 4.837972937821178e-07
expression O 0 1.866048648935248e-07
of O 0 7.644312205457027e-08
genes O 0 5.599406449618982e-07
is O 0 9.6611962874249e-08
conserved O 0 2.486939081336459e-07
between O 0 1.854207596352353e-07
mouse O 0 1.2729980880976655e-05
and O 0 1.1927294281122158e-06
human O 0 2.646396524141892e-07
, O 0 3.343180026149639e-07
and O 0 5.6173189477704e-07
indicate O 0 1.5800201254023705e-06
that O 0 8.729978873134314e-08
the O 0 1.2752511224789487e-07
mouse O 0 7.41178928365116e-06
is O 0 1.2513240221778688e-07
a O 0 1.9952193497374537e-07
suitable O 0 2.4520470560673857e-06
model O 0 2.383201263000956e-06
system O 0 1.4331734519146266e-06
in O 0 2.1990234699842404e-07
which O 0 2.568742729636142e-07
to O 0 1.9019606156689406e-07
investigate O 0 5.046996420787764e-07
the O 0 1.5470811831619358e-07
molecular O 0 2.4518085410818458e-06
mechanisms O 0 9.4710225084782e-07
of O 0 1.192860850096622e-07
imprinting O 0 2.5794466637307778e-05
in O 0 4.3482441469677724e-07
this O 0 8.059017631012466e-08
region O 0 2.310873128408275e-07
of O 0 1.5995325952644635e-07
the O 0 6.584469360859657e-07
genome O 0 5.030944976169849e-06
. O 0 1.2271826790311025e-06
. O 0 8.172711204679217e-06

Mutations O 0 0.000468214217107743
of O 0 7.996597560122609e-06
the O 0 3.755065336008556e-06
ATM O 0 0.000448294886155054
gene O 0 1.612207415746525e-05
detected O 0 2.1394411305664107e-05
in O 0 2.1167284103285056e-06
Japanese O 0 0.002060845261439681
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.9907124638557434
: O 0 1.768284960235178e-06
possible O 0 1.0046665011032019e-06
preponderance O 0 8.562465154682286e-06
of O 0 2.1480238387994177e-07
the O 0 5.895225854146702e-07
two O 0 1.3398200735537102e-06
founder O 0 8.591220830567181e-05
mutations O 0 1.58898183144629e-05
4612del165 O 0 2.7438336474006064e-05
and O 0 3.832466518360889e-06
7883del5 O 0 0.00017412161105312407
. O 0 2.5694980649859644e-05

The O 0 8.35357786854729e-05
ATM O 0 0.025114992633461952
( O 0 2.023352681135293e-05
A O 1 0.962129533290863
- O 1 0.9954202175140381
T O 1 0.9999940395355225
, O 0 1.1745715937649948e-06
mutated O 0 5.65009395359084e-06
) O 0 4.561538275993371e-07
gene O 0 1.3297851637616986e-06
on O 0 1.579651097927126e-06
human O 0 5.467779828904895e-06
chromosome O 0 0.0006056129350326955
11q22 O 0 0.0004003730427939445
. O 0 2.721936471061781e-05

3 O 0 0.0003241507802158594
has O 0 1.3702768228540663e-05
recently O 0 1.1291671398794279e-05
been O 0 1.6630300478936988e-06
identified O 0 1.2933625157529605e-06
as O 0 1.6793936197245785e-07
the O 0 3.0929356853448553e-07
gene O 0 1.6497075421284535e-06
responsible O 0 6.935615601832978e-07
for O 0 1.3410786436907074e-07
the O 0 2.2620363324676873e-06
human O 0 3.609044142649509e-05
recessive B-Disease 1 0.9999836683273315
disease I-Disease 1 0.9999934434890747
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
telangiectasia I-Disease 1 1.0
( O 0 0.0002298308099852875
A B-Disease 1 0.9999895095825195
- I-Disease 1 0.9999974966049194
T I-Disease 1 0.9999998807907104
) O 0 8.105098459054716e-06
. O 0 1.4186789485393092e-05

In O 0 2.9437089324346744e-05
order O 0 4.833932962355902e-06
to O 0 1.2112255944884964e-06
define O 0 2.0774866698047845e-06
the O 0 3.438429700963752e-07
types O 0 1.610680783414864e-06
of O 0 2.5818776521191467e-06
disease O 0 0.27589476108551025
- O 0 0.017366737127304077
causing O 0 0.0001240767742274329
ATM O 0 0.07028404623270035
mutations O 0 4.08925479860045e-05
in O 0 2.191636440329603e-06
Japanese O 0 9.82684941845946e-05
A B-Disease 1 0.9999703168869019
- I-Disease 1 0.9999971389770508
T I-Disease 1 1.0
patients O 0 0.0002638700243551284
as O 0 3.081573822782957e-07
well O 0 2.5203419795616355e-07
as O 0 1.302815064718743e-07
to O 0 2.4703263079572935e-07
look O 0 1.0797447203003685e-06
for O 0 1.585363378353577e-07
possible O 0 9.175035984299029e-07
mutational O 0 6.248777935979888e-05
hotspots O 0 3.946399374399334e-05
, O 0 1.3968799521535402e-06
reverse O 0 2.015726022364106e-05
- O 0 0.00017536744417157024
transcribed O 0 9.632447472540662e-06
RNA O 0 2.0919180769851664e-06
derived O 0 7.845841309972457e-07
from O 0 4.871205305789772e-07
ten O 0 2.795484761008993e-06
patients O 0 6.500650670204777e-06
belonging O 0 3.942410785384709e-06
to O 0 4.923800247524923e-07
eight O 0 2.438735691612237e-06
unrelated O 0 5.974468876956962e-06
Japanese O 0 2.1125171770108864e-05
A B-Disease 1 0.995900571346283
- I-Disease 1 0.9998929500579834
T I-Disease 1 0.9999998807907104
families O 0 1.725956281006802e-05
was O 0 1.3654424947162624e-05
analyzed O 0 2.0152424440311734e-06
for O 0 1.5825280286208e-07
mutations O 0 1.9204071577405557e-06
by O 0 1.7988108425015525e-07
the O 0 4.984321435586025e-07
restriction O 0 3.0819373932899907e-06
endonuclease O 0 7.72270723246038e-05
fingerprinting O 0 4.3677187932189554e-05
method O 0 2.947130451502744e-05
. O 0 2.733095061557833e-05

As O 0 6.474465772043914e-05
has O 0 1.1558925507415552e-05
been O 0 5.941003109910525e-06
reported O 0 4.248491677572019e-06
by O 0 3.967020631989726e-07
others O 0 9.888896101983846e-07
, O 0 5.279913466438302e-07
mutations O 0 9.773864348971983e-07
that O 0 1.2111915737023082e-07
lead O 0 6.969537480472354e-07
to O 0 2.7834659022119013e-07
exon O 0 1.4248304069042206e-05
skipping O 0 3.898115028277971e-05
or O 0 1.042465191858355e-05
premature O 0 8.039867680054158e-05
protein O 0 2.47849379775289e-06
truncation O 0 1.4888772057020105e-05
were O 0 4.3570912566792686e-06
also O 0 5.845902819601179e-07
predominant O 0 4.068914222443709e-06
in O 0 1.3698229395231465e-06
our O 0 4.083682597411098e-06
mutants O 0 8.501525007886812e-05
. O 0 1.4544254554493818e-05

Six O 0 6.310986645985395e-05
different O 0 4.517675279203104e-06
mutations O 0 2.9555514629464597e-05
were O 0 5.176530066819396e-06
identified O 0 2.4682544790266547e-06
on O 0 6.420958129638166e-07
12 O 0 8.990137985165347e-07
of O 0 1.849282256216611e-07
the O 0 1.0120249953615712e-06
16 O 0 1.646612690819893e-05
alleles O 0 1.721925218589604e-05
examined O 0 6.707452121190727e-05
. O 0 2.0705201677628793e-05

Four O 0 0.0001056753535522148
were O 0 2.0422052330104634e-05
deletions O 0 2.6636662369128317e-05
involving O 0 7.129467121558264e-06
a O 0 1.3062220205029007e-05
loss O 0 3.311318141641095e-05
of O 0 2.1625062629482272e-07
a O 0 1.2002328730886802e-06
single O 0 7.100439233909128e-06
exon O 0 9.624734047974925e-06
exon O 0 9.085722922463901e-06
7 O 0 3.0949086067266762e-06
, O 0 4.327023077621561e-07
exon O 0 3.0616245112469187e-06
16 O 0 1.3310780104802689e-06
, O 0 4.832637614526902e-07
exon O 0 6.591457804461243e-06
33 O 0 5.917514044995187e-06
or O 0 1.9910596620320575e-06
exon O 0 4.528402132564224e-05
35 O 0 3.5985620343126357e-05
. O 0 2.127624065906275e-05

The O 0 2.070421578537207e-05
others O 0 1.0113772987097036e-05
were O 0 2.436601562294527e-06
minute O 0 2.5743834157765377e-06
deletions O 0 6.672985364275519e-06
, O 0 1.0061028206109768e-06
4649delA O 0 7.252769592014374e-06
in O 0 7.030164397292538e-07
exon O 0 1.2217935363878496e-05
33 O 0 5.490604053193238e-06
and O 0 1.0902306257776218e-06
7883del5 O 0 1.2203191545268055e-05
in O 0 9.575264812156092e-07
exon O 0 3.59818477591034e-05
55 O 0 2.482245872670319e-05
. O 0 1.25161895994097e-05

The O 0 6.359565304592252e-05
mutations O 0 0.0002149321953766048
4612del165 O 0 0.00012294288899283856
and O 0 4.171662567387102e-06
7883del5 O 0 9.883102757157758e-05
were O 0 6.9187567532935645e-06
found O 0 1.0393295042376849e-06
in O 0 1.2707181440418935e-07
more O 0 4.7210185982748953e-08
than O 0 7.290804404647133e-08
two O 0 2.194582009451551e-07
unrelated O 0 3.3453150081186322e-06
families O 0 1.3643171996591263e-06
; O 0 2.344521305985836e-07
44 O 0 1.7012245052683284e-06
% O 0 4.232346100252471e-07
( O 0 9.28948651335304e-08
7 O 0 5.371924771679915e-07
of O 0 7.73955690647199e-08
16 O 0 1.7849245068646269e-06
) O 0 6.450996181683877e-08
of O 0 3.0136643403011476e-08
the O 0 2.563236876085284e-07
mutant O 0 8.029111995710991e-06
alleles O 0 2.096511707350146e-06
had O 0 3.2387870305683464e-06
one O 0 1.4094436551204126e-07
of O 0 7.922157863049506e-08
the O 0 5.685252517650952e-07
two O 0 2.752428144958685e-06
mutations O 0 4.535416519502178e-05
. O 0 8.901888577383943e-06

The O 0 4.8602658353047445e-05
4612del165 O 0 0.0003531491383910179
mutations O 0 4.8923338908934966e-05
in O 0 2.093123384838691e-06
three O 0 7.266743864420278e-07
different O 0 3.07978183400337e-07
families O 0 1.184084339911351e-06
were O 0 1.3456102578857099e-06
all O 0 1.121377053436845e-07
ascribed O 0 8.206217785300396e-07
to O 0 2.5002108827720804e-07
the O 0 3.120867404504679e-07
same O 0 3.0756891646888107e-06
T O 0 0.005774130579084158
- O 0 2.9642958907061256e-05
- O 0 1.983461515919771e-05
> O 0 2.0879758722003317e-06
A O 0 4.66986790570445e-07
substitution O 0 6.16904230810178e-07
at O 0 1.701503606454935e-06
the O 0 3.382581894584291e-07
splice O 0 8.00680645625107e-05
donor O 0 1.0931416909443215e-05
site O 0 8.192867426259909e-06
in O 0 4.322306722315261e-06
intron O 0 0.0006743887206539512
33 O 0 8.25601164251566e-05
. O 0 1.8095548512064852e-05

Microsatellite O 0 0.004235442727804184
genotyping O 0 0.0010845828801393509
around O 0 5.067785969004035e-05
the O 0 4.50429979537148e-06
ATM O 0 0.00029146173619665205
locus O 0 7.370954699581489e-05
also O 0 8.652298674860504e-06
indicated O 0 6.215040684764972e-06
that O 0 1.8994862216459296e-07
a O 0 8.728227953724854e-07
common O 0 3.8559219319722615e-06
haplotype O 0 0.000435556226875633
was O 0 4.734115645987913e-05
shared O 0 1.0120132856172859e-06
by O 0 1.3377473351283697e-07
the O 0 3.842739602077927e-07
mutant O 0 9.629885425965767e-06
alleles O 0 2.9478421765816165e-06
in O 0 8.378731877201062e-07
both O 0 3.2521827506570844e-06
mutations O 0 8.5747946286574e-05
. O 0 2.459817005728837e-05

This O 0 1.978153522941284e-05
suggests O 0 9.205753485730384e-06
that O 0 4.1745610701582336e-07
these O 0 2.0680880652435008e-07
two O 0 5.77057619466359e-07
founder O 0 5.2345731091918424e-05
mutations O 0 2.119175587722566e-05
may O 0 2.3796267214493128e-06
be O 0 2.72856965466417e-07
predominant O 0 1.923735680975369e-06
among O 0 5.56910947580036e-07
Japanese O 0 4.484870260057505e-06
ATM O 0 0.00042514532105997205
mutant O 0 0.00012412625073920935
alleles O 0 8.106196037260816e-05
. O 0 2.26211213885108e-05

W474C O 0 0.004984643310308456
amino O 0 0.0002131749497493729
acid O 0 2.616894562379457e-05
substitution O 0 4.322512722865213e-06
affects O 0 3.435480493862997e-06
early O 0 7.217575443974056e-07
processing O 0 1.219917749040178e-06
of O 0 1.2916352432057465e-07
the O 0 2.291652521080323e-07
alpha O 0 7.837151088097016e-07
- O 0 7.334649012591399e-07
subunit O 0 5.696932134924282e-07
of O 0 1.3858928582521912e-07
beta O 0 1.886530981209944e-06
- O 0 2.7536267225514166e-05
hexosaminidase O 0 5.350933861336671e-05
A O 0 4.1955290726036765e-06
and O 0 1.9766257537412457e-06
is O 0 3.811475437487388e-07
associated O 0 1.6984588455670746e-06
with O 0 1.9591017917264253e-05
subacute O 1 0.994236171245575
G B-Disease 1 0.7183436751365662
( I-Disease 0 5.70189058635151e-06
M2 I-Disease 0 0.01961490511894226
) I-Disease 0 8.269670615845826e-06
gangliosidosis I-Disease 0 0.00032303339685313404
. O 0 2.557343577791471e-05

Mutations O 0 0.0015210384735837579
in O 0 2.5075731173274107e-05
the O 0 7.55526252760319e-06
HEXA O 0 0.0009133656858466566
gene O 0 7.717599146417342e-06
, O 0 2.402799736955785e-07
encoding O 0 6.265866545618337e-07
the O 0 1.965792932878685e-07
alpha O 0 4.909939548269904e-07
- O 0 3.7271081509970827e-07
subunit O 0 3.973662217049423e-07
of O 0 1.20552655857864e-07
beta O 0 1.396361767547205e-06
- O 0 1.996067112486344e-05
hexosaminidase O 0 7.81981652835384e-05
A O 0 3.763651648114319e-06
( O 0 3.095473459779896e-07
Hex O 0 6.909617241035448e-06
A O 0 3.5474758988129906e-06
) O 0 1.9264992090484157e-07
, O 0 1.2627113221697073e-07
that O 0 1.2956621731063933e-07
abolish O 0 4.345373326941626e-06
Hex O 0 1.1382361662981566e-05
A O 0 2.797890374495182e-06
enzyme O 0 9.215688805852551e-06
activity O 0 7.901189746917225e-06
cause O 0 0.0003503771440591663
Tay B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
Sachs I-Disease 1 1.0
disease I-Disease 1 0.954418420791626
( O 0 3.6035639823239762e-06
TSD B-Disease 0 0.002965266816318035
) O 0 9.531750606583955e-07
, O 0 5.296969902701676e-07
the O 0 2.2108251869212836e-06
fatal O 0 0.017522308975458145
infantile B-Disease 0 0.003583812154829502
form I-Disease 0 1.6357364529540064e-06
of I-Disease 0 1.0694678849176853e-06
G I-Disease 0 0.20355041325092316
( I-Disease 0 8.349418294528732e-07
M2 I-Disease 0 0.0014050268800929189
) I-Disease 0 7.771017180857598e-07
gangliosidosis I-Disease 0 3.123433270957321e-05
, I-Disease 0 6.973140216359752e-07
Type I-Disease 0 6.122777904238319e-06
1 I-Disease 0 9.314374437963124e-06
. O 0 1.0413175004941877e-05

Less O 0 0.0010175288189202547
severe O 1 0.9869741201400757
, O 0 0.00033375760540366173
subacute O 1 0.9948523640632629
( O 0 8.591195364715531e-05
juvenile O 0 0.38734567165374756
- O 1 0.9535604119300842
onset O 1 0.9984238147735596
) O 0 1.8252818335895427e-05
and O 0 0.00025813706452026963
chronic O 1 0.9993810653686523
( O 0 5.634495209960733e-06
adult O 0 0.0002956009702757001
- O 1 0.8259625434875488
onset O 1 0.6961327791213989
) O 0 9.21081380056421e-07
variants O 0 2.7152864277013578e-06
are O 0 6.878230465190427e-07
characterized O 0 1.9456513200566405e-06
by O 0 1.4577722140529659e-07
a O 0 7.693224119975639e-07
broad O 0 2.7008650249626953e-06
spectrum O 0 3.0707944915775442e-06
of O 0 4.536142625966022e-07
clinical O 0 0.0003517719451338053
manifestations O 0 1.8452268705004826e-05
and O 0 3.0038454497116618e-06
are O 0 6.389566351572284e-07
associated O 0 9.801634632822243e-07
with O 0 8.684355634613894e-07
residual O 0 3.6955432733520865e-05
levels O 0 2.0181023501208983e-06
of O 0 1.8404465151888871e-07
Hex O 0 1.6257014067377895e-05
A O 0 4.01214720113785e-06
enzyme O 0 2.126484105247073e-05
activity O 0 1.0656932317942847e-05
. O 0 9.57710562943248e-06

We O 0 5.8580255426932126e-05
identified O 0 3.321444819448516e-05
a O 0 1.0216803275397979e-05
1422 O 0 0.0007160699460655451
G O 0 0.0016070379642769694
- O 0 0.0001421942433807999
- O 0 0.000519020133651793
> O 0 6.340641266433522e-05
C O 0 0.00012647711264435202
( O 0 6.829391168139409e-07
amino O 0 2.1488426682481077e-06
acid O 0 1.93073833543167e-06
W474C O 0 2.754466095211683e-06
) O 0 1.3002868115563615e-07
substitution O 0 2.0909678255520703e-07
in O 0 1.2904311574857275e-07
the O 0 1.6235473765391362e-07
first O 0 3.387224012385559e-07
position O 0 6.746564054083137e-07
of O 0 6.982910605302095e-08
exon O 0 3.5131624827045016e-06
13 O 0 1.0314390692656161e-06
of O 0 2.1247142001357133e-07
HEXA O 0 0.00013523473171517253
of O 0 1.6840012051488884e-07
a O 0 1.3886026408727048e-06
non O 0 1.6853023225849029e-06
- O 0 2.0714842321467586e-05
Jewish O 0 6.293118531175423e-06
proband O 0 0.000604793312959373
who O 0 7.864397957746405e-06
manifested O 0 7.530431503255386e-06
a O 0 4.325729150878033e-06
subacute O 0 0.013781831599771976
variant O 0 5.988478733343072e-05
of O 0 5.693326784239616e-06
G B-Disease 0 0.13066135346889496
( I-Disease 0 6.6879506448458415e-06
M2 I-Disease 0 0.006284045521169901
) I-Disease 0 6.556061180162942e-06
gangliosidosis I-Disease 0 0.00023537626839242876
. O 0 1.3262125321489293e-05

On O 0 4.8754969611763954e-05
the O 0 9.367716302222107e-06
second O 0 4.563943366520107e-05
maternally O 0 0.0010341000743210316
inherited O 0 0.005841439589858055
allele O 0 4.1549916204530746e-05
, O 0 1.5496358400923782e-06
we O 0 1.0603420150800957e-06
identified O 0 1.008490926324157e-06
the O 0 5.135159995006688e-07
common O 0 1.9169201550539583e-05
infantile O 1 0.9849799275398254
disease O 1 0.7865311503410339
- O 0 0.022972295060753822
causing O 0 0.00013856121222488582
4 O 0 1.1783362424466759e-05
- O 0 9.329099702881649e-05
bp O 0 6.696402124362066e-05
insertion O 0 8.3228542280267e-06
, O 0 1.792216494322929e-06
+ O 0 7.920010830275714e-06
TATC O 0 0.00013202814443502575
1278 O 0 8.313573925988749e-05
, O 0 8.238823738793144e-07
in O 0 1.8755218889054959e-06
exon O 0 4.6070159442024305e-05
11 O 0 2.32553302339511e-05
. O 0 1.5065840671013575e-05

Pulse O 0 0.00460224412381649
- O 0 0.0020435231272131205
chase O 0 0.0001379316090606153
analysis O 0 5.777013939223252e-06
using O 0 4.612580596585758e-06
proband O 0 0.00017822915106080472
fibroblasts O 0 1.4469575944531243e-05
revealed O 0 8.746562343731057e-06
that O 0 3.5345519222573785e-07
the O 0 4.073834816153976e-07
W474C O 0 5.8558293858368415e-06
- O 0 3.702808044181438e-06
containing O 0 9.510440008853038e-07
alpha O 0 1.1233233863094938e-06
- O 0 1.2661180335271638e-06
subunit O 0 1.168714447885577e-06
precursor O 0 2.2837969027023064e-06
was O 0 2.9767620617349166e-06
normally O 0 6.23507332875306e-07
synthesized O 0 1.652218884373724e-06
, O 0 2.3380417246698926e-07
but O 0 1.2137007843193715e-07
not O 0 9.154751978712738e-08
phosphorylated O 0 7.90808542205923e-07
or O 0 3.1058613103596144e-07
secreted O 0 1.1014735719072632e-06
, O 0 1.1039536929047244e-07
and O 0 1.5217064230910182e-07
the O 0 5.484405392053304e-07
mature O 0 1.3067576674075099e-06
lysosomal O 0 1.1083109711762518e-05
alpha O 0 2.0105969724681927e-06
- O 0 1.7899532167575671e-06
subunit O 0 4.176566562819062e-06
was O 0 8.429244189755991e-06
not O 0 1.994741069211159e-06
detected O 0 3.7405156035674736e-05
. O 0 1.1687061487464234e-05

When O 0 9.572686394676566e-05
the O 0 1.1719416761479806e-05
W474C O 0 6.0606478655245155e-05
- O 0 8.79318940860685e-06
containing O 0 3.1021661470731487e-06
alpha O 0 2.111846924890415e-06
- O 0 1.538946548862441e-06
subunit O 0 2.7013134058506694e-06
was O 0 8.887001968105324e-06
transiently O 0 1.9190383682143874e-05
co O 0 9.320648132415954e-06
- O 0 5.8466052905714605e-06
expressed O 0 2.4063635351012636e-07
with O 0 1.3181711722154432e-07
the O 0 2.119684694434909e-07
beta O 0 3.7587807355521363e-07
- O 0 8.176236292456451e-07
subunit O 0 3.812529882907256e-07
to O 0 3.039883438304969e-07
produce O 0 5.982274728921766e-07
Hex O 0 7.052592536638258e-06
A O 0 2.003056124522118e-06
( O 0 3.204922620625439e-07
alphabeta O 0 1.1088249266322237e-05
) O 0 1.5313497669922072e-07
in O 0 5.147697947904817e-07
COS O 0 0.024498017504811287
- O 0 5.524694643099792e-05
7 O 0 1.2136168152210303e-05
cells O 0 1.2360034133962472e-06
, O 0 6.47752926852263e-08
the O 0 1.178530837364633e-07
mature O 0 2.1786503623388853e-07
alpha O 0 3.820427707523777e-07
- O 0 4.2607027239682793e-07
subunit O 0 5.942324037278013e-07
was O 0 1.4490802868749597e-06
present O 0 1.8145276214909245e-07
, O 0 1.1343530559315695e-07
but O 0 5.873094011121793e-08
its O 0 5.192803342879415e-08
level O 0 3.1922331800160464e-07
was O 0 1.571820462231699e-06
much O 0 1.0486208879001424e-07
lower O 0 4.4492887241176504e-07
than O 0 5.680250581008295e-08
that O 0 5.09709821017168e-08
from O 0 1.2738824750613276e-07
normal O 0 5.461606633616611e-07
alpha O 0 7.126029117898725e-07
- O 0 1.0400334531368571e-06
subunit O 0 1.5036870308904327e-06
transfections O 0 1.0497197763470467e-05
, O 0 2.8057948497917096e-07
although O 0 1.3862378978046763e-07
higher O 0 2.5300133188466134e-07
than O 0 1.0465888067301421e-07
in O 0 1.392534301203341e-07
those O 0 2.3641945290364674e-07
cells O 0 1.4649513104814105e-06
transfected O 0 7.042041033855639e-06
with O 0 1.216964591321812e-07
an O 0 2.5528589731038664e-07
alpha O 0 1.7883954797071056e-06
- O 0 3.6352403185446747e-06
subunit O 0 3.402405582164647e-06
associated O 0 5.336521098797675e-06
with O 0 1.3710769053432159e-05
infantile O 0 0.4624815583229065
TSD B-Disease 0 0.29025542736053467
. O 0 6.443016172852367e-05

Furthermore O 0 0.00019453860295470804
, O 0 4.948235527990619e-06
the O 0 9.256179964722833e-07
precursor O 0 2.6890838853432797e-06
level O 0 7.999625495358487e-07
of O 0 1.5570353184557462e-07
the O 0 3.9136943996709306e-07
W474C O 0 4.36209347753902e-06
alpha O 0 9.588843568053562e-07
- O 0 8.585570299146639e-07
subunit O 0 1.1258877066211426e-06
was O 0 2.1106509393575834e-06
found O 0 4.142552825214807e-07
to O 0 4.92079607283813e-07
accumulate O 0 8.295231054944452e-06
in O 0 1.2974452090475097e-07
comparison O 0 4.077239452726644e-07
to O 0 1.3114514274548128e-07
the O 0 2.7184685791326046e-07
normal O 0 1.0303114095222554e-06
alpha O 0 1.5968668094501481e-06
- O 0 3.529085461195791e-06
subunit O 0 8.671571777085774e-06
precursor O 0 1.4824634490651079e-05
levels O 0 1.271224482479738e-05
. O 0 1.2240629075677134e-05

We O 0 8.19861379568465e-05
conclude O 0 2.8149763238616288e-05
that O 0 1.0997795243383734e-06
the O 0 2.2610181531490525e-06
1422 O 0 0.0003576950402930379
G O 0 0.0006190328276716173
- O 0 8.291009726235643e-05
- O 0 0.00040782149881124496
> O 0 4.010677366750315e-05
C O 0 0.00015417083341162652
mutation O 0 7.397481567750219e-06
is O 0 1.912282101557139e-07
the O 0 1.9640314974367357e-07
cause O 0 5.618481395686103e-07
of O 0 2.681800310710969e-07
Hex B-Disease 0 0.0030390426982194185
A I-Disease 0 0.4204385280609131
enzyme I-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9998874664306641
in O 0 2.2650260689260904e-06
the O 0 4.823024482902838e-06
proband O 0 0.001907241647131741
. O 0 1.0380355888628401e-05

The O 0 6.733748159604147e-05
resulting O 0 7.289936911547557e-05
W474C O 0 9.399070404469967e-05
substitution O 0 1.250611967407167e-05
clearly O 0 7.155774255807046e-06
interferes O 0 6.304098405962577e-06
with O 0 3.6976700812374474e-07
alpha O 0 1.6061667338362895e-06
- O 0 1.5191095599220716e-06
subunit O 0 1.33566857130063e-06
processing O 0 1.3908436358178733e-06
, O 0 2.3345504018834617e-07
but O 0 1.5954557852637663e-07
because O 0 7.368618071268429e-08
the O 0 8.302191645270796e-08
base O 0 9.62738340604119e-07
substitution O 0 3.9053389855325804e-07
falls O 0 6.119240424595773e-06
at O 0 7.845339382583916e-07
the O 0 9.31258483660713e-08
first O 0 1.612600755152016e-07
position O 0 6.765848183931666e-07
of O 0 1.0702070341039871e-07
exon O 0 6.687019322271226e-06
13 O 0 1.4447597322941874e-06
, O 0 3.597636464292009e-07
aberrant O 0 5.099736881675199e-06
splicing O 0 2.261456575070042e-05
may O 0 1.014847839542199e-05
also O 0 4.365500103631348e-07
contribute O 0 4.920416358800139e-07
to O 0 7.692526651226217e-07
Hex B-Disease 0 0.0015407437458634377
A I-Disease 0 0.010628470219671726
deficiency I-Disease 0 0.09973879158496857
in O 0 5.116257284498715e-07
this O 0 6.912965204719512e-07
proband O 0 0.0001599200040800497
. O 0 2.0834208953601774e-06
. O 0 6.0236120589252096e-06

Two O 0 0.00012167233944637701
frequent O 0 0.0003222287632524967
missense O 0 0.004455357789993286
mutations O 0 0.007515103090554476
in O 0 0.006751465145498514
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0005225366912782192

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.4956643879413605
an O 1 0.9802489876747131
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.6425685286521912
by O 0 1.9082746803178452e-05
early O 0 0.011030708439648151
childhood O 1 0.9999856948852539
deafness B-Disease 1 1.0
and O 1 0.9887009859085083
goiter B-Disease 1 1.0
. O 0 0.0006082924082875252

A O 0 0.00015122034528758377
century O 0 3.370120612089522e-05
after O 0 9.883213351713493e-06
its O 0 7.201521157185198e-07
recognition O 0 1.4199741826814716e-06
as O 0 1.1178549357282463e-06
a O 0 0.0005034380592405796
syndrome O 1 0.9998155236244202
by O 0 1.2236147313160473e-06
Vaughan O 0 0.0004806828801520169
Pendred O 0 0.0003775749064516276
, O 0 1.3382531278693932e-06
the O 0 4.985323357686866e-06
disease O 0 0.0070306784473359585
gene O 0 9.632760338718072e-06
( O 0 8.549431527171691e-07
PDS O 0 0.00038407015381380916
) O 0 7.787843401274586e-07
was O 0 7.412029390252428e-06
mapped O 0 1.4122699212748557e-05
to O 0 3.2521954835829092e-06
chromosome O 0 0.0008967965259216726
7q22 O 0 0.0004880778433289379
- O 0 0.0006834710948169231
q31 O 0 0.0005931809428147972
. O 0 1.9667993910843506e-05

1 O 0 9.845533350016922e-05
and O 0 1.3751417100138497e-05
, O 0 2.8822455533372704e-06
recently O 0 5.568298547586892e-06
, O 0 3.6847296769337845e-07
found O 0 4.4010943156536086e-07
to O 0 2.9177792271184444e-07
encode O 0 3.510797796479892e-06
a O 0 8.601849913247861e-06
putative O 0 0.00032073433976620436
sulfate O 0 0.0004821076581720263
transporter O 0 0.0019255280494689941
. O 0 4.409140456118621e-05

We O 0 9.153736027656123e-05
performed O 0 5.382597373682074e-05
mutation O 0 9.964242053683847e-06
analysis O 0 9.899681572278496e-07
of O 0 2.6835454036699957e-07
the O 0 1.1414516620789072e-06
PDS B-Disease 0 0.0008704557549208403
gene O 0 4.241010628902586e-06
in O 0 2.059447069768794e-06
patients O 0 1.9485854863887653e-05
from O 0 8.170320029421418e-07
14 O 0 6.17435443928116e-06
Pendred B-Disease 0 4.712904410553165e-05
families O 0 7.68013080687524e-07
originating O 0 5.050588356425578e-07
from O 0 2.730144501583709e-07
seven O 0 7.053797048683919e-07
countries O 0 1.2873508126176603e-07
and O 0 1.2228787227286375e-06
identified O 0 3.5090704386675498e-06
all O 0 6.891375505801989e-07
mutations O 0 2.5244718926842324e-05
. O 0 7.826321962056682e-06

The O 0 4.7677644033683464e-05
mutations O 0 5.7372824812773615e-05
include O 0 2.3253542167367414e-06
three O 0 1.7991865206568036e-06
single O 0 9.109444363275543e-06
base O 0 8.823883035802282e-06
deletions O 0 9.838252481131349e-06
, O 0 8.91926617896388e-07
one O 0 8.005028462321206e-07
splice O 0 0.00026692819665186107
site O 0 2.9674696634174325e-05
mutation O 0 1.602745942363981e-05
and O 0 1.7596012185094878e-06
10 O 0 6.781961474189302e-06
missense O 0 0.00013688291073776782
mutations O 0 0.0001088325516320765
. O 0 2.8808282877434976e-05

One O 0 0.0001112135942094028
missense O 0 0.0004333601682446897
mutation O 0 8.991808135760948e-05
( O 0 4.0392214941675775e-06
L236P O 0 0.00011417593486839905
) O 0 1.5823861758690327e-06
was O 0 2.4897515686461702e-05
found O 0 1.8165567325922893e-06
in O 0 4.0882545704334916e-07
a O 0 3.454627858445747e-06
homozygous O 0 0.00015457636618521065
state O 0 2.0482831075696595e-07
in O 0 2.723243142099818e-07
two O 0 7.692922849855677e-07
consanguineous O 0 0.0035849015694111586
families O 0 5.714279723179061e-06
and O 0 6.172678581606306e-07
in O 0 3.4057063658110565e-07
a O 0 1.8392707943348796e-06
heterozygous O 0 1.704151145531796e-05
state O 0 3.0247272775341116e-07
in O 0 2.779489705062588e-07
five O 0 4.2048876025546633e-07
additional O 0 8.891927336662775e-07
non O 0 4.234043444739655e-06
- O 0 0.00043206766713410616
consanguineous O 0 0.005021707154810429
families O 0 3.4149776183767244e-05
. O 0 1.531556154077407e-05

Another O 0 0.00025499911862425506
missense O 0 0.0006795410299673676
mutation O 0 0.00019747515034396201
( O 0 5.066448011348257e-06
T416P O 0 0.00010641424887580797
) O 0 1.5330755331888213e-06
was O 0 1.180358503916068e-05
found O 0 1.5069484788909904e-06
in O 0 2.532311498271156e-07
a O 0 1.9912683910661144e-06
homozygous O 0 2.3498147129430436e-05
state O 0 1.1996041848760797e-07
in O 0 1.9104756177057425e-07
one O 0 5.76564730181417e-07
family O 0 2.7821863568533445e-06
and O 0 5.971501764179266e-07
in O 0 2.3690650152730086e-07
a O 0 1.6214197557928856e-06
heterozygous O 0 2.1214869775576517e-05
state O 0 2.463541193264973e-07
in O 0 3.5623961025521567e-07
four O 0 2.440671551084961e-06
families O 0 7.393814485112671e-06
. O 0 7.907899089332204e-06

Pendred B-Disease 1 0.8917288184165955
patients O 1 0.6619640588760376
in O 0 1.4333772014651913e-05
three O 0 5.3004041546955705e-06
non O 0 9.092189429793507e-06
- O 0 0.000273994286544621
consanguineous O 0 0.0024501183070242405
families O 0 1.1244198503845837e-05
were O 0 4.537096174317412e-06
shown O 0 1.0464356137163122e-06
to O 0 3.8575811345253896e-07
be O 0 7.936871497804532e-07
compound O 0 8.461355719191488e-06
heterozygotes O 0 9.205596143146977e-06
for O 0 5.862372063347721e-07
L236P O 0 5.282875645207241e-05
and O 0 5.27968950336799e-06
T416P O 0 0.00011842333333333954
. O 0 8.103321306407452e-06

In O 0 3.973176353611052e-05
total O 0 1.2006887118332088e-05
, O 0 8.491714424962993e-07
one O 0 2.4072124915619497e-07
or O 0 2.842612332187855e-07
both O 0 4.8914923667098265e-08
of O 0 4.765548311524981e-08
these O 0 1.7334502899757354e-07
mutations O 0 3.2895206913963193e-06
were O 0 2.2190124582266435e-06
found O 0 9.337019264421542e-07
in O 0 2.501195979220938e-07
nine O 0 5.374517968448345e-07
of O 0 1.04887099894313e-07
the O 0 8.770031172389281e-07
14 O 0 5.878282536286861e-06
families O 0 2.52904146691435e-06
analyzed O 0 1.9422255718382075e-05
. O 0 9.215925274475012e-06

The O 0 2.086291897285264e-05
identification O 0 1.1479097338451538e-05
of O 0 1.3865277423974476e-06
two O 0 1.7321526684099808e-06
frequent O 0 3.471497257123701e-05
PDS B-Disease 0 0.38272976875305176
mutations O 0 5.443581540021114e-05
will O 0 1.0205556009168504e-06
facilitate O 0 1.6967330793704605e-06
the O 0 1.3467182498061447e-06
molecular O 0 0.013441426679491997
diagnosis O 1 0.9960837364196777
of O 0 0.0022027704399079084
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.000304542452795431

Insertional O 0 0.005089893937110901
mutation O 0 0.0002336430043214932
by O 0 6.218301678018179e-06
transposable O 0 5.408519791672006e-05
element O 0 6.131800546427257e-06
, O 0 2.0682846297859214e-06
L1 O 0 0.003909138031303883
, O 0 1.5717349697297323e-06
in O 0 8.474417541037838e-07
the O 0 5.4702413763152435e-06
DMD B-Disease 1 0.9999971389770508
gene O 0 2.693986607482657e-05
results O 0 1.7107655366999097e-05
in O 0 6.762224074918777e-06
X B-Disease 1 0.9944925308227539
- I-Disease 1 0.9943236112594604
linked I-Disease 1 0.9118035435676575
dilated I-Disease 1 0.99918133020401
cardiomyopathy I-Disease 1 0.9999994039535522
. O 0 0.000143658893648535

X B-Disease 1 0.9965639710426331
- I-Disease 1 0.9985896944999695
linked I-Disease 1 0.9905843734741211
dilated I-Disease 1 0.9999831914901733
cardiomyopathy I-Disease 1 1.0
( O 0 0.00035005193785764277
XLDCM B-Disease 1 0.9116898775100708
) O 0 2.91256560558395e-06
is O 0 3.881538361838466e-07
a O 0 4.260240984876873e-06
clinical O 0 0.0005485775182023644
phenotype O 0 0.00019350704678799957
of O 0 7.486697768399608e-07
dystrophinopathy B-Disease 0 0.09297585487365723
which O 0 1.634657223803515e-06
is O 0 5.103635771774861e-07
characterized O 0 1.7905730373968254e-06
by O 0 5.624389700642496e-07
preferential O 0 0.0020770917180925608
myocardial B-Disease 1 0.9998458623886108
involvement I-Disease 0 4.1982864786405116e-05
without O 0 1.971768369912752e-06
any O 0 5.654744654748356e-07
overt O 0 3.0649014661321416e-05
clinical O 0 0.0054963878355920315
signs O 0 0.0007725080358795822
of O 0 0.0001346271892543882
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.001654720981605351

To O 0 2.5039575120899826e-05
date O 0 1.0164441846427508e-05
, O 0 5.936467459832784e-07
several O 0 3.4190261999356153e-07
mutations O 0 4.18252147937892e-06
in O 0 9.112294492297224e-07
the O 0 1.563252772029955e-05
Duchenne B-Disease 1 0.9995126724243164
muscular I-Disease 1 0.9980694651603699
dystrophy I-Disease 1 0.9995579123497009
gene O 0 0.0026633525267243385
, O 0 5.040640462539159e-05
DMD O 1 0.9999997615814209
, O 0 1.3279564882395789e-05
have O 0 6.580855369975325e-06
been O 0 1.3577813660958782e-05
identified O 0 5.948237230768427e-06
in O 0 2.2924402856006054e-06
patients O 0 5.214917837292887e-05
with O 0 4.850293407798745e-06
XLDCM B-Disease 1 0.5039286017417908
, O 0 9.549429478283855e-07
but O 0 2.773619200979738e-07
a O 0 4.0020600522439054e-07
pathogenic O 0 1.7677588175502024e-06
correlation O 0 1.128594703914132e-06
of O 0 1.4238860046589252e-07
these O 0 4.461925868781691e-07
cardiospecific O 0 0.0009181717177852988
mutations O 0 1.8622653442434967e-05
in O 0 1.1110244486189913e-05
DMD O 1 0.9999994039535522
with O 0 1.2929671356687322e-05
the O 0 1.7640773876337335e-05
XLDCM B-Disease 1 0.9080087542533875
phenotype O 0 0.001802012207917869
has O 0 4.910486950393533e-06
remained O 0 1.0505209502298385e-05
to O 0 1.1475420933493297e-06
be O 0 5.22316304341075e-06
elucidated O 0 0.00022894502035342157
. O 0 2.22018024942372e-05

We O 0 8.131808135658503e-05
report O 0 5.261242677079281e-06
here O 0 3.932239565074269e-07
the O 0 1.4195663311511453e-07
identification O 0 3.4188795439149544e-07
of O 0 6.918757122775787e-08
a O 0 6.678279760308214e-07
unique O 0 9.836553545028437e-07
de O 0 8.881182111508679e-06
novo O 0 5.9755966503871605e-06
L1 O 0 0.000108056039607618
insertion O 0 6.228943675523624e-06
in O 0 6.881491003696283e-07
the O 0 9.56735107138229e-07
muscle O 0 5.672477709595114e-05
exon O 0 2.606456291687209e-05
1 O 0 5.5421332945115864e-06
in O 0 8.993920346256346e-06
DMD O 1 0.9999986886978149
in O 0 1.3301097169460263e-05
three O 0 4.982512109563686e-05
XLDCM B-Disease 1 0.9941930174827576
patients O 0 6.189058331074193e-05
from O 0 8.184076705219923e-07
two O 0 1.2949891470270813e-06
unrelated O 0 8.629342119093053e-06
Japanese O 0 2.039404535025824e-05
families O 0 1.9492970750434324e-05
. O 0 1.5132365660974756e-05

The O 0 3.570048284018412e-05
insertion O 0 0.00010417496378067881
was O 0 3.3270054700551555e-05
a O 0 2.133173666152288e-06
5 O 0 2.0387251424835995e-06
- O 0 6.21002254774794e-06
truncated O 0 3.089382516918704e-06
form O 0 4.94154960506421e-07
of O 0 2.952846216430771e-07
human O 0 9.949467312253546e-07
L1 O 0 0.00017357013712171465
inversely O 0 1.1859030564664863e-05
integrated O 0 1.3405559911916498e-05
in O 0 4.855584165852633e-07
the O 0 6.277350621530786e-07
5 O 0 2.3168786356109194e-06
- O 0 1.5548375813523307e-05
untranslated O 0 3.987478339695372e-05
region O 0 1.7837436416812125e-06
in O 0 4.810800646737334e-07
the O 0 8.102116453301278e-07
muscle O 0 2.9151804483262822e-05
exon O 0 1.5135829016799107e-05
1 O 0 2.069910578939016e-06
, O 0 2.540545267493144e-07
which O 0 1.4116457691670803e-07
affected O 0 3.4101654478035925e-07
the O 0 8.805969997638385e-08
transcription O 0 1.042380858962133e-06
or O 0 3.2715269071559305e-07
the O 0 2.0750876217334735e-07
stability O 0 7.517921289945662e-07
of O 0 5.0853383726234824e-08
the O 0 5.219893637331552e-07
muscle O 0 1.2748715562338475e-05
form O 0 3.3385092024218466e-07
of O 0 1.5608769388109067e-07
dystrophin O 0 3.931940591428429e-05
transcripts O 0 1.0602960173855536e-05
but O 0 7.823679766261193e-07
not O 0 1.4220948685306212e-07
that O 0 5.752845311235433e-08
of O 0 8.382338023693592e-08
the O 0 1.7415211459592683e-06
brain O 0 0.034900132566690445
or O 0 4.884332156507298e-06
Purkinje O 0 0.00021829117031302303
cell O 0 7.567139255115762e-05
form O 0 2.8099902920075692e-06
, O 0 1.8396917766949628e-06
probably O 0 3.4977440463990206e-06
due O 0 5.849371405020065e-07
to O 0 2.941002890111122e-07
its O 0 2.623719410621561e-07
unique O 0 2.9310851346053823e-07
site O 0 1.2417963262123521e-06
of O 0 3.7876870351283287e-07
integration O 0 9.721818059915677e-06
. O 0 1.1437418834248092e-05

We O 0 5.630946179735474e-05
speculate O 0 9.67267533269478e-06
that O 0 5.013521331420634e-07
this O 0 1.535789948547972e-07
insertion O 0 1.4235075695978594e-06
of O 0 1.6858652429618814e-07
an O 0 1.042376766235975e-06
L1 O 0 0.011893674731254578
sequence O 0 8.257329682237469e-06
in O 0 2.3028898795018904e-05
DMD O 1 1.0
is O 0 4.684735813498264e-06
responsible O 0 2.451527961966349e-06
for O 0 6.18043003441926e-08
some O 0 4.502104289372255e-08
of O 0 5.4094130064186174e-08
the O 0 2.1335142719181022e-07
population O 0 1.6403089375671698e-07
of O 0 6.688376430474818e-08
Japanese O 0 7.745796210656408e-06
patients O 0 1.108013020711951e-05
with O 0 2.073494442811352e-06
XLDCM B-Disease 0 0.2256397157907486
. O 0 3.90743571188068e-06
. O 0 1.4099793588684406e-05

Severe O 1 0.9676548838615417
early O 0 0.0019783650059252977
- O 1 0.9977994561195374
onset O 1 0.9999921321868896
obesity B-Disease 1 1.0
, O 1 0.8213136792182922
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.009598331525921822
red O 0 0.22935988008975983
hair O 1 0.9992400407791138
pigmentation O 1 0.8392200469970703
caused O 0 0.0005326134851202369
by O 0 7.935320354590658e-06
POMC O 0 0.29018986225128174
mutations O 0 0.00010056006431113929
in O 0 7.132187874958618e-06
humans O 0 2.95923491648864e-05
. O 0 1.572880137246102e-05

Sequential O 0 0.0002929655893240124
cleavage O 0 0.000231508442084305
of O 0 2.6105860797542846e-06
the O 0 1.5703925555499154e-06
precursor O 0 4.800745500688208e-06
protein O 0 3.4663469250517664e-06
pre O 0 2.251602927572094e-05
- O 0 5.9082482039229944e-05
pro O 0 3.808581823250279e-05
- O 0 0.00034248665906488895
opiomelanocortin O 0 0.00028503977227956057
( O 0 1.0854355423361994e-06
POMC O 0 7.16849826858379e-05
) O 0 5.962681370874634e-07
generates O 0 1.6065175714174984e-06
the O 0 1.2739800467898021e-06
melanocortin O 0 7.945343531901017e-05
peptides O 0 1.0713220945035573e-05
adrenocorticotrophin O 0 0.00015943490143399686
( O 0 1.7632396520639304e-06
ACTH O 0 5.80556079512462e-05
) O 0 8.940888278630155e-07
, O 0 5.686575832442031e-07
melanocyte O 0 4.032814467791468e-05
- O 0 0.00010220644617220387
stimulating O 0 1.4934521459508687e-05
hormones O 0 8.89206330612069e-06
( O 0 5.800243343401235e-07
MSH O 0 1.4467022992903367e-05
) O 0 2.381219701419468e-07
alpha O 0 6.457507879531477e-07
, O 0 1.533421993826778e-07
beta O 0 2.78646183460296e-07
and O 0 1.355594747565192e-07
gamma O 0 8.35322509828984e-07
as O 0 1.1990415771379048e-07
well O 0 1.8135018819975812e-07
as O 0 1.232273092455216e-07
the O 0 3.132705614916631e-07
opioid O 0 4.7578919293300714e-06
- O 0 7.505823759856867e-06
receptor O 0 6.696330274280626e-06
ligand O 0 1.0783189281937666e-05
beta O 0 2.1904887034907006e-05
- O 0 0.000125238235341385
endorphin O 0 0.001056290348060429
. O 0 3.181377542205155e-05

While O 0 4.627847738447599e-05
a O 0 4.758626801049104e-06
few O 0 1.6647883285259013e-06
cases O 0 6.720582064190239e-07
of O 0 1.9231306396250147e-06
isolated O 1 0.7152338624000549
ACTH B-Disease 1 0.9999760389328003
deficiency I-Disease 1 0.998497486114502
have O 0 1.6384487025788985e-05
been O 0 2.4784045308479108e-05
reported O 0 3.0168966986821033e-05
( O 0 2.339434104214888e-06
OMIM O 0 0.004498070105910301
201400 O 0 9.478917490923777e-05
) O 0 4.4156575995657477e-07
, O 0 3.699137209878245e-07
an O 0 4.9682748795021325e-06
inherited O 1 0.9879597425460815
POMC O 1 0.9748530983924866
defect O 0 0.07388078421354294
has O 0 4.807851837540511e-06
not O 0 2.295822696396499e-06
been O 0 3.1054398732521804e-06
described O 0 5.304722435539588e-06
so O 0 1.4342741678774473e-06
far O 0 5.4346432989405e-06
. O 0 8.722606253286358e-06

Recent O 0 6.996404408710077e-05
studies O 0 2.0784536900464445e-05
in O 0 4.16018065152457e-06
animal O 0 3.943219326174585e-06
models O 0 3.1813028726901393e-06
elucidated O 0 1.1533687029441353e-05
a O 0 6.914970072102733e-07
central O 0 5.980061814625515e-07
role O 0 3.318137373753416e-07
of O 0 1.0121313920308239e-07
alpha O 0 1.6926197758948547e-06
- O 0 1.95405646081781e-05
MSH O 0 5.0762449973262846e-05
in O 0 3.2986798714773613e-07
the O 0 2.700417098822072e-07
regulation O 0 9.983646123146173e-07
of O 0 8.32224742453036e-08
food O 0 8.026034379327029e-07
intake O 0 1.745811346154369e-06
by O 0 1.209651827593916e-07
activation O 0 7.1131017875814e-07
of O 0 1.2114088576709037e-07
the O 0 7.973789593052061e-07
brain O 0 6.798670801799744e-05
melanocortin O 0 5.749819683842361e-05
- O 0 2.1229094272712246e-05
4 O 0 2.6289017114322633e-06
- O 0 1.7782096620067023e-05
receptor O 0 3.8072791994636646e-06
( O 0 6.590273642359534e-07
MC4 O 0 8.146656182361767e-05
- O 0 3.437982013565488e-05
R O 0 0.00010791673412313685
; O 0 8.66970879087603e-07
refs O 0 1.65732235473115e-05
3 O 0 1.750636329234112e-06
- O 0 1.545034501759801e-05
5 O 0 1.2212051387905376e-06
) O 0 1.2059267362474202e-07
and O 0 7.888383635190621e-08
the O 0 1.0011336826210027e-07
linkage O 0 2.8866495540569304e-06
of O 0 1.9369410608760518e-07
human O 0 2.1639989427058026e-06
obesity B-Disease 1 0.9935131669044495
to O 0 3.7277127376000863e-06
chromosome O 0 0.004209115635603666
2 O 0 3.568108468243736e-06
in O 0 6.174786335577664e-07
close O 0 3.310240117571084e-06
proximity O 0 2.3405855245073326e-06
to O 0 7.389390930256923e-07
the O 0 1.64301889071794e-06
POMC O 0 0.00036698885378427804
locus O 0 1.2836627320211846e-05
, O 0 4.236953827785328e-07
led O 0 3.091284384026949e-07
to O 0 1.196278560655628e-07
the O 0 1.1567812663315635e-07
proposal O 0 1.674174114896232e-07
of O 0 4.238703610326411e-08
an O 0 3.1157225066635874e-07
association O 0 8.156890203281364e-07
of O 0 2.3110473534870835e-07
POMC O 0 0.001284678583033383
with O 0 3.7358340705395676e-06
human O 0 2.3296661311178468e-05
obesity B-Disease 1 0.9996092915534973
. O 0 3.882029341184534e-05

The O 0 1.7778567780624144e-05
dual O 0 2.965014209621586e-05
role O 0 4.49817434855504e-06
of O 0 6.601741233680514e-07
alpha O 0 6.528583980980329e-06
- O 0 6.323167326627299e-05
MSH O 0 7.34926579752937e-05
in O 0 6.533514920192829e-07
regulating O 0 3.5440909869066672e-06
food O 0 1.2573605090437923e-06
intake O 0 4.984401130059268e-06
and O 0 2.014062829402974e-06
influencing O 0 2.618197504489217e-05
hair O 1 0.5881893038749695
pigmentation O 0 0.007943005301058292
predicts O 0 4.559397712000646e-05
that O 0 4.6584850110775733e-07
the O 0 1.1439210538810585e-06
phenotype O 0 0.0012283559190109372
associated O 0 1.841881044128968e-06
with O 0 1.361373278996325e-06
a O 0 9.975513239623979e-05
defect O 0 0.03761769458651543
in O 0 9.63897218753118e-06
POMC O 0 0.012800903059542179
function O 0 2.9316013296920573e-06
would O 0 2.469791979820002e-06
include O 0 3.937511337426258e-06
obesity B-Disease 1 0.9999257326126099
, O 0 3.8285138543869834e-06
alteration O 0 3.474203185760416e-05
in O 0 2.177969872718677e-05
pigmentation O 1 0.8675644397735596
and O 0 0.2328827679157257
ACTH B-Disease 1 0.9999940395355225
deficiency I-Disease 1 0.9939796924591064
. O 0 4.2549563659122214e-05

The O 0 1.7549056792631745e-05
observation O 0 3.240387377445586e-05
of O 0 1.6839817362779286e-06
these O 0 3.1206104722514283e-06
symptoms O 0 0.0072286357171833515
in O 0 1.212056417898566e-06
two O 0 1.8575806279841345e-06
probands O 0 0.0003540913457982242
prompted O 0 3.7780216644023312e-06
us O 0 5.186736302675854e-07
to O 0 3.044586378564418e-07
search O 0 9.201998523167276e-07
for O 0 3.6601332453756186e-07
mutations O 0 3.581202690838836e-06
within O 0 7.292653094737034e-07
their O 0 7.877894859120715e-06
POMC O 0 0.002318968763574958
genes O 0 2.9074066333123483e-05
. O 0 1.5706495105405338e-05

Patient O 1 0.588884174823761
1 O 0 0.00013269353075884283
was O 0 0.00010759776341728866
found O 0 3.5407160794420633e-06
to O 0 9.874779607343953e-07
be O 0 4.7642168965467135e-07
a O 0 7.462874123120855e-07
compound O 0 2.6867312044487335e-05
heterozygote O 0 8.056102160480805e-06
for O 0 1.9318567012760468e-07
two O 0 5.764311481470941e-07
mutations O 0 4.338917733548442e-06
in O 0 6.796450406909571e-07
exon O 0 1.096606229111785e-05
3 O 0 3.8860821405251045e-06
( O 0 4.8967666543831e-07
G7013T O 0 1.395505023538135e-05
, O 0 6.370078153850045e-07
C7133delta O 0 2.1115420167916454e-05
) O 0 1.6864474616795633e-07
which O 0 1.1976278813108365e-07
interfere O 0 3.556191074949311e-07
with O 0 8.185022437601219e-08
appropriate O 0 2.4665973796800245e-07
synthesis O 0 9.777779723663116e-07
of O 0 4.761868410696479e-07
ACTH O 0 5.5164709920063615e-05
and O 0 1.5085358882060973e-06
alpha O 0 2.3617396436748095e-05
- O 0 0.0002885888097807765
MSH O 0 0.0016752819065004587
. O 0 2.3130098270485178e-05

Patient O 1 0.6644916534423828
2 O 0 0.00022179819643497467
was O 0 9.910263906931505e-05
homozygous O 0 3.12215561280027e-05
for O 0 5.667426421496202e-07
a O 0 1.8196326436736854e-06
mutation O 0 6.688926532660844e-06
in O 0 1.2310684951444273e-06
exon O 0 2.9948643714305945e-05
2 O 0 4.698534212366212e-06
( O 0 1.3341510793907219e-06
C3804A O 0 3.6950885260012e-05
) O 0 9.907446383294882e-07
which O 0 1.4661001159765874e-06
abolishes O 0 0.00031610310543328524
POMC O 0 0.0008875765488483012
translation O 0 2.2819835066911764e-05
. O 0 2.743540426308755e-05

These O 0 1.6082945876405574e-05
findings O 0 5.05175239595701e-06
represent O 0 9.041950761456974e-07
the O 0 1.8617255648223363e-07
first O 0 2.993941734530381e-07
examples O 0 1.9706958198639768e-07
of O 0 2.603308928428305e-07
a O 0 0.002258959459140897
genetic B-Disease 1 0.9999983310699463
defect I-Disease 1 0.9999357461929321
within O 0 1.544224460303667e-06
the O 0 1.6271836784653715e-06
POMC O 0 0.01214178092777729
gene O 0 4.299095962778665e-06
and O 0 9.456202860746998e-07
define O 0 3.12059842144663e-06
a O 0 3.0046589927223977e-06
new O 0 3.572118657757528e-05
monogenic B-Disease 1 0.9906641244888306
endocrine I-Disease 1 0.998917818069458
disorder I-Disease 1 0.6880718469619751
resulting O 0 9.579078323440626e-06
in O 0 1.7224340354005108e-06
early O 0 4.848211392527446e-05
- O 1 0.9977586269378662
onset O 1 0.9999803304672241
obesity B-Disease 1 1.0
, O 0 0.3510662615299225
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.0009650554857216775
red O 0 0.02245134860277176
hair O 1 0.9875358939170837
pigmentation O 0 0.0684799775481224
. O 0 9.883317034109496e-06
. O 0 2.5940204068319872e-05

A O 0 0.00017691745597403497
European O 0 4.223802898195572e-05
multicenter O 0 0.0012231809087097645
study O 0 1.986452298297081e-05
of O 0 5.932298518018797e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 0.9999995231628418
deficiency I-Disease 1 1.0
: O 0 1.6583169326622738e-06
classification O 0 3.663007191789802e-06
of O 0 2.46256433911185e-07
105 O 0 1.129351403506007e-05
mutations O 0 1.034411798173096e-05
and O 0 7.084775575094682e-07
a O 0 6.807542831666069e-07
general O 0 4.1141271367450827e-07
system O 0 9.87654061646026e-07
for O 0 2.9685136837542814e-07
genotype O 0 0.00014986185124143958
- O 0 9.702108218334615e-05
based O 0 1.7478088238931377e-06
prediction O 0 1.0557615496509243e-05
of O 0 1.2715852335531963e-06
metabolic O 1 0.6757223010063171
phenotype O 0 0.011371118016541004
. O 0 3.399666820769198e-05

Phenylketonuria B-Disease 1 0.9994868040084839
( O 0 0.0008835280896164477
PKU B-Disease 1 0.830254077911377
) O 0 2.3772046915837564e-05
and O 0 7.806002395227551e-05
mild B-Disease 1 0.9819955825805664
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.014290192164480686
MHP B-Disease 1 0.9999998807907104
) O 0 6.678498721157666e-06
are O 0 2.2617214199271984e-06
allelic B-Disease 0 0.12625843286514282
disorders I-Disease 1 0.9999042749404907
caused O 0 0.0004075432079844177
by O 0 1.4497852589556715e-06
mutations O 0 1.4325763913802803e-05
in O 0 5.407070489127364e-07
the O 0 1.1989652648480842e-06
gene O 0 7.767648639855906e-06
encoding O 0 3.578948599169962e-05
phenylalanine O 0 0.011928783729672432
hydroxylase O 0 0.00577964074909687
( O 0 1.8975497368955985e-05
PAH O 0 0.09937547892332077
) O 0 8.675169738125987e-06
. O 0 1.2966381291334983e-05

Previous O 0 0.00011926556908292696
studies O 0 1.2238656381668989e-05
have O 0 2.708582769628265e-06
suggested O 0 1.8666266896616435e-06
that O 0 2.256984572568399e-07
the O 0 3.679332678530045e-07
highly O 0 3.4587485515658045e-06
variable O 0 4.5721197238890454e-05
metabolic O 0 0.15454019606113434
phenotypes O 0 0.0020238696597516537
of O 0 0.00031420448794960976
PAH B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9979720711708069
correlate O 0 0.0011046258732676506
with O 0 0.001098628039471805
PAH O 1 0.999413013458252
genotypes O 0 0.0034999875351786613
. O 0 8.139690180541947e-05

We O 0 0.0001317761925747618
identified O 0 2.480433431628626e-05
both O 0 3.6018527680425905e-06
causative O 0 9.454137762077153e-05
mutations O 0 4.057143451063894e-05
in O 0 4.837294909521006e-06
686 O 0 0.001167177688330412
patients O 0 0.00010946098336717114
from O 0 1.3513742942450335e-06
seven O 0 3.3245846680074465e-06
European O 0 5.9224262258794624e-06
centers O 0 2.358491656195838e-05
. O 0 1.1220504347875249e-05

On O 0 2.2700216504745185e-05
the O 0 1.646318992243323e-06
basis O 0 5.335501782610663e-07
of O 0 1.8452814742886403e-07
the O 0 4.5464071263268124e-07
phenotypic O 0 2.989219638038776e-06
characteristics O 0 2.0729924017359735e-06
of O 0 8.346966069439077e-07
297 O 0 0.00011726927186828107
functionally O 0 0.001192706055007875
hemizygous O 0 0.017949458211660385
patients O 0 9.679680806584656e-05
, O 0 3.117357323390024e-07
105 O 0 5.841639563186618e-07
of O 0 7.714972838357426e-08
the O 0 7.071531626934302e-07
mutations O 0 7.872322385082953e-06
were O 0 1.337289859293378e-06
assigned O 0 1.4421992773350212e-06
to O 0 1.5443289669292426e-07
one O 0 1.1505332508932042e-07
of O 0 9.711874326967518e-08
four O 0 9.482355949330667e-07
arbitrary O 0 9.019231583806686e-06
phenotype O 0 0.0002466642763465643
categories O 0 1.5367349988082424e-05
. O 0 1.0414257303636987e-05

We O 0 4.101768718101084e-05
proposed O 0 5.993300419504521e-06
and O 0 2.442469167363015e-06
tested O 0 1.290637555939611e-05
a O 0 5.908678417654301e-07
simple O 0 7.427599939546781e-07
model O 0 9.746927389642224e-07
for O 0 1.1505639463393891e-07
correlation O 0 1.72458567249123e-06
between O 0 5.781113827652007e-07
genotype O 0 5.0850001571234316e-05
and O 0 1.8423131677991478e-06
phenotypic O 0 3.200292485416867e-05
outcome O 0 3.7751906347693875e-05
. O 0 2.2988260752754286e-05

The O 0 4.913776501780376e-05
observed O 0 6.745637801941484e-05
phenotype O 0 0.0005254686111584306
matched O 0 6.060543819330633e-05
the O 0 3.4999934541701805e-06
predicted O 0 2.602211679914035e-05
phenotype O 0 5.865163620910607e-05
in O 0 1.1124504908366362e-06
79 O 0 1.1704315511451568e-05
% O 0 3.1334826644524583e-07
of O 0 6.887381687192828e-08
the O 0 4.870777843279939e-07
cases O 0 2.26863122065879e-07
, O 0 3.0896012503944803e-07
and O 0 3.8820380154902523e-07
in O 0 1.6574837502503215e-07
only O 0 1.2354620082533074e-07
5 O 0 2.7719875106413383e-07
of O 0 1.1934935173485428e-07
184 O 0 9.86251779977465e-06
patients O 0 1.1554726370377466e-05
was O 0 5.94948505749926e-06
the O 0 2.941675916190434e-07
observed O 0 1.4132892829366028e-06
phenotype O 0 2.8769043183274334e-06
more O 0 6.205092972777493e-08
than O 0 6.465938895416912e-08
one O 0 1.810477670005639e-07
category O 0 6.91882235059893e-07
away O 0 6.097344567024265e-07
from O 0 1.9519315230809298e-07
that O 0 4.952650556333538e-07
expected O 0 3.544905439412105e-06
. O 0 6.882797606522217e-06

Among O 0 4.444424121174961e-05
the O 0 7.924325473140925e-06
seven O 0 5.335966761776945e-06
contributing O 0 4.6623927119071595e-06
centers O 0 2.109354909407557e-06
, O 0 2.6550142706582847e-07
the O 0 2.2042013370082714e-07
proportion O 0 8.937990969570819e-07
of O 0 3.023060628493113e-07
patients O 0 1.0793949513754342e-05
for O 0 2.6359106186646386e-07
whom O 0 1.5157493180595338e-06
the O 0 3.138237616440165e-07
observed O 0 3.2151797313417774e-06
phenotype O 0 2.6589250410324894e-05
did O 0 1.967797288671136e-06
not O 0 2.1838424402176315e-07
match O 0 1.748615659380448e-06
the O 0 6.747703196197108e-07
predicted O 0 1.737649472488556e-05
phenotype O 0 3.9369046135107055e-05
was O 0 7.454945716744987e-06
4 O 0 1.7263611198359285e-06
% O 0 9.55228983912093e-07
- O 0 2.545503775763791e-05
23 O 0 5.463859906740254e-06
% O 0 7.836598001631501e-07
( O 0 5.141790779816802e-07
P O 0 0.00043634040048345923
< O 0 9.94392939901445e-06
. O 0 2.801155858378479e-07
0001 O 0 2.410051820334047e-05
) O 0 2.660229938555858e-07
, O 0 1.3765682638222643e-07
suggesting O 0 9.214047054229013e-07
that O 0 1.2089331846709683e-07
differences O 0 3.98194742956548e-07
in O 0 2.3985549546523544e-07
methods O 0 1.6784694025773206e-06
used O 0 2.1664191081072204e-06
for O 0 4.6355816607501765e-07
mutation O 0 1.983321453735698e-05
detection O 0 5.3696890972787514e-05
or O 0 3.584430305636488e-05
phenotype O 0 0.06408850103616714
classification O 0 0.00036588116199709475
may O 0 1.3637379197461996e-05
account O 0 8.839286920192535e-07
for O 0 1.771541349171457e-07
a O 0 5.516966439245152e-07
considerable O 0 1.0751025456556818e-06
proportion O 0 3.2427988116978668e-06
of O 0 9.006476489048509e-07
genotype O 0 0.0306546688079834
- O 0 0.08373488485813141
phenotype O 0 0.005259309895336628
inconsistencies O 0 0.00020430577569641173
. O 0 5.256688018562272e-05

Our O 0 9.177124593406916e-05
data O 0 3.0056280593271367e-05
indicate O 0 1.328364396613324e-05
that O 0 1.2800254580724868e-06
the O 0 4.519226422416978e-06
PAH O 0 0.36748671531677246
- O 0 0.00015551334945484996
mutation O 0 2.212946674262639e-05
genotype O 0 5.660940587404184e-05
is O 0 2.5181003593388596e-07
the O 0 3.233159588944545e-07
main O 0 1.4259750287237694e-06
determinant O 0 3.879594260070007e-06
of O 0 5.832982310494117e-07
metabolic O 0 0.35642609000205994
phenotype O 0 0.0026255508419126272
in O 0 2.2638791961071547e-06
most O 0 5.463192792376503e-06
patients O 0 0.05509340763092041
with O 1 0.7107575535774231
PAH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9847155809402466
. O 0 3.151573400828056e-05

In O 0 2.3191014406620525e-05
the O 0 3.4804479582817294e-06
present O 0 2.1277853647916345e-06
study O 0 1.0973362805088982e-06
, O 0 2.866711383830989e-07
the O 0 2.043228164438915e-07
classification O 0 2.1413918602775084e-06
of O 0 3.470013894002477e-07
105 O 0 0.0004881813656538725
PAH O 1 0.9643300771713257
mutations O 0 4.265454117557965e-05
may O 0 2.6303537197236437e-06
allow O 0 2.142792112636016e-07
the O 0 2.823688305397809e-07
prediction O 0 3.903159722540295e-06
of O 0 8.387856098579505e-08
the O 0 6.641467393819767e-07
biochemical O 0 9.273646719520912e-05
phenotype O 0 4.442898716661148e-05
in O 0 1.0758440112113021e-06
> O 0 1.3854364624421578e-05
10 O 0 1.1584190815483453e-06
, O 0 3.828247372439364e-07
000 O 0 7.793327085892088e-07
genotypes O 0 5.856532879988663e-06
, O 0 4.5144611249270383e-07
which O 0 7.164269959503144e-07
may O 0 3.0577609777537873e-06
be O 0 1.316065834089386e-07
useful O 0 1.0967153230012627e-07
for O 0 7.311888339245343e-08
the O 0 3.781046302719915e-07
management O 0 4.5363176468526945e-06
of O 0 6.959706979614566e-07
hyperphenylalaninemia B-Disease 1 0.9997225403785706
in O 0 4.819953392143361e-05
newborns O 0 0.2838842272758484
. O 0 3.9652575651416555e-05

Somatic O 0 0.0018200167687609792
instability O 0 0.00041429890552535653
of O 0 7.286310847121058e-06
the O 0 6.9880652517895214e-06
CTG O 0 0.001391833764500916
repeat O 0 2.093256807711441e-05
in O 0 1.905563976833946e-06
mice O 0 0.00018009582709055394
transgenic O 0 4.869240456173429e-06
for O 0 6.334946647257311e-07
the O 0 4.086070111952722e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.00028775306418538094
is O 0 4.983602593711112e-06
age O 0 6.696713171550073e-06
dependent O 0 1.7313071793978452e-06
but O 0 4.320034179272625e-07
not O 0 1.8707650895066763e-07
correlated O 0 8.264540269919962e-07
to O 0 1.0380837522916408e-07
the O 0 2.3828597761621495e-07
relative O 0 3.360522441653302e-06
intertissue O 0 4.575556886265986e-05
transcription O 0 7.4514482548693195e-06
levels O 0 4.29507144872332e-06
and O 0 3.84861095881206e-06
proliferative O 0 0.005708320531994104
capacities O 0 0.0003058471193071455
. O 0 4.3974840082228184e-05

A O 0 0.0003289349842816591
( O 0 3.321356052765623e-05
CTG O 0 0.00042572643724270165
) O 0 2.8793913315894315e-06
nexpansion O 0 1.7415313777746633e-05
in O 0 3.940318151762767e-07
the O 0 7.615576578245964e-07
3 O 0 3.9418882806785405e-06
- O 0 6.705079431412742e-05
untranslated O 0 0.00011102054850198328
region O 0 3.7139873256819556e-06
( O 0 7.161906410146912e-07
UTR O 0 1.5765082935104147e-05
) O 0 3.443046523443627e-07
of O 0 1.587799403068857e-07
the O 0 3.689463028422324e-06
DM O 1 0.9999936819076538
protein O 0 2.5529552658554167e-05
kinase O 0 0.0001553528563817963
gene O 0 1.6619915186311118e-05
( O 0 1.3573701380664716e-06
DMPK O 0 0.0002634441771078855
) O 0 4.949779963681067e-07
is O 0 2.812942909713456e-07
responsible O 0 4.42390364696621e-06
for O 0 4.7703319978609215e-06
causing O 1 0.7137045860290527
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.007347050588577986
DM B-Disease 1 0.9999998807907104
) O 0 2.989898894156795e-05
. O 0 1.8271070075570606e-05

Major O 0 0.00037623505340889096
instability O 0 0.00033714817254804075
, O 0 6.904723250045208e-06
with O 0 9.490932484368386e-07
very O 0 5.258236228655733e-07
large O 0 2.772291907149338e-07
expansions O 0 8.366874340026698e-07
between O 0 1.9600852851908712e-07
generations O 0 4.517635261436226e-07
and O 0 3.8998976492621296e-07
high O 0 4.493792403081898e-06
levels O 0 4.942557438880613e-07
of O 0 1.1459460580454106e-07
somatic O 0 1.6089712516986765e-05
mosaicism O 0 0.00018725260451901704
, O 0 1.0148023648071103e-06
is O 0 4.481841813230858e-07
observed O 0 3.449028554314282e-06
in O 0 7.512699085054919e-06
patients O 0 0.00013086972467135638
. O 0 1.94241656572558e-05

There O 0 4.344977787695825e-05
is O 0 3.4960635275638197e-06
a O 0 2.1475805169757223e-06
good O 0 2.2477254333352903e-06
correlation O 0 2.242372829641681e-06
between O 0 8.366634460799105e-07
repeat O 0 1.975148552446626e-05
size O 0 1.0911731806118041e-05
( O 0 3.1446910497834324e-07
at O 0 3.9745636968291365e-06
least O 0 3.8268896673798736e-07
in O 0 1.3158190768081113e-06
leucocytes O 0 0.0027534333057701588
) O 0 6.02211457589874e-07
, O 0 1.1145453981953324e-06
clinical O 0 3.351314444444142e-05
severity O 0 0.0007596057839691639
and O 0 9.410731763637159e-06
age O 0 2.3021739252726547e-05
of O 0 2.3975264866749058e-06
onset O 0 0.1996293067932129
. O 0 4.078082201885991e-05

The O 0 0.00017524976283311844
trinucleotide O 0 0.033446650952100754
repeat O 0 0.0010146989952772856
instability O 0 0.00011989499762421474
mechanisms O 0 6.670615402981639e-05
involved O 0 1.0067986295325682e-05
in O 0 1.5925164916552603e-05
DM B-Disease 1 1.0
and O 0 2.144034624507185e-05
other O 0 2.4560984002164332e-06
human O 0 6.78325814078562e-05
genetic B-Disease 1 0.9999997615814209
diseases I-Disease 1 0.9999998807907104
are O 0 1.0993830983352382e-05
unknown O 0 7.411970000248402e-05
. O 0 1.5331472241086885e-05

We O 0 6.282464892137796e-05
studied O 0 3.1762818252900615e-05
somatic O 0 6.618821498705074e-05
instability O 0 3.36820594384335e-05
by O 0 1.3299944612299441e-06
measuring O 0 0.0011016777716577053
the O 0 5.293978119880194e-06
CTG O 0 0.0011565550230443478
repeat O 0 1.4361672583618201e-05
length O 0 5.271156624075957e-06
at O 0 8.861258720571641e-06
several O 0 2.949783777239645e-07
ages O 0 3.82997404813068e-06
in O 0 2.031976862326701e-07
various O 0 2.2025579937690054e-07
tissues O 0 5.232021976553369e-06
of O 0 2.23577586666579e-07
transgenic O 0 1.9448796592769213e-05
mice O 0 3.984658178524114e-05
carrying O 0 4.591264769260306e-06
a O 0 2.4020648652367527e-06
( O 0 1.0302406963091926e-06
CTG O 0 5.304901787894778e-05
) O 0 3.4300879292459285e-07
55expansion O 0 7.350113264692482e-06
surrounded O 0 1.4247923445509514e-06
by O 0 1.0185104315496574e-07
45 O 0 5.166775736142881e-07
kb O 0 2.0515417418209836e-05
of O 0 1.4293513572738448e-07
the O 0 8.939167628341238e-07
human O 0 2.73455043497961e-06
DM B-Disease 1 0.999993085861206
region O 0 4.539138899417594e-06
, O 0 3.980033795869531e-07
using O 0 9.853227993517066e-07
small O 0 2.9476677809725516e-06
- O 0 0.0001367931254208088
pool O 0 0.0001302308519370854
PCR O 0 0.0003694531333167106
. O 0 3.08787239191588e-05

These O 0 4.321625237935223e-05
mice O 0 0.0022548402193933725
have O 0 5.730619704991113e-06
been O 0 3.887646471412154e-06
shown O 0 1.5853935337872826e-06
to O 0 6.825790705988766e-07
reproduce O 0 1.1568244190129917e-05
the O 0 3.552455609678873e-07
intergenerational O 0 8.179018550436012e-06
and O 0 9.867934522844735e-07
somatic O 0 8.907356459531002e-06
instability O 0 3.465239615252358e-06
of O 0 2.1967682073409378e-07
the O 0 1.2594319969139178e-06
55 O 0 3.259068762417883e-05
CTG O 0 0.0002487681631464511
repeat O 0 1.0358284271205775e-05
suggesting O 0 1.919711166920024e-06
that O 0 1.7231160143182933e-07
surrounding O 0 6.362670319504105e-07
sequences O 0 8.190393145923736e-07
and O 0 3.957717638058966e-07
the O 0 4.340512873568514e-07
chromatin O 0 7.249229383887723e-06
environment O 0 4.51168170911842e-06
are O 0 2.753431544988416e-07
involved O 0 1.339216964879597e-06
in O 0 1.964242756002932e-06
instability O 0 6.057770224288106e-05
mechanisms O 0 0.00011865257692988962
. O 0 3.803050276474096e-05

As O 0 1.6095284081529826e-05
observed O 0 5.296866675053025e-06
in O 0 4.753383677780221e-07
some O 0 1.1449061787516257e-07
of O 0 9.109481879931991e-08
the O 0 6.102952738729073e-07
tissues O 0 7.361021562246606e-05
of O 0 6.207571004779311e-06
DM B-Disease 1 1.0
patients O 0 0.14187024533748627
, O 0 2.0119664441153873e-06
there O 0 4.876220032201672e-07
is O 0 1.2948024163961236e-07
a O 0 5.215673581915325e-07
tendency O 0 2.1073683456052095e-06
for O 0 4.0709997506382933e-07
repeat O 0 1.3443735952023417e-05
length O 0 5.237068762653507e-06
and O 0 1.2591173117471044e-06
somatic O 0 1.4938565982447471e-05
mosaicism O 0 0.00011304148938506842
to O 0 7.361031748587266e-07
increase O 0 4.505729691572924e-07
with O 0 3.789952245369932e-07
the O 0 5.568397796196223e-07
age O 0 2.738418288572575e-06
of O 0 1.7102807703395229e-07
the O 0 1.3616174783237511e-06
mouse O 0 0.00010603450937196612
. O 0 1.3987387319502886e-05

Furthermore O 0 0.00037344888551160693
, O 0 1.0832301086338703e-05
we O 0 2.141871846106369e-06
observed O 0 1.3907840639149072e-06
no O 0 3.682123121961922e-07
correlation O 0 8.96069252576126e-07
between O 0 2.8804629437217955e-07
the O 0 3.992107053818472e-07
somatic O 0 1.4451427887252066e-05
mutation O 0 1.890674866444897e-05
rate O 0 7.1024846874934155e-06
and O 0 8.612250894657336e-06
tissue O 0 0.06513193249702454
proliferation O 0 0.00022686980082653463
capacity O 0 2.9987138987053186e-05
. O 0 1.5529496522503905e-05

The O 0 4.121353413211182e-05
somatic O 0 0.0001734486868372187
mutation O 0 7.76142260292545e-05
rates O 0 9.852750736172311e-06
in O 0 7.643232038390124e-07
different O 0 5.414469796960475e-07
tissues O 0 9.100427996600047e-05
were O 0 1.4829738574917428e-05
also O 0 7.031344466668088e-07
not O 0 2.0033779435379984e-07
correlated O 0 7.96011306647415e-07
to O 0 1.0558077434552615e-07
the O 0 1.8793861045196536e-07
relative O 0 1.8481024426364456e-06
inter O 0 9.217332262778655e-06
- O 0 0.003399617737159133
tissue O 0 0.0004166993894614279
difference O 0 1.2086248943887767e-06
in O 0 2.8101061388952076e-07
transcriptional O 0 3.843369995593093e-06
levels O 0 8.024266549000458e-07
of O 0 7.564525361658525e-08
the O 0 1.4062294440009282e-07
three O 0 3.972169508870138e-07
genes O 0 1.4964653018978424e-06
( O 0 4.557946056138462e-07
DMAHP O 0 0.00013563715037889779
, O 0 6.673225243503111e-07
DMPK O 0 7.991208985913545e-05
and O 0 1.420250441697135e-06
59 O 0 5.630869054584764e-06
) O 0 1.8943214286082366e-07
surrounding O 0 6.066360356271616e-07
the O 0 7.287529228960921e-07
repeat O 0 1.3823865629092325e-05
. O 0 1.5663855492675793e-06
. O 0 5.223945208854275e-06

A O 0 0.00013899178884457797
novel O 0 7.756095146760345e-05
missense O 0 0.00015139405149966478
mutation O 0 6.297141953837126e-05
in O 0 8.325538146891631e-06
patients O 0 9.327471343567595e-05
from O 0 2.2589922537008533e-06
a O 0 1.664868977968581e-05
retinoblastoma B-Disease 0 0.3083551526069641
pedigree O 0 0.0351705476641655
showing O 0 4.875985177932307e-05
only O 0 1.0248606940876925e-06
mild O 0 1.8862860088120215e-05
expression O 0 9.990370699597406e-07
of O 0 3.637625525243493e-07
the O 0 1.6593434338574298e-05
tumor B-Disease 0 0.09335268288850784
phenotype O 0 0.0008630348602309823
. O 0 3.514011041261256e-05

We O 0 7.285975880222395e-05
have O 0 5.266252628643997e-06
used O 0 3.2772809390735347e-06
single O 0 5.065240657131653e-06
strand O 0 1.1808695489889942e-05
conformation O 0 1.2174828043498565e-05
polymorphism O 0 9.131396836892236e-06
analysis O 0 1.0583789844531566e-06
to O 0 4.6935269892856013e-07
study O 0 4.3566370777625707e-07
the O 0 3.283858518443594e-07
27 O 0 4.959365469403565e-06
exons O 0 2.415257085885969e-06
of O 0 1.958737954055323e-07
the O 0 1.8147974287785473e-06
RB1 O 0 0.000337983132340014
gene O 0 1.9806186628557043e-06
in O 0 3.9945442154021293e-07
individuals O 0 1.8726126427281997e-07
from O 0 2.2397004784124874e-07
a O 0 2.6551711016509216e-06
family O 0 1.590579813637305e-05
showing O 0 5.1317801990080625e-05
mild O 0 3.774027936742641e-05
expression O 0 1.1209989452254376e-06
of O 0 4.1090297031587397e-07
the O 0 8.161456207744777e-06
retinoblastoma B-Disease 0 0.08736209571361542
phenotype O 0 0.012856083922088146
. O 0 5.4867919971002266e-05

In O 0 8.0555459135212e-05
this O 0 6.1219548115332145e-06
family O 0 2.636002864164766e-05
affected O 0 8.87449368747184e-06
individuals O 0 1.1754882507375441e-06
developed O 0 2.7086784029961564e-05
unilateral B-Disease 0 0.03144507110118866
tumors I-Disease 1 1.0
and O 0 0.0002405820705462247
, O 0 1.4696865946461912e-06
as O 0 1.9435356080066413e-07
a O 0 7.009905971244734e-07
result O 0 4.886214810539968e-07
of O 0 1.090187353725014e-07
linkage O 0 3.70578418369405e-05
analysis O 0 2.4958255835372256e-06
, O 0 3.81078825739678e-06
unaffected O 0 7.793752592988312e-05
mutation O 0 1.7449676306569017e-05
carriers O 0 9.297210453951266e-06
were O 0 4.552196060103597e-06
also O 0 1.238143454429519e-06
identified O 0 2.1957052922516596e-06
within O 0 5.595888410425687e-07
the O 0 2.8719862257275963e-06
pedigree O 0 0.000998924719169736
. O 0 2.5096804165514186e-05

A O 0 0.0001371002581436187
single O 0 2.5978950361604802e-05
band O 0 1.4663834917882923e-05
shift O 0 4.607278697221773e-06
using O 0 2.8339095479168463e-06
SSCP O 0 0.00023321520711760968
was O 0 9.71181088971207e-06
identified O 0 1.0871978020077222e-06
in O 0 3.931849619220884e-07
exon O 0 1.017739123199135e-05
21 O 0 7.085463948897086e-06
which O 0 4.92989443046099e-07
resulted O 0 1.3546982700063381e-06
in O 0 3.579337715109432e-07
a O 0 1.2861669347330462e-06
missense O 0 1.505442378402222e-05
mutation O 0 3.6414924124983372e-06
converting O 0 2.50273524216027e-06
a O 0 2.2114472812972963e-06
cys O 0 0.0005477076629176736
- O 0 0.0001074727697414346
- O 0 0.00010118047794094309
> O 0 1.2968434930371586e-05
arg O 0 7.410064881696599e-06
at O 0 4.6643717723782174e-06
nucleotide O 0 6.88852378516458e-06
position O 0 3.6064759569853777e-06
28 O 0 3.982163434557151e-06
in O 0 6.260162876969844e-07
the O 0 1.6845086747707683e-06
exon O 0 5.9301328292349353e-05
. O 0 1.4977366845414508e-05

The O 0 6.344295252347365e-05
mutation O 0 0.00012620001507457346
destroyed O 0 6.585496885236353e-05
an O 0 3.3354267543472815e-06
NdeI O 0 0.0001239507255377248
restriction O 0 1.0066028153232764e-05
enzyme O 0 2.4185706934076734e-05
site O 0 3.056028799619526e-05
. O 0 1.9672439520945773e-05

Analysis O 0 2.7240188501309603e-05
of O 0 2.08283495339856e-06
all O 0 9.816404826779035e-07
family O 0 3.884826128341956e-06
members O 0 4.866627136834722e-07
demonstrated O 0 1.199949110741727e-06
that O 0 1.4383545021701138e-07
the O 0 5.204792046242801e-07
missense O 0 2.7517891794559546e-05
mutation O 0 1.9442826669546776e-05
co O 0 4.231741331750527e-05
- O 0 4.8921938287094235e-05
segregated O 0 7.806895882822573e-05
with O 0 1.4246660612116102e-05
patients O 0 0.002116429153829813
with O 0 0.005281048361212015
tumors B-Disease 1 1.0
or O 0 0.0012115002609789371
who O 0 6.138754542917013e-05
, O 0 6.831150471953151e-07
as O 0 1.6880677833341906e-07
a O 0 4.6040628376431414e-07
result O 0 3.4182403396698646e-07
of O 0 1.0504606251515725e-07
linkage O 0 3.4154691093135625e-05
analysis O 0 1.926800223372993e-06
had O 0 5.318330295267515e-05
been O 0 2.879023213608889e-06
predicted O 0 1.7265093674723175e-06
to O 0 4.466174345907348e-07
carry O 0 4.102954790141666e-06
the O 0 4.007008101325482e-06
predisposing O 0 0.00046519178431481123
mutation O 0 0.00010722096340032294
. O 0 2.8570038921316154e-05

These O 0 8.410967893723864e-06
observations O 0 8.930833246267866e-06
point O 0 3.049781298614107e-06
to O 0 3.9627556702725997e-07
another O 0 5.192318894842174e-07
region O 0 3.909292729531444e-07
of O 0 1.8265839685227547e-07
the O 0 3.2861216823221184e-06
RB1 O 0 0.0009676983463577926
gene O 0 3.027543243661057e-06
where O 0 1.2416257959557697e-06
mutations O 0 2.063855163214612e-06
only O 0 2.5778768986128853e-07
modify O 0 1.1226904916838976e-06
the O 0 1.6226186971834977e-07
function O 0 1.335817216840951e-07
of O 0 3.836894890696385e-08
the O 0 1.8295965276138304e-07
gene O 0 8.85207555256784e-07
and O 0 2.786156017009489e-07
raise O 0 9.703511523184716e-07
important O 0 1.153925381913723e-07
questions O 0 2.153913243319039e-07
for O 0 2.3704075147179537e-07
genetic O 0 3.357962123118341e-05
counseling O 0 0.00018633143918123096
in O 0 2.128130290657282e-06
families O 0 3.823463430308038e-06
with O 0 5.18414481120999e-07
these O 0 4.177806829375186e-07
distinctive O 0 1.692409387032967e-05
phenotypes O 0 6.483065226348117e-05
. O 0 3.697349256981397e-06
. O 0 1.0709216439863667e-05

Maternal B-Disease 1 0.5446298122406006
disomy I-Disease 1 0.6336252689361572
and O 0 0.11143755912780762
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.000813045771792531
with O 0 2.636744648043532e-05
gamete O 0 0.00044167268788442016
complementation O 0 0.04295330494642258
in O 0 2.4988930817926303e-06
a O 0 2.962372946058167e-06
case O 0 7.417732490466733e-07
of O 0 5.193130618863506e-07
familial O 0 0.0038777547888457775
translocation O 0 0.0032725422643125057
( O 0 2.5244846710847924e-06
3 O 0 3.7980171327944845e-06
; O 0 5.017821536057454e-07
15 O 0 1.3069918622932164e-06
) O 0 2.6003215225500753e-07
( O 0 2.335728481739352e-07
p25 O 0 5.610440894088242e-06
; O 0 5.444575208457536e-07
q11 O 0 9.329425665782765e-06
. O 0 2.7639762834041903e-07
2 O 0 3.2875730084924726e-06
) O 0 3.1456916076422203e-06
. O 0 1.0057583494926803e-05

Maternal B-Disease 1 0.9103238582611084
uniparental I-Disease 1 0.9952811598777771
disomy I-Disease 1 0.9426059126853943
( I-Disease 0 0.0004595579521264881
UPD I-Disease 1 0.9999853372573853
) I-Disease 0 6.61930653222953e-06
for I-Disease 0 1.4169547739584232e-06
chromosome I-Disease 0 0.010396136902272701
15 I-Disease 0 7.985516276676208e-06
is O 0 3.8581475791943376e-07
responsible O 0 1.339745836048678e-06
for O 0 1.3666425502378843e-07
an O 0 4.7676027747911576e-07
estimated O 0 1.0885351002798416e-06
30 O 0 4.6186983126972336e-07
% O 0 1.8500708165447577e-07
of O 0 1.0724629362357518e-07
cases O 0 7.007833460193069e-07
of O 0 1.7717045921017416e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.005763327237218618
PWS B-Disease 1 0.9999995231628418
) O 0 2.8663920602411963e-05
. O 0 3.5135486541548744e-05

We O 0 9.873881208477542e-05
report O 0 4.621717380359769e-06
on O 0 6.089127850827936e-07
an O 0 3.236136478790286e-07
unusual O 0 5.0221154879182e-07
case O 0 2.9605354257000727e-07
of O 0 2.9103838983246533e-07
maternal B-Disease 0 0.006954551674425602
disomy I-Disease 0 0.02990337274968624
15 I-Disease 0 1.9901193809346296e-05
in O 0 5.745593807660043e-05
PWS B-Disease 1 1.0
that O 0 1.5313249832615838e-06
is O 0 2.1312062870038062e-07
most O 0 1.310603749971051e-07
consistent O 0 1.1153822470078012e-06
with O 0 4.3102687641294324e-07
adjacent O 0 1.3890520676795859e-05
- O 0 0.00016800028970465064
1 O 0 1.2191803762107156e-06
segregation O 0 1.255162260349607e-06
of O 0 9.833743064291411e-08
a O 0 3.0481414796668105e-06
paternal O 0 0.009313509799540043
t O 0 0.014169569127261639
( O 0 2.1889886170356476e-07
3 O 0 7.421072041324805e-07
; O 0 1.9854306287925283e-07
15 O 0 8.52695052344643e-07
) O 0 2.002879426754589e-07
( O 0 2.4713818902455387e-07
p25 O 0 3.746066340681864e-06
; O 0 3.2313502629222057e-07
q11 O 0 5.774903911515139e-06
. O 0 1.159947373707837e-07
2 O 0 3.989907213508559e-07
) O 0 1.0577629439012526e-07
with O 0 1.3907865081819182e-07
simultaneous O 0 3.5969615055364557e-06
maternal O 0 0.0007387641817331314
meiotic O 0 0.000431907013989985
nondisjunction O 0 0.0020626031327992678
for O 0 2.0021777800138807e-06
chromosome O 0 0.0021968067158013582
15 O 0 3.9250848203664646e-05
. O 0 1.931921360665001e-05

The O 0 8.154902025125921e-05
patient O 0 0.0056414855644106865
( O 0 5.8722152971313335e-06
J O 0 0.031060833483934402
. O 0 8.969977898232173e-07
B O 0 2.383842547715176e-05
. O 0 1.6493410726070579e-07
) O 0 1.0468124145290858e-07
, O 0 8.045088151220625e-08
a O 0 3.455197088442219e-07
17 O 0 4.33201694249874e-06
- O 0 1.3090365428070072e-05
year O 0 1.8673994190976373e-06
- O 0 6.31250295555219e-05
old O 0 0.00016331981169059873
white O 0 6.361727628245717e-06
male O 0 4.272007117833709e-06
with O 0 1.0981823834299576e-05
PWS B-Disease 1 0.9999998807907104
, O 0 6.743869107594946e-06
was O 0 2.73702298727585e-05
found O 0 1.5532992847511196e-06
to O 0 4.0193063455262745e-07
have O 0 1.10463577129849e-06
47 O 0 8.514586625096854e-06
chromosomes O 0 6.874138762213988e-06
with O 0 1.0346418548579095e-06
a O 0 6.020018190611154e-06
supernumerary O 0 0.0024367861915379763
, O 0 4.518782589002512e-06
paternal O 0 0.002248430158942938
der O 0 0.06804262846708298
( O 0 3.7511998129957647e-07
15 O 0 6.2829684566168e-07
) O 0 6.711199063147433e-08
consisting O 0 1.0291687857488796e-07
of O 0 5.2432628905307865e-08
the O 0 7.195493481049198e-07
short O 0 1.3016210687055718e-05
arm O 0 0.07987847179174423
and O 0 1.2272552112335688e-06
the O 0 7.597643616463756e-07
proximal O 0 0.0015624966472387314
long O 0 0.00017378888151142746
arm O 0 0.010358787141740322
of O 0 6.715168296977936e-07
chromosome O 0 0.0016518962802365422
15 O 0 8.43298312247498e-06
, O 0 7.384699074464152e-07
and O 0 2.6351719952799613e-06
distal O 0 0.0045953295193612576
chromosome O 0 0.4801765978336334
arm O 1 0.919952929019928
3p O 1 0.9238898754119873
. O 0 7.998847286216915e-05

The O 0 0.00012237313785590231
t O 0 0.0016562483506277204
( O 0 1.9224960396968527e-06
3 O 0 2.126466824847739e-06
; O 0 4.175273886630748e-07
15 O 0 6.639073717451538e-07
) O 0 1.333042831674902e-07
was O 0 1.9671856534841936e-06
present O 0 1.5857263235830032e-07
in O 0 1.2144961658577813e-07
the O 0 2.5813901061155775e-07
balanced O 0 1.2244657909832313e-06
state O 0 2.3536750859420863e-07
in O 0 1.9495520575674163e-07
the O 0 1.6206359987336327e-06
patients O 0 2.0256346033420414e-05
father O 0 1.896876528917346e-05
and O 0 1.2127767377023702e-06
a O 0 9.713302461022977e-06
sister O 0 0.0016880029579624534
. O 0 2.1784893760923296e-05

Fluorescent O 0 0.0002694162249099463
in O 0 1.2492351743276231e-05
situ O 0 3.92065521737095e-05
hybridization O 0 6.781676802347647e-06
analysis O 0 2.6667455585993594e-06
demonstrated O 0 4.883773272013059e-06
that O 0 4.366720247617195e-07
the O 0 3.316528363939142e-06
PWS B-Disease 1 0.9999960660934448
critical O 0 9.300527381128632e-06
region O 0 4.515986802289262e-06
resided O 0 2.6352839995524846e-05
on O 0 9.913154599416885e-07
the O 0 5.20767173384229e-07
derivative O 0 6.51605705570546e-06
chromosome O 0 4.4208958570379764e-05
3 O 0 1.4612423910875805e-06
and O 0 8.067920020948804e-07
that O 0 3.551561178483098e-07
there O 0 5.378547598411387e-07
was O 0 9.749001947056968e-06
no O 0 5.640541758111794e-07
deletion O 0 3.1158883757598232e-06
of O 0 2.623441730520426e-07
the O 0 1.400125529471552e-05
PWS B-Disease 1 0.999998927116394
region O 0 4.862275090999901e-06
on O 0 2.7816026886284817e-06
the O 0 7.532101449214679e-07
normal O 0 1.1299957805022132e-06
pair O 0 1.3981421034259256e-06
of O 0 2.448277598432469e-07
15s O 0 2.468683487677481e-05
present O 0 2.2301057924778434e-06
in O 0 4.792726485902676e-06
J O 1 0.6626591086387634
. O 0 1.5078605429152958e-05

B O 0 0.017767053097486496
. O 0 0.0010825414210557938

Methylation O 0 0.00035879903589375317
analysis O 0 3.32370400428772e-05
at O 0 9.850889910012484e-06
exon O 0 1.4720637409482151e-05
alpha O 0 2.0844981918344274e-06
of O 0 1.7317913147962827e-07
the O 0 3.979016867106111e-07
small O 0 2.9017473934800364e-06
nuclear O 0 6.287223368417472e-05
ribonucleoprotein O 0 5.879909440409392e-05
- O 0 6.357867823680863e-05
associated O 0 5.349484581529396e-06
polypeptide O 0 2.5527580874040723e-05
N O 0 9.89450272754766e-05
( O 0 9.220833021572616e-07
SNRPN O 0 7.904693484306335e-05
) O 0 3.967543023009057e-07
gene O 0 1.064522507476795e-06
showed O 0 3.031345386261819e-06
a O 0 5.582014068750141e-07
pattern O 0 2.1867947452847147e-06
characteristic O 0 6.578920306310465e-07
of O 0 1.0758763124840698e-07
only O 0 3.5859284253092483e-07
the O 0 1.536298213977716e-06
maternal O 0 0.010987034998834133
chromosome O 0 0.014420758932828903
15 O 0 2.3169064661487937e-05
in O 0 1.5845011148485355e-05
J O 1 0.8039105534553528
. O 0 4.491650906857103e-05

B O 0 0.013959255069494247
. O 0 0.0005561933503486216

Maternal B-Disease 0 0.4534030854701996
disomy I-Disease 0 0.36050179600715637
was O 0 0.0002664674539119005
confirmed O 0 1.1214042388019152e-05
by O 0 7.485348305635853e-07
polymerase O 0 1.2228681043779943e-05
chain O 0 2.5253844796679914e-05
reaction O 0 7.894868190305715e-07
analysis O 0 7.082444994921389e-07
of O 0 3.0615845503234596e-07
microsatellite O 0 5.961783608654514e-05
repeats O 0 8.008655640878715e-06
at O 0 2.8396016205078922e-06
the O 0 4.884495297119429e-07
gamma O 0 6.089068392611807e-06
- O 0 7.084907701937482e-05
aminobutyric O 0 0.00013839271559845656
acid O 0 6.825069704063935e-06
receptor O 0 6.527003279188648e-06
beta3 O 0 2.0573663277900778e-05
subunit O 0 5.065840014140122e-06
( O 0 2.0531365407805424e-06
GABRB3 O 0 0.00013922312064096332
) O 0 4.1067751226364635e-06
locus O 0 7.861873746151105e-05
. O 0 2.1422869394882582e-05

A O 0 0.00041766362846828997
niece O 0 0.06639298796653748
( O 0 1.5706376871094108e-05
B O 0 8.610092481831089e-05
. O 0 6.198859523465217e-07
B O 0 1.4413039934879635e-05
. O 0 1.7694577536531142e-07
) O 0 9.137045964280333e-08
with O 0 1.1015958278903781e-07
45 O 0 1.0839542028406868e-06
chromosomes O 0 2.033484634011984e-06
and O 0 2.6271871433891647e-07
the O 0 2.237221963241609e-07
derivative O 0 2.744570110735367e-06
3 O 0 1.1414451819291571e-06
but O 0 3.4015840810752707e-07
without O 0 7.162999509091605e-07
the O 0 1.1541227422640077e-06
der O 0 0.023339733481407166
( O 0 3.1441481951333117e-07
15 O 0 8.520203209627653e-07
) O 0 1.8691262937409192e-07
demonstrated O 0 1.0672274584067054e-06
a O 0 9.238780194209539e-07
phenotype O 0 7.212912169052288e-05
consistent O 0 2.1839268811163493e-06
with O 0 5.993992999719921e-07
that O 0 4.719110222595191e-07
reported O 0 3.1186139040073613e-06
for O 0 2.958483662496292e-07
haploinsufficiency O 0 2.9537537557189353e-05
of O 0 7.663983296879451e-07
distal O 0 0.000389535358408466
3 O 0 0.00011892849579453468
p O 0 0.0025667103473097086
. O 0 2.1801333787152544e-05

Uniparental B-Disease 1 0.999972939491272
disomy I-Disease 1 0.9998925924301147
associated O 0 0.00036552935489453375
with O 0 1.72528834809782e-05
unbalanced O 0 0.001134437508881092
segregation O 0 3.779333201237023e-05
of O 0 8.444978334409825e-07
non O 0 8.194852853193879e-06
- O 0 0.0002321556385140866
Robertsonian O 0 0.00016060707275755703
translocations O 0 5.74315017729532e-05
has O 0 8.352240911335684e-06
been O 0 7.42963629818405e-06
reported O 0 1.4215989722288214e-05
previously O 0 1.0525868674449157e-05
but O 0 5.247405283625994e-07
has O 0 4.1985683196799073e-07
not O 0 2.4007863430597354e-07
, O 0 7.023624704061149e-08
to O 0 8.747580437784563e-08
our O 0 2.0901184427657427e-07
knowledge O 0 3.488066511181387e-07
, O 0 1.2937360338582948e-07
been O 0 3.0817091101198457e-07
observed O 0 2.0597934735633316e-07
in O 0 1.0485528889603302e-07
a O 0 7.997832085493428e-07
case O 0 1.3179841289456817e-06
of O 0 2.8452045626181643e-06
PWS B-Disease 1 0.9999985694885254
. O 0 2.9902181267971173e-05

Furthermore O 0 0.0003774527576752007
, O 0 1.2835379493481014e-05
our O 0 5.202219199418323e-06
findings O 0 2.17033561966673e-06
are O 0 3.1231391517394513e-07
best O 0 7.502729317820922e-07
interpreted O 0 7.696423267589125e-07
as O 0 2.749102350207977e-07
true O 0 1.556695224280702e-06
gamete O 0 1.6512358342879452e-05
complementation O 0 0.0005362265510484576
resulting O 0 9.115718967223074e-06
in O 0 8.771906323090661e-06
maternal B-Disease 1 0.8155767917633057
UPD I-Disease 1 0.9999970197677612
15 I-Disease 0 0.000512834929395467
and O 0 0.001150278141722083
PWS B-Disease 1 0.9999872446060181

Schwartz B-Disease 1 0.827618420124054
- I-Disease 1 0.9749641418457031
Jampel I-Disease 1 0.9989051818847656
syndrome I-Disease 1 0.9999945163726807
type I-Disease 0 0.00029587020981125534
2 I-Disease 0 1.7758999092620797e-05
and O 0 3.404065137146972e-05
Stuve B-Disease 1 0.9729734063148499
- I-Disease 1 0.9999213218688965
Wiedemann I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999996423721313
: O 0 1.651719458095613e-06
a O 0 2.1654234387824545e-06
case O 0 1.0430410384287825e-06
for O 0 3.716048979640618e-07
" O 0 3.6077897220820887e-06
lumping O 0 4.068153793923557e-05
" O 0 9.888444765238091e-06
. O 0 9.24506184674101e-06

Recent O 0 7.291870133485645e-05
studies O 0 2.0353398213046603e-05
demonstrated O 0 1.4844962606730405e-05
the O 0 7.967221904436883e-07
existence O 0 9.519469017504889e-07
of O 0 1.5389305474400317e-07
a O 0 3.808383326031617e-06
genetically O 0 1.0194981769018341e-05
distinct O 0 7.453983243976836e-07
, O 0 5.30839884049783e-07
usually O 0 6.628331448155222e-07
lethal O 0 1.177528133666783e-06
form O 0 2.9158152869968035e-07
of O 0 1.9637730019894661e-07
the O 0 6.017515261191875e-06
Schwartz B-Disease 0 0.03853717818856239
- I-Disease 1 0.980745792388916
Jampel I-Disease 1 0.9996541738510132
syndrome I-Disease 1 0.9999762773513794
( O 0 6.499510618596105e-06
SJS B-Disease 1 0.6265667080879211
) O 0 5.775977456323744e-07
of O 0 5.472247721627355e-07
myotonia B-Disease 0 0.3304353952407837
and O 0 0.00024095304252114147
skeletal B-Disease 1 0.9733494520187378
dysplasia I-Disease 1 0.9999102354049683
, O 0 2.2651733161183074e-05
which O 0 2.4607616069260985e-06
we O 0 1.8452319636708125e-06
called O 0 9.063465768122114e-06
SJS B-Disease 0 0.4669817388057709
type I-Disease 0 3.9272341382456943e-05
2 I-Disease 0 2.341100298508536e-05
. O 0 2.8718477551592514e-05

This O 0 0.00027668155962601304
disorder O 1 0.9782163500785828
is O 0 3.0396652164199622e-06
reminiscent O 0 8.909769348974805e-06
of O 0 4.397884652007633e-07
another O 0 6.507983016490471e-06
rare O 0 2.1397025193437003e-05
condition O 0 0.0022633937187492847
, O 0 1.6252528212135076e-06
the O 0 3.563323843991384e-06
Stuve B-Disease 1 0.9322859048843384
- I-Disease 1 0.9996238946914673
Wiedemann I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999990463256836
( O 0 5.21943366038613e-06
SWS B-Disease 0 0.4528600573539734
) O 0 1.1181577974639367e-06
, O 0 2.947348320958554e-07
which O 0 1.726982077343564e-07
comprises O 0 7.08268146354385e-07
campomelia B-Disease 0 8.384222746826708e-05
at O 0 2.0740539184771478e-05
birth O 0 0.00013814232079312205
with O 0 1.6192059774766676e-05
skeletal B-Disease 1 0.9902111887931824
dysplasia I-Disease 1 0.9998476505279541
, O 0 2.5643163098720834e-05
contractures B-Disease 1 0.6395791172981262
, O 0 4.3682625801011454e-06
and O 0 2.6524553504714277e-06
early B-Disease 0 1.12947091110982e-05
death I-Disease 0 9.961843170458451e-05
. O 0 2.109790875692852e-05

To O 0 4.2174353438895196e-05
test O 0 2.5182876925100572e-05
for O 0 1.2252203305251896e-06
possible O 0 3.2450138860440347e-06
nosologic O 0 0.0002805055119097233
identity O 0 4.299973625165876e-06
between O 0 1.282830112359079e-06
these O 0 4.165726750215981e-06
disorders O 1 0.9437742233276367
, O 0 3.2284256121783983e-06
we O 0 8.634443133814784e-07
reviewed O 0 2.4635554041196883e-07
the O 0 1.3830660350322432e-07
literature O 0 1.0756956925206396e-07
and O 0 4.076275388342765e-07
obtained O 0 1.6116748611239018e-06
a O 0 3.577532652343507e-07
follow O 0 3.2665323601577256e-07
- O 0 9.250150469597429e-06
up O 0 3.321810311263107e-07
of O 0 2.903142259924607e-08
the O 0 8.742343027279276e-08
only O 0 8.891149860801306e-08
two O 0 6.77726518460986e-07
surviving O 0 0.0011801705695688725
patients O 0 1.228996643476421e-05
, O 0 3.7436549860103696e-07
one O 0 3.62488520977422e-07
with O 0 1.5623587614754797e-06
SJS B-Disease 1 0.7229201793670654
type I-Disease 0 1.8659360648598522e-05
2 I-Disease 0 3.2277789614454377e-06
at O 0 4.2754072637762874e-05
age O 0 1.0652156561263837e-05
10 O 0 4.4450007408158854e-07
years O 0 3.2966545404633507e-07
and O 0 1.7527668205730151e-07
another O 0 5.579794901677815e-07
with O 0 1.7680555401966558e-06
SWS B-Disease 1 0.5913733839988708
at O 0 0.00033001520205289125
age O 0 2.537104046496097e-05
7 O 0 7.941770491015632e-06
years O 0 4.323238044889877e-06
. O 0 7.049297437333735e-06

Patients O 1 0.9958284497261047
reported O 0 0.0008978251134976745
as O 0 9.406165190739557e-06
having O 0 4.963130777468905e-05
either O 0 7.604697748320177e-05
neonatal O 1 0.9999996423721313
SJS B-Disease 1 0.9999978542327881
or O 0 0.00020161992870271206
SWS B-Disease 1 0.8194640874862671
presented O 0 4.751738288177876e-06
a O 0 1.6639216937619494e-06
combination O 0 3.877633844240336e-06
of O 0 3.056729838135652e-07
a O 0 2.7209398467675783e-05
severe O 1 0.8589770793914795
, O 0 9.604194929124787e-05
prenatal O 1 0.9999973773956299
- O 1 0.9999995231628418
onset O 1 0.9999998807907104
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 0.9999995231628418
( O 0 8.759232150623575e-05
with O 0 0.17420616745948792
congenital B-Disease 1 1.0
joint I-Disease 1 0.9983818531036377
contractures I-Disease 1 0.9999997615814209
, O 0 0.4344407320022583
respiratory O 1 0.9998952150344849
and O 0 0.003401699010282755
feeding O 0 0.020688241347670555
difficulties O 0 0.0014819424832239747
, O 0 1.6843753201101208e-06
tendency O 0 2.0510619833657984e-06
to O 0 3.1126894555200124e-06
hyperthermia B-Disease 0 0.079764723777771
, O 0 1.2627681371668587e-06
and O 0 9.251450023839425e-07
frequent O 0 4.333037395554129e-06
death O 0 3.861220830003731e-05
in O 0 3.8194693843252026e-06
infancy O 0 0.024528276175260544
) O 0 2.9207109264461906e-07
with O 0 1.9617439761532296e-07
a O 0 1.9469803191896062e-06
distinct O 0 7.020046723482665e-06
campomelic B-Disease 0 0.012629872187972069
- I-Disease 0 0.4160422086715698
metaphyseal I-Disease 1 0.7834105491638184
skeletal I-Disease 1 0.9577575922012329
dysplasia I-Disease 1 0.9995126724243164
. O 0 0.00022898083261679858

The O 0 1.9126218830933794e-05
similarity O 0 7.701953109062742e-06
of O 0 7.059981612655974e-07
the O 0 1.8295561403647298e-06
clinical O 0 0.00021350693714339286
and O 0 1.7943053535418585e-05
radiographic O 0 0.12262017279863358
findings O 0 2.434872294543311e-05
is O 0 9.06739046513394e-07
so O 0 4.70392279794396e-07
extensive O 0 1.9889585018972866e-06
that O 0 2.0692987163783982e-06
these O 0 5.4293750508804806e-06
disorders O 1 0.9434675574302673
appear O 0 8.435436029685661e-06
to O 0 9.525825817036093e-07
be O 0 1.3147803201718489e-06
a O 0 2.3807479010429233e-06
single O 0 2.571868935774546e-05
entity O 0 2.7913134545087814e-05
. O 0 9.310670975537505e-06

The O 0 2.1614850993501022e-05
follow O 0 8.852363862388302e-06
- O 0 1.3021301128901541e-05
up O 0 1.8716142449193285e-06
observation O 0 3.2383177313022316e-06
of O 0 1.618026175265186e-07
an O 0 6.294117724792159e-07
identical O 0 2.044295979430899e-05
and O 0 6.508912520075683e-07
unique O 0 4.1351282220603025e-07
pattern O 0 3.1453976134798722e-06
of O 0 6.518715167658229e-07
progressive O 0 0.21080243587493896
bone B-Disease 1 0.9991958737373352
dysplasia I-Disease 1 0.9998348951339722
in O 0 2.5177399948006496e-05
the O 0 1.4386043403646909e-05
two O 0 0.00017472701438236982
patients O 0 0.000570038566365838
( O 0 1.9968220499322342e-07
one O 0 2.6101503181052976e-07
with O 0 3.995453425886808e-06
SJS B-Disease 1 0.9611005783081055
type I-Disease 0 2.282802051922772e-05
2 I-Disease 0 2.556213985371869e-06
, O 0 4.916804527965724e-07
one O 0 3.743451770787942e-07
with O 0 1.7333359210169874e-06
SWS B-Disease 0 0.3146088719367981
) O 0 5.214182010604418e-07
surviving O 0 4.810543941857759e-06
beyond O 0 3.4735012377495877e-06
infancy O 0 8.510909538017586e-05
adds O 0 9.63596335168404e-07
to O 0 1.388495149967639e-07
the O 0 1.6883801379208307e-07
evidence O 0 2.507204897028714e-07
in O 0 2.561812095791538e-07
favor O 0 8.563214350942872e-07
of O 0 3.8613575270574074e-07
identity O 0 2.1744130208389834e-05
. O 0 1.2131366020184942e-05

The O 0 4.153363624936901e-05
hypothesis O 0 4.064136737724766e-05
that O 0 5.135633728059474e-06
SWS B-Disease 0 0.01703985221683979
and O 0 2.3683973267907277e-05
SJS B-Disease 1 0.8547218441963196
type I-Disease 0 3.9637638110434636e-05
2 I-Disease 0 2.421858198431437e-06
are O 0 2.2786662157159299e-07
the O 0 6.362452609209868e-07
same O 0 5.1523711590562016e-05
disorder O 1 0.7650110721588135
should O 0 1.1869219633808825e-06
be O 0 2.256713429460433e-07
testable O 0 1.5566031379421474e-06
by O 0 3.1084451279639325e-07
molecular O 0 6.946935627638595e-06
methods O 0 4.191597781755263e-06
. O 0 3.4614740798133425e-06
. O 0 1.2338208762230352e-05

A O 0 0.00012292599421925843
mouse O 0 0.00021313471370376647
model O 0 2.7793868866865523e-05
of O 0 2.1610503608826548e-05
severe O 1 0.999996542930603
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.017902633175253868
defects O 1 0.9997872710227966
in O 0 0.00028451281832531095
hemostasis O 1 0.9993914365768433
and O 0 0.017014075070619583
thrombosis B-Disease 1 0.9998488426208496
. O 0 0.00022459855244960636

von B-Disease 1 0.9998937845230103
Willebrand I-Disease 1 0.9996792078018188
factor I-Disease 0 0.0028038693126291037
( I-Disease 0 0.0002787723205983639
vWf I-Disease 0 0.25906598567962646
) I-Disease 0 0.15341781079769135
deficiency I-Disease 1 0.9999617338180542
causes O 0 0.4552502930164337
severe O 1 0.9999992847442627
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.00027466434403322637
humans O 0 0.0003124805516563356
. O 0 3.4449589293217286e-05

We O 0 3.82413636543788e-05
generated O 0 8.164975952240638e-06
a O 0 2.3998600227059796e-06
mouse O 0 1.3436813787848223e-05
model O 0 1.6823926216602558e-06
for O 0 4.6057229496909713e-07
this O 0 8.094555710158602e-07
disease O 0 6.405376916518435e-05
by O 0 1.9629602832083037e-07
using O 0 1.3116118680045474e-06
gene O 0 7.5120969995623454e-06
targeting O 0 4.218658068566583e-05
. O 0 1.8002530850935727e-05

vWf B-Disease 0 0.020488886162638664
- I-Disease 1 0.8621516823768616
deficient I-Disease 1 0.8352328538894653
mice O 0 0.008941149339079857
appeared O 0 6.939982995390892e-05
normal O 0 1.4541785276378505e-05
at O 0 2.9140355763956904e-05
birth O 0 0.0013064449885860085
; O 0 8.852903192746453e-07
they O 0 9.74395220509905e-07
were O 0 1.840757136051252e-06
viable O 0 3.4845400023186812e-06
and O 0 1.833052579058858e-06
fertile O 0 3.104384086327627e-05
. O 0 1.0028065844380762e-05

Neither O 0 0.0018691825680434704
vWf O 0 0.004070771858096123
nor O 0 0.0005739947664551437
vWf O 0 0.0011541590793058276
propolypeptide O 0 0.0025368202477693558
( O 0 4.06295876018703e-05
von B-Disease 1 0.9486672282218933
Willebrand I-Disease 1 0.8646063804626465
antigen O 0 0.0014823623932898045
II O 0 0.005277588032186031
) O 0 1.6513571381437941e-06
were O 0 2.4524656510038767e-06
detectable O 0 1.20687082016957e-05
in O 0 9.744770750330645e-07
plasma O 0 1.9106932086287998e-05
, O 0 2.4685534754098626e-06
platelets O 0 3.710806049639359e-05
, O 0 6.04847571139544e-07
or O 0 1.4681189668408479e-06
endothelial O 0 7.359904884651769e-06
cells O 0 1.1979790315308492e-06
of O 0 1.3065640303011605e-07
the O 0 1.5832496274015284e-06
homozygous O 0 0.00015328341396525502
mutant O 0 0.00012868166959378868
mice O 0 0.0002683622878976166
. O 0 3.092829865636304e-05

The O 0 0.00014714134158566594
mutant O 0 0.002125989645719528
mice O 0 0.16544313728809357
exhibited O 0 0.22986914217472076
defects O 1 0.9993311166763306
in O 0 3.6454399378271773e-05
hemostasis O 1 0.6459402441978455
with O 0 7.759607797197532e-06
a O 0 2.6348494429839775e-05
highly O 0 6.682795356027782e-05
prolonged O 1 0.6124710440635681
bleeding O 1 0.9775176644325256
time O 0 6.169174866954563e-06
and O 0 3.8105592921056086e-06
spontaneous O 0 3.0180131943779998e-05
bleeding O 0 0.04016473516821861
events O 0 8.314455612890015e-07
in O 0 6.635389695475169e-07
approximately O 0 8.621795473118254e-07
10 O 0 1.086194515664829e-06
% O 0 7.883748480708164e-07
of O 0 1.1626823379629059e-06
neonates O 0 0.0009130076505243778
. O 0 1.564818921906408e-05

As O 0 3.634218228398822e-05
in O 0 3.7171905660216e-06
the O 0 1.96141263586469e-06
human O 0 6.201653832249576e-06
disease O 0 0.005675922147929668
, O 0 3.8491913301186287e-07
the O 0 3.127833565486071e-07
factor O 0 9.447982733945537e-07
VIII O 0 8.43603047542274e-05
level O 0 1.2856089597335085e-06
in O 0 3.4240676427543804e-07
these O 0 3.4761183087539393e-07
mice O 0 0.0005813465104438365
was O 0 3.601772550609894e-05
reduced O 0 8.120387064991519e-07
strongly O 0 3.0119699090391805e-07
as O 0 7.493170528505289e-08
a O 0 3.49635939755899e-07
result O 0 3.7650448803105974e-07
of O 0 5.905230793246119e-08
the O 0 3.4895040812443767e-07
lack O 0 9.014020747599716e-07
of O 0 1.910672438043548e-07
protection O 0 3.012670049429289e-06
provided O 0 2.0338547983556055e-06
by O 0 3.3687690574879525e-06
vWf O 0 0.00022381632879842073
. O 0 2.4547318389522843e-05

Defective O 1 0.9386672973632812
thrombosis B-Disease 1 0.9987805485725403
in O 0 0.0001243473234353587
mutant O 0 0.0038604578003287315
mice O 0 0.32230085134506226
was O 0 0.000432228553108871
also O 0 3.7928011806798168e-06
evident O 0 4.43599492427893e-06
in O 0 2.9562667691607203e-07
an O 0 4.5049563368593226e-07
in O 0 1.2434020391083322e-06
vivo O 0 4.5310673158383e-05
model O 0 4.420281129569048e-06
of O 0 3.821706286544213e-06
vascular B-Disease 1 0.999853253364563
injury I-Disease 1 0.9959762692451477
. O 0 9.00491068023257e-05

In O 0 1.8243141312268563e-05
this O 0 1.126040274357365e-06
model O 0 2.405765144430916e-06
, O 0 5.030053671362111e-07
the O 0 8.647479035062133e-07
exteriorized O 0 0.00016729709750507027
mesentery O 0 0.00033588253427296877
was O 0 3.800968988798559e-05
superfused O 0 0.00010921867215074599
with O 0 5.050461822975194e-06
ferric O 0 0.004248909652233124
chloride O 0 3.425464092288166e-05
and O 0 2.272551455462235e-06
the O 0 8.517246214978513e-07
accumulation O 0 3.210464683434111e-06
of O 0 5.514262397809944e-07
fluorescently O 0 0.004732236731797457
labeled O 0 9.450008656131104e-05
platelets O 0 0.00010687481699278578
was O 0 1.5943232938298024e-05
observed O 0 3.1442759791389108e-06
by O 0 1.6465043017888092e-06
intravital O 0 7.241796265589073e-05
microscopy O 0 5.9606634749798104e-05
. O 0 2.048941132670734e-05

We O 0 7.82321731094271e-05
conclude O 0 1.560985401738435e-05
that O 0 6.206963121258013e-07
these O 0 5.525770347958314e-07
mice O 0 7.904625090304762e-05
very O 0 1.8936219703391544e-06
closely O 0 2.0923866031807847e-05
mimic O 0 0.1067080870270729
severe O 1 0.9007893204689026
human O 0 0.007362604606896639
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.00033790836459957063
will O 0 1.5093106412678026e-05
be O 0 1.6773173001638497e-06
very O 0 2.0044615212100325e-07
useful O 0 1.7941165708634799e-07
for O 0 9.937370037960136e-08
investigating O 0 6.098013614064257e-07
the O 0 1.6730919583096693e-07
role O 0 2.905436531364103e-07
of O 0 9.324083549699935e-08
vWf O 0 3.6344983982417034e-06
in O 0 5.663644060405204e-07
normal O 0 8.190211701730732e-06
physiology O 0 3.596966416807845e-05
and O 0 4.036864538647933e-06
in O 0 3.389543780940585e-05
disease O 0 0.04934309050440788
models O 0 1.7118785763159394e-05
. O 0 2.160462599931634e-06
. O 0 8.27681924420176e-06

Oral O 0 0.0019276718376204371
contraceptives O 0 0.47625839710235596
and O 0 1.8655162421055138e-05
the O 0 1.2672689990722574e-05
risk O 0 0.00018953028484247625
of O 0 0.00011288077075732872
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0003364733711350709

Hereditary B-Disease 1 0.9999998807907104
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999954700469971
Clinical O 1 0.7847725749015808
Study O 0 0.0004573026089929044
Group O 0 0.0003692944592330605
. O 0 5.268476888886653e-05

BACKGROUND O 0 0.0014179318677634
Women O 0 0.00020417939231265336
with O 0 8.433658877038397e-06
mutations O 0 3.673449464258738e-05
in O 0 9.630524573367438e-07
either O 0 1.35517120725126e-06
the O 0 1.3263414757602732e-06
BRCA1 O 0 0.0019553061574697495
or O 0 1.1346953669999493e-06
the O 0 5.931034934292256e-07
BRCA2 O 0 6.804299482610077e-05
gene O 0 2.4183480036299443e-06
have O 0 6.144662734186568e-07
a O 0 8.952825396590924e-07
high O 0 0.00030646531376987696
lifetime O 0 0.0012094866251572967
risk O 0 0.0017599276034161448
of O 0 0.0015025908360257745
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 7.479771738871932e-05

Oral O 0 0.004746746737509966
contraceptives O 1 0.9768800735473633
protect O 0 0.17706313729286194
against O 1 0.9822577834129333
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 1.8276732589583844e-05
general O 0 4.138187705393648e-06
, O 0 3.93231039197417e-06
but O 0 6.247012152016396e-07
it O 0 2.677583665899874e-07
is O 0 1.1924969101073657e-07
not O 0 1.1876586114567544e-07
known O 0 1.757798742119121e-07
whether O 0 1.962032172286854e-07
they O 0 3.7840149502699205e-07
also O 0 3.004304289788706e-07
protect O 0 1.20602953757043e-06
against O 0 1.362402031190868e-06
hereditary B-Disease 0 0.016073716804385185
forms I-Disease 0 9.211163160216529e-06
of I-Disease 0 0.23964892327785492
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.00013814956764690578

METHODS O 0 0.0001837938470998779
We O 0 1.492234969191486e-05
enrolled O 0 3.4035881981253624e-05
207 O 0 0.00010669886250980198
women O 0 3.8299975130939856e-05
with O 0 0.006321728695183992
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.627249366720207e-05
161 O 0 1.005349895422114e-05
of O 0 3.4052322916977573e-07
their O 0 5.343737939256243e-06
sisters O 0 0.00022370922670233995
as O 0 4.4878382254864846e-07
controls O 0 3.7843865356990136e-06
in O 0 4.915098088531522e-07
a O 0 3.301129481769749e-06
case O 0 3.1225097245624056e-06
- O 0 0.0002292346762260422
control O 0 2.626034438435454e-05
study O 0 9.77631952991942e-06
. O 0 1.2256959962542169e-05

All O 0 2.05978885787772e-05
the O 0 1.2396212696330622e-05
patients O 0 7.101899245753884e-05
carried O 0 5.474113550008042e-06
a O 0 2.5885638024192303e-06
pathogenic O 0 1.5820958651602268e-05
mutation O 0 8.307850293931551e-06
in O 0 1.006719003271428e-06
either O 0 5.64338415642851e-06
BRCA1 O 0 0.0003919961745850742
( O 0 8.165981739693962e-07
179 O 0 4.531107151706237e-06
women O 0 9.955950190487783e-06
) O 0 4.902911427961953e-07
or O 0 1.1749368695745943e-06
BRCA2 O 0 9.131104161497205e-05
( O 0 7.008595730439993e-07
28 O 0 9.093455446418375e-06
women O 0 5.302921636030078e-06
) O 0 2.8198828658787534e-06
. O 0 6.608087005588459e-06

The O 0 3.0198383683455177e-05
control O 0 9.839451377047226e-05
women O 0 1.986789720831439e-05
were O 0 5.864486411155667e-06
enrolled O 0 4.721333880297607e-06
regardless O 0 4.7256133939299616e-07
of O 0 9.876487894189268e-08
whether O 0 6.453112746385159e-07
or O 0 1.3820497315464308e-06
not O 0 8.881605140231841e-07
they O 0 2.032712700383854e-06
had O 0 2.0009745639981702e-05
either O 0 5.987987606204115e-06
mutation O 0 4.056547550135292e-05
. O 0 1.1932382221857551e-05

Lifetime O 0 0.0007998144719749689
histories O 0 9.025345207192004e-05
of O 0 5.276236606732709e-06
oral O 0 4.091693335794844e-05
- O 0 0.004505877383053303
contraceptive O 0 0.016798455268144608
use O 0 3.0049970973777818e-06
were O 0 7.667875252082013e-06
obtained O 0 1.60477804911352e-06
by O 0 2.0909219244913402e-07
interview O 0 8.720942787476815e-06
or O 0 3.983090550718771e-07
by O 0 9.774390008487899e-08
written O 0 1.801440845383695e-07
questionnaire O 0 3.0657615752716083e-06
and O 0 9.642765235184925e-07
were O 0 3.7386605526990024e-06
compared O 0 9.748033562573255e-07
between O 0 8.087641276688373e-07
patients O 0 7.881997589720413e-06
and O 0 1.6563632243560278e-06
control O 0 0.00010410546383354813
women O 0 1.6683497960912064e-05
, O 0 7.871922775848361e-07
after O 0 1.8802264776240918e-06
adjustment O 0 1.485861048422521e-06
for O 0 1.448755284627623e-07
year O 0 2.891888470912818e-07
of O 0 2.2108770281192847e-07
birth O 0 5.2763556595891714e-05
and O 0 4.5752408368571196e-06
parity O 0 6.746860162820667e-05
. O 0 1.2053432328684721e-05

RESULTS O 0 0.0006459369324147701
The O 0 1.428986342943972e-05
adjusted O 0 0.0007887343526817858
odds O 0 0.0002148883359041065
ratio O 0 0.00028590665897354484
for O 0 0.07441157102584839
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 4.0985036321217194e-05
with O 0 1.3660683180205524e-06
any O 0 2.3714251540241094e-07
past O 0 3.241239028284326e-07
use O 0 2.5523550561956654e-07
of O 0 1.9455569599813316e-07
oral O 0 9.322106052422896e-06
contraceptives O 0 0.24305908381938934
was O 0 0.0008078849059529603
0 O 0 5.330516069079749e-05
. O 0 1.4392012417374644e-05

5 O 0 0.00018381858535576612
( O 0 1.741537926136516e-05
95 O 0 1.2112775948480703e-05
percent O 0 1.0373508303018752e-05
confidence O 0 8.189532309188507e-06
interval O 0 6.099919119151309e-06
, O 0 4.6981395485090616e-07
0 O 0 9.213097200699849e-07
. O 0 9.865623695759496e-08
3 O 0 3.19760800948643e-07
to O 0 3.1197723160403257e-07
0 O 0 3.696475005199318e-06
. O 0 3.7521334661505534e-07
8 O 0 4.375308890303131e-06
) O 0 2.0095540094189346e-06
. O 0 7.278428256540792e-06

The O 0 0.00011728962999768555
risk O 0 0.0006846181349828839
decreased O 0 4.5758359192404896e-05
with O 0 1.1029535471607232e-06
increasing O 0 1.3576237734014285e-06
duration O 0 2.8805584406654816e-06
of O 0 1.8429072667913715e-07
use O 0 1.005444801194244e-06
( O 0 4.192143023828976e-07
P O 0 0.0001028454425977543
for O 0 1.870560026873136e-07
trend O 0 1.1879637895617634e-06
, O 0 3.757949400551297e-07
< O 0 4.265079041942954e-06
0 O 0 1.9822059584839735e-06
. O 0 1.298061533816508e-07
001 O 0 5.780314950243337e-06
) O 0 1.7208924418810057e-07
; O 0 9.747096640921882e-08
use O 0 1.9087563885022973e-07
for O 0 2.653249850936845e-07
six O 0 2.025376943493029e-06
or O 0 5.154786890670948e-07
more O 0 9.283907331791852e-08
years O 0 1.3238091014500242e-06
was O 0 9.555921678838786e-06
associated O 0 2.9716576932514727e-07
with O 0 2.7196611540603044e-07
a O 0 2.4945575205492787e-06
60 O 0 5.337829406926176e-06
percent O 0 1.0384296729171183e-05
reduction O 0 5.012984729546588e-06
in O 0 4.632025138562312e-06
risk O 0 0.00011539218394318596
. O 0 8.673085176269524e-06

Oral O 0 0.0014566573081538081
- O 0 0.0013615450588986278
contraceptive O 0 0.005365239456295967
use O 0 4.570917008095421e-05
protected O 0 0.0243032518774271
against O 1 0.8997642397880554
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
both O 0 2.398665401415201e-06
for O 0 8.880164727997908e-07
carriers O 0 3.3832056942628697e-06
of O 0 1.2509352131928608e-07
the O 0 1.4230705573936575e-06
BRCA1 O 0 0.003261409467086196
mutation O 0 1.7813954400480725e-05
( O 0 8.046789048421488e-07
odds O 0 2.1874286176171154e-05
ratio O 0 9.87014027487021e-06
, O 0 4.3909992086810234e-07
0 O 0 1.6311130366375437e-06
. O 0 1.4508873391605448e-07
5 O 0 6.306404429778922e-07
; O 0 2.6541027864368516e-07
95 O 0 8.809143423604837e-07
percent O 0 2.6754141799756326e-06
confidence O 0 3.307311999378726e-06
interval O 0 4.61837316834135e-06
, O 0 2.3577685226428002e-07
0 O 0 5.497648771779495e-07
. O 0 6.424828313811304e-08
3 O 0 2.1021004670274124e-07
to O 0 1.5028682298634521e-07
0 O 0 1.1496824754431145e-06
. O 0 8.426693653973416e-08
9 O 0 1.4107858987699728e-06
) O 0 7.95650194618247e-08
and O 0 7.366355703197769e-08
for O 0 1.121255053249115e-07
carriers O 0 5.092812216389575e-07
of O 0 1.0457826249421487e-07
the O 0 1.9270482880529016e-06
BRCA2 O 0 0.0004143431724514812
mutation O 0 9.601851161278319e-06
( O 0 5.181337314752454e-07
odds O 0 1.4892464605509304e-05
ratio O 0 4.93054312755703e-06
, O 0 3.57503608938714e-07
0 O 0 7.760782523291709e-07
. O 0 8.376824212064093e-08
4 O 0 4.398941939598444e-07
; O 0 2.0903675590489001e-07
95 O 0 7.469396337000944e-07
percent O 0 2.088911742248456e-06
confidence O 0 5.273479928291636e-06
interval O 0 4.560291017696727e-06
, O 0 3.668019701308367e-07
0 O 0 7.44980411582219e-07
. O 0 7.421652981065563e-08
2 O 0 2.2348507400238304e-07
to O 0 2.0836903047438682e-07
1 O 0 7.391321901195624e-07
. O 0 2.65148173639318e-07
1 O 0 1.8584789813758107e-06
) O 0 1.1959573384956457e-06
. O 0 5.152460289536975e-06

CONCLUSIONS O 0 0.0005927056772634387
Oral O 0 0.0003253812319599092
- O 0 0.0020324508659541607
contraceptive O 0 0.02956138551235199
use O 0 3.33834504999686e-05
may O 0 5.852787944604643e-05
reduce O 0 4.989156877854839e-06
the O 0 1.9724041067092912e-06
risk O 0 9.49101013247855e-05
of O 0 0.00023811905703041703
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 1.5560506653855555e-05
women O 0 1.2552624866657425e-05
with O 0 1.2971213436685503e-06
pathogenic O 0 2.166737431252841e-05
mutations O 0 6.954624950594734e-06
in O 0 6.11280825069116e-07
the O 0 3.106352323811734e-06
BRCA1 O 0 0.005205916706472635
or O 0 7.087231642799452e-05
BRCA2 O 0 0.005768489092588425
gene O 0 0.0005016017821617424

A O 0 0.00025901253684423864
Japanese O 0 7.685078162467107e-05
family O 0 5.240511381998658e-05
with O 0 2.0283041521906853e-05
adrenoleukodystrophy B-Disease 1 0.9999994039535522
with O 0 4.730397449748125e-06
a O 0 5.457433417177526e-06
codon O 0 2.0093539205845445e-05
291 O 0 1.0633621968736406e-05
deletion O 0 4.0670369344297796e-05
: O 0 6.319432372947631e-07
a O 0 3.6762112358701415e-06
clinical O 0 0.00019366948981769383
, O 0 2.668106390046887e-06
biochemical O 0 0.00015684649406466633
, O 0 2.1755868147010915e-06
pathological O 0 4.913448356091976e-05
, O 0 2.3470477117371047e-06
and O 0 3.896881480613956e-06
genetic O 0 0.00018265668768435717
report O 0 1.12336629172205e-05
. O 0 9.434572348254733e-06

We O 0 8.95855700946413e-05
report O 0 8.611921657575294e-06
a O 0 2.345013854210265e-06
Japanese O 0 1.018353668769123e-05
family O 0 5.07878721691668e-05
with O 0 0.0002834709011949599
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.003630426712334156
ALD B-Disease 1 1.0
) O 0 2.358349092901335e-06
with O 0 6.313107974165177e-07
a O 0 2.702655820030486e-06
three O 0 3.39761322720733e-06
base O 0 3.916372588719241e-05
pair O 0 2.6496354621485807e-05
deletion O 0 4.974445982952602e-05
( O 0 7.281103080458706e-07
delGAG O 0 1.3925270650361199e-05
291 O 0 5.853640232089674e-06
) O 0 4.4351730821290403e-07
in O 0 5.852797357874806e-07
the O 0 1.2604132280102931e-05
ALD B-Disease 1 0.9999986886978149
gene O 0 9.309496090281755e-05
. O 0 1.68932783708442e-05

A O 0 5.531088754651137e-05
variety O 0 6.560727342730388e-06
of O 0 1.3498646467269282e-06
phenotypes O 0 9.477245475864038e-05
were O 0 5.220737875788473e-06
observed O 0 3.116381321888184e-06
within O 0 6.53727965982398e-07
this O 0 6.365110607475799e-07
family O 0 1.6773185052443296e-05
. O 0 1.1319856639602222e-05

While O 0 6.774027860956267e-05
the O 0 1.3515867067326326e-05
proband O 0 0.0006970070535317063
( O 0 4.372530838736566e-06
patient O 0 0.00013073837908450514
1 O 0 3.5589903291111114e-06
) O 0 5.767615789409319e-07
was O 0 2.7174079150427133e-05
classified O 0 6.342935648717685e-06
as O 0 4.867750362791412e-07
having O 0 2.8980612114537507e-06
a O 0 1.1498492540340521e-06
rare O 0 1.734165948619193e-06
intermediate O 0 4.813857231056318e-06
type O 0 2.514302195777418e-06
of O 0 2.7203202535019955e-07
adult O 0 4.378903759061359e-05
cerebral O 0 0.23784887790679932
and O 0 8.62428278196603e-05
cerebello O 1 0.9239981770515442
- O 1 0.507909893989563
brain O 0 0.17855499684810638
stem O 0 7.244377684401115e-06
forms O 0 4.544759804048226e-07
, O 0 4.5568424411612796e-07
his O 0 6.795414265070576e-06
younger O 0 3.1586139812134206e-05
brother O 0 0.00013525781105272472
( O 0 9.556963505019667e-07
patient O 0 1.1378692761354614e-05
2 O 0 1.789316570466326e-06
) O 0 4.934024104841228e-07
and O 0 1.3852006759407232e-06
nephew O 0 0.00708482600748539
( O 0 1.497873199696187e-06
patient O 0 2.0639261492760852e-05
3 O 0 3.2432812986371573e-06
) O 0 6.012135145283537e-07
had O 0 1.0577247849141713e-05
a O 0 4.030396303278394e-05
childhood O 1 0.9864702820777893
ALD B-Disease 1 0.9999998807907104
type O 0 0.0023487324360758066
. O 0 5.2635150495916605e-05

Another O 0 0.00021988710795994848
nephew O 0 0.030494408681988716
( O 0 1.3168259101803415e-05
patient O 0 0.00015626073582097888
4 O 0 6.287934866122669e-06
) O 0 2.6234167194161273e-07
of O 0 2.3759027101277752e-07
patient O 0 0.0002845442504622042
1 O 0 7.022658337518806e-06
was O 0 0.0001891246356535703
classified O 0 4.927299869450508e-06
as O 0 3.819262133220036e-07
having O 0 3.5120501706842333e-06
an O 0 1.4407902426682995e-06
adolescent O 0 0.0003131240955553949
form O 0 1.0255147572024725e-05
. O 0 1.7583195585757494e-05

The O 0 2.9720235033892095e-05
tau O 0 2.9129350878065452e-05
level O 0 5.002974376111524e-06
in O 0 1.1306037777103484e-06
the O 0 4.522718882071786e-06
cerebrospinal O 0 0.3229790925979614
fluid O 0 0.009216652251780033
( O 0 7.256208391481778e-06
CSF O 1 0.7166484594345093
) O 0 5.325680376699893e-07
in O 0 8.063843210948107e-07
patient O 0 9.214234887622297e-05
1 O 0 2.9624973194586346e-06
was O 0 2.1894089513807558e-05
as O 0 2.1304846598013683e-07
high O 0 2.745627853073529e-06
as O 0 1.14497382242007e-07
that O 0 9.014281232566645e-08
of O 0 4.448219783625973e-07
patients O 0 0.0004323194152675569
with O 0 0.0034563897643238306
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9980857372283936
( O 0 4.398989403853193e-06
AD B-Disease 0 0.00011547088070074096
) O 0 4.75820934298099e-06
. O 0 1.0653498065948952e-05

His O 0 0.0004805009812116623
brain O 0 0.001940988120622933
magnetic O 0 3.915312481694855e-05
resonance O 0 7.017981261014938e-05
image O 0 0.00013472209684550762
( O 0 3.7153652101551415e-06
MRI O 1 0.8304355144500732
) O 0 9.744615454110317e-06
showed O 0 0.0032577374950051308
abnormalities B-Disease 1 0.9397290349006653
in I-Disease 0 1.619015392861911e-06
the I-Disease 0 9.88830265669094e-07
bilateral I-Disease 0 1.1008582987415139e-05
cerebellar I-Disease 0 0.0007983064861036837
hemispheres I-Disease 0 0.0009630408021621406
and O 0 0.00037643988616764545
brain O 1 0.8255271315574646
stem O 0 0.00023889927251730114
, O 0 1.847667363108485e-06
but O 0 7.350172950282285e-07
not O 0 3.4481791999496636e-07
in O 0 2.025418268658541e-07
the O 0 1.5588672113153734e-06
cerebral O 0 0.20010752975940704
white O 0 1.833881833590567e-05
matter O 0 7.0157108211788e-07
, O 0 2.4087142946882523e-07
where O 0 5.645761689265782e-07
marked O 0 1.1919584039787878e-06
reductions O 0 1.1519895224409993e-06
of O 0 1.0679090678422654e-07
the O 0 1.289369947699015e-06
cerebral O 0 0.05490617826581001
blood O 0 0.00021388509776443243
flow O 0 3.480477971606888e-06
and O 0 4.825992164114723e-06
oxygen O 0 0.0009637796320021152
metabolism O 0 5.164403410162777e-05
were O 0 4.443154921318637e-06
clearly O 0 1.816080271055398e-06
demonstrated O 0 1.1433779718572623e-06
by O 0 5.810208563161723e-07
positron O 0 4.248947152518667e-05
emission O 0 1.904750934045296e-05
tomography O 0 0.0003189127892255783
( O 0 5.9086555665999185e-06
PET O 0 0.0003163039218634367
) O 0 5.092092578706797e-06
. O 0 7.635286237928085e-06

In O 0 0.0001316066918661818
patients O 0 0.005031881388276815
2 O 0 9.210425560013391e-06
and O 0 2.274049393236055e-06
3 O 0 4.653734777093632e-06
, O 0 4.2826275148399873e-07
the O 0 5.407740673035732e-07
autopsy O 0 0.0029637219849973917
findings O 0 4.39074938185513e-06
showed O 0 2.593956196506042e-05
massive O 0 0.00013530903379432857
demyelination B-Disease 1 0.9994615912437439
of I-Disease 0 8.574998560106906e-07
the I-Disease 0 7.460806500603212e-06
cerebral I-Disease 1 0.8364005088806152
white I-Disease 0 3.144404399790801e-05
matter I-Disease 0 2.563809005096118e-07
with O 0 1.7772507021618367e-07
sparing O 0 6.657105018348375e-07
of O 0 9.53539043280216e-08
the O 0 1.3663341178471455e-06
U O 0 0.005576592404395342
- O 0 0.09208536893129349
fibers O 0 0.0014869450824335217
, O 0 6.046525982128514e-07
compatible O 0 1.2436391898518195e-06
with O 0 4.477450090689672e-07
the O 0 8.790092920207826e-07
findings O 0 2.9954064757475862e-06
of O 0 5.2051373131689616e-06
childhood O 1 0.8784062266349792
ALD B-Disease 1 0.9999995231628418
. O 0 0.0001404043287038803

Oleic O 0 0.007679169066250324
and O 0 0.00015752964827697724
erucic O 0 0.0075501203536987305
acids O 0 6.233410385902971e-05
( O 0 2.891333451771061e-06
Lorenzos O 0 4.889768024440855e-05
Oil O 0 1.9546305338735692e-06
) O 0 1.69718816778186e-07
were O 0 3.5986008128929825e-07
administered O 0 5.521619073078909e-07
to O 0 7.915842274996976e-07
patients O 0 9.505602065473795e-06
1 O 0 7.937659347589943e-07
and O 0 9.793336630536942e-07
4 O 0 4.096234079042915e-06
, O 0 4.6690175281582924e-07
but O 0 2.2919455489045504e-07
sufficient O 0 1.3036681139055872e-06
effectiveness O 0 5.268146196613088e-06
was O 0 1.7389556887792423e-05
not O 0 1.0396129255241249e-06
obtained O 0 7.520785402448382e-06
. O 0 6.368781669152668e-06

The O 0 4.991390960640274e-05
findings O 0 2.604024120955728e-05
in O 0 2.3596721803187393e-06
this O 0 5.947437671238731e-07
family O 0 7.238866601255722e-06
suggest O 0 1.8638766050571576e-06
that O 0 4.851792709814617e-07
delGAG291 O 0 1.1960340088990051e-05
is O 0 9.24302199223348e-08
part O 0 8.079672397798277e-08
of O 0 6.355065806928906e-08
the O 0 5.782723633274145e-07
cause O 0 2.436878048683866e-06
of O 0 4.151023915710539e-07
Japanese O 0 0.0006624056841246784
ALD B-Disease 1 0.9999988079071045
with O 0 7.674079824937508e-06
phenotypic O 0 0.00015837459068279713
variations O 0 0.00014370903954841197
. O 0 5.0842823839047924e-05

Moreover O 0 0.00045314422459341586
, O 0 1.0256888344883919e-05
although O 0 1.2252110082044965e-06
the O 0 3.665596466362331e-07
scale O 0 1.5871742107265163e-06
of O 0 9.627698460690226e-08
the O 0 3.5935491382588225e-07
study O 0 6.014073505866691e-07
is O 0 2.1331399580049037e-07
limited O 0 6.801456038374454e-07
, O 0 4.3546307892938785e-07
there O 0 2.2721755499333085e-07
is O 0 1.10016166843252e-07
a O 0 5.261696855995979e-07
possibility O 0 6.119878435129067e-07
that O 0 3.483651767055562e-07
PET O 0 0.0003479761944618076
can O 0 1.8217283468402456e-06
detect O 0 0.0005383836687542498
an O 0 2.7040455279347952e-06
insidious B-Disease 0 0.0020293262787163258
lesion I-Disease 0 0.4725954532623291
which O 0 5.846176009072224e-06
is O 0 1.668708137003705e-06
undetectable O 0 2.4016042516450398e-05
by O 0 4.24817329758298e-07
computed O 0 1.5494701074203476e-05
tomogram O 0 0.0001329711521975696
( O 0 7.992350106178492e-07
CT O 0 0.008011887781322002
) O 0 5.592132765741553e-07
or O 0 6.065087632123323e-07
MRI O 0 0.003112673992291093
analysis O 0 1.7376788719047909e-06
, O 0 3.935533641197253e-07
and O 0 3.240926673697686e-07
that O 0 6.819148268277786e-08
the O 0 1.1405644073647636e-07
higher O 0 6.770063123440195e-07
level O 0 3.546271329923911e-07
of O 0 1.3729993497690884e-07
tau O 0 2.014322035392979e-06
reflects O 0 2.957888227683725e-07
the O 0 1.2015576089652313e-07
process O 0 1.8818396085862332e-07
of O 0 3.996289308361156e-07
neuronal B-Disease 0 0.0016528110718354583
degeneration I-Disease 0 0.2953151762485504
in O 0 0.0003328602761030197
ALD B-Disease 1 0.9999995231628418
. O 0 8.704527135705575e-05

Lorenzos O 0 0.010081925429403782
Oil O 0 4.248173354426399e-05
should O 0 2.4305813894898165e-06
be O 0 2.2455927251030516e-07
given O 0 1.0220210100442273e-07
in O 0 1.0292002627920738e-07
the O 0 2.6068417469105043e-07
early O 0 2.2778283437219216e-06
stage O 0 4.95426902489271e-05
. O 0 2.0203765416226815e-06
. O 0 7.837593329895753e-06

Nonsense O 0 0.001239282893948257
mutation O 0 0.00010573361942078918
in O 0 5.2235218390705995e-06
exon O 0 2.734696136030834e-05
4 O 0 3.746845095520257e-06
of O 0 5.376958256420039e-07
human O 0 9.975481134461006e-07
complement O 0 4.26332235292648e-06
C9 O 0 0.0007477959152311087
gene O 0 4.609071766026318e-06
is O 0 3.835841653199168e-07
the O 0 3.571417153125367e-07
major O 0 1.0868328672586358e-06
cause O 0 2.0883740035060328e-06
of O 0 8.165388862835243e-07
Japanese O 0 7.930779975140467e-05
complement B-Disease 0 0.0033741069491952658
C9 I-Disease 1 0.9998996257781982
deficiency I-Disease 1 0.9596806764602661
. O 0 4.052881558891386e-05

Deficiency B-Disease 1 0.9972695708274841
of I-Disease 0 8.204142432077788e-06
the I-Disease 0 5.9889703152293805e-06
ninth I-Disease 0 8.831192826619372e-05
component I-Disease 0 1.6003505152184516e-06
of I-Disease 0 2.0925637045365875e-07
human I-Disease 0 5.33709965111484e-07
complement I-Disease 0 3.3045375857909676e-06
( O 0 6.809983688071952e-07
C9 O 0 0.0019529605051502585
) O 0 4.491229219638626e-07
is O 0 8.618896174539259e-08
the O 0 1.0301821617986207e-07
most O 0 2.589398206964688e-07
common O 0 1.6142104868777096e-05
complement B-Disease 1 0.9999898672103882
deficiency I-Disease 1 0.9999994039535522
in O 0 2.6514107958064415e-06
Japan O 0 7.53916465328075e-05
but O 0 1.6551538237763452e-06
is O 0 2.4076487648017064e-07
rare O 0 3.144913023334084e-07
in O 0 4.0504903608962195e-07
other O 0 2.881380680719303e-07
countries O 0 9.73921487457119e-07
. O 0 8.46593229653081e-06

We O 0 4.8497608077013865e-05
studied O 0 1.2182226782897487e-05
the O 0 9.318179081674316e-07
molecular O 0 4.18460422224598e-06
basis O 0 9.899777069222182e-07
of O 0 1.7436716461816104e-06
C9 B-Disease 1 0.9998327493667603
deficiency I-Disease 0 0.4672062397003174
in O 0 6.133626584414742e-07
four O 0 2.0151251192146447e-06
Japanese O 0 4.7377427108585835e-05
C9 B-Disease 1 0.5416852235794067
- I-Disease 1 0.9017425775527954
deficient I-Disease 1 0.8668084144592285
patients O 0 0.00035488363937474787
who O 0 3.9066890167305246e-05
had O 0 0.041893571615219116
suffered O 1 0.9987291693687439
from O 0 0.011667204089462757
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 0.9999988079071045
. O 0 0.0001608437014510855

Direct O 0 7.870958506828174e-05
sequencing O 0 7.144994742702693e-05
of O 0 4.8731890274211764e-06
amplified O 0 5.2734736527781934e-05
C9 O 0 0.0001350907696178183
cDNA O 0 1.5993686247384176e-05
and O 0 3.682913757074857e-06
DNA O 0 2.59870030276943e-05
revealed O 0 1.1349085070833098e-05
a O 0 1.0146078466277686e-06
nonsense O 0 5.11436292072176e-06
substitution O 0 1.3870461543774582e-06
( O 0 5.712105348720797e-07
CGA O 0 7.710066711297259e-06
- O 0 3.56447599187959e-05
- O 0 6.383899744832888e-05
> O 0 1.9402114048716612e-05
TGA O 0 8.918598177842796e-05
) O 0 6.326614538920694e-07
at O 0 1.2125015018682461e-06
codon O 0 2.2953629468247527e-06
95 O 0 8.797490522738372e-07
in O 0 3.6876684816888883e-07
exon O 0 6.781928732380038e-06
4 O 0 1.1500904975036974e-06
in O 0 4.3891819245800434e-07
the O 0 6.435155341932841e-07
four O 0 1.237649757968029e-05
C9 B-Disease 1 0.6886255741119385
- I-Disease 1 0.862494707107544
deficient I-Disease 0 0.0627724751830101
individuals O 0 6.541222774103517e-06
. O 0 1.477757359680254e-05

An O 0 6.029989890521392e-05
allele O 0 0.00010387105430709198
- O 0 2.7800866519100964e-05
specific O 0 1.8157080603486975e-06
polymerase O 0 1.913424421218224e-05
chain O 0 6.810572085669264e-05
reaction O 0 1.7295841416853364e-06
system O 0 1.4789943634241354e-06
designed O 0 1.1010766684194095e-05
to O 0 7.137196575968119e-07
detect O 0 6.081119136069901e-05
exclusively O 0 7.349247539423232e-07
only O 0 1.171965209323389e-07
one O 0 9.005568557540755e-08
of O 0 5.1210605533924536e-08
the O 0 3.068971636821516e-07
normal O 0 1.2356344996078406e-06
and O 0 4.0885703356252634e-07
mutant O 0 1.0499259587959386e-05
alleles O 0 2.5045046641025692e-06
indicated O 0 2.2328872546495404e-06
that O 0 1.13967715265062e-07
all O 0 7.863116735506992e-08
the O 0 3.3378279340468e-07
four O 0 5.771611540694721e-06
patients O 0 1.9537341358955018e-05
were O 0 3.884747911797604e-06
homozygous O 0 1.102333226299379e-05
for O 0 8.470266266158433e-08
the O 0 3.646092920916999e-07
mutation O 0 1.2335317478573415e-06
in O 0 2.3748063426864974e-07
exon O 0 3.649161499197362e-06
4 O 0 1.79599771854555e-06
and O 0 2.8760817372130987e-07
that O 0 8.05425415251193e-08
the O 0 2.1392189353264257e-07
parents O 0 1.7415909496776294e-06
of O 0 3.0211123203116586e-07
patient O 0 4.625041765393689e-05
2 O 0 6.376085821102606e-06
were O 0 1.1254282981099095e-05
heterozygous O 0 8.811055158730596e-05
. O 0 1.3483384464052506e-05

The O 0 4.9322075938107446e-05
common O 0 9.92884179140674e-06
mutation O 0 1.4546154488925822e-05
at O 0 3.8658154153381474e-06
codon O 0 7.131126494641649e-06
95 O 0 2.226367996627232e-06
in O 0 6.658120810243418e-07
exon O 0 1.2454274838091806e-05
4 O 0 7.806993380654603e-06
might O 0 2.3358850285148947e-06
be O 0 4.777688786816725e-07
responsible O 0 8.598697149864165e-07
for O 0 2.2721192749486363e-07
most O 0 5.464336823024496e-07
Japanese O 0 0.00045089758350513875
C9 B-Disease 1 0.9999648332595825
deficiency I-Disease 1 0.9685686230659485
. O 0 5.05566640640609e-06
. O 0 1.6807354768388905e-05

BRCA1 O 0 0.008801274001598358
required O 0 4.9163449148181826e-05
for O 0 4.8254673856718e-06
transcription O 0 6.217511690920219e-05
- O 0 0.00180436996743083
coupled O 0 0.00020825646060984582
repair O 0 0.03608797863125801
of O 0 3.2238535823125858e-06
oxidative O 0 0.02358371764421463
DNA O 0 0.010963774286210537
damage O 0 0.009119654074311256
. O 0 3.303256744402461e-05

The O 0 0.00041229944326914847
breast B-Disease 1 0.999988317489624
and I-Disease 1 0.9997645020484924
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.4689246118068695
gene O 0 0.00032582730636931956
BRCA1 O 0 0.00176039501093328
encodes O 0 3.3043939765775576e-05
a O 0 2.8283204301260412e-05
zinc O 0 0.10563579946756363
finger O 0 0.005559634417295456
protein O 0 5.825883363286266e-06
of O 0 8.461802849524247e-07
unknown O 0 1.417141447745962e-05
function O 0 8.30790577310836e-06
. O 0 1.354666892439127e-05

Association O 0 5.666552533512004e-05
of O 0 2.3265188247023616e-06
the O 0 3.0101714401098434e-06
BRCA1 O 0 0.0002601797750685364
protein O 0 3.2091879802464973e-06
with O 0 4.69895496735262e-07
the O 0 9.484887755206728e-07
DNA O 0 5.073535066912882e-05
repair O 0 0.035871557891368866
protein O 0 1.1926853403565474e-05
Rad51 O 0 0.00010808747174451128
and O 0 6.688031817247975e-07
changes O 0 2.0451874149785e-07
in O 0 1.0146170126290599e-07
the O 0 9.794656818939984e-08
phosphorylation O 0 6.050264005352801e-07
and O 0 3.757934621262393e-07
cellular O 0 1.2550039173220284e-05
localization O 0 1.944816403920413e-06
of O 0 1.0969161223783885e-07
the O 0 6.737466264894465e-07
protein O 0 3.1276924801204586e-06
after O 0 1.1018161785614211e-05
exposure O 0 1.6610470993327908e-05
to O 0 8.085567060334142e-07
DNA O 0 2.9317072403500788e-05
- O 0 0.0009257376077584922
damaging O 0 8.751569112064317e-05
agents O 0 1.5524640275543788e-06
are O 0 1.4255138580665516e-07
consistent O 0 4.278349479136523e-07
with O 0 1.7817004049902607e-07
a O 0 8.511863143212395e-07
role O 0 7.348350550273608e-07
for O 0 5.944194754192722e-07
BRCA1 O 0 0.0002503213472664356
in O 0 4.322801487433026e-06
DNA O 0 0.0005150405340828001
repair O 1 0.6987220644950867
. O 0 7.077566988300532e-05

Here O 0 3.321235635667108e-05
, O 0 3.379435838724021e-06
it O 0 5.41635017725639e-07
is O 0 1.972062761979032e-07
shown O 0 2.008319057722474e-07
that O 0 2.646199561695539e-07
mouse O 0 1.1033333976229187e-05
embryonic O 0 1.6228465028689243e-05
stem O 0 4.132916728849523e-05
cells O 0 3.4399916330585256e-05
deficient B-Disease 0 9.033204696606845e-05
in I-Disease 0 1.0272570989400265e-06
BRCA1 I-Disease 0 0.0005578364944085479
are O 0 9.481397000854486e-07
defective O 0 0.00010989877773681656
in O 0 5.402601459536527e-07
the O 0 4.3280795125610894e-07
ability O 0 1.0861915598070482e-06
to O 0 2.0236922182448325e-07
carry O 0 1.1402310065022903e-06
out O 0 1.697241259535076e-06
transcription O 0 6.852422302472405e-06
- O 0 0.0005649019149132073
coupled O 0 4.7396177251357585e-05
repair O 0 0.0042650047689676285
of O 0 7.157850632211193e-07
oxidative O 0 0.012628169730305672
DNA O 0 0.008985326625406742
damage O 0 0.009829609654843807
, O 0 1.2234887662998517e-06
and O 0 5.456686835714208e-07
are O 0 2.675342614111287e-07
hypersensitive O 0 4.1876264731399715e-05
to O 0 1.6529894537598011e-06
ionizing O 0 0.0001382325863232836
radiation O 0 0.0007027980173006654
and O 0 9.359348950965796e-06
hydrogen O 0 0.00010093570745084435
peroxide O 0 0.00972457230091095
. O 0 2.7500158466864377e-05

These O 0 3.224269312340766e-05
results O 0 2.5725827072164975e-05
suggest O 0 5.871313533134526e-06
that O 0 8.179371207006625e-07
BRCA1 O 0 0.00010287408076692373
participates O 0 3.781586883633281e-06
, O 0 5.497607276083727e-07
directly O 0 7.338475711549108e-07
or O 0 8.697152793502028e-07
indirectly O 0 2.252018930448685e-06
, O 0 1.9128054873362998e-07
in O 0 2.4875464532669866e-07
transcription O 0 3.842743353743572e-06
- O 0 0.00026004781830124557
coupled O 0 5.4870484746061265e-05
repair O 0 0.003411183599382639
of O 0 7.593710051878588e-07
oxidative O 0 0.0033962009474635124
DNA O 0 0.003984034992754459
damage O 0 0.0039037736132740974
. O 0 6.305812348728068e-06
. O 0 1.5489056750084274e-05

Truncation O 0 0.004585211165249348
mutations O 0 0.0008771075517870486
in O 0 1.1272220035607461e-05
the O 0 3.5305768051330233e-06
transactivation O 0 7.837590237613767e-05
region O 0 4.630616786016617e-06
of O 0 1.133678665610205e-06
PAX6 O 0 0.0012470578076317906
result O 0 4.5598690121551044e-06
in O 0 1.1834205224658945e-06
dominant O 0 3.182688669767231e-05
- O 0 0.0003135856823064387
negative O 0 1.6116848200908862e-05
mutants O 0 6.518990994663909e-05
. O 0 1.2850517123297323e-05

PAX6 O 0 0.014793925918638706
is O 0 1.780770435289014e-05
a O 0 5.89446699450491e-06
transcription O 0 1.527917447674554e-05
factor O 0 2.68871463049436e-06
with O 0 4.244403442044131e-07
two O 0 7.879087888795766e-07
DNA O 0 2.061009217868559e-05
- O 0 2.6856425392907113e-05
binding O 0 2.802320523187518e-06
domains O 0 3.3530573091411497e-06
( O 0 5.272074190543208e-07
paired O 0 9.924374353431631e-06
box O 0 6.57404525554739e-05
and O 0 3.6644396459450945e-06
homeobox O 0 1.3933108675701078e-05
) O 0 4.1412650375605153e-07
and O 0 3.79379997639262e-07
a O 0 8.300322065224464e-07
proline O 0 1.1839209037134424e-05
- O 0 1.6242880519712344e-05
serine O 0 1.159331532107899e-05
- O 0 2.9758124583167955e-05
threonine O 0 2.1575740902335383e-05
( O 0 1.1079295063609607e-06
PST O 0 6.040406515239738e-05
) O 0 1.3821446600559284e-06
- O 0 1.8767455912893638e-05
rich O 0 7.802676918799989e-06
transactivation O 0 0.00010734258830780163
domain O 0 2.5413030016352423e-05
. O 0 1.684975541138556e-05

PAX6 O 0 0.021450767293572426
regulates O 0 0.0006154970615170896
eye O 0 0.0028948914259672165
development O 0 1.0241269592370372e-05
in O 0 2.3825286916689947e-06
animals O 0 1.1945143114644452e-06
ranging O 0 1.2194454939162824e-06
from O 0 8.687039212418313e-07
jellyfish O 0 3.7066201912239194e-06
to O 0 4.825324708690459e-07
Drosophila O 0 4.178024482826004e-06
to O 0 1.5227298035824788e-06
humans O 0 7.887366336944979e-06
. O 0 8.644224180898163e-06

Heterozygous O 0 0.005135636311024427
mutations O 0 0.0002695292641874403
in O 0 7.081438070599688e-06
the O 0 1.9788365079875803e-06
human O 0 1.8770089127428946e-06
PAX6 O 0 0.00042851283797062933
gene O 0 8.749666449148208e-06
result O 0 1.4370878034242196e-06
in O 0 2.4703169287931814e-07
various O 0 4.383802547636151e-07
phenotypes O 0 8.869364683050662e-05
, O 0 1.2570046692417236e-06
including O 0 8.792510016064625e-06
aniridia B-Disease 1 0.9999998807907104
, O 0 0.0013240736443549395
Peters B-Disease 1 0.9999934434890747
anomaly I-Disease 1 0.999980092048645
, O 0 9.136966400546953e-05
autosomal B-Disease 1 0.5168606638908386
dominant I-Disease 0 0.01987631805241108
keratitis I-Disease 0 0.22551117837429047
, O 0 1.9243016140535474e-05
and O 0 3.40428960043937e-05
familial B-Disease 1 0.9488841891288757
foveal I-Disease 1 0.9972741007804871
dysplasia I-Disease 1 0.9999762773513794
. O 0 0.00030430618789978325

It O 0 3.4297456295462325e-05
is O 0 2.5169890705001308e-06
believed O 0 2.3758216229907703e-06
that O 0 1.4236742629236687e-07
the O 0 2.4511817287020676e-07
mutated O 0 5.118881290400168e-06
allele O 0 3.9918663787830155e-06
of O 0 5.056371605860477e-07
PAX6 O 0 0.00016505582607351243
produces O 0 2.1933110474492423e-06
an O 0 8.912778639569297e-07
inactive O 0 1.3515519640350249e-05
protein O 0 2.1740934244007803e-06
and O 0 4.659978912968654e-06
aniridia B-Disease 1 0.9999943971633911
is O 0 2.4768517050688388e-06
caused O 0 1.7046160792233422e-05
due O 0 3.9111714613682125e-06
to O 0 5.534986485145055e-06
genetic O 0 0.0004270743520464748
haploinsufficiency O 0 0.0022662123665213585
. O 0 2.673112066986505e-05

However O 0 5.303794387145899e-05
, O 0 4.1851549212879036e-06
several O 0 1.2377349776215851e-06
truncation O 0 5.213151962379925e-05
mutations O 0 5.579386561294086e-05
have O 0 3.3568260278116213e-06
been O 0 3.209986971342005e-06
found O 0 1.6434545386800892e-06
to O 0 4.920880201098043e-07
occur O 0 5.975500698696123e-07
in O 0 2.5891341692840797e-07
the O 0 1.6042117749748286e-06
C O 0 0.0012634624727070332
- O 0 7.240857667056844e-05
terminal O 0 1.9762055671890266e-05
half O 0 4.895319420938904e-07
of O 0 1.9524509298207704e-07
PAX6 O 0 8.406687993556261e-05
in O 0 3.026013473572675e-06
patients O 0 2.350150862184819e-05
with O 0 5.342606527847238e-06
Aniridia B-Disease 1 0.9999281167984009
resulting O 0 1.354248342977371e-05
in O 0 9.346382512376294e-07
mutant O 0 6.126890184532385e-06
proteins O 0 4.2179365777883504e-07
that O 0 2.1172584752093826e-07
retain O 0 3.094076419074554e-06
the O 0 6.438053219426365e-07
DNA O 0 6.155352821224369e-06
- O 0 8.032918231037911e-06
binding O 0 1.4711926041854895e-06
domains O 0 3.1172760373010533e-06
but O 0 5.995536298541992e-07
have O 0 5.065488721811562e-07
lost O 0 3.7967859043419594e-06
most O 0 6.245559092121766e-08
of O 0 1.1275366063046022e-07
the O 0 1.4039476354810176e-06
transactivation O 0 0.0001289758802158758
domain O 0 3.145988375763409e-05
. O 0 1.9225955838919617e-05

It O 0 3.893281609634869e-05
is O 0 2.9138602712919237e-06
not O 0 6.294291097219684e-07
clear O 0 7.610240118083311e-07
whether O 0 2.6046151901937264e-07
such O 0 1.0294554186884852e-07
mutants O 0 3.548213862814009e-05
really O 0 5.626988240692299e-06
behave O 0 1.867524133558618e-06
as O 0 3.919390678674972e-07
loss O 0 8.048875315580517e-06
- O 0 1.0765700608317275e-05
of O 0 3.842871478809684e-07
- O 0 5.4370037105400115e-05
function O 0 2.103128281305544e-06
mutants O 0 1.0021221896749921e-05
as O 0 8.145944434545527e-07
predicted O 0 7.94931020209333e-06
by O 0 2.208182877438958e-06
haploinsufficiency O 0 0.00037052363040857017
. O 0 1.363077353744302e-05

Contrary O 0 0.00014989840565249324
to O 0 5.2858003982692026e-06
this O 0 6.876715588077786e-07
theory O 0 9.610650977265323e-07
, O 0 3.666264092316851e-07
our O 0 3.637746885942761e-07
data O 0 9.25203210044856e-07
showed O 0 3.8316256905090995e-06
that O 0 1.003979051006354e-07
these O 0 7.993922679361276e-08
mutants O 0 2.0491363557084696e-06
are O 0 1.5128277652820543e-07
dominant O 0 2.3534221327281557e-06
- O 0 2.0411711375345476e-05
negative O 0 1.6478709312650608e-06
in O 0 5.590010800915479e-07
transient O 0 7.969297257659491e-06
transfection O 0 5.3583222324959934e-05
assays O 0 1.9426755898166448e-05
when O 0 6.233316980797099e-06
they O 0 8.191486244868429e-07
are O 0 1.5269048958543863e-07
coexpressed O 0 9.096665053220931e-06
with O 0 8.367496775463223e-07
wild O 0 9.659870556788519e-06
- O 0 0.000141172218718566
type O 0 0.00014616624685004354
PAX6 O 0 0.002016674727201462
. O 0 3.1157193006947637e-05

We O 0 5.603455792879686e-05
found O 0 5.437639629235491e-06
that O 0 3.18834793233691e-07
the O 0 3.700922661664663e-07
dominant O 0 6.183512141433312e-06
- O 0 5.91618700127583e-05
negative O 0 4.255579824530287e-06
effects O 0 4.095566055184463e-06
result O 0 9.104146556637716e-07
from O 0 1.3360465800360544e-07
the O 0 2.544880999266752e-07
enhanced O 0 5.954116659268038e-06
DNA O 0 9.903129466692917e-06
binding O 0 2.3431002773577347e-06
ability O 0 9.983436939364765e-07
of O 0 2.690109965897136e-07
these O 0 5.371360884964815e-07
mutants O 0 3.7399877328425646e-05
. O 0 8.522848474967759e-06

Kinetic O 0 0.00027883739676326513
studies O 0 2.5311639546998776e-05
of O 0 2.4936509817052865e-06
binding O 0 1.1260788596700877e-05
and O 0 4.9541563384991605e-06
dissociation O 0 0.00011400796211091802
revealed O 0 1.3579056030721404e-05
that O 0 1.4717424789978395e-07
various O 0 1.1333214189335195e-07
truncation O 0 1.4119534171186388e-05
mutants O 0 2.7006359232473187e-05
have O 0 3.78136689960229e-07
3 O 0 9.424602467333898e-07
- O 0 8.413800060225185e-06
5 O 0 1.0546982593950815e-06
- O 0 6.148781267256709e-06
fold O 0 2.0223139927111333e-06
higher O 0 4.418577077558439e-07
affinity O 0 5.045437205808412e-07
to O 0 1.1755707163274565e-07
various O 0 8.704871845566231e-08
DNA O 0 2.071816425086581e-06
- O 0 4.501135208556661e-06
binding O 0 6.671016876680369e-07
sites O 0 7.330893367907265e-07
when O 0 7.645346613571746e-07
compared O 0 4.258541252966097e-07
with O 0 1.8934834145056811e-07
the O 0 4.1887062707246514e-07
wild O 0 2.9782188448734814e-06
- O 0 9.626842802390456e-05
type O 0 0.00010430399561300874
PAX6 O 0 0.001927111530676484
. O 0 3.362833376741037e-05

These O 0 1.8607986930874176e-05
results O 0 1.6140596926561557e-05
provide O 0 1.4620146657762234e-06
a O 0 7.661477070541878e-07
new O 0 7.590437576254772e-07
insight O 0 1.0820909892572672e-06
into O 0 1.787091576943567e-07
the O 0 1.8411925850614352e-07
role O 0 3.143155709040002e-07
of O 0 2.3346082400621526e-07
mutant O 0 3.034621840924956e-05
PAX6 O 0 0.0002549352066125721
in O 0 6.538297839142615e-06
causing O 0 0.0009096321882680058
aniridia B-Disease 1 0.9996073842048645
. O 0 9.639578820497263e-06
. O 0 1.5775445717736147e-05

Reversal O 0 0.002185323741286993
of O 0 0.0001264797756448388
severe O 1 0.9999856948852539
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
and O 0 0.005730354692786932
excellent O 0 0.0015582829946652055
neuropsychologic O 0 0.10187127441167831
outcome O 0 1.0641088920237962e-05
in O 0 1.4803223393755616e-06
very B-Disease 0 2.7638018309517065e-06
- I-Disease 0 0.0004902629880234599
long I-Disease 0 3.600203126552515e-05
- I-Disease 0 0.00028628032305277884
chain I-Disease 0 0.0002844710252247751
acyl I-Disease 0 0.00014100619591772556
- I-Disease 0 0.0006397438119165599
coenzyme I-Disease 0 0.00023684676853008568
A I-Disease 0 0.0007376277935691178
dehydrogenase I-Disease 1 0.8489831686019897
deficiency I-Disease 1 0.581807017326355
. O 0 4.8853591579245403e-05

Very B-Disease 0 0.0001778887235559523
- I-Disease 0 0.0004263730370439589
long I-Disease 0 7.765643385937437e-05
- I-Disease 0 0.0001904556411318481
chain I-Disease 0 0.00011039579112548381
acyl I-Disease 0 3.971047408413142e-05
- I-Disease 0 7.145226118154824e-05
coenzyme I-Disease 0 1.6476305972901173e-05
A I-Disease 0 2.2596932467422448e-05
dehydrogenase I-Disease 0 0.0002678183955140412
( I-Disease 0 4.952275958203245e-06
VLCAD I-Disease 1 0.941053569316864
) I-Disease 0 0.00021604330686386675
deficiency I-Disease 0 0.19666272401809692
is O 0 5.263061666482827e-07
a O 0 9.505330126557965e-06
disorder O 0 0.07189105451107025
of O 0 1.071529140972416e-06
fatty O 0 8.017495565582067e-05
acid O 0 1.0651242519088555e-05
beta O 0 1.4795587048865855e-06
oxidation O 0 3.05074718198739e-06
that O 0 7.811706836946541e-07
reportedly O 0 1.0559730981185567e-05
has O 0 3.7134736885491293e-07
high O 0 5.208235506870551e-06
rates O 0 1.8430564523441717e-06
of O 0 8.263626796178869e-07
morbidity O 0 0.02259654551744461
and O 0 6.710792513331398e-05
mortality O 0 0.05495944991707802
. O 0 5.3379524615593255e-05

We O 0 4.655299926525913e-05
describe O 0 1.1963066754105967e-05
the O 0 1.0787041446747025e-06
outcome O 0 8.821063488539949e-07
of O 0 1.6964114024631272e-07
a O 0 1.2894842029709253e-06
5 O 0 1.7886546856971108e-06
- O 0 1.832519774325192e-05
year O 0 1.6467115528939757e-06
- O 0 8.296102896565571e-05
old O 0 0.0020592049695551395
girl O 0 0.059598494321107864
with O 0 0.003966182935982943
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
who O 0 4.379764504847117e-05
was O 0 2.486602716089692e-05
first O 0 9.895293260342441e-07
seen O 0 3.4254826459800825e-06
at O 0 5.137210791872349e-06
5 O 0 7.620872679581225e-07
months O 0 5.439167694021307e-07
of O 0 1.4591937258501275e-07
age O 0 5.4945252486504614e-05
with O 0 0.0005343644879758358
severe O 1 0.9999898672103882
hypertrophic B-Disease 1 0.9999998807907104
cardiomyopathy I-Disease 1 1.0
, O 1 0.6287376880645752
hepatomegaly B-Disease 1 1.0
, O 0 0.3426426351070404
encephalopathy B-Disease 1 0.9923793077468872
, O 0 6.193793069542153e-06
and O 0 1.9211825929232873e-05
hypotonia B-Disease 0 0.30204275250434875
. O 0 3.658786590676755e-05

Biochemical O 0 0.013544120825827122
studies O 0 0.0038111794274300337
indicated O 1 0.9990482926368713
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.0018014009110629559
by O 0 3.0876005894242553e-06
a O 0 1.494640400778735e-05
stable O 0 0.0007461008499376476
yet O 0 1.125853304984048e-05
inactive O 0 8.84076434886083e-05
enzyme O 0 4.9244907131651416e-05
. O 0 1.7762080460670404e-05

Molecular O 0 0.001910091144964099
genetic O 0 0.0004047029069624841
analysis O 0 1.257950316357892e-05
of O 0 2.7696646611730102e-06
her O 0 0.0003096259606536478
VLCAD O 0 0.3766709864139557
gene O 0 3.701669629663229e-05
revealed O 0 5.5884389439597726e-05
a O 0 6.788354312448064e-06
T1372C O 0 0.000248557364102453
( O 0 1.353585048491368e-06
F458L O 0 1.844459620770067e-05
) O 0 7.114593927326496e-07
missense O 0 1.3114932698954362e-05
mutation O 0 5.565633273363346e-06
and O 0 1.519068973721005e-06
a O 0 1.3676240996574052e-05
1668 O 0 0.33448177576065063
ACAG O 0 0.0326903872191906
1669 O 0 0.0007639871910214424
splice O 0 0.001594268949702382
site O 0 0.00019726269238162786
mutation O 0 0.0001979522785404697
. O 0 3.804835068876855e-05

After O 0 0.0003250054724048823
initial O 0 5.74193436477799e-05
treatment O 0 3.246153210056946e-05
with O 0 2.909478553192457e-06
intravenous O 0 0.00016203205450437963
glucose O 0 0.0005216312711127102
and O 0 7.344626737904036e-06
carnitine O 0 0.00032477875356562436
, O 0 9.544739896227838e-07
the O 0 7.387911296063976e-07
patient O 0 3.268830187153071e-05
has O 0 8.702711511432426e-07
thrived O 0 3.834561084659072e-06
on O 0 5.405275942393928e-07
a O 0 1.2511073919085902e-06
low O 0 4.9051432142732665e-05
- O 0 0.00042912212666124105
fat O 0 4.141462704865262e-05
diet O 0 2.8062677301932126e-06
supplemented O 0 2.5871843263303163e-06
with O 0 5.117408932164835e-07
medium O 0 1.677835280133877e-05
- O 0 7.924021338112652e-05
chain O 0 9.117356967180967e-05
triglyceride O 0 3.22257837979123e-05
oil O 0 1.5060290934343357e-06
and O 0 5.81635163143801e-07
carnitine O 0 2.2189928131410852e-05
and O 0 9.974909289667266e-07
avoidance O 0 1.3293856682139449e-05
of O 0 2.166160811611917e-06
fasting O 0 0.00019652188348118216
. O 0 2.3065229470375925e-05

Her O 0 0.1023336797952652
ventricular O 1 0.9862915873527527
hypertrophy O 1 0.7682066559791565
resolved O 0 0.00023412801965605468
significantly O 0 2.135979593731463e-05
over O 0 1.55050497596676e-06
1 O 0 1.9530280042090453e-06
year O 0 6.999231345616863e-07
, O 0 4.6577298462580075e-07
and O 0 2.7168666747456882e-06
cognitively O 0 0.00047019607154652476
, O 0 4.052255917486036e-07
she O 0 5.006314950151136e-06
is O 0 9.615696683340502e-08
in O 0 1.1674807609551863e-07
the O 0 2.806817178679921e-07
superior O 0 2.037551212197286e-06
range O 0 1.216950067828293e-06
for O 0 1.0443301334817079e-06
age O 0 3.399747583898716e-05
. O 0 1.0609332093736157e-05

Clinical O 0 0.01388617604970932
recognition O 0 0.0001499447535024956
of O 0 0.002139652380719781
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 4.858872216573218e-06
important O 0 5.058339525021438e-07
because O 0 1.1237711987632792e-06
it O 0 2.956712421564589e-07
is O 0 4.539380071832966e-08
one O 0 4.59092674987005e-08
of O 0 2.6287754195664093e-08
the O 0 1.7608019220460847e-07
few O 0 5.496490302903112e-07
directly O 0 9.481420420343056e-06
treatable O 0 0.21120640635490417
causes O 0 4.656033979699714e-06
of O 0 3.1515530736214714e-06
cardiomyopathy B-Disease 1 0.9999997615814209
in O 0 4.6815483074169606e-05
children O 0 0.00035072636092081666
. O 0 3.881004431605106e-06
. O 0 1.3555391888075974e-05

Cloning O 0 0.00016493139264639467
of O 0 4.163661287748255e-06
a O 0 3.1752347240399104e-06
novel O 0 1.3700398540095193e-06
member O 0 5.12554606757476e-07
of O 0 1.4235358491987427e-07
the O 0 5.938720732956426e-07
low O 0 2.3118676836020313e-05
- O 0 8.522011921741068e-05
density O 0 1.316768248216249e-05
lipoprotein O 0 0.0015023726737126708
receptor O 0 7.334116526180878e-05
family O 0 4.78078582091257e-05
. O 0 1.9208051526220515e-05

A O 0 8.904575952328742e-05
gene O 0 2.9600250854855403e-05
encoding O 0 7.684522643103264e-06
a O 0 1.9479239199426956e-06
novel O 0 1.458911583540612e-06
transmembrane O 0 1.6340482034138404e-05
protein O 0 7.857966011215467e-06
was O 0 1.937255001394078e-05
identified O 0 2.2054869077692274e-06
by O 0 1.4394508696113917e-07
DNA O 0 1.747783812788839e-06
sequence O 0 7.400103072541242e-07
analysis O 0 3.442944489506772e-07
within O 0 1.5865295210915065e-07
the O 0 8.487294280712376e-07
insulin B-Disease 0 0.02037699520587921
- I-Disease 1 0.981306254863739
dependent I-Disease 1 0.9452677965164185
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 3.8664464227622375e-05
IDDM B-Disease 0 0.3586706519126892
) O 0 3.8406619751185644e-06
locus O 0 0.00017402501543983817
IDDM4 O 0 0.0018065209733322263
on O 0 3.424451278988272e-05
chromosome O 0 0.009264870546758175
11q13 O 0 0.001081952708773315
. O 0 4.354464545031078e-05

Based O 0 4.9763959395932034e-05
on O 0 8.063657332968432e-06
its O 0 2.8127117275289493e-06
chromosomal O 0 0.001537814037874341
position O 0 2.6177131076110527e-05
, O 0 5.055200062997756e-07
this O 0 8.403084450492315e-08
gene O 0 5.724424454456312e-07
is O 0 6.630759941117503e-08
a O 0 2.1877070821574307e-07
candidate O 0 5.679178229911486e-07
for O 0 3.7131906083232025e-07
conferring O 0 4.723657912109047e-05
susceptibility O 0 0.004617749247699976
to O 0 0.00012314891500864178
diabetes B-Disease 1 0.9984049201011658
. O 0 3.9453268982470036e-05

The O 0 2.3107124434318393e-05
gene O 0 2.016599137277808e-05
, O 0 1.4143329281068873e-06
termed O 0 6.534289695991902e-06
low O 0 1.1807311238953844e-05
- O 0 5.290922490530647e-05
density O 0 8.551872269890737e-06
lipoprotein O 0 0.00029320004978217185
receptor O 0 9.262147614208516e-06
related O 0 1.4654264077762491e-06
protein O 0 2.3727150164631894e-06
5 O 0 1.8021401047008112e-06
( O 0 4.980230414730613e-07
LRP5 O 0 9.698787471279502e-05
) O 0 1.8011195379585843e-07
, O 0 1.4010824145316292e-07
encodes O 0 5.835074716742383e-07
a O 0 2.3791903913661372e-07
protein O 0 6.609230922549614e-07
of O 0 1.601868291345454e-07
1615 O 0 6.478529394371435e-05
amino O 0 2.1660412130586337e-06
acids O 0 3.3933474696823396e-07
that O 0 6.438592947688448e-08
contains O 0 9.935891398527019e-08
conserved O 0 3.991520713952923e-07
modules O 0 6.606433657907473e-07
which O 0 1.936398064117384e-07
are O 0 4.5837342810273185e-08
characteristic O 0 2.474926930062793e-07
of O 0 9.92625004414549e-08
the O 0 4.1403134787287854e-07
low O 0 5.563697050092742e-05
- O 0 0.00023636850528419018
density O 0 2.1112804461154155e-05
lipoprotein O 0 0.013248740695416927
( O 0 4.600095962814521e-06
LDL O 0 0.0003783522988669574
) O 0 2.3808638616173994e-06
receptor O 0 2.1126823412487283e-05
family O 0 2.3679298465140164e-05
. O 0 1.4315630323835649e-05

These O 0 1.1081894626840949e-05
modules O 0 1.5603052816004492e-05
include O 0 1.4892530089127831e-06
a O 0 1.6750952909205807e-06
putative O 0 1.495527340011904e-05
signal O 0 7.831541552150156e-06
peptide O 0 9.824834705796093e-07
for O 0 7.764189291492585e-08
protein O 0 8.9775261358227e-07
export O 0 5.797998028356233e-07
, O 0 1.461792891177538e-07
four O 0 7.90176784448704e-07
epidermal O 0 1.191616593132494e-05
growth O 0 2.2549868390342453e-06
factor O 0 1.7363967117489665e-06
( O 0 5.673142595696845e-07
EGF O 0 5.216383942752145e-05
) O 0 3.9896710291031923e-07
repeats O 0 2.217375140389777e-06
with O 0 8.54334302857751e-07
associated O 0 3.0501360015477985e-06
spacer O 0 4.509483551373705e-05
domains O 0 1.3555870282289106e-05
, O 0 1.6062325585153303e-06
three O 0 5.277695890981704e-06
LDL O 0 0.0027605113573372364
- O 0 0.00025689887115731835
receptor O 0 8.708923814992886e-06
( O 0 5.086066039439174e-07
LDLR O 0 0.00011430393351474777
) O 0 2.8958294251424377e-07
repeats O 0 1.435392050552764e-06
, O 0 1.7224589043962624e-07
a O 0 5.100847602079739e-07
single O 0 2.6297241220163414e-06
transmembrane O 0 9.823459549807012e-06
spanning O 0 9.218721061188262e-06
domain O 0 6.936819772818126e-06
, O 0 6.44473630018183e-07
and O 0 4.7471681341448857e-07
a O 0 2.1296284558047773e-06
cytoplasmic O 0 8.516536763636395e-05
domain O 0 4.8888916353462264e-05
. O 0 2.388566645095125e-05

The O 0 2.0510604372248054e-05
encoded O 0 1.7448262951802462e-05
protein O 0 7.5657321758626495e-06
has O 0 7.11654820406693e-07
a O 0 6.294543481999426e-07
unique O 0 5.10716063217842e-07
organization O 0 4.349824394012103e-07
of O 0 1.6531866720015387e-07
EGF O 0 9.136661537922919e-05
and O 0 4.742606961372076e-06
LDLR O 0 0.08347166329622269
repeats O 0 2.324349043192342e-05
; O 0 9.334971196039987e-07
therefore O 0 9.143685133494728e-07
, O 0 7.823352348168555e-07
LRP5 O 0 0.003027167171239853
likely O 0 1.536348008812638e-06
represents O 0 3.2356857104787196e-07
a O 0 3.3445957114963676e-07
new O 0 2.881155012346426e-07
category O 0 9.055654572875937e-07
of O 0 2.1240556691282109e-07
the O 0 4.1640228118922096e-06
LDLR O 0 0.09736701101064682
family O 0 6.490853411378339e-05
. O 0 1.3219431821198668e-05

Both O 0 3.124955765088089e-05
human O 0 1.544607221148908e-05
and O 0 5.290182798489695e-06
mouse O 0 0.00013107704580761492
LRP5 O 0 0.016718994826078415
cDNAs O 0 0.00013565240078605711
have O 0 2.6908360268862452e-06
been O 0 1.742860376907629e-06
isolated O 0 2.069677748295362e-06
and O 0 2.032292911735567e-07
the O 0 1.5669293418341113e-07
encoded O 0 1.1935668453588733e-06
mature O 0 6.560525207532919e-07
proteins O 0 2.540118941851688e-07
are O 0 8.205530832583463e-08
95 O 0 5.68482448670693e-07
% O 0 6.830042593719554e-07
identical O 0 7.167275725805666e-06
, O 0 4.6867992864463304e-07
indicating O 0 2.1141804609214887e-06
a O 0 5.837362664351531e-07
high O 0 6.166292678244645e-06
degree O 0 1.7827554756877362e-06
of O 0 1.7534489415993448e-07
evolutionary O 0 4.9438303904025815e-06
conservation O 0 3.2449456739414018e-06
. O 0 1.102337364500272e-06
. O 0 4.425144197739428e-06

The O 0 5.364294338505715e-05
APC B-Disease 0 0.0001856300950748846
variants O 0 3.019993891939521e-05
I1307K O 0 7.495007594116032e-05
and O 0 5.2677246458188165e-06
E1317Q O 0 0.00011898249795194715
are O 0 1.4428087524720468e-06
associated O 0 4.8453090130351484e-05
with O 1 0.9687830209732056
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.03291117399930954
but O 0 2.6022664314950816e-05
not O 0 4.188500952295726e-06
always O 0 1.4247381159293582e-06
with O 0 4.433413494098204e-07
a O 0 8.514975888829213e-06
family O 0 4.264079689164646e-05
history O 0 1.2566230907395948e-05
. O 0 1.567665458424017e-05

Classical O 0 0.07373066246509552
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 1.0
( O 0 0.03928450495004654
FAP B-Disease 0 0.08139513432979584
) O 0 1.2849219274357893e-05
is O 0 1.6711255739210173e-06
a O 0 5.527611847355729e-06
high O 0 0.08386172354221344
- O 1 0.9977189898490906
penetrance O 1 0.9543483257293701
autosomal B-Disease 1 0.9968852400779724
dominant I-Disease 1 0.9376128911972046
disease I-Disease 1 0.8977240324020386
that O 0 1.1541447975105257e-06
predisposes O 0 5.686581789632328e-05
to O 0 1.053638698067516e-06
hundreds O 0 1.1769308230213937e-06
or O 0 7.770891556901915e-07
thousands O 0 1.1167915090481983e-06
of O 0 2.5851695681922138e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9910141825675964
carcinoma I-Disease 1 1.0
and O 0 0.0002805547555908561
that O 0 2.4268222205137135e-06
results O 0 1.0451038178871386e-05
from O 0 9.626998007661314e-07
truncating O 0 2.637524448800832e-05
mutations O 0 7.235588327603182e-06
in O 0 7.351350745921081e-07
the O 0 2.556728531999397e-06
APC B-Disease 0 7.576908683404326e-05
gene O 0 4.109117071493529e-05
. O 0 1.800959034881089e-05

A O 0 0.00014144560554996133
variant O 0 0.00018535983690526336
of O 0 1.6459218386444263e-05
FAP B-Disease 0 0.001699733198620379
is O 0 6.389126065187156e-05
attenuated B-Disease 1 0.9505612254142761
adenomatous I-Disease 1 0.9999990463256836
polyposis I-Disease 1 0.9999959468841553
coli I-Disease 1 0.9999959468841553
, O 0 2.8590424335561693e-05
which O 0 2.3521811272075865e-06
results O 0 6.651167041127337e-06
from O 0 2.270218374178512e-06
germ O 0 0.0014808936975896358
- O 0 0.0004457696049939841
line O 0 0.00010241776908515021
mutations O 0 3.3056533084163675e-06
in O 0 2.4043032453846536e-07
the O 0 2.9244930033200944e-07
5 O 0 8.61953481035016e-07
and O 0 2.3015040540030895e-07
3 O 0 3.259605705352442e-07
regions O 0 2.42615726619988e-07
of O 0 1.4242908719097613e-07
the O 0 2.076743612633436e-06
APC B-Disease 0 8.276332664536312e-05
gene O 0 3.595783346099779e-05
. O 0 1.7464109987486154e-05

Attenuated B-Disease 1 0.999872088432312
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9999998807907104
patients O 1 0.9999926090240479
have O 0 0.0035871134605258703
" O 0 6.15984172327444e-05
multiple O 0 0.0020743892528116703
" O 1 0.9047502279281616
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
( O 0 1.329423685092479e-05
typically O 0 5.34641412741621e-06
fewer O 0 8.208738222492684e-07
than O 0 1.51524204738962e-07
100 O 0 5.443245640890382e-07
) O 0 1.5175066891970346e-07
without O 0 2.1406067673979123e-07
the O 0 5.047905915489537e-07
florid O 0 7.259704580064863e-05
phenotype O 0 4.845688090426847e-05
of O 0 9.127375619755185e-07
classical O 0 3.0563729524146765e-05
FAP B-Disease 0 0.0005031580803915858
. O 0 1.8330372768105008e-05

Another O 0 0.00010009892866946757
group O 0 1.2252355190867092e-05
of O 0 1.0681866342565627e-06
patients O 0 5.48372081539128e-05
with O 0 1.6049341411417117e-06
multiple O 0 0.0005466207512654364
adenomas B-Disease 0 0.32016515731811523
has O 0 1.125035578297684e-05
no O 0 4.383653504191898e-06
mutations O 0 4.045921741635539e-06
in O 0 2.404628958174726e-07
the O 0 8.373834816666204e-07
APC B-Disease 0 1.2835379493481014e-05
gene O 0 1.6530619859622675e-06
, O 0 3.2654236292728456e-07
and O 0 6.260275995373377e-07
their O 0 2.97839505947195e-06
phenotype O 0 0.00010248868784401566
probably O 0 2.7516671252669767e-06
results O 0 8.111819056466629e-07
from O 0 2.02908381652378e-07
variation O 0 9.32954264953878e-07
at O 0 7.861278390919324e-06
a O 0 1.915369693961111e-06
locus O 0 7.819115126039833e-05
, O 0 1.490599856879271e-06
or O 0 1.3186479463911382e-06
loci O 0 2.6302834612579318e-06
, O 0 4.86209899008827e-07
elsewhere O 0 7.556217269666377e-07
in O 0 3.0796084615758446e-07
the O 0 1.1732886378013063e-06
genome O 0 1.3866922927263658e-05
. O 0 1.2235376743774395e-05

Recently O 0 0.0011212794343009591
, O 0 1.4323032701213378e-05
however O 0 2.5226893285434926e-06
, O 0 5.296667495713336e-07
a O 0 8.93603044005431e-07
missense O 0 1.0753417882369831e-05
variant O 0 7.0281662374327425e-06
of O 0 9.118509751715465e-07
APC B-Disease 0 6.109309470048174e-05
( O 0 9.507220966042951e-07
I1307K O 0 3.6765122786164284e-05
) O 0 4.339933354913228e-07
was O 0 5.8532218645268586e-06
described O 0 1.3609917459689314e-06
that O 0 2.1714897968649893e-07
confers O 0 1.9005983631359413e-06
an O 0 9.70731548477488e-07
increased O 0 2.395017145317979e-05
risk O 0 0.0027281343936920166
of O 0 0.01032311376184225
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0004637154925148934
including O 0 9.561700608173851e-06
multiple O 0 0.003496736055240035
adenomas B-Disease 0 0.26406893134117126
, O 0 5.799652171845082e-06
in O 0 9.701017006591428e-06
Ashkenazim O 0 0.0009037661948241293
. O 0 3.471033778623678e-05

We O 0 5.25585601280909e-05
have O 0 2.514369271011674e-06
studied O 0 2.309719548065914e-06
a O 0 8.387373782170471e-07
set O 0 6.962255838516285e-07
of O 0 3.2269312555399665e-07
164 O 0 0.00019132198940496892
patients O 0 0.0005355083267204463
with O 0 3.979099346906878e-05
multiple O 1 0.9993489384651184
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.5058504939079285
/ I-Disease 1 0.9872296452522278
or I-Disease 0 0.43304526805877686
carcinoma I-Disease 1 1.0
and O 0 2.6174986487603746e-05
analyzed O 0 5.34493665327318e-05
codons O 0 1.6847763617988676e-05
1263 O 0 9.898740972857922e-05
- O 0 3.499937884043902e-05
1377 O 0 4.167491715634242e-05
( O 0 9.331633350484481e-07
exon O 0 8.96688288776204e-06
15G O 0 3.330141771584749e-05
) O 0 2.733025610268669e-07
of O 0 9.402610601227934e-08
the O 0 3.341420438118803e-07
APC B-Disease 0 7.100033144524787e-06
gene O 0 1.9661524675029796e-06
for O 0 1.036998810377554e-06
germ O 0 0.00016980129294097424
- O 0 0.00010507127444725484
line O 0 5.152823359821923e-05
variants O 0 2.9792483474011533e-05
. O 0 1.7627959095989354e-05

Three O 0 0.0004184702120255679
patients O 0 0.004313336219638586
with O 0 3.6493634070211556e-06
the O 0 2.458317567288759e-06
I1307K O 0 8.891254401532933e-05
allele O 0 1.7091137124225497e-05
were O 0 5.497614893101854e-06
detected O 0 7.167063813540153e-06
, O 0 1.7074955849238904e-07
each O 0 2.3297573648051184e-07
of O 0 7.794813541295298e-07
Ashkenazi O 0 0.00020719841995742172
descent O 0 0.00011261692270636559
. O 0 2.596292324597016e-05

Four O 0 0.0006992828566581011
patients O 0 0.13045373558998108
had O 0 0.00015080736193340272
a O 0 9.141695954895113e-06
germ O 0 0.0071187252178788185
- O 0 0.00010942319931928068
line O 0 2.0747678718180396e-05
E1317Q O 0 1.8203794752480462e-05
missense O 0 9.357501767226495e-06
variant O 0 4.434387392393546e-06
of O 0 4.93799689138541e-07
APC O 0 1.849222280725371e-05
that O 0 5.4127769999468e-07
was O 0 1.6671217963448726e-05
not O 0 3.127908314581873e-07
present O 0 1.8018874925473938e-07
in O 0 2.704834969335934e-07
controls O 0 8.504263860231731e-06
; O 0 2.281999940123569e-07
one O 0 6.007704911326073e-08
of O 0 3.443459561935924e-08
these O 0 1.026823710503777e-07
individuals O 0 2.3775481849952484e-07
had O 0 3.6308260860096198e-06
an O 0 2.1282713191794755e-07
unusually O 0 2.664551402631332e-06
large O 0 3.1350251106232463e-07
number O 0 1.299342216043442e-07
of O 0 1.8136920232336706e-07
metaplastic B-Disease 0 0.009029925800859928
polyps I-Disease 0 4.214235013932921e-05
of I-Disease 0 4.435511300471262e-07
the I-Disease 0 5.9331164266041014e-06
colorectum I-Disease 0 0.002345532411709428
. O 0 2.3286065697902814e-05

There O 0 7.060209463816136e-05
is O 0 4.236014319758397e-06
increasing O 0 2.8780020784324734e-06
evidence O 0 1.1686163361446233e-06
that O 0 2.790474695757439e-07
there O 0 5.81470999350131e-07
exist O 0 1.0762288411569898e-06
germ O 0 3.1047151423990726e-05
- O 0 1.9112634618068114e-05
line O 0 4.670576799981063e-06
variants O 0 5.157427267477033e-07
of O 0 6.988439338329044e-08
the O 0 6.000124130878248e-07
APC B-Disease 0 8.907798473956063e-06
gene O 0 8.823723192108446e-07
that O 0 1.682487464904625e-07
predispose O 0 1.860434963418811e-06
to O 0 1.4097770417720312e-07
the O 0 1.536185436634696e-07
development O 0 2.559572465088422e-07
of O 0 4.409278062666999e-07
multiple O 1 0.7541783452033997
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9986922144889832
carcinoma I-Disease 1 1.0
, O 0 0.0003709714219439775
but O 0 2.0108000171603635e-06
without O 0 5.679757464349677e-07
the O 0 3.294885004834214e-07
florid O 0 6.219747592695057e-05
phenotype O 0 1.6762038285378367e-05
of O 0 1.6223773968704336e-07
classical O 0 2.8450419904402224e-06
FAP B-Disease 0 2.4307471903739497e-05
, O 0 8.258646744252474e-07
and O 0 8.184615012396534e-07
possibly O 0 2.3541740574728465e-06
with O 0 7.886470712037408e-07
importance O 0 1.2422272448020522e-05
for O 1 0.8863882422447205
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.18955294787883759
in O 0 7.244117341542733e-07
the O 0 5.588534008893475e-07
general O 0 8.02983208814112e-07
population O 0 5.309553898769082e-07
. O 0 8.333714731634245e-07
. O 0 5.021980541641824e-06

Genomic O 0 0.0008061889093369246
structure O 0 6.543798372149467e-05
of O 0 3.3702858672768343e-06
the O 0 1.6786660125944763e-05
human O 0 0.003165022237226367
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999985694885254
diarrhea I-Disease 1 1.0
( O 0 0.0019684124272316694
CLD B-Disease 1 0.9967384934425354
) O 0 1.290403633902315e-05
gene O 0 4.47688034910243e-05
. O 0 1.866436105046887e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999996423721313
diarrhea I-Disease 1 1.0
( O 0 0.2405920773744583
CLD B-Disease 1 0.9999500513076782
) O 0 2.9447928682202473e-05
is O 0 2.1181238025747007e-06
caused O 0 1.0843123163795099e-05
by O 0 5.251440029496734e-07
mutations O 0 7.194661975518102e-06
in O 0 3.855157331145165e-07
a O 0 1.9347528450452955e-06
gene O 0 3.082613602600759e-06
which O 0 4.2906154362754023e-07
encodes O 0 6.378993020916823e-06
an O 0 6.290244527917821e-06
intestinal O 0 0.005146398209035397
anion O 0 0.0005344661185517907
transporter O 0 0.002177994232624769
. O 0 5.630274608847685e-05

We O 0 0.00010778920113807544
report O 0 9.168481483357027e-06
here O 0 7.647847724001622e-07
the O 0 3.38606781724593e-07
complete O 0 1.4130521321931155e-06
genomic O 0 4.829481440538075e-06
organization O 0 5.547079808820854e-07
of O 0 8.601242029726563e-08
the O 0 4.834348033000424e-07
human O 0 1.152013737737434e-06
CLD B-Disease 0 0.0005983687588013709
gene O 0 4.0293680285685696e-06
which O 0 6.979347517699352e-07
spans O 0 3.896547241311055e-06
approximately O 0 1.7530720697322977e-06
39kb O 0 5.261413025436923e-05
, O 0 4.662494177409826e-07
and O 0 4.988881983081228e-07
comprises O 0 1.5795937997609144e-06
21 O 0 9.797992788662668e-06
exons O 0 5.4810865549370646e-05
. O 0 1.4867545360175427e-05

All O 0 3.880563599523157e-05
exon O 0 0.0002541023714002222
/ O 0 0.0001409510732628405
intron O 0 0.00039804232073947787
boundaries O 0 1.952154707396403e-05
conform O 0 1.138576953962911e-05
to O 0 1.5743933090561768e-06
the O 0 2.8058557290933095e-06
GT O 0 0.004073792602866888
/ O 0 0.002078291727229953
AG O 1 0.9985491633415222
rule O 0 4.4570981117431074e-05
. O 0 2.7836889785248786e-05

An O 0 2.6694333428167738e-05
analysis O 0 6.38274150333018e-06
of O 0 5.654970891555422e-07
the O 0 1.1465652960396255e-06
putative O 0 1.7459615264669992e-05
promoter O 0 1.6645990399410948e-05
region O 0 1.399683128511242e-06
sequence O 0 1.0839314654731425e-06
shows O 0 1.1595286650845082e-06
a O 0 2.063626880044467e-06
putative O 0 0.00011345442908350378
TATA O 0 0.2872565984725952
box O 0 6.440890865633264e-05
and O 0 3.3860849271150073e-06
predicts O 0 1.0752649359346833e-05
multiple O 0 2.3732920908514643e-06
transcription O 0 9.807173228182364e-06
factor O 0 4.503578566072974e-06
binding O 0 5.960548151051626e-06
sites O 0 9.060423508344684e-06
. O 0 1.175700526800938e-05

The O 0 4.298136627767235e-05
genomic O 0 0.00013778620632365346
structure O 0 4.362290565040894e-05
was O 0 2.1259202185319737e-05
determined O 0 1.9066692402702756e-06
using O 0 7.230052005979815e-07
DNA O 0 2.570536707935389e-06
from O 0 2.0318567806043575e-07
several O 0 1.59677540523262e-07
sources O 0 1.9738520506962232e-07
including O 0 1.7300300214628805e-07
multiple O 0 1.5466446257050848e-06
large O 0 5.4467741392727476e-06
- O 0 0.0007202471606433392
insert O 0 0.000167434336617589
libaries O 0 0.00017798272892832756
and O 0 1.1492396652101888e-06
genomic O 0 1.2108525879739318e-05
DNA O 0 1.3427847079583444e-05
from O 0 3.523435907482053e-06
Finnish O 0 0.11099859327077866
CLD B-Disease 1 0.9984947443008423
patients O 0 0.0016674584476277232
and O 0 1.4404535249923356e-05
controls O 0 0.00045524947927333415
. O 0 3.3260184864047915e-05

Exon O 0 0.0015284059336408973
- O 0 0.0001762318570399657
specific O 0 8.20156856207177e-06
primers O 0 5.835845149704255e-05
developed O 0 1.0151789865631144e-05
in O 0 6.58593819480302e-07
this O 0 1.6743943831443175e-07
study O 0 2.9919297617198026e-07
will O 0 1.4254051450279803e-07
facilitate O 0 5.46382068478124e-07
mutation O 0 1.6188857898669085e-06
screening O 0 2.3219020022224868e-06
studies O 0 8.877285608832608e-07
of O 0 4.168446992025565e-07
patients O 0 5.69954609090928e-05
with O 0 3.520957079672371e-06
the O 0 0.0002360203507123515
disease O 0 0.18043994903564453
. O 0 1.8296492271474563e-05

Genomic O 0 0.0005310738924890757
sequencing O 0 0.00014945314615033567
of O 0 9.858145858743228e-06
a O 0 3.096462387475185e-05
BAC O 0 0.03226948529481888
clone O 0 0.002566640730947256
H O 1 0.999990701675415
_ O 0 6.959667643968714e-06
RG364P16 O 0 5.2257553761592135e-05
revealed O 0 8.5193296399666e-06
the O 0 3.398134253984608e-07
presence O 0 2.672988728136261e-07
of O 0 7.447745531408145e-08
another O 0 8.146558343469223e-07
, O 0 2.073564360216551e-07
highly O 0 3.669240697945497e-07
homologous O 0 1.241430481968564e-06
gene O 0 1.3174262676329818e-06
3 O 0 4.393001233893301e-07
of O 0 8.913477955729832e-08
the O 0 1.8999024860022473e-06
CLD B-Disease 0 0.026930613443255424
gene O 0 6.645904250035528e-06
, O 0 3.571131230728497e-07
with O 0 1.762572736652146e-07
a O 0 1.0147946341021452e-06
similar O 0 6.121757678556605e-07
genomic O 0 7.437250133079942e-06
structure O 0 8.62710385263199e-06
, O 0 9.850043625192484e-07
recently O 0 5.2172736104694195e-06
identified O 0 1.5802598909431254e-06
as O 0 5.505991680365696e-07
the O 0 6.138673052191734e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.0002318207552889362
( O 0 2.913576736318646e-06
PDS B-Disease 0 0.0013324851170182228
) O 0 2.135247541446006e-06
. O 0 1.95419238480099e-06
. O 0 1.1554351658560336e-05

The O 0 0.00011606179759837687
APCI1307K O 0 0.0035334022250026464
allele O 0 0.0002923835418187082
and O 0 0.0006339671090245247
cancer B-Disease 1 0.9866214990615845
risk O 0 0.00014131443458609283
in O 0 8.412544048042037e-07
a O 0 1.9100580175290816e-06
community O 0 8.834264804136183e-07
- O 0 3.736679718713276e-05
based O 0 4.6733916292396316e-07
study O 0 3.6578475715032255e-07
of O 0 4.6152115373843117e-07
Ashkenazi O 0 0.00011607618216658011
Jews O 0 1.5173160136328079e-05
. O 0 1.2567189514811616e-05

Mutations O 0 0.003453498939052224
in O 0 3.642966112238355e-05
APC O 0 0.0006648507551290095
are O 0 5.2635914471466094e-06
classically O 0 0.27979207038879395
associated O 0 0.00016009790124371648
with O 0 0.02964695356786251
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.001004085293971002
FAP B-Disease 0 0.008740529417991638
) O 0 6.172164830786642e-06
, O 0 2.1621383439196507e-06
a O 0 2.411629247944802e-05
highly O 0 0.027120167389512062
penetrant O 1 0.9999737739562988
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999819993972778
disorder I-Disease 1 1.0
characterized O 0 0.017553480342030525
by O 0 9.58477994572604e-06
multiple O 0 0.11054246127605438
intestinal O 1 0.999704897403717
polyps B-Disease 0 0.3374556303024292
and O 0 1.835521288739983e-05
, O 0 6.992638645897387e-06
without O 0 9.949648301699199e-06
surgical O 0 0.0960659384727478
intervention O 0 8.236300345743075e-06
, O 0 5.600405188488367e-07
the O 0 4.003613582881371e-07
development O 0 3.3843414257717086e-06
of O 0 0.011765433475375175
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00010982440289808437
CRC B-Disease 0 0.11384262889623642
) O 0 1.0540011317061726e-05
. O 0 1.6206537111429498e-05

APC B-Disease 0 0.0024872359354048967
is O 0 2.0368039258755744e-05
a O 0 2.712328205234371e-05
tumour O 1 0.999982476234436
- O 0 0.00018210959387943149
suppressor O 0 4.967202403349802e-05
gene O 0 8.06269690656336e-06
, O 0 6.4991616000043e-07
and O 0 5.437850063572114e-07
somatic O 0 5.743917063227855e-05
loss O 0 0.0006688596331514418
occurs O 0 7.848334462323692e-06
in O 0 3.110853140242398e-05
tumours B-Disease 1 0.9999955892562866
. O 0 6.212676089489833e-05

The O 0 0.00010023877985076979
germline O 0 0.0014994664816185832
T O 0 0.0026000028010457754
- O 0 3.484858098090626e-05
to O 0 2.2245640138862655e-06
- O 0 5.2805084123974666e-05
A O 0 1.1965656995016616e-05
transversion O 0 0.0003235194308217615
responsible O 0 2.8698400456050877e-06
for O 0 2.3092738388186262e-07
the O 0 7.528266792178329e-07
APC O 0 1.4276635738497134e-05
I1307K O 0 1.3243166904430836e-05
allele O 0 6.377794306899887e-06
converts O 0 1.9432777662586886e-06
the O 0 4.959655370839755e-07
wild O 0 1.2070789807694382e-06
- O 0 3.3126341349998256e-06
type O 0 1.897383754112525e-06
sequence O 0 1.088128215087636e-06
to O 0 8.383823342228425e-07
a O 0 1.8897841073339805e-05
homopolymer O 1 0.629817008972168
tract O 0 0.07797587662935257
( O 0 3.7956995129206916e-06
A8 O 0 0.33764463663101196
) O 0 1.189460249406693e-06
that O 0 3.567726878372923e-07
is O 0 4.977087542101799e-07
genetically O 0 6.717206360917771e-06
unstable O 0 4.263823575456627e-05
and O 0 1.327234713244252e-06
prone O 0 0.00012820350821129978
to O 0 2.1318862764019286e-06
somatic O 0 0.00015891160001046956
mutation O 0 7.459633343387395e-05
. O 0 1.8172437194152735e-05

The O 0 0.00010267543257214129
I1307K O 0 0.000353122828528285
allele O 0 0.0001178769234684296
was O 0 3.8615227822447196e-05
found O 0 5.3305602705222555e-06
in O 0 3.4951999623444863e-06
6 O 0 5.2160707127768546e-05
. O 0 2.0512912669801153e-05

1 O 0 6.400437268894166e-05
% O 0 1.1573607480386272e-05
of O 0 1.6502598327861051e-06
unselected O 0 0.00013728458725381643
Ashkenazi O 0 0.00011226824426557869
Jews O 0 7.139353328966536e-06
and O 0 1.65817141350999e-06
higher O 0 3.3408132367185317e-06
proportions O 0 5.236764081928413e-06
of O 0 3.0095233682914113e-07
Ashkenazim O 0 5.556968244491145e-05
with O 0 1.8688871250560624e-06
family O 0 2.176209272874985e-05
or O 0 1.919279156936682e-06
personal O 0 3.9362048482871614e-06
histories O 0 4.344225544627989e-06
of O 0 1.0933438261417905e-06
CRC B-Disease 0 0.020109234377741814
( O 0 1.8294497294846224e-06
ref O 0 0.01409820280969143
. O 0 6.920828354850528e-07
2 O 0 3.4909160149254603e-06
) O 0 2.47438219957985e-06
. O 0 5.3581084102916066e-06

To O 0 4.012184217572212e-05
evaluate O 0 2.2245501895667985e-05
the O 0 2.100548499583965e-06
role O 0 1.5021433910078485e-06
of O 0 5.165825314179529e-07
I1307K O 0 0.00010890043631661683
in O 0 1.6453192074550316e-05
cancer B-Disease 0 0.023366641253232956
, O 0 2.1036998987256084e-06
we O 0 1.5707250895502511e-06
genotyped O 0 3.058611764572561e-05
5 O 0 1.7777028915588744e-06
, O 0 8.13437793567573e-07
081 O 0 6.621649663429707e-05
Ashkenazi O 0 3.13494929287117e-05
volunteers O 0 3.840588760795072e-06
in O 0 4.927478585159406e-07
a O 0 2.0408144791872473e-06
community O 0 3.025015075763804e-06
survey O 0 5.560260251513682e-05
. O 0 1.287027589569334e-05

Risk O 0 0.0011339540360495448
of O 0 9.353719178761821e-06
developing O 0 0.0024915316607803106
colorectal B-Disease 1 0.9999998807907104
, I-Disease 0 0.002295415150001645
breast I-Disease 1 0.9849886894226074
and I-Disease 0 2.6783094654092565e-05
other I-Disease 0 4.885310318059055e-06
cancers I-Disease 1 0.5435943603515625
were O 0 1.713819074211642e-05
compared O 0 2.305107273059548e-06
between O 0 1.4274826298787957e-06
genotyped O 0 0.0003564647922758013
I1307K O 0 3.98343509004917e-05
carriers O 0 2.9797984097967856e-06
and O 0 5.374943157221423e-07
non O 0 1.308211494688294e-06
- O 0 2.8282935090828687e-05
carriers O 0 3.2381694836658426e-06
and O 0 2.6510542738833465e-07
their O 0 4.0691247704671696e-07
first O 0 2.149404053852777e-06
- O 0 0.00012263889948371798
degree O 0 3.7750392948510125e-05
relatives O 0 0.00011645202175714076
. O 0 1.8635017113410868e-05

Sperm O 0 0.001992977922782302
DNA O 0 0.00015693565364927053
analysis O 0 1.4591129911423195e-05
in O 0 5.9150879678782076e-06
a O 0 2.8679394745267928e-05
Friedreich B-Disease 1 0.5215656161308289
ataxia I-Disease 1 0.9917656779289246
premutation O 0 0.4163835644721985
carrier O 0 0.0005054341163486242
suggests O 0 4.852435722568771e-06
both O 0 5.493739081430249e-07
meiotic O 0 1.871835411293432e-05
and O 0 1.923321178765036e-06
mitotic O 0 2.173399116145447e-05
expansion O 0 3.1164943266048795e-06
in O 0 8.579791597185249e-07
the O 0 1.975498889805749e-06
FRDA B-Disease 0 0.002224703086540103
gene O 0 2.2667467419523746e-05
. O 0 1.4589960301236715e-05

Friedreich B-Disease 1 0.9988204836845398
ataxia I-Disease 1 0.9999715089797974
is O 0 0.001236800686456263
usually O 0 0.00021729504805989563
caused O 0 2.9397981052170508e-05
by O 0 3.242058426167205e-07
an O 0 2.0328374716882536e-07
expansion O 0 6.186988343870325e-07
of O 0 3.2449131026623945e-07
a O 0 9.511968528386205e-06
GAA O 0 0.008495772257447243
trinucleotide O 0 0.00020154420053586364
repeat O 0 7.069778348522959e-06
in O 0 5.887298470952373e-07
intron O 0 0.00010641029075486585
1 O 0 1.5182695278781466e-06
of O 0 3.0581819032704516e-07
the O 0 2.387701215411653e-06
FRDA B-Disease 0 0.002216363325715065
gene O 0 3.600731724873185e-05
. O 0 1.8023696611635387e-05

Occasionally O 0 0.0007453748839907348
, O 0 6.93351330482983e-06
a O 0 3.1675465379521484e-06
fully O 0 3.404034714549198e-06
expanded O 0 1.695927494438365e-06
allele O 0 4.227160843583988e-06
has O 0 5.653320727105893e-07
been O 0 1.0445521638757782e-06
found O 0 6.760585051779344e-07
to O 0 3.4851336749852635e-07
arise O 0 5.036542916059261e-07
from O 0 1.3231156970050506e-07
a O 0 4.785103442372929e-07
premutation O 0 8.573153536417522e-06
of O 0 1.0268080075093167e-07
100 O 0 4.254425221006386e-07
or O 0 8.167912710632663e-07
less O 0 3.013299419762916e-06
triplet O 0 0.010621799156069756
repeats O 0 0.00016146140114869922
. O 0 2.1654297597706318e-05

We O 0 6.0758902691304684e-05
have O 0 7.6227356657909695e-06
examined O 0 9.765016329765785e-06
the O 0 1.4004173181092483e-06
sperm O 0 9.81617358775111e-06
DNA O 0 4.05118044000119e-06
of O 0 6.809009960306867e-07
a O 0 1.3446313460008241e-05
premutation O 0 0.003603416495025158
carrier O 0 0.00047048949636518955
. O 0 2.1376179574872367e-05

This O 0 4.780986637342721e-05
mans O 0 0.00030033045914024115
leucocyte O 0 0.0007948451093398035
DNA O 0 5.988855627947487e-05
showed O 0 1.2094978046661709e-05
one O 0 4.864102720603114e-07
normal O 0 1.5769854826430674e-06
allele O 0 3.0409928513108753e-06
and O 0 4.3431961671558383e-07
one O 0 2.8418239139682555e-07
allele O 0 1.7516016441732063e-06
of O 0 2.036633048874137e-07
approximately O 0 1.9340479866514215e-06
100 O 0 4.560304205369903e-06
repeats O 0 3.023797762580216e-05
. O 0 1.0600229870760813e-05

His O 0 0.0002455871435813606
sperm O 0 0.0003143085050396621
showed O 0 2.9325237846933305e-05
an O 0 1.4816838529441156e-06
expanded O 0 2.8518520593934227e-06
allele O 0 6.056208803784102e-06
in O 0 5.698991571989609e-07
a O 0 8.753694942242873e-07
tight O 0 2.0832518202951178e-05
range O 0 1.0267409606967703e-06
centering O 0 2.112781658070162e-06
on O 0 6.647715622420947e-07
a O 0 4.948084892930638e-07
size O 0 1.7261008906643838e-06
of O 0 5.481806510942988e-07
approximately O 0 4.7620769692002796e-06
320 O 0 4.2203762859571725e-05
trinucleotide O 0 0.0007991146994754672
repeats O 0 8.310561679536477e-05
. O 0 3.125754665234126e-05

His O 0 0.0003900288138538599
affected O 0 0.0002063555730273947
son O 0 0.00324463052675128
has O 0 2.2707079097017413e-06
repeat O 0 6.647894679190358e-06
sizes O 0 4.965480002283584e-06
of O 0 8.095373686956009e-07
1040 O 0 0.0001350764650851488
and O 0 6.071568350307643e-06
540 O 0 6.450332148233429e-05
. O 0 1.6254254660452716e-05

These O 0 2.1762260075774975e-05
data O 0 8.227256330428645e-06
suggest O 0 1.8813493625202682e-06
that O 0 2.3233762647123513e-07
expansion O 0 6.860345820314251e-07
occurs O 0 2.570796482359583e-07
in O 0 1.1764354468368765e-07
two O 0 2.1279910811244918e-07
stages O 0 5.627433438348817e-06
, O 0 1.920801082633261e-07
the O 0 8.507247173383803e-08
first O 0 2.9690147584915394e-07
during O 0 5.744533382312511e-07
meiosis O 0 1.6343050219802535e-06
followed O 0 4.1320416244161606e-07
by O 0 1.5126980201785045e-07
a O 0 1.0316958878320293e-06
second O 0 8.610566510469653e-06
mitotic O 0 8.893900667317212e-05
expansion O 0 4.3819702113978565e-05
. O 0 2.2982254449743778e-05

We O 0 5.203025648370385e-05
also O 0 3.7328672988223843e-06
show O 0 1.9418844203755725e-06
that O 0 2.3226583323321393e-07
in O 0 1.4908302148342045e-07
all O 0 1.0862727606308908e-07
informative O 0 9.508979701422504e-07
carrier O 0 1.2654272723011672e-05
father O 0 1.264263210032368e-05
to O 0 6.353163257699634e-07
affected O 0 2.483654498064425e-06
child O 0 1.2370797776384279e-05
transmissions O 0 9.676699846750125e-05
, O 0 7.534961241617566e-07
with O 0 1.8750019137314666e-07
the O 0 2.0929347499532014e-07
notable O 0 4.0283703128807247e-07
exception O 0 3.2615022860227327e-07
of O 0 1.4298626638264977e-07
the O 0 1.0683517075449345e-06
premutation O 0 0.0005478906678035855
carrier O 0 3.0890067137079313e-05
, O 0 2.7530768420547247e-07
the O 0 2.4006536136766954e-07
expansion O 0 1.0488064390301588e-06
size O 0 7.578541499242419e-06
decreases O 0 1.414708276570309e-05
. O 0 3.023945055247168e-06
. O 0 1.02653430076316e-05

The O 0 8.603977767052129e-05
R496H O 0 0.0003509096277412027
mutation O 0 5.843753751832992e-05
of O 0 3.308996610940085e-06
arylsulfatase O 0 0.000753705040551722
A O 0 5.030570537201129e-05
does O 0 5.987519216432702e-06
not O 0 1.2308593795751221e-05
cause O 0 0.0004880873893853277
metachromatic B-Disease 1 0.9999878406524658
leukodystrophy I-Disease 1 0.9999847412109375
. O 0 0.0001324721670243889

Deficiency B-Disease 1 0.9996005892753601
of I-Disease 0 2.789767131616827e-05
arylsulfatase I-Disease 0 0.013905052095651627
A I-Disease 0 0.0001192021300084889
( O 0 9.727864380693063e-06
ARSA O 0 0.013088321313261986
) O 0 2.0111376670683967e-06
enzyme O 0 1.186393819807563e-05
activity O 0 9.395648703502957e-06
causes O 0 0.0001893066946649924
metachromatic B-Disease 1 0.9999945163726807
leukodystrophy I-Disease 1 0.9999984502792358
( O 0 0.0002908926398959011
MLD B-Disease 1 0.9999922513961792
) O 0 2.7286363547318615e-05
. O 0 2.3302727640839294e-05

A O 0 5.4713935242034495e-05
number O 0 5.281804533296963e-06
of O 0 2.5261704195145285e-06
ARSA O 0 0.016158822923898697
gene O 0 2.1928257410763763e-05
mutations O 0 1.9502285795169882e-05
responsible O 0 9.339850294054486e-06
for O 0 5.047341801400762e-06
MLD B-Disease 1 0.9999980926513672
have O 0 1.7967815438169055e-05
been O 0 2.165435944334604e-05
identified O 0 6.009405115037225e-05
. O 0 2.311259049747605e-05

Recently O 0 0.00032892744638957083
, O 0 6.980738362472039e-06
the O 0 2.4204082365031354e-06
R496H O 0 3.211178773199208e-05
mutation O 0 5.605596015811898e-06
of O 0 7.721905603830237e-07
ARSA O 0 0.028897209092974663
was O 0 1.9728729967027903e-05
proposed O 0 6.931304596946575e-07
to O 0 4.494168308610824e-07
be O 0 4.01183484655121e-07
a O 0 1.071305291588942e-06
cause O 0 4.718390300695319e-06
of O 0 1.201041186504881e-06
MLD B-Disease 1 0.9999942779541016
( O 0 2.7475266506371554e-06
Draghia O 0 0.0002174183464376256
et O 0 0.0001683527952991426
al O 0 0.0003846056351903826
. O 0 6.27087615612254e-07
, O 0 9.624409358366393e-07
1997 O 0 6.3810430219746195e-06
) O 0 2.506062401153031e-06
. O 0 6.855682840978261e-06

We O 0 0.00011134772648802027
have O 0 7.274785275512841e-06
investigated O 0 7.429806373693282e-06
the O 0 1.0473891052242834e-06
R496H O 0 3.3273892768193036e-05
mutation O 0 4.627473117579939e-06
and O 0 9.515829333395232e-07
found O 0 1.3114217836118769e-06
this O 0 9.730192829238149e-08
mutation O 0 1.8603675471240422e-06
at O 0 2.8723316063405946e-06
a O 0 6.877626788082125e-07
relatively O 0 5.019980449105788e-07
high O 0 1.2223260910104727e-06
frequency O 0 2.053684738712036e-06
in O 0 1.9950537932800216e-07
an O 0 2.1320376220046455e-07
African O 0 3.6968344829801936e-07
American O 0 1.951935360011703e-07
population O 0 2.1201093147737993e-07
( O 0 1.2969998408607353e-07
f O 0 4.657259978557704e-06
= O 0 1.3107917766319588e-05
0 O 0 2.2206766061572125e-06
. O 0 2.7716941986000165e-07
09 O 0 2.003204463107977e-05
, O 0 1.0197130677624955e-06
n O 0 2.9464448743965477e-05
= O 0 4.01574834540952e-05
61 O 0 5.8478990467847325e-06
subjects O 0 6.409336037904723e-06
) O 0 3.4785700790962437e-06
. O 0 8.743042599235196e-06

The O 0 0.00011183571768924594
ARSA O 0 0.004786264151334763
enzyme O 0 5.4846419516252354e-05
activity O 0 8.437052201770712e-06
in O 0 1.26775637454557e-06
subjects O 0 2.2495246412290726e-06
with O 0 9.456726388634706e-07
and O 0 3.6414160149433883e-06
without O 0 1.655772621234064e-06
the O 0 5.545344947677222e-07
R496H O 0 4.877938408753835e-05
mutation O 0 3.753540113393683e-06
was O 0 7.279518285940867e-06
determined O 0 1.226883114213706e-06
and O 0 6.655556603618606e-07
found O 0 1.5260270629369188e-06
to O 0 7.583086585327692e-07
be O 0 1.3020280675846152e-06
normal O 0 8.981637620308902e-06
. O 0 6.105238753661979e-06

It O 0 5.0151898904005066e-05
is O 0 4.314243142289342e-06
therefore O 0 1.148074034063029e-06
concluded O 0 1.7630951560931862e-06
that O 0 1.0898194346964374e-07
the O 0 3.139734587875864e-07
R496H O 0 1.3531264812627342e-05
mutation O 0 2.2706340132572223e-06
of O 0 4.5244087232276797e-07
ARSA O 0 0.010958160273730755
does O 0 9.725625886858325e-07
not O 0 2.8498163828771794e-07
negatively O 0 5.57853923055518e-07
influence O 0 2.937930503321695e-07
the O 0 1.517726673228026e-07
activity O 0 4.0440909288008697e-07
of O 0 2.4907797069317894e-07
ARSA O 0 0.017187176272273064
and O 0 1.653103026910685e-06
is O 0 2.7964927085122326e-07
not O 0 2.3133229376526288e-07
a O 0 1.7187387584272074e-06
cause O 0 1.3658826901519205e-05
of O 0 2.710042826947756e-05
MLD B-Disease 1 0.9999840259552002

Down O 0 0.0007327898638322949
- O 0 0.00011686696234392002
regulation O 0 9.882505764835514e-06
of O 0 1.4202518059391878e-06
transmembrane O 0 4.924819586449303e-05
carbonic O 0 7.519075006712228e-05
anhydrases O 0 0.0005204560002312064
in O 0 0.00019042401982005686
renal B-Disease 1 0.9999990463256836
cell I-Disease 1 0.9999929666519165
carcinoma I-Disease 1 1.0
cell O 0 0.13061900436878204
lines O 0 3.061862662434578e-05
by O 0 7.218952191578865e-07
wild O 0 4.292606263334164e-06
- O 0 0.00021143793128430843
type O 0 0.00017520447727292776
von B-Disease 1 0.9595032930374146
Hippel I-Disease 1 0.9604769945144653
- I-Disease 0 0.36993077397346497
Lindau I-Disease 1 0.8322484493255615
transgenes O 0 0.002351256785914302
. O 0 0.00010651475167833269

To O 0 5.644020711770281e-05
discover O 0 0.00010779166041174904
genes O 0 2.3490214516641572e-05
involved O 0 8.30480803415412e-06
in O 0 5.87760496273404e-06
von B-Disease 1 0.8215169906616211
Hippel I-Disease 1 0.9410353899002075
- I-Disease 0 0.37255698442459106
Lindau I-Disease 1 0.966666042804718
( O 0 1.2238189810886979e-05
VHL B-Disease 0 0.0010383381741121411
) O 0 2.4523510546714533e-06
- O 0 4.401436308398843e-05
mediated O 0 5.331705688149668e-05
carcinogenesis O 0 0.0005264163482934237
, O 0 3.029100071216817e-06
we O 0 3.7355348467826843e-06
used O 0 0.0004025090020149946
renal B-Disease 1 0.999996542930603
cell I-Disease 1 0.999969482421875
carcinoma I-Disease 1 1.0
cell O 1 0.5212157964706421
lines O 0 0.0007425760850310326
stably O 0 0.0006557197775691748
transfected O 0 0.00017790637502912432
with O 0 3.4020488328678766e-06
wild O 0 1.4310442566056736e-05
- O 0 0.0007459749467670918
type O 0 0.0010929977288469672
VHL O 0 0.3570424020290375
- O 0 0.0009842091239988804
expressing O 0 6.557328742928803e-05
transgenes O 0 0.00038235291140154004
. O 0 3.701729656313546e-05

Large O 0 8.578842243878171e-05
- O 0 8.03208167781122e-05
scale O 0 3.2632608053972945e-05
RNA O 0 1.1581148100958671e-05
differential O 0 5.302375484461663e-06
display O 0 5.0347271098871715e-06
technology O 0 8.410157533944584e-06
applied O 0 1.492161572969053e-06
to O 0 4.5181911900726845e-07
these O 0 2.9569773118964804e-07
cell O 0 1.3860576473234687e-05
lines O 0 9.071715794561896e-06
identified O 0 1.4734672504346236e-06
several O 0 1.3010719612793764e-07
differentially O 0 5.586090082942974e-06
expressed O 0 3.897685303400067e-07
genes O 0 8.234432584686147e-07
, O 0 1.372792439724435e-07
including O 0 1.121391974834296e-07
an O 0 5.167125891603064e-07
alpha O 0 7.785714842611924e-06
carbonic O 0 2.397370735707227e-05
anhydrase O 0 3.925358396372758e-05
gene O 0 1.2556432011479046e-05
, O 0 4.2910596675937995e-06
termed O 0 8.043578418437392e-05
CA12 O 0 0.001398436608724296
. O 0 3.322502743685618e-05

The O 0 4.354676275397651e-05
deduced O 0 8.407280984101817e-05
protein O 0 1.5256955521181226e-05
sequence O 0 5.809671165479813e-06
was O 0 1.5336663636844605e-05
classified O 0 2.461879148540902e-06
as O 0 2.2953884126764024e-07
a O 0 7.085126867423241e-07
one O 0 1.3039032182859955e-06
- O 0 7.493463635910302e-05
pass O 0 1.9779496142291464e-05
transmembrane O 0 0.0001933713210746646
CA O 0 0.0002392097085248679
possessing O 0 5.8104251365875825e-06
an O 0 1.9563722162274644e-06
apparently O 0 8.465186692774296e-05
intact O 0 6.654066510236589e-06
catalytic O 0 3.68649079973693e-06
domain O 0 1.4275630064730649e-06
in O 0 3.3186753967129334e-07
the O 0 1.0593938668534975e-06
extracellular O 0 9.271471208194271e-05
CA O 0 0.0015196566237136722
module O 0 0.000288507406366989
. O 0 2.0784853404620662e-05

Reintroduced O 0 0.0009176351595669985
wild O 0 0.00013546482659876347
- O 0 0.0003377391258254647
type O 0 0.00017914391355589032
VHL B-Disease 0 0.00434466265141964
strongly O 0 8.375660399906337e-06
inhibited O 0 1.0539769391471054e-05
the O 0 5.768964115304698e-07
overexpression O 0 3.855995601043105e-06
of O 0 2.190839012428114e-07
the O 0 1.0033030548584065e-06
CA12 O 0 0.00043855843250639737
gene O 0 2.840498154910165e-06
in O 0 5.767511765952804e-07
the O 0 5.170688382349908e-06
parental O 1 0.9913461804389954
renal B-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999977350234985
carcinoma I-Disease 1 1.0
cell O 1 0.8393704891204834
lines O 0 0.005189609248191118
. O 0 9.819738625083119e-05

Similar O 0 9.977378067560494e-05
results O 0 6.812455103499815e-05
were O 0 1.441577660443727e-05
obtained O 0 4.7221042223100085e-06
with O 0 3.5581147130869795e-06
CA9 O 0 0.0006903255707584321
, O 0 5.127276381244883e-07
encoding O 0 1.4912000096956035e-06
another O 0 2.705616225284757e-06
transmembrane O 0 0.00022477397578768432
CA O 0 0.0018449935596436262
with O 0 7.160868449318514e-07
an O 0 2.7716096155927517e-06
intact O 0 4.150200038566254e-05
catalytic O 0 4.0114995499607176e-05
domain O 0 5.696965308743529e-05
. O 0 2.5734194423421286e-05

Although O 0 3.422466397751123e-05
both O 0 2.6508269002079032e-06
domains O 0 4.910271400149213e-06
of O 0 5.00692749483278e-07
the O 0 1.7226673207915155e-06
VHL B-Disease 0 0.0012432537041604519
protein O 0 3.4929305456898874e-06
contribute O 0 7.505020107601013e-07
to O 0 1.728079439544672e-07
regulation O 0 8.570582963329798e-07
of O 0 2.1973717423406924e-07
CA12 O 0 0.0005383793031796813
expression O 0 7.697641990489501e-07
, O 0 2.8705193244604743e-07
the O 0 5.264853939479508e-07
elongin O 0 4.2738622141769156e-05
binding O 0 3.6011726933793398e-06
domain O 0 5.671855888067512e-06
alone O 0 1.043736392603023e-05
could O 0 2.9516622817027383e-06
effectively O 0 1.7528584066894837e-05
regulate O 0 3.120024484815076e-05
CA9 O 0 0.0006549918325617909
expression O 0 1.7846365153673105e-05
. O 0 2.0333085558377206e-05

We O 0 7.253932562889531e-05
mapped O 0 0.00027564101037569344
CA12 O 0 0.003471254836767912
and O 0 1.9823306502075866e-05
CA9 O 0 0.0010123486863449216
loci O 0 4.567213181871921e-05
to O 0 2.977883696075878e-06
chromosome O 0 0.00026147684548050165
bands O 0 4.7625930164940655e-05
15q22 O 0 8.532973151886836e-05
and O 0 1.0028075848822482e-05
17q21 O 0 0.00045993374078534544
. O 0 2.415977360215038e-05

2 O 0 0.000261093198787421
respectively O 0 5.8176978200208396e-05
, O 0 2.519289864721941e-06
regions O 0 3.525143483784632e-06
prone O 0 0.00011372023436706513
to O 0 1.091732997338113e-06
amplification O 0 3.84606137231458e-05
in O 0 1.1465236866570194e-06
some O 0 9.134864740190096e-07
human O 0 2.0632352971006185e-05
cancers B-Disease 0 0.04039256274700165
. O 0 2.2663274648948573e-05

Additional O 0 4.644275759346783e-05
experiments O 0 5.8693774917628616e-05
are O 0 1.522443881185609e-06
needed O 0 2.4796879642963177e-06
to O 0 6.498170250779367e-07
define O 0 1.725353854453715e-06
the O 0 4.172435694727028e-07
role O 0 5.005371122024371e-07
of O 0 3.180448686634918e-07
CA O 0 0.000776244152802974
IX O 0 0.00018413836369290948
and O 0 8.247569894592743e-06
CA O 0 0.0002367117558605969
XII O 0 7.900389755377546e-05
enzymes O 0 3.3220555906154914e-06
in O 0 3.355004025706876e-07
the O 0 1.9268374273906375e-07
regulation O 0 1.2751627309626201e-06
of O 0 1.9415459462379658e-07
pH O 0 4.561258538160473e-05
in O 0 3.892577637998329e-07
the O 0 5.255207611298829e-07
extracellular O 0 7.264967734954553e-06
microenvironment O 0 3.6592748074326664e-05
and O 0 4.998787517251913e-07
its O 0 2.6889017590292497e-07
potential O 0 6.820981752753141e-07
impact O 0 1.691872739684186e-06
on O 0 1.8070506484946236e-05
cancer B-Disease 0 0.09509684890508652
cell O 0 0.0003455322585068643
growth O 0 2.3581947971251793e-05
. O 0 1.56462501763599e-05

A O 0 0.00012242415687069297
gene O 0 3.272822141298093e-05
encoding O 0 1.026238805934554e-05
a O 0 4.96415441375575e-06
transmembrane O 0 2.0627316189347766e-05
protein O 0 5.299559688864974e-06
is O 0 4.7046091822267044e-07
mutated O 0 9.003332706924994e-06
in O 0 4.680569418269442e-06
patients O 0 0.002319258637726307
with O 0 0.05014844983816147
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9873284101486206
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999988079071045
( O 1 0.7720494866371155
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 4.429090768098831e-05
. O 0 2.9613380320370197e-05

Wolfram B-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
( O 0 0.10051474720239639
WFS B-Disease 1 0.9997820258140564
; O 0 0.00039048102917149663
OMIM O 1 0.9727103114128113
222300 O 0 0.0676056370139122
) O 0 7.033013389445841e-06
is O 0 2.198907168349251e-06
an O 0 5.6026219681371003e-05
autosomal B-Disease 1 0.9999880790710449
recessive I-Disease 1 0.9999997615814209
neurodegenerative I-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999123811721802
defined O 0 2.3738313757348806e-05
by O 0 1.0663513876352226e-06
young O 0 1.3346370906219818e-05
- O 0 0.0028595016337931156
onset O 0 0.0130999106913805
non O 0 7.598790398333222e-05
- O 1 0.6713516712188721
immune O 0 0.017402566969394684
insulin B-Disease 0 0.05233662202954292
- I-Disease 1 0.9806006550788879
dependent I-Disease 1 0.8364885449409485
diabetes I-Disease 1 1.0
mellitus I-Disease 1 0.9999998807907104
and O 0 0.013186107389628887
progressive O 1 0.8103857040405273
optic B-Disease 1 0.9999995231628418
atrophy I-Disease 1 0.997409999370575
. O 0 0.00020967867749277502

Linkage O 0 0.00083790352800861
to O 0 2.5670833565527573e-05
markers O 0 0.0001407987583661452
on O 0 3.282932084403001e-05
chromosome O 1 0.6481606960296631
4p O 1 0.9961005449295044
was O 0 0.0005193711840547621
confirmed O 0 1.1271359653619584e-05
in O 0 9.548609796183882e-07
five O 0 5.3497137741942424e-06
families O 0 1.2672834600380156e-05
. O 0 1.2607089956873097e-05

On O 0 2.85085043287836e-05
the O 0 3.076950861213845e-06
basis O 0 1.7568009980095667e-06
of O 0 8.139630836012657e-07
meiotic O 0 0.0002316632162546739
recombinants O 0 0.09385689347982407
and O 0 0.00015963875921443105
disease O 1 0.7043012380599976
- O 0 0.003733355086296797
associated O 0 1.0145430678676348e-05
haplotypes O 0 3.274389382568188e-05
, O 0 1.0082196695293533e-06
the O 0 1.296342247769644e-06
WFS B-Disease 0 0.018124772235751152
gene O 0 6.32882074569352e-06
was O 0 6.256233973545022e-06
localized O 0 3.5105636015941855e-06
to O 0 8.958675721260079e-07
a O 0 3.8074244912422728e-06
BAC O 0 0.0001590278698131442
/ O 0 1.1729009202099405e-05
P1 O 0 0.00010469531844137236
contig O 0 3.214705429854803e-05
of O 0 1.818859090008118e-07
less O 0 5.686667918780586e-07
than O 0 5.225232939665148e-07
250 O 0 3.6605035802494967e-06
kb O 0 0.0023001539520919323
. O 0 2.1808547899127007e-05

Mutations O 0 0.0019080915953963995
in O 0 2.187866448366549e-05
a O 0 1.0653954632289242e-05
novel O 0 1.0205331818724517e-05
gene O 0 1.0696661775000393e-05
( O 0 1.1111843605249305e-06
WFS1 O 0 8.743376383790746e-05
) O 0 2.395437093127839e-07
encoding O 0 5.845311648045026e-07
a O 0 5.220779826231592e-07
putative O 0 6.3878078435664065e-06
transmembrane O 0 6.6795873863156885e-06
protein O 0 3.3640178571658907e-06
were O 0 8.259960850409698e-06
found O 0 1.2911417570649064e-06
in O 0 2.460015195993037e-07
all O 0 1.9769566961258533e-07
affected O 0 1.6135926443894277e-06
individuals O 0 1.5114808604721475e-07
in O 0 3.255237572830083e-07
six O 0 1.2629039702005684e-05
WFS B-Disease 1 0.8124104142189026
families O 0 1.3443530406220816e-05
, O 0 6.006656576573732e-07
and O 0 4.942161808685341e-07
these O 0 1.8718662886385573e-07
mutations O 0 5.175369551579934e-06
were O 0 2.5210779313056264e-06
associated O 0 1.4104078900345485e-06
with O 0 2.196274863308645e-06
the O 0 0.00023496839276049286
disease O 1 0.5651684999465942
phenotype O 0 0.0021733895409852266
. O 0 3.8453097658930346e-05

WFS1 O 0 0.11234334111213684
appears O 0 0.00011359277414157987
to O 0 6.3333914113172796e-06
function O 0 3.389050789337489e-06
in O 0 1.482230914007232e-06
survival O 0 2.1679114070138894e-05
of O 0 4.3268371996418864e-07
islet O 0 0.00012218367191962898
beta O 0 9.678978130978066e-06
- O 0 0.00010050676792161539
cells O 0 4.76267223348259e-06
and O 0 1.2812430441044853e-06
neurons O 0 1.7212687453138642e-05
. O 0 2.1917239791946486e-06
. O 0 1.1179616194567643e-05

Stable O 0 0.00048090514610521495
interaction O 0 9.834202501224354e-06
between O 0 1.788202553143492e-06
the O 0 6.714656137774e-07
products O 0 6.202501481311629e-07
of O 0 1.4704167483614583e-07
the O 0 9.575575177223072e-07
BRCA1 O 0 0.00020995551312807947
and O 0 1.3656196642841678e-05
BRCA2 O 0 0.027008235454559326
tumor B-Disease 0 0.0003160102933179587
suppressor O 0 4.067607005708851e-05
genes O 0 5.293937647365965e-06
in O 0 1.4672609722765628e-06
mitotic O 0 3.8403701182687655e-05
and O 0 1.709235948510468e-05
meiotic O 0 0.0021278962958604097
cells O 0 0.00014844871475361288
. O 0 2.2413561964640394e-05

BRCA1 O 0 0.39364200830459595
and O 0 0.00014004705008119345
BRCA2 O 0 0.004458531737327576
account O 0 1.3317915545485448e-05
for O 0 6.566396564267052e-07
most O 0 3.384750471013831e-07
cases O 0 3.3150664080494607e-07
of O 0 2.035652499898788e-07
familial O 0 0.023393772542476654
, O 0 7.785714842611924e-06
early O 0 2.2092228391557e-05
onset O 1 0.8704721927642822
breast B-Disease 1 0.9948904514312744
and I-Disease 0 0.018387535586953163
/ I-Disease 1 0.9981726408004761
or I-Disease 1 0.9996953010559082
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
and O 0 5.9822455114044715e-06
encode O 0 1.0024107723438647e-05
products O 0 4.973811883246526e-06
that O 0 1.9836117814975296e-07
each O 0 2.66238743051872e-07
interact O 0 1.3931867215433158e-06
with O 0 2.5029526113939937e-06
hRAD51 O 0 0.00026378806796856225
. O 0 2.0434852558537386e-05

Results O 0 0.0002922623243648559
presented O 0 1.3441043847706169e-05
here O 0 2.42154419538565e-06
show O 0 2.5611357159505133e-06
that O 0 7.294628403542447e-07
BRCA1 O 0 0.00023123665596358478
and O 0 1.0180264325754251e-05
BRCA2 O 0 0.0038235788233578205
coexist O 0 1.7156342437374406e-05
in O 0 7.575266067760822e-07
a O 0 2.911854608100839e-06
biochemical O 0 0.00013466260861605406
complex O 0 8.916382284951396e-06
and O 0 2.741917342063971e-06
colocalize O 0 9.589223918737844e-05
in O 0 1.0564579042693367e-06
subnuclear O 0 4.2012499761767685e-05
foci O 0 1.2377736311464105e-05
in O 0 6.34064008409041e-07
somatic O 0 1.4007076060806867e-05
cells O 0 4.6140326048771385e-06
and O 0 2.6531259322837286e-07
on O 0 3.28848727804143e-07
the O 0 1.932230873080698e-07
axial O 0 1.6757873027017922e-06
elements O 0 4.2391567944832786e-07
of O 0 5.015299961996789e-07
developing O 0 1.5834453733987175e-05
synaptonemal O 0 0.0006761701079085469
complexes O 0 0.00010217779345111921
. O 0 2.0640618458855897e-05

Like O 0 0.0002928991161752492
BRCA1 O 0 0.004051872529089451
and O 0 7.228645699797198e-05
RAD51 O 0 0.010124120861291885
, O 0 1.948880890267901e-05
BRCA2 O 0 0.000269989890512079
relocates O 0 7.543752144556493e-05
to O 0 6.9334205363702495e-06
PCNA O 0 0.0006283065304160118
+ O 0 9.096456778934225e-06
replication O 0 6.910527190484572e-06
sites O 0 2.1984083105053287e-06
following O 0 1.1740362424461637e-06
exposure O 0 8.487055310979486e-06
of O 0 5.86047747219709e-07
S O 0 0.00013575695629697293
phase O 0 9.396616405865643e-06
cells O 0 5.822806087962817e-06
to O 0 1.777041916284361e-06
hydroxyurea O 0 0.00011390754661988467
or O 0 7.866167834436055e-06
UV O 0 0.0009241359075531363
irradiation O 0 0.00018223606457468122
. O 0 3.4362314181635156e-05

Thus O 0 0.00019217234512325376
, O 0 1.69319064298179e-05
BRCA1 O 0 0.00029146813903935254
and O 0 6.486730399046792e-06
BRCA2 O 0 0.00021048751659691334
participate O 0 2.5530152925057337e-06
, O 0 9.740375617184327e-07
together O 0 1.917791678351932e-06
, O 0 2.3402233750857704e-07
in O 0 2.7318762363393034e-07
a O 0 2.4189591840695357e-06
pathway O 0 9.38174343900755e-06
( O 0 4.2023461332973966e-07
s O 0 2.0010871594422497e-05
) O 0 1.7775796834484936e-07
associated O 0 2.5754934540600516e-07
with O 0 1.3404637400071806e-07
the O 0 3.0663503025607497e-07
activation O 0 7.913653803370835e-07
of O 0 1.787940533404253e-07
double O 0 2.0307255908846855e-05
- O 0 0.0018731270683929324
strand O 0 0.00016536223120056093
break O 0 0.00014027958968654275
repair O 0 0.12262017279863358
and O 0 1.1468297088867985e-05
/ O 0 4.4417884055292234e-05
or O 0 3.5057723835052457e-06
homologous O 0 2.1835852749063633e-05
recombination O 0 7.130074664019048e-05
. O 0 2.8993024898227304e-05

Dysfunction O 1 0.848491370677948
of O 0 1.20105869427789e-05
this O 0 3.728238880285062e-06
pathway O 0 5.6881872296798974e-05
may O 0 1.0838119123945944e-05
be O 0 2.4860000280568784e-07
a O 0 3.2904574709391454e-07
general O 0 2.846795723598916e-07
phenomenon O 0 6.396101639438712e-07
in O 0 1.2218465883506724e-07
the O 0 2.1295259955422807e-07
majority O 0 2.2424018197853002e-07
of O 0 5.977734929274447e-08
cases O 0 1.9199752898657607e-07
of O 0 7.553530281256826e-07
hereditary B-Disease 1 0.9968681931495667
breast I-Disease 1 0.9992713332176208
and I-Disease 0 0.015852322801947594
/ I-Disease 1 0.9994625449180603
or I-Disease 1 0.9997187256813049
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.4847942768246867e-05
. O 0 2.003422378038522e-05

A O 0 0.00031239655800163746
novel O 0 8.160097786458209e-05
Arg362Ser O 0 0.0003217851626686752
mutation O 0 1.4511861991195474e-05
in O 0 2.0056270386703545e-06
the O 0 2.490248107278603e-06
sterol O 0 0.00013207283336669207
27 O 0 3.790388655033894e-05
- O 0 8.88916983967647e-05
hydroxylase O 0 4.647040623240173e-05
gene O 0 3.646670847956557e-06
( O 0 5.253493782220175e-07
CYP27 O 0 0.00010667892638593912
) O 0 3.112711226549436e-07
: O 0 1.4106323931173392e-07
its O 0 1.614903055724426e-07
effects O 0 8.417182471021079e-07
on O 0 5.297147254168522e-07
pre O 0 8.657862053951249e-06
- O 0 4.299256033846177e-06
mRNA O 0 1.51799292780197e-06
splicing O 0 6.259503606997896e-06
and O 0 1.2620314464584226e-06
enzyme O 0 9.88064130069688e-06
activity O 0 6.459913038270315e-06
. O 0 9.106499419431202e-06

A O 0 0.00014178900164552033
novel O 0 5.0017115427181125e-05
C O 0 0.00011054158676415682
to O 0 1.7052822158802883e-06
A O 0 4.676932803704403e-06
mutation O 0 4.488772447075462e-06
in O 0 4.89422234295489e-07
the O 0 9.566338121658191e-07
sterol O 0 6.883386231493205e-05
27 O 0 2.338690319447778e-05
- O 0 4.299546708352864e-05
hydroxylase O 0 3.273487163824029e-05
gene O 0 3.168132707287441e-06
( O 0 3.562552421954024e-07
CYP27 O 0 0.00010816398571478203
) O 0 4.7321972829195147e-07
was O 0 1.784027631401841e-06
identified O 0 6.741913693986135e-07
by O 0 2.478335261457687e-07
sequencing O 0 3.76275443159102e-06
amplified O 0 1.1530377378221601e-05
CYP27 O 0 0.00016077897453214973
gene O 0 3.619724566306104e-06
products O 0 1.3621473726743716e-06
from O 0 7.122632155187603e-07
a O 0 5.342423264664831e-06
patient O 0 0.0001240057172253728
with O 0 2.5608604119042866e-05
cerebrotendinous B-Disease 1 0.9999966621398926
xanthomatosis I-Disease 1 0.9999886751174927
( O 0 3.3583466574782506e-05
CTX B-Disease 0 0.46463239192962646
) O 0 9.791435331862886e-06
. O 0 1.8528338841861114e-05

The O 0 5.513210271601565e-05
mutation O 0 0.0001561954995850101
changed O 0 1.545321720186621e-05
the O 0 2.7037306153943064e-06
adrenodoxin O 0 5.012684050598182e-05
cofactor O 0 1.6414700439781882e-05
binding O 0 1.0593539627734572e-05
residue O 0 4.642806379706599e-05
362Arg O 0 4.3003914470318705e-05
to O 0 2.752538421191275e-06
362Ser O 0 4.808668381883763e-05
( O 0 1.007962055155076e-06
CGT O 0 3.248165739933029e-05
362Arg O 0 1.2346778021310456e-05
to O 0 1.278565036955115e-06
AGT O 0 0.0002545735624153167
362Ser O 0 7.02495890436694e-05
) O 0 3.855753050174826e-07
, O 0 1.8091813558385184e-07
and O 0 5.791156922896334e-07
was O 0 0.00020064630371052772
responsible O 0 1.546104613225907e-05
for O 0 5.301263172441395e-06
deficiency O 0 0.005663510411977768
in O 0 4.45380550218033e-07
the O 0 6.428855954254686e-07
sterol O 0 5.47349191037938e-05
27 O 0 1.0516537258808967e-05
- O 0 1.3730475075135473e-05
hydroxylase O 0 6.2177023210097104e-06
activity O 0 5.201428052714618e-07
, O 0 1.3360440220822056e-07
as O 0 1.012954058410287e-07
confirmed O 0 2.2066747362714523e-07
by O 0 4.2146872658577195e-08
expression O 0 1.6534895053155196e-07
of O 0 6.393521800873714e-08
mutant O 0 2.7695750759448856e-06
cDNA O 0 3.6019594062963733e-06
into O 0 3.396126658117282e-06
COS O 0 0.00047138417721726
- O 0 6.355970253935084e-05
1 O 0 6.869918252050411e-06
cells O 0 1.5696463378844783e-05
. O 0 9.420779861102346e-06

Quantitative O 0 0.00025041826302185655
analysis O 0 2.600058724055998e-05
showed O 0 1.6901061826501973e-05
that O 0 2.8793036221941293e-07
the O 0 2.5822171778600023e-07
expression O 0 2.4101436224555073e-07
of O 0 1.953581687530459e-07
CYP27 O 0 3.5872002627002075e-05
gene O 0 1.3424239568848861e-06
mRNA O 0 8.263122026619385e-07
in O 0 3.096935188295902e-07
the O 0 8.204042387660593e-07
patient O 0 1.8930995793198235e-05
represented O 0 7.767470378894359e-06
52 O 0 6.231003499124199e-05
. O 0 2.0434928956092335e-05

5 O 0 9.486431372351944e-05
% O 0 6.053535344108241e-06
of O 0 1.1513327535794815e-06
the O 0 1.3786008139504702e-06
normal O 0 1.0447003660374321e-05
level O 0 1.865110607468523e-05
. O 0 1.261153920495417e-05

As O 0 2.8213700716150925e-05
the O 0 8.884197995939758e-06
mutation O 0 2.2263266146183014e-05
occurred O 0 6.837225555500481e-06
at O 0 5.102358500153059e-06
the O 0 1.0994983767886879e-06
penultimate O 0 1.7576910977368243e-05
nucleotide O 0 2.609523335195263e-06
of O 0 2.438516446545691e-07
exon O 0 6.125651452748571e-06
6 O 0 3.25047744809126e-06
( O 0 2.1034158237398515e-07
- O 0 2.3826969481888227e-06
2 O 0 5.940476626165037e-07
position O 0 4.336656900250091e-07
of O 0 1.1133402466612097e-07
exon O 0 5.266714651952498e-06
6 O 0 3.4292381769773783e-06
- O 0 2.283687899762299e-05
intron O 0 0.00011687675578286871
6 O 0 3.141680281260051e-06
splice O 0 7.54399734432809e-05
site O 0 4.600622105499497e-06
) O 0 1.3872323734176462e-07
of O 0 4.861709257397706e-08
the O 0 1.6254624313205568e-07
gene O 0 1.3912642771174433e-06
, O 0 2.257367839320068e-07
we O 0 3.5242689477854583e-07
hypothesized O 0 1.0510353831705288e-06
that O 0 1.214519329550967e-07
the O 0 5.56843986032618e-07
mutation O 0 1.4951108823879622e-05
may O 0 1.218056604557205e-05
partially O 0 2.1027006368967704e-05
affect O 0 3.585053036658792e-07
the O 0 2.3242449742610916e-07
normal O 0 7.01580461281992e-07
splicing O 0 3.347651045260136e-06
efficiency O 0 2.178472641389817e-06
in O 0 3.8493931242555846e-07
exon O 0 5.903906640014611e-06
6 O 0 3.0882217743055662e-06
and O 0 9.288474416280224e-07
cause O 0 8.383999556826893e-07
alternative O 0 7.493898692700895e-07
splicing O 0 7.488564278901322e-06
elsewhere O 0 4.983901817467995e-06
, O 0 4.3719703057831794e-07
which O 0 2.987869152093481e-07
resulted O 0 1.7776453660189873e-06
in O 0 5.640197286993498e-07
decreased O 0 8.790765605226625e-06
transcript O 0 5.220593266130891e-06
in O 0 7.071808454384154e-07
the O 0 4.562183221423766e-06
patient O 0 0.00013282518193591386
. O 0 1.335896558884997e-05

Transfection O 0 0.004397379234433174
of O 0 4.166271537542343e-05
constructed O 0 0.00044842224451713264
minigenes O 0 0.00638593640178442
, O 0 3.3247335977648618e-06
with O 0 1.2665999520322657e-06
or O 0 2.1676735286746407e-06
without O 0 6.589374947907345e-07
the O 0 3.380833675237227e-07
mutation O 0 3.25601263284625e-06
, O 0 4.1382924109711894e-07
into O 0 9.952846085070632e-07
COS O 0 0.003207899397239089
- O 0 4.9672402383293957e-05
1 O 0 2.6046748189401114e-06
cells O 0 1.677677346378914e-06
confirmed O 0 7.040295599836099e-07
that O 0 5.021933446869298e-08
the O 0 1.5510950390762446e-07
mutant O 0 1.2913048522023018e-05
minigene O 0 0.00015867054753471166
was O 0 1.629000689717941e-05
responsible O 0 1.093314608624496e-06
for O 0 1.12636087123974e-07
a O 0 3.844319280688069e-07
mRNA O 0 1.4429641623792122e-06
species O 0 3.5500781336850196e-07
alternatively O 0 1.6406842178184888e-06
spliced O 0 2.453598972351756e-05
at O 0 1.7934349671122618e-05
an O 0 1.5306183058783063e-06
activated O 0 6.536913133459166e-05
cryptic O 0 1.1435696251282934e-05
5 O 0 1.4984190102040884e-06
splice O 0 5.898543167859316e-05
site O 0 9.527874681225512e-06
88 O 0 1.1146230463054962e-05
bp O 0 2.0357785615487956e-05
upstream O 0 1.299670998378133e-06
from O 0 2.219231731714899e-07
the O 0 2.401374956662039e-07
3 O 0 7.454978572241089e-07
end O 0 5.434459353637067e-07
of O 0 6.400073857548705e-07
exon O 0 5.635141133097932e-05
6 O 0 2.723037323448807e-05
. O 0 1.6175297787413e-05

Our O 0 8.391509618377313e-05
data O 0 1.11305525933858e-05
suggest O 0 2.9868429010093678e-06
that O 0 2.771075742202811e-07
the O 0 4.748870878756861e-07
C O 0 1.8387729141977616e-05
to O 0 4.411785141655855e-07
A O 0 2.62604021372681e-06
mutation O 0 3.3773965242289705e-06
at O 0 1.087190526050108e-06
the O 0 2.49410987862575e-07
penultimate O 0 8.127855835482478e-06
nucleotide O 0 1.8972662019223208e-06
of O 0 8.469039158853775e-08
exon O 0 3.3992919270531274e-06
6 O 0 1.231147052749293e-06
of O 0 8.430005493664794e-08
the O 0 6.543267545566778e-07
CYP27 O 0 0.0011043219128623605
gene O 0 2.140252718163538e-06
not O 0 3.318434949051152e-07
only O 0 3.359931497470825e-07
causes O 0 1.984137043109513e-06
the O 0 9.940144991560373e-06
deficiency B-Disease 0 0.008082976564764977
in I-Disease 0 4.5958591954331496e-07
the I-Disease 0 8.932153718888003e-07
sterol I-Disease 0 3.356131128384732e-05
27 I-Disease 0 8.31248689792119e-06
- I-Disease 0 6.74760030960897e-06
hydroxylase I-Disease 0 7.2264920163434e-06
activity I-Disease 0 8.69161397076823e-07
, O 0 2.089598183374619e-07
but O 0 2.2806206345649116e-07
also O 0 5.125888264956302e-07
partially O 0 3.6332994568510912e-06
leads O 0 1.5430248367920285e-07
to O 0 7.554259440212263e-08
alternative O 0 2.4411107801824983e-07
pre O 0 2.544250492064748e-06
- O 0 1.3586366094386904e-06
mRNA O 0 8.068120109783194e-07
splicing O 0 2.0304710233176593e-06
of O 0 2.700010384160123e-07
the O 0 1.5521399063800345e-06
gene O 0 2.134666283382103e-05
. O 0 1.732827331579756e-05

To O 0 2.0712472178274766e-05
our O 0 5.526889708562521e-06
knowledge O 0 2.2080523649492534e-06
, O 0 5.539097855944419e-07
this O 0 1.45632995440792e-07
is O 0 1.1547157896529825e-07
the O 0 1.6880291298093653e-07
first O 0 1.7203917650476797e-06
report O 0 6.638238119194284e-07
regarding O 0 2.231602707070124e-07
effects O 0 5.607865887213848e-07
on O 0 3.2075922717922367e-07
pre O 0 5.614177098323125e-06
- O 0 2.5123390514636412e-06
mRNA O 0 4.6754604454690707e-07
splicing O 0 1.5274888482963433e-06
of O 0 1.9267308459802734e-07
a O 0 7.50773267554905e-07
mutation O 0 1.5992931139408029e-06
at O 0 1.7589100025361404e-06
the O 0 2.423650471428118e-07
- O 0 1.2338938176981173e-05
2 O 0 8.586765716245282e-07
position O 0 4.013510874756321e-07
of O 0 6.481027270410777e-08
a O 0 6.409388788597425e-07
5 O 0 1.8103014554071706e-06
splice O 0 0.0002224133932031691
site O 0 3.974836363340728e-05
. O 0 9.32713010115549e-06

ATM O 0 0.060616012662649155
germline O 0 0.00965845212340355
mutations O 0 0.0006739075179211795
in O 0 2.8850265152868815e-05
classical O 0 0.000994125846773386
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
patients O 1 0.9720988273620605
in O 0 6.316784947557608e-06
the O 0 4.068378530064365e-06
Dutch O 0 0.0002548557531554252
population O 0 6.387272151187062e-06
. O 0 1.0971355550282169e-05

Germline O 0 0.010844063945114613
mutations O 0 0.0006859945715405047
in O 0 6.960689461266156e-06
the O 0 2.6872071430261713e-06
ATM O 0 0.003970766440033913
gene O 0 1.2678660823439714e-05
are O 0 5.931917144152976e-07
responsible O 0 4.786719273397466e-06
for O 0 1.8138994164473843e-06
the O 0 0.4101296663284302
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00520434882491827
A B-Disease 1 0.9999959468841553
- I-Disease 1 0.9999990463256836
T I-Disease 1 0.9999998807907104
) O 0 1.2797124327335041e-05
. O 0 1.1517563507368322e-05

In O 0 5.223841799306683e-05
our O 0 1.028356928145513e-05
study O 0 3.2964328511297936e-06
, O 0 1.5740960179755348e-06
we O 0 8.992324183054734e-07
have O 0 3.5936929521085403e-07
determined O 0 5.662910211867711e-07
the O 0 3.2998599408529117e-07
ATM O 0 8.978090772870928e-05
mutation O 0 2.9839786748198094e-06
spectrum O 0 1.699414724498638e-06
in O 0 6.807659360674734e-07
19 O 0 5.1528832045733e-06
classical O 0 6.131554982857779e-06
A B-Disease 1 0.9999823570251465
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 0.0009657858172431588
, O 0 2.8348588898552407e-07
including O 0 1.2100763058242592e-07
some O 0 1.0473836198343633e-07
immigrant O 0 1.4113848010310903e-06
populations O 0 5.185509621696838e-07
, O 0 1.0101467751155724e-07
as O 0 7.134406843078978e-08
well O 0 8.926765815431281e-08
as O 0 9.771817133241711e-08
12 O 0 4.0627773501000775e-07
of O 0 1.2809984184514178e-07
Dutch O 0 1.6308753401972353e-05
ethnic O 0 2.0111415324208792e-06
origin O 0 8.158017408277374e-06
. O 0 1.3237080565886572e-05

Both O 0 3.272166941314936e-05
the O 0 5.0990365707548335e-06
protein O 0 1.168134440376889e-05
truncation O 0 1.6610409147688188e-05
test O 0 2.9683555112569593e-05
( O 0 1.3660892363986932e-06
PTT O 0 1.9263063222751953e-05
) O 0 1.410175087812604e-07
and O 0 1.4380650270595652e-07
the O 0 2.3050141351177444e-07
restriction O 0 1.1551204579518526e-06
endonuclease O 0 3.735133577720262e-05
fingerprinting O 0 2.0763100110343657e-05
( O 0 1.5925020306895021e-06
REF O 0 0.002406432293355465
) O 0 3.230801723930199e-07
method O 0 4.544491218894109e-07
were O 0 9.817134696277208e-07
used O 0 7.197106697276467e-07
and O 0 8.42028157421737e-07
compared O 0 1.1777347026509233e-06
for O 0 6.82456047229607e-08
their O 0 4.948090008838335e-07
detection O 0 4.703484137280611e-06
efficiency O 0 3.739491376109072e-06
, O 0 3.925944440652529e-07
identifying O 0 2.2936037566978484e-06
76 O 0 1.6825787270136061e-06
% O 0 2.3177770458460145e-07
and O 0 1.941933049920408e-07
60 O 0 3.842468458969961e-07
% O 0 1.509239666575013e-07
of O 0 6.612535230487993e-08
the O 0 4.998001372769068e-07
mutations O 0 8.714956493349746e-06
, O 0 9.76600063040678e-07
respectively O 0 1.165037065220531e-05
. O 0 8.668322152516339e-06

Most O 0 6.894185935379937e-05
patients O 0 0.00649512792006135
were O 0 1.8368662495049648e-05
found O 0 4.034216544823721e-06
to O 0 1.8560735952632967e-06
be O 0 3.858820491586812e-06
compound O 0 6.583808863069862e-05
heterozygote O 0 0.00030691447318531573
. O 0 1.9321591025800444e-05

Seventeen O 0 0.0005439551896415651
mutations O 0 0.0002756617614068091
were O 0 9.111303370445967e-06
distinct O 0 2.923022520917584e-06
, O 0 3.8595166529376e-07
of O 0 1.8451899563842744e-07
which O 0 6.396803087227454e-07
10 O 0 1.4055310657568043e-06
were O 0 4.844611794396769e-06
not O 0 1.6721473912184592e-06
reported O 0 1.2902608432341367e-05
previously O 0 2.0664174371631816e-05
. O 0 1.2054881153744645e-05

Mutations O 0 0.00226387195289135
are O 0 8.91218314791331e-06
small O 0 6.740210665157065e-06
deletions O 0 3.755162106244825e-05
or O 0 1.1584870662773028e-05
point O 0 1.1757543688872829e-05
mutations O 0 3.732875848072581e-05
frequently O 0 1.0728771485446487e-05
affecting O 0 2.0352234059828334e-05
splice O 0 0.00078281678725034
sites O 0 9.751853212947026e-05
. O 0 6.197657785378397e-05

Moreover O 0 0.00039155196282081306
, O 0 1.9684131984831765e-05
a O 0 1.6679328837199137e-05
16 O 0 3.262202881160192e-05
. O 0 2.1350348106352612e-05

7 O 0 0.0007945652469061315
- O 0 0.00026267123757861555
kb O 0 0.0005918928072787821
genomic O 0 5.957367466180585e-05
deletion O 0 3.204439417459071e-05
of O 0 5.290306148708623e-07
the O 0 6.030988402017101e-07
3 O 0 1.1169587423864868e-06
end O 0 3.534383381520456e-07
of O 0 7.653868294710264e-08
the O 0 3.571379636468919e-07
gene O 0 1.1382752518329653e-06
, O 0 1.9555218955247256e-07
most O 0 8.198413325999354e-08
likely O 0 4.369786097413453e-07
a O 0 3.4928336845041486e-07
result O 0 3.212153387721628e-07
of O 0 7.079845687485431e-08
recombination O 0 5.158672138350084e-07
between O 0 3.7883188497289666e-07
two O 0 1.4370906455951626e-06
LINE O 0 0.0005545958993025124
elements O 0 2.0116269752179505e-06
, O 0 1.3160938578948844e-06
was O 0 3.4462111216271296e-05
identified O 0 1.61285643116571e-05
. O 0 8.306123163492884e-06

The O 0 2.6199208150501363e-05
most O 0 6.112649316492025e-06
frequently O 0 1.3605812455352861e-05
found O 0 7.32162607164355e-06
mutation O 0 9.457120540901087e-06
, O 0 6.220349746399734e-07
identified O 0 2.625972456371528e-06
in O 0 4.80114806578058e-07
three O 0 1.0932791383311269e-06
unrelated O 0 1.4205283150658943e-05
Turkish O 0 4.494796667131595e-05
A B-Disease 1 0.999839186668396
- I-Disease 1 0.9999415874481201
T I-Disease 1 0.9999998807907104
individuals O 0 1.4847477132207132e-06
, O 0 5.385641088651028e-07
was O 0 1.7808572010835633e-05
previously O 0 3.468942850304302e-06
described O 0 1.1594911484280601e-06
to O 0 3.102625498740963e-07
be O 0 3.8293501347652636e-07
a O 0 9.838880714596598e-07
Turkish O 0 1.850993612606544e-05
A B-Disease 1 0.9994982481002808
- I-Disease 1 0.9999366998672485
T I-Disease 1 0.9999985694885254
founder O 0 0.00036522038863040507
mutation O 0 7.279586134245619e-05
. O 0 1.7875165212899446e-05

The O 0 2.0926661818521097e-05
presence O 0 9.306809261033777e-06
of O 0 1.3764988580078352e-06
a O 0 4.45048681285698e-06
founder O 0 3.57481803803239e-05
mutation O 0 6.151796242193086e-06
among O 0 3.2066901667349157e-07
relatively O 0 4.62378409338271e-07
small O 0 2.0524736044080782e-07
ethnic O 0 2.221713657490909e-07
population O 0 2.090963704404203e-07
groups O 0 7.18667436672149e-08
in O 0 6.98245727903668e-08
Western O 0 3.1295763847083435e-07
Europe O 0 5.210481504036579e-06
could O 0 4.0026689021033235e-06
indicate O 0 1.4237436971598072e-06
a O 0 7.935569783512619e-07
high O 0 8.134524250635877e-06
carrier O 0 2.3245196643983945e-05
frequency O 0 6.3066604525374714e-06
in O 0 5.346305442799348e-07
such O 0 8.320753863699792e-07
communities O 0 7.044942321954295e-06
. O 0 1.0897184438363183e-05

In O 0 0.0001483622327214107
patients O 0 0.00044525531120598316
of O 0 2.058759719147929e-06
Dutch O 0 3.340074181323871e-05
ethnic O 0 1.2262373729754472e-06
origin O 0 1.4960315866119345e-06
, O 0 9.290582170251582e-07
however O 0 6.088065447329427e-07
, O 0 2.8283403707973775e-07
no O 0 5.233481488176039e-07
significant O 0 5.352804919311893e-07
founder O 0 1.441770109522622e-05
effect O 0 1.6085824654510361e-06
could O 0 1.6619583220744971e-06
be O 0 1.2482828424253967e-06
identified O 0 8.847679964674171e-06
. O 0 9.458419299335219e-06

The O 0 4.415503281052224e-05
observed O 0 4.4665946916211396e-05
genetic O 0 3.3126638300018385e-05
heterogeneity O 0 1.4281211406341754e-05
including O 0 8.817009984340984e-07
the O 0 8.775720061748871e-07
relative O 0 5.850347861269256e-06
high O 0 1.0690900126064662e-05
percentage O 0 5.343737939256243e-06
of O 0 1.8814556312918285e-07
splice O 0 0.018160494044423103
- O 0 0.00343846483156085
site O 0 4.5932109060231596e-05
mutations O 0 2.8937807655893266e-05
had O 0 1.1725453077815473e-05
no O 0 4.138927920394053e-07
reflection O 0 9.454706741962582e-07
on O 0 1.273590100936417e-06
the O 0 4.833919319935376e-06
phenotype O 0 0.0006761829718016088
. O 0 1.7054842828656547e-05

All O 0 9.249430149793625e-05
patients O 0 0.0029583992436528206
manifested O 0 0.00012237908958923072
classical O 0 3.0520473956130445e-05
A B-Disease 1 0.9971332550048828
- I-Disease 1 0.9987573623657227
T I-Disease 1 0.9999908208847046
and O 0 2.3584302653034683e-06
increased O 0 4.211178293189732e-06
cellular O 0 0.00018826300220098346
radioresistant O 0 0.0004515897308010608
DNA O 0 2.5900311811710708e-05
synthesis O 0 3.134231883450411e-05
. O 0 1.9754274035221897e-05

Determination O 0 8.693461859365925e-05
of O 0 5.042222710471833e-06
the O 0 2.3283189420908457e-06
genomic O 0 1.225663254444953e-05
structure O 0 2.745826805039542e-06
of O 0 3.4338319210291957e-07
the O 0 1.5399713220176636e-06
COL4A4 O 0 0.0032957647927105427
gene O 0 1.946733391378075e-06
and O 0 5.084388021714403e-07
of O 0 6.775061933694815e-07
novel O 0 3.820039637503214e-05
mutations O 0 0.0016473799478262663
causing O 0 0.14843666553497314
autosomal B-Disease 1 0.9999713897705078
recessive I-Disease 1 0.9999992847442627
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 0.0004210431652609259

Autosomal B-Disease 1 0.9999978542327881
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.000151651373016648
a O 0 9.335222421213984e-05
progressive O 0 0.11906462907791138
hematuric B-Disease 1 0.9996998310089111
glomerulonephritis I-Disease 1 0.9999998807907104
characterized O 0 0.004898850340396166
by O 0 2.3938160666148178e-05
glomerular B-Disease 1 0.90578293800354
basement I-Disease 1 0.9999116659164429
membrane I-Disease 1 0.8948771357536316
abnormalities I-Disease 1 0.9999517202377319
and O 0 6.227689300430939e-05
associated O 0 1.4653041944256984e-05
with O 0 5.2201453399902675e-06
mutations O 0 3.462025415501557e-05
in O 0 9.601819783711107e-07
either O 0 1.622771719667071e-06
the O 0 1.1835332998089143e-06
COL4A3 O 0 0.0037132827565073967
or O 0 5.484734515448508e-07
the O 0 4.769399311044253e-07
COL4A4 O 0 0.0002509976620785892
gene O 0 1.6036473198255408e-06
, O 0 1.8019287040260679e-07
which O 0 1.5773824202369724e-07
encode O 0 8.269278737316199e-07
the O 0 5.382231620387756e-07
alpha3 O 0 5.389151556300931e-05
and O 0 1.7070459534807014e-06
alpha4 O 0 0.00015590533439535648
type O 0 8.855808846419677e-05
IV O 0 0.12061351537704468
collagen O 0 0.0002031033072853461
chains O 0 0.0009733870974741876
, O 0 3.8850444070703816e-06
respectively O 0 3.926926729036495e-05
. O 0 7.970649676281027e-06

To O 0 4.260015703039244e-05
date O 0 1.603057717147749e-05
, O 0 2.21694585889054e-06
mutation O 0 2.597788125058287e-06
screening O 0 2.7354556095815497e-06
in O 0 4.2942752997987554e-07
the O 0 2.55284930972266e-07
two O 0 4.5635525225407036e-07
genes O 0 2.3742725261399755e-06
has O 0 1.4101550505074556e-06
been O 0 2.6573850391287124e-06
hampered O 0 1.7368111002724618e-05
by O 0 1.1946971767429204e-07
the O 0 2.2217305684080202e-07
lack O 0 8.711945724826364e-07
of O 0 3.3990934866778844e-07
genomic O 0 2.603016037028283e-05
structure O 0 2.1722615201724693e-05
information O 0 8.953500582720153e-06
. O 0 1.7659609511611052e-05

We O 0 0.00012249420979060233
report O 0 7.547758741566213e-06
here O 0 8.658339538669679e-07
the O 0 2.9072825213916076e-07
complete O 0 8.649376468383707e-07
characterization O 0 1.6045438542278134e-06
of O 0 1.1192379645308392e-07
the O 0 2.9583085847662005e-07
48 O 0 9.1764445642184e-07
exons O 0 1.0867096307265456e-06
of O 0 8.34645845770865e-08
the O 0 8.188487754523521e-07
COL4A4 O 0 0.00035654022940434515
gene O 0 1.6124020021379692e-06
, O 0 2.0394396926803893e-07
a O 0 2.8920041472701996e-07
comprehensive O 0 1.5439034086739412e-06
gene O 0 1.2061906318194815e-06
screen O 0 4.451505446922965e-06
, O 0 2.912296963586414e-07
and O 0 1.3937619769421872e-07
the O 0 8.333064727139572e-08
subsequent O 0 2.8425932896425365e-07
detection O 0 1.1655911293928511e-06
of O 0 2.022017611125193e-07
10 O 0 1.2841288707932108e-06
novel O 0 8.712335670679749e-07
mutations O 0 5.0288917918805964e-06
in O 0 1.2140264971094439e-06
eight O 0 0.009007995948195457
patients O 1 0.962246835231781
diagnosed O 1 0.9999581575393677
with O 0 0.041782017797231674
autosomal B-Disease 1 0.9999992847442627
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0003920808667317033

Furthermore O 0 0.00028898532036691904
, O 0 1.2495580449467525e-05
we O 0 3.4095255614374764e-06
identified O 0 2.2268011434789514e-06
a O 0 4.5419778871291783e-07
glycine O 0 3.526206000969978e-06
to O 0 5.781698177997896e-07
alanine O 0 5.247997705737362e-06
substitution O 0 4.03972734375202e-07
in O 0 3.9661355799580633e-07
the O 0 4.924613108414633e-07
collagenous O 0 5.868795051355846e-05
domain O 0 3.0208493626560085e-06
that O 0 4.943472049490083e-07
is O 0 3.9155202102847397e-07
apparently O 0 7.063456450850936e-06
silent O 0 3.794588565142476e-06
in O 0 2.3220958667025116e-07
the O 0 6.352727268676972e-07
heterozygous O 0 2.0758347091032192e-05
carriers O 0 7.32435000827536e-06
, O 0 6.857873700027994e-07
in O 0 1.500472535553854e-06
11 O 0 2.0622399460989982e-05
. O 0 1.0700793609430548e-05

5 O 0 8.765458187554032e-05
% O 0 6.279611170612043e-06
of O 0 3.8361085330507194e-07
all O 0 3.5153502153661975e-07
control O 0 1.2554492059280165e-05
individuals O 0 5.639691948999825e-07
, O 0 2.6532651986599376e-07
and O 0 4.548167851226026e-07
in O 0 3.809019233358413e-07
one O 0 4.248692277997179e-07
control O 0 3.724457656062441e-06
individual O 0 5.310404276315239e-07
homozygous O 0 9.828454494709149e-06
for O 0 1.937617213343401e-07
this O 0 5.270555902825436e-07
glycine O 0 2.2793235984863713e-05
substitution O 0 1.2077919564035255e-05
. O 0 1.444701774744317e-05

There O 0 6.016801853547804e-05
has O 0 7.202742381196003e-06
been O 0 2.739376668614568e-06
no O 0 5.525960204977309e-07
previous O 0 4.1318330090689415e-07
finding O 0 3.1265065558727656e-07
of O 0 5.1844409654222545e-08
a O 0 4.7011963033583015e-07
glycine O 0 3.23707035931875e-06
substitution O 0 6.56108852581383e-07
that O 0 2.4070749304883066e-07
is O 0 3.1184100635073264e-07
not O 0 3.484296371425444e-07
associated O 0 6.172289772621298e-07
with O 0 5.197074415264069e-07
any O 0 8.577370067541779e-07
obvious O 0 1.340857761533698e-05
phenotype O 0 0.0001611153711564839
in O 0 6.516317625937518e-06
homozygous O 0 0.0007597389630973339
individuals O 0 6.499547907878878e-06
. O 0 1.7162037693196908e-05

Founder O 0 0.003245508298277855
BRCA1 O 0 0.012467887252569199
and O 0 4.852837446378544e-05
BRCA2 O 0 0.0019054580479860306
mutations O 0 4.681936843553558e-05
in O 0 4.198682745482074e-06
French O 0 6.582213973160833e-05
Canadian O 0 0.042502567172050476
breast B-Disease 1 0.9999951124191284
and I-Disease 1 0.9999748468399048
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0010037561878561974
. O 0 4.8405152483610436e-05

We O 0 8.652108954265714e-05
have O 0 5.608001629298087e-06
identified O 0 3.2528280371479923e-06
four O 0 7.54468317154533e-07
mutations O 0 2.6423842882650206e-06
in O 0 2.3702267526459764e-07
each O 0 1.3642178942063765e-07
of O 0 2.1360916946377984e-07
the O 0 6.801808922318742e-05
breast B-Disease 1 0.9999163150787354
cancer I-Disease 1 0.9543866515159607
- O 0 0.025573186576366425
susceptibility O 0 0.0007117659552022815
genes O 0 9.7064403234981e-06
, O 0 1.3022987559452304e-06
BRCA1 O 0 0.00020804547239094973
and O 0 7.955249202495907e-06
BRCA2 O 0 0.00019485865777824074
, O 0 1.0369880101279705e-06
in O 0 9.500712963017577e-07
French O 0 3.1523370125796646e-05
Canadian O 0 0.010839457623660564
breast B-Disease 1 0.9999802112579346
cancer I-Disease 1 0.9954386353492737
and O 0 0.30789029598236084
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.00022439711028710008
from O 0 1.962590977200307e-05
Quebec O 0 0.0003305722202640027
. O 0 3.193329393980093e-05

To O 0 7.293086673598737e-05
identify O 0 0.00010055316670332104
founder O 0 6.234837201191112e-05
effects O 0 2.9365148293436505e-05
, O 0 2.754670958893257e-06
we O 0 1.1092002978330129e-06
examined O 0 4.3060877032985445e-06
independently O 0 4.897065082332119e-06
ascertained O 0 1.4524654943670612e-05
French O 0 1.1793546946137212e-05
Canadian O 0 0.00019920060003641993
cancer B-Disease 0 0.07182373106479645
families O 0 2.517169150451082e-06
for O 0 1.4288293925801554e-07
the O 0 1.2342113109298225e-07
distribution O 0 2.23834462076411e-07
of O 0 1.023263536126251e-07
these O 0 2.518338249046792e-07
eight O 0 3.746016091099591e-06
mutations O 0 4.994761911802925e-05
. O 0 1.33731400637771e-05

Mutations O 0 0.003215867793187499
were O 0 5.114012674312107e-05
found O 0 1.0816836947924457e-05
in O 0 1.8383134374744259e-06
41 O 0 7.2648845161893405e-06
of O 0 7.527771686000051e-07
97 O 0 2.572712764958851e-05
families O 0 2.478664646332618e-05
. O 0 1.5746722056064755e-05

Six O 0 8.147091284627095e-05
of O 0 4.8198380682151765e-06
eight O 0 1.2695938494289294e-05
mutations O 0 2.4523964384570718e-05
were O 0 4.614780664269347e-06
observed O 0 2.279549562445027e-06
at O 0 6.51902746540145e-06
least O 0 2.3282168513105717e-06
twice O 0 1.869469997473061e-05
. O 0 8.490665095450822e-06

The O 0 7.345595804508775e-05
BRCA1 O 0 0.00401704665273428
C4446T O 0 0.0007204643916338682
mutation O 0 8.80692241480574e-05
was O 0 1.547418833069969e-05
the O 0 4.3003404925912037e-07
most O 0 3.122558496215788e-07
common O 0 1.2145151231379714e-06
mutation O 0 1.0332858437323011e-05
found O 0 3.700439492604346e-06
, O 0 4.96571374242194e-07
followed O 0 8.149519317157683e-07
by O 0 4.189225535355945e-07
the O 0 4.2039960135298315e-06
BRCA2 O 0 0.0006361572304740548
8765delAG O 0 0.0002938725519925356
mutation O 0 0.00013768704957328737
. O 0 3.020045733137522e-05

Together O 0 0.00020992053032387048
, O 0 4.297693976695882e-06
these O 0 7.415808340738295e-07
mutations O 0 8.8511314970674e-06
were O 0 2.749524128375924e-06
found O 0 9.21909190765291e-07
in O 0 4.444411558779393e-07
28 O 0 3.89986371374107e-06
of O 0 1.2900005685878568e-07
41 O 0 7.698890840401873e-06
families O 0 1.5890551594566205e-06
identified O 0 1.6616462517049513e-06
to O 0 2.9595585715469497e-07
have O 0 7.01682154158334e-07
a O 0 5.701770987798227e-06
mutation O 0 0.0001322365424130112
. O 0 1.1832402378786355e-05

The O 0 3.053441832889803e-05
odds O 0 5.431567115010694e-05
of O 0 9.398644351676921e-07
detection O 0 4.276043000572827e-06
of O 0 1.8526732503687526e-07
any O 0 1.1105153419066482e-07
of O 0 7.594754691808703e-08
the O 0 4.211818804833456e-07
four O 0 2.531010295570013e-06
BRCA1 O 0 0.006790629588067532
mutations O 0 3.424680107855238e-05
was O 0 5.31172045157291e-05
18 O 0 1.8905700926552527e-05
. O 0 1.1577592886169441e-05

7x O 0 0.007654507644474506
greater O 0 4.9398331611882895e-05
if O 0 4.068510406796122e-06
one O 0 5.284961162033142e-07
or O 0 4.0401357637165347e-07
more O 0 1.329216701151381e-07
cases O 0 8.273033813566144e-07
of O 0 0.006361993961036205
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.002575572580099106
also O 0 5.441603207145818e-06
present O 0 1.097771701097372e-06
in O 0 1.137211938839755e-06
the O 0 5.717790827475255e-06
family O 0 8.954697113949805e-05
. O 0 1.1831341907964088e-05

The O 0 3.4024396882159635e-05
odds O 0 5.578237323788926e-05
of O 0 1.0164023933612043e-06
detection O 0 5.3702628974861e-06
of O 0 2.2331973070777167e-07
any O 0 1.4339046572331426e-07
of O 0 1.222949350676572e-07
the O 0 1.003172997116053e-06
four O 0 6.514037067972822e-06
BRCA2 O 0 0.007825043052434921
mutations O 0 4.822251503355801e-05
was O 0 4.554191400529817e-05
5 O 0 1.587618862686213e-05
. O 0 1.2783414604200516e-05

3x O 0 0.004029738251119852
greater O 0 7.046246901154518e-05
if O 0 8.1307398431818e-06
there O 0 1.7174542108477908e-06
were O 0 3.171064918205957e-06
at O 0 3.366797272974509e-06
least O 0 2.740887339314213e-07
five O 0 3.239746035887947e-07
cases O 0 3.346127073200478e-07
of O 0 3.8687471715093125e-06
breast B-Disease 1 0.9999977350234985
cancer I-Disease 1 0.9705109000205994
in O 0 3.201359504600987e-06
the O 0 1.0031787496700417e-05
family O 0 0.0001384407514706254
. O 0 1.2361150766082574e-05

Interestingly O 0 0.0005265761283226311
, O 0 6.734460839652456e-06
the O 0 1.1706932809829595e-06
presence O 0 5.952499577688286e-07
of O 0 3.062892801608541e-07
a O 0 0.0013316554250195622
breast B-Disease 1 0.9999847412109375
cancer I-Disease 1 0.9534032344818115
case O 0 4.913794327876531e-06
< O 0 2.7601836336543784e-05
36 O 0 3.250836925872136e-06
years O 0 5.660814395014313e-07
of O 0 1.7275141317441012e-07
age O 0 1.2816602975362912e-05
was O 0 7.921597898530308e-06
strongly O 0 3.3520618103466404e-07
predictive O 0 9.368415589960932e-07
of O 0 5.5663807785322206e-08
the O 0 1.3193306358516566e-07
presence O 0 1.6687543791249482e-07
of O 0 2.610508076372753e-08
any O 0 3.552265326334236e-08
of O 0 4.014188093037774e-08
the O 0 3.702864432852948e-07
eight O 0 5.098817837279057e-06
mutations O 0 3.700078377733007e-05
screened O 0 8.669171802466735e-05
. O 0 9.809941730054561e-06

Carriers O 0 0.00029549808823503554
of O 0 4.898708994005574e-06
the O 0 1.346655267298047e-06
same O 0 1.2007481018372346e-06
mutation O 0 2.6194268230028683e-06
, O 0 1.7947462538359105e-07
from O 0 1.209395605883401e-07
different O 0 1.0731996269441879e-07
families O 0 7.29567261714692e-07
, O 0 1.7575237620803819e-07
shared O 0 4.892565357295098e-07
similar O 0 5.617999363494164e-07
haplotypes O 0 2.022538501478266e-05
, O 0 9.90911757980939e-07
indicating O 0 2.755059767878265e-06
that O 0 1.0029570063352367e-07
the O 0 2.619611620957585e-07
mutant O 0 5.461494765768293e-06
alleles O 0 1.4514453141600825e-06
were O 0 4.28336488766945e-06
likely O 0 1.7421905340597732e-06
to O 0 7.056468120936188e-07
be O 0 1.0104163266078103e-06
identical O 0 1.5149890941756894e-06
by O 0 1.0575853792715861e-07
descent O 0 2.468179218340083e-06
for O 0 2.0730188055040344e-07
a O 0 2.373706365688122e-06
mutation O 0 4.5422652874549385e-06
in O 0 5.212685323385813e-07
the O 0 1.7945476429304108e-06
founder O 0 4.5196742576081306e-05
population O 0 2.581336048024241e-06
. O 0 6.288582881097682e-06

The O 0 1.3867914276488591e-05
identification O 0 1.3180495443521068e-05
of O 0 2.381054400757421e-06
common O 0 9.673587555880658e-06
BRCA1 O 0 0.03759840875864029
and O 0 4.4192605855641887e-05
BRCA2 O 0 0.08956173807382584
mutations O 0 3.714516424224712e-05
will O 0 8.390621815124177e-07
facilitate O 0 2.087923803628655e-06
carrier O 0 2.3483988115913235e-05
detection O 0 1.1690282008203212e-05
in O 0 1.9764486296480754e-06
French O 0 2.1472820662893355e-05
Canadian O 0 0.0019203567644581199
breast B-Disease 1 0.9998587369918823
cancer I-Disease 1 0.9965471625328064
and O 0 0.3283420503139496
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.001090236590243876
. O 0 5.972788858343847e-05

Are O 0 7.505878602387384e-05
Dp71 O 0 0.0008586280746385455
and O 0 2.2750366042600945e-05
Dp140 O 0 0.0007358451839536428
brain O 0 0.0016000226605683565
dystrophin O 0 0.00018828455358743668
isoforms O 0 1.4627268683398142e-05
related O 0 6.14943837717874e-06
to O 0 6.353917797241593e-06
cognitive B-Disease 0 0.011950277723371983
impairment I-Disease 1 0.577477753162384
in O 0 0.0006722980178892612
Duchenne B-Disease 1 0.9999977350234985
muscular I-Disease 1 0.999990701675415
dystrophy I-Disease 1 0.9999926090240479
? O 0 0.003355720080435276

Molecular O 0 0.0005831167218275368
study O 0 3.144392394460738e-05
and O 0 9.740080713527277e-06
neuropsychological O 0 0.0002801503287628293
analysis O 0 5.493233402376063e-06
were O 0 1.4998863662185613e-05
performed O 0 1.5821984561625868e-05
concurrently O 0 2.814130994011066e-06
on O 0 5.148741820448777e-06
49 O 0 0.0007044616504572332
patients O 0 3.636634937720373e-05
with O 0 4.042884029331617e-05
Duchenne B-Disease 1 0.9999984502792358
muscular I-Disease 1 0.9999951124191284
dystrophy I-Disease 1 0.9999990463256836
( O 0 0.004553947132080793
DMD B-Disease 1 1.0
) O 0 4.062144398631062e-06
in O 0 7.731396181043237e-07
order O 0 5.285576207825216e-07
to O 0 2.895456532314711e-07
find O 0 5.511828362614324e-07
a O 0 3.925135843019234e-07
molecular O 0 1.0539468348724768e-05
explanation O 0 4.954639507559477e-07
for O 0 1.4120375624315784e-07
the O 0 1.3739178257310414e-06
cognitive B-Disease 0 0.0009669481660239398
impairment I-Disease 0 0.0011426954297348857
observed O 0 1.1386095138732344e-05
in O 0 4.587487637763843e-06
most O 0 5.622376556857489e-05
DMD B-Disease 1 1.0
patients O 0 0.24042899906635284
. O 0 5.1824892580043525e-05

Complete O 0 0.0001095518164220266
analysis O 0 1.3179490451875608e-05
of O 0 1.7126341163020697e-06
the O 0 2.0855302409472642e-06
dystrophin O 0 0.00010975069017149508
gene O 0 1.3662162018590607e-05
was O 0 1.6848085579113103e-05
performed O 0 9.860007594397757e-06
to O 0 3.367482861449389e-07
define O 0 1.2224099918967113e-06
the O 0 2.5266763259423897e-07
localization O 0 9.925915946951136e-07
of O 0 1.3096291695546824e-07
deletions O 0 2.4190330805140547e-06
and O 0 6.587546295122593e-07
duplications O 0 7.352013199124485e-06
in O 0 1.2101519359930535e-06
relation O 0 1.5688059420426725e-06
to O 0 6.408857302631077e-07
the O 0 1.2402209677020437e-06
different O 0 6.298642347246641e-06
DMD B-Disease 1 0.9999984502792358
promoters O 0 0.0006324792047962546
. O 0 3.8978101656539366e-05

Qualitative O 0 0.00019471954146865755
analysis O 0 1.4489624845737126e-05
of O 0 1.5363568763859803e-06
the O 0 1.720893919809896e-06
Dp71 O 0 0.00010197184019489214
transcript O 0 9.32937200559536e-06
and O 0 1.6227037349381135e-06
testing O 0 4.850131517741829e-06
for O 0 1.2545491756554839e-07
the O 0 1.5592360114169423e-07
specific O 0 1.573536252408303e-07
first O 0 2.90599103891509e-07
exon O 0 1.8262544472236186e-06
of O 0 2.5881590204335225e-07
Dp140 O 0 2.772456173261162e-05
were O 0 1.8181182213083957e-06
also O 0 5.330736030373373e-07
carried O 0 5.32394005858805e-06
out O 0 7.3143819463439286e-06
. O 0 8.40054690343095e-06

Neuropsychological O 0 0.008891175501048565
analysis O 0 8.555371459806338e-05
assessed O 0 7.252384239109233e-05
verbal O 0 4.433604044606909e-05
and O 0 1.769361006154213e-05
visuospatial O 0 0.015124390833079815
intelligence O 0 0.00012144838547101244
, O 0 2.0249676708772313e-06
verbal O 0 1.8235261450172402e-05
memory O 0 0.0006587093812413514
, O 0 1.4993839840826695e-06
and O 0 2.2452124994742917e-06
reading O 0 7.072460721246898e-05
skills O 0 0.00019128623534925282
. O 0 2.624156877573114e-05

Comparison O 0 7.199957326520234e-05
of O 0 5.75284047954483e-06
molecular O 0 4.838355380343273e-05
and O 0 6.210780156834517e-06
psychometric O 0 0.0004931918228976429
findings O 0 8.216811693273485e-06
demonstrated O 0 3.1511351608060068e-06
that O 0 1.5328065217090625e-07
deletions O 0 1.940225729413214e-06
and O 0 8.1321439893145e-07
duplications O 0 1.3248572940938175e-05
that O 0 1.175223701466166e-06
were O 0 6.30791146249976e-06
localized O 0 6.891440989420516e-06
in O 0 9.66657580647734e-07
the O 0 6.819889222242637e-07
distal O 0 2.196923924202565e-05
part O 0 5.138241476743133e-07
of O 0 8.547485919052633e-08
the O 0 4.6712349899280525e-07
gene O 0 2.3748384592181537e-06
seemed O 0 2.5629660740378313e-06
to O 0 1.8545701152561378e-07
be O 0 3.498624323583499e-07
preferentially O 0 2.3326306290982757e-06
associated O 0 1.6258451296380372e-06
with O 0 4.9614941417530645e-06
cognitive B-Disease 0 0.004369319882243872
impairment I-Disease 0 0.010279973037540913
. O 0 2.845190101652406e-05

Two O 0 0.00010851566185010597
altered O 0 0.00012715248158201575
Dp71 O 0 0.00012539704039227217
transcripts O 0 1.219882869918365e-05
and O 0 1.2558243724924978e-06
two O 0 9.313772011410038e-07
deleted O 0 2.1359835955081508e-05
Dp140 O 0 1.3499623491952661e-05
DNA O 0 1.978938371394179e-06
sequences O 0 1.0491025932424236e-06
were O 0 2.5871001980704023e-06
found O 0 1.6038139847296407e-06
in O 0 6.775869678676827e-07
four O 0 1.2625522685993928e-05
patients O 0 0.00040921548497863114
with O 0 0.0001483284286223352
severe O 1 0.9999548196792603
cerebral B-Disease 1 0.9999985694885254
dysfunction I-Disease 1 0.9984241724014282
. O 0 8.879569941200316e-05

These O 0 1.9108716514892876e-05
findings O 0 1.4907058357493952e-05
suggest O 0 3.4123295336030424e-06
that O 0 2.4200011239372543e-07
some O 0 1.299707719226717e-07
sequences O 0 4.871176884080342e-07
located O 0 1.7752955727701192e-06
in O 0 4.6344766246875224e-07
the O 0 2.9551506486313883e-07
distal O 0 7.54192979002255e-06
part O 0 4.1616428347879264e-07
of O 0 8.132642648206456e-08
the O 0 4.4798932208323095e-07
gene O 0 1.5568318758596433e-06
and O 0 8.390589982809615e-07
, O 0 2.4144617327692686e-07
in O 0 1.3057294268037367e-07
particular O 0 2.9239768650768383e-07
, O 0 1.8444175964305032e-07
some O 0 1.714090274163027e-07
DMD B-Disease 1 0.9988170862197876
isoforms O 0 2.314597168151522e-06
expressed O 0 4.6210865889406705e-07
in O 0 7.416572316287784e-07
the O 0 5.903602868784219e-06
brain O 1 0.9044213891029358
may O 0 6.818421388743445e-05
be O 0 3.895548559285089e-07
related O 0 2.5445120854783454e-07
to O 0 2.696906733490323e-07
the O 0 2.5816852939897217e-06
cognitive B-Disease 0 0.013896685093641281
impairment I-Disease 0 0.09863295406103134
associated O 0 2.3172224246081896e-05
with O 0 0.000234608247410506
DMD B-Disease 1 1.0
. O 0 4.195148721919395e-05
. O 0 3.0302180675789714e-05

I1307K O 0 0.008162960410118103
APC O 0 0.0014123697765171528
and O 0 3.2352869311580434e-05
hMLH1 O 0 0.0002518313704058528
mutations O 0 3.166304304613732e-05
in O 0 1.3073859008727595e-06
a O 0 1.7616664536035387e-06
non O 0 4.053522843605606e-06
- O 0 4.8558926209807396e-05
Jewish O 0 5.083358701085672e-06
family O 0 8.143542800098658e-06
with O 0 7.2265338530996814e-06
hereditary B-Disease 1 0.9972244501113892
non I-Disease 1 0.8779844641685486
- I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.001026949961669743

We O 0 9.889192006085068e-05
describe O 0 3.270931847509928e-05
a O 0 7.231317795231007e-06
French O 0 3.161983477184549e-05
Canadian O 0 0.00018333335174247622
hereditary B-Disease 1 0.9965895414352417
non I-Disease 1 0.9026083946228027
- I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.017459329217672348
HNPCC B-Disease 1 0.9998199343681335
) O 0 1.4127546819509007e-05
kindred O 0 0.00021512633247766644
which O 0 1.6156900528585538e-06
carries O 0 3.6106193874729797e-06
a O 0 3.906600795744453e-06
novel O 0 7.181267392297741e-06
truncating O 0 7.714699313510209e-05
mutation O 0 3.618159098550677e-05
in O 0 9.718981345940847e-06
hMLH1 O 0 0.0005292269634082913
. O 0 2.8798531275242567e-05

Interestingly O 0 0.0005718574393540621
, O 0 1.036792036757106e-05
the O 0 2.9919146982138045e-06
I1307K O 0 8.102548599708825e-05
APC O 0 1.5491064914385788e-05
polymorphism O 0 1.3512207260646392e-05
, O 0 1.2386394701024983e-06
associated O 0 1.0133738896911382e-06
with O 0 5.090448098599154e-07
an O 0 3.2202460715780035e-06
increased O 0 2.3279382730834186e-05
risk O 0 0.002015997190028429
of O 0 0.0014664932386949658
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 9.404324373463169e-05
is O 0 9.79980200099817e-07
also O 0 6.54758707696601e-07
present O 0 5.345137878975947e-07
in O 0 8.58982900808769e-07
this O 0 1.1596415561143658e-06
family O 0 4.018130857730284e-05
. O 0 1.7719276002026163e-05

The O 0 2.95475656457711e-05
I1307K O 0 0.00015355741197708994
polymorphism O 0 7.394031854346395e-05
has O 0 5.155891358299414e-06
previously O 0 6.653006948909024e-06
only O 0 2.431823418191925e-07
been O 0 1.0104722605319694e-06
identified O 0 1.1588964525799383e-06
in O 0 2.7663918444886804e-07
individuals O 0 2.1967052532545495e-07
of O 0 1.8582488792162621e-07
self O 0 7.365923374891281e-05
- O 0 0.0041379984468221664
reported O 0 2.6431389414938167e-05
Ashkenazi O 0 3.36741613864433e-05
Jewish O 0 5.880559001525398e-06
origins O 0 2.607836177048739e-05
. O 0 1.597926348040346e-05

In O 0 3.1306226446758956e-05
addition O 0 8.834257641865406e-06
, O 0 1.22072549402219e-06
in O 0 4.046386266054469e-07
this O 0 1.877472897149346e-07
family O 0 2.4980615762615344e-06
, O 0 2.213378991200443e-07
there O 0 1.9228887992994714e-07
appears O 0 5.47306228781963e-07
to O 0 3.9714723243378103e-07
be O 0 5.628252779388276e-07
no O 0 4.3043121422670083e-07
relationship O 0 4.233201593706326e-07
between O 0 1.9517639771038375e-07
the O 0 5.637164122163085e-07
I1307K O 0 1.542670179333072e-05
polymorphism O 0 5.2952855185139924e-06
and O 0 5.945282737229718e-07
the O 0 3.6731830732605886e-07
presence O 0 6.979301474530075e-07
or O 0 7.508907629016903e-07
absence O 0 2.2872691261e-06
of O 0 2.7404639695305377e-06
cancer B-Disease 0 0.10249025374650955
. O 0 3.220129428882501e-06
. O 0 1.386942221870413e-05

Identification O 0 8.326425449922681e-05
of O 0 4.638589871319709e-06
a O 0 4.022994289698545e-06
novel O 0 3.6224216728442116e-06
mutation O 0 2.3263878574653063e-06
of O 0 2.644905521265173e-07
the O 0 6.673747066088254e-07
CPO O 0 2.6012938178610057e-05
gene O 0 2.479014028722304e-06
in O 0 5.874740622857644e-07
a O 0 2.7047417461290024e-06
Japanese O 0 9.988000965677202e-05
hereditary B-Disease 1 0.9308102130889893
coproporphyria I-Disease 0 0.18716643750667572
family O 0 0.00013812533870805055
. O 0 2.3838332708692178e-05

Hereditary B-Disease 1 0.9999258518218994
coproporphyria I-Disease 1 0.9980984330177307
( O 0 0.0010874035069718957
HCP B-Disease 1 0.9189940690994263
) O 0 1.303360204474302e-05
is O 0 1.47359367019817e-06
an O 0 2.345882785448339e-05
autosomal B-Disease 1 0.9998955726623535
dominant I-Disease 1 0.9998687505722046
disease I-Disease 1 0.9978253841400146
characterized O 0 0.00018886370526161045
by O 0 2.289137000843766e-06
a O 0 0.006088564172387123
deficiency B-Disease 1 0.7217226028442383
of I-Disease 0 9.513732948107645e-07
coproporphyrinogen I-Disease 0 0.07461651414632797
oxidase I-Disease 0 0.00010150246816920117
( O 0 1.5186923292276333e-06
CPO O 0 9.16993449209258e-05
) O 0 4.818101047021628e-07
caused O 0 1.1619750921454397e-06
by O 0 1.67261489991688e-07
a O 0 1.0606697742332472e-06
mutation O 0 3.436647148191696e-06
in O 0 6.957808977858804e-07
the O 0 3.4252016121172346e-06
CPO O 0 0.00030195145518518984
gene O 0 5.9481430071173236e-05
. O 0 1.961741509148851e-05

Only O 0 2.792037594190333e-05
11 O 0 1.766232162481174e-05
mutations O 0 6.848528300906764e-06
of O 0 2.758551431725209e-07
the O 0 5.372949658521975e-07
gene O 0 3.46501497006102e-06
have O 0 1.3418352864391636e-06
been O 0 3.035160943909432e-06
reported O 0 1.4929366443539038e-05
in O 0 1.575687747390475e-05
HCP B-Disease 1 0.9820368885993958
patients O 0 0.0014447771245613694
. O 0 2.6101301045855507e-05

We O 0 0.00010092396405525506
report O 0 1.311812229687348e-05
another O 0 3.667736791612697e-06
mutation O 0 7.24713481758954e-06
in O 0 8.534833000339859e-07
a O 0 2.4067380763881374e-06
Japanese O 0 2.033418968494516e-05
family O 0 3.6325654946267605e-05
. O 0 9.952970685844775e-06

Polymerase O 0 0.0011545649031177163
chain O 0 0.0006233530002646148
reaction O 0 3.0745322874281555e-05
- O 0 3.3457963581895456e-05
single O 0 5.3342569117376115e-06
strand O 0 1.0436667253088672e-05
conformational O 0 3.4686979688558495e-06
polymorphism O 0 5.920246167079313e-06
and O 0 1.1190496707058628e-06
direct O 0 7.7838558354415e-07
sequence O 0 1.3737973176830565e-06
analyses O 0 3.288949528723606e-06
demonstrated O 0 2.47326397584402e-06
a O 0 1.3264527751744026e-06
C O 0 4.1667288314783946e-05
to O 0 9.790508102014428e-07
T O 0 2.322248474229127e-05
substitution O 0 3.57567728315189e-07
in O 0 2.1131613436864427e-07
exon O 0 3.1008291898615425e-06
1 O 0 4.186501598724135e-07
of O 0 8.889199420991645e-08
the O 0 4.561920832202304e-07
CPO O 0 1.3983720236865338e-05
gene O 0 1.750596311467234e-06
at O 0 3.269853550591506e-06
nucleotide O 0 2.96518805953383e-06
position O 0 2.912904619734036e-06
85 O 0 2.0515628875728e-06
, O 0 3.3280505817856465e-07
which O 0 2.8155756126579945e-07
lies O 0 9.952029813575791e-07
in O 0 1.4452915308993397e-07
the O 0 4.3111813852192427e-07
putative O 0 1.5567320588161238e-05
presequence O 0 3.304271012893878e-05
for O 0 4.880142228103068e-07
targeting O 0 8.69571158546023e-06
to O 0 4.182757038506679e-06
mitochondria O 0 0.0001841135963331908
. O 0 2.9805103622493334e-05

This O 0 1.68265378306387e-05
mutation O 0 2.9671582524315454e-05
changes O 0 1.9868807612510864e-06
the O 0 7.085782272042707e-07
codon O 0 4.698301381722558e-06
for O 0 3.108626174253004e-07
glutamine O 0 3.1605582080374006e-06
to O 0 3.342778143178293e-07
a O 0 1.235600393556524e-06
termination O 0 7.645166078873444e-06
codon O 0 9.917893294186797e-06
at O 0 1.1849398106278386e-05
amino O 0 8.46742568683112e-06
acid O 0 6.864770512038376e-06
position O 0 8.191445886041038e-06
29 O 0 3.9139198634075e-05
. O 0 1.0349959666200448e-05

MaeI O 0 0.0035375466104596853
restriction O 0 4.910750067210756e-05
analysis O 0 1.2720418453682214e-05
showed O 0 1.0779734111565631e-05
two O 0 4.571929537178221e-07
other O 0 2.7932301804867166e-07
carriers O 0 3.4774686810123967e-06
in O 0 5.392404887061275e-07
the O 0 3.475751327641774e-06
family O 0 3.907605787389912e-05
. O 0 1.5752699255244806e-05

The O 0 0.00018819517572410405
C O 0 0.006481762044131756
- O 0 0.022995194420218468
T O 0 0.031212246045470238
mutation O 0 8.10973779152846e-06
is O 0 4.7141799086602987e-07
located O 0 1.3834001038048882e-06
within O 0 4.218423157453799e-07
a O 0 9.365288633489399e-07
recently O 0 4.4539601731230505e-06
proposed O 0 7.848018412914826e-07
putative O 0 3.948829998989822e-06
alternative O 0 1.0418938245493337e-06
translation O 0 1.510283482275554e-06
initiation O 0 3.1147117169894045e-06
codon O 0 1.3756583939539269e-05
( O 0 1.1845032759083551e-06
TIC O 0 6.241964001674205e-05
- O 0 2.6087815058417618e-05
1 O 0 1.3848970183971687e-06
) O 0 1.4439164885970968e-07
, O 0 1.0286938589842975e-07
supporting O 0 3.465053737272683e-07
that O 0 3.138536897040467e-07
TIC O 0 0.0004339267034083605
- O 0 0.00015213729056995362
1 O 0 1.2916947298435844e-06
is O 0 1.343924793673068e-07
the O 0 3.279655231835932e-07
real O 0 1.9838967091345694e-06
TIC O 0 3.928128717234358e-05
rather O 0 4.7151152671176533e-07
than O 0 4.156958084422513e-07
TIC O 0 0.00011884768173331395
- O 0 3.7640249502146617e-05
2 O 0 3.4130518997699255e-06
. O 0 1.6341460877811187e-06
. O 0 8.085412446234841e-06

Human B-Disease 0 0.0005039162351749837
complement I-Disease 0 0.0010363010223954916
factor I-Disease 0 0.3130044639110565
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999866485595703
associated O 0 0.003631009953096509
with O 1 0.9705259203910828
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0009672323940321803

This O 0 1.5250510841724463e-05
study O 0 6.202954864420462e-06
reports O 0 2.807180635500117e-06
on O 0 1.165115463663824e-06
six O 0 2.9707357498409692e-06
cases O 0 5.133696276971023e-07
of O 0 3.690500761877047e-06
deficiency B-Disease 0 0.3163098096847534
in I-Disease 0 5.671838607668178e-07
the I-Disease 0 4.56963675787847e-07
human I-Disease 0 3.8519124245794956e-07
complement I-Disease 0 1.8298650275028194e-06
regulatory I-Disease 0 5.218004844209645e-06
protein I-Disease 0 7.417593678837875e-06
Factor I-Disease 0 8.597159649070818e-06
H I-Disease 1 0.9998849630355835
( O 0 1.5191443480944145e-06
FH O 0 0.003537875832989812
) O 0 1.972538541394897e-07
in O 0 7.892928266528543e-08
the O 0 1.192377538927758e-07
context O 0 3.016922960341617e-07
of O 0 5.24610413776827e-07
an O 0 0.3367839455604553
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0005805518594570458

Five O 0 3.615258538047783e-05
of O 0 1.4183229950504028e-06
the O 0 1.821540763558005e-06
cases O 0 9.479932714384631e-07
were O 0 2.4336659407708794e-06
observed O 0 1.713311917228566e-06
in O 0 9.63424440669769e-07
children O 0 1.4011831808602437e-05
presenting O 0 3.405432289582677e-05
with O 1 0.5746446847915649
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.036724865436553955
HUS B-Disease 1 0.9999991655349731
) O 0 6.0837406635982916e-05
. O 0 3.578317046049051e-05

Two O 0 1.679517845332157e-05
of O 0 2.989687118315487e-06
the O 0 2.688170980036375e-06
children O 0 5.169764335732907e-05
exhibited O 0 0.00024726963602006435
a O 0 0.0019304832676425576
homozygous O 1 0.9998323917388916
deficiency O 1 0.8852431178092957
characterized O 0 7.93376148067182e-06
by O 0 3.2655606219123e-07
the O 0 4.929621582050459e-07
absence O 0 6.935126179996587e-07
of O 0 8.810338414377838e-08
the O 0 2.689527605070907e-07
150 O 0 5.695927143278823e-07
- O 0 3.759185574381263e-06
kD O 0 3.341533101774985e-06
form O 0 2.612413823044335e-07
of O 0 2.1135221572876617e-07
Factor O 0 7.379429462162079e-06
H O 1 0.9998173117637634
and O 0 1.0119680382558727e-06
the O 0 4.0483197949470195e-07
presence O 0 2.826320724125253e-07
, O 0 8.496917303091323e-08
upon O 0 1.321946569987631e-07
immunoblotting O 0 3.737123961400357e-06
, O 0 7.090251585850638e-08
of O 0 4.174508916321429e-08
the O 0 2.3686449424076272e-07
42 O 0 2.853405476344051e-06
- O 0 7.271885351656238e-06
kD O 0 1.6026420780690387e-05
Factor O 0 2.794650299620116e-06
H O 1 0.9471486806869507
- O 0 1.6458167010569014e-05
like O 0 1.1283212870694115e-06
protein O 0 1.4666343304270413e-06
1 O 0 6.264898502195138e-07
( O 0 3.075388121942524e-07
FHL O 0 2.5635556085035205e-05
- O 0 1.6537762348889373e-05
1 O 0 7.933125516501605e-07
) O 0 1.5406999409606215e-07
and O 0 1.62085868282702e-07
other O 0 1.7911351335442305e-07
FH O 0 0.00964550580829382
- O 0 5.4167066991794854e-05
related O 0 2.8649669729929883e-06
protein O 0 8.633820471004583e-06
( O 0 1.722562160466623e-06
FHR O 0 0.00022739259293302894
) O 0 1.9196600078430492e-06
bands O 0 1.9633847841760144e-05
. O 0 1.456031168345362e-05

Southern O 0 0.0002798796631395817
blot O 0 0.0008508348255418241
and O 0 9.216716534865554e-06
PCR O 0 2.9559629183495417e-05
analysis O 0 1.8390884406471741e-06
of O 0 2.850811426924338e-07
DNA O 0 2.452416538289981e-06
of O 0 1.887306950720813e-07
one O 0 3.914910394087201e-06
patient O 0 0.0002986259351018816
with O 0 0.00013869443500880152
homozygous O 1 0.9996352195739746
deficiency O 1 0.8808155655860901
ruled O 0 1.1378952876839321e-05
out O 0 1.4154056771076284e-06
the O 0 2.4390374164795503e-07
presence O 0 2.2469872362762544e-07
of O 0 7.733535767329158e-08
a O 0 5.077100695416448e-07
large O 0 4.921270146951429e-07
deletion O 0 6.0854863477288745e-06
of O 0 1.5438607192663767e-07
the O 0 1.6733071106500574e-06
FH O 0 0.05862879753112793
gene O 0 3.111920705123339e-06
as O 0 3.541022977060493e-07
the O 0 1.6181326145670027e-06
underlying O 0 0.0001246758474735543
defect O 0 0.0005281175835989416
for O 0 2.0215138647472486e-06
the O 0 0.00022262913989834487
deficiency O 1 0.7331650257110596
. O 0 1.7592656149645336e-05

The O 0 1.7401798686478287e-05
other O 0 1.3398021110333502e-06
four O 0 2.2637930214841617e-06
children O 0 9.07095363800181e-06
presented O 0 1.991767931031063e-06
with O 0 1.2720249287667684e-05
heterozygous O 1 0.9972521662712097
deficiency O 1 0.9641860723495483
and O 0 3.442190518399002e-06
exhibited O 0 2.867512739612721e-05
a O 0 3.755573516173172e-06
normal O 0 1.9153139874106273e-05
immunoblotting O 0 0.00013136232155375183
pattern O 0 1.5001548945292598e-06
of O 0 1.2291557993648894e-07
proteins O 0 4.628593330835429e-07
of O 0 2.1447631581850146e-07
the O 0 6.614303856622428e-06
FH O 1 0.8612233400344849
family O 0 7.566648855572566e-05
. O 0 1.6628793673589826e-05

Factor B-Disease 1 0.9929552674293518
H I-Disease 1 1.0
deficiency I-Disease 1 0.9997302889823914
is O 0 2.257493633806007e-06
the O 0 1.6517824406037107e-06
only O 0 1.9430295651545748e-05
complement B-Disease 1 0.9999784231185913
deficiency I-Disease 1 0.9999995231628418
associated O 0 8.103173604467884e-05
with O 0 0.00015723583055660129
HUS B-Disease 1 0.9999971389770508
. O 0 0.00014397209451999515

These O 0 1.3949169442639686e-05
observations O 0 1.9181930838385597e-05
suggest O 0 7.779903171467595e-06
a O 0 1.5487345308429212e-06
role O 0 1.7192879795402405e-06
for O 0 6.404799819392792e-07
FH O 0 0.019566653296351433
and O 0 7.185494268924231e-06
/ O 0 6.503870827145875e-05
or O 0 6.780214789614547e-06
FH O 0 0.012657898478209972
receptors O 0 7.335946520470316e-06
in O 0 4.852903430219158e-07
the O 0 1.9267893094365718e-06
pathogenesis O 0 5.934675573371351e-05
of O 0 5.829395831824513e-06
idiopathic O 1 0.9917716383934021
HUS B-Disease 1 0.9999946355819702
. O 0 2.9286558856256306e-05
. O 0 2.5626804927014746e-05

Further O 0 3.7545782106462866e-05
evidence O 0 5.0669218580878805e-06
for O 0 4.867527536589478e-07
a O 0 1.8925422864413122e-06
major O 0 2.4890418899303768e-06
ancient O 0 4.3063919292762876e-06
mutation O 0 0.007819406688213348
underlying O 0 0.06940847635269165
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999996423721313
from O 0 5.8493620599620044e-05
linkage O 0 0.004475629888474941
disequilibrium O 0 0.006895447615534067
studies O 0 5.780149876954965e-06
in O 0 9.55926111601002e-07
the O 0 2.2676217668049503e-06
Japanese O 0 1.936732223839499e-05
population O 0 5.282439360598801e-06
. O 0 9.997471352107823e-06

The O 0 0.0067803882993757725
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 0 0.22022627294063568
DM B-Disease 1 1.0
) O 0 5.155998223926872e-05
mutation O 0 6.170082633616403e-05
is O 0 9.80668346528546e-07
an O 0 2.9081691081955796e-06
unstable O 0 0.024035101756453514
( O 0 1.6992576092889067e-06
CTG O 0 0.0001482286024838686
) O 0 7.613085699631483e-07
n O 0 1.3447607670968864e-05
repeat O 0 5.962276645732345e-06
, O 0 4.4712200519825274e-07
present O 0 3.512207058520289e-07
at O 0 3.1248093819158385e-06
a O 0 3.823278120762552e-07
copy O 0 5.460731813400344e-07
number O 0 5.2538542405500266e-08
of O 0 6.347543290985413e-08
5 O 0 1.190497528114065e-06
- O 0 1.952465572685469e-05
37 O 0 2.9440409434755566e-06
repeats O 0 1.094775370802381e-06
on O 0 3.9399836282427714e-07
normal O 0 1.2983156238988158e-06
chromosomes O 0 2.275355427627801e-06
but O 0 2.7721830520022195e-07
amplified O 0 2.2606388938584132e-06
to O 0 2.8909755656059133e-07
50 O 0 5.82173413476994e-07
- O 0 3.618885784817394e-06
3000 O 0 4.834260380448541e-06
copies O 0 1.6174844859051518e-06
on O 0 2.3784719815012068e-05
DM B-Disease 1 0.9999959468841553
chromosomes O 0 0.00036420204560272396
. O 0 2.6465493647265248e-05

Previous O 0 0.00013207535084802657
findings O 0 2.222612420155201e-05
in O 0 5.120702098793117e-06
Caucasian O 0 8.440489182248712e-05
populations O 0 5.5252667152672075e-06
of O 0 1.2056431160090142e-06
a O 0 0.0010122605599462986
DM B-Disease 1 1.0
founder O 0 0.0038440425414592028
chromosome O 0 0.0016402462497353554
raise O 0 6.567500804521842e-06
a O 0 1.9120591332466574e-06
question O 0 4.487050659918168e-07
about O 0 1.3271851173612959e-07
the O 0 1.3590238268079702e-07
molecular O 0 1.969353661479545e-06
events O 0 5.091569619253278e-07
involved O 0 7.226508387248032e-07
in O 0 1.9171410770013608e-07
the O 0 7.943914397401386e-07
expansion O 0 8.723621249373537e-06
mutation O 0 4.094744872418232e-05
. O 0 1.74281722138403e-05

To O 0 6.0191778175067157e-05
investigate O 0 4.58860449725762e-05
whether O 0 4.517399247561116e-06
a O 0 2.9333075417525833e-06
founder O 0 3.4954518923768774e-05
chromosome O 0 0.00016964852693490684
for O 0 1.236615275956865e-06
the O 0 1.6521649740752764e-05
DM B-Disease 1 1.0
mutation O 0 6.29754358669743e-05
exists O 0 6.670247216788994e-07
in O 0 2.324289312127803e-07
the O 0 2.090907855745172e-07
Japanese O 0 1.5563657598249847e-06
population O 0 2.2291757773018617e-07
, O 0 1.5341153414283326e-07
we O 0 4.068523367095622e-07
genotyped O 0 1.0855373147933278e-05
families O 0 5.278402568364982e-07
using O 0 5.741586619478767e-07
polymorphic O 0 8.4878320194548e-06
markers O 0 2.7232294087298214e-05
near O 0 8.220377640100196e-05
the O 0 2.8078393370378762e-06
( O 0 2.5468650619586697e-06
CTG O 0 0.00012547838559839875
) O 0 6.907218903506873e-07
n O 0 1.0677460522856563e-05
repeat O 0 7.137216016417369e-06
region O 0 3.0369649266503984e-06
and O 0 3.8060450151533587e-06
constructed O 0 0.0003717130748555064
haplotypes O 0 0.00021253403974696994
. O 0 3.034228393516969e-05

Six O 0 8.46016700961627e-05
different O 0 6.361988653225126e-06
haplotypes O 0 3.1613861210644245e-05
were O 0 1.1818452549050562e-05
found O 0 7.914907655504066e-06
and O 0 2.0959774701623246e-05
DM B-Disease 1 0.9999998807907104
alleles O 0 8.775996684562415e-05
were O 0 2.786924596875906e-05
always O 0 8.914648788049817e-06
haplotype O 0 7.975252083269879e-05
A O 0 5.620655792881735e-05
. O 0 2.21887221414363e-05

To O 0 3.0498447813442908e-05
find O 0 8.774432899372187e-06
an O 0 8.292472557513975e-07
origin O 0 7.040375749056693e-07
of O 0 1.7689279729893315e-07
the O 0 1.3019559901294997e-06
( O 0 1.4374579677678412e-06
CTG O 0 9.721434616949409e-05
) O 0 5.058850547356997e-07
n O 0 1.0969180038955528e-05
repeat O 0 7.514160643040668e-06
mutation O 0 2.9481934689101763e-06
and O 0 5.66065239127056e-07
to O 0 2.246800931970938e-07
investigate O 0 4.410190967973904e-07
the O 0 9.530536004831447e-08
mechanism O 0 2.5503283040961833e-07
of O 0 3.9056288869687705e-08
the O 0 1.1260579668714854e-07
expansion O 0 4.990304773855314e-07
mutation O 0 1.294737330681528e-06
in O 0 1.58578686182409e-07
the O 0 2.1223387136615202e-07
Japanese O 0 8.456914315502218e-07
population O 0 2.0621619967187144e-07
we O 0 2.0606049133675697e-07
have O 0 1.473024440201698e-07
studied O 0 1.3032878314334084e-06
90 O 0 1.096560026780935e-06
Japanese O 0 1.6369616787414998e-05
DM B-Disease 1 0.9999743700027466
families O 0 2.968306034745183e-06
comprising O 0 1.3821564834870514e-06
190 O 0 3.015846459675231e-06
affected O 0 2.6214208901365055e-06
and O 0 1.5248791669364437e-06
130 O 0 6.918413873790996e-06
unaffected O 0 6.43775929347612e-05
members O 0 4.393773451738525e-06
. O 0 8.516048183082603e-06

The O 0 8.274881110992283e-05
results O 0 6.050322554074228e-05
suggest O 0 5.440181212179596e-06
that O 0 3.175245524289494e-07
a O 0 7.878825272200629e-07
few O 0 4.614419140125392e-07
common O 0 9.822510946833063e-07
ancestral O 0 1.8839396943803877e-05
mutations O 0 6.4687287704146e-06
in O 0 4.0151380176212115e-07
both O 0 4.438566350017936e-07
Caucasian O 0 1.2018377674394287e-05
and O 0 1.4028328223503195e-06
Japanese O 0 3.058644779230235e-06
populations O 0 6.244891892492888e-07
have O 0 1.7385677608672268e-07
originated O 0 3.013066987023194e-07
by O 0 7.835807736000788e-08
expansion O 0 2.531256200200005e-07
of O 0 5.4544297967140665e-08
an O 0 2.8765592219315295e-07
ancestral O 0 1.2123074156988878e-05
n O 0 3.977171945734881e-05
= O 0 2.5619816369726323e-05
5 O 0 1.1376046131772455e-06
repeat O 0 5.405696811067173e-06
to O 0 1.4864067452435847e-06
n O 0 6.75874762237072e-05
= O 0 6.101682083681226e-05
19 O 0 8.046412403928116e-06
- O 0 2.6190715288976207e-05
37 O 0 9.313140253652819e-06
copies O 0 5.716645318898372e-06
. O 0 7.510392606491223e-06

These O 0 1.2091472854081076e-05
data O 0 7.043289770081174e-06
support O 0 1.9280905689811334e-06
multistep O 0 6.147456133476226e-06
models O 0 1.8187598698204965e-06
of O 0 5.708440085072652e-07
triplet O 0 0.00789161492139101
repeat O 0 2.060195583908353e-05
expansion O 0 1.7389156710123643e-06
that O 0 5.370383178160409e-07
have O 0 8.038444434532721e-07
been O 0 4.5430175532601424e-07
proposed O 0 2.66470919996209e-07
for O 0 1.6887230458451086e-07
both O 0 5.749669981014449e-06
DM B-Disease 1 0.9999998807907104
and O 0 7.801307219779119e-05
Friedreichs B-Disease 1 0.5048356056213379
ataxia I-Disease 1 0.9336562156677246
. O 0 1.3227780073066242e-05
. O 0 3.046856181754265e-05

The O 0 3.518216180964373e-05
molecular O 0 4.032133801956661e-05
basis O 0 4.156587692705216e-06
of O 0 5.562333535635844e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
in O 0 3.6638070923800115e-06
the O 0 1.3411034842647496e-06
western O 0 4.534928848443087e-06
Cape O 0 6.405254680430517e-05
, O 0 1.3062890502624214e-06
South O 0 3.5044620290136663e-06
Africa O 0 8.158437594829593e-06
. O 0 8.960334525909275e-06

Deficiency B-Disease 1 0.9979481101036072
of I-Disease 0 7.086220648488961e-06
the I-Disease 0 3.518895937304478e-06
sixth I-Disease 0 4.405072468216531e-05
component I-Disease 0 2.174508153984789e-06
of I-Disease 0 2.059995836134476e-07
human I-Disease 0 6.414176709768071e-07
complement I-Disease 0 2.4665087039466016e-06
( O 0 9.135177947428019e-07
C6 O 0 0.0005280470941215754
) O 0 4.6893924832147604e-07
has O 0 8.152573514053074e-07
been O 0 2.4548032797611086e-06
reported O 0 3.1330691854236647e-06
in O 0 1.2818087213872786e-07
a O 0 3.2546293482482724e-07
number O 0 8.881081470235586e-08
of O 0 7.748862174139504e-08
families O 0 7.704898621341272e-07
from O 0 1.8475019203378906e-07
the O 0 2.674434256277891e-07
western O 0 8.462771461381635e-07
Cape O 0 1.0358402505517006e-05
, O 0 5.131395255375537e-07
South O 0 3.0483738555631135e-06
Africa O 0 4.920866103930166e-06
. O 0 8.959702427091543e-06

Meningococcal B-Disease 1 0.9999643564224243
disease I-Disease 1 0.9999830722808838
is O 0 5.589622014667839e-05
endemic O 0 4.3776097299996763e-05
in O 0 2.0238690012774896e-06
the O 0 1.8021968344328343e-06
Cape O 0 3.775331060751341e-05
and O 0 6.530238465529692e-07
almost O 0 2.465694137754326e-07
all O 0 6.919456296827775e-08
pedigrees O 0 4.706113031716086e-06
of O 0 6.468738433795806e-07
total O 0 0.17070162296295166
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
( O 0 4.367133897176245e-06
C6Q0 O 0 0.04286663606762886
) O 0 1.1827119124063756e-06
have O 0 9.955086852642125e-07
been O 0 2.705918404899421e-06
ascertained O 0 2.2993610400590114e-05
because O 0 6.081165793148102e-07
of O 0 2.093051534757251e-06
recurrent O 1 0.9819452166557312
disease O 1 0.9501089453697205
. O 0 2.991747169289738e-05

We O 0 6.302710971795022e-05
have O 0 3.2007185382099124e-06
sequenced O 0 1.0030544217443094e-05
the O 0 5.172253167984309e-07
expressed O 0 5.727826533075131e-07
exons O 0 1.557295149723359e-06
of O 0 1.4998258279774745e-07
the O 0 6.373383598656801e-07
C6 O 0 8.866599091561511e-05
gene O 0 1.687222493274021e-06
from O 0 3.212086028270278e-07
selected O 0 5.550620585381694e-07
cases O 0 3.497039813282754e-07
and O 0 1.7390880202583503e-06
have O 0 2.617389100123546e-06
found O 0 2.389496330579277e-06
three O 0 3.1349281925940886e-06
molecular O 0 0.09961938112974167
defects O 1 0.9788818359375
leading O 0 1.620210059627425e-05
to O 0 1.3576207493315451e-05
total O 0 0.044187307357788086
deficiency O 1 0.672120988368988
879delG O 0 0.0001246305473614484
, O 0 1.2210141449031653e-06
which O 0 3.8920060774216836e-07
is O 0 1.3480169513968576e-07
the O 0 3.3472505833742616e-07
common O 0 2.911974206654122e-06
defect O 0 0.0003543172497302294
in O 0 4.546033949281991e-07
the O 0 6.537479180224182e-07
Cape O 0 2.4772181859589182e-05
and O 0 2.1135274437256157e-06
hitherto O 0 2.2443035049946047e-05
unreported O 0 3.951037797378376e-06
, O 0 4.096930865671311e-07
and O 0 7.013604204075818e-07
1195delC O 0 2.228818448202219e-05
and O 0 1.1621181101872935e-06
1936delG O 0 3.8781297917012125e-05
, O 0 4.357518150754913e-07
which O 0 3.4194695786027296e-07
have O 0 5.252391588328464e-07
been O 0 1.3741274642598e-06
previously O 0 3.1771492103871424e-06
reported O 0 1.3626671488964348e-06
in O 0 3.634528695783956e-07
African O 0 1.490238901169505e-06
- O 0 9.2544243671e-05
Americans O 0 1.118913041864289e-05
. O 0 7.771011951263063e-06

We O 0 0.00010668441973393783
also O 0 7.173019639594713e-06
show O 0 3.3884109598147916e-06
that O 0 3.3212086236744653e-07
the O 0 7.205746328509122e-07
879delG O 0 4.3790794734377414e-05
and O 0 8.879217602952849e-06
1195delC O 0 0.2488897293806076
defects O 1 0.9588843584060669
are O 0 7.418326504193828e-07
associated O 0 1.9486465134832542e-06
with O 0 3.0639728265668964e-06
characteristic O 0 0.0009047105559147894
C6 O 1 0.9088366627693176
/ O 0 0.0011319364421069622
C7 O 0 0.048972830176353455
region O 0 2.5382221792824566e-05
DNA O 0 6.258241774048656e-05
marker O 0 8.306219388032332e-05
haplotypes O 0 4.007798634120263e-05
, O 0 1.128698045249621e-06
although O 0 5.071100304121501e-07
small O 0 6.652878141721885e-07
variations O 0 3.6145261219644453e-06
were O 0 7.5740908869192936e-06
observed O 0 1.2302256436669268e-05
. O 0 6.572061920451233e-06

The O 0 0.00011270640970906243
1936delG O 0 0.002471442800015211
defect O 0 0.00927282590419054
was O 0 4.482383155846037e-05
observed O 0 2.6816878744284622e-06
only O 0 3.436898623476736e-07
once O 0 9.827936082729138e-07
in O 0 1.9832600628433283e-07
the O 0 5.238395033302368e-07
Cape O 0 1.0478213880560361e-05
, O 0 3.5104591233903193e-07
but O 0 1.6963369375844195e-07
its O 0 5.309918265083979e-07
associated O 0 4.002477908215951e-06
haplotype O 0 4.240349153405987e-05
could O 0 8.151507245202083e-06
be O 0 3.396453848836245e-06
deduced O 0 5.855735798832029e-05
. O 0 1.3332122762221843e-05

The O 0 1.7232130630873144e-05
data O 0 9.404362572240643e-06
from O 0 1.3789322110824287e-06
the O 0 1.1420462442401913e-06
haplotypes O 0 1.5575145880575292e-05
indicate O 0 5.507553851202829e-06
that O 0 1.9005062767973868e-07
these O 0 1.8965268111514888e-07
three O 0 1.7325954786429065e-06
molecular O 0 0.15291786193847656
defects O 1 0.9678186774253845
account O 0 1.974384076675051e-06
for O 0 5.671740836987738e-07
the O 0 5.196417532715714e-06
defects O 0 0.47136184573173523
in O 0 4.684019927481131e-07
all O 0 1.152841946350236e-07
the O 0 4.038301995024085e-07
38 O 0 1.0046396710094996e-05
unrelated O 0 6.0752809076802805e-06
C6Q0 O 0 0.0017472616164013743
individuals O 0 5.476095452650043e-07
we O 0 4.4274182187109545e-07
have O 0 4.4381263819559535e-07
studied O 0 1.925119704537792e-06
from O 0 7.464425948455755e-07
the O 0 2.2746914964955067e-06
Cape O 0 0.00014849909348413348
. O 0 1.4051924154045992e-05

We O 0 8.105052256723866e-05
have O 0 5.5977748161240015e-06
also O 0 1.945161557159736e-06
observed O 0 3.1318204491981305e-06
the O 0 1.5093102092578192e-06
879delG O 0 0.00023104005958884954
defect O 0 0.00011842491221614182
in O 0 1.7445931916881818e-06
two O 0 7.3290739237563685e-06
Dutch O 1 0.9370231628417969
C6 B-Disease 1 0.9999997615814209
- I-Disease 1 0.9998072981834412
deficient I-Disease 1 0.9999971389770508
kindreds O 0 0.00022786876070313156
, O 0 3.36640550813172e-06
but O 0 7.197127160907257e-07
the O 0 1.3244530236988794e-06
879delG O 0 0.00020160569692961872
defect O 0 7.094514148775488e-05
in O 0 5.508670142262417e-07
the O 0 1.0325502444175072e-06
Cape O 0 6.864160241093487e-05
probably O 0 1.0049434422398917e-05
did O 0 2.255685785712558e-06
not O 0 2.7729262797038245e-07
come O 0 1.7297017507189594e-07
from O 0 1.8456070449701656e-07
The O 0 5.512138727681304e-07
Netherlands O 0 1.4882157302054111e-05
. O 0 1.6172500636457698e-06
. O 0 8.387602065340616e-06

Complement B-Disease 1 0.9861684441566467
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.3273811166291125e-05
seven O 0 9.02773354027886e-06
further O 0 5.971131031401455e-06
molecular O 0 0.02795998379588127
defects O 1 0.9934332370758057
and O 0 1.0263170224789064e-05
their O 0 1.3314385796547867e-05
associated O 0 3.242035018047318e-05
marker O 0 0.00032944465056061745
haplotypes O 0 0.0005944714066572487
. O 0 6.32186493021436e-05

Seven O 0 7.513441232731566e-05
further O 0 1.3700338968192227e-05
molecular O 0 5.4368374549085274e-05
bases O 0 9.117356967180967e-05
of O 0 0.0005987889016978443
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.5972575056366622e-05
described O 0 0.00016006798250600696
. O 0 4.433773210621439e-05

All O 0 1.8914088286692277e-05
these O 0 3.519372512528207e-06
new O 0 6.520780971186468e-06
molecular O 0 0.001230706344358623
defects O 1 0.6414353251457214
involve O 0 5.399112524173688e-06
single O 0 2.291943928867113e-05
- O 0 5.9930029237875715e-05
nucleotide O 0 8.854762199916877e-06
events O 0 6.620119279432402e-07
, O 0 2.347949248360237e-07
deletions O 0 1.6690072470737505e-06
and O 0 4.861116167376167e-07
substitutions O 0 1.4112960116108297e-06
, O 0 2.447766291879816e-07
some O 0 4.4426233358763056e-08
of O 0 6.10566530667711e-08
which O 0 4.0331215700462053e-07
alter O 0 4.713254384114407e-06
splice O 0 4.077833364135586e-05
sites O 0 2.197024969063932e-06
, O 0 6.921105750734569e-07
and O 0 8.164128075804911e-07
others O 0 4.9294712880509906e-06
codons O 0 2.394071634626016e-05
. O 0 9.403626791026909e-06

They O 0 5.546242755372077e-05
are O 0 1.5011952427812503e-06
distributed O 0 1.1945211326747085e-06
along O 0 7.483463946300617e-07
the O 0 8.09012533409259e-07
C7 O 0 0.0003328821621835232
gene O 0 4.467096005100757e-06
, O 0 4.7498582489424734e-07
but O 0 1.800774356297552e-07
predominantly O 0 2.8808966590077034e-07
towards O 0 5.536942921935406e-07
the O 0 7.889644848546595e-07
3 O 0 4.694785729952855e-06
end O 0 1.0122863386641257e-05
. O 0 8.461806828563567e-06

All O 0 2.4737055355217308e-05
were O 0 1.4523685422318522e-05
found O 0 5.0840567382692825e-06
in O 0 3.1436043173016515e-06
compound O 0 6.212498556124046e-05
heterozygous O 0 0.00018795955111272633
individuals O 0 9.710393896966707e-06
. O 0 1.2632845027837902e-05

The O 0 0.00016789797518868
C6 O 0 0.11278914660215378
/ O 0 0.0015128981322050095
C7 O 0 0.0316355936229229
marker O 0 0.00031448653317056596
haplotypes O 0 0.00017556818784214556
associated O 0 1.809862078516744e-05
with O 0 4.303189598431345e-06
most O 0 2.525878335291054e-05
C7 B-Disease 1 0.9999841451644897
defects I-Disease 1 0.999768078327179
are O 0 1.1718590030795895e-05
tabulated O 0 0.01569094881415367
. O 0 4.176897164143156e-06
. O 0 1.2511118256952614e-05

A O 0 0.00022574907052330673
genome O 0 0.0001145926071330905
- O 0 6.606046372326091e-05
wide O 0 9.86723171081394e-06
search O 0 6.395853688445641e-06
for O 0 1.4400621921595302e-06
chromosomal O 0 0.018593501299619675
loci O 0 0.00012225429236423224
linked O 0 0.00016043425421230495
to O 0 1.2415355740813538e-05
mental O 1 0.6196935176849365
health O 0 0.0002529819030314684
wellness O 0 0.0033361250534653664
in O 0 5.443793270387687e-06
relatives O 0 9.397602116223425e-05
at O 0 0.00048209892702288926
high O 0 0.013473345898091793
risk O 0 0.0013873230200260878
for O 0 2.7809352104668505e-05
bipolar B-Disease 1 0.9999998807907104
affective I-Disease 1 0.9999642372131348
disorder I-Disease 1 0.9874558448791504
among O 0 1.2329448964010226e-06
the O 0 2.5114743493759306e-06
Old O 0 9.851525828707963e-05
Order O 0 8.031340257730335e-06
Amish O 0 0.0004938054480589926
. O 0 2.0350680642877705e-05

Bipolar B-Disease 1 0.9999998807907104
affective I-Disease 1 0.9999979734420776
disorder I-Disease 1 0.9999996423721313
( O 0 0.08818768709897995
BPAD B-Disease 1 1.0
; O 0 0.18189369142055511
manic B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
depressive I-Disease 1 1.0
illness I-Disease 1 0.9999923706054688
) O 0 6.578884949703934e-06
is O 0 8.142387173393217e-07
characterized O 0 1.7726242731441744e-06
by O 0 2.0914224307944096e-07
episodes O 0 1.010804794532305e-06
of O 0 3.397404952920624e-07
mania B-Disease 0 0.012835380621254444
and O 0 1.4614774954679888e-05
/ O 0 0.00039728032425045967
or O 0 2.105851126543712e-05
hypomania B-Disease 0 0.3470061719417572
interspersed O 0 5.5250733566936105e-05
with O 0 3.678171651699813e-06
periods O 0 1.1156833352288231e-05
of O 0 6.435894192691194e-06
depression B-Disease 1 0.5457550883293152
. O 0 3.39136749971658e-05

Compelling O 0 0.0001452160213375464
evidence O 0 1.9239163520978764e-05
supports O 0 6.639879757130984e-06
a O 0 2.099957555401488e-06
significant O 0 1.970302264453494e-06
genetic O 0 1.3825723726768047e-05
component O 0 1.8741326357485377e-06
in O 0 3.2551417916693026e-07
the O 0 8.045238359954965e-07
susceptibility O 0 5.151182267582044e-05
to O 0 9.264497748517897e-06
develop O 0 0.001162186381407082
BPAD B-Disease 1 0.9999967813491821
. O 0 6.513541302410886e-05

To O 0 3.1308703910326585e-05
date O 0 1.5837895261938684e-05
, O 0 9.102549256567727e-07
however O 0 5.49869241694978e-07
, O 0 2.9704591497647925e-07
linkage O 0 5.177837920200545e-06
studies O 0 9.853303026829963e-07
have O 0 6.379719934557215e-07
attempted O 0 5.074349246569909e-06
only O 0 2.969660499729798e-07
to O 0 5.587404530160711e-07
identify O 0 1.0136658602277748e-05
chromosomal O 0 0.004475933965295553
loci O 0 2.0729821699205786e-05
that O 0 9.599183385944343e-07
cause O 0 7.939112947497051e-06
or O 0 1.799416281755839e-06
increase O 0 9.666372307037818e-07
the O 0 1.983259380722302e-06
risk O 0 1.4313186511571985e-05
of O 0 1.1090078260167502e-06
developing O 0 0.00018422072753310204
BPAD B-Disease 1 0.999994158744812
. O 0 4.846288720727898e-05

To O 0 3.647526682470925e-05
determine O 0 1.997548133658711e-05
whether O 0 1.6438965531051508e-06
there O 0 8.027963644963165e-07
could O 0 2.0287213828851236e-06
be O 0 6.606672400266689e-07
protective O 0 1.721593798720278e-05
alleles O 0 2.821421048793127e-06
that O 0 4.15319391322555e-07
prevent O 0 1.2958890692971181e-05
or O 0 4.5796109588991385e-06
reduce O 0 8.050771612033714e-06
the O 0 1.386363805977453e-06
risk O 0 6.96252254783758e-06
of O 0 2.574501252183836e-07
developing O 0 4.2216521251248196e-05
BPAD B-Disease 1 0.9999992847442627
, O 0 1.514682935521705e-06
similar O 0 3.9526099726572284e-07
to O 0 7.687928587074566e-07
what O 0 2.964284249173943e-07
is O 0 9.016843449671796e-08
observed O 0 3.1622661822439113e-07
in O 0 4.313295107749582e-07
other O 0 5.072065960121108e-06
genetic B-Disease 1 0.9999978542327881
disorders I-Disease 1 0.9999998807907104
, O 0 1.6700401829439215e-05
we O 0 4.730325144919334e-06
used O 0 0.00026782043278217316
mental O 1 0.9401697516441345
health O 0 0.0008676911238580942
wellness O 0 0.10862836986780167
( O 0 7.304499831661815e-07
absence O 0 1.0410774393676547e-06
of O 0 3.35743635559993e-07
any O 0 6.0017078794771805e-05
psychiatric B-Disease 1 0.9998137354850769
disorder I-Disease 1 0.9863401651382446
) O 0 7.858796493565023e-07
as O 0 2.9468031925716787e-07
the O 0 6.896010518175899e-07
phenotype O 0 6.283207039814442e-05
in O 0 4.355918292731076e-07
our O 0 7.796330123710504e-07
genome O 0 1.2942040257257759e-06
- O 0 4.870322300121188e-06
wide O 0 2.1308719624357764e-06
linkage O 0 1.8041562725557014e-05
scan O 0 5.104989031678997e-05
of O 0 2.774534664240491e-07
several O 0 4.0935958622867474e-07
large O 0 1.1640358934528194e-06
multigeneration O 0 5.8589637774275616e-05
Old O 0 9.875186151475646e-06
Order O 0 7.451566830241063e-07
Amish O 0 3.461500455159694e-05
pedigrees O 0 4.204288052278571e-05
exhibiting O 0 1.3904358638683334e-05
an O 0 1.6254357433354016e-06
extremely O 0 2.1700501747545786e-05
high O 0 0.00016657094238325953
incidence O 0 0.003976345527917147
of O 0 2.0734547433676198e-05
BPAD B-Disease 1 0.9999988079071045
. O 0 0.00018076160631608218

We O 0 6.228644633665681e-05
have O 0 5.785675512015587e-06
found O 0 4.417866421135841e-06
strong O 0 1.480213541071862e-06
evidence O 0 5.375286491471343e-07
for O 0 2.4812726451273193e-07
a O 0 1.6125558204294066e-06
locus O 0 4.150944369030185e-05
on O 0 1.8602044292492792e-05
chromosome O 0 0.2015235871076584
4p O 1 0.9274970293045044
at O 0 5.6084059906424955e-05
D4S2949 O 0 3.5908255085814744e-05
( O 0 8.915889679883549e-07
maximum O 0 2.7410492293711286e-06
GENEHUNTER O 0 0.00018158977036364377
- O 0 1.5248183444782626e-05
PLUS O 0 5.451425295177614e-06
nonparametric O 0 2.272816163895186e-05
linkage O 0 2.3375911041512154e-05
score O 0 2.0960056644980796e-05
= O 0 2.7991181923425756e-05
4 O 0 1.273880457119958e-06
. O 0 3.6656697943726613e-07
05 O 0 6.484314508270472e-05
, O 0 1.2182865702925483e-06
P O 0 0.0001645452866796404
= O 0 6.252285402297275e-06
5 O 0 3.481121098047879e-07
. O 0 9.219991170539288e-08
22 O 0 4.3514302205949207e-07
x O 0 2.6706725293479394e-06
10 O 0 5.010968493479595e-07
( O 0 1.5138755316002062e-07
- O 0 4.101389549759915e-06
4 O 0 1.457226176171389e-06
) O 0 1.7250167161364516e-07
; O 0 3.49411948263878e-07
SIBPAL O 0 5.034121932112612e-05
Pempirical O 0 1.8859711417462677e-05
value O 0 3.7625932236551307e-07
< O 0 2.180089495595894e-06
3 O 0 5.157584723747277e-07
x O 0 4.985674877389101e-06
10 O 0 5.124021527080913e-07
( O 0 1.6919632628287218e-07
- O 0 9.302248145104386e-06
5 O 0 1.2514295804066933e-06
) O 0 1.443553117042029e-07
) O 0 7.073339958196811e-08
and O 0 1.787253438578773e-07
suggestive O 0 7.2733282650006e-06
evidence O 0 3.716786238783243e-07
for O 0 1.5464011937638134e-07
a O 0 2.0569973457895685e-06
locus O 0 6.278924411162734e-05
on O 0 3.188144546584226e-05
chromosome O 1 0.8108373880386353
4q O 1 0.722723126411438
at O 0 5.706441879738122e-05
D4S397 O 0 3.650965300039388e-05
( O 0 4.2272995415260084e-07
maximum O 0 2.3256934582605027e-06
GENEHUNTER O 0 0.00016627961304038763
- O 0 1.468110076530138e-05
PLUS O 0 4.548229753709165e-06
nonparametric O 0 8.901395631255582e-06
linkage O 0 2.1393800125224516e-05
score O 0 1.875990528787952e-05
= O 0 2.9172719223424792e-05
3 O 0 1.681701178313233e-06
. O 0 2.965992109693616e-07
29 O 0 2.9792470286338357e-06
, O 0 5.366998721001437e-07
P O 0 0.0001493314775871113
= O 0 8.5219462562236e-06
2 O 0 3.15573458919971e-07
. O 0 9.914234766483787e-08
57 O 0 1.047568957801559e-06
x O 0 3.68643441106542e-06
10 O 0 5.020210096517985e-07
( O 0 2.17976435124001e-07
- O 0 8.44273563416209e-06
3 O 0 2.3691379738011165e-06
) O 0 3.6919547596880875e-07
; O 0 5.500805855263025e-07
SIBPAL O 0 4.24590143666137e-05
Pempirical O 0 1.1391189218556974e-05
value O 0 2.604799078653741e-07
< O 0 1.3568238728112192e-06
1 O 0 5.506474849426013e-07
x O 0 8.311987585329916e-06
10 O 0 1.0552707863098476e-06
( O 0 2.7020402626476425e-07
- O 0 2.0266084902686998e-05
3 O 0 3.134796543236007e-06
) O 0 2.0137966316724487e-07
) O 0 6.642063254957975e-08
that O 0 6.553533893338681e-08
are O 0 1.6238757893916045e-07
linked O 0 2.384117578912992e-05
to O 0 7.461788754881127e-06
mental O 1 0.8617864847183228
health O 0 0.00032410473795607686
wellness O 0 0.024049052968621254
. O 0 2.8250153263797984e-05

These O 0 3.280837700003758e-05
findings O 0 1.7550462871440686e-05
are O 0 9.706482160254382e-07
consistent O 0 2.1587345599982655e-06
with O 0 3.221580868739693e-07
the O 0 4.5271448811945447e-07
hypothesis O 0 9.668723350841901e-07
that O 0 9.906560194394842e-08
certain O 0 1.985034998597257e-07
alleles O 0 3.958705747209024e-06
could O 0 2.8354747882985976e-06
prevent O 0 5.086685177957406e-06
or O 0 1.2919695109303575e-06
modify O 0 2.8037961783411447e-06
the O 0 5.037028358856332e-07
clinical O 0 7.084099252097076e-06
manifestations O 0 2.2247420474741375e-06
of O 0 1.4326515156426467e-06
BPAD B-Disease 1 0.9999994039535522
and O 0 1.208061530633131e-05
perhaps O 0 3.363036057635327e-06
other O 0 9.379822927257919e-07
related O 0 0.00012918956053908914
affective B-Disease 1 0.9992579817771912
disorders I-Disease 1 0.9997510313987732
. O 0 0.00012174592848168686

Segregation O 0 0.009465600363910198
distortion O 0 0.015605204738676548
in O 0 0.002906844252720475
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.0017520856345072389

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.9807072281837463
DM B-Disease 1 1.0
) O 0 0.00011025419371435419
is O 0 3.4281624721188564e-06
an O 0 6.77915431879228e-06
autosomal B-Disease 1 0.9865463972091675
dominant I-Disease 1 0.9572540521621704
disease I-Disease 1 0.9583092331886292
which O 0 4.662098945118487e-06
, O 0 8.803264108792064e-07
in O 0 3.317422283544147e-07
the O 0 5.030619831813965e-07
typical O 0 1.0570007361820899e-05
pedigree O 0 0.0005015229107812047
, O 0 3.364231417890551e-07
shows O 0 2.997641672664031e-07
a O 0 2.8405852958712785e-07
three O 0 5.601922339337762e-07
generation O 0 6.079987542761955e-06
anticipation O 0 1.7308371752733365e-05
cascade O 0 0.0001268454798264429
. O 0 1.6272957509499975e-05

This O 0 2.8583501261891797e-05
results O 0 4.967785207554698e-05
in O 0 7.039583579171449e-05
infertility B-Disease 1 0.9997852444648743
and O 1 0.9725471138954163
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0016171971801668406
CDM B-Disease 0 0.12546314299106598
) O 0 9.416040143150894e-07
with O 0 2.5423753413633676e-07
the O 0 6.283376023930032e-07
disappearance O 0 1.047124169417657e-05
of O 0 1.4014353837410454e-06
DM B-Disease 1 0.9999995231628418
in O 0 9.060769116331358e-06
that O 0 5.346980287868064e-06
pedigree O 0 0.0029544015415012836
. O 0 2.252481135656126e-05

The O 0 1.725956281006802e-05
concept O 0 8.859095032676123e-06
of O 0 1.1598051514738472e-06
segregation O 0 1.3639980352309067e-05
distortion O 0 3.330637264298275e-05
, O 0 7.929699563646864e-07
where O 0 4.897934218206501e-07
there O 0 9.09262638515429e-08
is O 0 6.581869627098058e-08
preferential O 0 6.732918222951412e-07
transmission O 0 6.3622619563830085e-06
of O 0 1.010754004937553e-07
the O 0 3.771977219457767e-07
larger O 0 1.2919103937747423e-06
allele O 0 7.822763109288644e-06
at O 0 1.1880898455274291e-05
the O 0 2.937246108558611e-06
DM B-Disease 1 0.9999926090240479
locus O 0 0.00021913196542300284
, O 0 2.0799507183255628e-06
has O 0 5.649586114486738e-07
been O 0 6.381667390087387e-07
put O 0 4.6073265025370347e-07
forward O 0 4.7549119130962936e-07
to O 0 5.966298886050936e-07
explain O 0 5.206726200412959e-06
partially O 0 1.952297861862462e-05
the O 0 2.7116638534607773e-07
maintenance O 0 2.0676870917668566e-05
of O 0 1.1486611128930235e-06
DM B-Disease 1 0.9999980926513672
in O 0 2.1105945506860735e-06
the O 0 2.871992137443158e-06
population O 0 5.204313310969155e-06
. O 0 1.1214256119274069e-05

In O 0 4.1371364204678684e-05
a O 0 1.0803569239214994e-05
survey O 0 2.593263707240112e-05
of O 0 2.236160526081221e-06
DM B-Disease 1 0.9999793767929077
in O 0 3.4031877476081718e-06
Northern O 0 5.289930868457304e-06
Ireland O 0 1.576676731929183e-05
, O 0 2.2525430267705815e-06
59 O 0 1.1399274626455735e-05
pedigrees O 0 8.689830428920686e-05
were O 0 3.363218274898827e-05
ascertained O 0 0.00017815046885516495
. O 0 2.8932672648807056e-05

Sibships O 0 0.005119904410094023
where O 0 2.6456611522007734e-05
the O 0 1.9937101569666993e-06
status O 0 7.702121251895733e-07
of O 0 1.2625402234789362e-07
all O 0 1.8842855808998138e-07
the O 0 3.9593408018845366e-07
members O 0 6.244933388188656e-07
had O 0 1.7515149011160247e-05
been O 0 1.615193809811899e-06
identified O 0 1.1514810012158705e-06
were O 0 6.625272703786322e-07
examined O 0 1.4123301070867456e-06
to O 0 1.5643625772554515e-07
determine O 0 7.817609457561048e-07
the O 0 2.439530533138168e-07
transmission O 0 8.754131158639211e-06
of O 0 2.514378536488948e-07
the O 0 5.796069217467448e-06
DM B-Disease 1 0.999988317489624
expansion O 0 2.2760846150049474e-06
from O 0 1.1790327789640287e-06
affected O 0 2.3265654363058275e-06
parents O 0 2.0554639377223793e-06
to O 0 8.012535772650153e-07
their O 0 6.770419076929102e-06
offspring O 0 6.321298133116215e-05
. O 0 1.230197540280642e-05

Where O 0 0.00010508268314879388
the O 0 1.9375984265934676e-05
transmitting O 0 0.0068851038813591
parent O 0 0.00010083180677611381
was O 0 2.018307350226678e-05
male O 0 1.2117328878957778e-05
, O 0 2.192487045249436e-06
58 O 0 1.6007050362532027e-05
. O 0 7.928255399747286e-06

3 O 0 8.842653187457472e-05
% O 0 5.056186637375504e-06
of O 0 4.0966889969240583e-07
the O 0 9.736104402691126e-07
offspring O 0 1.4854904293315485e-05
were O 0 4.344760327512631e-06
affected O 0 1.5342455981226522e-06
, O 0 2.9006912427576026e-07
and O 0 3.4352865441178437e-07
in O 0 2.5217843813152285e-07
the O 0 3.268876298534451e-07
case O 0 1.960141275958449e-07
of O 0 6.102929006601698e-08
a O 0 1.5735407714601024e-06
female O 0 5.837414937559515e-05
transmitting O 0 0.3540423810482025
parent O 0 0.00016199065430555493
, O 0 2.1193159227550495e-06
68 O 0 2.6926843929686584e-05
. O 0 1.0493344234419055e-05

7 O 0 0.0007623665733262897
% O 0 6.391612259903923e-05
were O 0 3.56882628693711e-05
affected O 0 6.499258597614244e-05
. O 0 3.6052708310307935e-05

Studies O 0 0.00014489829482045025
on O 0 1.827521737141069e-05
meiotic O 0 0.0001313139800913632
drive O 0 9.846397006185725e-05
in O 0 1.8184155123890378e-05
DM B-Disease 1 0.9999997615814209
have O 0 4.637740858015604e-06
shown O 0 1.2089591336916783e-06
increased O 0 7.618881454618531e-07
transmission O 0 9.194636731990613e-06
of O 0 9.13572080207814e-08
the O 0 1.8065246365495113e-07
larger O 0 8.266574127446802e-07
allele O 0 8.126026841637213e-06
at O 0 8.879929737304337e-06
the O 0 6.222970114322379e-06
DM B-Disease 1 0.9999736547470093
locus O 0 0.0001279129064641893
in O 0 3.159358584525762e-06
non O 0 4.180858377367258e-05
- O 1 0.6319862604141235
DM O 1 0.9999996423721313
heterozygotes O 0 0.0005052135675214231
for O 0 5.382301878853468e-06
CTGn O 0 0.0015115069691091776
. O 0 2.4666149329277687e-05

This O 0 1.1575152711884584e-05
study O 0 8.864918527251575e-06
provides O 0 2.9403202006506035e-06
further O 0 1.0308805258318898e-06
evidence O 0 6.205696649885795e-07
that O 0 3.2239350389318133e-07
the O 0 2.15743398257473e-06
DM B-Disease 1 0.9999841451644897
expansion O 0 4.345849902165355e-06
tends O 0 4.299497959436849e-06
to O 0 8.485489502163546e-07
be O 0 2.364707142987754e-06
transmitted O 0 4.7943547542672604e-05
preferentially O 0 6.516398570965976e-05
. O 0 1.3722751646128017e-05

Diagnosis O 1 0.9995642304420471
of O 0 0.0015687489649280906
hemochromatosis B-Disease 1 0.9999996423721313
. O 0 0.000994074740447104

If O 0 0.0024310906883329153
untreated O 1 0.9971795082092285
, O 0 0.009105755016207695
hemochromatosis B-Disease 1 1.0
can O 0 0.03985856845974922
cause O 0 0.044906917959451675
serious O 0 0.11594367772340775
illness O 1 0.8659677505493164
and O 0 1.4481420294032432e-05
early B-Disease 0 3.978431050200015e-05
death I-Disease 0 0.00128245132509619
, O 0 1.834630211305921e-06
but O 0 9.523155313218012e-07
the O 0 6.827549441368319e-06
disease O 0 0.015736203640699387
is O 0 6.734607609359955e-07
still O 0 4.9772947932069656e-06
substantially O 0 2.5386192646692507e-05
under O 0 3.183848093613051e-05
- O 1 0.9711215496063232
diagnosed O 1 0.9932674169540405
. O 0 3.3448392059654e-05

The O 0 2.997882074851077e-05
cornerstone O 0 5.4831358283990994e-05
of O 0 1.0942513881673221e-06
screening O 0 6.981696969887707e-06
and O 0 2.2363608422892867e-06
case O 0 9.464945378567791e-07
detection O 0 7.269236903084675e-06
is O 0 2.377929178010163e-07
the O 0 1.714494004545486e-07
measurement O 0 3.3808253192546545e-06
of O 0 3.9771046544956334e-07
serum O 0 0.0001458129263482988
transferrin O 0 2.9797656679875217e-05
saturation O 0 1.5748013538541272e-05
and O 0 1.0064042044177768e-06
the O 0 2.0007346392958425e-06
serum O 0 0.00017870002193376422
ferritin O 0 0.00043719331733882427
level O 0 4.0246730350190774e-05
. O 0 2.0942910850862972e-05

Once O 0 0.0004039185296278447
the O 0 2.2259147954173386e-05
diagnosis O 1 0.8865098357200623
is O 0 6.580654371646233e-06
suspected O 0 0.00032622917206026614
, O 0 2.4778960323601495e-06
physicians O 0 6.449079592130147e-06
must O 0 7.271596587088425e-07
use O 0 1.701260202935373e-06
serum O 0 0.0006003904272802174
ferritin O 0 0.005977405235171318
levels O 0 2.706039413169492e-05
and O 0 1.711914228508249e-05
hepatic O 0 0.004377616103738546
iron O 0 0.06231211870908737
stores O 0 0.00016058639448601753
on O 0 5.469933239510283e-05
liver O 1 0.8155857920646667
biopsy O 1 0.990314781665802
specimens O 0 2.134147143806331e-05
to O 0 3.4417930692143273e-06
assess O 0 0.0016082258662208915
patients O 0 2.8606082196347415e-05
for O 0 1.798836564148587e-07
the O 0 6.69970120270591e-07
presence O 0 1.072757072506647e-06
of O 0 1.8836113895304152e-06
iron B-Disease 1 0.9445531964302063
overload I-Disease 0 0.25344038009643555
. O 0 2.777802183118183e-05

Liver O 1 0.9999872446060181
biopsy O 1 0.9999865293502808
is O 0 2.921888153650798e-05
also O 0 3.1543675049761077e-06
used O 0 1.3602326589534641e-06
to O 0 5.44276872460614e-07
establish O 0 1.956652113221935e-06
the O 0 4.1958986685131094e-07
presence O 0 5.650151706504403e-07
or O 0 4.0035260440163256e-07
absence O 0 6.578814009117195e-07
of O 0 6.56070028526301e-07
cirrhosis B-Disease 1 0.7094570398330688
, O 0 2.1166658825677587e-06
which O 0 1.3757967280980665e-06
can O 0 5.220797447691439e-06
affect O 0 3.161151471431367e-05
prognosis O 0 0.22859272360801697
and O 0 1.0618938176776282e-05
management O 0 0.0002277986059198156
. O 0 1.5208914192044176e-05

A O 0 0.00017891175230033696
DNA O 0 0.00010057636973215267
- O 0 7.132277823984623e-05
based O 0 2.199850996476016e-06
test O 0 1.8722676031757146e-06
for O 0 2.1842257069693005e-07
the O 0 1.298271058658429e-06
HFE O 0 0.0014107991009950638
gene O 0 2.6084135242854245e-06
is O 0 3.2380103220930323e-07
commercially O 0 1.0089950137626147e-06
available O 0 2.491703980922466e-07
, O 0 2.1375427650127676e-07
but O 0 6.155771359317441e-08
its O 0 1.0515330473026552e-07
place O 0 5.05366699599108e-07
in O 0 1.9568521736346156e-07
the O 0 1.77185506800015e-06
diagnosis O 1 0.6389415860176086
of O 0 8.224071279983036e-06
hemochromatosis B-Disease 1 1.0
is O 0 1.8718013961915858e-05
still O 0 1.5290253941202536e-05
being O 0 1.6959800632321276e-05
evaluated O 0 3.461691812844947e-05
. O 0 6.145627594378311e-06

Currently O 0 8.278385939775035e-05
, O 0 3.07333152704814e-06
the O 0 3.9810703356124577e-07
most O 0 1.973268695110164e-07
useful O 0 7.068214245009585e-07
role O 0 3.9530624462713604e-07
for O 0 1.1913954267583904e-07
this O 0 1.234486717294203e-07
test O 0 5.666503511747578e-06
is O 0 1.2327055287641997e-07
in O 0 1.0898901336986455e-07
the O 0 1.0747442047431832e-07
detection O 0 6.065566594770644e-06
of O 0 7.929669436634867e-07
hemochromatosis B-Disease 1 0.9999997615814209
in O 0 3.732906634468236e-06
the O 0 2.0315017081884434e-06
family O 0 3.4194247291452484e-06
members O 0 1.1401500898955419e-07
of O 0 1.4577291551631788e-07
patients O 0 1.3581257917394396e-05
with O 0 9.183973475046514e-07
a O 0 2.5105422537308186e-05
proven O 0 0.0007000390323810279
case O 0 4.726762483642233e-07
of O 0 4.91498042265448e-07
the O 0 3.9198661397676915e-05
disease O 0 0.05377741530537605
. O 0 1.2348096788628027e-05

It O 0 2.3449745640391484e-05
is O 0 4.191234438621905e-06
crucial O 0 1.0613136510073673e-05
to O 0 6.209892308106646e-05
diagnose O 1 0.9999991655349731
hemochromatosis B-Disease 1 1.0
before O 1 0.9740139842033386
hepatic B-Disease 1 0.9999805688858032
cirrhosis I-Disease 1 0.9999849796295166
develops O 0 0.014617455191910267
because O 0 5.7361117796972394e-05
phlebotomy O 1 0.5390718579292297
therapy O 0 0.39787089824676514
can O 0 0.0008725179359316826
avert O 1 0.9989888072013855
serious O 1 0.999599039554596
chronic O 1 1.0
disease O 1 0.9997921586036682
and O 0 5.250721733318642e-05
can O 0 1.0985657354467548e-05
even O 0 5.842357950314181e-06
lead O 0 1.0977740203088615e-05
to O 0 1.8575096873973962e-06
normal O 0 7.037354862404754e-06
life O 0 4.945376986142946e-06
expectancy O 0 2.1715470211347565e-05
. O 0 2.030517634921125e-06
. O 0 1.1413001629989594e-05

Prevalence O 0 0.004468187224119902
of O 0 9.299764315073844e-06
the O 0 6.399172889359761e-06
I1307K O 0 0.00012639813940040767
APC B-Disease 0 4.614125282387249e-05
gene O 0 6.776698228350142e-06
variant O 0 6.077454145270167e-06
in O 0 5.721051365981111e-07
Israeli O 0 2.9515383630496217e-06
Jews O 0 6.059838142391527e-07
of O 0 8.825340813700677e-08
differing O 0 4.845582566304074e-07
ethnic O 0 5.855119979969459e-07
origin O 0 1.6268780882455758e-06
and O 0 1.1422354873502627e-05
risk O 0 0.00435564573854208
for O 0 0.019861910492181778
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004716909024864435

BACKGROUND O 0 0.001798130921088159
& O 0 0.0015654467279091477
AIMS O 0 0.0001113812904804945
Israeli O 0 1.3691823369299527e-05
Jews O 0 3.0686283025715966e-06
of O 0 1.8060164563848957e-07
European O 0 2.6992840957973385e-06
birth O 0 0.0009798490209504962
, O 0 9.736614856592496e-07
i O 0 5.562322257901542e-06
. O 0 1.1118293485878894e-07
e O 0 1.2073276138835354e-06
. O 0 1.3422918243577442e-07
, O 0 2.2226460316687735e-07
Ashkenazim O 0 4.499178430705797e-06
, O 0 2.549180351252289e-07
have O 0 2.504265523839422e-07
the O 0 4.946164608554682e-06
highest O 1 0.9957793951034546
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.4161456227302551
of O 0 8.30179374133877e-07
any O 0 9.203964737025672e-07
Israeli O 0 2.443604898871854e-05
ethnic O 0 3.938382633350557e-06
group O 0 4.381351755000651e-05
. O 0 1.3863022104487754e-05

The O 0 7.096165791153908e-05
I1307K O 0 0.00033133517717942595
APC B-Disease 0 0.00011245704808970913
gene O 0 1.615387009223923e-05
variant O 0 2.9317798180272803e-05
was O 0 3.362278584972955e-05
found O 0 3.520211748764268e-06
in O 0 3.980986093665706e-06
6 O 0 4.10217180615291e-05
. O 0 1.4906234355294146e-05

1 O 0 6.266895070439205e-05
% O 0 6.102095539972652e-06
of O 0 7.742744969618798e-07
American O 0 1.4141900237518712e-06
Jews O 0 2.2295976123132277e-06
, O 0 3.173849734139367e-07
28 O 0 1.145324858953245e-06
% O 0 2.2850205994018324e-07
of O 0 1.8472182716777752e-07
their O 0 0.004830090794712305
familial O 1 0.9999995231628418
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.0006572824204340577
, O 0 8.641612112114672e-06
but O 0 2.339849061172572e-06
not O 0 5.523763206838339e-07
in O 0 5.824061304338102e-07
non O 0 7.38923290555249e-06
- O 0 0.0002825486590154469
Jews O 0 1.9818089640466496e-05
. O 0 1.3196154213801492e-05

We O 0 0.00013140116061549634
assessed O 0 5.05000316479709e-05
the O 0 4.537550466920948e-06
I1307K O 0 0.0001398492750013247
prevalence O 0 8.752503345021978e-05
in O 0 1.1139981097585405e-06
Israeli O 0 6.583931281056721e-06
Jews O 0 9.66936909208016e-07
of O 0 1.0507812220339474e-07
differing O 0 5.60967407636781e-07
ethnic O 0 4.672580757869582e-07
origin O 0 1.3164528809284093e-06
and O 0 1.3088905689073727e-05
risk O 0 0.0103318365290761
for O 0 0.062264688313007355
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0005521709099411964

METHODS O 0 0.00025858465232886374
DNA O 0 8.512849308317527e-05
samples O 0 1.1526331036293413e-05
from O 0 2.0953043531335425e-06
500 O 0 2.071034032269381e-06
unrelated O 0 1.464311594645551e-06
Jews O 0 5.184223823562206e-07
of O 0 1.172857437836683e-07
European O 0 1.559100610393216e-06
or O 0 1.5675151416871813e-06
non O 0 8.483992814944941e-07
- O 0 1.196745961351553e-05
European O 0 8.826482940094138e-07
origin O 0 4.0859669070414384e-07
, O 0 2.0075167128652538e-07
with O 0 3.671519550607627e-07
or O 0 1.7310429711869801e-06
without O 0 5.428554459285806e-07
a O 0 1.0324320101062767e-06
personal O 0 1.1399578397686128e-05
and O 0 2.0003180907224305e-05
/ O 0 0.00011023241677321494
or O 0 2.361797442063107e-06
family O 0 3.1450797450816026e-06
history O 0 4.0951812252387754e-07
of O 0 4.5416274474519014e-07
neoplasia B-Disease 0 0.055295154452323914
, O 0 3.0548928862117464e-06
were O 0 7.909075065981597e-06
examined O 0 1.226037238666322e-05
for O 0 2.3100227508621174e-07
the O 0 9.304662853537593e-07
I1307K O 0 1.9078743207501248e-05
variant O 0 3.4505846997490153e-06
by O 0 3.114261062364676e-07
the O 0 3.6761161936738063e-07
allele O 0 5.015347142034443e-06
- O 0 8.23622121970402e-06
specific O 0 9.30953603983653e-07
oligonucleotide O 0 5.448796218843199e-05
( O 0 2.3355310077022295e-06
ASO O 0 0.03341377153992653
) O 0 2.4845546704455046e-06
method O 0 1.1875847121700644e-05
. O 0 9.788707757252268e-06

RESULTS O 0 0.0007007342064753175
In O 0 1.0884928087762091e-05
persons O 0 8.293442988360766e-06
at O 0 8.879460074240342e-05
average O 0 0.0018190633272752166
risk O 0 0.002328137867152691
for O 0 0.00838027149438858
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.504046516260132e-05
I1307K O 0 0.008264579810202122
was O 0 0.00017010905139613897
found O 0 2.2739302494301228e-06
in O 0 1.602056158844789e-06
5 O 0 1.3708677215618081e-05
. O 0 9.612469511921518e-06

0 O 0 0.00017432992171961814
% O 0 7.111431386874756e-06
of O 0 7.543905553575314e-07
120 O 0 1.3214200862421421e-06
European O 0 1.5073595704961917e-06
and O 0 3.187750508004683e-06
1 O 0 1.3006235349166673e-05
. O 0 1.2535063433460891e-05

6 O 0 0.00021051020303275436
% O 0 9.056104318005964e-06
of O 0 1.4423740140045993e-06
188 O 0 9.475383194512688e-06
non O 0 2.8421620754670585e-06
- O 0 7.513759555877186e-06
European O 0 1.364164972983417e-06
Jews O 0 2.3647205580346053e-06
( O 0 1.2437459417924401e-06
P O 0 0.0018412732752040029
= O 0 5.68999930692371e-05
0 O 0 4.550334324449068e-06
. O 0 6.357248025778972e-07
08 O 0 2.843928632501047e-05
) O 0 6.535062311741058e-06
. O 0 9.916947419696953e-06

It O 0 5.7894223573384807e-05
occurred O 0 5.563575177802704e-05
in O 0 8.706814696779475e-06
15 O 0 3.301328979432583e-05
. O 0 1.9982437152066268e-05

4 O 0 0.00014960026601329446
% O 0 1.2868202247773297e-05
of O 0 1.5834021951377508e-06
52 O 0 1.2972071090189274e-05
Ashkenazi O 0 4.734472531708889e-05
Israelis O 0 1.8124666894436814e-05
with O 0 1.0854441825358663e-05
familial O 1 0.9832744002342224
cancer B-Disease 1 0.9923325777053833
( O 0 7.281712441908894e-06
P O 0 0.29989948868751526
= O 0 0.0001852421701187268
0 O 0 3.6281953725847416e-06
. O 0 4.511375095717085e-07
02 O 0 4.1836585296550766e-05
) O 0 1.6011136949600768e-07
and O 0 1.920771950381095e-07
was O 0 8.13837323221378e-06
not O 0 3.3480870342827984e-07
detected O 0 2.5462118173891213e-06
in O 0 3.8052647255426564e-07
51 O 0 2.6533382424531737e-06
non O 0 5.823355877510039e-07
- O 0 3.1676795515522826e-06
European O 0 5.929762210143963e-07
Jews O 0 1.4263584944274044e-06
at O 0 3.181890497216955e-05
increased O 0 0.0001240050041815266
cancer B-Disease 1 0.6572595834732056
risk O 0 0.000151400119648315
. O 0 1.6546186088817194e-05

Colorectal B-Disease 1 0.9999394416809082
neoplasia I-Disease 1 0.9979690909385681
occurred O 0 0.007079548668116331
personally O 0 0.01593426987528801
or O 0 1.1810610885731876e-05
in O 0 8.699392424205143e-07
the O 0 5.738805839428096e-07
families O 0 5.591471108346013e-07
of O 0 5.65516060646587e-08
13 O 0 6.355320465445402e-07
of O 0 9.358506503076569e-08
20 O 0 1.3103017408866435e-06
Ashkenazi O 0 2.1674564777640626e-05
I1307K O 0 2.2267746317083947e-05
carriers O 0 2.9642153549502837e-06
, O 0 2.2931720877750195e-07
8 O 0 4.859475666307844e-07
of O 0 1.1417985490425053e-07
whom O 0 3.713406385941198e-06
also O 0 1.2832400670959032e-06
had O 0 6.859665973024676e-06
a O 0 8.967394364844949e-07
personal O 0 1.1217069186386652e-05
or O 0 3.3464284570072778e-06
family O 0 4.3044497033406515e-06
history O 0 1.4720851595484419e-06
of O 0 2.7620469609246356e-06
noncolonic O 0 0.3143112063407898
neoplasia B-Disease 0 0.16218537092208862
. O 0 6.169082189444453e-05

CONCLUSIONS O 0 0.00023554623476229608
The O 0 2.2482836357085034e-05
I1307K O 0 0.00041763330227695405
APC O 0 0.00013232685159891844
variant O 0 0.00012272127787582576
may O 0 1.0694723641790915e-05
represent O 0 5.40937094228866e-07
a O 0 2.5168931188090937e-06
susceptibility O 0 7.955488399602473e-05
gene O 0 1.279573370993603e-05
for O 0 8.625006557849701e-06
colorectal B-Disease 1 0.9999998807907104
, I-Disease 0 1.943698589457199e-05
or I-Disease 0 3.1523647976428038e-06
other I-Disease 0 3.1751181950312457e-07
, I-Disease 0 3.732557843250106e-06
cancers I-Disease 0 0.005392574705183506
in O 0 1.1033533837689902e-06
Ashkenazi O 0 6.034661419107579e-05
Jews O 0 5.4137863116920926e-06
, O 0 8.112128284665232e-07
and O 0 2.2073702439229237e-06
partially O 0 0.00010042877693194896
explains O 0 1.021913249132922e-06
the O 0 1.831541425190153e-07
higher O 0 1.0541941264818888e-05
incidence O 0 0.008224008604884148
of O 0 0.00710145290941
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.0270375898689963e-05
European O 0 8.705963409738615e-05
Israelis O 0 0.0006445766193792224
. O 0 3.168497278238647e-05

Systematic O 0 0.0002847565046977252
analysis O 0 4.009909025626257e-05
of O 0 9.238751772500109e-06
coproporphyrinogen O 0 0.0013729340862482786
oxidase O 0 0.0005716258892789483
gene O 0 0.000430337997386232
defects O 1 0.5881901979446411
in O 0 1.0849722457351163e-05
hereditary B-Disease 1 0.969438910484314
coproporphyria I-Disease 1 0.5780500769615173
and O 0 5.682569826603867e-05
mutation O 0 0.0001246559841092676
update O 0 0.0001303174503846094
. O 0 5.340361167327501e-05

Hereditary B-Disease 1 0.9999358654022217
coproporphyria I-Disease 1 0.9955724477767944
( O 0 0.00034748821053653955
HC B-Disease 1 0.9989668130874634
) O 0 4.3800901039503515e-05
is O 0 6.045008376531769e-06
an O 0 0.0021762580145150423
acute O 1 0.9999959468841553
hepatic B-Disease 1 0.9999983310699463
porphyria I-Disease 1 0.9999988079071045
with O 0 0.14158041775226593
autosomal O 1 0.9998619556427002
dominant O 0 0.1883774846792221
inheritance O 0 0.13016192615032196
caused O 0 0.0025641992688179016
by O 0 3.584968453651527e-06
deficient B-Disease 0 0.003676164196804166
activity I-Disease 0 1.4848284308754955e-06
of I-Disease 0 5.762535693065729e-07
coproporphyrinogen I-Disease 0 0.003604755736887455
III I-Disease 0 0.0028334937524050474
oxidase I-Disease 0 3.958988963859156e-05
( O 0 2.4022504021559143e-06
CPO O 0 6.550753460032865e-05
) O 0 3.463607299636351e-06
. O 0 8.81679261510726e-06

Clinical O 0 0.05720207840204239
manifestations O 0 0.00032120433752425015
of O 0 8.733475624467246e-06
the O 0 0.0016128355637192726
disease O 1 0.9799178242683411
are O 0 4.150610493525164e-06
characterized O 0 5.935020453762263e-05
by O 0 1.231009628099855e-05
acute O 1 0.9866964221000671
attacks O 0 0.005767389200627804
of O 0 0.0002994866808876395
neurological B-Disease 1 0.9999998807907104
dysfunction I-Disease 1 0.9984002709388733
often O 0 0.00010644755093380809
precipitated O 0 0.00027588894590735435
by O 0 1.027875555337232e-06
drugs O 0 4.471673037187429e-06
, O 0 8.918016192183131e-07
fasting O 0 1.0741815458459314e-05
, O 0 1.1349800388416043e-06
cyclical O 0 0.00021961303718853742
hormonal O 0 0.000728481390979141
changes O 0 2.483048319845693e-06
, O 0 4.228176749165868e-06
or O 0 0.0004243276489432901
infectious B-Disease 1 0.8507020473480225
diseases I-Disease 0 0.13081088662147522
. O 0 3.197406476829201e-05

Skin O 1 0.9999775886535645
photosensitivity O 1 0.9995049238204956
may O 0 0.08202086389064789
also O 0 1.6370273442589678e-05
be O 0 3.3768876619433286e-06
present O 0 8.504336619807873e-06
. O 0 1.3119523828208912e-05

The O 0 3.239874422433786e-05
seven O 0 1.6280377167277038e-05
exons O 0 2.65979742835043e-05
, O 0 1.607056788088812e-06
the O 0 6.254285267459636e-07
exon O 0 1.3824182133248542e-05
/ O 0 7.813211595930625e-06
intron O 0 4.5570635847980157e-05
boundaries O 0 4.675184754887596e-06
and O 0 7.438204647769453e-07
part O 0 3.0124868999337195e-07
of O 0 1.848464279419204e-07
3 O 0 1.2042504522469244e-06
noncoding O 0 3.093049826929928e-06
sequence O 0 5.300851171341492e-07
of O 0 1.1435770375101129e-07
the O 0 7.292882742149231e-07
CPO O 0 2.5559689674992114e-05
gene O 0 2.25997291636304e-06
were O 0 1.4925572031643242e-06
systematically O 0 5.832910574099515e-06
analyzed O 0 1.1533745691849617e-06
by O 0 1.3029455203650286e-07
an O 0 2.3992208753043087e-07
exon O 0 5.5800310292397626e-06
- O 0 9.545446118863765e-06
by O 0 7.855318813199119e-07
- O 0 3.2918414945015684e-05
exon O 0 3.391131031094119e-05
denaturing O 0 0.00027612101985141635
gradient O 0 0.0001981175155378878
gel O 0 0.008727961219847202
electrophoresis O 0 0.00042248854879289865
( O 0 2.0507882254605647e-06
DGGE O 0 0.0007131160818971694
) O 0 5.938409799455258e-07
strategy O 0 1.022102310344053e-06
followed O 0 3.478373571397242e-07
by O 0 9.982335313907242e-08
direct O 0 2.709533930556063e-07
sequencing O 0 2.037069407379022e-06
in O 0 3.970131672303978e-07
seven O 0 2.2512201667268528e-06
unrelated O 0 9.291971764469054e-06
heterozygous O 0 0.00027243184740655124
HC B-Disease 1 0.9217810034751892
patients O 0 0.002344080014154315
from O 0 3.7138881907594623e-06
France O 0 0.00014814664609730244
, O 0 2.709921091081924e-06
Holland O 0 0.0003086342185270041
, O 0 8.238304758378945e-07
and O 0 9.611145515009412e-07
Czech O 0 2.2903379431227222e-05
Republic O 0 1.1070887921960093e-05
. O 0 1.34137171698967e-05

Seven O 0 0.000106722982309293
novel O 0 3.2161155104404315e-05
mutations O 0 2.786175173241645e-05
and O 0 1.1659780057016178e-06
two O 0 5.871626740372449e-07
new O 0 2.6842412808036897e-06
polymorphisms O 0 0.0001758692815201357
were O 0 2.1303605535649695e-05
detected O 0 0.00011158709821756929
. O 0 1.8931719750980847e-05

Among O 0 6.0573780501727015e-05
these O 0 7.317103154491633e-06
mutations O 0 2.072329880320467e-05
two O 0 1.5654342178095249e-06
are O 0 6.227074322850967e-07
missense O 0 1.8174585420638323e-05
( O 0 9.043226896210399e-07
G197W O 0 4.453541259863414e-05
, O 0 8.455768920612172e-07
W427R O 0 1.6271997083094902e-05
) O 0 1.6849602957336174e-07
, O 0 8.897137604435557e-08
two O 0 9.789091137690775e-08
are O 0 1.47686748164233e-07
nonsense O 0 3.1543613658868708e-06
( O 0 1.9085015878772538e-07
Q306X O 0 6.951614068384515e-06
, O 0 4.488904323807219e-07
Q385X O 0 1.861201599240303e-05
) O 0 1.9797546713107295e-07
, O 0 7.439879823323281e-08
two O 0 1.0541617712078732e-07
are O 0 1.2373072877380764e-07
small O 0 5.070104407423059e-07
deletions O 0 8.545530363335274e-06
( O 0 6.639377261308255e-07
662de14bp O 0 6.037171260686591e-05
; O 0 7.985356091921858e-07
1168del3bp O 0 2.8900411052745767e-05
removing O 0 2.6468935629964108e-06
a O 0 5.600362555924221e-07
glycine O 0 9.65683921094751e-06
at O 0 1.1952826753258705e-05
position O 0 3.1854560802457854e-06
390 O 0 1.296259370064945e-06
) O 0 9.976491810448351e-08
, O 0 7.246246269687617e-08
and O 0 1.4943574910830648e-07
one O 0 1.2851428721205593e-07
is O 0 8.936527251535153e-08
a O 0 4.1969269659603015e-07
splicing O 0 2.1593072233372368e-05
mutation O 0 6.875397502881242e-06
( O 0 8.00920474830491e-07
IVS1 O 0 0.00010135932825505733
- O 0 2.819866313075181e-05
15c O 0 3.48596804542467e-05
- O 0 5.9169655287405476e-05
- O 0 0.0004928485723212361
> O 0 5.4140622523846105e-05
g O 0 9.252959716832265e-05
) O 0 2.620543568809808e-07
which O 0 1.2455473097361391e-07
creates O 0 3.9331362700067984e-07
a O 0 2.5715959850458603e-07
new O 0 1.0697320931285503e-06
acceptor O 0 2.356773620704189e-05
splice O 0 0.0007266929023899138
site O 0 0.00011562039435375482
. O 0 3.2387004466727376e-05

The O 0 5.5254738981602713e-05
pathological O 0 0.00013420652248896658
significance O 0 5.746424903918523e-06
of O 0 8.772975093052082e-07
the O 0 1.4965081618356635e-06
point O 0 4.128002728975844e-06
mutations O 0 1.3437121197057422e-05
G197W O 0 2.1060157450847328e-05
, O 0 7.850960628275061e-07
W427R O 0 9.932432476489339e-06
, O 0 3.2156199836208543e-07
and O 0 2.899070636885881e-07
the O 0 3.179223995175562e-07
in O 0 8.208651820496016e-07
- O 0 0.0003188845294062048
frame O 0 0.007369668688625097
deletion O 0 0.0006405421299859881
390delGly O 0 0.0005020700627937913
were O 0 5.8454397731111385e-06
assessed O 0 1.0547636293267715e-06
by O 0 9.259114364112975e-08
their O 0 2.3073717159149965e-07
respective O 0 4.5434512685460504e-07
expression O 0 2.5687523930173484e-07
in O 0 1.432376706134164e-07
a O 0 6.64779179260222e-07
prokaryotic O 0 2.3297070583794266e-06
system O 0 1.2933403468196047e-06
using O 0 1.1831676829388016e-06
site O 0 1.4247286344470922e-05
- O 0 4.522614835877903e-05
directed O 0 1.5401330529130064e-05
mutagenesis O 0 0.00011256174184381962
. O 0 2.3822243747417815e-05

These O 0 3.10401082970202e-05
mutations O 0 8.44576206873171e-05
resulted O 0 1.0275451131747104e-05
in O 0 1.5655506331313518e-06
the O 0 1.6559083633183036e-06
absence O 0 1.076196349458769e-05
or O 0 1.4012911151439766e-06
a O 0 1.3645318404087448e-06
dramatic O 0 1.0680402738216799e-05
decrease O 0 6.498010861832881e-06
of O 0 1.032959971780656e-06
CPO O 0 0.00014479954552371055
activity O 0 1.4686772374261636e-05
. O 0 1.3404972378339153e-05

The O 0 2.268256139359437e-05
two O 0 7.869560249673668e-06
polymorphisms O 0 4.2043484427267686e-05
were O 0 6.282420599745819e-06
localized O 0 7.778939107083715e-06
in O 0 9.610889719624538e-07
noncoding O 0 7.163544523791643e-06
part O 0 5.412498467194382e-07
of O 0 9.772078612968471e-08
the O 0 2.813889921071677e-07
gene O 0 1.0842829851753777e-06
1 O 0 3.5963330446975306e-07
) O 0 1.7103394611694966e-07
a O 0 1.0655768392098253e-06
C O 0 0.00026259536389261484
/ O 0 1.301174324908061e-05
G O 0 0.0002276494342368096
polymorphism O 0 6.8479671426757704e-06
in O 0 5.461007503981818e-07
the O 0 9.571265309205046e-07
promotor O 0 4.911405630991794e-05
region O 0 1.1994777651125332e-06
, O 0 4.5601552756124875e-07
142 O 0 2.3071042960509658e-06
bp O 0 9.441188012715429e-06
upstream O 0 1.0675256589820492e-06
from O 0 1.6468609942421608e-07
the O 0 2.1686422257971572e-07
transcriptional O 0 2.4428045435342938e-06
initiation O 0 1.1099939456471475e-06
site O 0 3.2090074455481954e-06
( O 0 3.0864680411468726e-07
- O 0 1.108521428250242e-05
142C O 0 5.701057307305746e-05
/ O 0 2.080930607917253e-05
G O 0 0.0006414008093997836
) O 0 2.808010890475998e-07
, O 0 1.529898696617238e-07
and O 0 3.3573022051314183e-07
2 O 0 6.822061777711497e-07
) O 0 9.608473305888765e-08
a O 0 3.354818147727201e-07
6 O 0 3.948333414882654e-06
bp O 0 2.3488446458941326e-05
deletion O 0 4.885836460744031e-06
polymorphism O 0 7.255682248796802e-06
in O 0 5.012718133912131e-07
the O 0 3.0877635026627104e-07
3 O 0 1.3161277365725255e-06
noncoding O 0 2.710613671297324e-06
part O 0 2.3034056084725307e-07
of O 0 8.44432790358951e-08
the O 0 7.102242989276419e-07
CPO O 0 1.2685433830483817e-05
gene O 0 1.474721216254693e-06
, O 0 3.627215789947513e-07
574 O 0 4.669516783906147e-06
bp O 0 6.869446679047542e-06
downstream O 0 1.2054292710672598e-06
of O 0 1.1914521991229776e-07
the O 0 2.8898398340970743e-07
last O 0 6.178327112138504e-07
base O 0 8.466954000141413e-07
of O 0 7.419261294216994e-08
the O 0 3.7158895338507136e-07
normal O 0 2.6866023290494923e-06
termination O 0 5.9799863265652675e-06
codon O 0 6.211360414454248e-06
( O 0 8.722894335733145e-07
+ O 0 8.060082109295763e-06
574 O 0 2.5816070774453692e-05
delATTCTT O 0 5.284518556436524e-05
) O 0 5.222231720836135e-06
. O 0 6.539314654219197e-06

Five O 0 0.00021952218958176672
intragenic O 0 0.001663492526859045
dimorphisms O 0 0.0008132224902510643
are O 0 1.9439451079961145e-06
now O 0 1.6982904753604089e-06
well O 0 9.298294116888428e-07
characterized O 0 3.165118869219441e-06
and O 0 5.837279104525805e-07
the O 0 2.903796882947063e-07
high O 0 1.0614007805997971e-05
degree O 0 1.9739056824619183e-06
of O 0 3.586841614833247e-07
allelic O 0 2.0009363652206957e-05
heterogeneity O 0 2.7102985768578947e-05
in O 0 1.1253091543039773e-05
HC B-Disease 1 0.9858766198158264
is O 0 3.253976046835305e-06
demonstrated O 0 5.2617447181546595e-06
with O 0 4.587845410242153e-07
seven O 0 8.655928809275792e-07
new O 0 2.45473984250566e-07
different O 0 1.341191335768599e-07
mutations O 0 1.4344452665682184e-06
making O 0 1.7160742515898164e-07
a O 0 2.8643992777688254e-07
total O 0 2.5561598704371136e-07
of O 0 9.491604657796415e-08
nineteen O 0 1.567360777698923e-05
CPO O 0 0.0005012777401134372
gene B-Disease 0 6.97597861289978e-05
defects I-Disease 0 0.3531220555305481
reported O 0 2.9246257327031344e-05
so O 0 1.5830654547244194e-06
far O 0 2.3320656055147992e-06
. O 0 1.5698084325777018e-06
. O 0 7.187358733062865e-06

Coincidence O 0 0.00012597879685927182
of O 0 2.999385515067843e-06
two O 0 2.08528945222497e-06
novel O 0 4.1006387618836015e-06
arylsulfatase O 0 3.884266334353015e-05
A O 0 3.1910051347949775e-06
alleles O 0 5.723879894503625e-06
and O 0 1.4416203839573427e-06
mutation O 0 1.367399818263948e-05
459 O 0 2.4273023882415146e-05
+ O 0 1.590822466823738e-05
1G O 0 0.00018935848493129015
> O 0 1.4410250514629297e-05
A O 0 3.1172464787232457e-06
within O 0 6.937209491297835e-07
a O 0 5.797567155241268e-06
family O 0 5.957560279057361e-05
with O 0 4.4573145714821294e-05
metachromatic B-Disease 1 0.9999990463256836
leukodystrophy I-Disease 1 0.9999945163726807
: O 0 2.9060067845421145e-06
molecular O 0 1.3033154573349748e-05
basis O 0 1.0149610716325697e-06
of O 0 2.1885639398533385e-06
phenotypic O 0 0.00013750966172665358
heterogeneity O 0 0.0005254310672171414
. O 0 5.8332752814749256e-05

In O 0 5.040265023126267e-05
a O 0 1.3885199223295785e-05
family O 0 1.4626571100961883e-05
with O 0 8.328104854626872e-07
three O 0 1.8862538126995787e-06
siblings O 0 0.0009074026602320373
, O 0 4.7752200771356e-07
one O 0 3.3939335253307945e-07
developed O 0 2.870940534194233e-06
classical O 0 7.149935299821664e-06
late O 0 0.00017511362966615707
infantile O 1 0.994619607925415
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.9999995231628418
( O 0 0.00015277371858246624
MLD B-Disease 1 0.9999943971633911
) O 0 9.045487786352169e-06
, O 0 3.1061683785083005e-06
fatal O 0 0.003345472039654851
at O 0 0.00034676925861276686
age O 0 4.249198536854237e-05
5 O 0 2.5344183995912317e-06
years O 0 1.715480038910755e-06
, O 0 4.2659070231820806e-07
with O 0 2.9973923574289074e-06
deficient O 0 0.03632967919111252
arylsulfatase O 0 6.063526598154567e-05
A O 0 5.359467650123406e-06
( O 0 6.69970120270591e-07
ARSA O 0 0.00012188577238703147
) O 0 1.9216879820760369e-07
activity O 0 3.0738340228708694e-07
and O 0 2.790663700125151e-07
increased O 0 3.2549785373703344e-06
galactosylsulfatide O 0 0.0011741028865799308
( O 0 6.818602287239628e-06
GS O 1 0.9999688863754272
) O 0 1.0470042980159633e-05
excretion O 0 8.695615542819723e-05
. O 0 2.4456981918774545e-05

The O 0 1.4134499906504061e-05
two O 0 2.514959305699449e-06
other O 0 8.319722155647469e-07
siblings O 0 0.0002117685944540426
, O 0 1.6603756876065745e-06
apparently O 0 2.6290386813343503e-05
healthy O 0 3.748006520254421e-06
at O 0 4.407459073263453e-06
12 O 0 1.4235075695978594e-06
( O 0 2.410998547475174e-07
1 O 0 5.157870077709958e-07
/ O 0 2.080561898765154e-06
2 O 0 1.1011942433469812e-06
) O 0 1.190371037296245e-07
and O 0 1.8283128611074062e-07
15 O 0 9.180751021631295e-07
years O 0 4.5336949483498756e-07
, O 0 1.8249002664560976e-07
respectively O 0 1.4263449656937155e-06
, O 0 1.294264251328059e-07
and O 0 2.2482798556211492e-07
their O 0 1.529154815216316e-06
father O 0 5.1824303227476776e-05
, O 0 6.952184321562527e-07
apparently O 0 8.86466477822978e-06
healthy O 0 5.910831077926559e-07
as O 0 1.0187318366661202e-07
well O 0 1.896320469541024e-07
, O 0 2.924172122220625e-07
presented O 0 1.7209135876328219e-06
ARSA O 0 0.004307384602725506
and O 0 9.956537724065129e-06
GS O 1 0.9999535083770752
values O 0 2.0251550267857965e-06
within O 0 4.3188765630475245e-07
the O 0 3.589305492823769e-07
range O 0 2.8192318950459594e-06
of O 0 6.765474608982913e-06
MLD B-Disease 1 0.9999995231628418
patients O 0 0.009679253213107586
. O 0 2.6077615984831937e-05

Mutation O 0 0.0002818575012497604
screening O 0 8.627985516795889e-05
and O 0 5.379418325901497e-06
sequence O 0 3.0035246254556114e-06
analysis O 0 2.1366754481277894e-06
disclosed O 0 8.622967470728327e-06
the O 0 2.980566478072433e-07
involvement O 0 9.274948524762294e-07
of O 0 1.526757813508084e-07
three O 0 8.145182732732792e-07
different O 0 1.6262202962025185e-06
ARSA O 0 0.20456071197986603
mutations O 0 2.2294605514616705e-05
being O 0 1.5539703781541903e-06
the O 0 4.979019081474689e-07
molecular O 0 4.805376192962285e-06
basis O 0 1.3906434332966455e-06
of O 0 1.6319656879204558e-06
intrafamilial O 0 0.0003346171579323709
phenotypic O 0 0.00017473433399572968
heterogeneity O 0 0.0006203214870765805
. O 0 5.180780135560781e-05

The O 0 4.98029803566169e-05
late O 0 0.000147133061545901
infantile O 1 0.9246397018432617
patient O 1 0.7238986492156982
inherited O 0 0.4660901725292206
from O 0 4.949500180373434e-06
his O 0 0.0002212220279034227
mother O 0 0.0007218567770905793
the O 0 4.7187950258376077e-07
frequent O 0 3.3239664389839163e-06
0 O 0 1.151661854237318e-05
- O 0 5.932926433160901e-05
type O 0 1.684670314716641e-05
mutation O 0 1.6573651009821333e-05
459 O 0 1.8018472474068403e-05
+ O 0 9.264055734092835e-06
1G O 0 7.576641655759886e-05
> O 0 1.051984781952342e-05
A O 0 3.160139385727234e-06
, O 0 5.345249860511103e-07
and O 0 4.2748175133056066e-07
from O 0 3.9558912590109685e-07
his O 0 7.400050890282728e-06
father O 0 2.0260556993889622e-05
a O 0 5.287078579385707e-07
novel O 0 4.5728975806014205e-07
, O 0 2.1134293604063714e-07
single O 0 2.2304566300590523e-06
basepair O 0 2.344124914088752e-05
microdeletion O 0 1.0792179637064692e-05
of O 0 2.9039378546258376e-07
guanine O 0 3.2302550607710145e-06
at O 0 2.559814674896188e-06
nucleotide O 0 3.271953119110549e-06
7 O 0 1.3006095969103626e-06
in O 0 6.082593131395697e-07
exon O 0 8.057162631303072e-06
1 O 0 3.3835929116321495e-06
( O 0 1.5222942693071673e-06
7delG O 0 6.099372330936603e-05
) O 0 4.107950644538505e-06
. O 0 9.20415641303407e-06

The O 0 4.844523573410697e-05
two O 0 1.4415790246857796e-05
clinically O 0 0.11821798235177994
unaffected O 0 0.000207437202334404
siblings O 0 0.00012801050615962595
carried O 0 6.49352659820579e-06
the O 0 1.4948022908356506e-06
maternal O 0 0.0002007429429795593
mutation O 0 2.2538135453942232e-05
459 O 0 2.4131890313583426e-05
+ O 0 1.4932812518964056e-05
1G O 0 0.00016267791215796024
> O 0 1.479553884564666e-05
A O 0 6.056572601664811e-06
and O 0 1.5644999393771286e-06
, O 0 2.334574844553572e-07
on O 0 3.8381540434784256e-07
their O 0 1.3908130540585262e-06
paternal O 0 1.9579158106353134e-05
allele O 0 5.063395747129107e-06
, O 0 2.807427392781392e-07
a O 0 7.229990046653256e-07
novel O 0 1.3008514088141965e-06
cytosine O 0 3.4182444323960226e-06
to O 0 6.605935709558253e-07
thymidine O 0 9.80128152150428e-06
transition O 0 4.068813268531812e-06
at O 0 5.434798822534503e-06
nucleotide O 0 1.1636635463219136e-05
2435 O 0 3.123790884274058e-05
in O 0 6.116878807915782e-07
exon O 0 6.539326932397671e-06
8 O 0 3.1197057523968397e-06
, O 0 2.3432025386682653e-07
resulting O 0 3.796862131366652e-07
in O 0 1.3162139111955184e-07
substitution O 0 2.785106971714413e-07
of O 0 2.5923833391061635e-07
alanine O 0 3.097469380008988e-05
464 O 0 1.1292468116153032e-05
by O 0 1.542269956189557e-06
valine O 0 0.0003212937735952437
( O 0 2.4632881832076237e-06
A464V O 0 5.416623753262684e-05
) O 0 3.3568455819477094e-06
. O 0 1.2706948837148957e-05

The O 0 9.086215868592262e-05
fathers O 0 0.0005141780129633844
genotype O 0 0.0004695286916103214
thus O 0 3.002416451636236e-05
was O 0 4.2028648749692366e-05
7delG O 0 0.00035943000693805516
/ O 0 0.0001908879348775372
A464V O 0 0.0006738876109011471
. O 0 3.2198171538766474e-05

Mutation O 0 0.001836123876273632
A464V O 0 0.0020800598431378603
was O 0 0.00019319143029861152
not O 0 2.895975057981559e-06
found O 0 3.455010073594167e-06
in O 0 1.3906965250498615e-06
18 O 0 7.801612082403153e-05
unrelated O 0 0.0007787669310346246
MLD B-Disease 1 0.9999986886978149
patients O 0 0.0034282547421753407
and O 0 3.050997065656702e-06
50 O 0 9.358143870485947e-06
controls O 0 0.00015041673032101244
. O 0 2.811311605910305e-05

A464V O 0 0.003294585505500436
, O 0 2.8304115403443575e-05
although O 0 5.397310360422125e-06
clearly O 0 7.441095931426389e-06
modifying O 0 3.11992916977033e-05
ARSA O 0 0.001367914373986423
and O 0 3.407914482522756e-05
GS O 1 0.9999991655349731
levels O 0 4.138153963140212e-05
, O 0 2.302835355294519e-06
apparently O 0 1.3188845514378045e-05
bears O 0 3.5635277981782565e-06
little O 0 4.89131480208016e-07
significance O 0 5.249757464298455e-07
for O 0 2.7115501666230557e-07
clinical O 0 2.597718957986217e-05
manifestation O 0 8.861562491802033e-06
of O 0 2.19161961467762e-06
MLD B-Disease 1 0.9999982118606567
, O 0 5.378971764002927e-06
mimicking O 0 7.118145731510594e-05
the O 0 2.69048700829444e-06
frequent O 0 4.871002602158114e-05
ARSA O 0 0.18143285810947418
pseudodeficiency O 0 0.000773823237977922
allele O 0 0.00015880783030297607
. O 0 2.8340522476355545e-05

Our O 0 9.755145583767444e-05
results O 0 2.3066373614710756e-05
demonstrate O 0 7.488078608730575e-06
that O 0 4.55687285239037e-07
in O 0 5.013587838220701e-07
certain O 0 1.108808987737575e-06
genetic O 0 0.00015059181896504015
conditions O 0 0.009973461739718914
MLD B-Disease 1 0.9999920129776001
- O 0 0.019815335050225258
like O 0 3.286201899754815e-05
ARSA O 0 0.4016226828098297
and O 0 9.149669494945556e-05
GS O 1 0.9999977350234985
values O 0 6.139699053164804e-06
need O 0 2.563143880252028e-06
not O 0 7.290643679880304e-07
be O 0 3.791608094161347e-07
paralleled O 0 2.645949734869646e-06
by O 0 2.2651493054581806e-06
clinical O 1 0.5299956798553467
disease O 1 0.8754420280456543
, O 0 9.418124022886332e-07
a O 0 1.8940771724373917e-06
finding O 0 5.448395313578658e-06
with O 0 5.287529802444624e-06
serious O 0 7.730723154963925e-05
diagnostic O 0 0.011570853181183338
and O 0 0.00017710818792693317
prognostic O 0 0.1794491708278656
implications O 0 0.00012270022125449032
. O 0 2.7145430067321286e-05

Moreover O 0 0.0002566990733612329
, O 0 1.7951339032151736e-05
further O 0 1.3316468539414927e-05
ARSA O 0 0.0016814410919323564
alleles O 0 2.3153228539740667e-05
functionally O 0 2.8323851438472047e-05
similar O 0 1.0326584742870182e-06
to O 0 1.434538148714637e-06
A464V O 0 0.00011958466348005459
might O 0 3.2440484574181028e-06
exist O 0 4.6808185061308905e-07
which O 0 2.645934671363648e-07
, O 0 2.3069361532179755e-07
together O 0 8.192392897399259e-07
with O 0 9.383079486724455e-07
0 O 0 3.272216781624593e-05
- O 0 0.0005748163093812764
type O 0 8.348410483449697e-05
mutations O 0 7.479884516214952e-05
, O 0 2.8991198632866144e-06
may O 0 2.9705897759413347e-05
cause O 0 9.942848009814043e-06
pathological O 0 0.00012720814265776426
ARSA O 0 0.34765034914016724
and O 0 0.00021690544963348657
GS O 1 1.0
levels O 0 5.8893030654871836e-05
, O 0 1.0624190736052697e-06
but O 0 4.792341883330664e-07
not O 0 6.128802283456025e-07
clinical O 0 1.1785339665948413e-05
outbreak O 0 1.2159511243226007e-05
of O 0 3.709700422405149e-07
the O 0 3.936510256608017e-05
disease O 0 0.17969746887683868
. O 0 2.4593257421656745e-06
. O 0 1.4677657418360468e-05

Human O 0 0.0034128064289689064
MLH1 O 1 0.999909520149231
deficiency O 1 0.999539852142334
predisposes O 0 0.004137664567679167
to O 0 7.724563329247758e-05
hematological B-Disease 1 0.9988006353378296
malignancy I-Disease 1 0.999514102935791
and O 0 0.0012322934344410896
neurofibromatosis B-Disease 1 0.9999895095825195
type I-Disease 0 0.0044107940047979355
1 I-Disease 0 0.00012398313265293837
. O 0 3.2804342481540516e-05

Heterozygous O 0 0.0035538224037736654
germ O 0 0.008077442646026611
- O 0 0.0007683021249249578
line O 0 0.00015376636292785406
mutations O 0 1.7159060007543303e-05
in O 0 8.209427164729277e-07
the O 0 1.4377458228409523e-06
DNA O 0 0.00011708547390298918
mismatch O 0 0.10144586861133575
repair O 1 0.6388768553733826
genes O 0 8.003815310075879e-05
lead O 0 7.606119470437989e-05
to O 0 0.00010379301966167986
hereditary B-Disease 1 0.9999986886978149
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.000809197430498898

The O 0 0.0005007750005461276
disease O 1 0.8568545579910278
susceptibility O 0 0.0003075145941693336
of O 0 2.046052941295784e-06
individuals O 0 8.598660315328743e-06
who O 0 3.509534144541249e-05
constitutionally O 0 3.700050001498312e-05
lack O 0 2.138708168786252e-06
both O 0 6.891020234434109e-07
wild O 0 4.45576552010607e-06
- O 0 0.00019294493540655822
type O 0 3.840245699393563e-05
alleles O 0 1.4263164302974474e-05
is O 0 2.691166855584015e-06
unknown O 0 1.7581052816240117e-05
. O 0 1.0048494914371986e-05

We O 0 7.644403376616538e-05
have O 0 5.6670546655368526e-06
identified O 0 6.157888947200263e-06
three O 0 1.4440063296206063e-06
offspring O 0 1.712714583845809e-05
in O 0 1.1614920367719606e-06
a O 0 0.00015225513197947294
hereditary B-Disease 1 0.9999992847442627
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.4250299334526062
who O 0 0.0006455322727560997
developed O 0 0.0018614721484482288
hematological B-Disease 1 0.9930902123451233
malignancy I-Disease 1 0.9969698786735535
at O 0 0.0002149538922822103
a O 0 2.164890702260891e-06
very O 0 9.260842261937796e-07
early O 0 2.4440719244012143e-06
age O 0 7.3765449997154064e-06
, O 0 3.1388572097057477e-07
and O 0 5.838069228047971e-07
at O 0 1.0185168321186211e-05
least O 0 1.3670205589733087e-07
two O 0 5.977073413987455e-08
of O 0 7.310968186402533e-08
them O 0 2.3732350484806375e-07
displayed O 0 4.661418643081561e-06
signs O 0 5.863994374522008e-06
of O 0 1.40308827667468e-06
neurofibromatosis B-Disease 1 0.9947366118431091
type I-Disease 0 0.00013649137690663338
1 I-Disease 0 2.5820454538916238e-05
( O 0 7.70176211517537e-06
NF1 B-Disease 0 0.0007208476308733225
) O 0 7.995025953277946e-06
. O 0 1.1880038073286414e-05

DNA O 0 0.0002922753628809005
sequence O 0 2.0092311387998052e-05
analysis O 0 4.5840811253583524e-06
and O 0 1.8838987898561754e-06
allele O 0 1.735642035782803e-05
- O 0 2.661898724909406e-05
specific O 0 1.217674480358255e-06
amplification O 0 1.347297256870661e-05
in O 0 8.421566803917813e-07
two O 0 2.4259936708403984e-06
siblings O 0 0.0008066822774708271
revealed O 0 3.113646016572602e-05
a O 0 7.915164133009966e-06
homozygous O 0 0.00032567043672315776
MLH1 O 0 0.004515435080975294
mutation O 0 1.9492728824843653e-05
( O 0 9.766484936335473e-07
C676T O 0 2.6763102141558193e-05
- O 0 0.00016503034566994756
- O 0 0.0024547053035348654
> O 0 0.00015399965923279524
Arg226Stop O 0 0.00047359103336930275
) O 0 6.414858034986537e-06
. O 0 1.0222690434602555e-05

Thus O 0 0.00017969647888094187
, O 0 7.08517336533987e-06
a O 0 1.2810323823941872e-05
homozygous O 0 0.00027870427584275603
germ O 0 0.0006191777065396309
- O 0 0.0003297145594842732
line O 0 0.0003061435418203473
MLH1 O 0 0.00724345026537776
mutation O 0 3.2249732612399384e-05
and O 0 6.162318641145248e-06
consequent O 0 0.18016445636749268
mismatch O 1 0.9999690055847168
repair O 1 1.0
deficiency O 1 0.9999994039535522
results O 0 0.0007172952173277736
in O 0 4.8759925448393915e-06
a O 0 4.778998845722526e-05
mutator O 1 0.7100512385368347
phenotype O 0 0.031987786293029785
characterized O 0 4.188161256024614e-05
by O 0 1.5514071492361836e-05
leukemia B-Disease 1 0.9998328685760498
and O 0 0.001121393870562315
/ O 1 0.93791264295578
or O 1 0.9787923693656921
lymphoma B-Disease 1 1.0
associated O 0 0.004316315054893494
with O 0 0.0003178782935719937
neurofibromatosis B-Disease 1 0.9999959468841553
type I-Disease 0 0.0021862690337002277
1 I-Disease 0 2.428925654385239e-05
. O 0 3.258367087255465e-06
. O 0 9.523332664684858e-06

Missense O 0 0.004312750417739153
mutations O 0 0.0007591582252644002
in O 0 6.607393515878357e-06
the O 0 1.0231361784462933e-06
most O 0 2.9108448984516144e-07
ancient O 0 3.913608566108451e-07
residues O 0 1.64602374752576e-06
of O 0 1.9156826169819396e-07
the O 0 1.3653467476615333e-06
PAX6 O 0 0.0004064770182594657
paired O 0 2.9679877115995623e-05
domain O 0 5.863474143552594e-06
underlie O 0 1.038476239045849e-05
a O 0 1.123228116739483e-06
spectrum O 0 7.92225546319969e-06
of O 0 4.136862116865814e-06
human O 0 0.0020958860404789448
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999784231185913
malformations I-Disease 1 0.9999289512634277
. O 0 0.0002481773553881794

Mutations O 0 0.0006149163236841559
of O 0 1.0466848834767006e-05
the O 0 6.712013146170648e-06
human O 0 1.4734512660652399e-05
PAX6 O 0 0.0029941853135824203
gene O 0 0.0004745698824990541
underlie O 0 0.3013661503791809
aniridia B-Disease 1 0.9999998807907104
( O 0 0.005289258435368538
congenital B-Disease 1 0.9999980926513672
absence I-Disease 0 0.0001242832950083539
of I-Disease 0 9.292106710745429e-07
the I-Disease 0 6.814299013058189e-06
iris I-Disease 0 0.011992967687547207
) O 0 5.962533577985596e-07
, O 0 2.1778734549116052e-07
a O 0 1.2879123687525862e-06
rare O 0 6.1321161410887726e-06
dominant O 0 0.007474434096366167
malformation B-Disease 1 0.9901713728904724
of I-Disease 0 1.1831428992081783e-06
the I-Disease 0 2.067959212581627e-05
eye I-Disease 0 0.37847310304641724
. O 0 4.2799969378393143e-05

The O 0 2.391953967162408e-05
spectrum O 0 3.2640389690641314e-05
of O 0 3.2757341159594944e-06
PAX6 O 0 0.0016729038907215
mutations O 0 0.00014159621787257493
in O 0 4.8855454224394634e-05
aniridia B-Disease 1 1.0
patients O 0 0.15085098147392273
is O 0 9.486209364695242e-07
highly O 0 1.2347192068773438e-06
biased O 0 5.5936443459359e-06
, O 0 2.4759043526501046e-07
with O 0 3.837268423012574e-07
92 O 0 3.6777646528207697e-06
% O 0 1.8200215379238216e-07
of O 0 4.885170667989769e-08
all O 0 2.2987796910456382e-07
reported O 0 1.4832242413831409e-05
mutations O 0 7.085254765115678e-06
leading O 0 2.604118435556302e-06
to O 0 3.012532488355646e-06
premature O 0 0.00021753904002252966
truncation O 0 9.623228834243491e-06
of O 0 2.4968062461994123e-07
the O 0 1.0680429340936826e-06
protein O 0 3.1494046197622083e-06
( O 0 4.5538274662249023e-07
nonsense O 0 2.413493348285556e-06
, O 0 2.131147311956738e-07
splicing O 0 3.0230828542698873e-06
, O 0 4.030253251130489e-07
insertions O 0 3.0128769594739424e-06
and O 0 6.055701646801026e-07
deletions O 0 2.8163890419818927e-06
) O 0 2.739215005931328e-07
and O 0 4.5665959191865113e-07
just O 0 2.088812152578612e-06
2 O 0 5.814942483084451e-07
% O 0 1.7727276713230822e-07
leading O 0 3.0517549021169543e-07
to O 0 8.672142115528914e-08
substitution O 0 1.3852968550054356e-07
of O 0 6.514427042247917e-08
one O 0 4.301431602016237e-07
amino O 0 1.9871727090503555e-06
acid O 0 1.0759691804196336e-06
by O 0 1.763130939025359e-07
another O 0 7.93753770267358e-07
( O 0 1.1236180625928682e-06
missense O 0 1.875668385764584e-05
) O 0 4.219532456772868e-06
. O 0 1.3427694284473546e-05

The O 0 1.6872509149834514e-05
extraordinary O 0 1.3414868590189144e-05
conservation O 0 2.494421778465039e-06
of O 0 4.2513548237366194e-07
the O 0 7.395115062536206e-07
PAX6 O 0 0.00010775138071039692
protein O 0 2.8931153792655095e-06
at O 0 3.3557314509380376e-06
the O 0 4.091449170573469e-07
amino O 0 2.4445496364933206e-06
acid O 0 1.5112775599845918e-06
level O 0 6.268197694225819e-07
amongst O 0 9.762760555531713e-07
vertebrates O 0 3.4145887184422463e-06
predicts O 0 5.699650500901043e-06
that O 0 5.178699211683124e-07
pathological O 0 3.2854717574082315e-05
missense O 0 9.007606422528625e-05
mutations O 0 4.287353658583015e-05
should O 0 1.2444792218957446e-06
in O 0 6.695281058455294e-07
fact O 0 9.48957506352599e-07
be O 0 5.135948413226288e-07
common O 0 3.6301608474786917e-07
even O 0 8.730110039323336e-07
though O 0 4.831047704101366e-07
they O 0 3.445694005677069e-07
are O 0 1.3161084666535317e-07
hardly O 0 2.061431814581738e-06
ever O 0 2.678917098819511e-06
seen O 0 6.342887445498491e-06
in O 0 8.871726095094346e-06
aniridia B-Disease 1 0.9999977350234985
patients O 0 0.0019528301199898124
. O 0 2.2270678528002463e-05

This O 0 2.6408715712022968e-05
indicates O 0 1.9767447156482376e-05
that O 0 7.871839784456824e-07
there O 0 4.6885878646207857e-07
is O 0 1.9475396584311966e-07
a O 0 6.285030167418881e-07
heavy O 0 0.0003613202425185591
ascertainment O 0 0.0005186104099266231
bias O 0 4.472099590202561e-06
in O 0 3.2855720633051533e-07
the O 0 1.841183916440059e-07
selection O 0 2.988234086842567e-07
of O 0 4.15637941841851e-07
patients O 0 1.6874568245839328e-05
for O 0 6.114931352385611e-07
PAX6 O 0 0.001580568146891892
mutation O 0 6.807258159824414e-06
analysis O 0 7.433552582369884e-07
and O 0 6.126956009211426e-07
that O 0 3.2131552529790497e-07
the O 0 7.875181609051651e-07
missing O 0 3.3947293559322134e-05
PAX6 O 0 0.0006208627019077539
missense O 0 0.00022526616521645337
mutations O 0 0.00012840330600738525
frequently O 0 3.5215129173593596e-05
may O 0 4.540548616205342e-05
underlie O 0 0.00027936912374570966
phenotypes O 0 0.00011115443339804187
distinct O 0 5.748332114308141e-06
from O 0 7.434739927703049e-06
textbook O 0 0.0007609928725287318
aniridia B-Disease 1 0.9999557733535767
. O 0 9.065539779840037e-05

Here O 0 6.455932452809066e-05
we O 0 5.60903936275281e-06
present O 0 1.6112645653265645e-06
four O 0 2.0876848338957643e-06
novel O 0 3.437584382481873e-06
PAX6 O 0 0.000101270925370045
missense O 0 4.088026980753057e-05
mutations O 0 2.0102930648135953e-05
, O 0 5.641219331664615e-07
two O 0 4.012596548363945e-07
in O 0 1.1450343890828663e-06
association O 0 3.717672825587215e-06
with O 0 2.2736417122359853e-06
atypical O 0 0.0009811859345063567
phenotypes O 0 0.008063807152211666
ectopia B-Disease 0 0.048728641122579575
pupillae I-Disease 0 0.012255998328328133
( O 0 1.0885744359256933e-06
displaced B-Disease 0 5.682770279236138e-06
pupils I-Disease 0 4.2301071516703814e-05
) O 0 3.3316562166874064e-06
and O 0 0.00020400501671247184
congenital B-Disease 1 0.9999964237213135
nystagmus I-Disease 0 0.11429993808269501
( O 0 1.2932194977111067e-06
searching B-Disease 0 1.7060439859051257e-05
gaze I-Disease 0 0.0002887930895667523
) O 0 4.824924531021679e-07
, O 0 2.549010105212801e-07
and O 0 2.387199629083625e-07
two O 0 3.2441428743368306e-07
in O 0 1.1816285905297264e-06
association O 0 2.12909640140424e-06
with O 0 5.119625257066218e-07
more O 0 6.738198408129392e-07
recognizable O 0 0.0001832466950872913
aniridia B-Disease 1 0.9997542500495911
phenotypes O 0 0.0008161250152625144
. O 0 3.774319338845089e-05

Strikingly O 0 0.0018516663694754243
, O 0 1.1348241059749853e-05
all O 0 5.233940783000435e-07
four O 0 1.1063499414376565e-06
mutations O 0 4.391377387946704e-06
are O 0 2.0615385665223585e-07
located O 0 1.7655146393735777e-06
within O 0 4.308049312840012e-07
the O 0 8.86987265857897e-07
PAX6 O 0 0.00010967359412461519
paired O 0 1.1886792890436482e-05
domain O 0 2.157468770747073e-06
and O 0 6.950778583814099e-07
affect O 0 1.4652279105575872e-06
amino O 0 1.359842258352728e-06
acids O 0 4.663934873860853e-07
which O 0 1.1163725588403395e-07
are O 0 6.993653300924052e-08
highly O 0 1.7337066537947976e-07
conserved O 0 3.012475247032853e-07
in O 0 1.1400033628206074e-07
all O 0 1.214837936913682e-07
known O 0 9.47985142829566e-07
paired O 0 5.270131168799708e-06
domain O 0 5.0569246923259925e-06
proteins O 0 6.776646387152141e-06
. O 0 8.468604391964618e-06

Our O 0 6.244071846595034e-05
results O 0 1.7995220332522877e-05
support O 0 1.3622850474348525e-06
the O 0 5.167312906451116e-07
hypothesis O 0 7.44784358630568e-07
that O 0 6.715168865412124e-08
the O 0 1.4119191860118008e-07
under O 0 6.697810022160411e-07
- O 0 2.074693156828289e-06
representation O 0 3.5225386341153353e-07
of O 0 3.1369239650302916e-07
missense O 0 0.00012403182336129248
mutations O 0 3.8933521864237264e-05
is O 0 4.848162120651978e-07
caused O 0 2.8626125185837736e-06
by O 0 6.387214170899824e-07
ascertainment O 0 0.00012700936349574476
bias O 0 8.869010343914852e-06
and O 0 3.060806875510025e-06
suggest O 0 1.6659080301906215e-06
that O 0 1.5995722435491189e-07
a O 0 9.195471761813678e-07
substantial O 0 2.8708116133202566e-06
burden O 0 5.880957905901596e-05
of O 0 1.2289592632441781e-06
PAX6 B-Disease 0 0.33431094884872437
- I-Disease 0 0.3323085308074951
related I-Disease 0 0.0008554350933991373
disease I-Disease 0 0.23646380007266998
remains O 0 5.884694019187009e-06
to O 0 1.6799588138383115e-06
be O 0 2.815985908455332e-06
uncovered O 0 0.00012228275591041893
. O 0 2.1063879103166983e-06
. O 0 9.837333891482558e-06

The O 0 4.605021604220383e-05
chromosomal O 0 0.0010720329592004418
order O 0 5.802434316137806e-06
of O 0 1.3486217085301178e-06
genes O 0 1.4560741874447558e-05
controlling O 0 2.7540154405869544e-05
the O 0 1.009361653814267e-06
major O 0 2.3224067717819707e-06
histocompatibility O 0 6.518562440760434e-05
complex O 0 6.8401604949031025e-06
, O 0 1.1807802593466477e-06
properdin O 0 6.187187682371587e-05
factor O 0 1.911711024149554e-06
B O 0 3.0686303944094107e-05
, O 0 8.067381713772193e-07
and O 0 1.2243735000083689e-05
deficiency B-Disease 0 0.0003620900388341397
of I-Disease 0 8.086671954288249e-08
the I-Disease 0 3.0413477247748233e-07
second I-Disease 0 2.6895556857198244e-06
component I-Disease 0 2.244063125544926e-06
of I-Disease 0 6.579472824341792e-07
complement I-Disease 0 1.6993733879644424e-05
. O 0 1.2865232747572009e-05

The O 0 1.8408785763313062e-05
relationship O 0 9.385081284563057e-06
of O 0 6.952820967853768e-07
the O 0 7.142733124965162e-07
genes O 0 2.3362595129583497e-06
coding O 0 5.742217581428122e-06
for O 0 5.386894486036908e-07
HLA O 0 5.594550020759925e-05
to O 0 6.182104925755993e-07
those O 0 4.42952114099171e-07
coding O 0 6.638924332946772e-06
for O 0 8.937164466260583e-07
properdin O 0 0.0002839967783074826
Factor O 0 4.096839347766945e-06
B O 0 5.9296748077031225e-05
allotypes O 0 5.5904965847730637e-05
and O 0 2.7220223728363635e-06
for O 0 6.676269549643621e-06
deficiency B-Disease 0 0.018375469371676445
of I-Disease 0 1.0692358642927502e-07
the I-Disease 0 3.201189997525944e-07
second I-Disease 0 2.6269067348039243e-06
component I-Disease 0 1.0029060604210827e-06
of I-Disease 0 1.6372426614452706e-07
complement I-Disease 0 3.4919416975753848e-06
( O 0 6.475985401266371e-07
C2 O 0 0.015095898881554604
) O 0 3.058257789234631e-07
was O 0 3.0601183880207827e-06
studied O 0 1.577871444169432e-06
in O 0 5.060597345618589e-07
families O 0 6.523255251522642e-07
of O 0 3.020501537775999e-07
patients O 0 2.6577539756544866e-05
with O 0 4.361878745839931e-05
connective O 1 0.9999517202377319
tissue O 1 0.9999921321868896
disorders O 1 0.999975323677063
. O 0 0.00010389679664513096

Patients O 1 0.9452800750732422
were O 0 0.00010629529424477369
selected O 0 1.539207914902363e-05
because O 0 2.733966539381072e-06
they O 0 1.5593459465890191e-06
were O 0 3.2266216294374317e-06
heterozygous O 0 2.5415600248379633e-05
or O 0 7.550292139058001e-06
homozygous O 0 0.003623620141297579
for O 0 0.006303089205175638
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
. O 0 0.0001601930271135643

12 O 0 0.0003620301722548902
families O 0 3.528720117174089e-05
with O 0 3.7910219816694735e-06
15 O 0 8.35449554870138e-06
matings O 0 5.9610385505948216e-05
informative O 0 3.73156217392534e-05
for O 0 0.025238042697310448
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 0.0002161100710509345
found O 0 6.0592319641727954e-05
. O 0 2.7699350539478473e-05

Of O 0 2.513069375709165e-05
57 O 0 6.713583570672199e-05
informative O 0 1.5157151210587472e-05
meioses O 0 0.00015402668213937432
, O 0 5.893910497434263e-07
two O 0 3.5602019465841295e-07
crossovers O 0 3.5867124097421765e-06
were O 0 2.7561843580770073e-06
noted O 0 4.7495004196207447e-07
between O 0 6.10625363606232e-07
the O 0 0.0014578367117792368
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999969005584717
gene O 0 5.211515144765144e-06
and O 0 1.0134232297787094e-06
the O 0 1.3412364978648839e-06
HLA O 0 8.070062176557258e-05
- O 0 0.0003195756580680609
B O 0 6.028351344866678e-05
gene O 0 1.76481944436091e-06
, O 0 1.664459858830014e-07
with O 0 9.505990306024614e-08
a O 0 5.135684091328585e-07
recombinant O 0 8.788048262431403e-07
fraction O 0 7.570066031803435e-07
of O 0 6.248496333682851e-07
0 O 0 3.227329580113292e-05
. O 0 1.4456307326327078e-05

035 O 0 0.1326972246170044
. O 0 0.0017027956200763583

A O 0 0.00017637644486967474
lod O 0 0.0020057668443769217
score O 0 2.3887443603598513e-05
of O 0 7.787338631715102e-07
13 O 0 6.124074843683047e-06
was O 0 5.447252078738529e-06
calculated O 0 1.2533022299976437e-06
for O 0 2.466719593030575e-07
linkage O 0 7.24993587937206e-05
between O 0 0.006417610216885805
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
and O 0 1.9831702957162634e-05
HLA O 0 0.001223230268806219
- O 0 0.008792247623205185
B O 0 0.0009986720979213715
at O 0 3.9793540054233745e-06
a O 0 5.042319912718085e-07
maximum O 0 6.622177011195163e-07
likelihood O 0 6.284203095674457e-07
value O 0 7.074959285091609e-08
of O 0 4.622144089694302e-08
the O 0 2.1536421002110728e-07
recombinant O 0 1.4505804983855342e-06
fraction O 0 1.1146103133796714e-06
of O 0 5.930605198045669e-07
0 O 0 2.901645530073438e-05
. O 0 1.0476815077709034e-05

04 O 0 0.061635904014110565
. O 0 0.0012988904491066933

18 O 0 0.0005639921873807907
families O 0 3.4624841646291316e-05
with O 0 2.606352154543856e-06
21 O 0 5.997989319439512e-06
informative O 0 1.6642962918922422e-06
matings O 0 1.114897349907551e-05
for O 0 3.306128064650693e-07
both O 0 8.431828746324754e-07
properdin O 0 0.00027176440926268697
Factor O 0 3.2076397928904044e-06
B O 0 1.2594879990501795e-05
allotype O 0 1.3947121260571294e-05
and O 0 9.875089972410933e-07
HLA O 0 8.352159784408286e-05
- O 0 0.0014091876801103354
B O 0 0.0001645201991777867
were O 0 4.817108219867805e-06
found O 0 1.0641982953529805e-05
. O 0 1.3767845302936621e-05

Of O 0 3.364957228768617e-05
72 O 0 6.029472206137143e-05
informative O 0 2.4500401195837185e-05
meioses O 0 0.0002647878718562424
, O 0 1.2740091506202589e-06
three O 0 5.973922156954359e-07
recombinants O 0 6.590341217815876e-05
were O 0 3.0394448913284577e-06
found O 0 9.387358090862108e-07
, O 0 1.7864576307147217e-07
giving O 0 2.0900826314118603e-07
a O 0 3.5975128298559866e-07
recombinant O 0 1.3505446077033412e-06
fraction O 0 9.795046480576275e-07
of O 0 9.233777973349788e-07
0 O 0 3.014748108398635e-05
. O 0 1.0004118848883081e-05

042 O 0 0.03745671734213829
. O 0 0.0017819978529587388

A O 0 0.00016071154095698148
lod O 0 0.0012493891408666968
score O 0 1.4409810319193639e-05
of O 0 1.0595282446956844e-06
16 O 0 2.973592927446589e-06
between O 0 8.847578101267572e-07
HLA O 0 9.264066466130316e-05
- O 0 0.0004148407606408
B O 0 7.566475687781349e-05
and O 0 1.4595796073990641e-06
Factor O 0 1.648487113925512e-06
B O 0 8.86740417627152e-06
allotypes O 0 2.1263500457280315e-05
was O 0 4.9280138227913994e-06
calculated O 0 7.639457635377767e-07
at O 0 8.787729370851594e-07
a O 0 1.6440066019640653e-07
maximum O 0 6.576950681846938e-07
likelihood O 0 4.297782254525373e-07
value O 0 3.8175354433178654e-08
of O 0 2.05643466699712e-08
the O 0 8.91363072241802e-08
recombinant O 0 6.808425609960977e-07
fraction O 0 5.602637997981219e-07
of O 0 4.04804183062879e-07
0 O 0 2.351520561205689e-05
. O 0 9.083523764275014e-06

04 O 0 0.18835870921611786
. O 0 0.0014801414217799902

A O 0 6.734865746693686e-05
crossover O 0 2.774212225631345e-05
was O 0 3.486330388113856e-05
shown O 0 1.6514343315066071e-06
to O 0 4.759398564146977e-07
have O 0 5.390975275076926e-07
occurred O 0 9.261513582714542e-07
between O 0 2.2078135941683286e-07
genes O 0 7.224978730846487e-07
for O 0 2.461559347466391e-07
Factor O 0 1.2161356153228553e-06
B O 0 7.344052846747218e-06
and O 0 1.3519439789888565e-06
HLA O 0 4.532182720140554e-05
- O 0 0.00048576894914731383
D O 0 0.007608551997691393
, O 0 4.89042861318012e-07
in O 0 2.1542008710184746e-07
which O 0 6.994780505920062e-07
HLA O 0 4.076441109646112e-05
- O 0 0.0003688019351102412
D O 0 0.004643403925001621
segregared O 0 6.187453254824504e-05
with O 0 1.429464759894472e-06
HLA O 0 0.00026273782714270055
- O 0 0.00010911270510405302
A O 0 1.3166099051886704e-05
and O 0 1.0087043847306632e-05
B O 0 0.0003321337280794978
. O 0 7.894290320109576e-06

These O 0 2.2995320250629447e-05
studies O 0 1.1111123967566527e-05
suggest O 0 2.9869283935113344e-06
that O 0 3.313884064937156e-07
the O 0 2.9559649306065694e-07
genes O 0 6.946100938876043e-07
for O 0 3.552868861333991e-07
Factor O 0 3.8005896385584492e-06
B O 0 0.004296979866921902
and O 0 0.016124745830893517
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
are O 0 3.4821704275600496e-07
located O 0 1.3307125072969939e-06
outside O 0 7.659986636099347e-07
those O 0 1.2852187580847385e-07
for O 0 2.264807079654929e-07
HLA O 0 0.00014314352301880717
, O 0 2.9644454002664133e-07
that O 0 8.877542256868765e-08
the O 0 1.0601867472814774e-07
order O 0 1.530710136421476e-07
of O 0 1.3966705125767476e-07
genese O 0 4.197630187263712e-05
is O 0 4.662422838919156e-07
HLA O 0 1.3449302059598267e-05
- O 0 2.0182091247988865e-05
A O 0 4.988319233234506e-06
, O 0 8.433365223936562e-07
- O 0 3.1908999517327175e-05
B O 0 2.966145439131651e-05
, O 0 4.3959892082057195e-07
- O 0 4.3636093323584646e-05
D O 0 0.00031073167338036
, O 0 4.681483574131562e-07
Factor O 0 1.4465038020716747e-06
B O 0 6.954100535949692e-05
allotype O 0 0.005186533089727163
, O 0 0.0019210046157240868
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999964237213135
, O 0 8.220959557547758e-07
that O 0 1.2249383019025117e-07
the O 0 2.655229422998673e-07
genes O 0 2.9214088499429636e-06
coding O 0 6.07239235250745e-05
for O 0 0.000459130184026435
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
and O 0 1.5891637303866446e-05
Factor O 0 6.874859536765143e-06
B O 0 6.98893636581488e-05
allotypes O 0 3.310418105684221e-05
are O 0 1.8894229469879065e-07
approximately O 0 4.409993152876268e-07
3 O 0 7.354843205575889e-07
- O 0 8.871971658663824e-06
- O 0 1.1468024240457453e-05
5 O 0 9.843272437137784e-07
centimorgans O 0 6.645372195634991e-06
from O 0 2.999059915964608e-07
the O 0 4.5114569502402446e-07
HLA O 0 2.057019082712941e-05
- O 0 8.835301741783042e-06
A O 0 3.3831861401267815e-06
and O 0 2.4422872684226604e-06
HLA O 0 9.195012535201386e-05
- O 0 0.0002893933851737529
B O 0 4.750826337840408e-05
loci O 0 1.8983395193572505e-06
, O 0 1.8557732062163268e-07
and O 0 1.6688881032678182e-07
that O 0 9.692332980648644e-08
the O 0 2.0600155892225303e-07
apparent O 0 5.381285973271588e-06
lack O 0 4.4143271793473104e-07
of O 0 1.1818826806120342e-07
recombinants O 0 1.9164925106451847e-05
between O 0 3.471070044724911e-07
the O 0 7.870871741033625e-07
Factor O 0 2.2520489437738433e-06
B O 0 4.0546368836658075e-05
gene O 0 1.045910448738141e-05
and O 0 0.01585589535534382
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
gene O 0 1.2614198567462154e-05
suggests O 0 1.1274436246822006e-06
that O 0 1.240461813267757e-07
these O 0 5.956236392989922e-08
two O 0 2.3099788393210474e-07
genes O 0 2.099010544043267e-06
lie O 0 1.0497898983885534e-05
in O 0 2.5198613684551674e-07
close O 0 1.9414289909036597e-06
proximity O 0 2.0909208160446724e-06
to O 0 8.473917318951862e-07
one O 0 1.9300866824778495e-06
another O 0 9.910007065627724e-06
. O 0 1.647677709115669e-05

Distribution O 0 6.697979551972821e-05
of O 0 8.876778338162694e-06
emerin O 0 0.0004197987145744264
and O 0 8.643754881632049e-06
lamins O 0 0.000216023123357445
in O 0 1.6514186427230015e-06
the O 0 1.8478909851182834e-06
heart O 0 0.0007544243126176298
and O 0 1.4158159729049657e-06
implications O 0 3.5242492231191136e-06
for O 0 1.3403234788711416e-06
Emery B-Disease 0 0.013972852379083633
- I-Disease 1 0.880532443523407
Dreifuss I-Disease 1 0.9968340992927551
muscular I-Disease 1 0.9995675683021545
dystrophy I-Disease 1 0.9995021820068359
. O 0 0.00014592113438993692

Emerin O 0 0.012645669281482697
is O 0 9.549926289764699e-06
a O 0 3.829923116427381e-06
nuclear O 0 2.5909799660439603e-05
membrane O 0 9.464501090405975e-06
protein O 0 4.6513073357346e-06
which O 0 5.935362992204318e-07
is O 0 4.012213707937917e-07
missing O 0 5.127044914843282e-06
or O 0 1.850712692430534e-06
defective O 0 0.0001307461061514914
in O 0 4.584093858284177e-06
Emery B-Disease 0 0.06368428468704224
- I-Disease 1 0.8797128200531006
Dreifuss I-Disease 1 0.9982036352157593
muscular I-Disease 1 0.999943733215332
dystrophy I-Disease 1 0.9999891519546509
( O 0 0.0001872972643468529
EDMD B-Disease 1 0.9999985694885254
) O 0 1.749468174239155e-05
. O 0 2.1630832634400576e-05

It O 0 2.688158565433696e-05
is O 0 1.853618300629023e-06
one O 0 4.0150615632228437e-07
member O 0 2.667076159923454e-07
of O 0 1.2240705871136015e-07
a O 0 1.4227257452148478e-06
family O 0 6.404795840353472e-06
of O 0 4.865420351052308e-07
lamina O 0 0.0016003120690584183
- O 0 0.004814106971025467
associated O 0 2.561964038250153e-06
proteins O 0 8.355407885574095e-07
which O 0 2.818797213421931e-07
includes O 0 9.523918151899124e-07
LAP1 O 0 0.00033427379094064236
, O 0 1.7928643956111046e-06
LAP2 O 0 0.0001345412019873038
and O 0 3.4942768252221867e-06
lamin O 0 0.0008196595008485019
B O 0 0.0034597257617861032
receptor O 0 3.7559104384854436e-05
( O 0 1.0371589269198012e-05
LBR O 0 0.0009372681379318237
) O 0 8.331446224474348e-06
. O 0 1.776726458047051e-05

A O 0 9.536761353956535e-05
panel O 0 1.5766630895086564e-05
of O 0 2.2640133465756662e-06
16 O 0 1.3112794476910494e-05
monoclonal O 0 3.061570896534249e-05
antibodies O 0 1.603519376658369e-05
( O 0 1.0915653092524735e-06
mAbs O 0 1.7372598449583165e-05
) O 0 4.3209115574427415e-07
has O 0 2.436073600620148e-07
been O 0 4.6083061988611007e-07
mapped O 0 3.2750406262493925e-06
to O 0 2.7102058197669976e-07
six O 0 3.9473667357015074e-07
specific O 0 1.4881695165058773e-07
sites O 0 5.436812671177904e-07
throughout O 0 2.466522062150034e-07
the O 0 3.617004722400452e-07
emerin O 0 8.87299574969802e-06
molecule O 0 8.742974273445725e-07
using O 0 6.490657256108534e-07
phage O 0 3.867574378091376e-06
- O 0 5.520152626559138e-06
displayed O 0 2.590707481431309e-06
peptide O 0 1.4117590581008699e-06
libraries O 0 5.271742224977061e-07
and O 0 6.250993465073407e-07
has O 0 6.094321634009248e-07
been O 0 4.0125198097484827e-07
used O 0 3.32844109607322e-07
to O 0 5.38679159944877e-07
localize O 0 4.552723839879036e-05
emerin O 0 9.85259612207301e-05
in O 0 1.1454952755229897e-06
human O 0 1.7221777852682862e-06
and O 0 1.2397383216011804e-05
rabbit O 0 0.02456674538552761
heart O 0 0.006434229668229818
. O 0 1.7910369933815673e-05

Several O 0 9.11181268747896e-05
mAbs O 0 0.0004892243887297809
against O 0 1.596777656232007e-05
different O 0 2.683685806914582e-06
emerin O 0 0.00026336711016483605
epitopes O 0 0.00012616752064786851
did O 0 8.75290425028652e-06
not O 0 9.296502980760124e-07
recognize O 0 1.8140880229111644e-06
intercalated O 0 6.557966844411567e-05
discs O 0 9.791025513550267e-05
in O 0 2.2288152194960276e-06
the O 0 3.434844984440133e-06
heart O 0 0.0042024520225822926
, O 0 1.124554955822532e-06
though O 0 5.677629246747529e-07
they O 0 4.999741349820397e-07
recognized O 0 5.327803478394344e-07
cardiomyocyte O 0 9.232023330696393e-06
nuclei O 0 2.4581345314800274e-06
strongly O 0 7.909277428552741e-07
, O 0 2.1692213181268016e-07
both O 0 1.3573995261140226e-07
at O 0 6.328989456960699e-06
the O 0 3.228762750495662e-07
rim O 0 4.994631581212161e-06
and O 0 5.827211566611368e-07
in O 0 6.451242597904638e-07
intranuclear O 0 0.00010527164704399183
spots O 0 1.8538465155870654e-05
or O 0 4.313107638154179e-06
channels O 0 2.763486554613337e-05
. O 0 1.5135858120629564e-05

A O 0 0.0003904748591594398
polyclonal O 0 0.0017420995282009244
rabbit O 0 0.0011100571136921644
antiserum O 0 0.0006730108871124685
against O 0 2.1335446945158765e-05
emerin O 0 0.0008974838419817388
did O 0 1.0114101314684376e-05
recognize O 0 1.9962176338594873e-06
both O 0 4.575261982608936e-07
nuclear O 0 2.5273529900005087e-05
membrane O 0 6.352966920530889e-06
and O 0 1.7150186977232806e-06
intercalated O 0 0.00018886389443650842
discs O 0 0.00017243879847228527
but O 0 1.4034081914360286e-06
, O 0 2.2903876129021228e-07
after O 0 4.5630088152393e-07
affinity O 0 1.1527258720889222e-06
purification O 0 2.4981329715956235e-06
against O 0 5.849148010383942e-07
a O 0 1.2558903108583763e-06
pure O 0 3.033722578038578e-06
- O 0 4.5571025111712515e-05
emerin O 0 5.5465490731876343e-05
band O 0 3.427724095672602e-06
on O 0 3.145017899441882e-07
a O 0 4.831789510717499e-07
western O 0 1.6057516631917679e-06
blot O 0 0.0008064413559623063
, O 0 1.7145445099231438e-06
it O 0 5.358254497878079e-07
stained O 0 0.0004769990046042949
only O 0 3.236750671931077e-07
the O 0 5.264718652142619e-07
nuclear O 0 3.2983462006086484e-05
membrane O 0 2.8169984943815507e-05
. O 0 1.2648034498852212e-05

These O 0 3.203400774509646e-05
results O 0 4.093371535418555e-05
would O 0 4.78036008644267e-06
not O 0 8.252364409599977e-07
be O 0 3.026738397693407e-07
expected O 0 4.697691338151344e-07
if O 0 3.635798009327118e-07
immunostaining O 0 3.1064118957147e-05
at O 0 9.383703400089871e-06
intercalated O 0 0.0007392670959234238
discs O 0 0.0014298473251983523
were O 0 3.4743789001367986e-05
due O 0 1.8158690409109113e-06
to O 0 2.872901916362025e-07
a O 0 5.775708018518344e-07
product O 0 2.954197952931281e-07
of O 0 4.3523677106804826e-08
the O 0 4.15822313470926e-07
emerin O 0 7.712160731898621e-05
gene O 0 1.352137360299821e-06
and O 0 1.1078554962296039e-06
, O 0 5.502474209606589e-07
therefore O 0 2.0955872059857938e-07
, O 0 7.09804552911919e-08
cast O 0 2.2368335805822426e-07
some O 0 6.470577318395954e-08
doubt O 0 4.802833473149803e-07
upon O 0 1.993758473872731e-07
the O 0 2.1643178627073212e-07
hypothesis O 0 2.2647711830359185e-06
that O 0 4.537875156529481e-06
cardiac B-Disease 1 0.9987735152244568
defects I-Disease 1 0.999248206615448
in O 0 0.0004816786095034331
EDMD B-Disease 1 1.0
are O 0 7.382667718047742e-06
caused O 0 1.3535897778638173e-05
by O 0 4.880951678387646e-07
absence O 0 2.188826783822151e-06
of O 0 5.151842970008147e-07
emerin O 0 0.0003812396025750786
from O 0 5.706263891624985e-06
intercalated O 0 0.0033663485664874315
discs O 0 0.0013861662009730935
. O 0 4.715457180282101e-05

Although O 0 0.00012566866644192487
emerin O 0 0.0009076085407286882
was O 0 4.068014459335245e-05
abundant O 0 3.8737166505598e-06
in O 0 7.38564324365143e-07
the O 0 6.179994329613692e-07
membranes O 0 9.111877261602785e-06
of O 0 7.591987127852917e-07
cardiomyocyte O 0 0.00029735485441051424
nuclei O 0 2.3154310838435777e-05
, O 0 9.782798997548525e-07
it O 0 4.36480490861868e-07
was O 0 9.29955149331363e-06
absent O 0 1.0971124311254243e-06
from O 0 1.4652681556981406e-07
many O 0 1.2552780503938266e-07
non O 0 1.6056321783253225e-06
- O 0 8.439274097327143e-05
myocyte O 0 0.0003686442505568266
cells O 0 3.638708221842535e-06
in O 0 7.489111339964438e-07
the O 0 4.306334176362725e-06
heart O 0 0.0021160519681870937
. O 0 2.5473593268543482e-05

This O 0 1.2763460290443618e-05
distribution O 0 6.378080342983594e-06
of O 0 1.5507446278206771e-06
emerin O 0 0.0006663186359219253
was O 0 1.6274603694910184e-05
similar O 0 4.4025131273883744e-07
to O 0 4.726775841845665e-07
that O 0 1.5052034996188013e-07
of O 0 2.018992404373421e-07
lamin O 0 5.554478047997691e-05
A O 0 5.408182460087119e-06
, O 0 3.8151046055645566e-07
a O 0 4.2832485291910416e-07
candidate O 0 8.55993164350366e-07
gene O 0 8.021550570447289e-07
for O 0 1.7833765753039188e-07
an O 0 2.2089200228947448e-06
autosomal O 0 0.0007246814202517271
form O 0 4.741783868666971e-06
of O 0 1.620239345356822e-05
EDMD B-Disease 1 0.9999990463256836
. O 0 6.791776104364544e-05

In O 0 5.83940782235004e-05
contrast O 0 4.6032782847760245e-05
, O 0 1.9981065634055994e-05
lamin O 0 0.014717352576553822
B1 O 1 0.7854178547859192
was O 0 5.3492654842557386e-05
absent O 0 1.018227430904517e-05
from O 0 1.3872155477656634e-06
cardiomyocyte O 0 8.518826507497579e-05
nuclei O 0 1.373605482513085e-05
, O 0 8.828251338854898e-07
showing O 0 4.553307462629164e-06
that O 0 8.882028623702354e-07
lamin O 0 0.009403133764863014
B1 O 1 0.5441619753837585
is O 0 5.063851631348371e-07
not O 0 2.809977388551488e-07
essential O 0 1.869611168103802e-07
for O 0 1.2314870900809183e-07
localization O 0 1.7482171870142338e-06
of O 0 2.535863927732862e-07
emerin O 0 9.012727969093248e-05
to O 0 9.994278116209898e-07
the O 0 3.5736761674343143e-06
nuclear O 0 0.0003064227057620883
lamina O 0 0.0007371556130237877
. O 0 2.6799500119523145e-05

Lamin O 1 0.914965033531189
B1 O 1 0.9964936375617981
is O 0 5.1352126320125535e-05
also O 0 1.2405248526192736e-05
almost O 0 8.052822522586212e-06
completely O 0 1.8202579667558894e-05
absent O 0 7.006062787695555e-06
from O 0 4.236127551848767e-06
skeletal O 0 0.008750001899898052
muscle O 0 0.008057013154029846
nuclei O 0 0.0008721069898456335
. O 0 4.2353021854069084e-05

In O 0 0.0003898802970070392
EDMD B-Disease 1 0.9999885559082031
, O 0 3.5771067814494018e-06
the O 0 3.813326259205496e-07
additional O 0 3.4311804597564333e-07
absence O 0 1.0704596888899687e-06
of O 0 4.5482460109269596e-07
lamin O 0 0.030079439282417297
B1 O 1 0.6619009971618652
from O 0 4.509892278292682e-06
heart O 0 0.002641236875206232
and O 0 1.2243419405422173e-05
skeletal O 0 0.19627051055431366
muscle O 0 0.013068139553070068
nuclei O 0 0.0002527993929106742
which O 0 5.201241947361268e-06
already O 0 1.6391360986744985e-05
lack O 0 7.309612556127831e-06
emerin O 0 0.004221065901219845
may O 0 3.79235643777065e-06
offer O 0 2.342152498613359e-07
an O 0 1.7574635080563894e-07
alternative O 0 4.198404326416494e-07
explanation O 0 4.3586484821389604e-07
of O 0 1.601516856908347e-07
why O 0 9.042028636940813e-07
these O 0 1.7359350579226884e-07
tissues O 0 1.949137367773801e-05
are O 0 5.619644412035996e-07
particularly O 0 3.5921552807849366e-06
affected O 0 9.371629857923836e-06
. O 0 3.2367247513320763e-06
. O 0 9.407143807038665e-06

Genetic O 0 0.00045886458246968687
mapping O 0 8.309134864248335e-05
of O 0 3.998381089331815e-06
the O 0 8.803014679870103e-06
copper B-Disease 0 0.0014548904728144407
toxicosis I-Disease 0 0.005640524905174971
locus O 0 5.6522938393754885e-05
in O 0 7.765692316752393e-06
Bedlington O 0 0.009523988701403141
terriers O 0 0.002074639778584242
to O 0 3.983105216320837e-06
dog O 0 0.002602073596790433
chromosome O 0 0.0005510578630492091
10 O 0 4.014558726339601e-06
, O 0 5.601441444014199e-07
in O 0 3.3624510820118303e-07
a O 0 1.628897848604538e-06
region O 0 3.106589247181546e-06
syntenic O 0 7.799633021932095e-05
to O 0 9.015706154968939e-07
human O 0 9.723800076244515e-07
chromosome O 0 7.818011363269761e-05
region O 0 9.263313586416189e-06
2p13 O 0 0.00031985490932129323
- O 0 0.0005525657907128334
p16 O 0 0.00023206512560136616
. O 0 1.823253114707768e-05

Abnormal O 1 0.998928964138031
hepatic B-Disease 1 0.9999245405197144
copper I-Disease 1 0.8712397217750549
accumulation I-Disease 0 0.01251461822539568
is O 0 2.6147495191253256e-06
recognized O 0 2.1792207007820252e-06
as O 0 2.1532221126108197e-06
an O 0 0.00025508011458441615
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
in O 0 1.099874953069957e-05
man O 0 0.000496452848892659
, O 0 9.155517091130605e-07
mouse O 0 2.7402822524891235e-05
, O 0 2.1515575099329e-06
rat O 0 0.00015174697909969836
and O 0 3.999955879407935e-06
dog O 0 0.0005468781455419958
. O 0 2.725520789681468e-05

The O 0 5.835472256876528e-05
major O 0 2.6568566681817174e-05
cause O 0 2.5364266548422165e-05
of O 0 3.1088416108104866e-06
hepatic B-Disease 1 0.9292963147163391
copper I-Disease 1 0.5018441677093506
accumulation I-Disease 0 0.0007675125380046666
in O 0 3.990686309407465e-06
man O 0 7.342149910982698e-05
is O 0 3.225355840186239e-07
a O 0 2.4468986339343246e-06
dysfunctional O 0 0.0013846621150150895
ATP7B O 0 0.002091818954795599
gene O 0 1.126519146055216e-05
, O 0 4.098558747500647e-06
causing O 0 0.0007659032708033919
Wilson B-Disease 0 0.07996872812509537
disease I-Disease 0 0.4014257490634918
( O 0 1.301295924349688e-05
WD B-Disease 1 0.97031569480896
) O 0 1.7026826753863133e-05
. O 0 1.2139757018303499e-05

Mutations O 0 0.0010881812777370214
in O 0 9.855193638941273e-06
the O 0 3.460998868831666e-06
ATP7B O 0 0.00125663832295686
genes O 0 5.10857125846087e-06
have O 0 1.1613834658419364e-06
also O 0 8.385518412978854e-07
been O 0 1.3552694326790515e-06
demonstrated O 0 1.2348158406894072e-06
in O 0 4.938665938425402e-07
mouse O 0 2.6460798835614696e-05
and O 0 6.615659913222771e-06
rat O 0 0.0008875722996890545
. O 0 1.1900131539732683e-05

The O 0 5.5370044719893485e-05
ATP7B O 0 0.001303590484894812
gene O 0 2.852803299902007e-05
has O 0 1.6605039263595245e-06
been O 0 1.5119695717658033e-06
excluded O 0 1.3869389476894867e-06
in O 0 1.1770347185802166e-07
the O 0 1.668713025537727e-07
much O 0 8.420498716077418e-07
rarer O 0 3.293323243269697e-05
human O 0 1.1060440556320827e-05
copper B-Disease 1 0.7252301573753357
overload I-Disease 1 0.9966897964477539
disease O 0 0.09675692766904831
non B-Disease 0 8.574331332056317e-06
- I-Disease 0 0.0002794495376292616
Indian I-Disease 0 1.734075522108469e-05
childhood I-Disease 0 0.37765657901763916
cirrhosis I-Disease 1 0.9738895297050476
, O 0 6.129502708063228e-06
indicating O 0 0.00012520348536781967
genetic O 0 0.00020438818319234997
heterogeneity O 0 0.00024627934908494353
. O 0 3.64313273166772e-05

By O 0 4.959771831636317e-05
investigating O 0 6.485501944553107e-05
the O 0 1.251798039447749e-05
common O 0 7.810738316038623e-05
autosomal O 1 0.9771703481674194
recessive O 1 0.9990173578262329
copper B-Disease 1 0.9703444242477417
toxicosis I-Disease 1 0.9759355187416077
( O 0 6.827907782280818e-06
CT B-Disease 0 0.37720876932144165
) O 0 1.0941741948045092e-06
in O 0 1.3358036312638433e-06
Bedlington O 0 0.01689595729112625
terriers O 0 0.13464412093162537
, O 0 2.7592484457272803e-06
we O 0 1.0051850267700502e-06
have O 0 6.066794639991713e-07
identified O 0 7.389222105302906e-07
a O 0 2.87643842966645e-07
new O 0 4.819098080588446e-07
locus O 0 2.2609992811339907e-05
involved O 0 4.245862783136545e-06
in O 0 3.2976604416035116e-05
progressive O 1 0.9992146492004395
liver B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 0.0003290849272161722

We O 0 5.6284978199983016e-05
examined O 0 5.281148332869634e-05
whether O 0 3.7482816424017074e-06
the O 0 1.9230608359066537e-06
WD B-Disease 0 0.40702781081199646
gene O 0 2.7036045139539056e-05
ATP7B O 0 0.010446999222040176
was O 0 4.102539605810307e-05
also O 0 9.755556220625294e-07
causative O 0 5.141779183759354e-06
for O 0 5.992267233523307e-07
CT B-Disease 0 0.13405349850654602
by O 0 9.56551730268984e-07
investigating O 0 2.7035039238398895e-06
the O 0 1.1036701152988826e-06
chromosomal O 0 0.005437438376247883
co O 0 0.00031349118216894567
- O 0 2.6021027224487625e-05
localization O 0 4.234883363096742e-06
of O 0 4.636386279344151e-07
ATP7B O 0 0.0008994477102532983
and O 0 1.4522069022859796e-06
C04107 O 0 1.3279045560921077e-05
, O 0 1.8879083540923602e-07
using O 0 3.5679516940945177e-07
fluorescence O 0 2.739290493991575e-06
in O 0 4.829113322557532e-07
situ O 0 6.35170044915867e-06
hybridization O 0 2.806061729643261e-06
( O 0 1.234302544617094e-06
FISH O 0 4.862961304752389e-06
) O 0 2.5897390969475964e-06
. O 0 8.020502718864009e-06

C04107 O 0 0.006903052795678377
is O 0 1.8213415387435816e-05
an O 0 5.419928584160516e-06
anonymous O 0 2.3729284293949604e-05
microsatellite O 0 0.0001062648807419464
marker O 0 7.179567910498008e-05
closely O 0 1.6216257790802047e-05
linked O 0 6.696274067508057e-05
to O 0 1.2498321666498668e-05
CT B-Disease 1 0.9247987270355225
. O 0 4.622356209438294e-05

However O 0 9.816892998060212e-05
, O 0 1.853798676165752e-05
BAC O 0 0.0002712422574404627
clones O 0 3.248629946028814e-05
containing O 0 1.1512599485286046e-05
ATP7B O 0 0.0006434028036892414
and O 0 2.4910937099775765e-06
C04107 O 0 2.606779344205279e-05
mapped O 0 9.028371096064802e-06
to O 0 7.046407972666202e-07
the O 0 8.87978387709154e-07
canine O 0 0.00029979145620018244
chromosome O 0 0.0016078141052275896
regions O 0 6.0459537962742615e-06
CFA22q11 O 0 0.00016055713058449328
and O 0 3.768421038330416e-06
CFA10q26 O 0 0.00010129497240995988
, O 0 5.393021638155915e-07
respectively O 0 2.3236430024553556e-06
, O 0 2.578550493126386e-07
demonstrating O 0 1.1561431847439962e-06
that O 0 7.964030714902037e-07
WD B-Disease 1 0.5058582425117493
cannot O 0 4.653468295146013e-06
be O 0 4.7043894824128074e-07
homologous O 0 3.958135494031012e-06
to O 0 6.277407919696998e-06
CT B-Disease 1 0.8479059338569641
. O 0 2.8290083719184622e-05

The O 0 7.18378578312695e-05
copper O 0 0.00011517407983774319
transport O 0 2.011865763051901e-05
genes O 0 1.5541556422249414e-05
CTR1 O 0 0.00024496979312971234
and O 0 3.8518128349096514e-06
CTR2 O 0 0.002370209898799658
were O 0 6.550274974870263e-06
also O 0 1.4064321476325858e-06
excluded O 0 1.1455651929281885e-06
as O 0 1.2937816507019306e-07
candidate O 0 3.855374188788119e-07
genes O 0 5.440215318230912e-07
for O 0 3.2769290214673674e-07
CT B-Disease 1 0.748772919178009
since O 0 4.410743258631555e-06
they O 0 3.610449823554518e-07
both O 0 2.9533924816860235e-07
mapped O 0 9.858935300144367e-06
to O 0 2.3222785330290208e-06
canine O 0 0.013531015254557133
chromosome O 0 0.04918305203318596
region O 0 8.156590774888173e-05
CFA11q22 O 0 0.003133967285975814
. O 0 3.286709761596285e-05

2 O 0 0.0007286312757059932
- O 0 0.0005991103244014084
22 O 0 0.0001729055802570656
. O 0 5.200971645535901e-05

5 O 0 0.0025489837862551212
. O 0 0.0004241636488586664

A O 0 9.429504279978573e-05
transcribed O 0 7.218560494948179e-05
sequence O 0 1.1594398529268801e-05
identified O 0 4.1769885683606844e-06
from O 0 6.575382371920568e-07
the O 0 7.363615281974489e-07
C04107 O 0 3.261008532717824e-05
- O 0 2.875265090551693e-05
containing O 0 1.0777432180475444e-05
BAC O 0 0.00048126993351615965
was O 0 3.69935150956735e-05
found O 0 8.379554969906167e-07
to O 0 1.5887522408775112e-07
be O 0 1.2614330557880749e-07
homologous O 0 4.846442607231438e-07
to O 0 1.71287112493701e-07
a O 0 7.363138365690247e-07
gene O 0 1.531210955363349e-06
expressed O 0 2.0500829123193398e-07
from O 0 3.2489634804733214e-07
human O 0 6.458518555518822e-07
chromosome O 0 6.195198511704803e-05
2p13 O 0 5.6689732446102425e-05
- O 0 6.367533205775544e-05
p16 O 0 2.5424738851143047e-05
, O 0 5.534810156859749e-07
a O 0 4.831720730180677e-07
region O 0 1.217716203427699e-06
devoid O 0 1.6780788882897468e-06
of O 0 1.6677299186085293e-07
any O 0 4.6677126874783426e-07
positional O 0 2.702135498111602e-05
candidate O 0 1.6958974811132066e-05
genes O 0 3.5695749829756096e-05
. O 0 2.427117397019174e-05

Molecular O 0 0.00015042706218082458
analysis O 0 8.86848647496663e-06
of O 0 1.411799416928261e-06
the O 0 2.2443132365879137e-06
APC B-Disease 0 1.948312456079293e-05
gene O 0 3.2066334370028926e-06
in O 0 7.622762723258347e-07
205 O 0 5.093019808555255e-06
families O 0 1.496659479016671e-06
: O 0 4.4290607092989376e-07
extended O 0 1.7944739738595672e-06
genotype O 0 8.854102634359151e-05
- O 0 7.33354318072088e-05
phenotype O 0 3.851548899547197e-05
correlations O 0 6.604709597013425e-06
in O 0 1.7935946061697905e-06
FAP B-Disease 0 2.517500070098322e-05
and O 0 8.168753993231803e-07
evidence O 0 2.1805709593536449e-07
for O 0 7.324367601313497e-08
the O 0 1.901311321717003e-07
role O 0 6.015639542056306e-07
of O 0 4.0815734791976865e-07
APC B-Disease 0 3.3923213777597994e-05
amino O 0 5.080813934910111e-06
acid O 0 8.419972800766118e-06
changes O 0 3.542513013599091e-06
in O 0 0.014896072447299957
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9888732433319092
. O 0 0.0001805230276659131

BACKGROUND O 0 0.0008630187949165702
/ O 0 0.00027626086375676095
AIMS O 0 5.035380308981985e-05
The O 0 1.574762791278772e-06
development O 0 2.6127006549359066e-06
of O 0 0.00013660777767654508
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.7804868548410013e-05
a O 0 3.5211585327488137e-06
variable O 0 6.444702194130514e-06
range O 0 9.878274340735516e-07
of O 0 5.236207698544604e-07
extracolonic O 0 0.011258856393396854
manifestations O 0 0.00013219821266829967
in O 0 0.002192562911659479
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999988079071045
polyposis I-Disease 1 1.0
( O 0 0.00016719264385756105
FAP B-Disease 0 0.0015268231509253383
) O 0 1.5488971030208631e-06
is O 0 1.7185227818572457e-07
the O 0 2.017756628447387e-07
result O 0 4.3566080876189517e-07
of O 0 1.2909174529340817e-07
the O 0 1.3363794550969033e-06
dominant O 0 4.600206375471316e-05
inheritance O 0 0.00010679494880605489
of O 0 8.597711712354794e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999977350234985
coli I-Disease 1 0.9999731779098511
( O 0 2.6534939024713822e-05
APC B-Disease 0 0.00023215032706502825
) O 0 5.054976554674795e-06
gene O 0 2.469364153512288e-05
mutations O 0 6.827673496445641e-05
. O 0 2.8446964279282838e-05

In O 0 1.995140155486297e-05
this O 0 1.3686659485756536e-06
study O 0 1.0772638461276074e-06
, O 0 2.237644451952292e-07
direct O 0 4.0135378753802797e-07
mutation O 0 1.6689086805854458e-06
analysis O 0 3.0409009355025773e-07
of O 0 1.2351284794931416e-07
the O 0 8.287065611511935e-07
APC B-Disease 0 1.7865093468572013e-05
gene O 0 1.6657141941323061e-06
was O 0 4.145811544731259e-06
performed O 0 3.974696483055595e-06
to O 0 4.949274625687394e-07
determine O 0 4.465763140615309e-06
genotype O 0 0.00026895449263975024
- O 0 0.0001494085299782455
phenotype O 0 1.904020791698713e-05
correlations O 0 3.702734147736919e-06
for O 0 2.4990023916870996e-07
nine O 0 4.672082468459848e-06
extracolonic O 0 0.00021206562814768404
manifestations O 0 2.578835847089067e-06
and O 0 4.184681472452212e-07
to O 0 3.302340303434903e-07
investigate O 0 1.3591187553174677e-06
the O 0 4.819277137357858e-07
incidence O 0 5.03525989188347e-05
of O 0 6.099397751313518e-07
APC B-Disease 0 6.792255589971319e-05
mutations O 0 8.166282896127086e-06
in O 0 2.701519406400621e-06
non O 0 0.0005227983347140253
- O 1 0.9999464750289917
FAP O 1 0.9999104738235474
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0002852891047950834

METHODS O 0 0.0001729403593344614
The O 0 1.3189121091272682e-05
APC B-Disease 0 6.988910172367468e-05
gene O 0 1.2791438166459557e-05
was O 0 6.718680197081994e-06
analysed O 0 6.366735306073679e-06
in O 0 6.760803898941958e-07
190 O 0 3.2345708405046025e-06
unrelated O 0 5.9083790802105796e-06
FAP B-Disease 0 1.1586970686039422e-05
and O 0 1.7477186702308245e-06
15 O 0 8.720218829694204e-06
non O 0 8.08448894531466e-05
- O 1 0.9999099969863892
FAP O 1 0.9999686479568481
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.143121138215065
using O 0 2.4296092306030914e-05
denaturing O 0 0.02150583826005459
gradient O 0 0.004470159765332937
gel O 0 0.33574074506759644
electrophoresis O 0 0.0004883163492195308
, O 0 1.4056249710847624e-06
the O 0 4.65043314079594e-07
protein O 0 3.017961034856853e-06
truncation O 0 1.1154397725476883e-05
test O 0 1.0306229341949802e-05
, O 0 6.112021537774126e-07
and O 0 5.948629109298054e-07
direct O 0 2.8506203761935467e-06
sequencing O 0 4.400932812131941e-05
. O 0 2.2839842131361365e-05

RESULTS O 0 0.0013392294058576226
Chain O 0 0.0002763266966212541
terminating O 0 9.07412832020782e-05
signals O 0 1.3261567801237106e-05
were O 0 2.70305531557824e-06
only O 0 3.11569891664476e-07
identified O 0 2.412181629551924e-06
in O 0 9.939603842212819e-07
patients O 0 1.1501056178531144e-05
belonging O 0 4.6902296162443236e-06
to O 0 5.519502792594722e-07
the O 0 2.1373684830905404e-06
FAP B-Disease 0 3.9401907997671515e-05
group O 0 6.1470282162190415e-06
( O 0 9.570827614879818e-07
105 O 0 1.0751838999567553e-05
patients O 0 2.8780386855942197e-05
) O 0 3.801158527494408e-06
. O 0 8.506778613082133e-06

Amino O 0 0.0004791142710018903
acid O 0 9.88031315500848e-05
changes O 0 5.326769041857915e-06
were O 0 5.592433353740489e-06
identified O 0 2.5494678084214684e-06
in O 0 5.397518521021993e-07
four O 0 4.961650574841769e-06
patients O 0 4.937158155371435e-05
, O 0 3.332106075504271e-07
three O 0 1.10070530467965e-07
of O 0 1.156679800828897e-07
whom O 0 2.6471359433344333e-06
belonged O 0 4.507329322223086e-06
to O 0 2.809312888985005e-07
the O 0 5.332205432750925e-07
non O 0 3.1056770239956677e-06
- O 0 0.00011471253674244508
FAP O 0 4.366344364825636e-05
group O 0 1.680173045315314e-05
of O 0 0.0003907200298272073
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9427582025527954
. O 0 0.00010118511272594333

Genotype O 0 0.199667826294899
- O 0 0.058198802173137665
phenotype O 0 0.004492835607379675
correlations O 0 0.00022422517940867692
identified O 0 5.635732668451965e-05
significant O 0 2.425001412120764e-06
differences O 0 3.781305622396758e-06
in O 0 9.84274720394751e-07
the O 0 7.546179858763935e-07
nature O 0 5.979804882372264e-07
of O 0 1.4225803113276925e-07
certain O 0 9.3360932851283e-07
extracolonic O 0 0.00023396266624331474
manifestations O 0 7.191924851213116e-06
in O 0 8.489256288157776e-06
FAP B-Disease 0 0.0022712606005370617
patients O 0 7.704428571742028e-05
belonging O 0 5.631346994050546e-06
to O 0 1.052220795827452e-06
three O 0 4.113705017516622e-06
mutation O 0 4.957435157848522e-05
subgroups O 0 8.927429735194892e-05
. O 0 1.6369616787414998e-05

CONCLUSIONS O 0 0.0007191079203039408
Extended O 0 0.00013542984379455447
genotype O 0 0.0005413254257291555
- O 0 0.00029918845393694937
phenotype O 0 0.00021907118207309395
correlations O 0 2.1906014808337204e-05
made O 0 3.6909161735820817e-06
in O 0 1.402086468260677e-06
this O 0 2.6163658617406327e-07
study O 0 9.696731240182999e-07
may O 0 6.6306984081165865e-06
have O 0 2.877771976272925e-07
the O 0 1.2525262604867748e-07
potential O 0 1.6839258876188978e-07
to O 0 1.529589468418635e-07
determine O 0 8.440155738753674e-07
the O 0 7.811097191279259e-08
most O 0 5.9006712405107464e-08
appropriate O 0 1.653256163081096e-07
surveillance O 0 2.5134559109574184e-06
and O 0 1.8466087112756213e-06
prophylactic O 0 0.0006930202362127602
treatment O 0 0.0003861786099150777
regimens O 0 0.00025244051357731223
for O 0 2.873421863114345e-06
those O 0 1.0472299436514731e-05
patients O 0 0.00010274016676703468
with O 0 3.883784756908426e-06
mutations O 0 0.00012523573241196573
associated O 0 4.898643965134397e-06
with O 0 6.717853466398083e-06
life O 0 0.00010468144319020212
threatening O 0 0.008071553893387318
conditions O 0 0.001041487674228847
. O 0 2.3325426809606142e-05

This O 0 1.4129110240901355e-05
study O 0 5.503836291609332e-06
also O 0 3.5283421766507672e-06
provided O 0 1.6322427427439834e-06
evidence O 0 3.0836318387628125e-07
for O 0 1.5712569734205317e-07
the O 0 5.474659587889619e-07
pathological O 0 1.5887244444456883e-05
nature O 0 4.328500722294848e-07
of O 0 1.806069889198625e-07
amino O 0 4.505485776462592e-06
acid O 0 2.4271578240586678e-06
changes O 0 3.4623946021383745e-07
in O 0 6.606559281863156e-07
APC O 0 2.0402896552695893e-05
associated O 0 6.891638122397126e-07
with O 0 2.721687621942692e-07
both O 0 6.215137204890198e-07
FAP B-Disease 0 2.5718885808601044e-05
and O 0 3.6267631458031246e-06
non O 0 0.00023887651332188398
- O 1 0.9999492168426514
FAP O 1 0.9999933242797852
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9473181962966919
. O 0 2.6070852982229553e-05
. O 0 3.2539013773202896e-05

Inherited B-Disease 1 0.9999974966049194
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999986886978149
and O 1 0.9789565205574036
cancer B-Disease 1 0.9999886751174927
risk O 0 0.0005841547390446067
of O 0 8.965701567831275e-07
the O 0 5.827394943480613e-06
APC O 0 0.00020241660240571946
I1307K O 0 0.00014012852625455707
polymorphism O 0 0.0001713928213575855
. O 0 4.32879023719579e-05

Germ O 0 0.033567044883966446
- O 0 0.0004882495559286326
line O 0 5.452747063827701e-05
and O 0 2.71697535936255e-06
somatic O 0 2.0079864043509588e-05
truncating O 0 3.0435516237048432e-05
mutations O 0 5.200751274969662e-06
of O 0 2.5995876740125823e-07
the O 0 5.606250965684012e-07
APC B-Disease 0 2.0975492589059286e-05
gene O 0 1.8697053292271448e-06
are O 0 2.136745820280339e-07
thought O 0 1.3022938674112083e-06
to O 0 1.139109258474491e-06
initiate O 0 0.0005630269879475236
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9963877201080322
formation O 0 0.0011638086289167404
in O 0 0.011908489279448986
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.007425785530358553
sporadic O 1 0.9894541501998901
colorectal O 1 1.0
carcinogenesis O 1 0.9988459348678589
, O 0 0.00010090596333611757
respectively O 0 0.0003222868253942579
. O 0 2.331933137611486e-05

Recently O 0 0.0006779415998607874
, O 0 1.3818224033457227e-05
an O 0 6.549787940457463e-06
isoleucine O 0 0.0015361133264377713
- O 0 0.00029569934122264385
- O 0 0.0001435400336049497
> O 0 3.952429324272089e-05
lysine O 0 2.2591651941183954e-05
polymorphism O 0 1.387983593303943e-05
at O 0 6.9674574660893995e-06
codon O 0 1.602256998012308e-05
1307 O 0 3.954254134441726e-05
( O 0 7.823732062206545e-07
I1307K O 0 6.402982307918137e-06
) O 0 1.5538637399004074e-07
of O 0 7.773999044502489e-08
the O 0 5.423462425824255e-07
APC B-Disease 0 1.0696682693378534e-05
gene O 0 1.2905915127703338e-06
has O 0 3.670000410238572e-07
been O 0 7.474769176951668e-07
identified O 0 6.313842391136859e-07
in O 0 1.7242798833194684e-07
6 O 0 2.17145384340256e-06
% O 0 5.864631020813249e-07
- O 0 1.17084355224506e-05
7 O 0 2.5475283109699376e-06
% O 0 2.0581362036864448e-07
of O 0 9.261163569362907e-08
the O 0 8.042998729251849e-07
Ashkenazi O 0 3.170541094732471e-05
Jewish O 0 6.57954979033093e-06
population O 0 4.692019501817413e-06
. O 0 6.492065494967392e-06

To O 0 5.4719312174711376e-05
assess O 0 0.00010618020314723253
the O 0 5.358752332540462e-06
risk O 0 1.8483406165614724e-05
of O 0 3.6510863310468267e-07
this O 0 3.0932423555896094e-07
common O 0 1.5123647472137236e-06
APC B-Disease 0 1.536717354611028e-05
allelic O 0 2.1615407604258507e-05
variant O 0 9.691715240478516e-05
in O 0 0.000207215387490578
colorectal O 1 1.0
carcinogenesis O 1 0.9809813499450684
, O 0 9.831591887632385e-05
we O 0 4.756984253617702e-06
have O 0 7.149561156438722e-07
analyzed O 0 1.3143479691279936e-06
a O 0 3.7485747839127725e-07
large O 0 5.305417971612769e-07
cohort O 0 1.1337748219375499e-05
of O 0 4.6100382178337895e-07
unselected O 0 0.00013231347838882357
Ashkenazi O 0 4.913003067485988e-05
Jewish O 0 3.951384314859752e-06
subjects O 0 4.496673227549763e-06
with O 0 1.0379198101873044e-05
adenomatous B-Disease 1 0.5894139409065247
polyps I-Disease 0 0.05079906806349754
and O 0 2.572963057900779e-05
. O 0 2.6694486223277636e-05
or O 1 0.9854655265808105
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 7.3107212301692925e-06
for O 0 9.783582299860427e-07
the O 0 7.095558885339415e-06
APC O 0 0.00017483465489931405
I1307K O 0 0.00014649190416093916
polymorphism O 0 0.0001385136420140043
. O 0 2.0361241695354693e-05

The O 0 7.21902833902277e-05
APC O 0 0.0002301320928381756
I1307K O 0 0.00010560847294982523
allele O 0 3.5770819522440434e-05
was O 0 1.7061773178284056e-05
identified O 0 3.2288442071148893e-06
in O 0 4.087279990017123e-07
48 O 0 4.547076059679966e-06
( O 0 1.5282145682249393e-07
10 O 0 3.034597284568008e-07
. O 0 9.358863906072656e-08
1 O 0 3.8312495576064975e-07
% O 0 2.154414460164844e-07
) O 0 9.911474307955359e-08
of O 0 2.600807533781335e-07
476 O 0 0.00014345053932629526
patients O 0 0.00013801277964375913
. O 0 1.4808299965807237e-05

Compared O 0 0.00020408908312674612
with O 0 2.220375790784601e-06
the O 0 5.76648858441331e-07
frequency O 0 4.1246025830332655e-06
in O 0 3.5640812257042853e-07
two O 0 1.9725084143829008e-07
separate O 0 8.792893595455098e-07
population O 0 3.09132275333468e-07
control O 0 1.2291199027458788e-06
groups O 0 1.8350765174091066e-07
, O 0 1.310147581534693e-07
the O 0 2.5260499114665436e-07
APC O 0 1.00963125078124e-05
I1307K O 0 1.1843523679999635e-05
allele O 0 4.502182946453104e-06
is O 0 2.2208004679669102e-07
associated O 0 3.9359014181172824e-07
with O 0 1.9259701389273687e-07
an O 0 5.812314611830516e-07
estimated O 0 2.9574669042631285e-06
relative O 0 1.966079253179487e-05
risk O 0 8.98210873856442e-06
of O 0 5.847464308317285e-07
1 O 0 1.1126742720080074e-05
. O 0 1.0288316843798384e-05

5 O 0 0.0006692041060887277
- O 0 0.000700246135238558
1 O 0 6.160634802654386e-05
. O 0 5.2184939704602584e-05

7 O 0 0.0020408304408192635
for O 0 0.0001557822834001854
colorectal B-Disease 1 0.9999998807907104
neoplasia I-Disease 1 0.9951851963996887
( O 0 2.7407373636378907e-05
both O 0 1.9519517081789672e-05
P O 1 0.7584294080734253
= O 0 0.0010835241992026567
. O 0 3.20924323204963e-06
01 O 0 0.0005275472649373114
) O 0 9.476160812482703e-06
. O 0 1.444732060917886e-05

Furthermore O 0 0.0003329392638988793
, O 0 1.61894040502375e-05
compared O 0 8.715304829820525e-06
with O 0 2.7204080197407166e-06
noncarriers O 0 0.0005405654665082693
, O 0 1.8618584363139234e-06
APC O 0 1.639702168176882e-05
I1307K O 0 1.7728807506500743e-05
carriers O 0 2.8282206585572567e-06
had O 0 4.665474989451468e-06
increased O 0 8.801753210718744e-07
numbers O 0 7.993295412234147e-07
of O 0 5.543399197449617e-07
adenomas B-Disease 0 0.007033132016658783
and O 0 0.05893080309033394
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.999966025352478
per O 0 0.0006698567885905504
patient O 0 0.1141151413321495
( O 0 3.5962273159384495e-06
P O 0 0.21303382515907288
= O 0 0.0001669347402639687
. O 0 5.868536163688987e-07
03 O 0 0.00020058928930666298
) O 0 1.733423857785965e-07
, O 0 9.479664697664703e-08
as O 0 6.500822991029054e-08
well O 0 1.0836507868816625e-07
as O 0 1.3107437268899957e-07
a O 0 7.832922506167961e-07
younger O 0 1.959359724423848e-05
age O 0 1.4277289665187709e-05
at O 0 6.028713323757984e-05
diagnosis O 0 0.052618131041526794
. O 0 2.2373411411535926e-05

We O 0 0.00010439574543852359
conclude O 0 2.0124414731981233e-05
that O 0 5.644679959004861e-07
the O 0 9.82998926701839e-07
APC O 0 1.5794577848282643e-05
I1307K O 0 1.8420179912936874e-05
variant O 0 1.0875454790948424e-05
leads O 0 3.5469547583488747e-06
to O 0 1.9993499336123932e-06
increased O 0 7.672864012420177e-05
adenoma B-Disease 1 0.9999961853027344
formation O 0 1.1828487913589925e-05
and O 0 1.240974711436138e-06
directly O 0 7.250573048622755e-07
contributes O 0 7.616658876941074e-07
to O 0 3.808423230111657e-07
3 O 0 1.1205382861589896e-06
% O 0 4.7392296664838796e-07
- O 0 8.372130650968757e-06
4 O 0 1.3581961866293568e-06
% O 0 2.441052515678166e-07
of O 0 1.396994377955707e-07
all O 0 1.4907619743098621e-06
Ashkenazi O 0 0.006564764771610498
Jewish O 1 0.6357121467590332
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00017092606867663562

The O 0 5.456699727801606e-05
estimated O 0 4.483263910515234e-05
relative O 0 4.246265962137841e-05
risk O 0 4.8341582441935316e-05
for O 0 1.4096091263127164e-06
carriers O 0 7.811170507920906e-05
may O 0 1.0887886674026959e-05
justify O 0 2.417815267108381e-06
specific O 0 2.688601909994759e-07
clinical O 0 6.905401733092731e-06
screening O 0 5.4400416047428735e-06
for O 0 2.2043484193545737e-07
the O 0 2.448634859320009e-07
360 O 0 2.2623555651080096e-06
, O 0 3.4378888358332915e-07
000 O 0 6.002092618473398e-07
Americans O 0 2.0886359664018528e-07
expected O 0 2.55023564932344e-07
to O 0 3.615663217715337e-07
harbor O 0 1.5123839148145635e-05
this O 0 1.2263971882475744e-07
allele O 0 2.3059560589899775e-06
, O 0 1.8355595443608763e-07
and O 0 3.681248870179843e-07
genetic O 0 2.7792586934083374e-06
testing O 0 1.6315035509251175e-06
in O 0 1.2440135321867274e-07
the O 0 1.6097735056064266e-07
setting O 0 9.668012808106141e-07
of O 0 2.1569390185049997e-07
long O 0 9.56481926550623e-06
- O 0 0.0001986367133213207
term O 0 5.741582299378933e-06
- O 0 6.395214586518705e-05
outcome O 0 1.0148662568099098e-06
studies O 0 7.914302386780037e-07
may O 0 2.432260089335614e-06
impact O 0 2.330400320715853e-06
significantly O 0 4.358340083854273e-05
on O 1 0.8970823287963867
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.040672823786735535
in O 0 2.4375499378948007e-06
this O 0 1.3158039564586943e-06
population O 0 5.698677796317497e-06
. O 0 1.1384411664039362e-05

Localization O 0 0.00035826757084578276
of O 0 1.3683403267350513e-05
human O 0 1.0579376066743862e-05
BRCA1 O 0 0.0004965652478858829
and O 0 4.000207809440326e-06
its O 0 2.9187719974288484e-06
loss O 0 3.5077504435321316e-05
in O 0 1.2467992291931296e-06
high O 0 7.243923027999699e-05
- O 0 0.0033289820421487093
grade O 0 0.00020364431838970631
, O 0 2.0761178802786162e-06
non B-Disease 0 2.2159836589707993e-05
- I-Disease 1 0.9927160143852234
inherited I-Disease 1 0.9998855590820312
breast I-Disease 1 0.9999176263809204
carcinomas I-Disease 1 0.9999985694885254
. O 0 0.00024771306198090315

Although O 0 3.3399883250240237e-05
the O 0 2.4645946723467205e-06
link O 0 6.0927800404897425e-06
between O 0 1.3258570561447414e-06
the O 0 5.8740856729855295e-06
BRCA1 O 1 0.5909738540649414
tumour B-Disease 1 0.9999957084655762
- O 0 0.0008295061998069286
suppressor O 0 0.00011374257155694067
gene O 0 1.1605239706113935e-05
and O 0 1.050789524015272e-05
hereditary B-Disease 1 0.9999046325683594
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999966621398926
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 7.773250217724126e-06
established O 0 3.956769432988949e-06
, O 0 2.792324664824264e-07
the O 0 1.457875100641104e-07
role O 0 5.386889370129211e-07
, O 0 2.124505442679947e-07
if O 0 5.938279556971793e-08
any O 0 3.814180260519606e-08
, O 0 7.530594103855037e-08
of O 0 1.3018600952818815e-07
BRCA1 O 0 7.689594349358231e-05
in O 0 1.4544882560585393e-06
non B-Disease 0 2.9660039217560552e-05
- I-Disease 1 0.7892417907714844
familial I-Disease 1 0.9888982176780701
cancers I-Disease 1 0.9959155917167664
is O 0 5.564009370573331e-06
unclear O 0 2.0767891328432597e-05
. O 0 1.2339291060925461e-05

BRCA1 O 1 0.9304494857788086
mutations O 0 0.005704532843083143
are O 0 1.1187209565832745e-05
rare O 0 9.001358193927445e-06
in O 0 6.8509389166138135e-06
sporadic B-Disease 0 0.010252326726913452
cancers I-Disease 1 0.9905145168304443
, O 0 1.4687178918393329e-05
but O 0 4.35170568380272e-06
loss O 0 1.3255802514322568e-05
of O 0 6.013299298501806e-07
BRCA1 O 0 0.003831305541098118
resulting O 0 4.04315233026864e-06
from O 0 7.258764753714786e-07
reduced O 0 5.759163741458906e-06
expression O 0 1.1828867627627915e-06
or O 0 1.3563685570261441e-06
incorrect O 0 1.1017236829502508e-05
subcellular O 0 6.128536188043654e-05
localization O 0 1.1324045772198588e-05
is O 0 4.6764503736085317e-07
postulated O 0 2.4579094315413386e-06
to O 0 4.370377837403794e-07
be O 0 2.5641412548793596e-07
important O 0 8.711249677162414e-08
in O 0 3.67659652056318e-07
non B-Disease 0 6.874112386867637e-06
- I-Disease 0 0.13040165603160858
familial I-Disease 1 0.9765526652336121
breast I-Disease 1 0.999994158744812
and I-Disease 1 0.999584972858429
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.0001932131708599627

Epigenetic O 0 0.005103797651827335
loss O 0 0.11212290078401566
, O 0 1.712268749543e-05
however O 0 2.031044459727127e-06
, O 0 4.284269721210876e-07
has O 0 4.074643129570177e-07
not O 0 1.20649957580099e-07
received O 0 3.176081122546748e-07
general O 0 2.0983429749321658e-07
acceptance O 0 1.912376546897576e-06
due O 0 1.425601112714503e-06
to O 0 2.0601137862286123e-07
controversy O 0 4.0663238110028033e-07
regarding O 0 2.85248091813628e-07
the O 0 1.7048985512246873e-07
subcellular O 0 1.0419780664960854e-05
localization O 0 2.405352233836311e-06
of O 0 3.364827989571495e-07
BRCA1 O 0 0.00029459092183969915
proteins O 0 1.236732032339205e-06
, O 0 3.0582461363337643e-07
reports O 0 4.000609976628766e-07
of O 0 8.619554137112573e-08
which O 0 5.910504796702298e-07
have O 0 3.604711196203425e-07
ranged O 0 3.4531785786384717e-06
from O 0 2.9576710858236765e-07
exclusively O 0 8.284963541882462e-07
nuclear O 0 1.4083962014410645e-05
, O 0 2.774540064365283e-07
to O 0 3.652374971352401e-07
conditionally O 0 4.462697688722983e-06
nuclear O 0 3.762549795283121e-06
, O 0 1.5077334580837487e-07
to O 0 1.3035545975981222e-07
the O 0 7.565656119368214e-07
ER O 0 0.0025471115950495005
/ O 0 1.636671368032694e-05
golgi O 0 0.0011398709611967206
, O 0 1.0629318012433941e-06
to O 0 5.230507440501242e-07
cytoplasmic O 0 1.9170920495525934e-05
invaginations O 0 9.28087392821908e-05
into O 0 1.6961118944891496e-06
the O 0 2.2413444185076514e-06
nucleus O 0 3.199657658115029e-05
. O 0 9.058557225216646e-06

In O 0 2.584928006399423e-05
an O 0 4.735159109259257e-06
attempt O 0 1.073003022611374e-05
to O 0 1.3420016102827503e-06
resolve O 0 9.42007864068728e-06
this O 0 3.544077173955884e-07
issue O 0 4.950417178406497e-07
, O 0 5.552976745093474e-07
we O 0 6.446949214478082e-07
have O 0 5.703276428903337e-07
comprehensively O 0 2.3010743461782113e-05
characterized O 0 2.541355115681654e-06
19 O 0 3.1815454804018373e-06
anti O 0 1.2038728527841158e-05
- O 0 0.004270181991159916
BRCA1 O 0 0.009012465365231037
antibodies O 0 0.00014207269123289734
. O 0 2.0710574972326867e-05

These O 0 4.6162200305843726e-05
reagents O 0 5.9953807067358866e-05
detect O 0 7.10598542355001e-05
a O 0 4.801899194717407e-06
220 O 0 1.0851501428987831e-05
- O 0 2.3980865080375224e-05
kD O 0 2.9125740184099413e-05
protein O 0 4.382667157187825e-06
localized O 0 6.72488522468484e-06
in O 0 8.166027782863239e-07
discrete O 0 4.516641183727188e-06
nuclear O 0 4.664000152843073e-05
foci O 0 3.019538962689694e-05
in O 0 1.010583105198748e-06
all O 0 8.136487963383843e-07
epithelial O 0 6.987730012042448e-05
cell O 0 0.0022963588126003742
lines O 0 3.318592644063756e-05
, O 0 3.615835453274485e-07
including O 0 1.8129432532987266e-07
those O 0 2.798117577640369e-07
derived O 0 1.4490608464257093e-06
from O 0 5.296735707815969e-06
breast B-Disease 1 0.7265926003456116
malignancies I-Disease 0 0.08534334599971771
. O 0 6.148222018964589e-05

Immunohistochemical O 0 0.007376291789114475
staining O 0 0.001205311855301261
of O 0 2.1344054403016344e-05
human O 0 3.1057334126671776e-05
breast O 1 0.8864395618438721
specimens O 0 5.035673166275956e-05
also O 0 1.463354601582978e-05
revealed O 0 0.00032384003861807287
BRCA1 O 0 0.005082953721284866
nuclear O 0 0.00019040513143409044
foci O 0 0.0004844917275477201
in O 0 4.747448110720143e-05
benign O 1 0.9018564820289612
breast O 1 0.9986938834190369
, O 0 0.00014398226630873978
invasive B-Disease 1 0.6059234738349915
lobular I-Disease 1 0.9999693632125854
cancers I-Disease 1 0.9988729357719421
and O 0 7.748288771836087e-05
low B-Disease 0 0.32686230540275574
- I-Disease 1 0.96811842918396
grade I-Disease 1 0.8969823122024536
ductal I-Disease 1 0.9973729848861694
carcinomas I-Disease 1 0.999997615814209
. O 0 0.000144153309520334

Conversely O 0 0.0005873889895156026
, O 0 1.882585638668388e-05
BRCA1 O 0 0.00025958361220546067
expression O 0 1.0171462236030493e-05
was O 0 4.364429696579464e-05
reduced O 0 8.93926880962681e-06
or O 0 3.7283916753949597e-06
undetectable O 0 4.791465835296549e-05
in O 0 3.4831435868909466e-07
the O 0 2.406133887689066e-07
majority O 0 1.769650168625958e-07
of O 0 1.0634677494181233e-07
high O 0 0.000274135876679793
- O 0 0.10734472423791885
grade O 0 0.006207563448697329
, O 0 7.704553354415111e-06
ductal B-Disease 0 0.48641735315322876
carcinomas I-Disease 1 0.9999964237213135
, O 0 1.3412795851763804e-05
suggesting O 0 1.0313326129107736e-05
that O 0 2.9740618856521905e-07
absence O 0 1.378240654048568e-06
of O 0 4.7032096972543513e-07
BRCA1 O 0 0.07280493527650833
may O 0 2.4624407160445116e-05
contribute O 0 5.935346507612849e-07
to O 0 2.1467849364853464e-07
the O 0 4.3218017253821017e-07
pathogenesis O 0 3.300953494544956e-06
of O 0 5.2146695850296965e-08
a O 0 5.238684934738558e-07
significant O 0 5.208873972151196e-07
percentage O 0 4.940328381053405e-06
of O 0 5.411372967500938e-07
sporadic B-Disease 0 0.21277910470962524
breast I-Disease 1 0.9999933242797852
cancers I-Disease 1 0.9973905682563782
. O 0 1.2359713764453772e-05
. O 0 1.925753713294398e-05

